--
-- PostgreSQL database dump
--

SET statement_timeout = 0;
SET lock_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SET check_function_bodies = false;
SET client_min_messages = warning;

SET search_path = public, pg_catalog;

--
-- Data for Name: users; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY users (id, email, name, url, username, created_at, updated_at, orcid) FROM stdin;
\.


--
-- Data for Name: audits; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY audits (id, auditable_id, auditable_type, associated_id, associated_type, user_id, user_type, username, action, audited_changes, version, comment, remote_address, request_uuid, created_at) FROM stdin;
1	1	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 238\nname: ALK\ndescription: ALK amplifications, fusions and mutations have been shown to be driving\n  events in non-small cell lung cancer. While crizontinib has demonstrated efficacy\n  in treating the amplification, mutations in ALK have been shown to confer resistance\n  to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied\n  success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been\n  shown to be cytostatic in ALK-altered cell lines.\nofficial_name: anaplastic lymphoma receptor tyrosine kinase\nclinical_description: \n	1	\N	\N	ed6e531c-7abf-45d2-b17d-81bce5efe0bc	2015-05-20 18:09:52.33329
2	2	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 207\nname: AKT1\ndescription: AKT1, also referred to as protein kinase B, is a known oncogene. AKT\n  activation relies on the PI3K pathway, and is recognized as a critical node in the\n  pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been\n  shown to result in activation of the protein. Mutations in AKT1 have also been shown\n  to confer resistance to allosteric kinase inhibitors in vitro.\nofficial_name: v-akt murine thymoma viral oncogene homolog 1\nclinical_description: \n	1	\N	\N	eef9a21e-94b6-4d18-9897-5c4643958747	2015-05-20 18:09:52.582641
3	3	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 369\nname: ARAF\ndescription: ARAF has recently become increasingly considered for its oncogenic potential.\n  Its potential as a target for informing clinical action was demonstrated by a single\n  case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated\n  with sorafenib, acheived near-complete clinical remission. This finding has brought\n  new focus on ARAF as a marker that should be assayed for in cancer treatment.\nofficial_name: A-Raf proto-oncogene, serine/threonine kinase\nclinical_description: \n	1	\N	\N	192a0d6a-1f51-469f-a193-fccc38ce32b2	2015-05-20 18:09:52.813487
4	4	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 25\nname: ABL1\ndescription: ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein\n  that has become a signature of chronic myeloid leukemia (CML). Cells harboring this\n  fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook\n  of the disease. However, additional mutations in ABL1 have been shown to confer\n  resistance to imatinib. In these resistance cases, second-generation tyrosine kinase\n  inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are\n  currently undergoing clinical trials for treating acquired resistance in CML.\nofficial_name: ABL proto-oncogene 1, non-receptor tyrosine kinase\nclinical_description: \n	1	\N	\N	9e9c8ddb-e4e7-4133-8c76-e3a8fdc9f722	2015-05-20 18:09:53.054725
5	5	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 673\nname: BRAF\ndescription: BRAF mutations are found to be recurrent in many cancer types. Of these,\n  the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E\n  has been determined to be an activating mutation, and cells that harbor it, along\n  with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is\n  also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK\n  inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations\n  have also been correlated with poor prognosis in many cancer types, although there\n  is at least one study that questions this conclusion in papillary thyroid cancer.\nofficial_name: B-Raf proto-oncogene, serine/threonine kinase\nclinical_description: \n	1	\N	\N	17ce5fa0-adc9-448e-857b-e23672a27dcd	2015-05-20 18:09:53.318379
6	6	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 672\nname: BRCA1\ndescription: BRCA1 mutations in the germline have become a hallmark for hereditary\n  breast and ovarian cancers. Variants that have been demonstrated to reduce the function\n  of the protein have been shown to increase risk for these cancers, as well as prostate\n  and pancreatic cancer. These findings have been the impetus for the increased popularity\n  of genetic testing of healthy indivudals to assess risk.\nofficial_name: breast cancer 1, early onset\nclinical_description: \n	1	\N	\N	b4c24779-b6c1-4340-ab90-63011e931ae0	2015-05-20 18:09:53.575537
7	7	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 675\nname: BRCA2\ndescription: BRCA2 mutations in the germline have become a hallmark for hereditary\n  breast and ovarian cancers. Variants that have been demonstrated to reduce the function\n  of the protein have been shown to increase risk for these cancers, as well as prostate\n  and pancreatic cancer. These findings have been the impetus for the increased popularity\n  of genetic testing of healthy indivudals to assess risk.\nofficial_name: breast cancer 2, early onset\nclinical_description: \n	1	\N	\N	492970bf-3a01-4688-a92f-b7beeac945d3	2015-05-20 18:09:53.839107
8	8	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 595\nname: CCND1\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, ranging from genomic amplification to changes in promoter methylation.\n  While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin\n  D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been\n  shown to lead to poorer outcomes in a number of studies, and currently there are\n  no FDA-approved targeted therapies.\nofficial_name: cyclin D1\nclinical_description: \n	1	\N	\N	689790a7-8546-40ea-b2ca-011a9529e6b2	2015-05-20 18:09:54.070084
9	9	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 894\nname: CCND2\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, ranging from genomic amplification to changes in promoter methylation.\n  While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin\n  D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been\n  shown to lead to poorer outcomes in a number of studies, and currently there are\n  no FDA-approved targeted therapies.\nofficial_name: cyclin D2\nclinical_description: \n	1	\N	\N	9e948d02-53f5-4c88-af47-a219e1c70c19	2015-05-20 18:09:54.283917
10	10	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 896\nname: CCND3\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, ranging from genomic amplification to changes in promoter methylation.\n  Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared\n  to the amplifcations and overexpressions of the other cyclin D's. In a mouse study,\n  the targeted therapeutic palbociclib significantly increased the median survival\n  of the cyclin D3 knockouts.\nofficial_name: cyclin D3\nclinical_description: \n	1	\N	\N	13d85ba8-d6f6-4b25-8aa0-5b892c819905	2015-05-20 18:09:54.481204
41	41	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5728\nname: PTEN\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: phosphatase and tensin homolog\nclinical_description: \n	1	\N	\N	550c76fb-d7b0-4031-9260-65877cb0a937	2015-05-20 18:10:01.629383
11	11	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 898\nname: CCNE1\ndescription: Cyclin E, while currenly not as widely implicated as its cyclin D counterparts,\n  has been implicated in various carcinomas, including breast, gastric, stomach and\n  colorectal. High levels of cyclin E, either by gene amplification or overexpression,\n  have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements\n  are correlated with later stage disease. In lung cancer, neoplastic cells with higher\n  levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly\n  expressed counterparts.\nofficial_name: cyclin E1\nclinical_description: \n	1	\N	\N	a097c316-02d3-4fc8-93eb-94ba0080b136	2015-05-20 18:09:54.688718
12	12	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1021\nname: CDK6\ndescription: CDK6, along with its partner CDK4, are key players in cell cycle progression.\n  The complex has been implicated in a number of cancer types, and is the focus of\n  therapeutic research and development. One targeted therapy for CDK inhibition is\n  palbociclib, which may slow the growth of advanced stage breast cancers. It has\n  also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors\n  to PI3K inhibitors.\nofficial_name: cyclin-dependent kinase 6\nclinical_description: \n	1	\N	\N	630709d8-af3e-4049-9afa-ed26b039468d	2015-05-20 18:09:54.885915
13	13	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1019\nname: CDK4\ndescription: CDK4, along with its partner CDK6, are key players in cell cycle progression.\n  The complex has been implicated in a number of cancer types, and is the focus of\n  therapeutic research and development. One targeted therapy for CDK inhibition is\n  palbociclib, which may slow the growth of advanced stage breast cancers. It has\n  also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors\n  to PI3K inhibitors.\nofficial_name: cyclin-dependent kinase 4\nclinical_description: \n	1	\N	\N	2f74f381-e1b5-4be4-99e1-6f0139eb2051	2015-05-20 18:09:55.091769
14	14	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1029\nname: CDKN2A\ndescription: CDKN2A loss has been shown to be a significant event in a number of cancer\n  types. While no targeted therapeutic has been engaged in clinical trials, the prognostic\n  impact has been studied by a number of meta-analyses. One mechanism by which loss\n  of CDKN2A can occur is by hypermethylation of the promoter region for the gene.\n  However, the prognostic impact of promoter hypermethylation has been relatively\n  ambiguous. Many studies have suggesting poorer prognostic outcome for patients with\n  hypermethylation in colorectal, liver, and younger lung cancer patients. This being\n  said, there is still research to be done before this becomes a widely-accepted prognostic\n  indicator.\nofficial_name: cyclin-dependent kinase inhibitor 2A\nclinical_description: \n	1	\N	\N	a50259d7-abd3-4628-afbb-e33d6d4f9798	2015-05-20 18:09:55.380225
15	15	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1050\nname: CEBPA\ndescription: AML with mutated CEBPA' is a provisional entity in the WHO classification\n  of acute myeloid leukemia (AML) and is recommended to be tested for in patients\n  with AML. CEBPA mutations are particularly associated with cytogenetically normal\n  AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation\n  in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha\n  protein while C-terminal mutations reduce the DNA-binding potential of this transcription\n  factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1\n  and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations\n  may have prognostic implications.\nofficial_name: CCAAT/enhancer binding protein (C/EBP), alpha\nclinical_description: \n	1	\N	\N	9913c580-a144-4083-b74b-36137bb1c9e1	2015-05-20 18:09:55.629621
16	16	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3337\nname: DNAJB1\ndescription: DNAJB1 works upstream of MDM2, stabilizing the complex and facilitating\n  p53 turnover. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1\n  to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In\n  one study, this fusion was observed in 15/15 FL-HCC cases examined and functional\n  studies found that the fusion retained kinase activity.\nofficial_name: DnaJ (Hsp40) homolog, subfamily B, member 1\nclinical_description: \n	1	\N	\N	c658a04c-dcb9-4afa-8f0d-2061f16d3c79	2015-05-20 18:09:55.852491
17	17	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5566\nname: PRKACA\ndescription: PRKACA has been studied in breast cancer and has been found to mediate\n  resistance to HER2 targeted therapies. It has also been found to contain a mutation\n  hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular\n  fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be\n  a diagnostic marker for this rare subtype of HCC. In one study, this fusion was\n  observed in 15/15 FL-HCC cases examined and functional studies found that the fusion\n  retained kinase activity.\nofficial_name: protein kinase, cAMP-dependent, catalytic, alpha\nclinical_description: \n	1	\N	\N	4dc2e18e-826c-4800-b659-81070324ce37	2015-05-20 18:09:56.055481
18	18	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1788\nname: DNMT3A\ndescription: DNMT3A is one of several epigenetic modifiers identified as recurrently\n  mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically\n  normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant\n  negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers.\n  AML patient bone marrow harboring R882 mutations were similarly demonstrated to\n  be hypomethylated compared to patients with wildtype DNMT3A. These studies also\n  indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner\n  from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes\n  and treatment protocols may need to be considered for these two classes of DNMT3A\n  mutations.\nofficial_name: DNA (cytosine-5-)-methyltransferase 3 alpha\nclinical_description: \n	1	\N	\N	cb8f005d-e995-429c-b83c-2dfb00ed18b0	2015-05-20 18:09:56.265101
19	19	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1956\nname: EGFR\ndescription: EGFR is widely recognized for its importance in cancer. Amplification\n  and mutations have been shown to be driving events in many cancer types. Its role\n  in non-small cell lung cancer has spurred many research and drug development efforts.\n  Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably\n  gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance\n  to these drugs, particularly the variant T790M, which has been functionally characterized\n  as a resistance marker for both of these drugs. The later generation TKI's have\n  seen some success in treating these resistant cases, and targeted sequencing of\n  the EGFR locus has become a common practice in non-small cell lung cancer.\nofficial_name: epidermal growth factor receptor\nclinical_description: \n	1	\N	\N	f32d58ca-9a09-443e-a670-d1c9877e11e4	2015-05-20 18:09:56.500581
20	20	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2064\nname: ERBB2\ndescription: ERBB2, commonly referred to as HER2, is amplified in HER2-positive breast\n  cancer, and is treated in a separate manner than the other subtypes of breast cancer.\n  Apart from being amplified, ERBB2 activating mutations have been shown to have clinical\n  importance in HER2-negative breast cancer. These mutations have shown sensitivity\n  to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical\n  sequencing efforts in treating breast cancer.\nofficial_name: erb-b2 receptor tyrosine kinase 2\nclinical_description: \n	1	\N	\N	576e9e5f-bdf9-427a-9a47-d883f846a33f	2015-05-20 18:09:56.840003
21	21	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2099\nname: ESR1\ndescription: ESR1 has been a focus in breast cancer for quite some time, but has also\n  shown significance in endometrial, ovarian and other cancer types. ER-positive breast\n  cancer that is resistant to hormone therapy has instigated clinical sequencing efforts\n  to shed light on the mechanisms of this resistance. A number of mutations in the\n  ligand binding domain of the protein have been implicated in hormone resistance\n  and anti-estrogen therapies. This has spurred efforts to develop therapeutics that\n  act to degrade the protein, rather than act as an antagonist. These agents are currently\n  in clinical trials and have seen some success, highlighting the importance of sequencing\n  efforts in treating breast cancer.\nofficial_name: estrogen receptor 1\nclinical_description: \n	1	\N	\N	b030cbde-49d6-4445-8f3a-486f118ec1cc	2015-05-20 18:09:57.119524
22	22	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2263\nname: FGFR2\ndescription: The FGFR proteins are involved in a wide array of pathways known to play\n  a signficant role in cancer. Activation of these receptors can lead to activation\n  of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by\n  which FGFR can be misregulated vary between cancers. Amplification of the receptors\n  has been observed in lung and breast cancers, coding mutations and deletions have\n  been seen in many cancers, and more recently, FGFR fusions that lead to pathway\n  actiation have been demonstrated to have oncogenic potential across multiple cancer\n  types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success\n  in treating over-active FGFR signalling, prompting use of diagnostic sequencing\n  targeting the FGFR genes, especially in lung cancer patients.\nofficial_name: fibroblast growth factor receptor 2\nclinical_description: \n	1	\N	\N	3fb089b2-724f-44b8-9d05-9c17b7b24d9e	2015-05-20 18:09:57.405654
23	23	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2261\nname: FGFR3\ndescription: The FGFR proteins are involved in a wide array of pathways known to play\n  a signficant role in cancer. Activation of these receptors can lead to activation\n  of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by\n  which FGFR can be misregulated vary between cancers. Amplification of the receptors\n  has been observed in lung and breast cancers, coding mutations and deletions have\n  been seen in many cancers, and more recently, FGFR fusions that lead to pathway\n  actiation have been demonstrated to have oncogenic potential across multiple cancer\n  types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success\n  in treating over-active FGFR signalling, prompting use of diagnostic sequencing\n  targeting the FGFR genes, especially in lung cancer patients.\nofficial_name: fibroblast growth factor receptor 3\nclinical_description: \n	1	\N	\N	3491d640-40ca-4e88-9120-0fc45ffd6a58	2015-05-20 18:09:57.662919
24	24	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2322\nname: FLT3\ndescription: FLT3 is an important cytokine receptor involved in normal hematopoiesis.\n  Mutations in this gene are common in acute myeloid leukemia (AML) and screening\n  for mutations in this gene has been recommended by the World Health Organization\n  in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML).\n  FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated\n  with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have\n  been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD\n  mutations are still up for debate.\nofficial_name: fms-related tyrosine kinase 3\nclinical_description: \n	1	\N	\N	f6f14213-6f65-4abc-bcaf-63635d57fe2c	2015-05-20 18:09:57.897729
25	25	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2624\nname: GATA2\ndescription: GATA2 is a transcription factor involved in stem cell maintenance with\n  key roles in hematopoietic development. GATA2 mutations are associated with a variety\n  of inherited and acquired immune disorders including myelodysplastic syndrome and\n  acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance\n  GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell\n  lung cancer. Preclinical models have indicated therapeutic benefit from targeting\n  GATA2-mediated pathways in the context of KRAS-driven NSCLC.\nofficial_name: GATA binding protein 2\nclinical_description: \n	1	\N	\N	f843ee78-76f1-4aa8-9c84-0d814e4bc584	2015-05-20 18:09:58.10853
26	26	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3417\nname: IDH1\ndescription: IDH1 mutations have been observed in a number of cancer types, including\n  sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in\n  the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial\n  (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described\n  as mutually exclusive in many of these cancer types. The most frequent mutations\n  involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic\n  enzyme activity. The implications of mutations in this gene vary greatly by cancer\n  type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations\n  have been associated with worse outcome, shorter overall survival, and normal karyotype.\n  However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown\n  better overall survival than patients with wild-type IDH1. Unlike the association\n  with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated\n  with specific cytogenetic abnormalities, 1p and 19q deletions.\nofficial_name: isocitrate dehydrogenase 1 (NADP+), soluble\nclinical_description: \n	1	\N	\N	742edcbb-34fd-4ecc-97ad-ebb66517297f	2015-05-20 18:09:58.352383
27	27	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3418\nname: IDH2\ndescription: IDH2 mutations have been observed in a number of cancer types, including\n  sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in\n  the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial\n  (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described\n  as mutually exclusive in many of these cancer types. The most frequent mutations\n  involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic\n  enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall\n  prognosis in AML patients, its utility as a prognostic marker in MDS is still under\n  debate. Additionally, IDH2 (R140) has been associated with improved overall survival\n  in AML. IDH2 mutations have been associated with improved prognosis in gliomas.\nofficial_name: isocitrate dehydrogenase 2 (NADP+), mitochondrial\nclinical_description: \n	1	\N	\N	03538fb6-5cd5-4210-9dcd-0dac1c08889d	2015-05-20 18:09:58.598991
28	28	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3717\nname: JAK2\ndescription: JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative\n  diseases and cancers. The mutation V617F is the most clinically relevant variant,\n  and is seen in around half of myeloproliferative disorders. The variant is a known\n  activating mutation, and activated JAK2 is sufficient to drive myeloproliferative\n  disorders in mouse models. V617F, while most recurrent, is not the only mechanism\n  by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic\n  markers tested upon diagnosis with a myeloproliferative disorder.\nofficial_name: Janus kinase 2\nclinical_description: \n	1	\N	\N	81a76e5c-df8b-42fd-be76-85c72043aab3	2015-05-20 18:09:58.817772
194	139	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: G253C\ndescription: Activating mutations in DDR2, including G253C, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	11acae79-7224-43cd-b59d-1d965a305fde	2015-05-20 18:10:06.813839
29	29	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3815\nname: KIT\ndescription: c-KIT activation has been shown to have oncogenic activity in gastrointestinal\n  stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted\n  therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive\n  patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can\n  be the result of many genomic events from genomic amplification to overexpression\n  to missense mutations. Missense mutations have been shown to be key players in mediating\n  clinical response and acquired resistance in patients being treated with these targeted\n  therapeutics.\nofficial_name: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog\nclinical_description: \n	1	\N	\N	ce2911bb-1fba-41cf-b347-301c380e17e4	2015-05-20 18:09:59.031819
30	30	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 3845\nname: KRAS\ndescription: Mutations in the RAS family of proteins have frequently observed across\n  cancer types. The amino acid positions account for the overwhelming majority of\n  these mutations, G12, G13 and Q61. The isoforms, despite their raw similarity, also\n  behave very differently when expressed in non-native tissue types, likely due to\n  differences in the C-terminal hyper-variable regions. Mis-regulation of isoform\n  expression has been shown to be a driving event in cancer, as well as missense mutations\n  at the three hotspots previously mentioned. While highly recurrent in cancer, targeted\n  these RAS mutants has also been very elusive, and has not yet become common practice\n  in the clinic.\nofficial_name: Kirsten rat sarcoma viral oncogene homolog\nclinical_description: \n	1	\N	\N	8792b6ec-7dcd-4717-b2be-92dad4f90270	2015-05-20 18:09:59.30403
31	31	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5604\nname: MAP2K1\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: mitogen-activated protein kinase kinase 1\nclinical_description: \n	1	\N	\N	24f4cabd-97ac-49ff-a0be-ee31685a8af5	2015-05-20 18:09:59.539265
32	32	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4209\nname: MEF2D\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: myocyte enhancer factor 2D\nclinical_description: \n	1	\N	\N	c1cdb8ac-f073-4535-ad5c-1a03ff139bbf	2015-05-20 18:09:59.727249
33	33	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 1436\nname: CSF1R\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: colony stimulating factor 1 receptor\nclinical_description: \n	1	\N	\N	571f8fa5-b62a-4d48-9296-712610bb0fb8	2015-05-20 18:09:59.942414
34	34	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4255\nname: MGMT\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: O-6-methylguanine-DNA methyltransferase\nclinical_description: \n	1	\N	\N	7331df04-899d-43de-b5c1-ac9cfd456859	2015-05-20 18:10:00.131557
35	35	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4869\nname: NPM1\ndescription: AML with mutated NPM1 is provisional entity in the WHO classification\n  of AML and is recommended to be tested for in patients with cytogenetically normal\n  AML (CN-AML). Evaluation of FLT3 mutations should be evaluated concurrently as they\n  have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently\n  W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations\n  in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing\n  the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia,\n  indicating it may require additional mutations to promote leukemic development.\nofficial_name: nucleophosmin (nucleolar phosphoprotein B23, numatrin)\nclinical_description: \n	1	\N	\N	71379bd0-dd83-4ded-ada1-692c11f04a2d	2015-05-20 18:10:00.320769
36	36	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4893\nname: NRAS\ndescription: Mutations in the RAS family of proteins have frequently observed across\n  cancer types. The amino acid positions account for the overwhelming majority of\n  these mutations, G12, G13 and Q61. The isoforms, despite their raw similarity, also\n  behave very differently when expressed in non-native tissue types, likely due to\n  differences in the C-terminal hyper-variable regions. Mis-regulation of isoform\n  expression has been shown to be a driving event in cancer, as well as missense mutations\n  at the three hotspots previously mentioned. While highly recurrent in cancer, targeted\n  these RAS mutants has also been very elusive, and has not yet become common practice\n  in the clinic.\nofficial_name: neuroblastoma RAS viral (v-ras) oncogene homolog\nclinical_description: \n	1	\N	\N	4010d984-905a-4d4c-8004-5e658ddbff11	2015-05-20 18:10:00.536588
37	37	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5290\nname: PIK3CA\ndescription: PIK3CA is the most recurrently mutated gene in breast cancer, and has\n  been found to important in a number of cancer types. An integral part of the PI3K\n  pathway, PIK3CA has long been described as an oncogene, with two main hotspots for\n  activating mutations, the 542/545 region of the helical domain, and the 1047 region\n  of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways,\n  is the subject of an immense amount of research and development, and PI3K inhibition\n  has seen some limited success in recent clinical trials. While monotherapies seem\n  to be limited in their potential, there is a recent interest in pursuing PI3K inhibition\n  as part of a combination therapy regiment with inhibition partners including TKI's,\n  MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.\nofficial_name: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha\nclinical_description: \n	1	\N	\N	c9fe9379-afc5-4f0b-895e-b3b15a7cedef	2015-05-20 18:10:00.761925
38	38	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5156\nname: PDGFRA\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: platelet-derived growth factor receptor, alpha polypeptide\nclinical_description: \n	1	\N	\N	17fb4fa7-059d-4c99-8a2d-7ac421948bc3	2015-05-20 18:10:00.991532
39	39	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5371\nname: PML\ndescription: The PML-RARA fusion is the result of a recurrent, balanced translocation\n  between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event\n  in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown\n  sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA\n  fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for\n  treating these patients, and early results seem promising.\nofficial_name: promyelocytic leukemia\nclinical_description: \n	1	\N	\N	c1d61f53-72a0-484f-b5f0-013e441fbfcb	2015-05-20 18:10:01.198018
40	40	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5914\nname: RARA\ndescription: The PML-RARA fusion is the result of a recurrent, balanced translocation\n  between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event\n  in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown\n  sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA\n  fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for\n  treating these patients, and early results seem promising.\nofficial_name: retinoic acid receptor, alpha\nclinical_description: \n	1	\N	\N	6ca0df03-2e86-4c21-a678-482f1bd281b1	2015-05-20 18:10:01.394759
42	42	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 5979\nname: RET\ndescription: RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine\n  kinase receptor and are associated with thyroid cancers. RET point mutations are\n  the most common mutations identified in medullary thyroid cancer (MTC) with germline\n  and somatic mutations in RET associated with hereditary and sporadic forms, respectively.\n  The most common somatic form mutation is M918T (exon 16) and a variety of other\n  mutations effecting exons 10, 11 and 15 have been described. The prognostic significance\n  of these mutations have been hotly debated in the field, however, data suggests\n  that some RET mutation may confer drug resistence. No RET-specific agents are currently\n  clinically available but several promiscuous kinase inhibitors that target RET,\n  among others, have been approved for MTC treatment.\nofficial_name: ret proto-oncogene\nclinical_description: \n	1	\N	\N	5bd42dfe-f5a3-47f7-b1ac-5d856ad21776	2015-05-20 18:10:01.873518
43	43	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 861\nname: RUNX1\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: runt-related transcription factor 1\nclinical_description: \n	1	\N	\N	1c3c84d7-347e-41ec-bf96-2d6c7f72cc22	2015-05-20 18:10:02.113753
44	44	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 23451\nname: SF3B1\ndescription: SF3B1 mutations have been described in several myeloid malignancies,\n  predominantly myelodysplastic syndromes (MDS), as well as other hematologic malignancies\n  and breast cancer. SF3B1 is one of several genes involved in RNA splicing that has\n  been identified as recurrently mutated in MDS and other malignanices. The mutations\n  affecting SF3B1 are typically heterozygous, point mutations suspected to be functionally\n  deleterious with K700E described as a major hotspot mutation. MDS patients with\n  SF3B1 mutations have been reported to have better overall and event-free survival\n  than their wildtype counterparts. Additionally, these mutations are highly associated\n  with subtypes of MDS characterized by ringed sideroblasts (refractory anemia with\n  ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ring\n  sideroblasts).\nofficial_name: splicing factor 3b, subunit 1, 155kDa\nclinical_description: \n	1	\N	\N	db904695-2b4a-41c9-80c6-f03e7f1c7e47	2015-05-20 18:10:02.34262
45	45	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 7157\nname: TP53\ndescription: TP53 mutations are universal across cancer types. Loss of tumor suppressors\n  is most recognized by large deleterious events, such as frameshift mutations, or\n  premature stop codons. In TP53 however, many of the observed mutations in cancer\n  are found to be single nucleotide variants, or missense mutations. These variants\n  are also very broadly distributed throughout the gene, not localizing in any particular\n  hotspot. While a large proportion of cancer genomics research is focused on somatic\n  variants, TP53 is also of note in the germline. Germline TP53 mutations are the\n  hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) have been\n  found to have prognostic impact on patient outcomes.\nofficial_name: tumor protein p53\nclinical_description: \n	1	\N	\N	433f7c27-8f58-4127-85db-d26c895a554a	2015-05-20 18:10:02.605903
46	46	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 7248\nname: TSC1\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: tuberous sclerosis 1\nclinical_description: \n	1	\N	\N	650d1318-fbf4-4723-8b7d-e2ff67586bc2	2015-05-20 18:10:02.812907
47	47	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 7249\nname: TSC2\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: tuberous sclerosis 2\nclinical_description: \n	1	\N	\N	603342ac-3c74-4b13-9c2c-af5a5d933f37	2015-05-20 18:10:03.010629
48	48	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 7307\nname: U2AF1\ndescription: U2AF1 is one of several spliceosome complex genes frequently mutated\n  in a variety of hematologic malignancies, particularly de novo myelodysplastic syndromes\n  (MDS), as well as solid tumors such as lung and pancreatic cancers. Two hotspot\n  mutations (S34 and Q157) occur within the two zinc-finger domains of the U2AF1 protein.\n  These mutations have been associated with altered splicing patterns in vitro and\n  in vivo. U2AF1 mutations in MDS have been associated with an increased risk of transformation\n  to secondary acute myeloid leukemia, however, the impact of these mutations on overall\n  survival has been an area of debate.\nofficial_name: U2 small nuclear RNA auxiliary factor 1\nclinical_description: \n	1	\N	\N	d9dbdc6d-2576-4a32-9305-4dd6528d010f	2015-05-20 18:10:03.219884
49	49	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 7490\nname: WT1\ndescription: WT1 is a tumor suppressor gene associated with the development of Wilms'\n  Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently\n  identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy\n  resistance.\nofficial_name: Wilms tumor 1\nclinical_description: \n	1	\N	\N	5cc06bf4-437d-44bd-8a66-1e4660875d69	2015-05-20 18:10:03.454276
50	50	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 2475\nname: MTOR\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: mechanistic target of rapamycin (serine/threonine kinase)\nclinical_description: \n	1	\N	\N	1f30e548-46c1-4500-b277-49805d518167	2015-05-20 18:10:03.666035
51	51	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4851\nname: NOTCH1\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: notch 1\nclinical_description: \n	1	\N	\N	929e7f1d-d671-4d74-bd0d-93d7f35b7a1a	2015-05-20 18:10:03.867009
52	52	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4921\nname: DDR2\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: discoidin domain receptor tyrosine kinase 2\nclinical_description: \n	1	\N	\N	17fe408a-2bb7-4600-bee3-52decbcf0fac	2015-05-20 18:10:04.069383
53	53	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4233\nname: MET\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: MET proto-oncogene, receptor tyrosine kinase\nclinical_description: \n	1	\N	\N	072f7392-3301-4c5e-9e55-78876b45ca5d	2015-05-20 18:10:04.277993
54	54	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 4067\nname: LYN\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: LYN proto-oncogene, Src family tyrosine kinase\nclinical_description: \n	1	\N	\N	55b4ae0a-c2f1-467e-97a4-c5f6346ecbb0	2015-05-20 18:10:04.479206
55	55	Gene	\N	\N	\N	\N	\N	create	---\nentrez_id: 6697\nname: SPR\ndescription: A summary for this gene has yet to be developed! Add one now by clicking\n  the "Edit Gene" button.\nofficial_name: sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)\nclinical_description: \n	1	\N	\N	ce9b54d9-0093-4fe5-8f13-fddb3b83cc3a	2015-05-20 18:10:04.66091
71	16	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600R\ndescription: Patients harboring mutations in valine 600 residue of BRAF have been\n  shown to be sensitive to dabrafenib. For more information on the V600 locus, see\n  the V600E entry.\n	1	\N	\N	02f62f9c-d9aa-4f30-87ce-0360ab4a7425	2015-05-20 18:10:04.917067
195	140	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: G505S\ndescription: Activating mutations in DDR2, including G505S, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	4b626a07-2494-4000-8784-a7c42833dd20	2015-05-20 18:10:06.832088
56	1	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 4\nname: BCR-ABL\ndescription: The BCR-ABL fusion protein, commonly referred to as the philadelphia\n  chromosome, is the most well-studied fusion gene in cancer. It has widely been considered\n  the initiating event in chronic myelogenous leukemia (CML), but despite its ability\n  initiate disease in mice, its status an initiating mutation is in dispute. In what\n  is commonly used as the poster-child for targeted therapeutics, the development\n  and use of imatinib in the clinic has led to profound improvements in the prognosis\n  of the disease. However, imatinib resistance is still seen in patients with mutations\n  in the ABL kinase domain of the fusion, most notably the T315I variant. In patients\n  resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's\n  (dasatinib and nilotinib) have seen some success in delivering a tumor response.\n	1	\N	\N	3b1a35a3-95c7-435c-9af8-9fccbb8de1b8	2015-05-20 18:10:04.706569
57	2	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 4\nname: BCR-ABL T315I\ndescription: While the efficacy of imatinib has revolutionized chronic myelogenous\n  leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and\n  acquired resistance as a result of seleciton have been seen in a small subset of\n  CML patients. The ABL kinase domain mutation T315I has been shown to be one such\n  mutation that confers resistance to imatinib. Second generation TKI's (dasatinib\n  and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.\n	1	\N	\N	d762a3ad-9026-44c1-a7a9-59bc5551be06	2015-05-20 18:10:04.723738
58	3	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 4\nname: BCR-ABL E255K\ndescription: While the efficacy of imatinib has revolutionized chronic myelogenous\n  leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and\n  acquired resistance as a result of seleciton have been seen in a small subset of\n  CML patients. The ABL kinase domain mutation E255K has been shown to be one such\n  mutation that confers resistance to imatinib. Second generation TKI's (dasatinib\n  and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.\n	1	\N	\N	071bd782-caf1-43b9-8ff2-8763f9dec3ca	2015-05-20 18:10:04.73963
59	4	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 2\nname: E17K\ndescription: AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal,\n  lung, and ovarian cancer. It has been convincingly shown to be an activating mutation\n  resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation\n  decreases the cell's sensitivity to AKT1 allosteric kinase ihibitors. This, and\n  other AKT1 mutations, are the subject of much research and development for therapeutics.\n	1	\N	\N	918a6b72-3319-44a3-8449-3e6809f13290	2015-05-20 18:10:04.761962
60	5	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 1\nname: EML4-ALK\ndescription: The EML4-ALK fusion has been seen in non-small cell lung cancer, and\n  appears to be an alternative mechanism for ALK activation. Cells with this fusion\n  have been shown to be sensitive to the ALK inhibitor crizotinib.\n	1	\N	\N	cd899a22-fefa-4b12-bf06-9b73d5ed5762	2015-05-20 18:10:04.77514
61	6	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 1\nname: EML4-ALK C1156Y\ndescription: In patients with non-small cell lung cancer exhibiting EML4-ALK fusion,\n  this variant has been shown to confer resistance to crizotinib.\n	1	\N	\N	aec27668-664f-4af9-8561-f761038e1bcd	2015-05-20 18:10:04.787072
62	7	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 1\nname: EML4-ALK L1196M\ndescription: In patients with non-small cell lung cancer exhibiting EML4-ALK fusion,\n  this variant has been shown to confer resistance to crizotinib.\n	1	\N	\N	03b8748b-240e-4113-bbd9-0fe67191639b	2015-05-20 18:10:04.798823
63	8	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 1\nname: F1174L\ndescription: ALK F1174L has been observed as recurrent in neuroblastoma, non-small\n  cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing\n  this mutation have shown resistance to low doses of criztonib. However, increased\n  dosage can overcome this resistance in cell lines studies. TAE684 has also proven\n  effective in both NSCLC and neuroblastoma F1174L containing cells.\n	1	\N	\N	00f114ee-2a6a-4038-b7cf-9be4aaf51e32	2015-05-20 18:10:04.811227
64	9	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 1\nname: R1275Q\ndescription: ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma,\n  non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma\n  cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This,\n  and the geldanamycin deriviative 17-DMAG, has been shown to be effective in NSCLC\n  cell lines.\n	1	\N	\N	7c77e22a-ecaf-4432-a1ef-f9501264d2dd	2015-05-20 18:10:04.824138
65	10	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 3\nname: S214C\ndescription: ARAF S214C has been found to be a recurrent oncogenic mutation in non-small\n  cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib\n  in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this\n  mutation, sorafenib also acheived near-complete clinical remission. This case has\n  brought more interest to the variant from a research and clinical perspective.\n	1	\N	\N	81e277e4-a6d1-45b0-a4f1-fc3777493bd1	2015-05-20 18:10:04.842907
66	11	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600D\ndescription: Patients harboring mutations in valine 600 residue of BRAF have been\n  shown to be sensitive to dabrafenib. For more information on the V600 locus, see\n  the V600E entry.\n	1	\N	\N	4b4f3db9-1dd2-43f3-a8d4-78600ebf66f2	2015-05-20 18:10:04.854975
67	12	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600E\ndescription: BRAF V600E has been shown to be recurrent in many cancer types. It is\n  one of the most widely studied variants in cancer. This variant is correlated with\n  poor prognosis in certain cancer types, including colorectal cancer and papillary\n  thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective\n  in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib\n  has also shown to be effective when combined with the MEK inhibitor trametinib in\n  colorectal cancer and melanoma. However, in patients with TP53, KRAS, and CDK2NA\n  mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib,\n  and a number of combination therapies have been successful in treating V600E mutations.\n  While the drugs cetuximab and panitumumab have been largely shown to be ineffective\n  without supplementary treatment.\n	1	\N	\N	b77991c3-f249-407d-b217-665ae7cd6177	2015-05-20 18:10:04.866867
68	13	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600E/V600M\ndescription: A case study of a single patient harboring both a V600E and a V600M mutation,\n  dabrafenib was shown to acheive clinical response.\n	1	\N	\N	f8a7b952-b232-4cda-a5bf-959ac45dbe5c	2015-05-20 18:10:04.879072
69	14	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600E AMPLIFICATION\ndescription: Amplification of BRAF V600E has been shown to confer resistance to MEK\n  inhibitors. For more information on the V600 locus, see the V600E entry.\n	1	\N	\N	aa97f90c-eacf-4b14-a96e-51f255ba6514	2015-05-20 18:10:04.890524
70	15	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600M\ndescription: Patients harboring mutations in valine 600 residue of BRAF have been\n  shown to be sensitive to dabrafenib. For more information on the V600 locus, see\n  the V600E entry.\n	1	\N	\N	d51527ab-73f0-47cb-b606-da8c042b7af2	2015-05-20 18:10:04.902831
191	136	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 51\nname: S2275FS\ndescription: Activating mutations in NOTCH1, including a frameshift insertion at S2275,\n  have been shown to be poor prognostic markers in lung cancer.\n	1	\N	\N	29e03d23-ccb2-4e29-b50a-e3608c343e96	2015-05-20 18:10:06.759038
72	17	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: V600\ndescription: BRAF mutations of the valine 600 residue have been shown to be recurrent\n  in many cancer types. Of the V600 mutations, V600E is the most widely researched.\n  V600 mutations as a whole have been correlated to poorer prognosis in colorectal\n  and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity\n  to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual\n  mutation pages on the left sidebar.\n	1	\N	\N	308b425e-7c00-4846-9beb-8e4692bb286e	2015-05-20 18:10:04.933003
73	18	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 8\nname: AMPLIFICATION\ndescription: CCND1 amplification has been implicated in poorer prognosis in non-small\n  cell lung cancer.\n	1	\N	\N	a34ffc5e-65a7-4740-946c-493806686072	2015-05-20 18:10:04.950831
74	19	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 8\nname: EXPRESSION\ndescription: CCND1 expression, and its prognositc impact, is still in dispute. Three\n  experiments in non-small cell lung cancer have shown it to have no impact on survival,\n  but three additional studies have shown it results in poorer prognosis. There is\n  also some ambiguity in how the boundaries between expression and overexpression\n  are defined.\n	1	\N	\N	1556938b-29d2-45d8-88a5-7fa9f738b313	2015-05-20 18:10:04.964668
75	20	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 8\nname: OVEREXPRESSION\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, and range from genomic amplification to promoter methylation\n  changes. While Cyclin D2 has only been found to be significantly misregulated in\n  glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation\n  has been shown to lead to poorer outcomes in a number of studies, and currently\n  there are no FDA-approved targeted therapies.\n	1	\N	\N	d45bac0a-fef3-42f1-867a-e511987d35f2	2015-05-20 18:10:04.979586
76	21	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 9\nname: OVEREXPRESSION\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, and range from genomic amplification to promoter methylation\n  changes. While Cyclin D2 has only been found to be significantly misregulated in\n  glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation\n  has been shown to lead to poorer outcomes in a number of studies, and currently\n  there are no FDA-approved targeted therapies.\n	1	\N	\N	958cf5e4-b19f-4031-8190-af67a6199887	2015-05-20 18:10:04.994258
77	22	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 9\nname: PROMOTER DEMETHYLATION\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are misregulated\n  are widely variable, and range from genomic amplification to promoter methylation\n  changes. While Cyclin D2 has only been found to be significantly misregulated in\n  glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation\n  has been shown to lead to poorer outcomes in a number of studies, and currently\n  there are no FDA-approved targeted therapies.\n	1	\N	\N	e7d20f54-c696-4b15-b98b-707d9dbec1c1	2015-05-20 18:10:05.01006
78	23	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 10\nname: LOSS\ndescription: Cyclin D has been shown in many cancer types to be misregulated. Well\n  established for their oncogenic properties, the cyclins and the cyclin-dependent\n  kinases (CDK's) they activate have been the focus of major research and development\n  efforts over the past decade. The methods by which the cyclins are deregulated are\n  widely variable, and range from genomic amplification to promoter methylation changes.\n  Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL),\n  a seemingly unique trend when compared to the amplifcations and overexpressions\n  of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic\n  palbociclib significantly increased the median survival of a Notch-driven model\n  of T-ALL.\n	1	\N	\N	cf8587e5-75cf-427f-a72b-3def8a5b5ade	2015-05-20 18:10:05.023943
79	24	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 11\nname: OVEREXPRESSION\ndescription: Cyclin E, while currenly not as widely implicated as its counterpart,\n  cyclin D, has been implicated in various carcinomas, including breast, gastric,\n  stomach and colorectal. High levels of cyclin E, either by gene amplification or\n  overexpression, are correlated with later stage disease and have been shown to lead\n  to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer\n  specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex\n  are more radiosensitive than their lowly expressed counterparts.\n	1	\N	\N	cb18912a-6e06-42db-9fba-bfcd0208e6f3	2015-05-20 18:10:05.036402
80	25	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 13\nname: EXPRESSION\ndescription: CDK4, along with its partner CDK6, are key players in cell cycle progression.\n  The complex has been implicated in a number of cancer types, and is the focus of\n  therapeutic research and development. One targeted therapy for CDK inhibition is\n  palbociclib, which may slow the growth of advanced stage breast cancers. It has\n  also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors\n  to PI3K inhibitors.\n	1	\N	\N	ecc2b892-929a-488b-97c1-116c3f45dcc2	2015-05-20 18:10:05.052263
81	26	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 12\nname: EXPRESSION\ndescription: CDK6, along with its partner CDK4, are key players in cell cycle progression.\n  The complex has been implicated in a number of cancer types, and is the focus of\n  therapeutic research and development. One targeted therapy for CDK inhibition is\n  palbociclib, which may slow the growth of advanced stage breast cancers. It has\n  also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors\n  to PI3K inhibitors.\n	1	\N	\N	7e79be50-959f-47a3-ae10-31132b9a3f28	2015-05-20 18:10:05.07056
82	27	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 14\nname: PROMOTER HYPERMETHYLATION\ndescription: CDKN2A loss has been shown to be a significant event in a number of cancer\n  types. One mechanism by which this can occur is by hypermethylation of the CDKN2A\n  promoter region. While no targeted therapeutic has been engaged in clinical trials,\n  the prognostic impact has been studied by a number of meta-analyses. The prognostic\n  impact of promoter hypermethylation has been relatively ambiguous. Many studies\n  have shown significant p-values suggesting poorer prognostic outcomes for patients\n  with hypermethylation in colorectal, liver, and younger lung cancer patients. This\n  being said, there is still research to be done before this becomes a widely-accepted\n  prognostic indicator.\n	1	\N	\N	75656c79-a288-4839-b7eb-169990f9d3ee	2015-05-20 18:10:05.084955
192	137	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: L63V\ndescription: Activating mutations in DDR2, including L63V, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	d91ce135-5d35-44b9-82c2-066e4cb366f5	2015-05-20 18:10:06.776328
83	28	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 15\nname: N-TERMINAL FRAME SHIFT\ndescription: CEBPA N-terminal frame shift mutations that result in a premature stop\n  codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML).\n  CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3\n  mutations should also be assessed in CN-AML patients as concurrent mutations may\n  have prognostic implications.\n	1	\N	\N	05fe30f6-7d1e-49dd-8a82-131c48025c6d	2015-05-20 18:10:05.098259
84	29	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 15\nname: MUTATION\ndescription: CEBPA mutations are associated with cytogenetically normal acute myeloid\n  leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should\n  also be assessed in CN-AML patients as concurrent mutations may have prognostic\n  implications.\n	1	\N	\N	b29f4fbc-9d4f-428b-9a51-30bfef8e357e	2015-05-20 18:10:05.11539
85	30	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 33\nname: MEF2D-CSF1R\ndescription: MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia.\n  In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.\n	1	\N	\N	327e38b6-df49-4065-86d8-6465c91bb1be	2015-05-20 18:10:05.129992
86	31	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 16\nname: DNAJB1-PRKACA\ndescription: This fusion has been found to be very recurrent in the rare form of adolescent\n  liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion\n  was observed in 15/15 FL-HCC cases examined and functional studies found that the\n  fusion retained kinase activity. The presence of this fusion may be used as a diagnostic\n  marker for this rare tumor type.\n	1	\N	\N	13cbdbc4-28bb-458c-a94a-03fbbd6166f7	2015-05-20 18:10:05.145585
87	32	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 18\nname: R882\ndescription: DNMT3A R882 mutations are associated with cytogenetically normal acute\n  myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A\n  have largely been associated with poorer prognosis, however this is not consistent\n  across all studies. This may be a result of patient age or combining R882 and non-R882\n  mutations during analysis as studies have indicated independent mechanisms of action\n  and differential prognostic implications for these mutation types. One study that\n  independently analyzed R882 and non-R882 mutations showed R882 mutations were associated\n  with poorer prognosis than patients with wildtype and non-R882 mutations, but only\n  in older patients with AML.\n	1	\N	\N	e651988d-689e-4862-8308-0fdd25cf72ff	2015-05-20 18:10:05.161482
88	33	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 19\nname: L858R\ndescription: EGFR L858R has long been recognized as a functionally significant mutation\n  in cancer, and is one of the most prevalent single mutations in lung cancer. Best\n  described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity\n  to first and second generation TKI's like gefitinib and neratinib. NSCLC patients\n  with this mutation treated with TKI's show increased overall and progression-free\n  survival, as compared to chemotherapy alone. Third generation TKI's are currently\n  in clinical trials that specifically focus on mutant forms of EGFR, a few of which\n  have shown efficacy in treating patients that failed to respond to earlier generation\n  TKI therapies.\n	1	\N	\N	0b62fead-3b30-4d18-9144-d5986830d5f7	2015-05-20 18:10:05.177878
89	34	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 19\nname: T790M\ndescription: EGFR T790M was one of the very first mutations recognized to confer resistance\n  to targeted therapies. While successful in amplified EGFR, the efficacy of the first\n  and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients\n  harboring this mutation before treatment is notably lower. This lack of efficacy\n  can likely be to blame for the poorer prognosis for patients with this mutation\n  as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately\n  half of EGFR mutant tumors with acquired resistance to TKI inhibition have been\n  shown to harbor this mutation, implicating it as a mechanism of acquired therapy\n  resistence. The third generation TKI's are being developed with this resistance\n  problem in mind, and early stage experiments have shown some efficacy of these drugs\n  in previously resistant tumors with mutant EGFR.\n	1	\N	\N	79cf3e83-232b-4cf4-a6a4-8a7b36f822b5	2015-05-20 18:10:05.191317
90	35	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: D769H\ndescription: ERBB2 D769H was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	0a2cd41a-5048-4f77-a24d-467e33cd1a9d	2015-05-20 18:10:05.204809
91	36	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: D769Y\ndescription: ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	ae546f76-74e2-4e91-9d6a-01f0eca474ea	2015-05-20 18:10:05.21965
92	37	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: DEL 755-759\ndescription: ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants\n  to be functionally classified (Bose et al. 2012). This mutation was shown to be\n  an activating mutation in an in vitro assay. In the same paper, this mutation (along\n  with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been\n  shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may\n  show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase\n  inhibitors, which is the topic of current clinical trials and research.\n	1	\N	\N	6cb8df0d-c3ae-4e9c-b98d-e34bdbf41fbf	2015-05-20 18:10:05.233014
93	38	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: G309A\ndescription: ERBB2 G309A was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	dc9fb531-11f5-4861-835c-06cdd78cf18b	2015-05-20 18:10:05.248658
94	39	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: L755S\ndescription: ERBB2 L755S was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was not shown to be an activating mutation, unlike\n  many of the other variants queried. This mutation was also shown to confer resistance\n  to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.\n	1	\N	\N	99ce7867-b338-431e-b35e-5e233fcd07fd	2015-05-20 18:10:05.261652
95	40	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: L755W\ndescription: ERBB2 L755W was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	bef61a1e-e5e2-4046-9209-cef0d2981eea	2015-05-20 18:10:05.274671
96	41	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: P780INS\ndescription: ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally\n  classified (Bose et al. 2012). This mutation was shown to be an activating mutation\n  in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	b3722033-c86b-4151-8f43-674e541cb7c2	2015-05-20 18:10:05.288029
97	42	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: R678Q\ndescription: ERBB2 R678Q was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	7d5e0f8c-1f89-41af-8880-4afeb4ff3eb7	2015-05-20 18:10:05.300316
98	43	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: R896C\ndescription: ERBB2 R896C was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	eb14157d-7926-4f83-ae8e-2da1f6ec7cd3	2015-05-20 18:10:05.313076
99	44	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: V777L\ndescription: ERBB2 V777L was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	a22de1a1-ef9b-4080-827b-475171aea085	2015-05-20 18:10:05.340161
100	45	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 20\nname: V842I\ndescription: ERBB2 V842I was one of the first ERBB2 variants to be functionally classified\n  (Bose et al. 2012). This mutation was shown to be an activating mutation in an in\n  vitro assay. In the same paper, this mutation (along with other ERBB2 activating\n  mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to\n  the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating\n  mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the\n  topic of current clinical trials and research.\n	1	\N	\N	17c1dfa8-7446-4554-b0dc-03a47c8582ec	2015-05-20 18:10:05.352918
101	46	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 21\nname: L536Q\ndescription: ESR1 biology has become a central focus in breast cancer therapy. In\n  ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer\n  resistance to hormone therapy. This evidence has led to an increased use of targeted\n  sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of\n  these ligand binding domain mutations, and is commonly implicated in this hormone\n  resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant,\n  may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.\n	1	\N	\N	0e2b0467-7ee7-4082-9a80-b9866ae52a5a	2015-05-20 18:10:05.365505
102	47	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 21\nname: N538G\ndescription: ESR1 biology has become a central focus in breast cancer therapy. In\n  ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer\n  resistance to hormone therapy. This evidence has led to an increased use of targeted\n  sequencing of the estrogen receptor in breast and ovarian cancer. N538G is one of\n  these ligand binding domain  , and is commonly implicated in this hormone resistance.\n  Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial\n  in treating ESR1 mutant, hormone resistant breast cancers.\n	1	\N	\N	146f208e-b03b-4f53-be83-e3c1d4930613	2015-05-20 18:10:05.37865
103	48	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 21\nname: Y537C\ndescription: ESR1 biology has become a central focus in breast cancer therapy. In\n  ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer\n  resistance to hormone therapy. This evidence has led to an increased use of targeted\n  sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of\n  these ligand binding domain  , and is commonly implicated in this hormone resistance.\n  Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial\n  in treating ESR1 mutant, hormone resistant breast cancers.\n	1	\N	\N	ac6888ff-1eaf-438c-a5bc-c14e65071523	2015-05-20 18:10:05.39191
104	49	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 21\nname: Y537N\ndescription: ESR1 biology has become a central focus in breast cancer therapy. In\n  ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer\n  resistance to hormone therapy. This evidence has led to an increased use of targeted\n  sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of\n  these ligand binding domain  , and is commonly implicated in this hormone resistance.\n  Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial\n  in treating ESR1 mutant, hormone resistant breast cancers.\n	1	\N	\N	9828588a-8a66-4ec2-bcb7-63cb778063af	2015-05-20 18:10:05.405041
105	50	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 21\nname: Y537S\ndescription: ESR1 biology has become a central focus in breast cancer therapy. In\n  ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer\n  resistance to hormone therapy. This evidence has led to an increased use of targeted\n  sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of\n  these ligand binding domain  , and is commonly implicated in this hormone resistance.\n  Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial\n  in treating ESR1 mutant, hormone resistant breast cancers.\n	1	\N	\N	e2344d9b-5e90-4855-8ac4-72abf7392663	2015-05-20 18:10:05.420443
106	51	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 22\nname: FGFR2-MGEA5\ndescription: In a clinical sequencing program for advanced stage cancers, Wu et al\n  (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with\n  many different cancer types. These fusions were also found to retain oligomerization\n  capability, and result in enhanced cell proliferation. Cell lines harboring these\n  fusions were shown to respond to pazopanib. Additionally, tumor size reduction was\n  achieved by both ponatinib and pazopanib treatments administered separately in a\n  single patient with intrahepatic cholangiocarcinoma and this fusion. The authors\n  use these cases to highlight the need for enhanced clinical sequencing efforts.\n	1	\N	\N	a0ddeb9e-88b3-4cf1-955a-316fda77a2c5	2015-05-20 18:10:05.432934
107	52	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 23\nname: FGFR3-BAIAP2L1\ndescription: In a clinical sequencing program for advanced stage cancers, Wu et al\n  (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with\n  many different cancer types. These fusions were also found to retain oligomerization\n  capability, and result in enhanced cell proliferation. These fusions were shown\n  to respond to pazopanib. The authors use these cases to highlight the need for enhanced\n  clinical sequencing efforts.\n	1	\N	\N	780e8d63-5331-4fda-91d3-0b74cfa91a61	2015-05-20 18:10:05.447657
108	53	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 23\nname: FGFR3-TACC3\ndescription: In a clinical sequencing program for advanced stage cancers, Wu et al\n  (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with\n  many different cancer types. These fusions were also found to retain oligomerization\n  capability, and result in enhanced cell proliferation. These fusions were shown\n  to respond to pazopanib. The authors use these cases to highlight the need for enhanced\n  clinical sequencing efforts.\n	1	\N	\N	41ea215d-6718-4510-bf9a-9c8eb24aacd8	2015-05-20 18:10:05.461599
109	54	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 24\nname: ITD MUTATIONS\ndescription: FLT3-ITD (internal tandem duplications) frequently occur in patients\n  with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid\n  leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically\n  normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of\n  FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated\n  sequence resulting in an in-frame duplication event. The length of these duplications\n  can vary widely which may have prognostic consequences, but this has not been conclusively\n  determined. FLT3-ITD mutations overall have generally been associated with poor\n  prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the\n  prognosis associated with this variant.\n	1	\N	\N	65f57780-7666-4471-96ed-c12411285b5a	2015-05-20 18:10:05.476448
110	55	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 24\nname: TKD MUTATIONS\ndescription: FLT3 tyrosine kinase domain mutations (aka FLT3-TKD) are much less common\n  than FLT3-ITD (internal tandem duplication) mutations and may not confer the same\n  prognostic impact. Although the majority of mutations are point mutations effecting\n  D835 (most frequently D835Y), a small proportion involve an in-frame deletion of\n  I836. These mutations are within the activation loop of the second tyrosine kinase\n  domain of FLT3 and thought to result in constitutive activation of the receptor.\n	1	\N	\N	24994197-0fd5-4965-aef3-a86b662e3340	2015-05-20 18:10:05.494128
111	56	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 25\nname: EXPRESSION\ndescription: GATA2 misregulation has been observed in a number of hematologic malignancies,\n  as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using\n  the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung\n  cancer.\n	1	\N	\N	78a523af-4674-408f-8a0d-ea3dd237b949	2015-05-20 18:10:05.507697
112	57	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 26\nname: R132\ndescription: IDH1 R132 mutations have been observed in a number of cancer types, and\n  appear to behave quite differently in different environments. In myelodysplastic\n  syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown\n  to be associated with worse outcome and shorter overall survival. They have also\n  been linked to cytogenetically normal AML, an intermediate risk subtype of the disease.\n  However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown\n  better overall survival than patients with wild-type IDH1. Also in contrast to AML,\n  in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic\n  abnormalities, 1p and 19q deletions.\n	1	\N	\N	245d0840-ceda-4ea5-be4e-9541aa3c8374	2015-05-20 18:10:05.521925
113	58	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 26\nname: R132C\ndescription: IDH1 R132 mutations have been observed in a number of cancer types, and\n  appear to behave quite differently in different environments. In myelodysplastic\n  syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown\n  to be associated with worse outcome and shorter overall survival. They have also\n  been linked to cytogenetically normal AML, an intermediate risk subtype of the disease.\n  However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown\n  better overall survival than patients with wild-type IDH1. Also in contrast to AML,\n  in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic\n  abnormalities, 1p and 19q deletions.\n	1	\N	\N	9ade7fc3-f466-4e5f-a5f7-a70231ced1b5	2015-05-20 18:10:05.53523
114	59	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 26\nname: R132H\ndescription: IDH1 R132 mutations have been observed in a number of cancer types, and\n  appear to behave quite differently in different environments. In myelodysplastic\n  syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown\n  to be associated with worse outcome and shorter overall survival. They have also\n  been linked to cytogenetically normal AML, an intermediate risk subtype of the disease.\n  However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown\n  better overall survival than patients with wild-type IDH1. Also in contrast to AML,\n  in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic\n  abnormalities, 1p and 19q deletions.\n	1	\N	\N	26d62577-0c0c-485e-a61a-32a2d967fea2	2015-05-20 18:10:05.551843
115	60	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 26\nname: R132L\ndescription: IDH1 R132 mutations have been observed in a number of cancer types, and\n  appear to behave quite differently in different environments. In myelodysplastic\n  syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown\n  to be associated with worse outcome and shorter overall survival. They have also\n  been linked to cytogenetically normal AML, an intermediate risk subtype of the disease.\n  However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown\n  better overall survival than patients with wild-type IDH1. Also in contrast to AML,\n  in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic\n  abnormalities, 1p and 19q deletions.\n	1	\N	\N	f934f2cb-15fb-497d-bbfe-663041c0300c	2015-05-20 18:10:05.563998
116	61	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 27\nname: R140Q/L\ndescription: IDH2 mutations have been observed in a number of hematologic malignancies.\n  In acute myeloid leukemia, the R140Q/L mutants have shown improved overall survival\n  as compared to their wild-type counterparts. In myelodysplastic syndromes, however,\n  no prognostic link was discovered between IDH2 mutation status and overall survival.\n	1	\N	\N	9bd281a9-98aa-4e43-90d4-a346a346f638	2015-05-20 18:10:05.576254
117	62	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 27\nname: R172K\ndescription: IDH2 mutations have been observed in a number of hematologic malignancies.\n  In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis\n  and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic\n  syndromes, studies did not find a prognostic association between this variant and\n  patient outcomes.\n	1	\N	\N	d61b089f-635e-46c9-97b4-167a8578af58	2015-05-20 18:10:05.590654
118	63	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 28\nname: V617F\ndescription: JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases,\n  occuring in around half of all MPD's. While less associated with cancer, when it\n  is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The\n  V617F mutation is an activating mutation, resulting in increased kinase activity.\n  The mutation seems to be restricted to hematologic malignancies. Treatment of JAK\n  mutant diseases with ruxolitinib has seen some clinical success.\n	1	\N	\N	13828257-eb18-4747-bf3b-13f7393f50c8	2015-05-20 18:10:05.603929
119	64	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: D816V\ndescription: KIT D816V is a mutation observed in acute myeloid leukemia (AML). This\n  variant has been linked to poorer prognosis and worse outcome in AML patients.\n	1	\N	\N	ac080229-dee9-4db0-ab10-6cb64c6d2994	2015-05-20 18:10:05.617735
120	65	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: EXON 11 MUTATIONS\ndescription: c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are\n  very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis\n  than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity\n  to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients\n  treated with the drug in the first year.\n	1	\N	\N	1f1e8d84-57db-47ad-bf17-34599e82af54	2015-05-20 18:10:05.632408
121	66	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: INTERNAL DUPLICATION\ndescription: c-KIT internal duplications have been observed in exon 11, within the\n  juxtamembrane domain. In a case study of an anal melanoma patient harboring this\n  event, imatinib confered marked response. Also, cells harboring exon 11 mutations\n  have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better\n  prognosis to patients treated with the drug in the first year.\n	1	\N	\N	e36b5be2-d42a-42ed-9691-588160158c30	2015-05-20 18:10:05.650744
122	67	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: EXON 13 MUTATIONS\ndescription: c-KIT exon 13 mutations are relatively rare compared to other c-KIT mutations.\n  These mutations lie within the tyrosine kinase 1 domain, and are found primarily\n  in melanoma and gastrointestinal stromal tumors. Cell lines harboring these mutations\n  show sensitivity to imatinib and sunitinib treatment. However, only imatinib has\n  seen use in clinical settings to date, with sunitinib entering trials in imatinib-resistant\n  cases.\n	1	\N	\N	bea3bacc-f3c9-4cb4-93c6-2ef8f1841f52	2015-05-20 18:10:05.663676
123	68	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: EXON 14 MUTATIONS\ndescription: c-KIT exon 14 mutations lie within the tyrosine kinase domain of the\n  protein. While relatively rare in primary gastrointestinal tumors, they are notably\n  more prevalent in refractory disease, suggesting a role in imatinib resistance.\n  Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.\n	1	\N	\N	65d96468-0743-45f5-ba85-afcb1141bfeb	2015-05-20 18:10:05.676511
124	69	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: EXON 17 MUTATIONS\ndescription: c-KIT exon 17 mutations lie within the TK2 domain, containing the activation\n  loop of the protein. In cell lines, mutations within this domain have been shown\n  to be sensitive to imatinib. However, in double KIT mutants in which the exon 17\n  mutation is a secondary mutation, cell lines have shown resistance to both imatinib\n  and sunitinib.\n	1	\N	\N	70e16793-3c12-4dec-acd5-d9a5c1584283	2015-05-20 18:10:05.689794
125	70	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: EXON 9 MUTATIONS\ndescription: c-KIT exon 9 mutations lie within the dimerization motif of the protein.\n  Relative to other KIT mutations, exon 9 mutations have been associated with better\n  overall survival. In exon 9 mutants, imatinib has shown efficacy both in vitro and\n  in vivo.\n	1	\N	\N	ca90c9ee-6ed0-4051-b554-d51e8d1c52db	2015-05-20 18:10:05.705169
126	71	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: L576P\ndescription: KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain.\n  It is one of the most recurrent KIT mutations in melanoma, and both in vitro and\n  in vivo studies have shown sensitivity to imatinib.\n	1	\N	\N	5df88565-dfc5-447b-99e3-3dd77d709fa1	2015-05-20 18:10:05.720593
127	72	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: V654A\ndescription: KIT V654A is an exon 13 mutation that lies within the tyrosine kinase\n  1 domain of the protein. It has been shown to be an activating mutation by in vitro\n  studies. This mutation is associated with imatinib resistance in melanoma patients.\n  However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have\n  seen success in acheiving tumor response.\n	1	\N	\N	95963442-e01e-41f6-b06a-3b8bf86da621	2015-05-20 18:10:05.73517
128	73	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: EXON 1 MUTATIONS\ndescription: A study by Livre et al in 2006 showed that colorectal cancer patients\n  with KRAS exon 1 mutations had low cetuximab response rates.\n	1	\N	\N	3418785b-f59b-4de4-9410-2f57aba04745	2015-05-20 18:10:05.757937
129	74	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: EXON 2 MUTATIONS\ndescription: In a study by Pao et al in 2005, non-small cell lung cancer patients\n  harboring KRAS exon 2 mutations were associated with resistance to the EGFR inhibitors\n  gefinitib and erlotinib.\n	1	\N	\N	8cff4324-85b3-431f-be31-c746b5a07bf9	2015-05-20 18:10:05.772357
130	75	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12\ndescription: While the KRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation,\n  along with the mutations affecting the neighboring G13 position, may result in a\n  less responsive tumor when treated with first-generation TKI's like gefitinib.\n	1	\N	\N	da9759de-d11a-4cfc-99e2-573de613195f	2015-05-20 18:10:05.786292
131	76	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12/G13\ndescription: While the KRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation\n  may result in a less responsive tumor when treated with first-generation TKI's like\n  gefitinib.\n	1	\N	\N	b598df3b-cfbb-42ee-b6bf-9fb32a33ca93	2015-05-20 18:10:05.801008
132	77	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12C\ndescription: While the KRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation,\n  along with the mutations affecting the neighboring G13 position, may result in a\n  less responsive tumor when treated with first-generation TKI's like gefitinib.\n	1	\N	\N	04496816-af6c-4c21-84b5-bb654229cb6b	2015-05-20 18:10:05.819971
133	78	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12D\ndescription: While the KRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation,\n  along with the mutations affecting the neighboring G13 position, may result in a\n  less responsive tumor when treated with first-generation TKI's like gefitinib.\n	1	\N	\N	988d66e6-5a81-4060-89f7-59867b19366e	2015-05-20 18:10:05.835385
134	79	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G13\ndescription: While the KRAS G13 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation,\n  along with the mutations affecting the neighboring G12 position, may result in a\n  less responsive tumor when treated with first-generation TKI's like gefitinib.\n	1	\N	\N	4a7e1460-1d19-4e60-93c9-0a460ad9aff7	2015-05-20 18:10:05.851884
135	80	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G13D\ndescription: While the KRAS G13 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated. Often associated with tumors that\n  are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients\n  with this mutation seems to be worse than the KRAS wild-type cohort. This mutation,\n  along with the mutations affecting the neighboring G12 position, may result in a\n  less responsive tumor when treated with first-generation TKI's like gefitinib.\n	1	\N	\N	72db4a4b-9550-4563-8408-b9d99b39b89a	2015-05-20 18:10:05.864826
136	81	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 31\nname: P124S\ndescription: MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder\n  and colon cancer to a lesser degree. The P124S mutation has been shown to contribute\n  to AZD6244 resistance in melanoma cell lines, but considerably less so than its\n  Q56P counterpart.\n	1	\N	\N	0bb1deac-bde8-44ec-8807-2bbb6185abc8	2015-05-20 18:10:05.878106
137	82	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 31\nname: Q56P\ndescription: MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This\n  mutation has been shown to confer considerable resistance to AZD6244 treatment of\n  melanoma cell lines.\n	1	\N	\N	434acaf5-82cb-4ab7-acab-302065f9f99c	2015-05-20 18:10:05.90524
138	83	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 32\nname: MEF2D-CSF1R\ndescription: MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia.\n  In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.\n	1	\N	\N	840e61b9-eb4f-4de1-8809-a4dedfc89489	2015-05-20 18:10:05.918882
139	84	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 34\nname: PROMOTER METHYLATION\ndescription: MGMT promoter methylation has been observed to impact tumor progression\n  in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating\n  agent carmustine has shown efficacy. In patients lacking methylation, combining\n  carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more\n  experiments are required. Clinical trials have also shown selective sensitivity\n  of promoter methylation-positive patients to temozolomide, making a case for wider\n  methylation screening in GBM patients.\n	1	\N	\N	336f1655-fabd-4345-8244-b6ebcfb15f8d	2015-05-20 18:10:05.931294
140	85	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 35\nname: EXON 12 MUTATIONS\ndescription: NPM1 exon 12 mutations are frequently identified in patients with cytogenetically\n  normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status\n  should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon\n  12 mutations have been identified as a predictor of good prognostic outcomes in\n  the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively\n  analyzed in the context of a number of therapies including variable results following\n  ATRA treatment as well as improved response to high-dose daunorubicin or valproic\n  acid. Additionally, multiple groups have shown increased surface expression of CD33\n  associated with NPM1 mutation, suggesting these patients may respond to anti-CD33\n  therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response\n  to induction therapy.\n	1	\N	\N	20c95e45-05bd-45c3-9dc9-c4b33c1e8dcb	2015-05-20 18:10:05.949564
141	86	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 35\nname: W288FS\ndescription: NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most\n  common NPM1 mutation identified in acute myeloid leukemia. This mutation results\n  in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response\n  to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation,\n  it is generally grouped with other exon 12 mutations for patient analysis (see NPM1\n  Exon 12 variants for more information).\n	1	\N	\N	9daffba7-e074-4c98-a065-8d82990aa4dc	2015-05-20 18:10:05.962398
142	87	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: EXON 1 MUTATIONS\ndescription: NRAS exon 1 mutations were studied by Jakob et al in 2012 and were shown\n  to be correlated with poorer overall survival relative to wild-type NRAS in melanoma\n  patients.\n	1	\N	\N	3d8c272d-1e24-4fc4-ae70-6d16d7c3fcae	2015-05-20 18:10:05.978394
143	88	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: EXON 2 MUTATIONS\ndescription: NRAS exon 2 mutations have been shown to be correlated with poorer overall\n  survival in melanoma patients and colorectal cancer patients, however no prognostic\n  impact was seen in acute myeloid leukemia patients.\n	1	\N	\N	6a49f705-320f-407a-b1ed-5a68fb72ee36	2015-05-20 18:10:05.992486
144	89	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: EXON 3 MUTATIONS\ndescription: In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS\n  exon 3 and 4 mutations were correlated with poorer overall survival.\n	1	\N	\N	967354a6-9010-4568-87ad-fcab730c4c41	2015-05-20 18:10:06.005655
145	90	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: EXON 4 MUTATIONS\ndescription: In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS\n  exon 3 and 4 mutations were correlated with poorer overall survival.\n	1	\N	\N	80cc55cf-9ced-400a-9aef-0d28714a26a9	2015-05-20 18:10:06.018841
146	91	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: G12\ndescription: While the NRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated.\n	1	\N	\N	9721bda0-d434-483c-b1b7-1f5854a8eee7	2015-05-20 18:10:06.032795
147	92	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: G13D\ndescription: While the NRAS G12 region is a widely studied recurrent region in cancer,\n  its impact on clinical action is still debated.\n	1	\N	\N	8274db03-acbd-4111-9f2b-751ef711af22	2015-05-20 18:10:06.050374
148	93	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: Q61\ndescription: NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal\n  stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations\n  at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide.\n  However, in colorectal cancer patients, mutations at this locus have been shown\n  to confer resistance to cetuximab. The prognostic impact of mutations at this locus\n  is currently under study.\n	1	\N	\N	c37734bd-a221-4786-9b62-66e83270cfd7	2015-05-20 18:10:06.065685
149	94	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: Q61L\ndescription: NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal\n  stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at\n  this locus responded to treatment with the akylating agent temozolomide. However,\n  in colorectal cancer patients, mutations at this locus have been shown to confer\n  resistance to cetuximab. The prognostic impact of mutations at this locus is currently\n  under study.\n	1	\N	\N	232382cb-2365-4a52-9dcb-21b3e2236b6b	2015-05-20 18:10:06.079091
150	95	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 36\nname: Q61R\ndescription: NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal\n  stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at\n  this locus responded to treatment with the akylating agent temozolomide. However,\n  in colorectal cancer patients, mutations at this locus have been shown to confer\n  resistance to cetuximab. The prognostic impact of mutations at this locus is currently\n  under study.\n	1	\N	\N	b8d5bf2e-37ad-4028-bdbe-c92df114c99b	2015-05-20 18:10:06.092865
151	96	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: D842I\ndescription: PDGFRA D842 mutations are characterized broadly as imatinib resistance\n  mutations. This is most well characterized in gastrointestinal stromal tumors, but\n  other cell lines containing these mutations have been shown to be resistant as well.\n  In imatinib resistant cell lines, a number of other therapeutics have demonstrated\n  efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).\n	1	\N	\N	f2773d80-b7ae-4310-af9c-e7c7ee06ec05	2015-05-20 18:10:06.105346
152	97	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: D842V\ndescription: PDGFRA D842 mutations are characterized broadly as imatinib resistance\n  mutations. This is most well characterized in gastrointestinal stromal tumors, but\n  other cell lines containing these mutations have been shown to be resistant as well.\n  In imatinib resistant cell lines, a number of other therapeutics have demonstrated\n  efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).\n	1	\N	\N	0866e7ba-161d-48f2-83be-fe3aadf3cf8a	2015-05-20 18:10:06.118291
153	98	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: D842Y\ndescription: PDGFRA D842 mutations are characterized broadly as imatinib resistance\n  mutations. This is most well characterized in gastrointestinal stromal tumors, but\n  other cell lines containing these mutations have been shown to be resistant as well.\n  In imatinib resistant cell lines, a number of other therapeutics have demonstrated\n  efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).\n	1	\N	\N	717b0183-a7b3-41aa-849f-2bd4dd312a47	2015-05-20 18:10:06.131714
154	99	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: DEL I843\ndescription: PDGFRA D842 mutations are characterized broadly as imatinib resistance\n  mutations. This is most well characterized in gastrointestinal stromal tumors, but\n  other cell lines containing these mutations have been shown to be resistant as well.\n  In imatinib resistant cell lines, a number of other therapeutics have demonstrated\n  efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).\n	1	\N	\N	bdd417ff-5053-432d-babd-3811a675c42e	2015-05-20 18:10:06.147756
155	100	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: DI842-843IM\ndescription: PDGFRA D842 mutations are characterized broadly as imatinib resistance\n  mutations. This is most well characterized in gastrointestinal stromal tumors, but\n  other cell lines containing these mutations have been shown to be resistant as well.\n  In imatinib resistant cell lines, a number of other therapeutics have demonstrated\n  efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).\n	1	\N	\N	59899a9f-a796-422b-80f1-85e2b686add7	2015-05-20 18:10:06.160091
156	101	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 37\nname: E542K\ndescription: PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in\n  breast cancer, and are highly recurrent mutations in many other cancer types. E545K,\n  and possibly the other mutations in the E545 region, may present patients with a\n  poorer prognosis than patients with either patients with other PIK3CA variant or\n  wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer\n  resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies\n  for variants in PIK3CA are still in early clinical trial phases.\n	1	\N	\N	10ccfb01-9c2e-407e-9c25-713b53f7b690	2015-05-20 18:10:06.172465
157	102	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 37\nname: E545K\ndescription: PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in\n  breast cancer, and are highly recurrent mutations in many other cancer types. E545K,\n  and possibly the other mutations in the E545 region, may present patients with a\n  poorer prognosis than patients with either patients with other PIK3CA variant or\n  wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer\n  resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies\n  for variants in PIK3CA are still in early clinical trial phases.\n	1	\N	\N	13bf504a-ae5c-40f1-8603-eadc3e78b661	2015-05-20 18:10:06.188302
158	103	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 37\nname: EXON 20 MUTATIONS\ndescription: PIK3CA H1047R is one of the most recurrent mutations in cancer, especially\n  breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation.\n  Meta-analyses have shown that patients harboring this mutation may have worse overall\n  survival, but other studies have shown no difference between H1047R and other PIK3CA\n  mutants from a prognostic standpoint. While very prevalent, targeted therapies for\n  this particular mutation are still in early clinical trial phases.\n	1	\N	\N	cf760c29-5fd0-4ce4-914a-d4f892cb5203	2015-05-20 18:10:06.2017
159	104	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 37\nname: EXON 9 MUTATIONS\ndescription: PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in\n  breast cancer, and are highly recurrent mutations in many other cancer types. E545K,\n  and possibly the other mutations in the E545 region, may present patients with a\n  poorer prognosis than patients with either patients with other PIK3CA variant or\n  wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer\n  resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies\n  for variants in PIK3CA are still in early clinical trial phases.\n	1	\N	\N	d2943487-9f97-4648-8142-7b192bbd4697	2015-05-20 18:10:06.214359
160	105	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 37\nname: H1047R\ndescription: PIK3CA H1047R is one of the most recurrent mutations in cancer, especially\n  breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation.\n  Meta-analyses have shown that patients harboring this mutation may have worse overall\n  survival, but other studies have shown no difference between H1047R and other PIK3CA\n  mutants from a prognostic standpoint. While very prevalent, targeted therapies for\n  this particular mutation are still in early clinical trial phases.\n	1	\N	\N	1b777b99-0b5e-4ffd-8157-db8d04238e59	2015-05-20 18:10:06.226809
161	106	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 39\nname: PML-RARA\ndescription: The PML-RARa fusion is seen as a diagnostic event in acute promyelocytic\n  leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA\n  in APL patients harboring the PML-RARa fusion. Recent interest has been shown in\n  combining ATRA and arsenic trioxide for treating these patients, and early results\n  seem promising.\n	1	\N	\N	52f48267-4930-41b6-926b-047b6055fb47	2015-05-20 18:10:06.241218
162	107	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 17\nname: DNAJB1-PRKACA\ndescription: This fusion has been found to be very recurrent in a rare form of adolescent\n  liver cancer, hepatocellular fibrolamellar carcinoma. In a 2014 study, authors found\n  Honeyman et al observed this fusion in all 15 of the FL-HCC cases they examined,\n  and functional studies found that the fusion retained kinase activity. The presence\n  of this fusion may be used as a diagnostic marker for this rare tumor type.\n	1	\N	\N	18d966f3-86c1-4d3f-803b-33f8526b98c6	2015-05-20 18:10:06.256891
163	108	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 41\nname: R233*\ndescription: PTEN R233* has been shown to be a loss of function mutation, and PTEN\n  loss has been the subject of considerable research in breast cancer. PTEN loss may\n  sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data\n  to support that PTEN loss is both associated with poorer prognosis, and no change\n  in prognosis.\n	1	\N	\N	8b748991-2164-401e-b135-bc265c7ccdb1	2015-05-20 18:10:06.270853
164	109	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 40\nname: PML-RARA\ndescription: The PML-RARa fusion is seen as a diagnostic event in acute promyelocytic\n  leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA\n  in APL patients harboring the PML-RARa fusion. Recent interest has been shown in\n  combining ATRA and Arsenic Trioxide for treating these patients, and early results\n  seem promising.\n	1	\N	\N	c4809538-2e71-4762-ba0e-fb9d331a5cd1	2015-05-20 18:10:06.286808
165	110	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 42\nname: C634W\ndescription: RET C639W has been implicated as an alternate mechanism of activating\n  RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting\n  agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity.\n  Data suggests however, that the C639W mutation may lead to drug resistance, especially\n  against the VEGFR-inhibitor motesanib.\n	1	\N	\N	b0d6d387-35d8-435c-bd56-9e0af7007800	2015-05-20 18:10:06.303132
166	111	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 42\nname: M918T\ndescription: RET M819T is the most common somatically acquired mutation in medullary\n  thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents,\n  promiscuous kinase inhibitors have seen some success in treating RET overactivity.\n  Data suggests however, that the M918T mutation may lead to drug resistance, especially\n  against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T\n  leads to more aggressive MTC with a poorer prognosis.\n	1	\N	\N	c779f18f-3fcf-4b2e-9075-0c1d31633f7b	2015-05-20 18:10:06.31811
167	112	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 44\nname: K666N\ndescription: SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic\n  leukemias, and more recently, breast cancer. This somatic mutation has been linked\n  to better overall outcome and event-free survival in MDS patients.\n	1	\N	\N	6c383330-9c9f-4a39-b97d-9a712f83d318	2015-05-20 18:10:06.332329
168	113	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 44\nname: K700E\ndescription: SF3B1 K700E is a variant found in myelodysplastic syndromes, chronic\n  leukemias, and more recently, breast cancer. This somatic mutation has been linked\n  to better overall outcome and event-free survival in MDS patients. Additionally,\n  these mutations are the most common SF3B1 mutation observed in MDS and highly associated\n  with subtypes of MDS that are defined by ringed sideroblasts.\n	1	\N	\N	d2e5eab8-58b7-473b-b469-3a1f2f5a66ee	2015-05-20 18:10:06.347971
169	114	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R175H\ndescription: While loss-of-function events in TP53 are very common in cancer, the\n  R175H variant seems not only to result in loss of tumor-suppression, but also acts\n  as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell\n  lines harboring this mutant is also more responsive to treatment with doxorubicin\n  than its wild-type counterparts. While the prognostic impact of individual TP53\n  mutations is influenced by the cohort being studied, it has been shown that the\n  R175H mutation is correlated with worse overall survival than wild-type TP53, but\n  is not as detrimental as the R248W variant.\n	1	\N	\N	3facdbcf-b988-467c-94f9-d395a9eb1677	2015-05-20 18:10:06.360408
170	115	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R248Q\ndescription: While loss-of-function events in TP53 are very common in cancer, the\n  R248 variants seem not only to result in loss of tumor-suppression, but also act\n  as a gain-of-function mutation that can promote tumorigenesis in mouse models. This\n  mutant is also more responsive to treatment with doxorubicin than its wild-type\n  counterparts. While the prognostic impact of individual TP53 mutations is influenced\n  by the cohort being studied, R248 mutations have been shown to confer worse overall\n  survival. The R248Q mutation has also shown an increased invasive behavior in cell\n  lines. This is specific to the 248Q variant.\n	1	\N	\N	d224bb70-b6d8-4553-b84a-6a4f9e367c6a	2015-05-20 18:10:06.37432
171	116	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R248W\ndescription: While loss-of-function events in TP53 are very common in cancer, the\n  R248 variants seem not only to result in loss of tumor-suppression, but also act\n  as a gain-of-function mutation that can promote tumorigenesis in mouse models. This\n  mutant is also more responsive to treatment with doxorubicin than its wild-type\n  counterparts. While the prognostic impact of individual TP53 mutations is influenced\n  by the cohort being studied, R248 mutations have been shown to confer worse overall\n  survival.\n	1	\N	\N	4b4fda1d-e4c8-4e71-91b2-b4ffbacbdd68	2015-05-20 18:10:06.38843
172	117	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R249T\ndescription: This mutant is also more responsive to treatment with doxorubicin than\n  its wild-type counterparts. While the prognostic impact of individual TP53 mutations\n  is influenced by the cohort being studied, it has been suggested that the R249 mutants\n  have been correlated with worse overall survival in breast cancer patients when\n  compared to wild-type.\n	1	\N	\N	21e3a9d4-b38f-4578-ba05-bccfdc318974	2015-05-20 18:10:06.403736
173	118	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R249W\ndescription: This mutant is also more responsive to treatment with doxorubicin than\n  its wild-type counterparts. While the prognostic impact of individual TP53 mutations\n  is influenced by the cohort being studied, it has been suggested that the R249 mutants\n  have been correlated with worse overall survival in breast cancer patients when\n  compared to wild-type.\n	1	\N	\N	7473dc21-c301-42d0-a1a9-f648be808de1	2015-05-20 18:10:06.416302
174	119	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R273C\ndescription: While loss-of-function events in TP53 are very common in cancer, the\n  R273 variants seem not only to result in loss of tumor-suppression, but also act\n  as a gain-of-function mutation that can promote tumorigenesis in mouse models. This\n  mutant is also more responsive to treatment with doxorubicin than its wild-type\n  counterparts. While the prognostic impact of individual TP53 mutations is influenced\n  by the cohort being studied, it has been suggested that the R273 mutants have been\n  correlated with worse overall survival in breast cancer patients when compared to\n  wild-type.\n	1	\N	\N	50207e15-c72b-49b9-83bd-542ff36765c0	2015-05-20 18:10:06.466982
193	138	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: L239R\ndescription: Activating mutations in DDR2, including L239R, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	ee4dd54f-1d38-427b-8b94-3b41b9db7632	2015-05-20 18:10:06.794804
175	120	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: R273H\ndescription: While loss-of-function events in TP53 are very common in cancer, the\n  R273 variants seem not only to result in loss of tumor-suppression, but also act\n  as a gain-of-function mutation that can promote tumorigenesis in mouse models. This\n  mutant is also more responsive to treatment with doxorubicin than its wild-type\n  counterparts. While the prognostic impact of individual TP53 mutations is influenced\n  by the cohort being studied, it has been suggested that the R273 mutants have been\n  correlated with worse overall survival in breast cancer patients when compared to\n  wild-type.\n	1	\N	\N	9636da3b-605a-43af-b81f-89acdfbf48cb	2015-05-20 18:10:06.483411
176	121	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 45\nname: V173G/A\ndescription: While the prognostic impact of individual TP53 mutations is influenced\n  by the cohort being studied, it has been suggested that the R249 mutants have been\n  correlated with worse overall survival in breast cancer patients when compared to\n  wild-type.\n	1	\N	\N	f976dffc-281d-412a-a92a-81dcb44fdc81	2015-05-20 18:10:06.499423
177	122	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 46\nname: FRAMESHIFT TRUNCATION\ndescription: In a small cohort study of bladder cancer, patients with TSC1 mutations\n  showed better responses to and increased treatment duration tolerance with the mTOR\n  inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with\n  TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2\n  wildtype cells.\n	1	\N	\N	fd99026d-e50d-4640-901d-06b98405fd7f	2015-05-20 18:10:06.517621
178	123	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 46\nname: LOSS-OF-FUNCTION\ndescription: In a small cohort study of bladder cancer, patients with TSC1 mutations\n  showed better responses to and increased treatment duration tolerance with the mTOR\n  inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with\n  TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2\n  wildtype cells.\n	1	\N	\N	f226084b-6743-468d-848f-fb2ebdfff1d2	2015-05-20 18:10:06.536332
179	124	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 47\nname: LOSS-OF-FUNCTION\ndescription: In a small cohort study of bladder cancer, patients with TSC1 mutations\n  showed better responses to and increased treatment duration tolerance with the mTOR\n  inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with\n  TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2\n  wildtype cells.\n	1	\N	\N	56ade673-a0ce-4e0a-9526-7f2d54acc1a8	2015-05-20 18:10:06.555392
180	125	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 48\nname: Q157P/R\ndescription: U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid\n  leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation\n  is less common than the S34F mutation, occurs in the second zinc finger domain of\n  U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations\n  on overall survival in MDS has been debated, however, patients with U2AF1 mutations\n  were shown to be at an increased risk of transformation to secondary AML. The presence\n  of this mutation was not associated with a specific prognostic outcome in AML when\n  compared to U2AF1 wildtype patients.\n	1	\N	\N	28978801-6671-43ce-9075-a87999fa0f44	2015-05-20 18:10:06.575119
181	126	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 48\nname: S34Y/F\ndescription: U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid\n  leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation\n  is the most commonly identified variant in MDS, occurs in the first zinc finger\n  domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1\n  mutations on overall survival in MDS has been debated, however, patients with U2AF1\n  mutations were shown to be at an increased risk of transformation to secondary AML.\n  The presence of this mutation was not associated with a specific prognostic outcome\n  in AML when compared to U2AF1 wildtype patients.\n	1	\N	\N	15724429-09b5-4c94-9bee-e3912d0ff20d	2015-05-20 18:10:06.591238
182	127	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 49\nname: EXON 7 MUTATIONS\ndescription: WT1 exon 7 mutations have been shown to be recurrent in acute myeloid\n  leukemia. Many sources have examined the prognostic impact of these, agreeing that\n  the mutant exon 7 cohort is correlated with worse overall survival and a number\n  of poor prognistic outcomes. This may be the result of an overall poor response\n  to chemotherapy from WT1 mutant tumors.\n	1	\N	\N	ed2a9505-27f1-4e06-9fb7-86c304ca63af	2015-05-20 18:10:06.606518
183	128	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 49\nname: EXON 9 MUTATIONS\ndescription: WT1 exon 9 mutations have been shown to be recurrent in acute myeloid\n  leukemia, although at a less frequent rate than their exon 7 counterparts. Many\n  sources have examined the prognostic impact of these, agreeing that the mutant exon\n  9 cohort is correlated with worse overall survival and a number of poor prognistic\n  outcomes. This may be the result of an overall poor response to chemotherapy from\n  WT1 mutant tumors.\n	1	\N	\N	8a89128a-990b-42cd-969b-aa9ca2a7bd5b	2015-05-20 18:10:06.62186
184	129	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 6\nname: LOSS-OF-FUNCTION\ndescription: BRCA1 loss of function mutations have been shown to increase risk of\n  breast and ovarian cancer in those carrying the allele in their germline. Treating\n  BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant\n  response.\n	1	\N	\N	c95fec03-78bf-4699-a478-0a0539fee713	2015-05-20 18:10:06.637104
185	130	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 7\nname: LOSS-OF-FUNCTION\ndescription: BRCA2 loss of function mutations have been shown to increase risk of\n  breast and ovarian cancer in those carrying the allele in their germline. Treating\n  BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant\n  response.\n	1	\N	\N	ae0d177d-9f2c-4dcf-a979-fd6c50e166cd	2015-05-20 18:10:06.65465
186	131	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 19\nname: EXON 19 DELETION\ndescription: Deletions within exon 19 of EGFR are most common in lung cancer. These\n  deletions, in non-small cell lung cancer, have been shown to be sensitive to the\n  EGFR tyrosine kinase inhibitors gefitinib and erlotinib. There is also data to suggest\n  that this event is a good prognostic marker in lung adenocarcinoma.\n	1	\N	\N	1e22b078-02a9-4ff6-9589-04dc7b6c7eca	2015-05-20 18:10:06.67307
187	132	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 19\nname: G719S\ndescription: While not as recurrent as the L858R mutation, EGFR G719S has also been\n  shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity\n  to the tyrosine kinase inhibitors gefitinib and erlotinib.\n	1	\N	\N	cc1074c6-8124-4cb0-8c3e-7034200fe56b	2015-05-20 18:10:06.689709
188	133	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 51\nname: D1643H\ndescription: Activating mutations in NOTCH1, including D1643H, have been shown to\n  be poor prognostic markers in lung cancer.\n	1	\N	\N	8bfc825c-653f-430b-83b9-5924251df62c	2015-05-20 18:10:06.706654
189	134	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 51\nname: R2328W\ndescription: Activating mutations in NOTCH1, including R2328W, have been shown to\n  be poor prognostic markers in lung cancer.\n	1	\N	\N	75a64a48-31b3-45a3-a79a-b19104956073	2015-05-20 18:10:06.722565
190	135	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 51\nname: V2444FS\ndescription: Activating mutations in NOTCH1, including a frameshift insertion at V2444,\n  have been shown to be poor prognostic markers in lung cancer.\n	1	\N	\N	04af879b-5cbb-4875-865d-843c4da650e0	2015-05-20 18:10:06.738369
196	141	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: I638F\ndescription: DDR2 I638F has been shown to be a loss of function mutation, but also\n  confers sensitivity to dasatinib in cell lines.\n	1	\N	\N	0741d828-4ff3-42ba-b811-44d3522eb1c9	2015-05-20 18:10:06.851435
197	142	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: G774V\ndescription: Activating mutations in DDR2, including G774V, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	1ac79b91-b6be-4d76-9140-f0ba11edaa64	2015-05-20 18:10:06.868306
198	143	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 52\nname: S768R\ndescription: Activating mutations in DDR2, including S768R, has been shown to be sensitive\n  to dasatinib in cell lines.\n	1	\N	\N	1b7ec133-9c72-47ae-9e0b-b5fd1b6a3547	2015-05-20 18:10:06.886335
199	144	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 53\nname: AMPLIFICATION\ndescription: MET amplification, like EGFR T790M, has been shown to be capable of driving\n  acquired resistance to dacomitinib in patients with lung adenocarcinoma.\n	1	\N	\N	acd5d296-693a-482f-a8e1-cc5cdf58deee	2015-05-20 18:10:06.904599
200	145	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12V\ndescription: KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired\n  resistance to tyrosine kinase inhibitors in lung adenocarcinoma.\n	1	\N	\N	22affbd6-3e17-4a21-9535-6ca81290f80e	2015-05-20 18:10:06.921772
201	146	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 30\nname: G12A\ndescription: KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired\n  resistance to tyrosine kinase inhibitors in lung adenocarcinoma.\n	1	\N	\N	00f19c92-4218-4a04-bba4-80e4238f8988	2015-05-20 18:10:06.938056
202	147	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 50\nname: Q2223K\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	30de17eb-2c1c-4bae-a2b0-b4cc0c34dc2f	2015-05-20 18:10:06.956401
203	148	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: G853D\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	7d20bf64-f72f-4e04-90c9-db0e1b680a2f	2015-05-20 18:10:06.975141
204	149	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 5\nname: G469L\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	ccb78670-ac1a-4677-a904-22fc46156c75	2015-05-20 18:10:06.991041
205	150	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 29\nname: K642E\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	d797350d-2f0f-4777-89f4-e7fa88c9dd64	2015-05-20 18:10:07.008787
206	151	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 54\nname: D189Y\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	fbd38b6e-dbe0-4bb8-bd0d-12ed24894e31	2015-05-20 18:10:07.025617
207	152	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 38\nname: V536E\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	5b9c90ba-ad54-4a22-ae5b-ad7f3bdf0641	2015-05-20 18:10:07.039615
208	153	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 55\nname: NM_003124:C.448A>G\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	c626e0a8-4144-46f9-b4d2-e8dc9898525a	2015-05-20 18:10:07.056635
209	154	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 22\nname: P235R\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	b48a9818-49b5-430c-9e92-b52da3d2a9f1	2015-05-20 18:10:07.08819
210	155	Variant	\N	\N	\N	\N	\N	create	---\ngene_id: 53\nname: M1268T\ndescription: A summary for this variant has yet to be developed! Add one now by clicking\n  the "Edit Variant" button.\n	1	\N	\N	2d30d874-737a-4d9d-bb26-be67f764857d	2015-05-20 18:10:07.10323
211	1	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Data from deep sequencing of a Ph-negative clone of a Ph-positive CML\n  patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion,\n  and may imply the possibility that BCR-ABL is not universally the initiating event\n  in CML.\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 1\ndisease_id: 1\nsource_id: 51\nvariant_id: 1\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	cf394053-fa5f-4328-87e0-63c95737be64	2015-05-20 18:10:07.241789
212	2	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of BCR-ABL fusion is considered the characterizing feature\n  of chronic myeloid leukemia, and has been widely thought of as the initiating event\n  in the disease.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 2\ndisease_id: 1\nsource_id: 52\nvariant_id: 1\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1279a192-2595-4956-8ba6-1160b44d5f2c	2015-05-20 18:10:07.299125
213	3	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The use of second-generation BCR-ABL targeted therapies has been effective\n  in patients resistant to imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 1\nsource_id: 52\nvariant_id: 1\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ac48dd78-fc8a-49de-b63a-7a408f2533b4	2015-05-20 18:10:07.338207
214	4	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: COS7 cell lines transfected with BCR/ABL constructs harboring E255K mutations\n  were shown to be resistant to imatinib and exhibited increased kinase activity.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 1\nsource_id: 53\nvariant_id: 3\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1b62f3f8-8054-4a65-97ae-3dbc32c7c3f9	2015-05-20 18:10:07.385513
215	1	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: Imatinib Resistance\ndescription: \n	1	\N	\N	e3e0e5a1-d4f3-40b4-888a-4f17e60137a1	2015-05-20 18:10:07.443552
216	5	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: COS7 cell lines transfected with BCR/ABL constructs harboring T315I mutations\n  were shown to be resistant to imatinib and exhibited increased kinase activity.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 1\nsource_id: 53\nvariant_id: 2\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4de7de28-c1e2-4deb-9aba-476f7b64a641	2015-05-20 18:10:07.485626
217	6	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In chronic myeloid leukemia patients with the ABL T315I mutation, tumors\n  have shown to be resistant to imatinib treatment.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 1\nsource_id: 52\nvariant_id: 2\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4cc9be65-e98f-4362-8832-82dd919c11ef	2015-05-20 18:10:07.523543
218	7	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PIK3CA mutation, but not AKT1 E17K, has been shown to confer sensitiity\n  to the AKT inhibitor MK-2206 in breast cancer cell lines.\nclinical_significance: Sensitivity\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 2\nsource_id: 54\nvariant_id: 4\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 14:105246551-105246551 (C->T)\ndrug_interaction_description: \n	1	\N	\N	03632919-5318-4e68-b008-823485ca52e3	2015-05-20 18:10:07.575658
219	8	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with non-small cell lung cancer harboring the EML4-ALK fusion,\n  treatment with crizotinib has shown to be effective in acheiving stable disease.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 55\nvariant_id: 5\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2c6cc206-761b-42e2-8310-9b8b3071a52d	2015-05-20 18:10:07.616903
220	2	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: ALK Fusions\ndescription: \n	1	\N	\N	4c1d244b-c515-4ca3-981a-9e609ea206e7	2015-05-20 18:10:07.638781
221	9	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with non-small cell lung cancer harboring EML4-ALK fusion,\n  the C1156Y variant has been shown to confer resistance to crizotinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 55\nvariant_id: 6\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	220dcd41-0bfb-4d23-a018-8fe0a87db7b1	2015-05-20 18:10:07.685002
222	3	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: Crizotinib Resistance\ndescription: \n	1	\N	\N	9530087d-1096-43df-92be-9be8bccdcfc7	2015-05-20 18:10:07.705785
223	10	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CH5424802 treatment resulted in significant tumor regression in xenograft\n  models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M\n  mutation\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 56\nvariant_id: 7\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	66392197-da7a-4722-a826-31394f963488	2015-05-20 18:10:07.739007
224	11	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with non-small cell lung cancer harboring EML4-ALK fusion,\n  the L1196M variant has been shown to confer resistance to crizotinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 55\nvariant_id: 7\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	95b5739d-0ec5-48e4-b790-e282213ae302	2015-05-20 18:10:07.776258
225	12	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation\n  were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK\n  without this mutation.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 4\nsource_id: 57\nvariant_id: 8\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	c74bc10a-6099-4575-a571-d6cd308e70cb	2015-05-20 18:10:07.820884
226	13	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant\n  in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 56\nvariant_id: 8\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	06faec34-acd1-4d7e-8710-30df764af7e0	2015-05-20 18:10:07.861573
227	14	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cells lines expressing ALK harboring the F1174L mutation are less sensitive\n  to growth inhibition by crizotinib than cells expressing the R1275Q mutation.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 58\nvariant_id: 8\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	13da0cd8-c3ba-47d6-be34-7b562a6b883d	2015-05-20 18:10:07.896769
228	15	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: High levels of crizotinib can overcome drug resistance of Ba/F3 cells\n  expressing the EML4-ALK fusion containing the F1174L mutation.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 59\nvariant_id: 8\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	cd649547-2759-4e9a-a91b-bb021c69b8ea	2015-05-20 18:10:07.934696
229	16	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing\n  ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 60\nvariant_id: 8\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	df44c03e-8371-44c0-8c87-38b169b4f7b6	2015-05-20 18:10:07.977564
230	17	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation\n  were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK\n  without this mutation.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 57\nvariant_id: 8\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29443695-29443695 (G->T)\ndrug_interaction_description: \n	1	\N	\N	d4ac3874-e7b9-4366-b0cd-555fc2d4687b	2015-05-20 18:10:08.013721
231	18	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cells lines expressing ALK harboring the F1174L mutation are less sensitive\n  to growth inhibition by crizotinib than cells expressing the R1275Q mutation\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 58\nvariant_id: 9\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29432664-29432664 (C->T)\ndrug_interaction_description: \n	1	\N	\N	0fdda2cc-67c0-4159-8320-1931a1d8a8ee	2015-05-20 18:10:08.055334
232	19	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however,\n  cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing\n  F1174L.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 60\nvariant_id: 9\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29432664-29432664 (C->T)\ndrug_interaction_description: \n	1	\N	\N	ef26b5e0-eb92-45b7-aefb-0aa2a3e0bf76	2015-05-20 18:10:08.088236
233	20	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The SMS-KCNR cell line harboring the R1275Q mutation was resistant to\n  TAE684.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 5\nsource_id: 60\nvariant_id: 9\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:29432664-29432664 (C->T)\ndrug_interaction_description: \n	1	\N	\N	67ef1f8b-b28e-4635-bc9b-305651dd6d3b	2015-05-20 18:10:08.125977
234	21	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In one patient with S214C mutation, the use of sorafenib has led to more\n  than 5 years of survival and near remission.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 61\nvariant_id: 10\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: X:47426121-47426121 (C->G)\ndrug_interaction_description: \n	1	\N	\N	6b2ef47e-5170-4d75-87db-ca62bde470bb	2015-05-20 18:10:08.16257
235	22	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar\n  colony formation of AALE cells expressing ARAF S214C in vitro\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 61\nvariant_id: 10\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: X:47426121-47426121 (C->G)\ndrug_interaction_description: \n	1	\N	\N	5c0a8976-bb1c-4842-b633-3603a68379a8	2015-05-20 18:10:08.210724
236	23	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar\n  colony formation of AALE cells expressing ARAF S214C in vitro\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 61\nvariant_id: 10\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: X:47426121-47426121 (C->G)\ndrug_interaction_description: \n	1	\N	\N	7da1af02-2558-46f4-a01c-93edb9c74c85	2015-05-20 18:10:08.242988
237	24	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations\n  were associated with poor progression free survival regardless of treatment (panitumumab\n  with best supportive care or best supportive care alone)\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 62\nvariant_id: 17\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b3d1814e-a33e-426c-852a-85fb43ae36c9	2015-05-20 18:10:08.285181
238	25	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Melanoma patients with BRAF V600E/K mutations had longer progression-free\n  survival, increased tumor regression,  and increased duration of response to combined\n  dabrafenib and trametinib treatment compared to dabrafenib alone\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 63\nvariant_id: 17\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4e70a131-919c-411d-958b-1e796eb454a4	2015-05-20 18:10:08.328085
239	26	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF mutations are associated with melanoma arising in non-chronic sun\n  damaged skin and with superficial spreading melanoma\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 64\nvariant_id: 17\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	08ecca36-7f16-4076-9e6c-8dd52c931555	2015-05-20 18:10:08.373885
240	27	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with other BRAF V600 mutations also respond well to the V600E\n  drug dabrafenib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 65\nvariant_id: 11\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453135-140453136 (CA->AT)\ndrug_interaction_description: \n	1	\N	\N	a4b7a955-faf9-4cb1-a124-ea5098a6686d	2015-05-20 18:10:08.406346
241	4	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: Other V600's\ndescription: \n	1	\N	\N	93880797-cd4a-4ad8-afe8-68a26bdfe16b	2015-05-20 18:10:08.424587
242	28	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cetuximab or panitumumab may be ineffective in patients with BRAF mutation\n  unless BRAF inhibitor such as Sorafenib is introduced.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 8\nsource_id: 66\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	ad609f03-0ed5-4725-9048-42bcdcac2d00	2015-05-20 18:10:08.461509
243	29	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Combined PD0325901 and PLX4720 administration to NSG mice subcutanousely\n  injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited\n  tumor growth and reduced cellular proliferation\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 8\nsource_id: 67\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	e1359a40-5db1-4521-a7eb-0dce37a2820b	2015-05-20 18:10:08.503694
244	30	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely\n  injected with the A357 colorectal cell line with a BRAF V600E mutation effectively\n  inhibited tumor growth significantly more than single agent therapy\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 8\nsource_id: 68\nvariant_id: 12\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	369517a5-1463-460c-ac16-81589c698a1c	2015-05-20 18:10:08.543851
245	31	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated\n  with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased\n  survival and reduced tumor burden compared to single and double agent therapies.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 6\nsource_id: 69\nvariant_id: 12\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	e050f346-cdbe-4095-9888-8926d317f98d	2015-05-20 18:10:08.590355
246	32	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Chemotherapy-refractory patients with colorectal cancer harboring BRAF\n  mutations had lower response and disease control rates as well as shorter progression\n  free and overall survival following cetuximab plus chemotherapy than those with\n  wildtype BRAF\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	666c3bf8-706a-4550-ab12-7a5d3f411e5c	2015-05-20 18:10:08.635876
247	33	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: V600E is associated with adverse pathological features of colorectal\n  cancer. This can be concluded as a marker of poor prognosis.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 2\ndisease_id: 6\nsource_id: 71\nvariant_id: 12\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	fa78bc3b-468f-460c-843a-bbab321db73f	2015-05-20 18:10:08.674235
248	34	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cell lines expressing the BRAF V600E mutation responded better to vemurafenib\n  treatment than cells wildtype for BRAF as measured by reduced cellular proliferation\n  and inhibition of MET and ERK phosphorylation\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 6\nsource_id: 69\nvariant_id: 12\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	4f3e4181-bc24-4cc0-9dce-3a08eb1d1d4a	2015-05-20 18:10:08.722781
249	35	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF status does not predict prognosis in patients treated with dacarbazine\n  or temozolomide.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 72\nvariant_id: 12\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	b798c317-f570-48fb-9c9a-24f927059934	2015-05-20 18:10:08.755681
250	36	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Dabrafenib with trametinib provides higher response rate and lower toxicity-as\n  compared to chemotherapy-in patients with melanoma.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 73\nvariant_id: 12\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	ee611893-04d9-4f46-9b8f-018cc2a717af	2015-05-20 18:10:08.799987
251	37	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In the setting of BRAF(V600E), NF1 loss resulted in elevated activation\n  of RAS-GTP but does not show resistance to MEK inhibitors.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 74\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	f0af4b45-13ce-4e9c-bc45-3e1b0de126b9	2015-05-20 18:10:08.839743
252	38	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In the setting of BRAF(V600E), NF1 loss resulted in elevated activation\n  of RAS-GTP and resistance to RAF inhibitors.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 74\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	2d51e482-6f45-4c32-925a-62aa78997b45	2015-05-20 18:10:08.875626
253	39	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF V600E is correlated with shorter disease-free and overall Survival\n  in a Spanish cohort of melanoma patients.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 75\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	7a127a10-b325-4c81-a536-6ab93981711e	2015-05-20 18:10:08.908851
254	40	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance\n  to dabrafenib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 76\nvariant_id: 12\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	c759d096-b2a2-47e7-866a-49a62157e1e3	2015-05-20 18:10:08.948076
255	41	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF V600E is shown to be associated with the tall-cell variant of papillary\n  thyroid cancer\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 77\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	9a7a6281-b9f3-43c8-b6d0-fb0fd958048c	2015-05-20 18:10:08.984968
256	42	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Thyroid nodule with BRAF V600E mutation is highly correlated with papillary\n  thyroid cancer.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 78\nvariant_id: 12\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	4f80bc21-77fc-4284-96eb-04a504c47a37	2015-05-20 18:10:09.021876
257	43	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Thyroid nodule with BRAF V600E mutation is highly correlated with papillary\n  thyroid cancer.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 79\nvariant_id: 12\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	f950e589-dd29-4d08-9d4f-de7daf9dcce2	2015-05-20 18:10:09.054227
258	44	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Unlike other studies that suggest a poorer outcome, BRAF mutation in\n  this study was not correlated with poorer prognosis in papillary thyroid cancer.\nclinical_significance: Poor Outcome\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 80\nvariant_id: 12\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	69fee417-f310-4061-be65-c1cc37dfed91	2015-05-20 18:10:09.093528
259	45	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF mutation correlated with poor prognosis in papillary thyroid cancer\n  in both older (>65 yo) and younger (<65 yo) cohorts.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 77\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	e854fcfb-97d4-49be-b76e-cce9eb07ed1a	2015-05-20 18:10:09.131948
260	46	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: BRAF V600E is correlated with poor prognosis in papillary thyroid cancer\n  in a study of 187 patients with PTC and other thyroid diseases.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 81\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	144e9c87-2882-4e41-9a1b-a9b74c9fe2b9	2015-05-20 18:10:09.168425
261	47	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: V600E is correlated with disease recurrence in both age cohorts (>65\n  and <65 yo).\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 9\nsource_id: 77\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453136 (A->T)\ndrug_interaction_description: \n	1	\N	\N	7459679f-6fde-43f0-a10f-63ab8780e267	2015-05-20 18:10:09.199525
262	48	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned\n  to be MEK inhibitor (AZD6244) resistant. The mechanim of this resistence was shown\n  to be amplification of the BRAF V600E gene.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 82\nvariant_id: 14\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	bd714557-a009-450b-acca-1d3442a6d56f	2015-05-20 18:10:09.237521
263	49	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A single patient with BRAF V600E/V600M bi-allelic mutation responded\n  to the V600E drug dabrafenib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 83\nvariant_id: 13\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	13b6a5cd-a654-4860-b1b9-67f64bbb05bc	2015-05-20 18:10:09.277432
264	50	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with other BRAF V600 mutations also respond well to the V600E\n  drug dabrafenib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 65\nvariant_id: 15\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453137-140453137 (C->T)\ndrug_interaction_description: \n	1	\N	\N	ecdea7f3-5387-4bc3-a3b1-832530ee70a7	2015-05-20 18:10:09.317546
265	51	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with other BRAF V600 mutations also respond well to the V600E\n  drug dabrafenib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 65\nvariant_id: 16\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:140453136-140453137 (AC->CT)\ndrug_interaction_description: \n	1	\N	\N	c67067f9-3465-45fb-8228-943d4f49043e	2015-05-20 18:10:09.359795
266	52	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The combination of PARP inhibition (Olaparib) with BRCA mutation results\n  in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation\n  positive women with high grade serous or undifferentiated ovarian cancer.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 10\nsource_id: 84\nvariant_id: 129\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 2\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1b27531d-13f2-4df3-8e6d-f1ad42b51cec	2015-05-20 18:10:09.410056
267	5	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: BRCA Germline Variants\ndescription: \n	1	\N	\N	1ae7b303-49e6-4c7f-aa34-a5240b2154d1	2015-05-20 18:10:09.434176
268	53	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The combination of PARP inhibition (Olaparib) with BRCA mutation results\n  in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation\n  positive women with high grade serous or undifferentiated ovarian cancer.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 10\nsource_id: 84\nvariant_id: 130\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 2\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5154fea2-6509-436a-91bd-863420c9e1cd	2015-05-20 18:10:09.470533
269	54	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Inceased copy number of CCND1 is associated with poorer overall survival.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 85\nvariant_id: 18\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e3371c7e-311b-4b87-85b6-20cbb10b5c67	2015-05-20 18:10:09.507967
270	55	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Three studies have found no significant survival impact for CCND1 in\n  lung cancer.\nclinical_significance: Poor Outcome\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 85\nvariant_id: 19\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4f467172-fb1c-4c2c-a103-fdc934f94e75	2015-05-20 18:10:09.541309
271	56	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Three studies have associated CCND1 expression with poorer survival.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 85\nvariant_id: 19\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	72970640-9948-47e0-aeea-044ccd1aff5f	2015-05-20 18:10:09.577518
272	57	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D1 overexpression is associated with the ER-positive subtype of\n  breast cancer.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 86\nvariant_id: 20\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3e43f0b1-0fdc-47fe-be9c-748f37cd3686	2015-05-20 18:10:09.627517
273	58	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In ER-positive breast cancer patients, Cyclin D1 overexpression is associated\n  with shorter overall survival and increased metastasis.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 86\nvariant_id: 20\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	83918b88-c15d-406e-8e43-78a00e948c4e	2015-05-20 18:10:09.666007
274	59	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D1 overexpression is associated with shorter overall survival\n  and increased metastasis in head and neck squamous cell carcinoma.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 12\nsource_id: 87\nvariant_id: 20\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	285ea605-72ee-4c5f-9f99-2742374e50aa	2015-05-20 18:10:09.703848
275	60	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D1 overexpression is associated with shorter overall survival\n  and increased metastasis in mantle cell lymphoma.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 13\nsource_id: 88\nvariant_id: 20\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	bd1553bd-e1bf-4490-9d55-818c94190060	2015-05-20 18:10:09.740033
276	61	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D2 overexpression is associated with poor prognosis in gastric\n  cancers.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 1\ndisease_id: 14\nsource_id: 89\nvariant_id: 21\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d72395d0-fb3e-4b2b-a1f7-5733c62d3b9d	2015-05-20 18:10:09.779242
277	62	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D2 overexpression is associated with the increased depth of cancer\n  invasion in gastric cancers.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 1\ndisease_id: 14\nsource_id: 89\nvariant_id: 21\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8abee03c-3593-4c67-b5b6-a2d0cc78e6c2	2015-05-20 18:10:09.813076
278	63	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D2 overexpression is associated with the presence pf lymph node\n  metastasis in gastric cancers.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 1\ndisease_id: 14\nsource_id: 89\nvariant_id: 21\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	751ec626-36c1-46c5-8a41-ac12af680660	2015-05-20 18:10:09.851791
279	64	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cyclin D2 overexpression is associated with vascular invasion by cancer\n  cells in gastric cancers.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 1\ndisease_id: 14\nsource_id: 89\nvariant_id: 21\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	f18f8803-92e1-47aa-840b-a8cabcb769c8	2015-05-20 18:10:09.89033
280	65	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CCND2 hypomethylation is seen to be more common in stage III and IV gastric\n  tumors than stage I and II.\nclinical_significance: Negative\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 1\ndisease_id: 14\nsource_id: 90\nvariant_id: 22\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1820808f-4b6a-4195-9790-36376adf4b32	2015-05-20 18:10:09.929173
281	66	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with\n  Palbociclib (PD-0332991) significantly increased median survival.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 15\nsource_id: 91\nvariant_id: 23\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0f15e4a5-2884-44e0-b500-94728d492623	2015-05-20 18:10:09.976267
282	67	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with high expression of total cyclin E and low-molecular weight\n  cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard\n  ratio for these patients in 13.3 times higher than those with normal cyclin E levels.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 92\nvariant_id: 24\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3fa7e6ce-6e2e-45b7-9be6-09c804191e25	2015-05-20 18:10:10.023113
283	68	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced\n  stage gastric carcinoma.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 16\nsource_id: 93\nvariant_id: 24\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	09e66922-a6e9-434e-b950-d8a6233f029d	2015-05-20 18:10:10.060266
284	69	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Elevated levels of CCNE1 mRNA has been shown to be correlated with increased\n  depth of tumor invasion in gastic carcinoma.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 16\nsource_id: 93\nvariant_id: 24\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	03f6244a-fd16-4346-ab41-aebbb57bd11d	2015-05-20 18:10:10.094762
285	70	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Elevated levels of CCNE1 mRNA has been shown to be correlated with increased\n  depth of tumor invasion in gastic carcinoma.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 17\nsource_id: 93\nvariant_id: 24\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	716752fd-5bcb-49d7-8bf3-3c3828d43969	2015-05-20 18:10:10.143219
286	71	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In mouse xenograft studies of PIK3CA mutant breast cancers, the combination\n  of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading\n  to tumor regressions.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 18\nsource_id: 94\nvariant_id: 25\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	37332f2b-cdca-48fa-ae88-97549579ad99	2015-05-20 18:10:10.186203
287	72	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Palbociclib has been shown to dramatically improve progression-free survival\n  by over 18 months in patients with ER+ Breast Cancer.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 18\nsource_id: 95\nvariant_id: 25\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5ef6164d-09fb-42bf-95b4-5a563a453148	2015-05-20 18:10:10.221594
288	73	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In mouse xenograft studies of PIK3CA mutant breast cancers, the combination\n  of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading\n  to tumor regressions.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 18\nsource_id: 94\nvariant_id: 26\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a3894de0-936d-4449-83ff-6ab225a997c9	2015-05-20 18:10:10.256483
289	74	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Palbociclib has been shown to dramatically improve progression-free survival\n  by over 18 months in patients with ER+ Breast Cancer.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 18\nsource_id: 95\nvariant_id: 26\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5d1d674b-8665-45fd-9a77-26d3720299ef	2015-05-20 18:10:10.293034
290	75	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A)\n  promoter hypermethylation is associated with shorter overall survival.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 96\nvariant_id: 27\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	957743ca-e5e7-4c3d-a5e5-c262b07cdb9f	2015-05-20 18:10:10.329251
291	76	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A)\n  promoter hypermethylation is associated with shorter time to recurrence.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 96\nvariant_id: 27\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	76562089-7d01-4135-a467-2e7c453e7e6c	2015-05-20 18:10:10.364374
292	77	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CEBPA mutation status had no impact on ATRA treatment response in older\n  (>60) patients with AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 97\nvariant_id: 29\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	efefe360-4eae-420b-aa36-42d6249c2ead	2015-05-20 18:10:10.408376
293	78	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CEBPA mutation was associated with improved overall survival in older\n  (>60) patients with AML\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 97\nvariant_id: 29\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	64c4c775-5689-451f-92d0-2562121819d9	2015-05-20 18:10:10.446213
294	79	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CEBPA mutation was significantly associated with complete remission\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 98\nvariant_id: 29\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	22d4e5a7-c6ac-420b-9616-129c8a405f05	2015-05-20 18:10:10.482542
295	80	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: FLT3 mutations did not alter overall survival in younger (16-60), cytogenetically\n  normal AML patients with CEBPA\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 99\nvariant_id: 28\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e907b7b6-87c6-431d-963b-945e3aed5303	2015-05-20 18:10:10.535295
296	81	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Overall survival was significantly longer in younger (16-60), cytogenetically\n  normal AML patients with CEBPA mutations\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 99\nvariant_id: 28\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3c8fda6c-a40b-456b-abe2-a1d7698642e1	2015-05-20 18:10:10.573603
297	82	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Remission duration was significantly longer in younger (16-60), cytogenetically\n  normal AML patients with CEBPA\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 99\nvariant_id: 28\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	93192c41-40f4-4c69-a87b-2695b31b853c	2015-05-20 18:10:10.604189
298	83	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase\n  inhibitors Imatinib and GW-2580\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 20\nsource_id: 100\nvariant_id: 30\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	dddce84b-ae19-4959-8956-9c88124a790e	2015-05-20 18:10:10.642796
299	84	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the G253C mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 139\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	bd147efb-60ec-46df-b00b-81a6cf512de3	2015-05-20 18:10:10.685089
300	85	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the G505S mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 140\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b42d011d-9b85-4065-87a9-3f0b26de01fa	2015-05-20 18:10:10.720346
301	86	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the G774V mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 142\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8a7614f5-6459-447e-bb48-e772cb044c9b	2015-05-20 18:10:10.753683
302	87	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the I638F mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 141\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	77dac00e-8bdb-4dd9-a694-8431ce369d3a	2015-05-20 18:10:10.787621
303	88	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the L239R mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 138\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8cc27c91-c5a5-4690-bdaf-3085741a3112	2015-05-20 18:10:10.819362
304	89	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In 3T3 fibroblasts expressing the L63V mutation have to be sensitive\n  to the tyrosine kinase inhibitor dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 101\nvariant_id: 137\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ad1d5bee-08b4-48f9-a33a-785bf8b78f83	2015-05-20 18:10:10.849424
305	90	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a patient expressing a DDR2 S768R mutation, treatment with dasatinib\n  plus erlotinib acheived a partial response.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 101\nvariant_id: 143\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e47e6368-005d-4c71-be69-ee19f32a1efe	2015-05-20 18:10:10.885467
306	91	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA\n  resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular\n  carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary\n  and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation\n  and Western blot analyses confirmed that the chimeric protein is expressed in tumor\n  tissue, and a cell culture assay indicated that it retains kinase activity.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 21\nsource_id: 102\nvariant_id: 31\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	f56a5886-d379-4cb0-b7d7-41344815faf5	2015-05-20 18:10:10.935923
307	92	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Daunorubicin treatment resulted in similar overall survival and disease\n  free survival in de novo AML patients with DNMT3A R882 mutation compared to those\n  who do not harbor this mutation.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 103\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d1f324b3-2535-405b-85b4-85d04316aeb9	2015-05-20 18:10:10.977764
308	93	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Idarubicin increases the overall survival and disease free survival in\n  de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor\n  this mutation.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 103\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8248e63e-6150-4015-9a8c-4a13d2140e62	2015-05-20 18:10:11.013047
309	94	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Therapy-related AML was less common in patients with DNMT3A mutations\n  (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of\n  younger (18-60) AML patients\nclinical_significance: Negative\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	79e8f06e-a28f-4cec-bff1-03cffc4d0633	2015-05-20 18:10:11.052442
310	95	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A mutations (59% of which were R882) were associated with an intermediate\n  risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 32\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	501ca592-0969-40bf-8f36-78c894cc67d6	2015-05-20 18:10:11.092091
311	96	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A mutations (59% of which were R882) were associated with intermediate\n  risk cytogenetics (including normal karyotype)\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6b89bef3-410a-4cae-a5ee-6b86729b8b87	2015-05-20 18:10:11.12862
312	97	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A mutations (64.5% R882) were associated with older age, higher\n  white blood cell count and cytogenetically normal AML in a large cohort of younger\n  (18-60) AML patients\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d7a99e8e-2aa4-41cc-8af2-9f0d82db8614	2015-05-20 18:10:11.160055
313	98	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A R882 mutations occur most often in de novo AML patients with intermediate\n  cytogenic risk.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 103\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0237918e-f653-465e-8334-f8c07336408d	2015-05-20 18:10:11.194878
314	99	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A R882 mutations were associated with cytogenetically normal AML\n  in a large cohort of younger (18-60) AML patients\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	451a0f98-76c6-4513-94bc-2276608a544e	2015-05-20 18:10:11.225773
315	100	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A R882 mutations were associated with older age, higher white blood\n  cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of\n  cytogenetically normal AML patients\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 106\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5ac01198-07d2-40d4-9268-5cd0b24d3393	2015-05-20 18:10:11.259764
316	101	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Young AML patients (<60 years old) with DNMT3A mutations (60% of which\n  were R882) were older in age, had higher white blood cell counts and had higher\n  platelet counts than patients wildtype for DNMT3A\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2a9f8330-30d7-4a65-a867-37365ad8fb9f	2015-05-20 18:10:11.295223
317	102	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Complete remission rates did not differ between patients with wildtype\n  or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 108\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e7bf8d1f-5e47-4b55-a24f-f2bcb161a2c4	2015-05-20 18:10:11.328725
318	103	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a large cohort of AML patients (mean = 48 years), DNMT3A mutation\n  (64.5% of which were R882) had no prognostic value on overall, relapse free and\n  event free survival.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c3104c73-6c91-45f6-90de-506bd7a5407b	2015-05-20 18:10:11.362828
319	104	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a large cohort of cytogenetically normal AML patients (18-60 years\n  old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value\n  for overall, relapse free and event free survival\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c789f842-b779-4556-bdb3-36b5cf865583	2015-05-20 18:10:11.397508
320	105	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In young AML patients (<60 years old), DNMT3A mutation status (60% of\n  which were R882) was not predictive of overall and relapse free survival in patients\n  with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7f8127e2-f013-42e7-a4aa-dcb0bfb6ed23	2015-05-20 18:10:11.433513
321	106	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: There is no difference in the complete remission rate of de novo AML\n  patients with DNMT3A mutation compared to those who are wild type for DNMT3A.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 103\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	94a3fc94-ee0e-4351-9401-078bdd8144dd	2015-05-20 18:10:11.46873
322	107	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A mutations were associated with achievement of complete remission\n  in a large cohort of younger (18-60) AML patients\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	f279a906-89ba-4900-b9f5-161294128b66	2015-05-20 18:10:11.505104
323	108	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML patients with DNMT3A mutations (59% of which were R882) showed worse\n  survival (event-free and overall) outcome than those without DNMT3A mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 32\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	73e7433a-5045-4019-9ce4-9370436d1eaa	2015-05-20 18:10:11.537218
324	109	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Complete remission rate was not different between young AML patients\n  (<60 years old) with or without DNMT3A mutations (60% of which were R882)\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0091b9fc-71ae-4843-832e-96cdd8aeb57d	2015-05-20 18:10:11.571648
325	110	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: De novo AML patients with DNMT3A D882 mutation showed worse survival\n  (event-free and overall) outcome than those without DNMT3A mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b6664110-f09b-4515-aaf7-64ce5a53a8de	2015-05-20 18:10:11.604737
326	111	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A mutations (62% of which were R882) were associated with reduced\n  disease-free survival in patients with cytogenetically normal AML.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 108\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b7db8981-170d-46ea-b6ee-8116b18a049d	2015-05-20 18:10:11.637376
327	112	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: DNMT3A R882 mutation was associated with reduced relapse free and overall\n  survival in ELN-unfavorable, cytogenetically normal AMLs\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d8727315-57ba-4f7c-ab86-ae1b7769216b	2015-05-20 18:10:11.672242
328	113	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a large cohort of young AML patients (18-60 years old), DNMT3A R882\n  mutations were associated with reduced relapse free survival in the entire cohort\n  as well as the subset of patients with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 2\ndisease_id: 19\nsource_id: 104\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	40dea01c-e39b-4cc6-85b7-690e81223156	2015-05-20 18:10:11.702939
329	114	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations\n  (including R882) were associated with worse overall survival compared to those without\n  DNMT3A mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 32\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7bd7c447-7e0a-4bad-9800-e196f6b3f04c	2015-05-20 18:10:11.737867
330	115	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In cytogenetically normal AML patients, DNMT3A R882 mutations are associated\n  with lower overall and disease free survival as compared to patients with wild type\n  DNMT3A.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 106\nvariant_id: 32\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ecec0913-2210-4b50-a22b-c442983614a2	2015-05-20 18:10:11.775554
345	129	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In non-small cell lung cancer, the appearance of T790M mutation leads\n  to resistance to gefitinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 116\nvariant_id: 34\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	bbbdf8a1-fb55-4ba5-adc9-de93902a07fc	2015-05-20 18:10:12.39141
331	116	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In older cytogenetically normal AML patients (>59 years), DNMT3A R882\n  mutation is prognostic for shorter disease free survival and overall survival compared\n  to patients without the mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 108\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8e44b316-a108-44bf-a06c-dd2253800cca	2015-05-20 18:10:11.811488
332	117	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In young AML patients (<60 years old), DNMT3A mutations were associated\n  with significantly reduced overall survival and relapse free survival in patients\n  wildtype for NPM1 and FLT3\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	336dd652-cebf-40a4-bd64-1b256ccee0bd	2015-05-20 18:10:11.851554
333	118	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations\n  other than R882 are prognostic for shorter disease free survival and overall survival\n  compared to patients without the mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 108\nvariant_id: 32\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	11c371b9-e689-45d6-a0f6-85922ea7597a	2015-05-20 18:10:11.894475
334	119	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Young AML patients (<60 years old) with DNMT3A mutation have shorter\n  overall survival and relapse-free survival than patients with wildtype DNMT3A\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8ec34d6b-d7ff-4152-951c-48c3c0f3ad00	2015-05-20 18:10:11.931356
335	120	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Young AML patients (<60 years old) with DNMT3A R882 mutations have shorter\n  overall survival and relapse-free survival than patients with wildtype DNMT3A\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 32\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	06ea92aa-2e72-4b1e-925c-60c39c7b8643	2015-05-20 18:10:11.963208
336	121	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Exon 19 deletion has been shown to be correlated with gefitinib response.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 109\nvariant_id: 131\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	185c70b7-d84e-403e-826e-b971f7537c98	2015-05-20 18:10:12.00283
337	122	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Gefinitib has been shown to be effective in treating cell lines with\n  G719S missense mutations.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 110\nvariant_id: 132\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	fa31336c-0da1-4433-b428-2c448dc9da66	2015-05-20 18:10:12.041894
338	123	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: There is no statistical difference in progression free survival between\n  lung cancer patients treated with gefitinib or erlotinib in the EGFR L858R setting.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 111\nvariant_id: 33\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55259514-55259515 (CT->AG)\ndrug_interaction_description: \n	1	\N	\N	5af77dc9-1666-4c2c-a13d-9d4c414d7633	2015-05-20 18:10:12.08714
339	124	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence\n  of L858R mutation is prognostic for better progression free survival.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 112\nvariant_id: 33\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55259514-55259515 (CT->AG)\ndrug_interaction_description: \n	1	\N	\N	a60ecd20-14fc-4829-a1b5-96645882a820	2015-05-20 18:10:12.141544
340	125	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Median survival of patients with EGFR L858R mutation is better than those\n  with wild type EGFR.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 113\nvariant_id: 33\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55259514-55259515 (CT->AG)\ndrug_interaction_description: \n	1	\N	\N	28487de1-8c86-4ff1-b0d7-0cf5b691bd3c	2015-05-20 18:10:12.179437
341	126	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Gefinitib has been shown to be effective in treating cell lines with\n  L858R missense mutations.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 110\nvariant_id: 33\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1bcd5c1a-d504-43c8-a353-a01097edfdf1	2015-05-20 18:10:12.241487
342	127	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The T790M mutation in EGFR has been shown to confer resistance to the\n  tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are\n  placed on the drug are likely to relapse.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 2\ndisease_id: 22\nsource_id: 114\nvariant_id: 34\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	048008ef-cf08-4b53-9858-2720a5d6decc	2015-05-20 18:10:12.288722
343	6	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: TKI Resistance\ndescription: \n	1	\N	\N	42565b65-f52c-469f-a8d1-3881565840f3	2015-05-20 18:10:12.306415
344	128	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a NSCLC patient with T790M and L858R mutation, combination treatment\n  with erlotinib and premetrexed has shown to be effective, reducing tumor size and\n  resulting in stable disease.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 115\nvariant_id: 34\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	01bb9ff0-becc-4f1f-98a4-2305953042e0	2015-05-20 18:10:12.344242
346	130	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC patients with T790M and another activating mutations, their\n  progression free survival is shorter compared to those who do not possess T790M\n  mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 117\nvariant_id: 34\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	359058bc-12a6-4efd-80b6-b5597b97a66f	2015-05-20 18:10:12.429648
347	131	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with NSCLC harboring EGFR T790M mutation have statistically\n  worse overall survival compared to patients with L858R or other exon 19 activating\n  mutations.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 118\nvariant_id: 34\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	cff3dd77-dbce-41cd-aad0-5f35a24110e4	2015-05-20 18:10:12.466903
348	132	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC containing a T790M mutation, staurosporine may be inhibitive\n  of EGFR, especially when an L858R mutation is also present.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 3\nsource_id: 119\nvariant_id: 34\nrating: 1\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 7:55249071-55249071 (C->T)\ndrug_interaction_description: \n	1	\N	\N	990224a3-2b9f-4762-be9c-b155ee0f3a29	2015-05-20 18:10:12.50942
349	133	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804),\n  MET amplification and EGFR T790M were found to be the primary drivers of resistance.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 120\nvariant_id: 34\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	cf44dffc-6412-4ba0-80b4-95fa00609d13	2015-05-20 18:10:12.546426
350	134	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the D769H mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 35\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37880261-37880261 (G->C)\ndrug_interaction_description: \n	1	\N	\N	9b8a64f7-376e-4588-bab2-7c7588cd4050	2015-05-20 18:10:12.588645
351	7	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: HER2 Activating\ndescription: \n	1	\N	\N	6bfec9ad-3b88-440e-b455-c44c742defc9	2015-05-20 18:10:12.608616
352	135	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the D769Y mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 36\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37880261-37880261 (G->T)\ndrug_interaction_description: \n	1	\N	\N	44f91914-854b-42a2-a044-20a94bf58458	2015-05-20 18:10:12.64099
353	136	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines retrovirally transduced with wildtype or mutant\n  ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown\n  to be sensitive to neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 37\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c3eca4de-5139-4e15-a311-2e3706037c72	2015-05-20 18:10:12.681343
354	137	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the G309A mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 38\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37868205-37868205 (G->C)\ndrug_interaction_description: \n	1	\N	\N	9676a587-c96d-4d55-b5ab-f2c06f25ffe4	2015-05-20 18:10:12.713549
355	138	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The L755S mutation was shown to confer resistance to lapatinib in MCF10A\n  cell lines retrovirally transduced with wildtype or mutant ERBB2.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 39\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37880220-37880220 (T->C)\ndrug_interaction_description: \n	1	\N	\N	f4bb011a-8db7-430b-8824-0ab1694cf490	2015-05-20 18:10:12.756926
356	139	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The L755S mutation showed mild response to neratinib in MCF10A cell lines\n  retrovirally transduced with wildtype or mutant ERBB2.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 39\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37880220-37880220 (T->C)\ndrug_interaction_description: \n	1	\N	\N	7eef9b3f-b493-47ae-a371-1d1e353c99e3	2015-05-20 18:10:12.790865
357	140	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive\n  to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 40\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	02d1bee3-1110-444c-af29-858d68d165b3	2015-05-20 18:10:12.821515
358	141	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the in-frame insertion of a single amino acid at\n  position 780 was shown to be sensitive to neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 41\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ab21a04f-c626-48ce-b0da-cc2adbe52e4d	2015-05-20 18:10:12.85064
359	142	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive\n  to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony\n  forming assay.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 42\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2addaaa2-358c-4aac-a1fe-9a58d3a4c16a	2015-05-20 18:10:12.894436
360	143	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the R896C mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 43\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37881616-37881616 (C->T)\ndrug_interaction_description: \n	1	\N	\N	2891b03d-8c12-475c-8d66-3cf271036ee1	2015-05-20 18:10:12.927304
361	144	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the V777L mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 44\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37881000-37881000 (G->T)\ndrug_interaction_description: \n	1	\N	\N	f33c274a-61f8-4879-884f-ee3d79249516	2015-05-20 18:10:12.963718
362	145	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In MCF10A cell lines, the V842I mutation was shown to be sensitive to\n  neratinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 121\nvariant_id: 45\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:37881332-37881332 (G->A)\ndrug_interaction_description: \n	1	\N	\N	83f08f57-e886-432c-9819-c25169da366b	2015-05-20 18:10:13.008655
363	146	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain\n  of ESR1 have shown resistance to hormone therapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 122\nvariant_id: 46\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	70cd3964-b633-4b5a-882e-50b06bc9adb8	2015-05-20 18:10:13.051013
364	8	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: ESR1 Ligand-Binding Domain\ndescription: \n	1	\N	\N	568dfa62-b81e-4f25-a1a7-8d4a8208b90c	2015-05-20 18:10:13.071347
365	147	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The L536Q ligand binding domain mutation have been shown to result in\n  constitutive activity and continued responsiveness to anti-estrogen therapies in\n  MCF7 cell lines.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 123\nvariant_id: 46\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	97efc7ae-937f-49c7-8724-967b8db7e15f	2015-05-20 18:10:13.108694
366	148	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF7 cell lines harboring the N538G mutation in the ligand-binding domain\n  of ESR1 have shown resistance to hormone therapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 122\nvariant_id: 47\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	601a69df-2973-4846-a18c-487db6470b90	2015-05-20 18:10:13.157806
367	149	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The N538G ligand binding domain mutations have been shown to result in\n  constitutive activity and continued responsiveness to anti-estrogen therapies in\n  vitro.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 123\nvariant_id: 47\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	204fc358-04a8-418a-b181-e19db56d1b5b	2015-05-20 18:10:13.204566
368	150	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain\n  of ESR1 have shown resistance to hormone therapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 122\nvariant_id: 48\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419923-152419923 (A->G)\ndrug_interaction_description: \n	1	\N	\N	6c3f9dd8-c170-45ed-8027-6dd030fa3abc	2015-05-20 18:10:13.252094
369	151	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The Y537C ligand binding domain mutations have been shown to result in\n  constitutive activity and continued responsiveness to anti-estrogen therapies in\n  vitro.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 123\nvariant_id: 48\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419923-152419923 (A->G)\ndrug_interaction_description: \n	1	\N	\N	cdc30bd1-585a-4a4d-a682-4f6108c9bf49	2015-05-20 18:10:13.306558
370	152	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain\n  of ESR1 have shown resistance to hormone therapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 122\nvariant_id: 49\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419922-152419922 (T->A)\ndrug_interaction_description: \n	1	\N	\N	50303cbc-9ef8-4674-8304-b656aac79604	2015-05-20 18:10:13.368166
371	153	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The Y537N ligand binding domain mutations have been shown to result in\n  constitutive activity and continued responsiveness to anti-estrogen therapies in\n  vitro.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 123\nvariant_id: 49\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419922-152419922 (T->A)\ndrug_interaction_description: \n	1	\N	\N	3701d75c-b8fe-400a-aafd-1de9ad502226	2015-05-20 18:10:13.423621
372	154	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MCF7 cell lines harboring the L537S mutation in the ligand-binding domain\n  of ESR1 have shown resistance to hormone therapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 122\nvariant_id: 50\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419923-152419923 (A->C)\ndrug_interaction_description: \n	1	\N	\N	bd567f12-017e-4730-a634-4c66d71e10e2	2015-05-20 18:10:13.51253
373	155	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The Y537S ligand binding domain mutations have been shown to result in\n  constitutive activity and continued responsiveness to anti-estrogen therapies in\n  vitro.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 123\nvariant_id: 50\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 6:152419923-152419923 (A->C)\ndrug_interaction_description: \n	1	\N	\N	d07d263d-a845-4747-8cac-f48c20b6499c	2015-05-20 18:10:13.560315
374	156	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a single patient with this fusion in intrahepatic cholangiocarcinoma.\n  Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic\n  sites and overall stable disease. However, this response did not meet criteria for\n  RECIST partial response.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 23\nsource_id: 124\nvariant_id: 51\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4ba10376-cc73-4f1e-8297-c3112503ecd9	2015-05-20 18:10:13.611369
375	9	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: FGFR fusions\ndescription: \n	1	\N	\N	110b4ce4-88db-451c-8ccf-55e4602b5c33	2015-05-20 18:10:13.629295
376	157	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Following identification of this fusion in a patient, this fusion was\n  expressed in HEK 293T cells leading to oligomerization in the absence of ligand,\n  induced morphologic changes in the cell and increased cellular proliferation consistent\n  with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors\n  an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR\n  inhibitor PD173074.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 24\nsource_id: 125\nvariant_id: 52\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	f31a63f1-4ff6-49ae-b216-47a72df0ae09	2015-05-20 18:10:13.663816
377	158	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma.\n  Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This\n  fusion is also shown to be recurrent in multiple other cancer types.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 23\nsource_id: 124\nvariant_id: 53\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4aa5610e-e3bc-4150-8678-ec3d81542046	2015-05-20 18:10:13.711582
378	159	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML\n  cells with FLT3 internal tandem repeat\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 126\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6ec6e9c7-7e7c-4a72-9181-7cc3676b9af5	2015-05-20 18:10:13.753684
379	160	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: ATRA treatment did not effect overall survival in patients <60 years\n  old with FLT3-ITD mutation\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 127\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	be08b8a5-db78-4037-a89d-3e22edbc556a	2015-05-20 18:10:13.79579
380	161	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated\n  AML patients with FLT3 mutations\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 128\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	102c014b-81c3-4624-b786-9f861e8bf35a	2015-05-20 18:10:13.832548
381	162	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have\n  more resistance to daunorubicin than cells with FLT3-ITD alone.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 129\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b9f7e2ba-0f05-4317-991f-433da0c3b173	2015-05-20 18:10:13.870453
382	163	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WBC counts were higher in AML patients with internal tandem repeat of\n  Flt3 compared to wild type\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 130\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	026ae6ba-0845-4ba3-997f-ce2656a48d26	2015-05-20 18:10:13.906117
383	164	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: FLT3-ITD mutation without NPM1 was associated with increased relapse\n  risk and reduced overall survival in young adult AML patients (median age 43)\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 131\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	04979551-8191-4392-800c-4efc0ef8ac08	2015-05-20 18:10:13.93897
384	165	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Increasing level of FLT3-ITD mutant correlated with reduced disease-free\n  and overall survival as well as increased relapse rate\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 131\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	828c179e-d1fd-4e79-a168-8bfbd37d3701	2015-05-20 18:10:13.971332
385	166	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: FLT3-ITD duplication length did not effect prognosis in patients with\n  an NPM1 mutation\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d59ac833-cf3b-4d6f-81b1-6dee59fd451b	2015-05-20 18:10:14.030893
386	167	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In young AML patients (<60 years old), DNMT3A mutation status was not\n  predictive of overall and relapse free survival in patients with NPM1 mutations\n  and wildtype FLT3 or wildtype NPM1 and FLT3-ITD\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	604d1493-ca07-4402-af17-c45ca7be6118	2015-05-20 18:10:14.0595
387	168	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Size of the FLT3-ITD mutant duplication had no impact on overall survival\n  or relapse rate\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 131\nvariant_id: 54\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e0c6ce85-2cf6-4710-bdb2-55d61561201c	2015-05-20 18:10:14.094597
388	169	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced\n  event-free and overall survival in old (>59) and younger patients (<60) with an\n  NPM1 mutation\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	56d990e8-09ef-4d8a-bccc-a29f3cec5a89	2015-05-20 18:10:14.128325
389	170	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML patients with internal tandem repeat of FLT3 has worse overall survival\n  than patients with wild type FLT3\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 130\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	25f05685-78e2-4259-8073-a0b9929bd4e6	2015-05-20 18:10:14.157526
390	171	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations\n  were associated with worse overall survival compared to those without DNMT3A mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 54\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4599d8af-3ea4-4ac6-9e8e-83d7b1b2c206	2015-05-20 18:10:14.191429
391	172	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Meta-analysis of studies involving cytogentically normal younger (<60)\n  patients showed reduced overall and relapse-free survival for patients with FLT3-ITD\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 2\ndisease_id: 19\nsource_id: 133\nvariant_id: 54\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b57ff1e0-5978-4468-bdc3-9a705c1fc6c5	2015-05-20 18:10:14.226766
392	173	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival\n  compared to patients with wildtype FLT3\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	69448175-203d-4cff-8e3a-867df75ed150	2015-05-20 18:10:14.256821
393	174	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads\n  to poor survival and inferior disease free survival in patients with AML.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 134\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4911cf8a-e794-47ad-b43c-a1804a932ec1	2015-05-20 18:10:14.289908
394	175	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable,\n  a higher ratio was associated with reduced event-free survival in patients with\n  an NPM1 mutation\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5403794e-38e8-4742-9cd8-02e92225b991	2015-05-20 18:10:14.319062
395	176	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Sorafenib is effective in patients with FLT3 internal tandem repeats,\n  but not in wild type or D835 mutation.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 135\nvariant_id: 54\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a56c9539-4e90-4dab-b825-9519c08e1f84	2015-05-20 18:10:14.351062
396	177	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have\n  more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells\n  with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 129\nvariant_id: 54\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	35b37582-d080-40d3-9ba7-756ca30c11fb	2015-05-20 18:10:14.384285
397	178	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated\n  AML patients with FLT3 mutations\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 128\nvariant_id: 55\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b7083102-d10c-4aa2-95b4-8b03b0c9104b	2015-05-20 18:10:14.414282
398	179	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have\n  more resistance to daunorubicin than cells with FLT3-ITD alone.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 129\nvariant_id: 55\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9534f147-51a4-4608-931f-5876dffc6d26	2015-05-20 18:10:14.443336
399	180	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WBC counts were not significantly different in AML patients with FLT3\n  D835 mutations compared to wild type\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 130\nvariant_id: 55\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2ccbc996-17e4-4b62-bdf2-dd39efe05dc2	2015-05-20 18:10:14.471948
400	181	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML patients with D835 mutation of FLT3 did not have worse overall survival\n  than patients with wild type FLT3\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 130\nvariant_id: 55\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a519158a-5a3a-4617-a6f0-2abe7b150de5	2015-05-20 18:10:14.510565
401	182	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Event-free survival was significantly improved in patients with both\n  NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone\n  2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis\n  3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal\n  karyotype patients were analyzed\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 136\nvariant_id: 55\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	927d2338-7bde-436b-9748-538812b4fc76	2015-05-20 18:10:14.542435
402	183	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In AML patients, FLT3-TKD mutation was associated with poorer disease\n  free survival compared to patients with wild type FLT3\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 137\nvariant_id: 55\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	94d2ab0a-9563-42b4-8de0-2983fc7d68d4	2015-05-20 18:10:14.58491
403	184	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Emergence of D835 mutation in AML patients with FLT3 tandem repeat is\n  associated with sorafenib resistance\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 138\nvariant_id: 55\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	594089bc-00e0-46dc-bb1f-ea84ff246915	2015-05-20 18:10:14.617882
404	185	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Sorafenib is effective in patients with FLT3 internal tandem repeat mutations,\n  but not in patients with wild type or D835 mutation.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 135\nvariant_id: 55\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	74a80036-05fc-4a2e-9888-abe9e444c5e3	2015-05-20 18:10:14.65344
405	186	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have\n  more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells\n  with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 129\nvariant_id: 55\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4b02fd06-1daf-42b7-8208-933d5d9eb191	2015-05-20 18:10:14.692396
406	187	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Targeting overactive GATA2-mediated pathways with inhibitors bortezomib\n  and fasudil led to dramatic tumor regression.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 25\nsource_id: 139\nvariant_id: 56\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	18119695-500e-460d-95b1-d978c964d04a	2015-05-20 18:10:14.726915
407	188	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In leukemia patients, IDH1 R132 mutation is associated with adults and\n  normal karyotype.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 140\nvariant_id: 57\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	087a16d4-b967-48ad-a5d4-3e9b75fecfdc	2015-05-20 18:10:14.767327
408	189	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Mutation status of IDH1 did not change event-free survival of patients\n  with an NPM1 mutation\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 141\nvariant_id: 57\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	cb6d37ca-85da-4944-9ce1-9271dce3aa88	2015-05-20 18:10:14.805682
409	190	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The complete remission and overall survival rates in patients with IDH1\n  R132 mutation is not significantly different from those who do not have this mutation\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 142\nvariant_id: 57\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	dba8d630-9f5b-4def-a154-c5a0633a5d8a	2015-05-20 18:10:14.840653
410	191	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic\n  for better survival compared to patients who harbor wild type mutation.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 26\nsource_id: 143\nvariant_id: 57\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7022f510-92a9-4775-8ecf-aba82fe0a647	2015-05-20 18:10:14.879995
411	192	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with glioblastoma, those harboring IDH1 R132 mutation has\n  higher overall survival compared to those who do not have IDH1 mutation\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 27\nsource_id: 144\nvariant_id: 57\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	61780817-570f-47c5-aad2-9ecedfbd8b27	2015-05-20 18:10:14.922508
412	193	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: IDH1 R132 mutation in patients suffering from myelodysplastic syndromes\n  is associated with worse overall survival\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 28\nsource_id: 145\nvariant_id: 57\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ae388402-2617-4255-a97b-4c40216adc3f	2015-05-20 18:10:14.965261
413	194	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: IDH1 R132 mutation is associated with patients of older age, high platelet\n  count during diagnosis, cytogenic normalcy and NPM1 mutation\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 146\nvariant_id: 58\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:209113113-209113113 (G->A)\ndrug_interaction_description: \n	1	\N	\N	e6f23db2-d6cc-4cb3-b387-a7aafe7428fb	2015-05-20 18:10:15.009807
414	195	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: IDH1 R132 mutation in patients with AML is not associated with any prognostic\n  value compared to patients with wild-type IDH1.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 146\nvariant_id: 58\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:209113113-209113113 (G->A)\ndrug_interaction_description: \n	1	\N	\N	101bc70e-29dc-479d-8230-7636d17e7e51	2015-05-20 18:10:15.042546
415	196	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: IDH1 R132 mutation in patients with AML is not associated with any prognostic\n  value compared to patients with wild-type IDH1.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 146\nvariant_id: 59\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:209113112-209113112 (C->T)\ndrug_interaction_description: \n	1	\N	\N	9e753305-a77a-4483-9e1f-2f3677d5a337	2015-05-20 18:10:15.073982
416	197	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: IDH1 R132 mutation in patients with AML is not associated with any prognostic\n  value compared to patients with wild-type IDH1.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 146\nvariant_id: 60\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:209113112-209113112 (C->A)\ndrug_interaction_description: \n	1	\N	\N	17d6cb31-719e-4622-8d91-abb04e247a2f	2015-05-20 18:10:15.110439
417	198	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML patients with IDH2 mutations such as R140Q/L have event free survival\n  and overall survival similar to those with wild-type IDH2\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 147\nvariant_id: 61\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	04a228e9-9e81-42e1-97e0-975dd899935c	2015-05-20 18:10:15.144298
418	199	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with IDH2 R140Q/L mutation, the presence of mutation does\n  not impact overall survival or disease free survival.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 148\nvariant_id: 61\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	67f067b8-de92-4f08-a38d-b015425afdab	2015-05-20 18:10:15.178093
419	200	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In AML, patients with IDH2 R140K mutation have improved overall survival\n  compared to those with wild-type IDH2\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 149\nvariant_id: 61\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7430353a-fa0a-4c88-8c9a-d9dfae285f90	2015-05-20 18:10:15.21196
420	201	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients suffering from MDS, the presence of IDH2 mutation such as\n  R140Q/L do not confer prognostic value (overall survival)\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 29\nsource_id: 150\nvariant_id: 61\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7705a375-153b-4bf4-a9b0-4254dab8c853	2015-05-20 18:10:15.251722
421	202	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: R140Q mutation in IDH2 does not have prognostic value in patients with\n  MDS.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 29\nsource_id: 151\nvariant_id: 61\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9dbbb58d-8e2d-46d8-a1a0-3c48161f579a	2015-05-20 18:10:15.292132
422	203	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML patients with IDH2 mutations such as R172K have event free survival\n  and overall survival similar to those with wild-type IDH2.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 147\nvariant_id: 62\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 15:90631838-90631838 (C->T)\ndrug_interaction_description: \n	1	\N	\N	9b3eca5c-64b9-45dc-b854-10dc6b1452db	2015-05-20 18:10:15.330654
423	204	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In AML, patients with an IDH2 R172K mutation have worse overall survival\n  compared to those with wild-type IDH2\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 149\nvariant_id: 62\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 15:90631838-90631838 (C->T)\ndrug_interaction_description: \n	1	\N	\N	86a5d3a4-30ab-4286-8bcb-23eb454656ba	2015-05-20 18:10:15.362039
424	205	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients suffering from MDS, the presence of IDH2 mutations such as\n  R172K do not confer prognostic value (overall survival)\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 29\nsource_id: 150\nvariant_id: 62\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 15:90631838-90631838 (C->T)\ndrug_interaction_description: \n	1	\N	\N	65788a5f-774a-415f-9717-946d5f471aaf	2015-05-20 18:10:15.401655
425	206	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical\n  CML).\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 1\nsource_id: 152\nvariant_id: 63\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	79b242e5-fda4-4b9b-be50-756ffc65a0ca	2015-05-20 18:10:15.436082
426	207	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML)\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 1\nsource_id: 152\nvariant_id: 63\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	76b8c446-46e6-448e-afa4-5eb1bed17d43	2015-05-20 18:10:15.477094
427	208	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL\n  or CLL).\nclinical_significance: Negative\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 30\nsource_id: 152\nvariant_id: 63\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	57162671-475c-41c0-8220-e6f14dc4f32a	2015-05-20 18:10:15.514369
428	209	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The SNP rs10974944 in the Jak2 locus is associated with increased predisposition\n  for JAK2 V617F mutation and its associated cancer\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 31\nsource_id: 153\nvariant_id: 63\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	8572ed7f-c98d-4260-a9f5-38a29de351c1	2015-05-20 18:10:15.578621
429	210	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads\n  to reduction in the percentage of cells harboring JAK2 V617F.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 32\nsource_id: 154\nvariant_id: 63\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	df050e79-f6ec-414e-b6f1-6552e572a934	2015-05-20 18:10:15.627148
430	211	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 32\nsource_id: 155\nvariant_id: 63\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 9:5073770-5073770 (G->T)\ndrug_interaction_description: \n	1	\N	\N	d68faf0b-8b49-4bc5-a7f7-e1d6ba1eae1b	2015-05-20 18:10:15.66388
431	212	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In acute myloid leukemia patients, D816 mutation is associated with earlier\n  relapse and poorer prognosis than wildtype KIT\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 33\nsource_id: 156\nvariant_id: 64\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55599321-55599321 (A->T)\ndrug_interaction_description: \n	1	\N	\N	df50be99-ae29-49bd-9bf0-aa892ec6994d	2015-05-20 18:10:15.7083
432	10	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: KIT Exon 17\ndescription: \n	1	\N	\N	02868e88-2a60-4199-bb75-43a2c78a7136	2015-05-20 18:10:15.724597
433	213	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutation is associated with larger, more invasive tumors, greater\n  pathologic histology and older patients compared to tumors with wildtype KIT\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 157\nvariant_id: 65\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	78bd1cb7-a210-4b63-937b-0e6c87cee179	2015-05-20 18:10:15.755634
434	11	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: KIT Exon 11\ndescription: \n	1	\N	\N	b63bd9bb-34a8-4940-8f9c-a3634323e30e	2015-05-20 18:10:15.777824
435	214	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutations were identified in morphologically benign, incidentally\n  discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients\n  indicating is not a prognostic marker for GIST\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 158\nvariant_id: 65\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ed54b91c-2658-4eef-b95b-24c697c58471	2015-05-20 18:10:15.817191
436	215	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: There is no significant association between wildtype KIT or KIT mutations\n  in exon 9 or 11 in survival among GIST patients.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 159\nvariant_id: 65\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a66751ef-6014-4709-a51e-69c7ae1c54df	2015-05-20 18:10:15.853817
437	216	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutation is associated with worse overall and cause-specific prognosis\n  in patients with GIST compared to patients with wildtype KIT\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 157\nvariant_id: 65\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6dc91bb4-05ed-4324-abe7-63060bf42f30	2015-05-20 18:10:15.898089
438	217	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutations detected in 5/60 patients showed no prognostic significance\n  in patients with small cell lung cancer\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 17\nsource_id: 160\nvariant_id: 65\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8c038723-3fba-4445-91de-41d71c064c9e	2015-05-20 18:10:15.935569
439	218	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Melanoma patients with KIT mutation but not KIT amplification showed\n  response to imatinib treatment in a small cohort of patients.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 161\nvariant_id: 65\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6ae4800d-6d81-4311-a19d-6e9ace6d378a	2015-05-20 18:10:15.972925
440	219	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Melanoma patients with KIT mutation but not KIT amplification showed\n  response to imatinib treatment in a small cohort of patients.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 161\nvariant_id: 67\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4b23080e-b1ca-4a52-bbad-7a12d13d2419	2015-05-20 18:10:16.017303
441	220	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: GIST patients with exon 14 KIT mutations had reduced overall survival\n  compared to patients wiltype for KIT\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 159\nvariant_id: 68\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1b66cc33-dbae-4858-90e3-194e17cd95cf	2015-05-20 18:10:16.057042
442	221	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutation is associated with larger, more invasive tumors, greater\n  pathologic histology and older patients compared to tumors with wildtype KIT\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 157\nvariant_id: 69\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0e938599-b6d1-46d3-bc10-9c667e04ceb9	2015-05-20 18:10:16.088543
443	222	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Melanoma patients with KIT mutation but not KIT amplification showed\n  response to imatinib treatment in a small cohort of patients.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 161\nvariant_id: 69\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8fdb034b-287b-425c-aa7e-2ce94cffb990	2015-05-20 18:10:16.139825
444	223	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: There is no significant association between wildtype KIT or KIT mutations\n  in exon 9 or 11 in survival among GIST patients.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 159\nvariant_id: 70\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	11302379-a095-4303-a57d-8043fa526a8d	2015-05-20 18:10:16.187681
445	224	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT mutations detected in 5/60 patients showed no prognostic significance\n  in patients with small cell lung cancer\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 17\nsource_id: 160\nvariant_id: 70\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d089012b-756f-48c9-927a-f51f0c89760d	2015-05-20 18:10:16.225917
446	225	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a case study, a patient with anal melanoma harboring a 7 codon duplication\n  in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after\n  imatinib treatment.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 35\nsource_id: 162\nvariant_id: 66\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3319cdf2-2d17-4131-ab1e-453d153407a8	2015-05-20 18:10:16.26709
447	226	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive\n  to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation\n  of KIT but did not alter the binding affinity of dasatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 163\nvariant_id: 71\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	88d72170-5263-4ee7-9b7b-36090fe01318	2015-05-20 18:10:16.315845
448	227	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The melanoma cell line WM3211, which harbors the L576P mutation, is not\n  sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the\n  L576P mutation alters the conformation of KIT and reduces the binding affinity of\n  imatinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 163\nvariant_id: 71\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b254361b-1987-4d0c-a194-0525cd520427	2015-05-20 18:10:16.358478
449	228	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Ba/F3 cells harboring the KIT L576P mutation are sensitive to dasantinib,\n  nilotinib and imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 164\nvariant_id: 71\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	da3efdfb-beba-4956-9853-90d8e5a7bc55	2015-05-20 18:10:16.40619
450	229	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KIT V654A results in imatinib resistance in GIST patient-derived cell\n  lines.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 34\nsource_id: 165\nvariant_id: 72\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55594258-55594258 (T->C)\ndrug_interaction_description: \n	1	\N	\N	4dff6a6a-7ea1-43b2-a956-6ec35ca1b514	2015-05-20 18:10:16.459774
451	230	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In GIST tumor cells and patients harboring KIT V654A mutation, SU11248\n  is effective for those that are refractory to imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 34\nsource_id: 166\nvariant_id: 72\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55594258-55594258 (T->C)\ndrug_interaction_description: \n	1	\N	\N	1a458ab2-a1d2-41f9-9fb0-e7723e3bb80a	2015-05-20 18:10:16.504226
452	231	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with colorectal cancer who harbor KRAS mutation have low response\n  rate to cetuximab\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 167\nvariant_id: 73\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	38a71a6b-6c4b-449c-8b32-c189d5720a80	2015-05-20 18:10:16.544381
453	232	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS mutation status was not predictive of response to regorafenib treatment\n  in patients that had received standard therapy and progressed within 3 months of\n  their last treatment\nclinical_significance: Sensitivity\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 168\nvariant_id: 74\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e1731235-2cf3-40dd-b4b2-7dfff8603f8b	2015-05-20 18:10:16.583701
454	233	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In NSCLC, Exon 2 KRAS mutations were associated with resistance to the\n  EGFR kinase inhibitors gefitinib and erlotinib\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 169\nvariant_id: 74\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	743bc1f3-8b7d-46b5-8385-0cfbb4a0d99b	2015-05-20 18:10:16.627336
455	234	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Children with early age leukaemia who had second hand smoke exposure\n  are more likely to harbor KRAS mutation.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 36\nsource_id: 170\nvariant_id: 75\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a5300417-f5ec-4248-96ae-9fb777270e71	2015-05-20 18:10:16.669465
456	235	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with stage III colorectal cancer undergoing chemotherapy,\n  KRAS G12 mutation did not impact overall or disease free survival.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 8\nsource_id: 171\nvariant_id: 75\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d56294a6-eae1-4236-ad7b-d157030f70f2	2015-05-20 18:10:16.708837
457	236	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of KRAS mutations in MM patients is prognostic for shorter\n  overall and progression free survival\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 37\nsource_id: 172\nvariant_id: 75\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	72cfa36c-f0a5-42ea-b871-3fb8ef175688	2015-05-20 18:10:16.745182
458	237	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS mutations in lung cancer patients are not associated with smoking\n  history, age or gender\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 173\nvariant_id: 75\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	51391df0-fb52-48bf-832a-eff354eb1d42	2015-05-20 18:10:16.784232
459	238	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: There is no strong association between KRAS mutation status and overall\n  or progression free survival in patients with NSCLC\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 174\nvariant_id: 75\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	155afb76-0d56-4dac-99c6-da9898c676a7	2015-05-20 18:10:16.819805
460	239	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A meta-analysis showed KRAS mutation is associated with worse outcome\n  in patients with NSCLC\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 175\nvariant_id: 75\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8f1b7b3b-a264-4276-8e27-ae292dd3f560	2015-05-20 18:10:16.855193
461	240	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Chemotherapy-refractory patients with colorectal cancer harboring KRAS\n  mutations (primarily G12/G13) had lower response and disease control rates and shorter\n  progression free and overall survival following cetuximab plus chemotherapy than\n  those with wildtype KRAS\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 76\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3f224bfa-e0d4-4a1a-849c-2c3bbb586e12	2015-05-20 18:10:16.886718
462	241	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS mutations were significantly associated with lack of response to\n  cetuximab in patients with advanced colorectal cancer\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 6\nsource_id: 176\nvariant_id: 76\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	89132598-1dc7-4124-af33-88659c16e605	2015-05-20 18:10:16.928631
463	242	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS mutations were significantly associated with reduced progression-free\n  and overall survival in patients with advanced colorectal cancer\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 1\ndisease_id: 6\nsource_id: 176\nvariant_id: 76\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e2f39365-b67a-4a5c-9018-9c79e6c8e72c	2015-05-20 18:10:16.958495
464	243	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12 mutations were the primary predictor of EGFR TKI resistance\n  in patients with lung adenocarcinoma.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 38\nsource_id: 177\nvariant_id: 146\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c45bc6d9-cf31-475c-9a64-7940e188e78b	2015-05-20 18:10:16.995441
465	244	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12C occur more frequently in women than men\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 17\nsource_id: 178\nvariant_id: 77\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398285-25398285 (C->A)\ndrug_interaction_description: \n	1	\N	\N	381489e4-018a-4837-b5f4-32d2f983ee11	2015-05-20 18:10:17.040544
466	245	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12 mutations were the primary predictor of EGFR TKI resistance\n  in patients with lung adenocarcinoma.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 38\nsource_id: 177\nvariant_id: 77\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d0215916-1d96-4afb-8e6d-9f5ce243fe71	2015-05-20 18:10:17.08612
467	246	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12D mutation occurs in never smokers significantly more often than\n  in smokers\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 17\nsource_id: 178\nvariant_id: 78\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398284-25398284 (C->T)\ndrug_interaction_description: \n	1	\N	\N	69d3b150-fc07-43f0-80b5-5c356913bc2a	2015-05-20 18:10:17.164911
468	247	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance\n  to dabrafenib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 179\nvariant_id: 78\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398284-25398284 (C->T)\ndrug_interaction_description: \n	1	\N	\N	8be4ae40-70fc-44fa-a6d6-022f96a74d26	2015-05-20 18:10:17.209123
469	248	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy,\n  in a lung cancer model with KRAS G12D mutation led to marked tumor regression.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 180\nvariant_id: 78\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398284-25398284 (C->T)\ndrug_interaction_description: \n	1	\N	\N	1d34139c-bd32-40ab-9867-2074c1e59a5a	2015-05-20 18:10:17.251514
470	249	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12 mutations were the primary predictor of EGFR TKI resistance\n  in patients with lung adenocarcinoma.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 38\nsource_id: 177\nvariant_id: 78\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d7276ead-f585-4df4-b4a5-a822aa461dd0	2015-05-20 18:10:17.288924
471	250	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G12 mutations were the primary predictor of EGFR TKI resistance\n  in patients with lung adenocarcinoma.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 38\nsource_id: 177\nvariant_id: 145\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2aab9358-6751-472d-9a09-506c29ccfc2f	2015-05-20 18:10:17.331554
472	251	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Children with early age leukaemia who had second hand smoke exposure\n  are more likely to harbor KRAS mutation.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 36\nsource_id: 170\nvariant_id: 79\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	81cc0e3d-ecac-460f-af5d-78e09e502d81	2015-05-20 18:10:17.368862
473	252	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of KRAS mutations in MM patients is prognostic for shorter\n  overall and progression free survival\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 39\nsource_id: 172\nvariant_id: 79\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9b220966-84ba-4307-9e64-9289e9c67caf	2015-05-20 18:10:17.410597
474	253	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS mutations in lung cancer patients are not associated with smoking\n  history, age or gender\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 173\nvariant_id: 79\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a366e2ac-f538-42cc-bad9-ea39cadf0838	2015-05-20 18:10:17.440377
475	254	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment\n  in isogenic SW48 cells and in a mouse xenograft model\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 8\nsource_id: 181\nvariant_id: 80\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398281-25398281 (C->T)\ndrug_interaction_description: \n	1	\N	\N	aa2e0213-2804-426f-ad86-283cae5a8193	2015-05-20 18:10:17.471507
476	255	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment\n  in isogenic SW48 cells and in a mouse xenograft model\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 8\nsource_id: 181\nvariant_id: 80\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398281-25398281 (C->T)\ndrug_interaction_description: \n	1	\N	\N	2447a5c6-fbd2-4d78-9e37-52b4e7bf4117	2015-05-20 18:10:17.508134
477	256	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G13D mutation is associated with better response to Cetuximab with\n  longer progression-free and overall survival in colorectal patients compared to\n  other KRAS\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 8\nsource_id: 181\nvariant_id: 80\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398281-25398281 (C->T)\ndrug_interaction_description: \n	1	\N	\N	10dc71fa-bae8-4fa6-9442-5da69261378e	2015-05-20 18:10:17.541266
478	257	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: KRAS G13D mutation is associated with better response to Cetuximab with\n  longer progression-free and overall survival in colorectal patients compared to\n  other KRAS\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 8\nsource_id: 181\nvariant_id: 80\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 12:25398281-25398281 (C->T)\ndrug_interaction_description: \n	1	\N	\N	4b5a1d2e-6338-4371-aafc-93aa829b00f3	2015-05-20 18:10:17.57191
479	258	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The MAP2K1 P124S mutation confers increased resistance to AZD6244 inhibition\n  by about 5 fold.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 182\nvariant_id: 81\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 15:66729162-66729162 (C->T)\ndrug_interaction_description: \n	1	\N	\N	bebaa375-50ec-4590-b3c2-b7f08437e879	2015-05-20 18:10:17.610584
480	259	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MAP2K1 Q56P confers increased resistance to inhibition by AZD6244 by\n  100 fold.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 7\nsource_id: 183\nvariant_id: 82\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 15:66727451-66727451 (A->C)\ndrug_interaction_description: \n	1	\N	\N	bcb46c2e-245f-4ff3-9778-e49c95d7b5d4	2015-05-20 18:10:17.648991
481	260	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase\n  inhibitors Imatinib and GW-2580\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 20\nsource_id: 100\nvariant_id: 83\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	90207675-3f1d-4da9-8408-2e7ca019b58a	2015-05-20 18:10:17.686385
482	261	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804),\n  MET amplification and EGFR T790M were found to be the primary drivers of resistance.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 120\nvariant_id: 144\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	fddf27fa-4e2f-4df6-a0e9-22416461cb20	2015-05-20 18:10:17.731087
483	262	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MGMT promoter methylation has been shown to confer sensitivity to alkylating\n  agents, such as carmustine, in glioblastoma cells.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 40\nsource_id: 184\nvariant_id: 84\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0b16da08-8fba-40e8-a094-5040de9de9d6	2015-05-20 18:10:17.778237
484	263	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: MGMT promoter methylation was associated with increased overall and disease-free\n  survival as well as tumor regression in patients with gliomas.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 40\nsource_id: 184\nvariant_id: 84\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	271e313d-18bc-4e67-b153-b1b238146f2e	2015-05-20 18:10:17.817655
485	264	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor,\n  such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may\n  be useful in treating patients with initial resistance to alkylating agents.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 40\nsource_id: 184\nvariant_id: 84\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	33b3ed9f-94ea-47b1-bf52-3db549bb7f9a	2015-05-20 18:10:17.852084
486	265	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a randomized clinical trial, patients with MGMT promoter methyaltion\n  benefitted from temozolomide. This benefit was also methylation status dependent,\n  as those without methylation did not see increased survival.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 2\ndisease_id: 40\nsource_id: 185\nvariant_id: 84\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4b2aa425-59d5-4c13-b984-bb2799e30bd3	2015-05-20 18:10:17.887663
487	266	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NOTCH1 gain-of-function mutations, including D1643H, have shown to be\n  correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 186\nvariant_id: 133\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	22115227-bb92-4f54-9a5b-ca43cf0b67ca	2015-05-20 18:10:17.925787
488	267	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NOTCH1 gain-of-function mutations, including R2328W, have shown to be\n  correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 186\nvariant_id: 134\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c4093118-b79b-4bf2-aacc-11e7cc66f3fc	2015-05-20 18:10:17.964632
489	268	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NOTCH1 gain-of-function mutations, including S2275fs, have shown to be\n  correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 186\nvariant_id: 136\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	fb6ed4c5-ba5a-4739-b9d9-ebecd3e9db84	2015-05-20 18:10:17.997982
490	269	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NOTCH1 gain-of-function mutations, including V2444fs, have shown to be\n  correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 3\nsource_id: 186\nvariant_id: 135\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9b2ede7b-e811-4e0b-9083-b146b90e4b09	2015-05-20 18:10:18.031516
491	270	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: ATRA treatment did not effect overall survival in patients <60 years\n  old with NPM1 mutation regardless of FLT3-ITD status\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 127\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6fa6d2eb-30ea-45c5-8608-b39d7dc27ad9	2015-05-20 18:10:18.065804
492	271	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: ATRA treatment improved overall and relapse-free survival in older (>60)\n  patients with mutant NPM1 and without FLT3-ITD\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 187\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4b487667-7bb2-4481-9fa8-8b1314a51c8c	2015-05-20 18:10:18.104772
493	272	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Young patients (18-60) with NPM1 mutations had improved overall survival\n  following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis.\n  However, the adjusted p-value for multiple testing is 0.11.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 188\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0c7d35f8-cec5-4df2-ab66-a48f4cc29e99	2015-05-20 18:10:18.144487
494	273	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were not associated with the M3 acute myeloid leukemia\n  FAB subtype (0/55).\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 189\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	785c7d80-11a7-468d-955e-535d42862649	2015-05-20 18:10:18.178059
495	274	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid\n  leukemia.\nclinical_significance: Negative\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 190\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9524d668-d797-4b0a-b092-75f8503f5f46	2015-05-20 18:10:18.215974
496	275	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: AML with mutated NPM1 is a provisional entity in WHO classification of\n  acute myeloid leukemia (AML). This mutation should be tested for in clinical trials\n  and is recommended for testing in patients with cytogentically normal AML.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 2\ndisease_id: 19\nsource_id: 191\nvariant_id: 85\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b4378f33-febf-4253-bc85-16c68432e124	2015-05-20 18:10:18.250511
497	276	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with de novo AML as well as M4 and M5\n  FAB subtypes\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 131\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	04168193-3b66-4c00-bfaf-d93cd9dabb04	2015-05-20 18:10:18.281169
498	277	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute\n  myeloid leukemia.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 190\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	339a4f0d-6d3a-43e2-a183-b7686222f007	2015-05-20 18:10:18.315403
499	278	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with M5a and M5b FAB subtypes of acute\n  myeloid leukemia\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 189\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a8e803b9-bb8b-4c86-8485-dc2c68e91ee3	2015-05-20 18:10:18.352612
500	279	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with normal karyotype in older (>60) patients\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 187\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d8857b31-0697-4a9c-9c1a-3ee8738ad6e9	2015-05-20 18:10:18.387192
501	280	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CD33 and CD123 expression was significantly increased in patients with\n  NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33\n  and anti-CD123 therapy\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 192\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9c6e592f-3e36-4769-87a4-9b5f3c8af8f0	2015-05-20 18:10:18.424733
502	281	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: CD33 expression was significantly increased in patients with NPM1 mutation\n  with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 192\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	bab38e56-93e0-49d9-bef3-caba6d71e8bf	2015-05-20 18:10:18.457103
503	282	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutation without FLT3-ITD was associated with reduced relapse risk\n  and increased overall survival in young adult acute myeloid leukemia patients (median\n  age 43)\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 131\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1af5766c-d917-41eb-af6e-a1221c1cc947	2015-05-20 18:10:18.487734
504	283	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with NPM1 mutations were associated with improved complete remission\n  rates as well as overall and disease free survival when all ages and karyotype were\n  analyzed; however, when only normal karyotype patients were analyzed, only complete\n  remission rates were improved\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 187\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c0a369be-b96d-469d-9b7f-207807eb879a	2015-05-20 18:10:18.527466
505	284	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In young AML patients (<60 years old), DNMT3A mutation status was not\n  predictive of overall and relapse free survival in patients with NPM1 mutations\n  and wildtype FLT3 or wildtype NPM1 and FLT3-ITD\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 107\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	22fc49bb-2213-4ec1-bfcc-1928c023a3cb	2015-05-20 18:10:18.563674
506	285	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Mutation status of IDH1 did not change event-free survival of patients\n  with an NPM1 mutation\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 141\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c61bff46-255d-4eec-a70e-3721a51410da	2015-05-20 18:10:18.627229
507	286	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Complete remission rates were higher and both disease-free and overall\n  survival were longer for patients with Exon 12 NPM1 mutations.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 189\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	44209327-5647-4d3c-80b7-6e3f6ae7f6e4	2015-05-20 18:10:18.661608
508	287	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Complete remission rates were higher and event-free survival was longer\n  for normal karyotype AML patients with Exon 12 NPM1 mutations.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 190\nvariant_id: 85\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7a008397-7cde-4c3d-b674-6828e4fc3b21	2015-05-20 18:10:18.693625
509	288	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cytoplasmic localization of NPM in AML patients was an independent prognositic\n  factor associated with complete remission in response to induction therapy in a\n  multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 193\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0f9f1d5a-b44b-4444-b90c-369a1be23a8a	2015-05-20 18:10:18.727188
510	289	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Event-free survival was significantly improved in patients with both\n  NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone\n  2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis\n  3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal\n  karyotype patients were analyzed\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 136\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b9233419-afc7-4407-afcb-990923b4d351	2015-05-20 18:10:18.762739
511	290	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Intermediate risk patients with mutant NPM1 had improved overall survival\n  with the presence of either IDH1 or IDH2 mutations than those wildtype for both\n  IDH1 and IDH2\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 188\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6e221c9d-a265-41fc-9dd1-72b7cb1ca6a3	2015-05-20 18:10:18.792576
512	291	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Normal karyotype patients with NPM1 mutation and without FLT3-ITD had\n  improved overall and relapse-free survival, complete remission rates and remission\n  duration compared to all other combinations of mutants\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 194\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b452efcc-d856-488f-a6d6-35ba91812beb	2015-05-20 18:10:18.826679
513	292	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutation was associated with higher complete remission rates, lower\n  cumulative incidence of relapse and higher overall survival in intermediate risk\n  AML patients\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 195\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	34cc2ac2-1f1c-48ff-86fe-e28cba427284	2015-05-20 18:10:18.860452
514	293	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutation was associated with increased overall, event-free and relapse-free\n  survival and remission after induction therapy in the entire cohort and in the cytogenetically\n  normal subset of patients\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 196\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	bed121db-cbfc-4898-90fd-d8df2c69df92	2015-05-20 18:10:18.895864
515	294	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutation without FLT3-ITD was significantly associated with complete\n  remission\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 98\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	97d784cc-04fb-46fe-bf69-ab87f36350aa	2015-05-20 18:10:18.932161
516	295	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with increased complete remission rates\n  as well as longer overall disease free survival in normal karyotype AML patients\n  >59 years old, particularly in those >69 years old\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 197\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	59c0ebbe-925f-4542-b033-0e4e39974a72	2015-05-20 18:10:18.965553
517	296	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation\n  and without FLT3-ITD have increased overall survival, relapse-free survival and\n  response to induction chemotherapy\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 198\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	2bc02bf4-3845-4de6-9d52-f2ce763b71b8	2015-05-20 18:10:18.997879
518	297	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Coocurrence of FLT3-ITD mutations significantly reduced overall survival\n  of normal karyotype AML patients\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 189\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	63e1a00a-64ae-491b-8527-9edc84e3e5c9	2015-05-20 18:10:19.03296
519	298	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse\n  in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction\n  in NPM1 levels following first line therapy (N=15)\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 199\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0159e21f-cc4d-452e-b9d5-e8d06a2d9bcf	2015-05-20 18:10:19.070629
520	299	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival\n  compared to patients with wildtype FLT3\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0c59a82e-6acb-4dba-b889-e7d87c612d99	2015-05-20 18:10:19.113362
521	300	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with NPM1 mutations and low levels of FLT3-ITD have worse overall\n  survival and cumulative incidence of relapse than those with NPM1 mutations alone\n  in intermediate risk AML patients\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 195\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	08825d0e-f7bf-45a6-b4b3-e73b93568471	2015-05-20 18:10:19.149206
522	301	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: TET2 mutation reduces overall survival of normal karyotype patients with\n  either an NPM1 mutation or NPM1 mutation without FLT3-ITD\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 200\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	3c9e201d-3291-4fdb-bad8-1d0e2d139937	2015-05-20 18:10:19.183166
523	302	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable,\n  a higher ratio was associated with reduced event-free survival in patients with\n  an NPM1 mutation\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 132\nvariant_id: 85\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	6744e4a2-dc5b-424c-9f29-db72a139f23b	2015-05-20 18:10:19.217226
524	303	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NSC348884 combined with ATRA treatment induces apoptosis in primary AML\n  cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1\n  and FLT3-ITD\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 201\nvariant_id: 85\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7e769fe6-e656-4cbb-a400-680a3f958b45	2015-05-20 18:10:19.254835
525	304	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: For patients with NPM1 mutation that achieved CR following induction\n  therapy, relapse-free survival was improved following treatment with valproic acid\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 202\nvariant_id: 85\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5193acd3-fca2-4f2a-b56a-ca4de1e55dce	2015-05-20 18:10:19.293026
526	305	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: No NPM1 mutations were identified in patients with favorable risk cytogenetics\n  (79/215 patients)\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 86\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 5:170837546-170837547 (0->TCAG)\ndrug_interaction_description: \n	1	\N	\N	f457ff9e-b2f6-42d7-911b-11babf4bce2e	2015-05-20 18:10:19.329157
527	12	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: NPM1 Exon 12\ndescription: \n	1	\N	\N	cce34214-7c5d-4cef-b03b-d48d9e043e1e	2015-05-20 18:10:19.349216
528	306	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutations were associated with intermediate risk cytogenetics (including\n  normal karyotype)\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 105\nvariant_id: 86\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 5:170837546-170837547 (0->TCAG)\ndrug_interaction_description: \n	1	\N	\N	f720da6b-1953-485e-b5b0-a781cb86b5db	2015-05-20 18:10:19.375777
529	307	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM\n  when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization\n  of NPM in AML patients was associated with good response to induction therapy.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 193\nvariant_id: 86\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 5:170837546-170837547 (0->TCAG)\ndrug_interaction_description: \n	1	\N	\N	f698cfaa-621c-423c-a58e-d86b0562861e	2015-05-20 18:10:19.41401
530	308	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 19\nsource_id: 201\nvariant_id: 86\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 5:170837546-170837547 (0->TCAG)\ndrug_interaction_description: \n	1	\N	\N	e0c9f0c9-c60d-4813-a04a-91bd6f7e0353	2015-05-20 18:10:19.455857
531	309	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with stage IV melanoma, NRAS mutation was associated with\n  reduced median survival compared to patients with wildtype NRAS\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 203\nvariant_id: 87\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a7fa1ecf-c737-4f95-9409-9ee673e1748f	2015-05-20 18:10:19.502334
560	338	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Rapamycin inhibits transformation induced by mutation in PIK3CA\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 215\nvariant_id: 102\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	6b4bce14-3e40-45c8-bad8-6865c2516d4e	2015-05-20 18:10:20.634913
532	310	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of NRAS mutation in AML patients does not impact diease\n  prognosis (resistant disease, disease-free survival, complete remission rate, relapse\n  rate, induction death)\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 204\nvariant_id: 88\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	470a9017-8605-410a-9f9c-2e2c6a5d38fe	2015-05-20 18:10:19.541948
533	311	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with colorectal cancer harboring NRAS mutation have poorer survival\n  outcome and worse prognosis than patients with wildtype NRAS.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 205\nvariant_id: 88\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	783045a5-5308-4616-b21f-fed44b34db36	2015-05-20 18:10:19.575422
534	312	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with stage IV melanoma, NRAS mutation was associated with\n  reduced median survival compared to patients with wildtype NRAS\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 203\nvariant_id: 88\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	aecaff07-7b60-4694-9e00-cbb13f3a13a1	2015-05-20 18:10:19.607832
535	313	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with colorectal cancer harboring NRAS mutation have poorer survival\n  outcome and worse prognosis than patients with wildtype NRAS.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 2\ndisease_id: 6\nsource_id: 205\nvariant_id: 89\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e1e9331d-2bc7-4ea5-8f95-9bf51ef1c946	2015-05-20 18:10:19.64421
536	314	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with colorectal cancer harboring NRAS mutation have poorer survival\n  outcome and worse prognosis than patients with wildtype NRAS.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 2\ndisease_id: 6\nsource_id: 205\nvariant_id: 90\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	79d40dfb-20ba-43ec-acf3-5a4e963c0bb5	2015-05-20 18:10:19.677936
537	315	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: NRAS mutation status does not impact overall, event-free or disease-free\n  survival in patients with AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 206\nvariant_id: 91\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	06c6f0f6-e411-4eaf-ba48-b03b747b6971	2015-05-20 18:10:19.714912
538	316	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Likely due to increased reliance of mutant NRAS on HSP90 for stabilization,\n  inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic\n  malignant melanoma with an NRAS G13D mutation\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 207\nvariant_id: 92\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 1:115258744-115258744 (C->T)\ndrug_interaction_description: \n	1	\N	\N	9d4de230-68b8-4bea-bdc6-36159b070d14	2015-05-20 18:10:19.750315
539	317	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In chemotherapy-refractory patients with colorectal cancer, NRAS mutation\n  status (primarily Q61) was not informative for disease control rate, progression\n  free survival or overall survival following cetuximab plus chemotherapy.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 93\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	42037f21-7194-4cd0-8a2b-4ceff6c7d68f	2015-05-20 18:10:19.789982
540	318	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Chemotherapy-refractory patients with colorectal cancer harboring NRAS\n  mutation (primarily Q61) have a significantly lower response rate to cetuximab than\n  patients wildtype for NRAS.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 93\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b9feb12b-32eb-4a6f-a24b-939476f477f0	2015-05-20 18:10:19.831665
541	319	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Melanoma associated with NRAS Q61 mutation was more often associated\n  with those at the extremity than those at the trunk\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 208\nvariant_id: 93\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	47e38d57-c631-4817-8c77-e4fcb780ab63	2015-05-20 18:10:19.868923
542	320	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 209\nvariant_id: 93\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	0c07b58d-d1da-4eab-8956-9170944444b3	2015-05-20 18:10:19.906591
543	321	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide\n  resulted in disease free survival of 14 months\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 210\nvariant_id: 94\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 1:115256528-115256529 (TT->CA)\ndrug_interaction_description: \n	1	\N	\N	ade2af9b-364e-45ed-9d8e-7b747beb2fdb	2015-05-20 18:10:19.945635
544	322	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In a melanoma patient with Q61R mutation, treatment with temozolomide\n  resulted in overall survival of 16 months\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 7\nsource_id: 210\nvariant_id: 95\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 1:115256528-115256529 (TT->CC)\ndrug_interaction_description: \n	1	\N	\N	c0f64a08-9e2d-4a92-9d82-1afd391d9c7e	2015-05-20 18:10:19.975493
545	323	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance,\n  crenolanib was significantly more potent at inhibiting kinase activity than imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 41\nsource_id: 211\nvariant_id: 96\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152092-55152093 (GA->AT)\ndrug_interaction_description: \n	1	\N	\N	5ac66bad-3a00-4cdc-9892-37d3c4229bcd	2015-05-20 18:10:20.043127
546	324	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance,\n  crenolanib was significantly more potent at inhibiting kinase activity than imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 41\nsource_id: 211\nvariant_id: 97\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152093-55152093 (A->T)\ndrug_interaction_description: \n	1	\N	\N	da492142-0e67-4a26-b545-65d0ed0493a2	2015-05-20 18:10:20.093597
547	325	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: GIST cancer with D842V mutation is resistant to imatinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 41\nsource_id: 212\nvariant_id: 97\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152093-55152093 (A->T)\ndrug_interaction_description: \n	1	\N	\N	1833806c-65bb-4ea3-93e8-3f0582a20bb6	2015-05-20 18:10:20.137004
548	326	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: While cancer with PVGFRA V561D mutation is known to be sensitive to Imatinib,\n  double mutation of V561D and D842V mutants are resistant to imatinib.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 41\nsource_id: 165\nvariant_id: 97\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152093-55152093 (A->T)\ndrug_interaction_description: \n	1	\N	\N	410e207d-918a-46e5-90e1-8ab63a7acf4d	2015-05-20 18:10:20.177473
549	327	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: GIST tumors harboring PDGFRA D842V mutation are more likely to be benign\n  than malignant.\nclinical_significance: Negative\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 41\nsource_id: 213\nvariant_id: 97\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152093-55152093 (A->T)\ndrug_interaction_description: \n	1	\N	\N	ad96c12b-857a-4ed5-bdeb-7b0c53196215	2015-05-20 18:10:20.219885
550	328	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance,\n  crenolanib was significantly more potent at inhibiting kinase activity than imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 41\nsource_id: 211\nvariant_id: 98\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 4:55152092-55152092 (G->T)\ndrug_interaction_description: \n	1	\N	\N	23bedd10-719d-4d2d-89c9-b709b8517bf8	2015-05-20 18:10:20.262755
551	329	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib\n  resistance, crenolanib was significantly more potent at inhibiting kinase activity\n  than imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 41\nsource_id: 211\nvariant_id: 99\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a92d671a-f42f-4e40-9063-ed5414a82f9e	2015-05-20 18:10:20.302354
552	330	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In CHO cells with PDGFRA D842-843IM mutation that have shown imatinib\n  resistance, crenolanib was significantly more potent at inhibiting kinase activity\n  than imatinib.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 41\nsource_id: 211\nvariant_id: 100\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	94592882-350c-4b07-b5e6-eaebe08dc016	2015-05-20 18:10:20.342051
553	331	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer cell lines with E542K/E545K mutations showed increased\n  sensitivity to CH5132799 than cells with wild-type PIK3CA gene.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 214\nvariant_id: 101\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	b53efb4b-9e74-4332-9c6f-a3c8c97ff393	2015-05-20 18:10:20.385846
554	332	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Rapamycin inhibits transformation induced by mutation in PIK3CA\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 215\nvariant_id: 101\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	e6afd59c-54a9-4efd-b9a3-30d1ecd55b72	2015-05-20 18:10:20.423796
555	333	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20\n  were associated with lack of panitumumab or cetuximab response.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 101\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	76854c31-d931-4947-8e91-458b7c6b1874	2015-05-20 18:10:20.458049
556	334	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not\n  either alone, is prognostic for worse overall survival and cancer specific survival.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 217\nvariant_id: 101\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	037feb2e-478d-4b7b-884e-2cb63d428c5f	2015-05-20 18:10:20.493417
557	335	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of exon 9 (such as E542K) or exon 20 mutations were associated\n  with poorer survival compared to those with wild-type PIK3CA mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 101\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	de31cfb3-1105-4edc-b00e-6f47692fa17a	2015-05-20 18:10:20.538302
558	336	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PIK3CA mutation status was not predictive of response to regorafenib\n  treatment in patients that had received standard therapy and progressed within 3\n  months of their last treatment\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 168\nvariant_id: 101\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936082-178936082 (G->A)\ndrug_interaction_description: \n	1	\N	\N	61bbb7f9-609d-4e4b-b7da-3d6def1e2448	2015-05-20 18:10:20.573981
559	337	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer cell lines with E542K/E545K mutations showed increased\n  sensitivity to CH5132799 than cells with wild-type PIK3CA gene.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 214\nvariant_id: 102\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	e1f8f643-5e5c-4639-bc81-54f9a735c78d	2015-05-20 18:10:20.603347
561	339	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20\n  were associated with lack of panitumumab or cetuximab response.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 102\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	9e8588d4-4222-4e1f-b249-26d5da22561d	2015-05-20 18:10:20.665721
562	340	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not\n  either alone, is prognostic for worse overall survival and cancer specific survival.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 217\nvariant_id: 102\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	e7c73579-ab18-477c-9ee5-99ce8966b78c	2015-05-20 18:10:20.713629
563	341	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of exon 9 (such as E545K) or exon 20 mutation may result\n  in poorer survival compared to those with wild-type PIK3CA mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 102\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	3c7f8ced-b77f-46a0-b854-67c21cac7050	2015-05-20 18:10:20.761505
564	342	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PIK3CA mutation status was not predictive of response to regorafenib\n  treatment in patients that had received standard therapy and progressed within 3\n  months of their last treatment\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 168\nvariant_id: 102\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178936091-178936091 (G->A)\ndrug_interaction_description: \n	1	\N	\N	452cf927-b028-4781-9bee-67f25cdec709	2015-05-20 18:10:20.814365
565	343	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Chemotherapy-refractory patients with colorectal cancer harboring Exon\n  20 PIK3CA mutations had lower response and disease control rates as well as shorter\n  progression free and overall survival following cetuximab plus chemotherapy than\n  those with wildtype PIK3CA\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 103\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	4be6435b-8514-403b-9332-9b45d237c663	2015-05-20 18:10:20.866713
566	344	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA\n  mutations (Exon 9) had no significant impact on response rate, disease control rate,\n  progression free surivival or overall survival following cetuximab plus chemotherapy\n  than those with wildtype PIK3CA\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 70\nvariant_id: 104\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	21484e66-e4e9-4689-ac3b-8e35369f105a	2015-05-20 18:10:20.90432
567	345	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer cell lines with H1047R mutation showed increased sensitivity\n  to CH5132799 than cells with wild-type PIK3CA gene.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 214\nvariant_id: 105\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178952085-178952085 (A->G)\ndrug_interaction_description: \n	1	\N	\N	181ae3ae-eb1f-47bf-9f55-a99db9c1d92b	2015-05-20 18:10:20.938689
568	346	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Rapamycin inhibits transformation induced by mutation in PIK3CA\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 215\nvariant_id: 105\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178952085-178952085 (A->G)\ndrug_interaction_description: \n	1	\N	\N	4eaa6bc4-9bf3-4d31-8243-8fba63418904	2015-05-20 18:10:20.970618
569	347	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R)\n  were associated with lack of panitumumab or cetuximab response.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 105\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178952085-178952085 (A->G)\ndrug_interaction_description: \n	1	\N	\N	43cabd90-dbd2-4fc5-a869-27620db1fe87	2015-05-20 18:10:21.007632
570	348	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The presence of exon 20 (such as H1047R) or exon 9 mutation may result\n  in poorer survival compared to those with wild-type PIK3CA mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 6\nsource_id: 216\nvariant_id: 105\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178952085-178952085 (A->G)\ndrug_interaction_description: \n	1	\N	\N	8b32338f-7a61-4adb-a06a-11f1fe393967	2015-05-20 18:10:21.046242
571	349	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PIK3CA mutation status was not predictive of response to regorafenib\n  treatment in patients that had received standard therapy and progressed within 3\n  months of their last treatment\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 6\nsource_id: 168\nvariant_id: 105\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 3:178952085-178952085 (A->G)\ndrug_interaction_description: \n	1	\N	\N	6cae551a-a8e0-4903-b4bf-ac5bd83fe496	2015-05-20 18:10:21.078022
572	350	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Fusion protein degradation is accelerated upon ATRA treatment of acute\n  promyelocytic cells at pharmalogical concentrations.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 42\nsource_id: 218\nvariant_id: 106\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8e4bf594-7ad4-45c5-b14c-a4a3f553eace	2015-05-20 18:10:21.115845
573	351	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA\n  resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular\n  carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary\n  and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation\n  and Western blot analyses confirmed that the chimeric protein is expressed in tumor\n  tissue, and a cell culture assay indicated that it retains kinase activity.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 21\nsource_id: 102\nvariant_id: 107\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	d99a62dc-ff31-4dde-84df-cf7524b2974d	2015-05-20 18:10:21.154742
574	352	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Cells with PTEN deficiency have been shown to exhibit slowed growth in\n  reponse to PI3K-mTOR inhibitors.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 2\nsource_id: 219\nvariant_id: 108\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:89717672-89717672 (C->T)\ndrug_interaction_description: \n	1	\N	\N	66ce8f83-54ba-4130-a4c3-cb00b20f1766	2015-05-20 18:10:21.195341
575	13	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: PTEN Loss-of-Function\ndescription: \n	1	\N	\N	b4ab534d-5e8d-41e7-8755-5cee2f6eeb14	2015-05-20 18:10:21.215944
576	353	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PTEN nonsense mutations, including R233*, have been shown to be inactivating\n  and loss-of-function, but do not have prognostic value in glioblastoma multiforme\n  patients.\nclinical_significance: Poor Outcome\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 40\nsource_id: 220\nvariant_id: 108\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:89717672-89717672 (C->T)\ndrug_interaction_description: \n	1	\N	\N	128cb1c8-1a64-427a-b8ca-8531d731bd54	2015-05-20 18:10:21.253502
577	354	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Fusion protein degradation is accelerated upon ATRA treatment of acute\n  promyelocytic cells at pharmalogical concentrations.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 42\nsource_id: 218\nvariant_id: 109\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ed4529b1-66a8-46b4-bbab-18268e44ed51	2015-05-20 18:10:21.29543
578	355	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Medullary thyroid cancer cells with RET C634W mutation are insensitive\n  to motesanib, compared to wild-type RET.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 43\nsource_id: 221\nvariant_id: 110\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:43609950-43609950 (C->G)\ndrug_interaction_description: \n	1	\N	\N	bc246f4a-95a6-49c9-af76-28a590c44f72	2015-05-20 18:10:21.339299
579	14	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: Motesanib Resistance\ndescription: \n	1	\N	\N	4145c55d-176a-4f03-ba1a-47d9a5911537	2015-05-20 18:10:21.363326
580	356	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led\n  to strong repression of tyroid cancer cell growth.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 43\nsource_id: 222\nvariant_id: 111\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:43617416-43617416 (T->C)\ndrug_interaction_description: \n	1	\N	\N	6ac905e6-15f7-4ae0-a814-2afb0d952d5e	2015-05-20 18:10:21.400037
581	357	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Medullary thyroid cancer cells with RET M918T mutation are insensitive\n  to motesanib, compared to wild-type RET.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 43\nsource_id: 221\nvariant_id: 111\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:43617416-43617416 (T->C)\ndrug_interaction_description: \n	1	\N	\N	20ace0ef-adb2-4f0e-83d8-1ab3d7402cd7	2015-05-20 18:10:21.472537
582	358	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with medullary carcinoma, the presence of RET M918T mutation\n  is associated with increased probability of lymph node metastases.\nclinical_significance: Positive\nevidence_direction: Supports\nevidence_type_id: 1\nevidence_level_id: 3\ndisease_id: 43\nsource_id: 223\nvariant_id: 111\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:43617416-43617416 (T->C)\ndrug_interaction_description: \n	1	\N	\N	c638e9c7-12cd-4db4-ab1b-7e13e5723967	2015-05-20 18:10:21.510394
583	359	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Compared to those who harbor a wild type RET, patients with RET M918T\n  mutation develop larger and more aggressive medullary thyroid cancer.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 43\nsource_id: 224\nvariant_id: 111\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 10:43617416-43617416 (T->C)\ndrug_interaction_description: \n	1	\N	\N	115d648b-2750-4161-b01e-4d6d009780af	2015-05-20 18:10:21.54574
584	360	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with SF3B1 mutations had a statistically significant longer\n  overall survival as well as event free-survival. Both before and after adjustment\n  for age, karyotype and sex.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 225\nvariant_id: 112\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:198267359-198267359 (C->A)\ndrug_interaction_description: \n	1	\N	\N	ec44fd3d-6de3-4c06-8248-ee21da5d521c	2015-05-20 18:10:21.582092
585	361	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with SF3B1 mutations had a statistically significant longer\n  overall survival as well as event free-survival. Both before and after adjustment\n  for age, karyotype and sex.\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 225\nvariant_id: 113\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 2:198266834-198266834 (T->C)\ndrug_interaction_description: \n	1	\N	\N	738a1520-aeb3-4a65-9263-134ad444ee96	2015-05-20 18:10:21.61406
586	362	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast tumors in a mouse model with R175H mutation are more responsive\n  to doxorubicin than breast tumors with wild type TP53.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 11\nsource_id: 226\nvariant_id: 114\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7578406-7578406 (C->T)\ndrug_interaction_description: \n	1	\N	\N	2167068b-5b88-484d-874f-d69ed2b971bb	2015-05-20 18:10:21.655538
587	363	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer patients who harbor R175H mutation have worse overall survival\n  than those with wild type TP53, but have better prognosis than those with R248W\n  mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 227\nvariant_id: 114\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7578406-7578406 (C->T)\ndrug_interaction_description: \n	1	\N	\N	e8321868-99d7-4cbb-a315-6b1c9c978620	2015-05-20 18:10:21.692329
588	364	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer patients who harbor R248Q mutation have worse overall survival\n  than those with wild type TP53, but have better prognosis than those with R248W\n  mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 227\nvariant_id: 115\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577538-7577538 (C->T)\ndrug_interaction_description: \n	1	\N	\N	4137f80c-d1cb-4608-a80f-b0e6bd095253	2015-05-20 18:10:21.728742
589	365	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients harboring TP53 mutation, mutations in DNA contact\n  regions such as R248 are prognostic for a worse relapse-free survival compared to\n  other non-silent mutations in TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 115\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577538-7577538 (C->T)\ndrug_interaction_description: \n	1	\N	\N	61cb8a63-f42d-4c88-b2c3-58cdc541e79d	2015-05-20 18:10:21.764999
590	366	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients harboring R248W mutation, the prognosis is\n  worse than any other hotspot TP53 mutation, as well as worse than patients with\n  wild type TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 227\nvariant_id: 116\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577539-7577539 (G->A)\ndrug_interaction_description: \n	1	\N	\N	fa9c694e-c782-4d81-848e-8d772a3dc7f3	2015-05-20 18:10:21.799314
591	367	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients harboring TP53 mutation, mutations in conserved\n  regions such as R249 are prognostic for a worse overall survival compared to those\n  harboring wild-type TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 117\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577535-7577535 (C->G)\ndrug_interaction_description: \n	1	\N	\N	4d483adf-f9f3-4613-b8f8-5f01d80d0b4d	2015-05-20 18:10:21.840511
592	368	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients harboring TP53 mutation, mutations in conserved\n  regions such as R249 are prognostic for a worse overall survival compared to those\n  harboring wild-type TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 118\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577536-7577536 (T->A)\ndrug_interaction_description: \n	1	\N	\N	f945b73c-2548-4ef1-80f8-175370648091	2015-05-20 18:10:21.872129
593	369	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer patients who harbor R273C mutation have worse overall survival\n  than those with wild type TP53, but have better prognosis than those with R248W\n  mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 227\nvariant_id: 119\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577121-7577121 (G->A)\ndrug_interaction_description: \n	1	\N	\N	869d24b0-1d46-42fd-a507-805da3048d13	2015-05-20 18:10:21.902916
594	370	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients  harboring TP53 mutation, mutations in DNA\n  contact regions such as R273 are prognostic for a worse relapse-free survival compared\n  to other non-silent mutations in TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 119\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577121-7577121 (G->A)\ndrug_interaction_description: \n	1	\N	\N	ca02592e-833b-427b-ba82-e0fa58d2da74	2015-05-20 18:10:21.936561
595	371	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast cancer patients who harbor R273H mutation have worse overall survival\n  than those with wild type TP53, but have better prognosis than those with R248W\n  mutation.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 227\nvariant_id: 120\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577120-7577120 (C->T)\ndrug_interaction_description: \n	1	\N	\N	2b4dcb08-c865-4e95-a068-5e94a1a90746	2015-05-20 18:10:21.969821
596	372	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In breast cancer patients harboring TP53 mutation, mutations in DNA contact\n  regions such as R273 are prognostic for a worse relapse-free survival compared to\n  other non-silent mutations in TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 120\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: 17:7577120-7577120 (C->T)\ndrug_interaction_description: \n	1	\N	\N	fdc027e0-06ca-44dd-bdbb-dba339e33dac	2015-05-20 18:10:22.007882
597	373	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Breast tumor with R175H mutation are more responsive to doxorubicin than\n  breast tumors with wild type TP53.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 11\nsource_id: 228\nvariant_id: 121\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	45c7ea10-6f3a-4cc5-8bf2-a4e48506647f	2015-05-20 18:10:22.046318
598	374	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: A patient with metastatic bladder cancer that responded well to the mTOR\n  inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del,\n  p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations\n  also had mild responses to everolimus.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 44\nsource_id: 229\nvariant_id: 122\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	59573790-5c33-4cd4-9d73-51b4584ebf0a	2015-05-20 18:10:22.085651
599	15	VariantGroup	\N	\N	\N	\N	\N	create	---\nname: TSC Loss\ndescription: \n	1	\N	\N	96e3cccd-8c3d-472a-8841-445b50e0c6a4	2015-05-20 18:10:22.106245
600	375	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Following rapamycin treatment of mice with KrasG12D-induced lung tumors,\n  mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung\n  exhibit increased overall survival, increased apoptosis, reduced proliferation and\n  reduced tumor burden compared to Tsc1 wildtype mice.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 3\nsource_id: 230\nvariant_id: 122\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7c691c55-dad1-4a24-ae06-b921cafbb080	2015-05-20 18:10:22.141593
601	376	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity\n  to everolimus than their wild-type counterparts.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 24\nsource_id: 231\nvariant_id: 123\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	14f6fd3e-90e6-4324-b317-e51b0e95c1eb	2015-05-20 18:10:22.183605
602	377	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity\n  to everolimus than their wild-type counterparts.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 24\nsource_id: 229\nvariant_id: 124\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a9d6d3a9-c396-43fd-9efd-4710bc7facc7	2015-05-20 18:10:22.230176
603	378	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Age, sex, FAB subtype and karyotypes were not statistically significant\n  between AML patients with U2AF Q157P/R mutations and those who harbor wild type\n  U2AF.\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 232\nvariant_id: 125\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	467aed5b-b33d-4eac-9d51-301196a6d17e	2015-05-20 18:10:22.26985
604	379	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with AML, those who harbor Q157P/R mutation of U2AF do not\n  show statistical significance in complete remission rate compared to those who harbor\n  wild type U2AF.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 232\nvariant_id: 125\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	9978eb1a-f0a2-4406-a2f3-3be13db5f805	2015-05-20 18:10:22.300843
605	380	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with MDS, those who harbor Q157P/R mutation of U2AF do not\n  show statistical significance in complete remission rate compared to those who harbor\n  wild type U2AF.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 232\nvariant_id: 125\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e2ae3fb7-4c4d-4ee5-997c-c6e9742e8092	2015-05-20 18:10:22.337023
606	381	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: After adjust for age and cancer stage, presence of U2AF mutation such\n  as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 233\nvariant_id: 125\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	7aa78254-30a4-4e65-b897-58e2c57dc9a0	2015-05-20 18:10:22.376329
607	382	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Age, sex, FAB subtype and karyotypes were not statistically significant\n  between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.\nclinical_significance: Positive\nevidence_direction: Does Not Support\nevidence_type_id: 1\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 232\nvariant_id: 126\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c5169b8a-47b7-46e1-8987-a73a8a953eab	2015-05-20 18:10:22.409364
608	383	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with AML, complete remission rates are not different between\n  patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 19\nsource_id: 232\nvariant_id: 126\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	60b27f36-77b8-4c08-8799-423568b27bec	2015-05-20 18:10:22.444011
609	384	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: In patients with AML, complete remission rates are not different between\n  patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 232\nvariant_id: 126\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	14bc3b44-3842-425d-b7ee-307bba2ea8cf	2015-05-20 18:10:22.480029
610	385	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: After adjust for age and cancer stage, the presence of U2AF mutations\n  such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 4\ndisease_id: 29\nsource_id: 233\nvariant_id: 126\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c081ee0c-1a35-4952-9ae6-3d2e0079ae72	2015-05-20 18:10:22.510059
611	386	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were associated with an inferior response to induction\n  chemotherapy with a higher rate of resistant disease in young (15-60+, median 45)\n  patients with cytogenetically normal AML\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	12520fe2-1c7e-4e27-8f72-7fae3fadc93b	2015-05-20 18:10:22.552629
612	387	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: No differences in relapse-free or overall survival were identified between\n  young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in\n  cytogenetically normal AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8b9adb0a-7a9e-4113-b297-b573c842809b	2015-05-20 18:10:22.585875
613	388	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Rates of complete remission and refractory disease are not different\n  in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young\n  (16-60) patients with cytogenetically normal AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 127\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c650fd36-5f17-4736-a965-0e5140516b58	2015-05-20 18:10:22.626322
614	389	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Mutations  in WT1 were associated with increased risk of recurrence in\n  young patients (15-50) with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 236\nvariant_id: 127\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	07fa3574-7a04-4c56-bfa9-c9405a4281ad	2015-05-20 18:10:22.668716
615	390	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Mutations in WT1 were associated with a worse overall prognosis than\n  patients wildtype for WT1 in young patients (15-50), primarily because of increased\n  risk of disease recurrence\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 236\nvariant_id: 127\nrating: 2\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8f667d48-a1f6-4caf-8674-aa931911f048	2015-05-20 18:10:22.701289
616	391	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had\n  significantly lower complete remission and higher refractory disease rates than\n  those with wildtype WT1 and without FLT3-ITD following induction therapy in young\n  (16-60) patients with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c1b85fb3-4b65-4cc5-80e5-df0efc76601f	2015-05-20 18:10:22.738533
617	392	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT mutations were associated with shorter overall and disease free survival\n  in a cohort of cytogenetically normal, young (<60) AML patients\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 237\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	22f71135-c812-4e5c-a023-150d97e323ec	2015-05-20 18:10:22.800151
618	393	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were a negative prognostic factor for overall survival\n  in young (15-60+, median 45) patients with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	b07ca3c0-b93f-4e79-9356-50fd5fb40048	2015-05-20 18:10:22.845837
619	394	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were associated with a higher cumulative incidence of relapse\n  and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically\n  normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 127\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ce00e698-445b-4885-9373-a21d9ecac668	2015-05-20 18:10:22.892867
620	395	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were associated with an inferior response to induction\n  chemotherapy with a higher rate of resistant disease in young (15-60+, median 45)\n  patients with cytogenetically normal AML\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	cd946866-57de-4088-84cd-f76c907316df	2015-05-20 18:10:22.93616
621	396	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: No differences in relapse-free or overall survival were identified between\n  young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in\n  cytogenetically normal AML\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1f78c473-2566-42e2-8303-3c959184ca77	2015-05-20 18:10:22.98059
622	397	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Rates of complete remission and refractory disease are not different\n  in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young\n  (16-60) patients with cytogenetically normal AML.\nclinical_significance: N / A\nevidence_direction: Does Not Support\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 128\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	8e652042-c21d-45ab-8db5-a060060b7150	2015-05-20 18:10:23.026404
623	398	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had\n  significantly lower complete remission and higher refractory disease rates than\n  those with wildtype WT1 and without FLT3-ITD following induction therapy in young\n  (16-60) patients with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 235\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	48abeb81-c834-4e31-b170-0a2353b1d45a	2015-05-20 18:10:23.070064
624	399	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were a negative prognostic factor for overall survival\n  in young (15-60+, median 45) patients with cytogenetically normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	312e21d3-8a8c-4889-9a54-9db813a5d1c3	2015-05-20 18:10:23.114606
625	400	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were associated with a higher cumulative incidence of relapse\n  and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically\n  normal AML\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 234\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ed50ff23-a7d2-4663-92d9-8dbb1de145bc	2015-05-20 18:10:23.156131
626	401	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: WT1 mutations were associated with shorter overall and disease free survival\n  in a cohort of cytogenetically normal, young (<60) AML patients\nclinical_significance: Poor Outcome\nevidence_direction: Supports\nevidence_type_id: 3\nevidence_level_id: 3\ndisease_id: 19\nsource_id: 237\nvariant_id: 128\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ff1b48df-455d-44e4-8a35-5cf5608bca94	2015-05-20 18:10:23.200666
637	412	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: The patient was confirmed as having a heterozygous MET mutation at M1268T.\n  The patient had a reduction of 35% in the sum of one-dimensional measurements of\n  target lesions after receiving treatment for 53 weeks, achieving a confirmed partial\n  response by RECIST version 1.04.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 53\nsource_id: 247\nvariant_id: 155\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a27a57df-8156-4f44-a66a-175e1b0d8bb0	2015-05-20 18:10:23.698177
627	402	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Two metastatic melanoma patients with the L576P KIT mutation were treated\n  with dasatinib, including one patient previously treated with imatinib. Both patients\n  had marked reduction (>50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity\n  by positron emission tomography (PET) imaging after dasatinib treatment. These data\n  support the selective inhibitory effect of dasatinib against cells harboring the\n  most common KIT mutation in melanoma, and thus has therapeutic implications for\n  acrallentiginous, chronic sun-damaged, and mucosal melanomas.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 45\nsource_id: 163\nvariant_id: 71\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	a0aefb10-6215-411b-833a-2947f5873966	2015-05-20 18:10:23.25262
628	403	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: To formally test this hypothesis, we took advantage of HCT116 cells in\n  which the KRAS D13 mutant allele had been genetically deleted by homologous recombination\n  (15). Strikingly, we found that HCT116-derivative cells retaining only the KRAS\n  WT allele (named HKh-2 and HKe-3; Supplemental Table 3) were sensitive to everolimus,\n  while the parental and the isogenic cells carrying mutated KRAS were equally resistant\n  to this compound (Figure 2A).\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 46\nsource_id: 238\nvariant_id: 80\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	ebe0eb62-2439-41d7-a456-fc6c541c3730	2015-05-20 18:10:23.30223
629	404	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Figure 1 of paper shows that V654A was associated with progression of\n  disease in one case of a mucosal melanoma. Results were from a Phase II clinical\n  trial.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 45\nsource_id: 239\nvariant_id: 72\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	1d67d8de-bb7e-468f-abb9-559b8b5805cb	2015-05-20 18:10:23.345596
630	405	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Dose-dependent, complete response to imatinib of a metastatic mucosal\n  melanoma with a K642E KIT mutation.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 45\nsource_id: 240\nvariant_id: 150\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e487523a-b9b4-4095-a352-7a696e3c2686	2015-05-20 18:10:23.390205
631	406	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: From the screen, we discovered that proteasome inhibitors show selectivity\n  toward BRAF V600Emutant cells, irrespective of PTEN or RB1 expression. Preferential\n  targeting of BRAF-mutant cells by proteasome inhibitors was corroborated in a second\n  BRAF V600E isogenic model, as well as in a panel of colorectal cancer cell lines\n  by the use of the proteasome inhibitor carfilzomib. Notably, carfilzomib also showed\n  striking in vivo activity in a BRAF-mutant human colorectal cancer xenograft model.\n  Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling,\n  because BRAF V600E blockade by PLX4720 reversed sensitivity to carfilzomib in BRAF-mutant\n  colorectal cancer cells. Our findings indicated that proteasome inhibition might\n  represent a valuable targeting strategy in BRAF V600Emutant colorectal tumors.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 47\nsource_id: 241\nvariant_id: 12\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	81153991-4b19-4322-a5af-00738aee338f	2015-05-20 18:10:23.431615
632	407	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: PDGFRA G853D mutation found in an acral melanoma sample. In vitro testing\n  showed that G853D induced IL-3independent growth could be inhibited by either imatinib\n  or crenolanib to different extent.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 48\nsource_id: 242\nvariant_id: 148\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	fdc34a8f-4724-45ae-bde3-2e1dde3e069f	2015-05-20 18:10:23.467326
633	408	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Here, we report the case of a patient with metastatic lung adenocarcinoma\n  with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model\n  of this very rare type of mutated BRAF kinase to explain the molecular mechanism\n  of drug resistance.\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 49\nsource_id: 243\nvariant_id: 149\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	5b38690d-dd92-4be2-9c18-839b7fe126ec	2015-05-20 18:10:23.5011
634	409	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: Authors of study investigated genomic changes in metastatic renal cancer\n  patients with long term benefit from rapalog treatment. Patient 3 (treated with\n  everolimus), in study, was found to have a novel MTOR mutation, Q2223K. This residue\n  was in the PI3K kinase domain structure. In vitro, functional validation confirmed\n  that this variant was activating and was sensitive to rapamycin and rapalogs, everolimus\n  and temsirolimus.\nclinical_significance: Sensitivity\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 50\nsource_id: 244\nvariant_id: 147\nrating: 5\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	c238a9de-215a-4474-8afb-b9baabe62bf0	2015-05-20 18:10:23.543804
635	410	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: 'Deep kinome sequencing in ER+ breast cancer clinical samples that progressed\n  on letrozole and discovered LYN D189Y mutation associated with lack of response.\n  Biochemical follow up studies show that this mutation is associated with lack of\n  response to letrozole. Experimental evidence: http://bit.ly/1KyZ8vU'\nclinical_significance: Resistance or Non-Response\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 1\ndisease_id: 51\nsource_id: 245\nvariant_id: 151\nrating: 3\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 1\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	f670eacb-c31f-4e4c-baef-2ebaa2b0751f	2015-05-20 18:10:23.59432
636	411	EvidenceItem	\N	\N	\N	\N	\N	create	---\ndescription: 'Identified through whole genome analysis of two patients with Dopa (3,4-dihydroxyphenylalanine)\n  responsive dystonia (DRD) [Mendelian Inheritance in Man (MIM) #128230]'\nclinical_significance: Better Outcome\nevidence_direction: Supports\nevidence_type_id: 2\nevidence_level_id: 3\ndisease_id: 52\nsource_id: 246\nvariant_id: 153\nrating: 4\nstatus: accepted\nremote_errors: \nremote_ids: \nvariant_origin_id: 2\nvariant_hgvs: N/A\ndrug_interaction_description: \n	1	\N	\N	e01f85f8-c5d1-4c57-946e-b8f07f249c79	2015-05-20 18:10:23.647092
638	1	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'While imatinib has shown to be incredibly successful in treating philadelphia chromosome\n  positive CML, patients that have shown primary or secondary resistance to the drug\n  have been observed to harbor T315I and E255K ABL kinase domain mutations. These\n  mutations, among others, have been observed both in primary refractory disease and\n  acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations\n  have also been shown to confer resistance to imatinib. '\n	2	\N	\N	33058710-7cf8-4d76-9b37-8c731c33e4ef	2015-05-20 18:10:23.7767
639	2	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset\n  of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase\n  the activity of the ALK oncogene relative to normal cells. While EML4 is the most\n  common fusion partner, other 5'' partners have been observed. The EML4-ALK fusion\n  has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. '\n	2	\N	\N	8812187e-0a6e-4396-8862-fdb99e2c370d	2015-05-20 18:10:23.790144
640	6	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'EGFR pathway activation is a nearly ubiquitous hallmark of cancer. Many tyrosine\n  kinase inhibitors have been developed to target EGFR pathway activity. One such\n  inhibitor, erlotinib, has demonstrated efficacy in an EGFR over-active setting.\n  However, the T790M missense mutation has shown to confer resistance to this inhibitor\n  in cell lines and case studies.  '\n	2	\N	\N	f0d91678-823c-4737-901a-ac8c218daca3	2015-05-20 18:10:23.804647
641	3	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'The ALK oncogene has long been considered a driving factor in non-small cell lung\n  cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be\n  effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance\n  to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive\n  this resistance. '\n	2	\N	\N	b01a4299-116c-4210-b700-0f5e3e7e3715	2015-05-20 18:10:23.816463
642	4	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants\n  have also been observed and studied to a lesser degree. At first approximation,\n  many of these variants seem to behave similarly to V600E, and treatment with dabrafenib\n  has been shown to be effective. '\n	2	\N	\N	8efb7645-f347-41ee-82bd-9a00fa62383a	2015-05-20 18:10:23.828078
643	7	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'HER2-positive breast cancer is widely recognized as a molecular subtype of breast\n  cancer. While amplification of ERBB2 is a common mechanism for activation of the\n  pathway, missense mutations have also demonstrated activation potential. These activating\n  missense mutations also confer senstivity to the targeted therapeutic neratinib. '\n	2	\N	\N	757fe7e6-b9db-483a-a9cb-3337f7557c1e	2015-05-20 18:10:23.843593
644	8	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'ER-positive breast cancer is the most common of the breast cancer subtypes. Hormone\n  therapy has been widely effective in treating the disease, however sequencing of\n  resistant patients has uncovered a number of missense mutations in mediating this\n  resistance. Many of these mutations lie within the ligand-binding domain, and contribute\n  to constitutive activity of the receptor. This has lead to the development of estrogen\n  receptor degrading agents such as fulvestrant, which have shown early efficacy in\n  clinical trials.  '\n	2	\N	\N	017e9b0c-bedb-4d4e-87e0-de945953d7fb	2015-05-20 18:10:23.854111
645	9	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'FGFR fusions have been demonstrated across many cancer types to have oncogenic\n  potential. FGFR2 and FGFR3 have been shown to be fused to many 3'' partners, which\n  may act as a vehicle for pathway activation. Treatment of cell lines harboring FGFR2\n  fusions with pazopanib has shown mild "anti-tumor" activities, and both ponatinib\n  and pazopanib have shown efficacy in case studies.  '\n	2	\N	\N	a65aa625-1f33-4d31-8a7e-f03686fd5d28	2015-05-20 18:10:23.863637
646	12	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- NPM1 exon 12 mutations are frequently identified in patients with cytogenetically\n  normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status\n  should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon\n  12 mutations have been identified as a predictor of good prognostic outcomes in\n  the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively\n  analyzed in the context of a number of therapies including variable results following\n  ATRA treatment as well as improved response to high-dose daunorubicin or valproic\n  acid. Additionally, multiple groups have shown increased surface expression of CD33\n  associated with NPM1 mutation, suggesting these patients may respond to anti-CD33\n  therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response\n  to induction therapy.\n	2	\N	\N	1a83964d-7539-41ac-bd9b-1e5c50550159	2015-05-20 18:10:23.875705
647	13	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'PTEN loss is a common event in breast cancer, as well as others. The most common\n  single nucleotide variant resulting in PTEN loss is a R233 nonsense mutation. Cell\n  lines harboring this mutation behave similarly to cell lines harboring larger insertion\n  or deletion events, in that they both respond to PI3K-mTOR inhibitors with impeded\n  growth. '\n	2	\N	\N	ee2b62dd-0486-4d9a-aa68-d7cf4dba4bfe	2015-05-20 18:10:23.888207
648	14	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'RET activation is a common oncogenic marker of medullary thyroid carcinoma. Treatment\n  of these patients with the targeted therapeutic motesanib has shown to be effective.\n  However, the missense mutations C634W and M918T have shown to confer motesanib resistance\n  in cell lines. '\n	2	\N	\N	bcc1d22a-beb2-469c-be91-7f89a65b0dce	2015-05-20 18:10:23.900008
649	15	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'Inactivating events in TSC1 and TSC2 have been observed in a number of cancer types.\n  Cell lines and case studies have shown that in the loss of TSC, the mTOR inhibitor\n  everolimus has seen significant anti-tumorigenic activity. '\n	2	\N	\N	17ff5db6-558a-4e8d-b779-5b497329877d	2015-05-20 18:10:23.909837
650	5	VariantGroup	\N	\N	\N	\N	\N	update	---\ndescription:\n- \n- 'BRCA germline variants have long been recognized as important potential predictors\n  of breast and ovarian cancer risk. '\n	2	\N	\N	925dfebc-2844-45d3-8c40-c9d434586075	2015-05-20 18:10:23.920579
\.


--
-- Name: audits_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('audits_id_seq', 650, true);


--
-- Data for Name: authorizations; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY authorizations (id, user_id, provider, uid, created_at, updated_at) FROM stdin;
\.


--
-- Name: authorizations_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('authorizations_id_seq', 1, false);


--
-- Data for Name: comments; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY comments (id, title, comment, commentable_id, commentable_type, user_id, role, created_at, updated_at) FROM stdin;
\.


--
-- Name: comments_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('comments_id_seq', 1, false);


--
-- Data for Name: data_versions; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY data_versions (id, version) FROM stdin;
\.


--
-- Name: data_versions_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('data_versions_id_seq', 1, false);


--
-- Data for Name: definitions; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY definitions (id, term, text, created_at, updated_at) FROM stdin;
\.


--
-- Name: definitions_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('definitions_id_seq', 1, false);


--
-- Data for Name: delayed_jobs; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY delayed_jobs (id, priority, attempts, handler, last_error, run_at, locked_at, failed_at, locked_by, queue, created_at, updated_at) FROM stdin;
\.


--
-- Name: delayed_jobs_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('delayed_jobs_id_seq', 1, false);


--
-- Data for Name: disease_ontology_mirrors; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY disease_ontology_mirrors (id, doid, name) FROM stdin;
1	0001816	Angiosarcoma
2	0002116	Pterygium
3	0014667	Disease Of Metabolism
4	0050001	Actinomadura Madurae Infectious Disease
5	0050002	Actinomadura Pelletieri Infectious Disease
6	0050003	Streptomyces Somaliensis Infectious Disease
7	0050004	Seminal Vesicle Acute Gonorrhea
8	0050007	Cutaneous Strongyloidiasis
9	0050009	Intestinal Strongyloidiasis
10	0050010	Mansonella Perstans Infectious Disease
11	0050011	Mansonella Streptocerca Infectious Disease
12	0050012	Chikungunya
13	0050013	Carbohydrate Metabolism Disease
14	0050014	Epizootic Hemorrhagic Disease
15	0050015	Rocio Virus Encephalitis
16	0050024	Ehrlichia Ewingii Ehrlichiosis
17	0050025	Human Granulocytic Anaplasmosis
18	0050026	Human Monocytic Ehrlichiosis
19	0050032	Mineral Metabolism Disease
20	0050035	African Tick-bite Fever
21	0050041	Astrakhan Spotted Fever
22	0050042	Indian Tick Typhus
23	0050043	Israeli Tick Typhus
24	0050046	Far Eastern Spotted Fever
25	0050047	Flinders Island Spotted Fever
26	0050050	Japanese Spotted Fever
27	0050051	Rickettsia Parkeri Spotted Fever
28	0050052	Rocky Mountain Spotted Fever
29	0050053	Rickettsia Honei Spotted Fever
30	0050059	Oropharyngeal Anthrax
31	0050061	Erysipeloid
32	0050063	Abortive Plague
33	0050065	Cutaneous Listeriosis
34	0050066	Listeria Meningoencephalitis
35	0050067	Listeria Septicaemia
36	0050068	Pestis Minor
37	0050069	Yersinia Pestis Infectious Disease
38	0050070	Plague Meningitis
39	0050072	Adiaspiromycosis
40	0050073	Invasive Aspergillosis
41	0050074	Tonsillar Aspergillosis
42	0050075	Pulmonary Blastomycosis
43	0050078	Cervix Tuberculosis
44	0050079	Niacin Deficiency
45	0050080	Iodine Deficiency
46	0050082	Hepatic Torque Teno Virus Infectious Disease
47	0050083	Keshan Disease
48	0050084	Rhinotracheitis
49	0050085	Entomophthoromycosis
50	0050086	Cutaneous Mucormycosis
51	0050088	Gastrointestinal Mucormycosis
52	0050089	Pulmonary Mucormycosis
53	0050090	Rhinocerebral Mucormycosis
54	0050091	Disseminated Paracoccidioidomycosis
55	0050092	Pulmonary Paracoccidioidomycosis
56	0050093	Disseminated Sporotrichosis
57	0050094	Lymphocutaneous Sporotrichosis
58	0050095	Pulmonary Sporotrichosis
59	0050096	Tinea Barbae
60	0050097	Ectothrix Infectious Disease
61	0050098	Microsporum Audouinii Tinea Capitis
62	0050099	Microsporum Canis Tinea Capitis
63	0050100	Microsporum Distortum Tinea Capitis
64	0050101	Microsporum Ferrugineum Tinea Capitis
65	0050102	Microsporum Gypseum Tinea Capitis
66	0050103	Microsporum Nanum Tinea Capitis
67	0050104	Trichophyton Verrucosum Tinea Capitis
68	0050105	Endothrix Infectious Disease
69	0050106	Trichophyton Soudanense Tinea Capitis
70	0050107	Trichophyton Tonsurans Tinea Capitis
71	0050108	Trichophyton Violaceum Tinea Capitis
72	0050110	Trichophyton Schoenleinii Tinea Capitis
73	0050111	Microsporum Fulvum Tinea Capitis
74	0050112	Trichophyton Megninii Tinea Capitis
75	0050113	Trichophyton Equinum Tinea Capitis
76	0050115	Trichophyton Yaoundei Tinea Capitis
77	0050116	Tinea Imbricata
78	0050117	Disease By Infectious Agent
79	0050118	La Crosse Encephalitis
80	0050119	West Nile Virus Neurological Syndrome
81	0050120	Hemophagocytic Lymphohistiocytosis
82	0050123	Tuberculous Encephalitis
83	0050125	Dengue Shock Syndrome
84	0050126	Tahyna Virus Encephalitis
85	0050127	Sinusitis
86	0050129	Secretory Diarrhea
87	0050130	Osmotic Diarrhea
88	0050131	Motility-related Diarrhea
89	0050132	Inflammatory Diarrhea
90	0050133	Superficial Mycosis
91	0050134	Cutaneous Mycosis
92	0050135	Subcutaneous Mycosis
93	0050136	Systemic Mycosis
94	0050138	Podoconiosis
95	0050139	Opisthorchis Felineus Infectious Disease
96	0050140	Acute Diarrhea
97	0050141	Intestinal Botulism
98	0050143	Asymptomatic Dengue
99	0050144	Kartagener Syndrome
100	0050145	Adenoiditis
101	0050146	Autoimmune Glomerulonephritis
102	0050147	Otomycosis
103	0050148	Laryngotracheitis
104	0050150	Pontiac Fever
105	0050151	Tracheobronchial Tuberculosis
106	0050152	Aspiration Pneumonia
107	0050153	Pulmonary Aspergilloma
108	0050154	Mycoplasmal Pneumonia
109	0050155	Sensory System Disease
110	0050156	Idiopathic Pulmonary Fibrosis
111	0050157	Cryptogenic Organizing Pneumonia
112	0050158	Desquamative Interstitial Pneumonia
113	0050159	Lymphoid Interstitial Pneumonia
114	0050160	Inhalation Anthrax
115	0050161	Lower Respiratory Tract Disease
116	0050162	Influenza Encephalopathy
117	0050163	Influenza Myocarditis
118	0050164	Influenza Myositis
119	0050165	Tuberculous Mesenteric Gland
120	0050166	Tuberculous Salpingitis
121	0050167	Autoimmune Polyendocrine Syndrome Type 1
122	0050168	Autoimmune Polyendocrine Syndrome Type 2
123	0050169	Cutaneous Lupus Erythematosus
124	0050170	Jamestown Canyon Encephalitis
125	0050171	Snowshoe Hare Encephalitis
126	0050172	Trivittatus Encephalitis
127	0050173	Inkoo Encephalitis
128	0050174	Kunjin Encephalitis
129	0050175	Tick-borne Encephalitis
130	0050177	Monogenic Disease
131	0050178	Complex Genetic Disease
132	0050179	Powassan Encephalitis
133	0050180	Colorado Tick Fever Encephalitis
134	0050181	Herpes Simplex Virus Encephalitis
135	0050182	Varicella-zoster Virus Encephalitis
136	0050183	Epstein-Barr Virus Encephalitis
137	0050184	Measles Virus Encephalitis
138	0050185	Erythema Multiforme
139	0050186	Cytomegalovirus Encephalitis
140	0050187	Rubella Virus Encephalitis
141	0050188	Coxsackievirus Encephalitis
142	0050189	Polioencephalitis
143	0050190	Adenovirus Encephalitis
144	0050191	Influenza Virus Encephalitis
145	0050192	Nipah Virus Encephalitis
146	0050193	Lymphocytic Choriomeningitis Virus Encephalitis
147	0050194	Argentine Hemorrhagic Fever
148	0050195	Bolivian Hemorrhagic Fever
149	0050196	Venezuelan Hemorrhagic Fever
150	0050197	Brazilian Hemorrhagic Fever
151	0050198	Chapare Hemorrhagic Fever
152	0050199	Whitewater Arroyo Hemorrhagic Fever
153	0050200	Korean Hemorrhagic Fever
154	0050201	Nephropathia Epidemica
155	0050202	Lujo Hemorrhagic Fever
156	0050203	Cytomegalovirus Hepatitis
157	0050204	Epstein-Barr Virus Hepatitis
158	0050205	Herpes Simplex Virus Hepatitis
159	0050206	Adenovirus Hepatitis
160	0050207	Rubella Virus Hepatitis
161	0050208	Yellow Fever Hepatitis
162	0050209	Measles Virus Hepatitis
163	0050210	Varicella-zoster Virus Hepatitis
164	0050211	Swine Influenza
165	0050212	Campylobacter Jejuni Gastroenteritis
166	0050213	Vibrio Gastroenteritis
167	0050214	Lambert-Eaton Myasthenic Syndrome
168	0050215	Staphylococcus Gastroenteritis
169	0050216	Bacillus Cereus Gastroenteritis
170	0050217	Sapovirus Gastroenteritis
171	0050218	Polycystic Echinococcosis
172	0050219	Hepeviridae Infectious Disease
173	0050220	Coxiella Burnetii Pneumonia
174	0050221	Coxiella Burnetii Hepatitis
175	0050222	Selective IgM Deficiency Disease
176	0050223	Candidal Gastritis
177	0050224	Helicobacter Heilmannii Infectious Disease
178	0050225	Histoplasma Capsulatum Gastritis
179	0050226	Morganella Morganii Intestinal Infectious Disease
180	0050227	Vibrio Cholerae O139 Cholera
181	0050228	Amebic Dysentery
182	0050229	Escherichia Coli Dysentery
183	0050230	Intestinal Capillariasis
184	0050231	Hepatic Capillariasis
185	0050232	Pulmonary Capillariasis
186	0050233	Balamuthia Mandrillaris Infectious Disease
187	0050234	Acanthamoeba Infectious Disease
188	0050235	Alveolata Infectious Disease
189	0050236	Heterolobosea Infectious Disease
190	0050237	Euglenozoa Infectious Disease
191	0050238	Parabasalia Infectious Disease
192	0050239	Fornicata Infectious Disease
193	0050240	Trichomonadida Infectious Disease
194	0050241	Tritrichomonadida Infectious Disease
195	0050242	Primary Amebic Meningoencephalitis
196	0050243	Apicomplexa Infectious Disease
197	0050244	Coccidia Infectious Disease
198	0050245	Aconoidasida Infectious Disease
199	0050246	Granulomatous Amebic Encephalitis
200	0050247	Parasitic Stramenopiles Infectious Disease
201	0050249	Brugia Timori Filariasis
202	0050250	Philophthalmiasis
203	0050251	Coenurosis
204	0050252	Dipylidium Caninum Infectious Disease
205	0050253	Mesocestoidiasis
206	0050254	Acanthocephaliasis
207	0050255	Uncinaria Stenocephala Infectious Disease
208	0050256	Angiostrongyliasis
209	0050257	Angiostrongylus Cantonensis Infectious Disease
210	0050258	Angiostrongylus Costaricensis Infectious Disease
211	0050259	Baylisascariasis
212	0050260	Dioctophymiasis
213	0050261	Thelaziasis
214	0050262	Acoelomata Infectious Disease
215	0050263	Pseudocoelomata Infectious Disease
216	0050264	Acanthocephala Infectious Disease
217	0050265	Tick Paralysis
218	0050266	Tungiasis
219	0050267	Ancylostoma Caninum Ancylostomiasis
220	0050268	Ophthalmomyiasis
221	0050269	Trichomonas Vaginalis Trichomoniasis
222	0050270	Trichomonas Tenax Trichomoniasis
223	0050271	Cutaneous Ascomycota Mycosis
224	0050272	Cutaneous Basidiomycota Mycosis
225	0050273	Neoscytalidium Dimidiatum Infectious Disease
226	0050274	Scopulariopsis Infectious Disease
227	0050275	Onychomycosis
228	0050276	Subcutaneous Ascomycota Mycosis
229	0050277	Subcutaneous Fungi Incertae Sedis Mycosis
230	0050278	Basidiobolomycosis
231	0050279	Conidiobolomycosis
232	0050280	Superficial Ascomycota Mycosis
233	0050281	Superficial Basidiomycota Mycosis
234	0050282	Primary Systemic Ascomycota Mycosis
235	0050283	Stachybotrys Infectious Disease
236	0050284	Opportunistic Ascomycota Mycosis
237	0050285	Opportunistic Basidiomycota Mycosis
238	0050286	Opportunistic Fungi Incertae Sedis Mycosis
239	0050287	Opportunistic Microsporidia Mycosis
240	0050288	Penicilliosis
241	0050289	Fusariosis
242	0050290	Trichosporonosis
243	0050291	Parasitic Ichthyosporea Infectious Disease
244	0050292	Primary Systemic Mycosis
245	0050293	Scopulariopsis Brevicaulis Infectious Disease
246	0050294	Scytalidium Hyalinum Infectious Disease
247	0050295	Cutaneous Sporotrichosis
248	0050296	Asfarviridae Infectious Disease
249	0050297	Primary Francisellaceae Infectious Disease
250	0050298	Adenovirus Infectious Disease
251	0050299	Simplexvirus Infectious Disease
252	0050300	Deltavirus Infectious Disease
253	0050301	Polyomaviridae Infectious Disease
254	0050302	Varicellovirus Infectious Disease
255	0050303	Hepacivirus Infectious Disease
256	0050304	Aniseikonia
257	0050305	Arteriviridae Infectious Disease
258	0050306	Familial Abdominal Aortic Aneurysm
259	0050307	Bornaviridae Infectious Disease
260	0050308	Alkhurma Hemorrhagic Fever
261	0050309	Measles Virus Infectious Disease
262	0050310	Primary Listeriaceae Infectious Disease
263	0050311	Primary Helicobacteraceae Infectious Disease
264	0050312	Primary Campylobacteraceae Infectious Disease
265	0050313	Primary Brucellaceae Infectious Disease
266	0050314	Primary Erysipelotrichaceae Infectious Disease
267	0050315	Commensal Clostridiaceae Infectious Disease
268	0050316	Commensal Staphylococcaceae Infectious Disease
269	0050317	Commensal Streptococcaceae Infectious Disease
270	0050318	Primary Burkholderiaceae Infectious Disease
271	0050319	Primary Legionellaceae Infectious Disease
272	0050320	Commensal Alcaligenaceae Infectious Disease
273	0050321	Opportunistic Pseudomonadaceae Infectious Disease
274	0050322	Primary Vibrionaceae Infectious Disease
275	0050323	Primary Coxiellaceae Infectious Disease
276	0050324	Physical Disorder OBSOLETED TERM
277	0050325	Genetic Disorder
278	0050327	Peripheral Dysostosis
279	0050328	Congenital Hypothyroidism
280	0050329	Mental Disorder
281	0050331	LADD Syndrome
282	0050332	Enlarged Vestibular Aqueduct
283	0050333	Congenital Anosmia
284	0050334	Thiourea Tasting
285	0050335	Bradyopsia
286	0050336	Hypophosphatemia
287	0050337	Burkholderia Cepacia Infectious Disease
288	0050338	Primary Bacterial Infectious Disease
289	0050339	Commensal Bacterial Infectious Disease
290	0050340	Opportunistic Bacterial Infectious Disease
291	0050341	Opportunistic Actinomycetales Infectious Disease
292	0050342	Commensal Actinomycetales Infectious Disease
293	0050343	Gardnerella Vaginalis Vaginosis
294	0050344	Commensal Bifidobacteriaceae Infectious Disease
295	0050345	Primary Thermomonosporaceae Infectious Disease
296	0050346	Primary Corynebacteriaceae Infectious Disease
297	0050347	Primary Mycobacteriaceae Infectious Disease
298	0050348	Primary Streptomycetaceae Infectious Disease
299	0050349	Opportunistic Nocardiaceae Infectious Disease
300	0050350	Primary Clostridiaceae Infectious Disease
301	0050351	Primary Clostridium Infectious Disease
302	0050352	Foodborne Botulism
303	0050353	Wound Botulism
304	0050354	Infant Botulism
305	0050355	Opportunistic Burkholderiaceae Infectious Disease
306	0050357	Burkholderia Cenocepacia Infectious Disease
307	0050358	Commensal Chlamydiaceae Infectious Disease
308	0050359	Bilophila Wadsworthia Necrotizing Fasciitis
309	0050360	Commensal Enterobacteriaceae Infectious Disease
310	0050361	Opportunistic Enterobacteriaceae Infectious Disease
311	0050362	Elizabethkingia Meningoseptica Infectious Disease
312	0050363	Capnocytophaga Canimorsus Infectious Disease
313	0050364	Opportunistic Flavobacteriaceae Infectious Disease
314	0050365	Chryseobacterium Indologenes Infectious Disease
315	0050366	Empedobacter Brevis Endophthalmitis
316	0050367	Myroides Odoratus Necrotizing Fasciitis
317	0050368	Commensal Fusobacteriaceae Infectious Disease
318	0050369	Primary Mycoplasmataceae Infectious Disease
319	0050370	Commensal Neisseriaceae Infectious Disease
320	0050371	Commensal Pasteurellaceae Infectious Disease
321	0050372	Commensal Haemophilus Infectious Disease
322	0050373	Leptospiraceae Infectious Disease
323	0050374	Spirochaetaceae Infectious Disease
324	0050375	Primary Spirillaceae Infectious Disease
325	0050376	Anaplasmosis
326	0050377	Burkholderia Cepacia Complex Infectious Disease
327	0050378	Opportunistic Campylobacteraceae Infectious Disease
328	0050379	Campylobacter Fetus Infectious Disease
329	0050380	Campylobacter Coli Infectious Disease
330	0050381	Chlamydia Trachomatis Epididymitis
331	0050382	Glandular Tularemia
332	0050383	Typhoidal Tularemia
333	0050384	Commensal Helicobacteraceae Infectious Disease
334	0050385	Commensal Helicobacter Infectious Disease
335	0050386	Acinetobacter Baumannii Pneumonia
336	0050387	Nonpapillary Renal Cell Carcinoma
337	0050388	Bacteroides Fragilis Peritonitis
338	0050389	Capnocytophaga Canimorsus Meningitis
339	0050390	Capnocytophaga Canimorsus Endocarditis
340	0050391	Elizabethkingia Meningoseptica Meningitis
341	0050392	Streptococcal Necrotizing Fasciitis
342	0050393	Chryseobacterium Indologenes Pneumonia
343	0050394	Nocardial Pneumonia
344	0050395	Nocardial Cellulitis
345	0050396	Nocardial Keratitis
346	0050397	Cerebral Bilophila Wadsworthia Infectious Disease
347	0050398	Carrion's Disease
348	0050399	Bordetella Pertussis Whooping Cough
349	0050400	Pseudomonas Urinary Tract Infectious Disease
350	0050401	Pseudomonas Endocarditis
351	0050402	Pseudomonas Keratitis
352	0050403	Commensal Mycoplasmatales Infectious Disease
353	0050404	Commensal Mycoplasmataceae Infectious Disease
354	0050405	Mycoplasma Genitalium Urethritis
355	0050406	Yersinia Pseudotuberculosis Mesenteric Lymphadenitis
356	0050407	Commensal Mycoplasma Infectious Disease
357	0050408	Staphylococcus Aureus Ecthyma
358	0050409	Streptococcus Pyogenes Ecthyma
359	0050410	Streptococcal Erysipelas
360	0050411	Staphylococcus Aureus Erysipelas
361	0050412	Streptococcus Impetigo
362	0050413	Staphylococcus Aureus Impetigo
363	0050414	Streptococcus Lymphangitis
364	0050415	Staphylococcus Aureus Lymphangitis
365	0050416	Streptococcus Agalactiae Meningitis
366	0050417	Streptococcus Equisimilis Meningitis
367	0050418	Streptococcus Zooepidemicus Meningitis
368	0050419	Complement Factor I Deficiency
369	0050420	Primary Streptococcaceae Infectious Disease
370	0050421	Primary Streptococcal Infectious Disease
371	0050422	Yersinia Pseudotuberculosis Gastroenteritis
372	0050423	Enteroaggregative Escherichia Coli Infectious Disease
373	0050424	Familial Adenomatous Polyposis
374	0050425	Restless Legs Syndrome
375	0050426	Stevens-Johnson Syndrome
376	0050427	Xeroderma Pigmentosum
377	0050428	Nonepidermolytic Palmoplantar Keratoderma
378	0050429	Hailey-Hailey Disease
379	0050430	Multiple Endocrine Neoplasia Type 2A
380	0050431	Arrhythmogenic Right Ventricular Cardiomyopathy
381	0050432	Asperger Syndrome
382	0050433	Fatal Familial Insomnia
383	0050434	Andersen-Tawil Syndrome
384	0050436	Mulibrey Nanism
385	0050437	Danon Disease
386	0050438	Frasier Syndrome
387	0050439	Usher Syndrome
388	0050440	Familial Partial Lipodystrophy
389	0050441	Mucosulfatidosis
390	0050444	Infantile Refsum Disease
391	0050445	X-linked Hypophosphatemia
392	0050448	Hereditary Mucosal Leukokeratosis
393	0050449	Pachyonychia Congenita
394	0050450	Gitelman Syndrome
395	0050451	Brugada Syndrome
396	0050452	Mevalonic Aciduria
397	0050453	Lissencephaly
398	0050454	Periventricular Nodular Heterotopia
399	0050455	Arachnodactyly
400	0050456	Buruli Ulcer Disease
401	0050457	Sertoli Cell-only Syndrome
402	0050458	Juvenile Myelomonocytic Leukemia
403	0050459	Hyperphosphatemia
404	0050460	Wolf-Hirschhorn Syndrome
405	0050461	Aspartylglucosaminuria
406	0050462	Antley-Bixler Syndrome
407	0050463	Campomelic Dysplasia
408	0050464	Farber Lipogranulomatosis
409	0050465	Muir-Torre Syndrome
410	0050466	Loeys-Dietz Syndrome
411	0050467	Erythrokeratodermia Variabilis
412	0050468	Yellow Nail Syndrome
413	0050469	Costello Syndrome
414	0050470	Donohue Syndrome
415	0050471	Carney Complex
416	0050472	Monilethrix
417	0050473	Alstrom Syndrome
418	0050474	Netherton Syndrome
419	0050475	Weill-Marchesani Syndrome
420	0050476	Barth Syndrome
421	0050477	Liddle Syndrome
422	0050478	Primary Escherichia Coli Infectious Disease
423	0050479	Commensal Klebsiella Infectious Disease
424	0050480	Epidemic Typhus
425	0050481	Endemic Typhus
426	0050482	Lymphangitis-associated Rickettsiosis
427	0050483	Rickettsia Aeschlimannii Spotted Fever
428	0050484	Aneruptive Fever
429	0050485	Sennetsu Fever
430	0050486	Exanthem
431	0050487	Bacterial Exanthem
432	0050488	Early Congenital Syphilis
433	0050489	Multinodular Goiter
434	0050490	Parenchymatous Neurosyphilis
435	0050491	Meningovascular Neurosyphilis
436	0050492	Tertiary Syphilitic Encephalitis
437	0050493	Tertiary Syphilitic Meningitis
438	0050494	Papillomaviridae Infectious Disease
439	0050495	Exanthema Subitum
440	0050496	Banna Virus Encephalitis
441	0050497	Anelloviridae Infectious Disease
442	0050498	DsDNA Virus Infectious Disease
443	0050499	SsDNA Virus Infectious Disease
444	0050500	DsDNA-RT Virus Infectious Disease
445	0050501	DsRNA Virus Infectious Disease
446	0050502	(+)ssRNA Virus Infectious Disease
447	0050503	(-)ssRNA Virus Infectious Disease
676	0050738	Y-linked Disease
448	0050504	SsRNA-RT Virus Infectious Disease
449	0050505	Human Papilloma Virus Related Anal Squamous Cell Carcinoma
450	0050506	Human Papilloma Virus Related Vaginal Squamous Cell Carcinoma
451	0050507	AIDS-related Cryptosporidiosis
452	0050508	Variola Major
453	0050509	AIDS-related Toxoplasmosis
454	0050510	AIDS-related Cystoisosporiasis
455	0050511	Human Torovirus Gastroenteritis
456	0050512	Saffold Virus Gastroenteritis
457	0050513	Spinal Polio
458	0050514	Bulbospinal Polio
459	0050515	Paralytic Poliomyelitis
460	0050516	O'nyong'nyong Fever
461	0050517	Barmah Forest Virus Disease
462	0050518	Ross River Fever
463	0050519	Lymphocytic Choriomeningitis Virus Meningitis
464	0050520	Lymphocytic Choriomeningitis Virus Meningoencephalitis
465	0050521	Oropouche Fever
466	0050522	Balkan Hemorrhagic Fever
467	0050523	Adult T-cell Leukemia
468	0050524	Maturity-onset Diabetes Of The Young
469	0050525	Acroosteolysis
470	0050526	Gamstorp-Wohlfart Syndrome
471	0050527	Familial Hypertriglyceridemia
472	0050528	Nonphotosensitive Trichothiodystrophy
473	0050529	Adult Spinal Muscular Atrophy
474	0050530	Intermediate Spinal Muscular Atrophy
475	0050531	Lentiginosis Profusa
476	0050532	Epidermal Nevus
477	0050533	Soldiers Heart
478	0050534	Congenital Stationary Night Blindness
479	0050535	Exudative Vitreoretinopathy
480	0050536	SC Phocomelia Syndrome
481	0050537	Posterior Polar Cataract
482	0050538	Charcot-Marie-Tooth Disease Type 1
483	0050539	Charcot-Marie-Tooth Disease Type 2
484	0050540	Charcot-Marie-Tooth Disease Type 3
485	0050541	Charcot-Marie-Tooth Disease Type 4
486	0050542	Charcot-Marie-Tooth Disease Type X
487	0050543	Charcot-Marie-Tooth Disease Intermediate Type
488	0050544	Hypermethioninemia
489	0050545	Visceral Heterotaxy
490	0050546	Congenital Adrenal Insufficiency
491	0050547	Familial Medullary Thyroid Carcinoma
492	0050548	Hereditary Sensory Neuropathy
493	0050549	Saldino-Noonan Syndrome
494	0050550	Majewski Syndrome
495	0050551	Verma-Naumoff Syndrome
496	0050552	Sugio-Kajii Syndrome
497	0050553	JMP Syndrome
498	0050554	X-linked Sideroblastic Anemia With Ataxia
499	0050556	Infantile Onset Spinocerebellar Ataxia
500	0050557	Congenital Muscular Dystrophy
501	0050558	Ullrich Congenital Muscular Dystrophy
502	0050559	Fukuyama Congenital Muscular Dystrophy
503	0050560	Walker-Warburg Syndrome
504	0050561	Lennox-Gastaut Syndrome
505	0050562	West Syndrome
506	0050563	Nonsyndromic Deafness
507	0050564	Autosomal Dominant Nonsyndromic Deafness
508	0050565	Autosomal Recessive Nonsyndromic Deafness
509	0050566	X-linked Nonsyndromic Deafness
510	0050567	Orofacial Cleft
511	0050568	Spondylocostal Dysostosis
512	0050569	Seckel Syndrome
513	0050570	Congenital Disorder Of Glycosylation Type I
514	0050571	Congenital Disorder Of Glycosylation Type II
515	0050572	Cone-rod Dystrophy
516	0050573	2-hydroxyglutaric Aciduria
517	0050574	L-2-hydroxyglutaric Aciduria
518	0050575	D-2-hydroxyglutaric Aciduria
519	0050576	Senior-Loken Syndrome
520	0050577	Sensenbrenner Syndrome
521	0050578	Occult Macular Dystrophy
522	0050579	Glycogen Storage Disease XV
523	0050580	Hereditary Lymphedema
524	0050581	Brachydactyly
525	0050582	Distal Hereditary Motor Neuropathy
526	0050583	Chlamydophila Pneumoniae Infectious Disease
527	0050584	Gummatous Syphilis
528	0050585	Congenital Generalized Lipodystrophy
529	0050587	Trichotillomania
530	0050588	Muscular Dystrophy-dystroglycanopathy
531	0050589	Inflammatory Bowel Disease
532	0050590	Severe Congenital Neutropenia
533	0050591	Tooth Agenesis
534	0050592	Asphyxiating Thoracic Dystrophy
535	0050593	Primary Congenital Glaucoma
536	0050594	Glycogen Storage Disease IX
537	0050595	Mucormycosis
538	0050596	Taeniasis
539	0050597	Intestinal Schistosomiasis
540	0050598	Extrapulmonary Tuberculosis
541	0050599	Abdominal Tuberculosis
542	0050600	ABCD Syndrome
543	0050601	ADULT Syndrome
544	0050602	Triple-A Syndrome
545	0050603	Acheiropody
546	0050604	Acrocapitofemoral Dysplasia
547	0050605	Acrodermatitis Enteropathica
548	0050606	Acrokeratosis Verruciformis
549	0050608	Askin's Tumor
550	0050610	Oral Cavity Carcinoma In Situ
551	0050611	Pharynx Carcinoma In Situ
552	0050612	Gall Bladder Carcinoma In Situ
553	0050613	Bile Duct Carcinoma In Situ
554	0050614	Bronchus Carcinoma In Situ
555	0050615	Respiratory System Cancer
556	0050616	Malignant Leydig Cell Tumor
557	0050617	Malignant Sertoli Cell Tumor
558	0050618	Malignant Sertoli-Leydig Cell Tumor
559	0050619	Paranasal Sinus Cancer
560	0050620	Infiltrating Renal Pelvis Transitional Cell Carcinoma
677	0050739	Autosomal Genetic Disease
561	0050621	Respiratory System Benign Neoplasm
562	0050622	Reproductive Organ Benign Neoplasm
563	0050623	Bladder Benign Neoplasm
564	0050624	Gastrointestinal System Benign Neoplasm
565	0050625	Biliary Tract Neoplasm
566	0050626	Gastrointestinal Neuroendocrine Tumor
567	0050628	Advanced Sleep Phase Syndrome
568	0050629	Aicardi-Goutieres Syndrome
569	0050630	Aland Island Eye Disease
570	0050631	Allan-Herndon-Dudley Syndrome
571	0050632	Oculocutaneous Albinism
572	0050633	Ocular Albinism
573	0050634	Alopecia Universalis
574	0050635	Alternating Hemiplegia Of Childhood
575	0050636	Familial Visceral Amyloidosis
576	0050637	Finnish Type Amyloidosis
577	0050638	Transthyretin Amyloidosis
578	0050639	Primary Cutaneous Amyloidosis
579	0050640	Anauxetic Dysplasia
580	0050641	Rh Deficiency Syndrome
581	0050642	Hypochromic Microcytic Anemia
582	0050643	Anonychia Congenita
583	0050644	Arterial Calcification Of Infancy
584	0050645	Arterial Tortuosity Syndrome
585	0050646	Distal Arthrogryposis
586	0050647	Arts Syndrome
587	0050648	Atelosteogenesis
588	0050649	Atransferrinemia
589	0050650	Familial Atrial Fibrillation
590	0050651	Atrioventricular Septal Defect
591	0050652	Soft Tissue Cancer
592	0050653	Dysplastic Nevus
593	0050654	Baller-Gerold Syndrome
594	0050655	Bamforth-Lazarus Syndrome
595	0050656	Pseudo-TORCH Syndrome
596	0050657	Bannayan-Riley-Ruvalcaba Syndrome
597	0050658	Bart-Pumphrey Syndrome
598	0050659	Biotin-responsive Basal Ganglia Disease
599	0050660	Beare-Stevenson Cutis Gyrata Syndrome
600	0050661	Vitelliform Macular Dystrophy
601	0050662	Bestrophinopathy
602	0050663	Bethlem Myopathy
603	0050664	Bietti Crystalline Corneoretinal Dystrophy
604	0050665	Fetal Alcohol Syndrome
605	0050666	Partial Fetal Alcohol Syndrome
606	0050667	Alcohol-related Neurodevelopmental Disorder
607	0050668	Alcohol-related Birth Defect
608	0050669	Spastic Cerebral Palsy
609	0050670	Ataxic Cerebral Palsy
610	0050671	Female Breast Cancer
611	0050672	Dyskinetic Cerebral Palsy
612	0050673	Mixed Cerebral Palsy
613	0050674	Congenital Bile Acid Synthesis Defect
614	0050675	Birk-Barel Syndrome
615	0050676	Birt-Hogg-Dube Syndrome
616	0050677	Bjornstad Syndrome
617	0050678	Blau Syndrome
618	0050679	Blue Cone Monochromacy
619	0050680	Boomerang Dysplasia
620	0050681	Borjeson-Forssman-Lehmann Syndrome
621	0050682	Athabaskan Brainstem Dysgenesis Syndrome
622	0050683	Bothnia Retinal Dystrophy
623	0050684	Bowen-Conradi Syndrome
624	0050685	Small Cell Carcinoma
625	0050686	Organ System Cancer
626	0050687	Cell Type Cancer
627	0050688	Anal Canal Cancer
628	0050689	Brachydactyly-syndactyly Syndrome
629	0050690	Brachyolmia
630	0050691	Branchiooculofacial Syndrome
631	0050692	Brody Myopathy
632	0050693	Brooke-Spiegler Syndrome
633	0050694	Brown-Vialetto-Van Laere Syndrome
634	0050695	Malignant Pleural Solitary Fibrous Tumor
635	0050696	Fetal Alcohol Spectrum Disorder
636	0050697	Chorioamnionitis
637	0050698	Funisitis
638	0050699	Dent Disease
639	0050700	Cardiomyopathy
640	0050701	Electroclinical Syndrome
641	0050702	Neonatal Period Electroclinical Syndrome
642	0050703	Infancy Electroclinical Syndrome
643	0050704	Childhood Electroclinical Syndrome
644	0050705	Adolescence-adult Electroclinical Syndrome
645	0050706	Variable Age At Onset Electroclinical Syndrome
646	0050707	Nonsyndromic Epilepsy
647	0050708	Early Onset Absence Epilepsy
648	0050709	Ohtahara Syndrome
649	0050710	3-Methylcrotonyl-CoA Carboxylase Deficiency
650	0050711	Aceruloplasminemia
651	0050712	AGAT Deficiency
652	0050713	Fatal Infantile Encephalocardiomyopathy
653	0050715	Methylmalonic Aciduria And Homocystinuria Type CblC
654	0050716	Methylmalonic Aciduria And Homocystinuria Type CblD
655	0050717	Methylmalonic Aciduria And Homocystinuria Type CblF
656	0050718	Vitamin Metabolic Disorder
657	0050719	Cerebral Folate Receptor Alpha Deficiency
658	0050720	Ornithine Translocase Deficiency
659	0050721	Serine Deficiency
660	0050722	PHGDH Deficiency
661	0050723	PSAT Deficiency
662	0050724	PSPH Deficiency
663	0050725	Tyrosinemia Type II
664	0050726	Tyrosinemia Type I
665	0050727	Tyrosinemia Type III
666	0050728	Glycogen Metabolism Disorder
667	0050729	Neutral Lipid Storage Disease
668	0050730	Coenzyme Q10 Deficiency Disease
669	0050731	Vitamin B12 Deficiency
670	0050732	Methylmalonic Aciduria And Homocystinuria Type CblE
671	0050733	Methylmalonic Aciduria And Homocystinuria Type CblG
672	0050734	Congenital Intrinsic Factor Deficiency
673	0050735	X-linked Disease
674	0050736	Autosomal Dominant Disease
675	0050737	Autosomal Recessive Disease
678	0050740	Qazi Markouizos Syndrome
679	0050741	Alcohol Dependence
680	0050742	Nicotine Dependence
681	0050743	Mature T-cell And NK-cell Lymphoma
682	0050744	Anaplastic Large Cell Lymphoma
683	0050745	Diffuse Large B-cell Lymphoma
684	0050746	Mantle Cell Lymphoma
685	0050747	Lymphoplasmacytic Lymphoma
686	0050748	Marginal Zone B-cell Lymphoma
687	0050749	Peripheral T-cell Lymphoma
688	0050750	Splenic Marginal Zone Lymphoma
689	0050751	T-cell Large Granular Lymphocyte Leukemia
690	0050752	Amyotrophic Lateral Sclerosis Type 8
691	0050753	Cerebellar Ataxia
692	0050754	Ataxia With Oculomotor Apraxia Type 1
693	0050755	Ataxia With Oculomotor Apraxia Type 2
694	0050756	Batten Disease
695	0050757	Deafness Dystonia Syndrome
696	0050758	Metabolic Acidosis
697	0050759	Myotonic Dystrophy Type 2
698	0050760	X-linked Myopathy With Excessive Autophagy
699	0050761	Paramyloidosis
700	0050762	Adenylosuccinase Lyase Deficiency
701	0050763	ARC Syndrome
702	0050764	Armfield Syndrome
703	0050765	Neuroacanthocytosis
704	0050766	Chorea-acanthocytosis
705	0050767	Midface Dysplasia
706	0050768	Mitochondrial Complex V (ATP Synthase) Deficiency, Nuclear Type 1
707	0050769	N Syndrome
708	0050770	Polycystic Liver Disease
709	0050771	Phaeochromocytoma
710	0050773	Paraganglioma
711	0050774	Rapadilino Syndrome
712	0050775	Schneckenbecken Dysplasia
713	0050776	Non-syndromic X-linked Intellectual Disability
714	0050777	Joubert Syndrome
715	0050778	Meckel Syndrome
716	0050779	Hydrolethalus Syndrome
717	0050780	Opitz-GBBB Syndrome
718	0050781	Ogden Syndrome
719	0050782	Zollinger-Ellison Syndrome
720	0050783	Secondary Progressive Multiple Sclerosis
721	0050784	Primary Progressive Multiple Sclerosis
722	0050785	Progressive Relapsing Multiple Sclerosis
723	0050786	Iridogoniodysgenesis Syndrome
724	0050787	Juvenile Polyposis Syndrome
725	0050788	Proximal Symphalangism
726	0050789	Tarsal-carpal Coalition Syndrome
727	0050790	Fibular Hypoplasia And Complex Brachydactyly
728	0050791	Persistent Mullerian Duct Syndrome
729	0050792	Multiple Cutaneous And Mucosal Venous Malformations
730	0050793	Short QT Syndrome
731	0050794	Multiple Synostoses Syndrome
732	0050795	Cone Dystrophy
733	0050796	Achalasia Microcephaly Syndrome
734	0050797	Peroxisomal Acyl-CoA Oxidase Deficiency
735	0050798	Cerebral Creatine Deficiency Syndrome
736	0050799	Guanidinoacetate Methyltransferase Deficiency
737	0050800	Creatine Transporter Deficiency
738	0050801	Androgenic Alopecia
739	0050802	Ehlers-Danlos Syndrome Progeroid Type
740	0050803	Glioblastoma Classical Subtype
741	0050804	Glioblastoma Proneural Subtype
742	0050805	Glioblastoma Mesenchymal Subtype
743	0050806	Glioblastoma Neural Subtype
744	0050807	Kahrizi Syndrome
745	0050808	Mucopolysaccharidosis IV
746	0050809	Mucopolysaccharidosis IX
747	0050810	Biotin Deficiency
748	0050811	Congenital Adrenal Hyperplasia
749	0050812	Spondyloepimetaphyseal Dysplasia, Pakistani Type
750	0050813	Spondyloepiphyseal Dysplasia With Congenital Joint Dislocations
751	0050814	Temtamy Preaxial Brachydactyly Syndrome
752	0050815	Eye Adnexa Disease
753	0050816	Urofacial Syndrome
754	0050817	Stargardt Disease
755	0050818	Transcobalamin II Deficiency
756	0050819	Matthew-Wood Syndrome
757	0050820	Atrioventricular Block
758	0050821	First-degree Atrioventricular Block
759	0050822	Second-degree Atrioventricular Block
760	0050823	Third-degree Atrioventricular Block
761	0050824	Sinoatrial Node Disease
762	0050825	Endocardium Disease
763	0050826	Tricuspid Valve Disease
764	0050827	Rheumatic Heart Disease
765	0050828	Artery Disease
766	0050829	Pericardium Disease
767	0050830	Peripheral Artery Disease
768	0050831	Familial Encephalopathy With Neuroserpin Inclusion Bodies
769	0050832	Pyrimidine Metabolic Disorder
770	0050833	Orotic Aciduria
771	0050834	CHARGE Syndrome
772	0050835	Generalized Dystonia
773	0050836	Focal Dystonia
774	0050837	Multifocal Dystonia
775	0050838	Segmental Dystonia
776	0050839	Anismus
777	0050840	Cervical Dystonia
778	0050841	Focal Hand Dystonia
779	0050842	Oculogyric Crisis
780	0050843	Oromandibular Dystonia
781	0050844	Spasmodic Dystonia
782	0050845	Cranio-facial Dystonia
783	0050846	Hemidystonia
784	0050847	Sleep Apnea
785	0050848	Obstructive Sleep Apnea
786	0050849	Periampullary Adenoma
787	0050850	Diabetic Encephalopathy
788	0050851	Glomerulosclerosis
789	0050852	Limb Ischemia
790	0050853	Chronic Venous Insufficiency
791	0050854	Muckle-Wells Syndrome
792	0050855	Renal Fibrosis
793	0050856	Oppositional Defiant Disorder
794	0050857	Perrault Syndrome
795	0050858	Marshall-Smith Syndrome
796	0050859	Hemorrhagic Cystitis
797	0050860	Colorectal Adenoma
798	0050861	Colorectal Adenocarcinoma
799	0050862	Pyometritis
800	0050863	Arteritic Anterior Ischemic Optic Neuropathy
801	0050864	Non-arteritic Anterior Ischemic Optic Neuropathy
802	0050865	Tongue Squamous Cell Carcinoma
803	0050866	Oral Squamous Cell Carcinoma
804	0050867	Jensen Syndrome
805	0050868	Hepatocellular Adenoma
806	0050869	Villous Adenoma
807	0050870	In Situ Pulmonary Adenocarcinoma
808	0050871	Fibroma
809	0050872	Large Cell Neuroendocrine Carcinoma
810	0050873	Follicular Lymphoma
811	0050875	Small Cell Neuroendocrine Carcinoma
812	0050876	Caroli Disease
813	0050877	Pancreatic Agenesis
814	0050878	CLONE OF Congenital Afibrinogenemia
815	0050879	Fragile X-associated Tremor/ataxia Syndrome
816	0050880	Koolen De Vries Syndrome
817	0050881	Inclusion Body Myopathy With Paget Disease Of Bone And Frontotemporal Dementia
818	0050882	Spinocerebellar Ataxia Type 5
819	0050883	Infantile Cerebellar-retinal Degeneration
820	0050884	Triosephosphate Isomerase Deficiency
821	0050885	IMAGe Syndrome
822	0050886	Troyer Syndrome
823	0050887	Townes-Brocks Syndrome
824	0050888	Syndromic Intellectual Disability
825	0050889	Non-syndromic Intellectual Disability
826	0050890	Synucleinopathy
827	0050891	Adrenal Cortical Adenoma
828	0050892	Adrenal Gland Pheochromocytoma
829	0050893	Gallbladder Adenoma
830	0050894	Ameloblastoma
831	0050895	Bone Ameloblastoma
832	0050896	Bone Squamous Cell Carcinoma
833	0050897	Bone Chondrosarcoma
834	0050898	Phalanx Chondroma
835	0050899	Brain Stem Medulloblastoma
836	0050900	Sacrum Chordoma
837	0050901	Corpus Callosum Oligodendroglioma
838	0050902	Medulloblastoma
839	0050903	Parietal Lobe Ependymoma
840	0050904	Salivary Gland Carcinoma
841	0050905	Inflammatory Myofibroblastic Tumor
842	0050906	Conjunctival Nevus
843	0050907	Mixed Extragonadal Germ Cell Cancer
844	0050908	Myelodysplastic Syndrome
845	0050909	MALT Lymphoma
846	0050910	Cecum Adenoma
847	0050911	Appendix Carcinoid Tumor
848	0050912	Colon Adenoma
849	0050913	Large Intestine Adenocarcinoma
850	0050914	Large Intestine Adenoma
851	0050915	Rectum Adenoma
852	0050916	Bronchus Mucoepidermoid Carcinoma
853	0050917	Lung Combined Type Small Cell Adenocarcinoma
854	0050918	Vaginal Carcinoma
855	0050919	Trachea Mucoepidermoid Carcinoma
856	0050920	Tonsil Squamous Cell Carcinoma
857	0050921	Pharynx Squamous Cell Carcinoma
858	0050922	Gastrointestinal Carcinoma
859	0050923	Spindle Epithelial Tumor With Thymus-like Differentiation Tumor
860	0050924	Striated Muscle Rhabdoid Tumor
861	0050925	Small Intestine Carcinoid Neuroendocrine Tumor
862	0050926	Jejunal Adenocarcinoma
863	0050927	Duodenum Adenoma
864	0050928	Ovarian Melanoma
865	0050929	Mucosal Melanoma
866	0050930	Sublingual Gland Adenoid Cystic Carcinoma
867	0050931	Parotid Gland Adenoid Cystic Carcinoma
868	0050932	Lung Mucoepidermoid Carcinoma
869	0050933	Ovarian Serous Carcinoma
870	0050934	Ovarian Clear Cell Carcinoma
871	0050935	Cervical Neuroblastoma
872	0050936	Extra-adrenal Pheochromocytoma
873	0050937	Retroperitoneal Neuroblastoma
874	0050938	Breast Lobular Carcinoma
875	0050939	Uterine Corpus Endometrial Carcinoma
876	0050940	Endocervical Adenocarcinoma
877	0060000	Infective Endocarditis
878	0060001	Withdrawal Disorder
879	0060002	C1 Inhibitor Deficiency
880	0060004	Autoimmune Disease Of Central Nervous System
881	0060005	Autoimmune Disease Of Endocrine System
882	0060006	Artemis Deficiency
883	0060007	CD3zeta Deficiency
884	0060008	Janus Kinase-3 Deficiency
885	0060009	MHC Class I Deficiency
886	0060010	Omenn Syndrome
887	0060011	Recombinase Activating Gene 1 Deficiency
888	0060012	Recombinase Activating Gene 2 Deficiency
889	0060013	Gamma Chain Deficiency
890	0060014	CD45 Deficiency
891	0060015	Interleukin-7 Receptor Alpha Deficiency
892	0060016	CD3delta Deficiency
893	0060017	CD3epsilon Deficiency
894	0060018	CD3gamma Deficiency
895	0060019	Coronin-1A Deficiency
896	0060020	Reticular Dysgenesis
897	0060021	DNA Ligase IV Deficiency
898	0060022	CD40 Ligand Deficiency
899	0060023	CD40 Deficiency
900	0060024	Lambda 5 Deficiency
901	0060025	Immunoglobulin Alpha Deficiency
902	0060026	Immunoglobulin Beta Deficiency
903	0060027	B Cell Linker Protein Deficiency
904	0060028	Good Syndrome
905	0060029	Autoimmune Disease Of Exocrine System
906	0060030	Autoimmune Disease Of Eyes, Ear, Nose And Throat
907	0060031	Autoimmune Disease Of Gastrointestinal Tract
1025	0060156	Visual Verbal Agnosia
908	0060032	Autoimmune Disease Of Musculoskeletal System
909	0060033	Autoimmune Disease Of Peripheral Nervous System
910	0060035	Medical Disorder
911	0060036	Intrinsic Cardiomyopathy
912	0060037	Developmental Disorder Of Mental Health
913	0060038	Specific Developmental Disorder
914	0060039	Autoimmune Disease Of Skin And Connective Tissue
915	0060040	Pervasive Developmental Disorder
916	0060041	Autism Spectrum Disorder
917	0060042	Atypical Autism
918	0060043	Sexual Disorder
919	0060044	Paraphilia Disorder
920	0060045	Munchausen By Proxy
921	0060046	Aphasia
922	0060047	Writing Disorder
923	0060048	Nosophobia
924	0060049	Autoimmune Disease Of Urogenital Tract
925	0060050	Autoimmune Disease Of Blood
926	0060051	Autoimmune Disease Of Cardiovascular System
927	0060052	Neurological Disorder
928	0060053	Peripheral Neuropathy
929	0060054	Autonomic Peripheral Neuropathy
930	0060055	Popliteal Pterygium Syndrome
931	0060056	Hypersensitivity Reaction Disease
932	0060057	Gluten Allergic Reaction
933	0060058	Lymphoma
934	0060060	Non-Hodgkin Lymphoma
935	0060061	Cutaneous T Cell Lymphoma
936	0060062	Familial Juvenile Hyperuricemic Nephropathy
937	0060063	X-linked Sideroblastic Anemia
938	0060064	Sideroblastic Anemia With Spinocerebellar Ataxia
939	0060065	Pyridoxine-refractory Autosomal Recessive Sideroblastic Anemia
940	0060066	Pyridoxine-responsive Sideroblastic Anemia
941	0060067	Pearson Syndrome
942	0060068	Marantic Endocarditis
943	0060069	Bacillus Cereus Pneumonia
944	0060071	Pre-malignant Neoplasm
945	0060072	Benign Neoplasm
946	0060073	Lymphatic System Cancer
947	0060074	Ductal Carcinoma In Situ
948	0060075	Estrogen-receptor Positive Breast Cancer
949	0060076	Estrogen-receptor Negative Breast Cancer
950	0060077	Progesterone-receptor Positive Breast Cancer
951	0060078	Progesterone-receptor Negative Breast Cancer
952	0060079	Her2-receptor Positive Breast Cancer
953	0060080	Her2-receptor Negative Breast Cancer
954	0060081	Triple-receptor Negative Breast Cancer
955	0060082	Breast Benign Neoplasm
956	0060083	Immune System Cancer
957	0060084	Cell Type Benign Neoplasm
958	0060085	Organ System Benign Neoplasm
959	0060086	Female Reproductive Organ Benign Neoplasm
960	0060087	Male Reproductive Organ Benign Neoplasm
961	0060088	Vestibular Gland Benign Neoplasm
962	0060089	Endocrine Organ Benign Neoplasm
963	0060090	Central Nervous System Organ Benign Neoplasm
964	0060091	Cardiovascular Organ Benign Neoplasm
965	0060092	Immune System Organ Benign Neoplasm
966	0060094	Bone Benign Neoplasm
967	0060095	Uterine Benign Neoplasm
968	0060096	Sensory Organ Benign Neoplasm
969	0060097	Thoracic Benign Neoplasm
970	0060098	Osteoblastoma
971	0060099	Musculoskeletal System Benign Neoplasm
972	0060100	Musculoskeletal System Cancer
973	0060101	Benign Glioma
974	0060102	Cartilage Cancer
975	0060103	Central Nervous System Primitive Neuroectodermal Neoplasm
976	0060104	Cerebellar Medulloblastoma
977	0060105	Brain Medulloblastoma
978	0060106	Brain Meningioma
979	0060108	Brain Glioma
980	0060109	Vulvar Benign Neoplasm
981	0060110	Cervical Benign Neoplasm
982	0060111	Fallopian Tube Benign Neoplasm
983	0060112	Ovarian Benign Neoplasm
984	0060114	Vaginal Benign Neoplasm
985	0060115	Nervous System Benign Neoplasm
986	0060116	Sensory System Cancer
987	0060117	Peritoneal Benign Neoplasm
988	0060118	Thoracic Disease
989	0060119	Pharynx Cancer
990	0060120	Skeletal System Benign Neoplasm
991	0060121	Integumentary System Benign Neoplasm
992	0060122	Integumentary System Cancer
993	0060123	Connective Tissue Benign Neoplasm
994	0060125	Heavy Chain Disease
995	0060126	Alpha Chain Disease
996	0060127	Gamma Heavy Chain Disease
997	0060128	Mu Chain Disease
998	0060129	Delta Chain Disease
999	0060130	Akinetopsia
1000	0060131	Alexithymia
1001	0060132	Amusia
1002	0060133	Anosognosia
1003	0060134	Apperceptive Agnosia
1004	0060135	Apraxia
1005	0060136	Associative Agnosia
1006	0060137	Auditory Agnosia
1007	0060138	Autotopagnosia
1008	0060139	Color Agnosia
1009	0060140	Cortical Deafness
1010	0060141	Finger Agnosia
1011	0060142	Form Agnosia
1012	0060143	Integrative Agnosia
1013	0060144	Mirror Agnosia
1014	0060145	Pain Agnosia
1015	0060146	Phonagnosia
1016	0060147	Semantic Agnosia
1017	0060148	Simultanagnosia
1018	0060149	Social Emotional Agnosia
1019	0060150	Astereognosia
1020	0060151	Tactile Agnosia
1021	0060152	Time Agnosia
1022	0060153	Topographical Agnosia
1023	0060154	Verbal Auditory Agnosia
1024	0060155	Visual Agnosia
1026	0060157	Diffuse Alopecia Areata
1027	0060158	Acquired Metabolic Disease
1028	0060159	Organic Acidemia
1029	0060160	Survival Motor Neuron Spinal Muscular Atrophy
1030	0060161	Kennedy's Disease
1031	0060162	Dentatorubral-pallidoluysian Atrophy
1032	0060163	Body Dysmorphic Disorder
1033	0060164	Pain Disorder
1034	0060165	Kleine-Levin Syndrome
1035	0060166	Bipolar Ll Disorder
1036	0060167	Seasonal Affective Disorder
1037	0060168	Histidinemia
1038	0060169	Benign Familial Infantile Epilepsy
1039	0060170	Generalized Epilepsy With Febrile Seizures Plus
1040	0060171	Dravet Syndrome
1041	0060172	Juvenile Absence Epilepsy
1042	0060173	Timothy Syndrome
1043	0060174	GABA Aminotransferase Deficiency
1044	0060175	Succinic Semialdehyde Dehydrogenase Deficiency
1045	0060176	Gamma-amino Butyric Acid Metabolism Disorder
1046	0060177	Homocarnosinosis
1047	0060178	Familial Hemiplegic Migraine
1048	0060179	Renpenning Syndrome
1049	0060180	Colitis
1050	0060181	Ischemic Colitis
1051	0060182	Microscopic Colitis
1052	0060183	Collagenous Colitis
1053	0060184	Lymphocytic Colitis
1054	0060185	Clostridium Difficile Colitis
1055	0060186	Chemical Colitis
1056	0060187	Diversion Colitis
1057	0060188	Jejunoileitis
1058	0060189	Ileitis
1059	0060190	Ileocolitis
1060	0060191	Gastroduodenal Crohn's Disease
1061	0060192	Crohn's Colitis
1062	0060193	Amyotrophic Lateral Sclerosis Type 1
1063	0060194	Amyotrophic Lateral Sclerosis Type 2
1064	0060195	Amyotrophic Lateral Sclerosis Type 3
1065	0060196	Amyotrophic Lateral Sclerosis Type 4
1066	0060197	Amyotrophic Lateral Sclerosis Type 5
1067	0060198	Amyotrophic Lateral Sclerosis Type 6
1068	0060199	Amyotrophic Lateral Sclerosis Type 7
1069	0060200	Amyotrophic Lateral Sclerosis Type 9
1070	0060201	Amyotrophic Lateral Sclerosis Type 10
1071	0060202	Amyotrophic Lateral Sclerosis Type 11
1072	0060203	Amyotrophic Lateral Sclerosis Type 12
1073	0060204	Amyotrophic Lateral Sclerosis Type 13
1074	0060205	Amyotrophic Lateral Sclerosis Type 14
1075	0060206	Amyotrophic Lateral Sclerosis Type 15
1076	0060207	Amyotrophic Lateral Sclerosis Type 16
1077	0060208	Amyotrophic Lateral Sclerosis Type 17
1078	0060209	Amyotrophic Lateral Sclerosis Type 18
1079	0060210	Amyotrophic Lateral Sclerosis Type 19
1080	0060211	Amyotrophic Lateral Sclerosis Type 20
1081	0060212	Amyotrophic Lateral Sclerosis Type 21
1082	0060213	FTDALS1
1083	0060214	FTDALS2
1084	0060215	Balo Concentric Sclerosis
1085	0060216	Cogan Syndrome
1086	0060217	Cogan-Reese Syndrome
1087	0060218	CREST Syndrome
1088	0060219	Lymph Node Adenoid Cystic Carcinoma
1089	0060220	Physical Urticaria
1090	0060221	Maffucci Syndrome
1091	0060222	Scheie Syndrome
1092	0060223	Agraphia
1093	0060224	Atrial Fibrillation
1094	0060225	3MC Syndrome
1095	0060226	Acrofrontofacionasal Dysostosis
1096	0060227	Adams-Oliver Syndrome
1097	0060228	Intracranial Berry Aneurysm
1098	0060229	Baraitser-Winter Syndrome
1099	0060230	Basal Ganglia Calcification
1100	0060231	Bruck Syndrome
1101	0060232	Branchiootic Syndrome
1102	0060233	Cardiofaciocutaneous Syndrome
1103	0060234	Carpenter Syndrome
1104	0060235	Carnitine Palmitoyltransferase II Deficiency
1105	0060236	Xanthinuria
1106	0060237	Warburg Micro Syndrome
1107	0060238	Van Maldergem Syndrome
1108	0060239	Van Der Woude Syndrome
1109	0060240	UV-sensitive Syndrome
1110	0060241	3-M Syndrome
1111	0060242	Synpolydactyly
1112	0060243	Stuttering
1113	0060244	Specific Language Impairment
1114	0060245	Mast Syndrome
1115	0060246	MASA Syndrome
1116	0060247	Smith-McCort Dysplasia
1117	0060248	Simpson-Golabi-Behmel Syndrome
1118	0060249	Scoliosis
1119	0060250	Idiopathic Scoliosis
1120	0060251	Sclerosteosis
1121	0060252	Sclerocornea
1122	0060253	Scapuloperoneal Myopathy
1123	0060254	Robinow Syndrome
1124	0060255	Rippling Muscle Disease
1125	0060256	Dowling-Degos Disease
1126	0060257	Dyschromatosis Symmetrica Hereditaria
1127	0060258	Reticulate Acropigmentation Of Kitamura
1128	0060259	Renal-hepatic-pancreatic Dysplasia
1129	0060260	Ptosis
1130	0060261	Congenital Ptosis
1131	0060262	Gallbladder Disease
1132	0060263	Porencephaly
1133	0060264	Pontocerebellar Hypoplasia
1134	0060265	Pontocerebellar Hypoplasia Type 1A
1135	0060266	Pontocerebellar Hypoplasia Type 1B
1136	0060267	Pontocerebellar Hypoplasia Type 2A
1137	0060268	Pontocerebellar Hypoplasia Type 2B
1138	0060269	Pontocerebellar Hypoplasia Type 2C
1139	0060270	Pontocerebellar Hypoplasia Type 2D
1140	0060271	Pontocerebellar Hypoplasia Type 2E
1141	0060272	Pontocerebellar Hypoplasia Type 3
1142	0060273	Pontocerebellar Hypoplasia Type 4
1143	0060274	Pontocerebellar Hypoplasia Type 5
1144	0060275	Pontocerebellar Hypoplasia Type 6
1145	0060276	Pontocerebellar Hypoplasia Type 7
1146	0060277	Pontocerebellar Hypoplasia Type 8
1147	0060278	Pontocerebellar Hypoplasia Type 9
1148	0060279	Pontocerebellar Hypoplasia Type 10
1149	0060280	Primary Pigmented Nodular Adrenocortical Disease
1150	0060281	Photosensitive Epilepsy
1151	0060282	Persistent Hyperplastic Primary Vitreous
1152	0060283	Peeling Skin Syndrome
1153	0060284	Paroxysmal Nocturnal Hemoglobinuria
1154	0060285	Parietal Foramina
1155	0060286	Combined Oxidative Phosphorylation Deficiency
1156	0060287	Cornea Plana
1157	0060288	Omodysplasia
1158	0060289	Ohdo Syndrome
1159	0060290	Blepharophimosis-intellectual Disability Syndrome, SBBYS Type
1160	0060291	Oculodentodigital Dysplasia
1161	0060292	X-linked Chondrodysplasia Punctata
1162	0060293	Autosomal Dominant Chondrodysplasia Punctata
1163	0060294	Cold-induced Sweating Syndrome
1164	0060295	Complement Component 2 Deficiency
1165	0060296	Congenital Secretory Chloride Diarrhea 1
1166	0060297	Complement Component 4a Deficiency
1167	0060298	Complement Component 4b Deficiency
1168	0060299	Complement Component 6 Deficiency
1169	0060300	Complement Component 7 Deficiency
1170	0060301	Type I Complement Component 8 Deficiency
1171	0060302	Type II Complement Component 8 Deficiency
1172	0060303	Complement Component 9 Deficiency
1173	0060304	Dyschromatosis Universalis Hereditaria
1174	0060305	Megalocornea
1175	0060306	Meier-Gorlin Syndrome
1176	0060307	Autosomal Dominant Non-syndromic Intellectual Disability
1177	0060308	Autosomal Recessive Non-syndromic Intellectual Disability
1178	0060309	Syndromic X-linked Intellectual Disability
1179	0060310	Uvulitis
1180	0060311	Adenoid Hypertrophy
1181	0060312	Angular Cheilitis
1182	0060313	Tracheomalacia
1183	0060314	Persistent Generalized Lymphadenopathy
1184	0060315	Oral Hairy Leukoplakia
1185	0060316	Orofaciodigital Syndrome Type I
1186	0060317	Lung Abscess
1187	0060318	Acute Promyelocytic Leukemia
1188	0060319	Cardiac Arrest
1189	0060320	Inguinal Hernia
1190	0060321	Umbilical Hernia
1191	0060322	Mastoiditis
1192	0060323	Breast Abscess
1193	0060324	Dental Abscess
1194	0060325	Cervical Polyp
1195	0060326	Myelomeningocele
1196	0060327	Omphalocele
1197	0060328	Anal Fistula
1198	0060329	Ectopic Pregnancy
1199	0060330	Rapp-Hodgkin Syndrome
1200	0060331	Mitochondrial Complex V (ATP Synthase) Deficiency Nuclear Type 2
1201	0060332	Mitochondrial Complex V (ATP Synthase) Deficiency Nuclear Type 3
1202	0060333	Mitochondrial Complex V (ATP Synthase) Deficiency Nuclear Type 4
1203	0060334	Transient Neonatal Diabetes Mellitus
1204	0070001	Neoplastic Disease
1205	0070003	Blastoma
1206	0070004	Myeloma
1207	0080000	Muscular Disease
1208	0080001	Bone Disease
1209	0080002	Autosomal Dominant Disease
1210	0080003	Autosomal Recessive Disease
1211	0080005	Bone Remodeling Disease
1212	0080006	Bone Development Disease
1213	0080007	Bone Deterioration Disease
1214	0080008	Ischemic Bone Disease
1215	0080009	X-linked Dominant Disease
1216	0080010	Bone Structure Disease
1217	0080011	Bone Resorption Disease
1218	0080012	X-linked Recessive Disease
1219	0080013	Mitochondrial Disease
1220	0080014	Chromosomal Disease
1221	0080015	Physical Disorder
1222	0080016	Spina Bifida
1223	0080017	Olivopontocerebellar Atrophy V
1224	0080018	Dysbaric Osteonecrosis
1225	0080019	Metaphyseal Dysplasia
1226	0080020	Jansen's Metaphyseal Chondrodysplasia
1227	0080021	Schmid Metaphyseal Chondrodysplasia
1228	0080022	McKusick Type Metaphyseal Dysplasia
1229	0080023	Schwachman Diamond Type Metaphyseal Dysplasia
1230	0080024	Pyles Dysplasia
1231	0080025	Spondyloepiphyseal Dysplasia Congenita
1232	0080026	Otospondylomegaepiphyseal Dysplasia
1233	0080027	Spondyloepimetaphyseal Dysplasia
1234	0080028	Spondyloepimetaphyseal Dysplasia, Strudwick Type
1235	0080030	Spondyloepimetaphyseal Dysplasia, Missouri Type
1236	0080031	Fibrous Dysplasia
1237	0080032	Craniodiaphyseal Dysplasia
1238	0080033	Craniometaphyseal Dysplasia
1239	0080034	Endosteal Hyperostosis
1240	0080036	SOST-related Sclerosing Bone Dysplasia
1241	0080037	Worth's Syndrome
1242	0080038	Pycnodysostosis
1243	0080039	Axial Osteomalacia
1244	0080040	Fibrogenesis Imperfecta Ossium
1245	0080041	Hypochondroplasia
1246	0080043	Achondrogenesis
1247	0080044	Hypochondrogenesis
1248	0080045	Kniest Dysplasia
1249	0080046	Stickler Syndrome
1250	0080047	Pseudoachondroplasia
1251	0080048	Trichorhinophalangeal Syndrome I
1252	0080049	Acromesomelic Dysplasia
1253	0080050	Acromesomelic Dysplasia, Maroteaux Type
1254	0080051	Acromesomelic Dysplasia, Hunter-Thompson Type
1255	0080052	Acromesomelic Dysplasia, Grebe Type
1256	0080053	Albright's Hereditary Osteodystrophy
1257	0080054	Achondrogenesis Type IA
1258	0080055	Achondrogenesis Type IB
1259	0080056	Achondrogenesis Type II
1260	100	Intestinal Infectious Disease
1261	10000	Visual Cortex Disorder Due To Neoplasm
1262	10003	Sensorineural Hearing Loss
1263	10007	Respiratory Syncytial Virus Bronchiolitis
1264	1001	Labor Complications
1265	10011	Thyroid Lymphoma
1266	10012	Metastatic Malignant Neoplasm To The Thyroid
1267	10013	Polyglandular Activity In Multiple Endocrine Adenomatosis
1268	10015	Polyglandular Dysfunction
1269	10016	Multiple Endocrine Neoplasia Type 2B
1270	10017	Multiple Endocrine Neoplasia Type 1
1271	10018	Papilledema Associated With Increased Intracranial Pressure
1272	1002	Endometritis
1273	10020	Ampulla Of Vater Cancer
1274	10021	Duodenum Cancer
1275	10022	Ampulla Of Vater Neoplasm
1276	10024	Migraine With Aura
1277	10027	Tabes Dorsalis
1278	1003	Pelvic Inflammatory Disease
1279	10030	Interstitial Emphysema
1280	10031	Compensatory Emphysema
1281	10032	Hyperlucent Lung
1282	10033	Cycloplegia
1283	10034	Eye Accommodation Disease
1284	10035	Asymptomatic Neurosyphilis
1285	10038	Old Burn Scar-related Melanoma Of Skin
1286	10039	Late Congenital Syphilis
1287	10040	Malignant Eyelid Melanoma
1288	10041	Dysplastic Nevus Syndrome
1289	10042	Regressing Skin Melanoma
1290	10044	Balloon Cell Malignant Melanoma
1291	10045	Malignant Giant Pigmented Nevus Melanoma
1292	10047	Nodular Malignant Melanoma
1293	10048	Malignant Junctional Nevus Melanoma
1294	10049	Desmoplastic Melanoma
1295	1005	Endometrial Disease
1296	10053	Malignant Skin Blue Nevus
1297	10054	Skin Amelanotic Melanoma
1298	10059	Congenital Or Acquired Abnormality Of Vagina Complicating Pregnancy, Childbirth, Or The Puerperium
1299	10066	Syphilitic Acoustic Neuritis
1300	10069	Subglottis Neoplasm
1301	10070	Larynx Leiomyoma
1302	10071	Larynx Squamous Papilloma
1303	10073	Syphilitic Meningitis
1304	10074	Hymenolepiasis
1305	10075	Diphyllobothriasis
1306	10079	Cysticercosis
1307	10080	Sparganosis
1308	10081	Syphilitic Encephalitis
1309	10087	Gastric Leiomyoma
1310	10095	Intracranial Abscess
1311	10111	Congenital Or Acquired Abnormality Of Vagina, With Delivery
1312	10112	Sleeping Sickness
1313	10113	Trypanosomiasis
1314	10114	Trypanosoma Brucei Rhodesiense Infectious Disease
1315	10116	Trypanosoma Brucei Gambiense Infectious Disease
1316	10120	Eyelid Degenerative Disease
1317	10121	Degenerative Disorder Of Eyelid And Periocular Area
1318	10122	Hyperpigmentation Of Eyelid
1319	10123	Pigmentation Disease
1320	10124	Corneal Disease
1321	10125	Acute Hydrops Keratoconus
1322	10126	Keratoconus
1323	10127	Cerebral Artery Occlusion
1324	10128	Venous Insufficiency
1325	10131	Psychologic Vaginismus
1326	10132	Psychosexual Disorder
1327	10138	Xerophthalmia
1328	10139	Conjunctival Degeneration
1329	10140	Dry Eye Syndrome
1330	10141	Asthenopia
1331	10142	Chlamydia Trachomatis Peritonitis
1332	10144	Secondary Malignant Neoplasm To The Thymus
1333	10145	Metastases To Mediastinum
1334	10146	Thymus Lymphoma
1335	10149	Long Bones Of Lower Limb Cancer
1336	10150	Lower Limb Cancer
1337	10151	Malignant Neoplasm Of Short Bones Of Lower Limb
1338	10152	Meckel's Diverticulum Cancer
1339	10153	Ileum Cancer
1340	10154	Small Intestine Cancer
1341	10155	Intestinal Cancer
1342	10156	Ileal Neoplasm
1343	10159	Osteonecrosis
1344	1016	Primary Tuberculosis
1345	10173	Tuberculous Myelitis
1346	10174	Lacrimal Passage Granuloma
1347	10175	Optic Papillitis
1348	10176	Neuroretinitis
1349	10177	Malignant Hypertensive Renal Disease
1350	10182	Diabetic Peripheral Angiopathy
1351	10183	Endobronchial Lipoma
1352	10184	Spindle Cell Lipoma
1353	10187	Esophageal Lipoma
1354	10188	Skin Lipoma
1355	1019	Osteomyelitis
1356	10190	Liver Lipoma
1357	10191	Autosomal Deletion Syndrome
1358	10192	Pleomorphic Lipoma
1359	10193	Classic Type Lipoma
1360	10194	Kidney Lipoma
1361	10195	Pleural Lipoma
1362	10199	Breast Lipoma
1363	10200	Chest Wall Lipoma
1364	10201	Gallbladder Lipoma
1365	10202	Lipoma Of Intrathoracic Organ
1366	10203	External Auditory Meatus Lipoma
1367	10204	Lipoma Of Intra-abdominal Organ
1368	10205	Axillary Lipoma
1369	10206	Lipoma Of Spermatic Cord
1370	10207	Paratesticular Lipoma
1371	10208	Chondroid Lipoma
1372	10209	Extrahepatic Bile Duct Lipoma
1373	10210	Calculus Of Gallbladder And Bile Duct Without Cholecystitis
1374	10211	Cholelithiasis
1375	1022	Pinta Disease
1376	10220	Failed Induction
1377	10222	Polymyositis
1378	10223	Dermatomyositis
1379	10226	Single Episode Manic Disorder
1380	10229	Partial Epilepsy, With Impairment Of Consciousness, With Intractable Epilepsy
1381	1023	Borderline Leprosy
1382	10230	Aortic Atherosclerosis
1383	10233	Histoplasma Capsulatum Pericarditis
1384	10234	Histoplasmosis Pericarditis
1385	10235	Brown's Tendon Sheath Syndrome
1386	10236	Exhibitionism
1387	10237	Pelvic Cancer
1388	10238	Malignant Neoplasm Of Rectum, Rectosigmoid Junction And Anus
1389	10239	Malignant Neoplasm Of Pelvic Bones, Sacrum And Coccyx
1390	1024	Leprosy
1391	10240	Malignant Neoplasm Of Pelvis
1392	10241	Thalassemia
1393	10242	Ehrlichiosis
1394	10245	Delayed Separation Of Umbilical Cord
1395	10247	Pleurisy
1396	1025	Tuberculoid Leprosy
1397	10250	Louping Ill
1398	10254	Strawberry Gallbladder
1399	10255	Conjunctival Degenerations And Deposits
1400	10256	Vitamin A Deficiency With Conjunctival Xerosis
1401	10257	Vitamin A Deficiency
1402	10261	Discharging Ear
1403	10263	Mumps Virus Hepatitis
1404	10264	Mumps
1405	10265	Hairy Cell Leukemia Of Spleen
1406	10266	Subendocardial Infarction Acute Myocardial Infarction
1407	10272	Left Bundle Branch Hemiblock
1408	10273	Heart Conduction Disease
1409	10274	Schizo-affective Type Schizophrenia In Remission
1410	10277	Pseudomonas Intestinal Infectious Disease
1411	10278	Vasa Previa Complicating Labor And Delivery
1412	10279	Vasa Previa
1413	10280	Vasa Previa Complicating Labor And Delivery, Delivered
1414	10283	Prostate Cancer
1415	10286	Prostate Carcinoma
1416	10287	Prostate Squamous Cell Carcinoma
1417	10288	Metastasis To Prostate
1418	10289	Prostate Malignant Phyllodes Tumor
1419	1029	Familial Periodic Paralysis
1420	10290	Prostate Lymphoma
1421	10293	Monocular Esotropia
1422	10294	Intermittent Monocular Esotropia
1423	10295	Monocular Esotropia With A Pattern
1424	10296	Monocular Esotropia With V Pattern
1425	10300	Raynaud Disease
1426	10301	Parotitis
1427	10302	Parotid Disease
1428	10303	Sialadenitis
1429	10304	Mumps Virus Infectious Disease
1430	10305	Mumps Virus Orchitis
1431	10307	Mumps Virus Polyneuritis
1432	10309	Mumps Virus Meningitis
1433	10310	Viral Meningitis
1434	10311	Mumps Virus Encephalitis
1435	10312	Mumps Virus Pancreatitis
1436	10314	Endocarditis
1437	10316	Pneumoconiosis
1438	10319	Mixed Mineral Dust Pneumoconiosis
1439	10320	Asbestosis
1440	10321	Baritosis
1441	10322	Berylliosis
1442	10323	Byssinosis
1443	10324	Anthracosilicosis
1444	10325	Silicosis
1445	10326	Caplan's Syndrome
1446	10327	Anthracosis
1447	10328	Siderosis
1448	10329	Pneumoconiosis Due To Talc
1449	10330	Slate Pneumoconiosis
1450	10331	Kaolin Pneumoconiosis
1451	10332	Disorder Of Optic Chiasm Due To Vascular Disorder
1452	10334	Craniofacial Abnormality
1453	10337	Glaucomatous Atrophy Of Optic Disc
1454	10338	Subchronic Schizophrenia
1455	10339	Schizophrenia Simplex
1456	10340	Residual Subchronic Schizophrenia
1457	10341	Chronic Meningitis
1458	10342	Subchronic Latent Schizophrenia
1459	10343	Latent Schizophrenia
1460	10348	Blepharophimosis
1461	10349	Solitary Cyst Of Breast
1462	1035	Natural Killer Cell Leukemia
1463	10350	Breast Cyst
1464	10351	Mammary Duct Ectasia
1465	10352	Breast Fibroadenosis
1466	10353	Fibrosclerosis Of Breast
1467	10354	Breast Fibrocystic Disease
1468	1036	Chronic Leukemia
1469	10361	Eosinophilic Meningitis
1470	10366	Epididymis Cancer
1471	10367	Metastatic Tumor To The Epididymis
1472	10368	Epididymis Adenocarcinoma
1473	1037	Lymphoblastic Leukemia
1474	10371	Yaws
1475	10375	Suppression Amblyopia
1476	10376	Amblyopia
1477	10377	Ametropic Amblyopia
1478	10378	Disuse Amblyopia
1479	1038	Mature T-cell Neoplasm
1480	10380	Precipitate Labor
1481	10381	Staphylococcal Meningitis
1482	10383	Amyotrophic Neuralgia
1483	10384	Papilledema Associated With Decreased Ocular Pressure
1484	1039	Prolymphocytic Leukemia
1485	10393	Secondary Hypertrophic Osteoarthropathy
1486	10398	Pneumonic Plague
1487	10399	Seminal Vesicle Chronic Gonorrhea
1488	104	Bacterial Infectious Disease
1489	1040	Chronic Lymphocytic Leukemia
1490	10400	Gonococcal Seminal Vesiculitis
1491	1042	Generalized Infection During Labor
1492	10423	Acute Pericementitis
1493	10426	Klippel-Feil Syndrome
1494	10428	Stable Condition Keratoconus
1495	10435	Purulent Acute Otitis Media
1496	10437	Metastasis To Lymph Node
1497	10439	Mooren's Ulcer
1498	1044	Nontraumatic Rupture Of Muscle
1499	10440	Mycotic Corneal Ulcer
1500	10441	Marginal Corneal Ulcer
1501	10442	Hypopyon Ulcer
1502	10443	Hypopyon
1503	10444	Ring Corneal Ulcer
1504	10445	Perforated Corneal Ulcer
1505	10447	Thyroid Dysfunction Complicating Pregnancy, Childbirth, Or The Puerperium
1506	1045	Fascia Disease
1507	10456	Tonsillitis
1508	10457	Legionnaires' Disease
1509	10458	Legionellosis
1510	10459	Common Cold
1511	10460	Nasopharyngitis
1512	10461	Dentin Caries
1513	10469	Diabetes Mellitus Juvenile Type, Uncontrolled, With Neurological Manifestations
1514	1047	Mental Disorder Complicating Pregnancy, Childbirth, Or The Puerperium
1515	10471	Patellar Tendinitis
1516	10472	Candidal Pneumonia
1517	10473	Wrist Or Carpus Enthesopathy
1518	10480	Diaphragmatic Eventration
1519	10481	Diaphragm Disease
1520	10483	Hypertonic, Incoordinate, Or Prolonged Uterine Contractions
1521	10485	Esophageal Atresia
1522	10486	Intestinal Atresia
1523	10487	Hirschsprung's Disease
1524	10488	Imperforate Anus
1525	10489	Transient Disorder Of Initiating Or Maintaining Wakefulness
1526	10493	Adrenal Cortical Hypofunction
1527	10494	Pulmonary Valve Syphilitic Endocarditis
1528	10499	Orbital Granuloma
1529	10501	Menopausal And Postmenopausal Disorder
1530	10505	Generalized Nonconvulsive Epilepsy Disease
1531	10507	Dressler's Syndrome
1532	10508	Bacillus Anthracis Pneumonia
1533	10510	Influenza Virus Pneumonia
1534	10516	Malignant Otitis Externa
1535	10518	Beach Ear
1536	10519	Chronic Fungal Otitis Externa
1537	10520	Acute Infection Of Pinna
1538	10521	Pinna Disease
1539	10525	Double Pterygium
1540	10526	Conjunctival Pterygium
1541	10527	Haemophilus Influenzae Pneumonia
1542	10528	Haemophilus Influenzae Infectious Disease
1543	10529	Primary Haemophilus Infectious Disease
1544	1053	Developmental Dislocation Of Joint
1545	10531	Pneumococcal Pneumonia
1546	10532	Streptococcal Pneumonia
1547	10533	Viral Pneumonia
1548	10534	Stomach Cancer
1549	10535	Coxsackie Myocarditis
1550	10536	Malignant Gastric Granular Cell Tumor
1551	10537	Recurrent Malignant Gastric Neoplasm
1552	10538	Gastric Fundus Cancer
1553	1054	Glaucoma Associated With Chamber Angle Anomalies
1554	10540	Gastric Lymphoma
1555	10541	Microinvasive Gastric Cancer
1556	10544	Pylorus Cancer
1557	10545	Coxsackievirus Infectious Disease
1558	10547	Pyloric Antrum Cancer
1559	10548	Cardia Cancer
1560	10549	Diabetes Mellitus Insulin Dependent Type, Not Stated As Uncontrolled, With Ophthalmic Manifestations
1561	1055	Glaucoma Associated With Congenital Anomalies, Dystrophies And Systemic Syndromes
1562	10550	Acute Eustachian Salpingitis
1563	10551	Cerebral Toxoplasmosis
1564	10554	Meningoencephalitis
1565	10556	Supine Hypotensive Syndrome
1566	10557	Maternal Distress
1567	1056	Oculocerebrorenal Syndrome
1568	10561	Yaws Hyperkeratosis
1569	10564	Gangosa Of Yaws
1570	10567	Late Yaws
1571	10568	Early Yaws
1572	10569	Myopathy Of Critical Illness
1573	1057	Inborn Amino Acid Transport Disorder
1574	10573	Osteomalacia
1575	10574	Vitamin D Deficiency
1576	10575	Calcium Metabolism Disease
1577	10579	Leukodystrophy
1578	1058	Amino Acid Transport Disease
1579	10581	Metachromatic Leukodystrophy
1580	10582	Refsum Disease
1581	10584	Retinitis Pigmentosa
1582	10585	Hereditary And Idiopathic Peripheral Neuropathy
1583	10587	Krabbe Disease
1584	10588	Adrenoleukodystrophy
1585	1059	Intellectual Disability
1586	10590	Mild Pre-eclampsia
1587	10591	Pre-eclampsia
1588	10593	Idiopathic Progressive Polyneuropathy
1589	10594	Idiopathic Neuropathy
1590	10595	Charcot-Marie-Tooth Disease
1591	10597	Gonococcal Meningitis
1592	106	Pleural Tuberculosis
1593	1060	Hartnup Disease
1594	10600	Chronic Tic Disorder
1595	10602	Steatorrhea
1596	10603	Glucose Intolerance
1597	10604	Lactose Intolerance
1598	10605	Short Bowel Syndrome
1599	10606	Blind Loop Syndrome
1600	10607	Tropical Sprue
1601	10608	Celiac Disease
1602	10609	Rickets
1603	1061	Renal Aminoaciduria
1604	10610	Pancreatic Steatorrhea
1605	10611	Protein-losing Enteropathy
1606	10612	Allergic Urticaria
1607	10615	Acute Gonococcal Cervicitis
1608	10616	Acute Cervicitis
1609	10619	Lymph Node Cancer
1610	1062	Fanconi Syndrome
1611	10621	Fissure Of Nipple Associated With Childbirth
1612	10626	Insulin Dependent Type Diabetes Mellitus Uncontrolled With Ketoacidosis
1613	10627	Primary Optic Atrophy
1614	10629	Microphthalmia
1615	1063	Interstitial Nephritis
1616	10630	Optic Atrophy Associated With Retinal Dystrophy
1617	10631	Partial Optic Atrophy
1618	10632	Wolfram Syndrome
1619	1064	Cystinosis
1741	10913	Benign Essential Hypertension
1620	10645	Chronic State Latent Schizophrenia With Acute Exacerbation
1621	10646	Schizotypal Personality Disorder
1622	10648	Acute Inferoposterior Infarction
1623	10649	Acute Inferolateral Myocardial Infarction
1624	10651	Acute Anterolateral Myocardial Infarction
1625	10652	Alzheimer's Disease
1626	10655	Lipoma Of Colon
1627	10656	Colon Leiomyoma
1628	10657	Colonic Lymphangioma
1629	10659	Colonic Ganglioneuroma
1630	1066	Residual Stage Of Open Angle Glaucoma
1631	10660	Mediastinum Neuroblastoma
1632	10661	Mediastinum Ganglioneuroblastoma
1633	1067	Open-angle Glaucoma
1634	1068	Juvenile Glaucoma
1635	10685	Separation Anxiety Disorder
1636	10686	Lactocele
1637	10688	Hypertrophy Of Breast
1638	10689	Galactorrhea Not Associated With Childbirth
1639	10690	Mastitis
1640	10691	Fat Necrosis Of Breast
1641	10697	Chronic Endophthalmitis
1642	10699	Paragonimiasis
1643	1070	Primary Open Angle Glaucoma
1644	10708	Passive-aggressive Personality Disorder
1645	10717	Meningococcal Septicemia
1646	10718	Giardiasis
1647	10719	Toxic Diffuse Goiter
1648	1073	Renal Hypertension
1649	10731	Nodular Lung Tuberculosis
1650	1074	Kidney Failure
1651	10742	Cerebral Lipidosis
1652	10744	Broad Ligament Malignant Neoplasm
1653	10747	Lymphoid Leukemia
1654	1075	Chronic Pyelonephritis With Lesion Of Renal Medullary Necrosis
1655	10754	Otitis Media
1656	10755	Petrositis
1657	1076	Chronic Pyelonephritis
1658	10760	Choroidal Rupture
1659	10762	Portal Hypertension
1660	10763	Hypertension
1661	10764	Liver Abscess And Sequelae Of Chronic Liver Disease
1662	1077	Spirurida Infectious Disease
1663	10772	Thrombotic Thrombocytopenic Purpura
1664	10773	Bubonic Plague
1665	10774	Cutaneous Plague
1666	10778	Fiedler's Myocarditis
1667	10779	Septic Myocarditis
1668	1078	Chromadorea Infectious Disease
1669	10780	Primary Polycythemia
1670	10782	Mesenteric Lymphadenitis
1671	10783	Methemoglobinemia
1672	10784	Queensland Tick Typhus
1673	10787	Premature Menopause
1674	10788	Osteitis Condensans
1675	1079	Setariasis
1676	10790	Chronic Frontal Sinusitis
1677	10791	Frontal Sinusitis
1678	10792	Chronic Maxillary Sinusitis
1679	10793	Chronic Sphenoidal Sinusitis
1680	10794	Sphenoid Sinusitis
1681	10795	Congenital Syphilitic Encephalitis
1682	1080	Filariasis
1683	10802	Acute Gonococcal Epididymo-orchitis
1684	10803	Haemophilus Influenzae Meningitis
1685	10808	Gastric Ulcer
1686	1081	Mansonelliasis
1687	10810	Tibialis Tendinitis
1688	10811	Nasal Cavity Cancer
1689	10812	Nasal Cavity Olfactory Neuroblastoma
1690	10813	Nasal Cavity Lymphoma
1691	10815	Recurrent Duodenal Cancer
1692	10816	Duodenum Adenocarcinoma
1693	10817	Sexual Sadism
1694	10818	Leptospiral Meningitis
1695	1082	Dirofilariasis
1696	10823	Malignant Essential Hypertension
1697	10824	Malignant Hypertension
1698	10825	Essential Hypertension
1699	10827	Gender Identity Disorder In Adolescent Or Adult
1700	10834	Voyeurism
1701	10835	Chylocele Of Tunica Vaginalis
1702	10836	Diabetes Mellitus With Hyperosmolarity
1703	10837	Diabetes Mellitus,insulin Dependent Type With Hyperosmolarity, Not Stated As Uncontrolled
1704	10838	Diabetes Mellitus, Insulin Dependent Type With Hyperosmolarity, Uncontrolled
1705	10841	Eastern Equine Encephalitis
1706	10842	Murray Valley Encephalitis
1707	10843	Western Equine Encephalitis
1708	10844	Japanese Encephalitis
1709	10845	St. Louis Encephalitis
1710	10846	Angiodysplasia Of Intestine
1711	10848	Intrauterine Hypoxia And Birth Asphyxia
1712	10849	Sexual Masochism
1713	1085	Edwards Syndrome
1714	10852	Middle Ear Cholesterol Granuloma
1715	10854	Salivary Gland Disease
1716	1086	Congenital Chromosomal Disease
1717	10863	Paralytic Squint
1718	10864	Partial Third-nerve Palsy
1719	10865	Abducens Nerve Disease
1720	10866	Total Third-nerve Palsy
1721	10869	Fourth Cranial Nerve Palsy
1722	10871	Age Related Macular Degeneration
1723	10873	Kuhnt-Junius Degeneration
1724	10875	Premature Labor
1725	10877	Disorganized Type Schizophrenia Chronic State With Acute Exacerbation
1726	1088	Meningocele
1727	10880	Iliac Vein Thrombophlebitis
1728	10881	Hand, Foot And Mouth Disease
1729	10882	Epidemic Pleurodynia
1730	10883	Herpangina
1731	10887	Lepromatous Leprosy
1732	1089	Tethered Spinal Cord Syndrome
1733	10892	Hypospadias
1734	10901	Leukemic Reticuloendotheliosis Of Lymph Nodes Of Axilla And Upper Limb
1735	10902	Pulmonary Actinomycosis
1736	10907	Microcephaly
1737	10908	Hydrocephalus
1738	1091	Tooth Disease
1739	10910	Echovirus Meningitis
1740	10911	Echovirus Infectious Disease
1742	10914	Amnestic Disorder
1743	10915	Wernicke-Korsakoff Syndrome
1744	10918	Transsexuality With Asexual History
1745	10919	Transsexualism
1746	10921	Siberian Tick Typhus
1747	10922	Sickle-cell Crisis
1748	10923	Sickle Cell Anemia
1749	10924	Catatonic Type Schizophrenia Chronic State
1750	10925	Catatonic Schizophrenia
1751	10927	Gastrojejunal Ulcer
1752	10930	Borderline Personality Disorder
1753	10931	Dependent Personality Disorder
1754	10932	Obsessive-compulsive Personality Disorder
1755	10933	Obsessive-compulsive Disorder
1756	10934	Multiple Personality Disorder
1757	10935	Dissociative Disorder
1758	10936	Schizoid Personality Disorder
1759	10937	Impulse Control Disorder
1760	10938	Paranoid Personality Disorder
1761	10939	Antisocial Personality Disorder
1762	1094	Attention Deficit Hyperactivity Disorder
1763	10941	Intracranial Aneurysm
1764	10944	Tongue Disease
1765	10952	Nephritis
1766	10955	Strongyloidiasis
1767	10957	Enterobacter Aerogenes Intestinal Infectious Disease
1768	10958	Salmonella Arizonae Intestinal Infectious Disease
1769	10959	Escherichia Coli Intestinal Infectious Disease
1770	10963	Cholesteatoma Of Attic
1771	10964	Cholesteatoma Of Middle Ear
1772	10965	Spastic Diplegia
1773	10966	Lipoid Nephrosis
1774	10967	Spastic Hemiplegia
1775	10968	Spastic Monoplegia
1776	10969	Hemiplegia
1777	1097	Hydrops Fetalis
1778	10970	Spastic Quadriplegia
1779	10971	Acute Salpingo-oophoritis
1780	10972	Salpingo-oophoritis
1781	10973	Acute Salpingitis
1782	10974	Oophoritis
1783	10976	Membranous Glomerulonephritis
1784	10978	Poliovirus Type III Nonparalytic Poliomyelitis
1785	10979	Poliovirus Type I Nonparalytic Poliomyelitis
1786	1098	Fetal Erythroblastosis
1787	10980	Poliovirus Type II Nonparalytic Poliomyelitis
1788	10983	Alport Syndrome
1789	10986	Discitis
1790	10989	Conjunctival Vascular Disease
1791	1099	Alpha Thalassemia
1792	10991	Basal Ganglia Cerebrovascular Disease
1793	10992	Acute Hemorrhagic Leukoencephalitis
1794	10993	Postinfectious Encephalitis
1795	10997	Immature Cataract
1796	10998	Chronic Glomerulonephritis With Lesion Of Membranoproliferative Glomerulonephritis
1797	110	Lens Disease
1798	1100	Ovarian Disease
1799	11000	Progressive Iris Atrophy
1800	11001	Iris And Ciliary Body Degeneration
1801	11002	Iridoschisis
1802	11003	Pupillary Margin Miotic Cyst
1803	11005	Atrophy Of Sphincter Of Iris
1804	11014	Anorectal Stricture
1805	11018	Postsurgical Testicular Hypofunction
1806	11019	Testicular Dysfunction
1807	11020	Chronic Glomerulonephritis With Lesion Of Proliferative Glomerulonephritis
1808	11027	Chronic Glomerulonephritis With Lesion Of Membranous Glomerulonephritis
1809	11028	Pseudopterygium
1810	11029	Pinguecula
1811	1103	Malignant Esophageal Neoplasm By Topographic Region
1812	11030	Corneal Edema
1813	11031	Bullous Keratopathy
1814	11032	Secondary Corneal Edema
1815	11033	Idiopathic Corneal Edema
1816	11034	Contact Lens Corneal Edema
1817	11036	Chronic Rapidly Progressive Glomerulonephritis
1818	11037	Dissociative Amnesia
1819	11038	Depersonalization Disorder
1820	11042	Felty's Syndrome
1821	11044	Gastroschisis
1822	11049	Meconium Aspiration Syndrome
1823	1105	Esophageal Metastasis
1824	11054	Urinary Bladder Cancer
1825	11055	Pasteurellosis
1826	11056	Pasteurella Hemorrhagic Septicemia
1827	1106	Esophagus Lymphoma
1828	11060	Placenta Praevia
1829	1107	Esophageal Carcinoma
1830	11074	Cyst Of Thyroid
1831	11076	Brucella Suis Brucellosis
1832	11077	Brucellosis
1833	11079	Leech Infestation
1834	1108	Esophagus Melanoma
1835	11080	Myiasis
1836	11086	Chorioretinal Scar
1837	11088	Asphyxia Neonatorum
1838	1109	Extracutaneous Melanoma
1839	11091	Perinatal Respiratory Disorder
1840	11092	Salmonella Gastroenteritis
1841	11093	Bacterial Gastroenteritis
1842	11096	Renal Syphilis
1843	11097	Pulmonary Syphilis
1844	11099	Primary Rickettsiaceae Infectious Disease
1845	1110	Gastrointestinal Melanoma
1846	11100	Q Fever
1847	11101	Trench Fever
1848	11102	Bartonella Infectious Disease
1849	11103	Rickettsialpox
1850	11104	Spotted Fever
1851	11105	Fundus Albipunctatus
1852	11106	Glaucoma Associated With Anterior Segment Anomaly
1853	11107	Glaucoma Associated With Ocular Disorder
1854	1111	Malignant Neoplasm Of Cervical Part Of Esophagus
1855	11110	Psychosexual Dysfunction With Female Orgasmic Disease
1856	11111	Hydronephrosis
1857	11118	Syphilitic Retrobulbar Neuritis
1858	11119	Gilles De La Tourette Syndrome
1859	1112	Neck Cancer
1860	11120	Psychologic Dyspareunia
1861	11121	Pulpitis
1862	11123	Henoch-Schoenlein Purpura
1863	11125	Qualitative Platelet Defect
1864	11126	Acquired Thrombocytopenia
1865	11129	Dislocation Of Ear Ossicle
1866	1113	Malignant Esophageal Neoplasm By Anatomic Region
1867	11130	Secondary Hypertension
1868	11132	Prostatic Hypertrophy
1869	11133	Prostatic Cyst
1870	11134	Prolapse Of Lacrimal Gland
1871	1114	Esophagus Sarcoma
1872	11144	Anthrax Septicemia
1873	11145	Pars Plana Primary Cyst
1874	11147	Vascular Lesions Of Cord Complicating Labor And Delivery
1875	11148	Hypersecretion Glaucoma
1876	11149	Aqueous Misdirection
1877	1115	Sarcoma
1878	11150	Glaucoma Due To Raised Episcleral Venous Pressure
1879	11151	Cholecystolithiasis
1880	11153	Miliaria Rubra
1881	11155	Hypohidrosis
1882	11156	Anhidrosis
1883	11158	Disorder Of Optic Chiasm Associated With Non-pituitary Neoplasm
1884	1116	Pertussis
1885	11161	Neonatal Respiratory Failure
1886	11162	Respiratory Failure
1887	11163	Apnea Of Prematurity
1888	11164	Band Keratopathy
1889	11165	Common Wart
1890	11166	Papillomavirus Infectious Disease
1891	11167	Uterine Cervix Condylomata Acuminata
1892	11168	Anogenital Venereal Wart
1893	11169	Vaginal Condylomata Acuminata
1894	11170	Vulvar Condylomata Acuminata
1895	11171	Urethral Condylomata Acuminata
1896	11172	Anal Condylomata Acuminata
1897	11175	Enophthalmos
1898	11177	Total Internal Ophthalmoplegia
1899	11179	Otitis Media With Effusion
1900	11180	Non-suppurative Otitis Media
1901	11181	Serous Glue Ear
1902	11182	Chronic Otitis Media With Effusion
1903	11183	Haemophilus Influenzae Septicemia
1904	11184	Acute Conjunctivitis
1905	11186	Allescheriosis
1906	11189	Pulp Degeneration
1907	1119	Large For Dates Affecting Management Of Mother
1908	11190	Pseudomembranous Conjunctivitis
1909	11193	Syndactyly
1910	11195	Acute Laryngopharyngitis
1911	11197	Serous Conjunctivitis Except Viral
1912	11198	DiGeorge Syndrome
1913	11199	Hypoparathyroidism
1914	112	Esophageal Varix
1915	11200	T Cell Deficiency
1916	11201	Parathyroid Gland Disease
1917	11202	Primary Hyperparathyroidism
1918	11203	Angelucci's Syndrome
1919	11204	Allergic Conjunctivitis
1920	11206	Opioid Abuse
1921	11211	Buphthalmos
1922	11212	Hydrophthalmos
1923	11213	Acute Contagious Conjunctivitis
1924	11215	Premature Rupture Of The Fetal Membranes
1925	11217	Chronic Tympanitis
1926	11219	Conjunctival Folliculosis
1927	1122	Spinal Enthesopathy
1928	11223	Small Intestine Diverticulitis
1929	11227	Acute Hemorrhagic Conjunctivitis
1930	1123	Spondyloarthropathy
1931	11230	Acute Orbital Inflammation
1932	11231	Orbital Periostitis
1933	11232	Orbital Osteomyelitis
1934	11233	Orbital Tenonitis
1935	11234	Orbital Cellulitis
1936	11235	Chronic Adhesive Otitis Media
1937	11239	Appendix Cancer
1938	11240	Appendiceal Neoplasm
1939	11241	Appendix Lymphoma
1940	11242	Plethora Of Newborn
1941	11243	Anemia Of Prematurity
1942	11244	Neonatal Anemia
1943	11245	Transient Neonatal Neutropenia
1944	11246	DIC In Newborn
1945	11247	Disseminated Intravascular Coagulation
1946	11248	Hemorrhagic Disease Of Newborn
1947	11249	Vitamin K Deficiency Hemorrhagic Disease
1948	11252	Microcytic Anemia
1949	11254	Brill-Zinsser Disease
1950	11256	Typhus
1951	11257	Social Phobia
1952	11258	Cat-scratch Disease
1953	11259	Cytomegalovirus Infectious Disease
1954	11260	Rabies
1955	11261	Foot And Mouth Disease
1956	11262	Ornithosis
1957	11263	Chlamydia Trachomatis Infectious Disease
1958	11264	Chlamydophila Infectious Disease
1959	11265	Trachoma
1960	11266	Hemorrhagic Fever With Renal Syndrome
1961	11267	Keratomalacia
1962	11268	Vitamin A Deficiency With Keratomalacia
1963	11269	Chronic Apical Periodontitis
1964	11271	Hypertension Secondary To Renal Disease, Complicating Pregnancy, Childbirth And The Puerperium
1965	11275	Muscle Syphilis
1966	11277	Plummer's Disease
1967	11282	Solar Retinopathy
1968	11283	Peripheral Scars Of Retina
1969	11284	Disseminated Scars Of Retina
1970	11285	Tick Paralysis
1971	11286	Neuromuscular Junction Toxic Disorder
1972	11287	Conditions Involving The Integument And Temperature Regulation Of Fetus And Newborn
1973	11289	Ventilation Pneumonitis
1974	1129	Pituitary Apoplexy
1975	11294	Arteriovenous Malformation
1976	11295	Retinal Microaneurysm
1977	11299	Vertebral Artery Occlusion
1978	113	Pneumopericardium
1979	1130	Pituitary Infarct
1980	11302	Cercarial Dermatitis
1981	11307	Subchronic State Latent Schizophrenia With Acute Exacerbation
1982	11308	Latent Schizophrenia In Remission
1983	11309	Chronic Latent Schizophrenia
1984	11312	Mobitz Type II Atrioventricular Block
1985	11314	Histoplasma Duboisii Retinitis
1986	11315	African Histoplasmosis
1987	11316	Histoplasmosis Retinitis
1988	11320	Kyasanur Forest Disease
1989	11327	Acute Schizophrenic Episode Subchronic State With Acute Exacerbation
1990	11328	Schizophreniform Disorder
1991	11329	Ainhum
1992	11330	Erysipelas
1993	11335	Sarcoidosis
1994	11336	Rhinoscleroma
1995	11337	Lemierre's Syndrome
1996	11338	Tetanus
1997	11339	Pneumocystosis
1998	1134	Gingival Recession
1999	11340	Pneumocystis Infectious Disease
2000	11341	Fungal Lung Infectious Disease
2001	11342	Arcus Senilis
2002	11343	Scleral Disease
2003	11346	Congenital Osteodystrophy
2004	11347	Meniere's Disease In Remission
2005	11349	Epilepsia Partialis Continua
2006	11350	Grand Mal Status Epilepticus
2007	11352	Epilepsia Partialis Continua With Intractable Epilepsy
2008	11353	Bladder Diverticulum
2009	11354	Stone In Bladder Diverticulum
2010	11355	Bladder Calculus
2011	11360	Phlebotomus Fever
2012	11361	Tickborne Fever
2013	11364	Lens Subluxation
2014	11367	Congenital Aphakia
2015	11371	Functional Diarrhea
2016	11372	Megacolon
2017	11374	Anal Spasm
2018	11377	Calculus Of Gallbladder And Bile Duct With Acute Cholecystitis
2019	11379	Gnathomiasis
2020	1138	Spinal Meningioma
2021	11382	Corneal Neovascularization
2022	11383	Cryptorchidism
2023	11385	Expressive Language Disorder
2024	11387	Epidural Abscess
2025	11389	Subdural Empyema
2026	11390	Cerebral Arteritis
2027	11394	Adult Respiratory Distress Syndrome
2028	11396	Pulmonary Edema
2029	114	Heart Disease
2030	1140	Spinal Canal And Spinal Cord Meningioma
2031	11400	Pyelonephritis
2032	11401	Xanthogranulomatous Pyelonephritis
2033	11403	Depressive State Induced By Drug
2034	11404	Diphtheritic Laryngotracheitis
2035	11405	Diphtheria
2036	11406	Choroiditis
2037	11409	Syphilitic Disseminated Chorioretinitis
2038	1141	Alternating Exotropia With V Pattern
2039	11418	Trichomonas Urethritis
2040	1142	Alternating Exotropia
2041	11421	Acquired Cavovarus Foot Deformity
2042	11424	Fallopian Tube Endometriosis
2043	11427	Endosalpingiosis
2044	11428	Endometriosis Of Intestine
2045	11429	Endometriosis Of Pelvic Peritoneum
2046	1143	Exotropia
2047	11430	Endometriosis In Scar Of Skin
2048	11431	Endometriosis Of Rectovaginal Septum And Vagina
2049	11432	Endometriosis Of Ovary
2050	11433	Middle Ear Cholesteatoma
2051	11436	Recurrent Cholesteatoma Post-mastoidectomy
2052	11441	Macrodactylia Of Toes
2053	11442	Malignant Mast Cell Tumors Involving Lymph Node Of Head
2054	11446	Sciatic Neuropathy
2055	11450	Allergic Cutaneous Vasculitis
2056	11451	Secondary Syphilitic Meningitis
2057	11452	Perinatal Jaundice Due To Hepatocellular Damage
2058	11457	Brain Compression
2059	11459	Pseudotumor Cerebri
2060	11465	Autonomic Nervous System Disease
2061	11472	Subglottis Cancer
2062	11476	Osteoporosis
2063	1148	Polydactyly
2064	11481	Constrictive Pericarditis
2065	11482	Hemopericardium
2066	11486	Horner's Syndrome
2067	11488	Idiopathic Peripheral Autonomic Neuropathy
2068	11489	Vitamin A Deficiency With Conjunctival Xerosis And Bitot's Spot
2069	11490	Vitamin A Deficiency With Night Blindness
2070	11491	Acquired Night Blindness
2071	115	Cardiac Tamponade
2072	1150	Bone And Joint Disorder Of Back, Pelvis And Lower Limbs Of Mother, Complicating Pregnancy, Childbirth, Or The Puerperium
2073	11502	Mitral Valve Insufficiency
2074	11503	Diabetic Autonomic Neuropathy
2075	11504	Autonomic Neuropathy
2076	11506	Suppurative Otitis Media
2077	11507	Rumination Disorder
2078	11512	Hepatic Vein Thrombosis
2079	11514	Fissured Tongue
2080	11516	Hypertensive Heart Disease
2081	11518	Abnormal Pupillary Function
2082	11520	Benign Hypertensive Renal Disease
2083	11523	Clostridium Perfringens Gastroenteritis
2084	11524	Hyphema Of Iris And Ciliary Body
2085	11525	Iris And Ciliary Body Vascular Disorder
2086	11527	Laryngostenosis
2087	11533	Hereditary Sensory And Autonomic Neuropathy
2088	11535	Dysplasia Of Prostate
2089	11541	Recurrent Corneal Erosion
2090	11543	Corneal Abscess
2091	11547	Corneal Deposit
2092	11549	Adie Syndrome
2093	11550	Oculomotor Nerve Paralysis
2094	11552	Bowman's Membrane Folds Or Rupture
2095	11554	Chandler Syndrome
2096	11555	Fuchs' Endothelial Dystrophy
2097	11557	Acute Serous Otitis Media
2098	11558	Acute Allergic Serous Otitis Media
2099	1156	Chondrocalcinosis
2100	11561	Hypertensive Retinopathy
2101	11563	Retinal Vasculitis
2102	11569	Neurocirculatory Asthenia
2103	11572	Listeria Meningitis
2104	11573	Listeriosis
2105	11574	Streptococcal Meningitis
2106	11575	Pneumococcal Meningitis
2107	11577	Cauda Equina Syndrome
2108	11578	Escherichia Coli Meningitis
2109	11581	Phlyctenulosis
2110	11582	Syphilitic Aortitis
2111	11584	Acute Schizophrenic Episode In Remission
2112	11589	Riley-Day Syndrome
2113	1159	Functional Gastric Disease
2114	11593	Bladder Lateral Wall Cancer
2115	11594	Ring Staphyloma
2116	11595	Scleral Staphyloma
2117	11597	Cold Injury Syndrome Of Newborn
2118	11599	Frey Syndrome
2119	116	Pericardium Cancer
2120	11600	Secondary Malignant Neoplasm Of Lymph Nodes Of Multiple Site
2121	11603	Infant Gynecomastia
2122	11604	Idiopathic Hydrops Fetalis
2123	11606	Ileal Disease
2124	11607	Candidal Meningitis
2125	11608	Fungal Meningitis
2126	11612	Polycystic Ovary Syndrome
2127	11613	Hyperandrogenism
2128	11615	Penile Cancer
2129	11623	Dental Pulp Necrosis
2130	11624	Penile Neoplasm
2131	11629	Pelvic Muscle Wasting
2132	11633	Thyroid Hormone Resistance Syndrome
2133	11634	Myxedema
2134	11637	Accommodative Spasm
2135	11638	Presbyopia
2136	11649	Transitory Tachypnea Of Newborn
2137	11650	Bronchopulmonary Dysplasia
2138	11653	Conjunctival Deposit
2139	11654	Nevus Of Ota
2140	11656	Cicatricial Pemphigoid
2141	1166	Palindromic Rheumatism
2142	11661	Blue Color Blindness
2143	11662	Color Vision Defect
2144	11664	Nephrosclerosis
2145	11665	Patau Syndrome
2146	11668	Hypopigmentation Of Eyelid
2147	11669	Hypertrichosis Of Eyelid
2148	11671	Hypotrichosis Of Eyelid
2149	11678	Onchocerciasis
2150	1168	Familial Hyperlipidemia
2151	11680	Ocular Onchocerciasis
2152	11683	Glaucoma Associated With Systemic Syndromes
2153	11684	Melanoacanthoma
2154	11685	Inflamed Seborrheic Keratosis
2155	11693	Acute Apical Periodontitis
2156	11695	Portal Vein Thrombosis
2157	11696	Chronic Hypomanic Disorder
2158	11699	Intrathoracic Lymph Node Tuberculosis
2159	117	Heart Cancer
2160	11701	Selective IgA Deficiency Disease
2161	11702	Dysgammaglobulinemia
2162	11705	Impaired Renal Function Disease
2163	1171	Hyperlipoproteinemia Type V
2164	11711	Pregnancy In Diabetics
2165	11712	Lipoatrophic Diabetes
2166	11713	Diabetic Angiopathy
2167	11714	Gestational Diabetes
2168	11716	Prediabetes Syndrome
2169	11717	Neonatal Diabetes Mellitus
2170	11718	Antidepressant Type Abuse
2171	11719	Oculopharyngeal Muscular Dystrophy
2172	1172	Hyperlipoproteinemia Type IV
2173	11720	Distal Muscular Dystrophy
2174	11721	Glycogen Storage Disease VII
2175	11722	Myotonic Dystrophy Type 1
2176	11723	Duchenne Muscular Dystrophy
2177	11724	Limb-girdle Muscular Dystrophy
2178	11725	Cornelia De Lange Syndrome
2179	11726	Emery-Dreifuss Muscular Dystrophy
2180	11727	Facioscapulohumeral Muscular Dystrophy
2181	11729	Lyme Disease
2182	1173	Polycystic Liver Disease
2183	11730	Borrelia Infectious Disease
2184	11732	Syphilitic Myocarditis
2185	11733	Syphilitic Aortic Aneurysm
2186	11734	Syphilitic Pericarditis
2187	11735	Single Manic Episode In Full Remission
2188	11736	Odontoclasia
2189	11741	Chlamydophila Pneumoniae Pneumonia
2190	11746	Parametrium Malignant Neoplasm
2191	11747	Uterine Adnexa Cancer
2192	11748	Round Ligament Malignant Neoplasm
2193	11750	Bordetella Parapertussis Whooping Cough
2194	11752	Acute Endophthalmitis
2195	11753	Biliary Calculus With Acute Cholecystitis
2196	11754	Siderosis Of Eye
2197	11755	Choledocholithiasis
2198	11756	Calculus Of Bile Duct With Acute Cholecystitis
2199	11758	Iron Deficiency Anemia
2200	11759	Hypochromic Anemia
2201	1176	Bronchial Disease
2202	11760	Kohler's Disease
2203	11766	Blind Hypotensive Eye
2204	11770	Hypersecretion Of Testicular Hormones
2205	11771	Spontaneous Ocular Nystagmus
2206	11772	Leukocoria
2207	11775	Hereditary Trophedema
2208	11776	Blind Hypertensive Eye
2209	11781	Regular Astigmatism
2210	11782	Astigmatism
2211	11783	Necrosis Of Ear Ossicle
2212	11786	Splenic Sequestration
2213	11787	Chronic Congestive Splenomegaly
2214	11793	Phthisical Cornea
2215	11797	Chronic Laryngitis
2216	118	Pericardial Effusion
2217	11801	Protein-energy Malnutrition
2218	11802	Protein Deficiency
2219	11806	Macrodactylia Of Fingers
2220	11809	Bladder Neck Cancer
2221	11810	Metastatic Neoplasm To The Bladder
2222	11811	Urinary Bladder Posterior Wall Cancer
2223	11812	Bladder Sarcoma
2224	11813	Bladder Trigone Cancer
2225	11814	Urinary Bladder Anterior Wall Cancer
2226	11815	Recurrent Malignant Bladder Neoplasm
2227	11816	Vitreous Syneresis
2228	11817	Urachus Cancer
2229	11818	Ureteric Orifice Cancer
2230	11819	Ureter Cancer
2231	11820	Bladder Dome Cancer
2232	11821	Bladder Lymphoma
2233	11823	Hepatorenal Syndrome
2234	11824	Multicentric Reticulohistiocytosis
2235	11828	Visual Cortex Disorder Due To Vascular Disorder
2236	11829	Degenerative Myopia
2237	1183	Nephrotic Syndrome With Lesion Of Membranoproliferative Glomerulonephritis
2238	11830	Myopia
2239	11831	Cortical Blindness
2240	11832	Visual Epilepsy
2241	11836	Clubfoot
2242	11837	Malignant Neoplasm Of Scapula And Long Bones Of Upper Limb
2243	11838	Penis Sarcoma
2244	11839	Glans Penis Cancer
2245	1184	Nephrotic Syndrome
2246	11840	Coronary Artery Vasospasm
2247	11843	Coronary Artery Anomaly
2248	11847	Coronary Thrombosis
2249	11849	Degenerative Changes Of Ciliary Body
2250	11850	Transient Refractive Change
2251	11851	Indeterminate Leprosy
2252	11852	Aortic Valve Syphilitic Endocarditis
2253	11853	Monocular Exotropia
2254	11854	Monocular Exotropia With A Pattern
2255	11855	Intermittent Monocular Exotropia
2256	11856	Monocular Exotropia With V Pattern
2257	11861	Prolonged Pregnancy
2258	11862	Late Pregnancy
2259	11864	Peripheral Focal Chorioretinitis
2260	11868	Chronic Erythremia
2261	1187	Tibial Neuropathy
2262	11870	Pick's Disease
2263	11871	Macular Keratitis
2264	11872	Staphylococcus Aureus Septicemia
2265	11873	Staphylococcal Septicemia
2266	11874	Abnormal Threshold Of Rods
2267	11875	Denture Stomatitis
2268	1188	Mononeuropathy
2269	11885	Ureteral Benign Neoplasm
2270	11887	Ureter Leiomyoma
2271	11888	Schwannoma Of Ureter
2272	11889	Female Breast Nipple And Areola Cancer
2273	11892	Amoebozoa Infectious Disease
2274	11893	Cutaneous Amebiasis
2275	11896	Acanthamoeba Keratitis
2276	11897	Blastocystis Hominis Infectious Disease
2277	119	Vaginal Cancer
2278	11902	Cerebral Amebiasis
2279	11905	Labium Majus Cancer
2280	11907	Ecthyma
2281	11914	Gastroparesis
2282	11917	Tinea Cruris
2283	1192	Peripheral Nervous System Neoplasm
2284	11920	Tracheal Cancer
2285	11934	Head And Neck Cancer
2286	11939	Schizo-affective Type Schizophrenia Subchronic State
2287	11943	Trichomonas Vaginitis
2288	11944	Trichomonas Prostatitis
2289	11945	Trichomonas Cystitis
2290	11946	Habitual Abortion
2291	11947	Recurrent Major Depression In Complete Remission
2292	11949	Creutzfeldt-Jakob Disease
2293	1195	Ischemic Neuropathy
2294	11950	Congenital Cardiovascular Disorder Complicating Pregnancy, Childbirth, Or The Puerperium
2295	11952	Congenital Cardiovascular Disorder Of Mother, With Delivery
2296	11954	Psychosexual Dysfunction With Inhibited Sexual Excitement
2297	11955	Malnutrition Of Moderate Degree
2298	11963	Esophagitis
2299	11964	Histoplasma Capsulatum Retinitis
2300	11968	Postmenopausal Atrophic Vaginitis
2301	11970	Symptomatic Menopausal Or Female Climacteric State
2302	11971	Synostosis
2303	11975	Coloboma Of Optic Nerve
2304	11976	Botulism
2305	11977	Disorder Of Magnesium Metabolism
2306	11978	Chronic Pyelonephritis Without Lesion Of Renal Medullary Necrosis
2307	11981	Morbid Obesity
2308	11983	Prader-Willi Syndrome
2309	11984	Hypertrophic Cardiomyopathy
2310	11987	Anorectal Gonorrhea
2311	11988	Conjunctival Concretion
2312	11990	Ulceroglandular Tularemia
2313	11991	Osteopoikilosis
2314	11994	Atrophy Of Testis
2315	11996	Spermatic Cord Torsion
2316	11997	Spermatocele
2317	120	Female Reproductive Organ Cancer
2318	12000	Secondary Malignant Neoplasm Of Trachea
2319	12001	Tracheal Lymphoma
2320	12002	Trachea Sarcoma
2321	12003	Trachea Squamous Cell Carcinoma
2322	1201	Trigeminal Nerve Neoplasm
2323	12010	Anterior Ischemic Optic Neuropathy
2324	12016	Frontal Lobe Neoplasm
2325	12017	Group B Streptococcal Pneumonia
2326	12019	Group A Streptococcal Pneumonia
2327	12020	Malignant Neoplasm Of Corpus Uteri, Except Isthmus
2328	12021	Leukemic Reticuloendotheliosis Of Intrathoracic Lymph Nodes
2329	12022	Spontaneous Abortion Complicated By Genital Tract And Pelvic Infectious Disease
2330	12028	Conn's Syndrome
2331	12029	Sympathetic Ophthalmia
2332	1203	Drug-induced Mental Disorder
2333	12030	Panuveitis
2334	1204	Arthropathy Due To Hypersensitivity Reaction
2335	12040	Immune Hydrops Fetalis
2336	12043	Kernicterus Due To Isoimmunization
2337	1205	Hypersensitivity Reaction Type I Disease
2338	12052	Cryptococcal Meningitis
2339	12053	Cryptococcosis
2340	12054	Trypanosoma Meningitis
2341	12055	Sarcoid Meningitis
2342	12056	Meningitis With Clear Cerebrospinal Fluid
2343	12058	Fetal-maternal Hemorrhage Affecting Management Of Mother
2344	1206	Rett Syndrome
2345	12061	Fetal Blood Loss
2346	12064	Mediastinum Neurofibroma
2347	12065	Ganglioneuroma Of The Mediastinum
2348	12070	Dieulafoy Lesion
2349	12072	Pylorospasm
2350	12076	Interstitial Emphysema And Related Conditions Of Newborn
2351	12084	Transient Arthropathy
2352	12087	Deep Corneal Vascularisation
2353	1209	Nutritional Optic Neuropathy
2354	12091	Vitamin A Deficiency With Corneal Xerosis
2355	12092	Galactorrhea Associated With Childbirth
2356	12096	Sodoku Disease
2357	12097	Rat-bite Fever
2358	12098	Trigeminal Neuralgia
2359	121	Vaginal Disease
2360	1210	Optic Neuritis
2361	12104	Vitamin A Deficiency With Corneal Xerosis And Ulcer
2362	12105	Inflammatory Spondylopathy
2363	12106	Tricuspid Valve Syphilitic Endocarditis
2364	12107	Primary Retinal Cyst
2365	12108	Bullous Retinoschisis
2366	12111	Vitamin A Deficiency With Xerophthalmic Corneal Scar
2367	12113	Nerve Deafness
2368	12115	Streptococcal Pharyngitis
2369	12117	Pulmonary Alveolar Microlithiasis
2370	12118	Pulmonary Hemosiderosis
2371	12119	Hemosiderosis
2372	12120	Pulmonary Alveolar Proteinosis
2373	12121	Secondary Syphilitic Periostitis
2374	12123	Postinflammatory Pulmonary Fibrosis
2375	12124	Episcleritis Periodica Fugax
2376	12125	Neurotrophic Keratoconjunctivitis
2377	12128	Pica Disease
2378	12129	Bulimia Nervosa
2379	1213	Tympanosclerosis Of Tympanic Membrane And Ossicles
2380	12132	Wegener's Granulomatosis
2381	12133	Yersinia Enterocolitica Intestinal Infectious Disease
2382	12134	Factor VIII Deficiency
2383	12135	Acquired Factor VIII Deficiency
2384	12136	Acquired Coagulation Factor Deficiency
2385	12139	Dysthymic Disorder
2386	1214	Tympanosclerosis
2387	12140	Chagas Disease
2388	12141	Adenovirus Meningitis
2389	12143	Neurogenic Bladder
2390	12144	Low Compliance Bladder
2391	12145	Detrusor Sphincter Dyssynergia
2392	12148	Alveolar Echinococcosis
2393	1215	Tympanosclerosis Of Tympanic Membrane Only
2394	12150	Calculus Of Gallbladder With Acute Cholecystitis, With Obstruction
2395	12151	Currently Pregnant Habitual Aborter
2396	12155	Lymphocytic Choriomeningitis
2397	12156	Arachnoiditis
2398	12157	Aseptic Meningitis
2399	12161	Peripheral Retinal Degeneration
2400	12162	Pseudoretinitis Pigmentosa
2401	12163	Senile Reticular Retinal Degeneration
2402	12164	Blessig's Cysts
2403	12165	Retinal Lattice Degeneration
2404	12166	Cobblestone Retinal Degeneration
2405	12167	Secondary Vitreoretinal Degeneration
2406	12168	Ulnar Nerve Lesion
2407	12169	Carpal Tunnel Syndrome
2408	1217	Fascioloidiasis
2409	12170	Radial Nerve Lesion
2410	12171	Radial Neuropathy
2411	12175	Dyshormonogenic Goiter
2412	12176	Goiter
2413	12177	Common Variable Immunodeficiency
2414	12179	Tinea Corporis
2415	1218	Echinostomiasis
2416	12180	Fetal Macrosomia
2417	12185	Otosclerosis
2418	12189	Metastatic Tumor To The Colon
2419	1219	Dicrocoeliasis
2420	12190	Descending Colon Cancer
2421	12191	Splenic Flexure Cancer
2422	12192	Sigmoid Colon Cancer
2423	12196	Superficial Keratitis
2424	12197	Punctate Epithelial Keratoconjunctivitis
2425	122	Abdominal Cancer
2426	12204	Catatonic Schizophrenia In Remission
2427	12205	Dengue Disease
2428	12206	Dengue Hemorrhagic Fever
2429	1221	Infiltrative Lung Tuberculosis
2430	12210	Wuchereria Bancrofti Filariasis
2431	12211	Filarial Elephantiasis
2432	12215	Oligohydramnios
2433	12217	Lewy Body Dementia
2434	1222	Cartilage Disease
2435	12221	Synovial, Tendon Or Bursa Disorder
2436	12223	Specific Bursitis Often Of Occupational Origin
2437	12224	Calcium Deposits In Tendon And Bursa
2438	12225	Plica Syndrome
2439	12226	Hearing Disease
2440	12228	Secondary Malignant Neoplasm Of Large Intestine And Rectum
2441	12234	Cascade Stomach
2442	12236	Primary Biliary Cirrhosis
2443	12237	Bile Reflux
2444	12239	Anal Margin Squamous Cell Carcinoma
2445	12241	Beta Thalassemia
2446	12245	Histoplasmosis Endocarditis
2447	12246	Histoplasmosis Meningitis
2448	12251	Hypoaldosteronism
2449	12252	Cushing's Syndrome
2450	12253	Testicular Lymphoma
2451	12254	Metastatic Tumor To The Testis
2452	12255	Congenital Adrenal Hyperplasia
2453	12256	Adrenogenital Disease
2454	12257	Medulloadrenal Hyperfunction
2455	12258	Acquired Factor IX Deficiency
2456	12259	Hemophilia B
2457	12265	Chronic Salpingo-oophoritis
2458	12268	Eclampsia With Delivery
2459	12269	Toxemia With Convulsions Complicating Pregnancy, Childbirth Or The Puerperium
2460	1227	Neutropenia
2461	12270	Coloboma
2462	12271	Aniridia
2463	12273	Anisometropia
2464	12274	Anisometropia And Aniseikonia
2465	12275	Cutaneous Diphtheria
2466	12276	Malignant Tumor Of Undescended Testis
2467	1228	Paranoid Type Schizophrenia In Remission
2468	12282	Femoral Vein Thrombophlebitis
2469	12284	Maternal Pyrexia In Labor
2470	12286	Testicular Leukemia
2471	12287	Crimean-Congo Hemorrhagic Fever
2472	1229	Paranoid Schizophrenia
2473	12292	Recurrent Malignant Endocervical Neoplasm
2474	12294	Atypical Depressive Disorder
2475	12297	Vogt-Koyanagi-Harada Disease
2476	12298	Intrahepatic Gall Duct Cancer
2477	12301	Speckled Lentiginous Nevus
2478	12302	Diphtheritic Membranous Angina
2479	12304	Conjunctival Pigmentation
2480	12305	Bloch-Sulzberger Syndrome
2481	12306	Vitiligo
2482	12307	Anterior Corneal Pigmentation
2483	12308	Dubin-Johnson Syndrome
2484	12309	Urticaria Pigmentosa
2485	1231	Chronic Schizophrenia
2486	12311	Stromal Corneal Pigmentation
2487	12318	Corneal Granular Dystrophy
2488	1232	Paranoid Type Schizophrenia Subchronic State With Acute Exacerbation
2489	12323	Cough Variant Asthma
2490	12324	Transsexuality With Homosexual History
2491	12325	Kyphoscoliotic Heart Disease
2492	12326	Chronic Pulmonary Heart Disease
2493	12328	Marasmus
2494	1233	Transvestism
2495	12332	Hematocele Of Tunica Vaginalis Testis
2496	12333	Male Genital Organ Stricture
2497	12335	Male Genital Organ Vascular Disease
2498	12336	Male Infertility
2499	12337	Varicocele
2500	12338	Redundant Prepuce And Phimosis
2501	12339	Retroperitoneal Lymphoma
2502	1234	Gender Identity Disorder
2503	12341	Retroperitoneal Sarcoma
2504	12342	Retroperitoneum Carcinoma
2505	12346	Hyperkinetic Heart Syndrome
2506	12347	Osteogenesis Imperfecta
2507	12349	Primary Eye Hypotony
2508	1235	Fetishism
2509	12351	Alcoholic Hepatitis
2510	12355	Prostatocystitis
2511	12356	Bacterial Prostatitis
2512	12357	Viral Labyrinthitis
2513	12358	Patulous Eustachian Tube
2514	12359	Endocrine Exophthalmos
2515	12360	Lateral Displacement Of Eye
2516	12361	Graves' Disease
2517	12362	Thyrotoxic Exophthalmos
2518	12363	Intermittent Proptosis
2519	12364	Pulsating Exophthalmos
2520	12365	Malaria
2521	12369	Prolapse Of Urethra
2522	1237	Corneal Degeneration
2523	12375	Bronchopneumonia
2524	12376	Juvenile Spinal Muscular Atrophy
2525	12377	Spinal Muscular Atrophy
2526	12378	Predominant Psychomotor Disturbance
2527	12379	Mixed Disorder As Reaction To Stress
2528	1238	Acute Erythremia And Erythroleukemia In Remission
2529	12380	Predominant Disturbance Of Consciousness
2530	12382	Complex Partial Epilepsy
2531	12384	Dysentery
2532	12385	Shigellosis
2533	12386	Balantidiasis
2534	12387	Nephrogenic Diabetes Insipidus
2535	12388	Neurohypophyseal Diabetes Insipidus
2536	1239	Acute Erythremia And Erythroleukemia
2537	12392	Leukemic Reticuloendotheliosis Involving Lymph Nodes Of Head, Face And Neck
2538	12395	Spastic Entropion
2539	12396	Entropion And Trichiasis Of Eyelid
2540	12397	Entropion
2541	12399	Pathological Gambling
2542	1240	Leukemia
2543	12400	Kleptomania
2544	12401	Intermittent Explosive Disorder
2545	12402	Pyromania
2546	12403	Tinea Pedis
2547	12404	Tinea
2548	1241	Luxation Of Globe
2549	12417	Psychogenic Dysmenorrhea
2550	1242	Globe Disease
2551	12424	Thyrocalcitonin Secretion Disease
2552	1243	Labia Minora Cancer
2553	12445	Conjugate Gaze Palsy
2554	12448	Hematologic Pregnancy Complication
2555	12449	Aplastic Anemia
2556	1245	Vulva Cancer
2557	12450	Pancytopenia
2558	12451	Sulfhemoglobinemia
2559	12465	Secondary Hyperparathyroidism Of Renal Origin
2560	12466	Secondary Hyperparathyroidism
2561	1247	Blood Coagulation Disease
2562	12474	Capillariasis
2563	12475	Pes Anserinus Tendinitis Or Bursitis
2564	1248	Ocular Hyperemia
2565	1249	Conjunctival Vascular Disorder And Cysts
2566	12491	Vagus Nerve Disease
2567	125	Vagina Leiomyoma
2568	12506	Bell's Palsy
2569	12508	Simple Type Schizophrenia Chronic State With Acute Exacerbation
2570	1251	Tuberculous Epididymitis
2571	12510	Retinal Ischemia
2572	12514	Retinal Perforation
2573	1252	Trichuriasis
2574	12522	Bagassosis
2575	12524	Plantar Nerve Lesion
2576	12525	Lateral Cutaneous Femoral Nerve Of Thigh Compression Or Syndrome
2577	12526	Tarsal Tunnel Syndrome
2578	12527	Common Peroneal Nerve Lesion
2579	12528	Lesion Of Sciatic Nerve
2580	12529	Tibial Nerve Palsy
2581	1253	Enoplea Infectious Disease
2582	12531	Von Willebrand's Disease
2583	12537	Hypermobility Of Coccyx
2701	12800	Mucopolysaccharidosis VI
2584	12538	Chlamydia Trachomatis Pharyngitis
2585	12539	Chlamydia Trachomatis Proctitis
2586	1254	Trichostrongylosis
2587	12541	Catatonic Type Schizophrenia Subchronic State
2588	12542	Catatonic Type Schizophrenia Subchronic State With Acute Exacerbation
2589	12543	Catatonic Type Schizophrenia Chronic State With Acute Exacerbation
2590	12546	Atrophic Nonflaccid Tympanic Membrane
2591	12549	Hepatitis A
2592	1255	Trichostrongyloidiasis
2593	12550	Hepatic Coma
2594	12551	Escherichia Coli Septicemia
2595	12554	Hemolytic-uremic Syndrome
2596	12555	Acute Renal Failure With Lesion Of Renal Cortical Necrosis
2597	12556	Acute Kidney Tubular Necrosis
2598	12557	Duane Retraction Syndrome
2599	12558	Chronic Progressive External Ophthalmoplegia
2600	12559	Idiopathic Juvenile Osteoporosis
2601	12566	Ulceration Of Vulva
2602	12568	Dyscalculia
2603	12569	Chagas Cardiomyopathy
2604	1257	Transient Hypertension Of Pregnancy
2605	12570	Phacolytic Glaucoma
2606	12571	Phacogenic Glaucoma
2607	12573	Neonatal Thyrotoxicosis
2608	12574	Posterior Uveitis
2609	12577	Urethral Obstruction
2610	12580	Cri-Du-Chat Syndrome
2611	12581	Olecranon Bursitis
2612	12582	Enthesopathy Of Elbow
2613	12583	Velocardiofacial Syndrome
2614	12584	Diabetes Mellitus Of Mother, With Delivery
2615	12594	Potter's Syndrome
2616	1260	Parametritis
2617	12603	Acute Leukemia
2618	12604	Secondary Malignant Neoplasm Of Suprarenal Gland
2619	12605	Metastasis To Adrenals
2620	12608	Staphylococcal Pneumonia
2621	1261	AIDS-related Pelvic Inflammatory Disease
2622	12610	Adrenal Hemorrhage Of Fetus Or Newborn
2623	12612	Gastrointestinal Hemorrhage Of Fetus Or Newborn
2624	12633	Cervicofacial Actinomycosis
2625	12634	Cerebral Actinomycosis
2626	12637	Perineocele
2627	12638	Hypertrophic Pyloric Stenosis
2628	12639	Pyloric Stenosis
2629	12641	Displacement Of Cardia Through Esophageal Hiatus
2630	12642	Hiatus Hernia
2631	12647	Congenital Or Acquired Abnormality Of Vulva, With Delivery
2632	1265	Genitourinary Cancer
2633	12651	Disorder Of Optic Chiasm Associated With Inflammatory Disorder
2634	12657	Vestibulocochlear Nerve Disease
2635	12661	Tooth Ankylosis
2636	12662	Paracoccidioidomycosis
2637	12663	Blastomycosis
2638	12667	Binocular Vision Disease
2639	12668	Abnormal Retinal Correspondence
2640	12670	Fusion With Defective Stereopsis
2641	12678	Hypercalcemia
2642	12679	Nephrocalcinosis
2643	12680	Pseudobulbar Palsy
2644	12683	Vestibular Neuronitis
2645	12685	Mixed Receptive-expressive Language Disorder
2646	12689	Acoustic Neuroma
2647	1269	Thyroid Gland Tuberculosis
2648	12694	Hyperemesis Gravidarum With Metabolic Disturbance
2649	12697	Locked-in Syndrome
2650	12698	Gynecomastia
2651	127	Leiomyoma
2652	1270	Hereditary Hemorrhagic Telangiectasia
2653	12700	Hyperprolactinemia
2654	12702	Rotator Cuff Shoulder Syndrome And Allied Disorder
2655	12704	Ataxia Telangiectasia
2656	12705	Friedreich Ataxia
2657	12707	Myoclonic Cerebellar Dyssynergia
2658	1271	Capillary Disease
2659	12710	Histoplasma Duboisii Pneumonia
2660	12711	Black Piedra
2661	12712	Nephronophthisis
2662	12713	Medullary Sponge Kidney
2663	12714	Ellis-Van Creveld Syndrome
2664	12715	Infectious Myositis
2665	12716	Newborn Respiratory Distress Syndrome
2666	12718	Chronic Gonococcal Salpingitis
2667	1272	Telangiectasis
2668	12720	Cerebral Atherosclerosis
2669	12721	Multiple Epiphyseal Dysplasia
2670	12722	Liver Metastasis
2671	12723	Lung Carcinoma Metastatic To The Liver
2672	12724	Breast Arcinoma Metastatic To The Liver
2673	12727	Retroverted Incarcerated Gravid Uterus
2674	1273	Respiratory Syncytial Virus Infectious Disease
2675	12731	Pars Planitis
2676	12732	Intermediate Uveitis
2677	12733	Hypercementosis
2678	12735	Hernia Of Ovary And Fallopian Tube
2679	12739	Bronchial Tuberculosis
2680	1275	Pneumovirus Infectious Disease
2681	12750	Cyclosporiasis
2682	12753	Corneal Staphyloma
2683	12756	Lacrimal Duct Cancer
2684	12758	Malignant Neoplasm Of Eyeball, Except Conjunctiva, Cornea, Retina And Choroid
2685	12759	Choroid Cancer
2686	12763	Classic Kaposi's Sarcoma
2687	12765	Peritonsillar Abscess
2688	12773	Endemic African Kaposi's Sarcoma
2689	12779	Recurrent Kaposi's Sarcoma
2690	1278	Tolosa-hunt Syndrome
2691	12782	Cicatricial Ectropion
2692	12783	Migraine Without Aura
2693	12784	Diabetes Mellitus Insulin Dependent Type, Not Stated As Uncontrolled, With Neurological Manifestations
2694	12785	Diabetic Polyneuropathy
2695	1279	Ocular Motility Disease
2696	12796	Posterior Synechiae
2697	12797	Hallucinogen Abuse
2698	12798	Mucopolysaccharidosis
2699	12799	Mucopolysaccharidosis II
2700	128	Vaginal Soft Tissue Tumor
2702	12801	Mucopolysaccharidosis III
2703	12802	Mucopolysaccharidosis I
2704	12803	Sly Syndrome
2705	12804	Mucopolysaccharidosis IV
2706	12809	Chronic Lacrimal Gland Enlargement
2707	12819	Clostridium Difficile Intestinal Infectious Disease
2708	1283	Enterocele
2709	12835	Quadriplegia
2710	12836	Senile Entropion
2711	12837	Thyroid Crisis
2712	12838	Secondary Thyroid Hyperplasia
2713	12839	Thyrotoxicosis From Ectopic Thyroid Nodule
2714	1284	Prolapse Of Female Genital Organ
2715	12840	Ancylostoma Ceylanicum Ancylostomiasis
2716	12841	Ancylostomiasis
2717	12842	Guillain-Barre Syndrome
2718	12843	Polyneuritis
2719	12849	Autistic Disorder
2720	1285	Rectal Disease
2721	12852	Adhesions Of Drum Head To Incus
2722	12853	Adhesions Of Drum Head To Promontorium
2723	12854	Adhesions Of Drum Head To Stapes
2724	12857	Achilles Bursitis
2725	12858	Huntington's Disease
2726	12859	Choreatic Disease
2727	12860	Non-neoplastic Nevus Of Skin
2728	12863	Senile Nevus
2729	12864	Acrosyringeal Nevus
2730	1287	Cardiovascular System Disease
2731	12879	Pars Plana Exudative Cyst
2732	12881	Idiopathic Urticaria
2733	12883	Hypochondriasis
2734	12888	Chlamydophila Psittaci Pneumonia
2735	12889	Miller Fisher Syndrome
2736	1289	Neurodegenerative Disease
2737	12894	Sjogren's Syndrome
2738	12895	Keratoconjunctivitis Sicca
2739	12897	Submandibular Gland Disease
2740	12899	Benign Lymphoepithelial Lesion Of Salivary Gland
2741	12900	Mikulicz Disease
2742	12901	Necrotizing Sialometaplasia
2743	12904	Mucocele Of Salivary Gland
2744	12905	Sialolithiasis
2745	12910	Sickle-cell/Hb-C Disease With Crisis
2746	12918	Thromboangiitis Obliterans
2747	12919	Plasmodium Ovale Malaria
2748	12921	Childhood Schizophrenia
2749	12922	Acute Undifferentiated Schizophrenia
2750	12923	Chronic Undifferentiated Schizophrenia
2751	12926	Hypodermyiasis
2752	12927	Screw Worm Infectious Disease
2753	12928	Nutritional Cardiomyopathy
2754	12929	Endocardial Fibroelastosis
2755	1293	Labia Minora Carcinoma
2756	12930	Dilated Cardiomyopathy
2757	12932	Endomyocardial Fibrosis
2758	12934	Kearns-Sayre Syndrome
2759	12935	Alcoholic Cardiomyopathy
2760	12936	Secondary Cardiomyopathy
2761	1294	Vulva Carcinoma
2762	12958	Paralytic Lagophthalmos
2763	12959	Lagophthalmos
2764	12960	Acrocephalosyndactylia
2765	12961	Poland Syndrome
2766	12965	Subleukemic Leukemia
2767	12969	Central Nervous System Leukemia
2768	12971	Hereditary Spherocytosis
2769	12972	Intrapelvic Lymph Node Leukemic Reticuloendotheliosis
2770	12973	Secondary Malignant Neoplasm Of Intrapelvic Lymph Node
2771	12978	Plasmodium Vivax Malaria
2772	12983	Transient Disorder Of Initiating Or Maintaining Sleep
2773	12984	Vagus Nerve Neoplasm
2774	12985	Functional Disorder Of Polymorphonuclear Neutrophils
2775	12986	Leukostasis
2776	12987	Agranulocytosis
2777	12995	Conduct Disorder
2778	12996	Acute Dacryocystitis
2779	12997	Phlegmonous Dacryocystitis
2780	130	Female Genitalia Nevus
2781	13001	Carotid Stenosis
2782	13002	Subclavian Steal Syndrome
2783	13003	Vertebrobasilar Insufficiency
2784	13005	Intra-abdominal Lymph Node Mast Cell Malignancy
2785	1301	RNA Virus Infectious Disease
2786	13014	Shipyard Eye
2787	13019	Cryptococcal Gastroenteritis
2788	13020	Pulmonary Cryptococcosis
2789	13021	AIDS-related Cryptococcosis
2790	13023	Sickle Cell Trait
2791	13025	Retinopathy Of Prematurity
2792	13026	Lobomycosis
2793	13027	Transient Global Amnesia
2794	13031	Balanoposthitis
2795	13032	Trichomonas Balanoposthitis
2796	13033	Balanitis
2797	13034	Relapsing Fever
2798	13035	Louse-borne Relapsing Fever
2799	13036	Tick-borne Relapsing Fever
2800	13037	Mechanical Lagophthalmos
2801	13038	Cicatricial Lagophthalmos
2802	13040	Syphilitic Optic Atrophy
2803	13042	Persistent Fetal Circulation Syndrome
2804	13046	Acute Sphenoidal Sinusitis
2805	13047	Ancylostoma Braziliense Ancylostomiasis
2806	13049	Ancylostoma Duodenale Ancylostomiasis
2807	1305	AIDS Dementia Complex
2808	13050	Corpus Luteum Cyst
2809	1306	HIV Encephalopathy
2810	13060	Traumatic Glaucoma
2811	13063	Moderate Recurrent Major Depression
2812	13068	Renal Osteodystrophy
2813	1307	Dementia
2814	13072	Acquired Hyperkeratosis
2815	13074	Tinea Unguium
2816	13076	Abdominal Actinomycosis
2817	13077	Cutaneous Actinomycosis
2818	13078	Eumycotic Mycetoma
2819	1308	AIDS Related Complex
2820	13080	Jaccoud's Syndrome
2821	13081	Hemangioma Of Subcutaneous Tissue
2822	13087	Lown-Ganong-Levine Syndrome
2823	13088	Periventricular Leukomalacia
2824	13089	Intracranial Arterial Disease
2825	13094	Branch Retinal Artery Occlusion
2826	13095	Vertebral Artery Insufficiency
2827	13096	Sneddon Syndrome
2828	13097	Intracranial Arteriosclerosis
2829	13098	Central Retinal Artery Occlusion
2830	13099	Moyamoya Disease
2831	13100	Intracranial Vasospasm
2832	13109	Bladder Leiomyoma
2833	1311	HIV-associated Nephropathy
2834	13110	Bladder Squamous Papilloma
2835	13112	Mechanical Entropion
2836	13113	Cicatricial Entropion
2837	13117	Paronychia
2838	1312	Focal Segmental Glomerulosclerosis
2839	13120	Protein-deficiency Anemia
2840	13121	Deficiency Anemia
2841	13127	Gonococcal Spondylitis
2842	13129	Severe Pre-eclampsia
2843	1313	HIV Wasting Syndrome
2844	13133	HELLP Syndrome
2845	13134	Hordeolum Externum
2846	13135	Exophthalmic Ophthalmoplegia
2847	13137	Werdnig-Hoffmann Disease
2848	13138	Acute Proliferative Glomerulonephritis
2849	13139	Crescentic Glomerulonephritis
2850	1314	Wasting Syndrome
2851	13140	Suppurative Uveitis
2852	13141	Uveitis
2853	13143	Benign Secondary Hypertension
2854	13145	Benign Renovascular Hypertension
2855	13146	Esophageal Candidiasis
2856	13147	Fungal Esophagitis
2857	13148	Acute Cystitis
2858	13149	Tuberculous Lung Fibrosis
2859	13157	Sensory Disorder Of Eyelid
2860	13159	Scrotum Squamous Cell Carcinoma
2861	13160	Scrotum Melanoma
2862	13164	Bordetella Pertussis Pneumonia
2863	13165	Aspergillus Pneumonia
2864	13166	Allergic Bronchopulmonary Aspergillosis
2865	13168	Prepuce Cancer
2866	13169	Spermatic Cord Cancer
2867	13174	Dissociated Nystagmus
2868	13175	Female Genital Tuberculosis
2869	13177	Chronic Erythremia In Remission
2870	13185	Esophageal Diverticulosis
2871	13186	Megaesophagus
2872	13189	Gout
2873	1319	Brain Cancer
2874	13192	Pulmonary Congestion And Hypostasis
2875	13194	Non-toxic Nodular Goiter
2876	13195	Nontoxic Goiter
2877	13196	Lingual Goiter
2878	13197	Nodular Goiter
2879	13198	Endemic Goiter
2880	13200	Substernal Goiter
2881	13202	Secondary Syphilitic Iridocyclitis
2882	13206	Nodular Prostate
2883	13207	Proliferative Diabetic Retinopathy
2884	13208	Background Diabetic Retinopathy
2885	13209	Right Bundle Branch Block
2886	13211	Secondary Malignant Neoplasm Of Brain And Spinal Cord
2887	13212	Metastasis To Skin
2888	13213	Metastatic Cancer To The Breast
2889	13214	Hole Retinal Cyst
2890	13219	Transsexuality With Heterosexual History
2891	13222	Submucous Uterine Fibroid
2892	13223	Uterine Fibroid
2893	13224	Introverted Personality
2894	13226	Oculoglandular Tularemia
2895	13227	Retinal Dystrophies Primarily Involving Bruch's Membrane
2896	1323	Malignant Neoplasm Of Trachea, Bronchus And Lung
2897	13232	Diffuse Cholesteatosis Of Middle Ear And Mastoid
2898	13238	Haverhill Fever
2899	13239	Internal Pathological Resorption
2900	1324	Lung Cancer
2901	13240	Tooth Resorption
2902	13241	Behcet's Disease
2903	13248	Mucocele Of Appendix
2904	13249	Pneumatosis Cystoides Intestinalis
2905	1325	Bronchus Cancer
2906	13250	Diarrhea
2907	13251	HIV Enteropathy
2908	13252	Mesenteric Vascular Occlusion
2909	13253	Jejunal Disease
2910	13254	Diverticulitis Of Colon
2911	13257	Histoplasma Duboisii Endocarditis
2912	13258	Typhoid Fever
2913	13262	Hallucinatory State Induced By Drug
2914	13268	Porphyria
2915	13269	Hereditary Coproporphyria
2916	13270	Erythropoietic Protoporphyria
2917	13271	Cutaneous Porphyria
2918	13272	Klebsiella Pneumonia
2919	13273	Escherichia Coli Pneumonia
2920	13274	Enzootic Pneumonia Of Calves
2921	13275	Rickettsial Pneumonia
2922	13276	Mycoplasma Pneumoniae Pneumonia
2923	13277	Mycoplasma Hyopneumoniae Pneumonia
2924	13278	Salmonella Pneumonia
2925	1328	Rift Valley Fever
2926	13282	Intestinal Tuberculosis
2927	13285	Enteroinvasive Escherichia Coli Infectious Disease
2928	13295	Crater-like Holes Of Optic Disc
2929	133	Vaginal Mullerian Papilloma
2930	13300	Scheuermann's Disease
2931	13305	Anterior Nasal Diphtheria
2932	13306	Diphtheritic Cystitis
2933	13307	Pseudomembranous Diphtheritic Conjunctivitis
2934	13308	Diphtheritic Myocarditis
2935	13309	Nasopharyngeal Diphtheria
2936	13310	Diphtheritic Peritonitis
2937	13313	Pancreatic Mucinous Ductal Ectasia
2938	13315	Relapsing Pancreatitis
2939	13316	Exocrine Pancreatic Insufficiency
2940	13317	Hyperinsulinemic Hypoglycemia
2941	13319	Lower Limb Lymph Node Mast Cell Malignancy
2942	1332	Bunyaviridae Infectious Disease
2943	13326	Chronic Follicular Conjunctivitis
2944	13327	Anatomical Narrow Angle Borderline Glaucoma
2945	13328	Diabetic Cataract
2946	13329	Toxic Optic Neuropathy
2947	1333	African Horse Sickness
2948	13333	Hypertrophy Of Tongue Papillae
2949	13335	Toxoplasma Hepatitis
2950	13336	Congenital Toxoplasmosis
2951	13338	Toxoplasma Myocarditis
2952	1334	Reoviridae Infectious Disease
2953	13341	Parasitic Conjunctivitis
2954	13342	Toxoplasma Pneumonia
2955	13343	Ocular Toxoplasmosis
2956	13348	Laryngeal Cartilage Cancer
2957	1335	Bluetongue
2958	13350	Gender Identity Disorder In Children
2959	13351	Pedophilia
2960	13352	Ego-dystonic Sexual Orientation
2961	13353	Diffuse Interstitial Keratitis
2962	13356	Senile Ectropion
2963	13357	Chondromalacia Patellae
2964	13359	Ehlers-Danlos Syndrome
2965	1336	Nairobi Sheep Disease
2966	13361	Nephrotic Syndrome With Lesion Of Proliferative Glomerulonephritis
2967	13364	Chronobiology Disease
2968	13365	Reading Disorder
2969	13366	Stiff-Person Syndrome
2970	13368	Tinea Profunda
2971	13369	Tinea Manuum
2972	13371	Scrub Typhus
2973	13372	Alpha 1-antitrypsin Deficiency
2974	13374	Fibrodysplasia Ossificans Progressiva
2975	13375	Temporal Arteritis
2976	13376	Congenital Aortic Insufficiency
2977	13378	Kawasaki Disease
2978	1338	Congenital Dyserythropoietic Anemia
2979	13380	Acute Pyelonephritis With Lesion Of Renal Medullary Necrosis
2980	13381	Pernicious Anemia
2981	13382	Megaloblastic Anemia
2982	13386	Gastrointestinal Anthrax
2983	13387	Upper Limb Cancer
2984	13389	Labia Majora Carcinoma
2985	1339	Diamond-Blackfan Anemia
2986	13397	Atypical Manic Disorder
2987	13398	Open Angle With Borderline Glaucoma Findings
2988	13399	Color Blindness
2989	134	Vaginal Glandular Tumor
2990	1340	Pure Red-cell Aplasia
2991	13401	Angioid Streaks
2992	13402	Skin Sarcoidosis
2993	13403	Cerebral Sarcoidosis
2994	13404	Uveoparotid Fever
2995	13405	Cardiac Sarcoidosis
2996	13406	Pulmonary Sarcoidosis
2997	13407	Hypercalcemic Sarcoidosis
2998	13408	Metastasis To Pleura
2999	13409	Perforation Of Bile Duct
3000	1341	Congenital Anemia
3001	13413	Hepatic Encephalopathy
3002	13416	Diabetes Mellitus Insulin Dependent Type, Not Stated As Uncontrolled, With Peripheral Circulatory Disorder
3003	13417	Alexia
3004	13419	Neurogenic Bowel
3005	1342	Congenital Hypoplastic Anemia
3006	1343	Urethritis
3007	13431	Bejel
3008	13444	Glanders
3009	13446	Basilar Artery Occlusion
3010	13447	Corneal Argyrosis
3011	13448	Posterior Corneal Pigmentation
3012	13450	Coccidioidomycosis
3013	13452	Scleritis
3014	13453	Gonococcal Bursitis
3015	13454	Gonococcal Synovitis
3016	13459	Secondary Syphilitic Hepatitis
3017	13461	Urethral Intrinsic Sphincter Deficiency
3018	13468	Primary Genital Syphilis
3019	13469	Secondary Cutaneous Syphilis
3020	13470	Primary Anal Syphilis
3021	13471	Secondary Syphilitic Lymphadenitis
3022	13473	Central Pterygium
3023	13474	Progressive Peripheral Pterygium
3024	13476	Supraglottis Cancer
3025	13477	Balanitis Xerotica Obliterans
3026	13480	Paranoid Type Schizophrenia Chronic State With Acute Exacerbation
3027	13481	Thanatophoric Dysplasia
3028	13482	Proteus Syndrome
3029	13484	Disorganized Type Schizophrenia Chronic State
3030	13487	Childhood Disintegrative Disease
3031	13490	Active Cochleovestibular Meniere's Disease
3032	13491	Active Vestibular Meniere's Disease
3033	13492	Active Cochlear Meniere's Disease
3034	13498	Urethral Syndrome
3035	13499	Jejunal Cancer
3036	135	Benign Vaginal Carcinosarcoma
3037	1350	Paranasal Sinus Neoplasm
3038	13500	Hairy Tongue
3039	13501	Mobius Syndrome
3040	13507	Trigonitis
3041	13514	Venous Tributary Occlusion Of Retina
3042	13515	Tuberous Sclerosis
3043	13518	Stiffness Of Joint
3044	1352	Paranasal Sinus Disease
3045	13520	Neonatal Infective Mastitis
3046	13521	Tetanus Neonatorum
3047	13523	Loiasis
3048	13526	Candidal Endocarditis
3049	13527	Candidal Otitis Externa
3050	13528	Candidal Enteritis
3051	13533	Osteopetrosis
3052	13534	Purulent Labyrinthitis
3053	13535	Intrapelvic Lymph Node Mast Cell Malignancy
3054	13538	Cornea Squamous Cell Carcinoma
3055	13543	Hyperparathyroidism
3056	13544	Low Tension Glaucoma
3057	13548	Secondary Parkinson Disease
3058	13549	Interval Angle-closure Glaucoma
3059	1355	Paranasal Sinus Lymphoma
3060	13550	Angle-closure Glaucoma
3061	13554	Gonococcal Peritonitis
3062	13555	Pharyngeal Gonorrhea
3063	13556	Gonococcal Keratosis
3064	13558	Gonococcal Urethritis
3065	1356	Lymphoma By Site
3066	13560	Subserous Uterine Fibroid
3067	13561	Optic Disk Drusen
3068	13562	Glaucoma Associated With Pupillary Block
3069	13564	Aspergillosis
3070	13565	Neuroaspergillosis
3071	13566	Tibial Collateral Ligament Bursitis
3072	1357	Maxillary Sinus Cancer
3073	13573	Schizo-affective Type Schizophrenia Chronic State With Acute Exacerbation
3074	13574	Cortical Senile Cataract
3075	13575	Non-renal Secondary Hyperparathyroidism
3076	13576	Twin-to-twin Transfusion Syndrome
3077	13577	Ascorbic Acid Deficiency
3078	13579	Kwashiorkor
3079	1358	Maxillary Sinus Neoplasm
3080	13580	Cholestasis
3081	13581	Magnesium Deficiency
3082	13582	Potassium Deficiency
3083	13583	Fetal Nutrition Disorder
3084	13585	Alveolar Periostitis
3085	13589	Female Infertility Of Uterine Origin
3086	13593	Eclampsia
3087	136	Vaginal Carcinosarcoma
3088	1360	Frontal Sinus Cancer
3089	13601	Enteropathogenic Escherichia Coli Infectious Disease
3090	13602	Acute Schizophrenic Episode Subchronic State
3091	13603	Obstructive Jaundice
3092	13604	Acute Schizophrenic Episode Chronic State With Acute Exacerbation
3093	13605	Acute Schizophrenic Episode Chronic State
3094	13608	Biliary Atresia
3095	1361	Frontal Sinus Neoplasm
3096	13619	Extrahepatic Cholestasis
3097	1362	Paranasal Sinus Sarcoma
3098	13620	Patent Foramen Ovale
3099	13622	Campylobacteriosis
3100	13623	Staphylococcal Enterocolitis
3101	13626	Photokeratitis
3102	13628	Glucose-6-phosphate Dehydrogenase Deficiency
3103	13629	Dentine Erosion
3104	1363	Ethmoid Sinus Cancer
3105	13636	Fanconi's Anemia
3106	1364	Ethmoidal Sinus Neoplasm
3107	13641	Exfoliation Syndrome
3108	13643	Pneumococcal Septicemia
3109	13644	Streptococcal Septicemia
3110	13648	Paranoid State
3111	13649	Polyneuropathy In Collagen Vascular Disease
3112	13650	Joint Disorder
3113	13651	Eversion Of Lacrimal Punctum
3114	13653	Stenosis Of Lacrimal Punctum
3115	13654	Stenosis Of Lacrimal Passage
3116	13655	Acquired Tear Duct Stenosis
3117	13656	Gastrin Secretion Abnormality
3118	13658	Infective Urethral Stricture
3119	13662	Ulcer Of Anus And Rectum
3120	13663	Acute Suppurative Otitis Media With Tympanic Membrane Intact
3121	13664	Post-vaccinal Encephalitis
3122	13668	Meningococcal Encephalitis
3123	13670	Hypocalcemia And Hypomagnesemia Of Newborn
3124	13676	Posterior Scleritis
3125	13677	SAPHO Syndrome
3126	13679	Simple Type Schizophrenia Subchronic State
3127	13680	Simple Type Schizophrenia Subchronic State With Acute Exacerbation
3128	13681	Simple Type Schizophrenia In Remission
3129	13682	Simple Type Schizophrenia Chronic State
3130	13687	Chronic Duodenal Ileus
3131	13689	Prostate Calculus
3132	13690	Acute Gonococcal Cystitis
3133	13691	Dermoid Cyst Of Skin
3134	13693	Disorder Of Ureter
3135	13694	Unilateral Vesicoureteral Reflux With Reflux Nephropathy
3136	13695	Bilateral Vesicoureteral Reflux With Reflux Nephropathy
3137	13696	Vesicoureteral Reflux With Reflux Nephropathy
3138	137	Vagina Squamous Papilloma
3139	13702	Postpartum Benign Essential Hypertension
3140	13709	Premature Ejaculation
3141	1371	Uterine Corpus Adenomatoid Tumor
3142	13711	Dental Fluorosis
3143	13714	Anodontia
3144	13717	Mature Cataract
3145	13720	Schistosoma Mattheei Infectious Disease
3146	13722	Neuroschistosomiasis
3147	13723	Schistosoma Bovis Infectious Disease
3148	13724	Scurvy
3149	13725	Beriberi
3150	1373	Endometrial Stromal Nodule
3151	13730	Malignant Renovascular Hypertension
3152	13731	Malignant Secondary Hypertension
3153	13732	Panophthalmitis
3154	13734	AIDS-related Pneumocystis Jirovecii Pneumonia
3155	13736	Uterine Inflammatory Disease
3156	13738	Infarct Of Liver
3157	13739	Nutmeg Liver
3158	13742	Neurofibroma Of Spinal Cord
3159	13743	Spinal Cord Lipoma
3160	1375	Neonatal Urinary Tract Infectious Disease
3161	13753	Histoplasma Duboisii Meningitis
3162	13754	Histoplasma Capsulatum Meningitis
3163	13755	Histoplasma Duboisii Pericarditis
3164	13756	Epiphora Due To Insufficient Drainage
3165	13757	Excessive Tearing
3166	1376	Perinatal Infectious Disease
3167	13760	Pthirus Pubis Infestation
3168	13762	Bovine Trypanosomiasis
3169	13763	Dourine
3170	13767	Clonorchiasis
3171	13768	Opisthorchiasis
3172	13774	Addison's Disease
3173	13775	Plantar Wart
3174	13777	Epidermodysplasia Verruciformis
3175	13778	Chancroid
3176	1378	Uterine Corpus Mixed Epithelial And Mesenchymal Tumor
3177	13781	Hypermobility Syndrome
3178	13787	Localized Anterior Staphyloma
3179	13788	Equatorial Staphyloma
3180	13789	Staphyloma Posticum
3181	13790	Acute Tympanitis
3182	13791	Myringitis Bullosa Hemorrhagica
3183	13794	Anterior Scleritis
3184	13799	Female Breast Central Part Cancer
3185	138	Vaginal Squamous Tumor
3186	1380	Endometrial Cancer
3187	13800	Inclusion Conjunctivitis
3188	13801	Pharyngoconjunctival Fever
3189	13809	Familial Combined Hyperlipidemia
3190	1381	Fox Fordyce Disease
3191	13810	Familial Hypercholesterolemia
3192	13811	Chronic Subinvolution Of Uterus
3193	13812	Adhesions Of Uterus
3194	13814	Hypoglossal Nerve Disease
3195	13817	Single Episode Manic Disease Moderate Degree
3196	13818	Single Episode Manic Disorder Mild Degree
3197	13819	Lymphogranuloma Venereum
3198	1382	Miliaria
3199	13820	Congenital Pneumonia
3200	13822	Tetanic Cataract
3201	13823	Parasitic Eyelid Infestation
3202	13825	Squamous Blepharitis
3203	1383	Sweat Gland Disease
3204	13832	Patent Ductus Arteriosus
3205	13837	Convergence Excess Or Spasm
3206	13839	Extrapyramidal And Movement Disease
3207	1384	Chlamydia Trachomatis Urethritis
3208	13844	Suppressed Lactation - Delivered
3209	13845	Suppressed Lactation
3210	13850	Acquired Hallux Varus
3211	1386	Abetalipoproteinemia
3212	13861	Scleroperikeratitis
3213	13862	Acute Closed-angle Glaucoma
3214	13864	Trochlear Nerve Disease
3215	13865	Facial Neuralgia
3216	13866	Multiple Cranial Nerve Palsy
3217	13867	Focal Labyrinthitis
3218	13868	Hypoactive Sexual Desire Disorder
3219	13869	Psychosexual Dysfunction With Male Orgasmic Disease
3220	1387	Hypolipoproteinemia
3221	1388	Tangier Disease
3222	13884	Sick Sinus Syndrome
3223	13887	Residual Chronic Schizophrenia
3224	1389	Polyneuropathy
3225	13891	Bird Fancier's Lung
3226	139	Squamous Cell Papilloma
3227	1390	Hypobetalipoproteinemia
3228	13902	White Piedra
3229	13906	Malignant Pleural Effusion
3230	13909	Red-green Color Blindness
3231	1391	Norum Disease
3232	13910	Red Color Blindness
3233	13911	Achromatopsia
3234	13912	Acquired Color Blindness
3235	13913	Lumbosacral Plexus Lesion
3236	13918	Somatization Disorder
3237	13919	Irregular Astigmatism
3238	1392	Pseudopapilledema
3239	13921	Bacterial Esophagitis
3240	13922	Eosinophilic Esophagitis
3241	13923	Acute Psychogenic Paranoid Psychosis
3242	13924	Necrotizing Ulcerative Gingivitis
3243	13929	Lacrimal Duct Obstruction
3244	1393	Visual Pathway Disease
3245	13934	Facial Paralysis
3246	13938	Amenorrhea
3247	1394	Urinary Schistosomiasis
3248	13941	Benign Paroxysmal Positional Nystagmus
3249	13942	Acute Gonococcal Salpingitis
3250	13943	Acute Gonococcal Prostatitis
3251	13945	Cadasil
3252	13948	Bladder Neck Obstruction
3253	13949	Interstitial Cystitis
3254	1395	Schistosomiasis
3255	13951	Uterine Corpus Epithelioid Leiomyoma
3256	13953	Uterine Corpus Dissecting Leiomyoma
3257	13954	Mitotically Active Variant Uterine Corpus Leiomyoma
3258	13955	Uterus Interstitial Leiomyoma
3259	13956	Uterine Corpus Myxoid Leiomyoma
3260	13957	Uterine Corpus Lipoleiomyoma
3261	13958	Uterine Corpus Bizarre Leiomyoma
3262	13962	Peripheral Focal Retinitis And Retinochoroiditis
3263	13963	Nuclear Senile Cataract
3264	13964	Morgagni Cataract
3265	13969	Schizo-affective Type Schizophrenia Subchronic State With Acute Exacerbation
3266	1397	Chronic Orbital Inflammation
3267	13970	Schizo-affective Type Schizophrenia Chronic State
3268	13972	Female Breast Lower-outer Quadrant Cancer
3269	13975	Metastatic Tumor To The Brain Stem
3270	13976	Peptic Esophagitis
3271	13979	Primary Pulmonary Coccidioidomycosis
3272	1398	Parasitic Infectious Disease
3273	13980	Coccidioidal Meningitis
3274	1399	Primary Lacrimal Atrophy
3275	13994	Cleidocranial Dysplasia
3276	13995	Secondary Malignant Neoplasm To The Small Intestine
3277	13996	Small Intestine Lymphoma
3278	13999	Contact Blepharoconjunctivitis
3279	1400	Lacrimal Apparatus Disease
3280	14000	Rubeosis Iridis
3281	14001	Diabetes Mellitus Insulin Dependent Type, Uncontrolled, With Peripheral Circulatory Disorder
3282	14004	Thoracic Aortic Aneurysm
3283	14006	Splenic Artery Aneurysm
3284	14018	Alcoholic Liver Cirrhosis
3285	14019	Brucella Canis Brucellosis
3286	1402	Agalactia
3287	14021	Tietze's Syndrome
3288	14022	Algoneurodystrophy
3289	14026	Folic Acid Deficiency Anemia
3290	14032	Malignant Parietal Pleura Tumor
3291	14033	Malignant Visceral Pleura Tumor
3292	14037	Aorta Atresia
3293	14038	Precocious Puberty
3294	14039	POEMS Syndrome
3295	1404	Residual Stage Angle-closure Glaucoma
3296	14040	Autoimmune Polyendocrine Syndrome
3297	14041	Endocrine Tuberculosis
3298	14042	Bipolar I Disorder
3299	14043	Neonatal Myasthenia Gravis
3300	14044	Rheumatic Pericarditis
3301	14045	Syndrome Of Infant Of A Diabetic Mother
3302	14049	Phaeohyphomycosis
3303	1405	Primary Angle-closure Glaucoma
3304	14056	Rheumatic Endocarditis
3305	14059	Paraurethral Gland Cancer
3306	1406	Iritis
3307	14063	Acute Glomerulonephritis With Lesion Of Rapidly Progressive Glomerulonephritis
3308	14064	Acute Poststreptococcal Glomerulonephritis
3309	14066	Acute Diffuse Nephritis
3310	14067	Plasmodium Falciparum Malaria
3311	14068	Blackwater Fever
3312	14069	Cerebral Malaria
3313	1407	Anterior Uveitis
3314	14070	Vestibular Nystagmus
3315	14072	Neoplastic Pregnancy Complications
3316	14075	Geniculate Ganglionitis
3317	14080	Glucocorticoid-remediable Aldosteronism
3318	14081	Toxic Labyrinthitis
3319	14087	Epicondylitis
3320	14089	Root Caries
3321	14090	Heartwater Disease
3322	14092	Renal Artery Atheroma
3323	14095	Boutonneuse Fever
3324	14096	Infertility Due To Extratesticular Cause
3325	14099	Acquired Gastric Outlet Stenosis
3326	14107	De Quervain Disease
3327	14108	Syphilitic Peritonitis
3328	14110	Anus Cancer
3329	14111	Median Rhomboid Glossitis
3330	14114	Congenital Adhesion Of Tongue
3331	14115	Toxic Shock Syndrome
3332	14116	Multiple Symmetric Lipomatosis
3333	14117	Group A Hyperlipidemia
3334	14118	Familial Lipoprotein Lipase Deficiency
3335	1412	Bacteriuria
3336	14121	Blue Toe Syndrome
3337	14125	Abducens Nerve Neoplasm
3338	14130	Lateral Cystocele
3339	14131	Midline Cystocele
3340	14133	Masters-Allen Syndrome
3341	14139	Anus Lymphoma
3342	1414	Ovarian Dysfunction
3343	14140	Pulp Erosion
3344	14145	Malignant Anus Melanoma
3345	14146	Ureterolithiasis
3346	1415	Gyrate Atrophy
3347	14150	Spinal Cord Lymphoma
3348	14151	Spinal Cord Melanoma
3349	14152	Spinal Cord Sarcoma
3350	14155	Acute Retrobulbar Neuritis
3351	14157	Malnutrition Of Mild Degree
3352	14159	Obstructive Hydrocephalus
3353	14163	Metastatic Malignant Tumor To The Anus
3354	14165	Bilateral Hyperactive Labyrinth
3355	1417	Choroid Disease
3356	14172	Rheumatic Congestive Heart Failure
3357	14174	Central Neurocytoma
3358	14175	Von Hippel-Lindau Disease
3359	14176	Selective IgG Deficiency Disease
3360	14177	Congenital Hypogammaglobulinemia
3361	14178	Immunodeficiency With Increased IgM
3362	14179	Bruton-type Agammaglobulinemia
3363	14181	Calcific Tendinitis
3364	14182	Metastatic Tumor To The Choroid
3365	14183	Alcoholic Neuropathy
3366	14184	Polyneuropathy Due To Drug
3367	14188	Frozen Shoulder
3368	1419	Residual Schizophrenia Subchronic State With Acute Exacerbation
3369	14190	Shared Paranoid Disease
3370	14191	Simple Paranoid State
3371	14192	Bicipital Tenosynovitis
3372	14199	Posterior Dislocation Of Lens
3373	14200	Diplopia
3374	14202	Adult Dermatomyositis
3375	14203	Childhood Type Dermatomyositis
3376	14213	Hypophosphatasia
3377	14215	Hyperamylasemia
3378	14218	Dihydropyrimidine Dehydrogenase Deficiency
3379	14219	Renal Tubular Acidosis
3380	14221	Metabolic Syndrome X
3381	14223	Ochronosis
3382	14224	Tracheal Calcification
3383	14225	Acute Frontal Sinusitis
3384	14227	Azoospermia
3385	14228	Oligospermia
3386	14230	Scleromalacia Perforans
3387	14233	Orbital Cyst
3388	14239	Gastrointestinal Tularemia
3389	14243	Chronic Perichondritis Of Pinna
3390	14244	Epiphora Due To Excess Lacrimation
3391	14245	Cystoid Macular Retinal Degeneration
3392	14247	Chronic Purulent Otitis Media
3393	14248	Chronic Atticoantral Disease
3394	1425	Pyoureter
3395	14250	Down Syndrome
3396	14251	Vitreoretinal Dystrophy
3397	14252	Dystrophies Primarily Involving The Retinal Pigment Epithelium
3398	14253	Retinal Dystrophy In Systemic Or Cerebroretinal Lipidoses
3399	14256	Adult-onset Still's Disease
3400	14258	Leukemic Reticuloendotheliosis Of Lymph Nodes Of Inguinal Region And Lower Limb
3401	1426	Ureteral Disease
3402	14261	Fragile X Syndrome
3403	14262	Oral Candidiasis
3404	14263	Fits In Newborn
3405	14264	Benign Neonatal Seizures
3406	14265	Pulmonary Valve Insufficiency
3407	14268	Sclerosing Cholangitis
3408	14269	Suppurative Cholangitis
3409	1427	Disorder Of Pancreatic Internal Secretion
3410	14270	Ascending Cholangitis
3411	14271	Acute Cholangitis
3412	14272	Pericholangitis
3413	14275	Atrophic Vulva
3414	14276	Shoulder Impingement Syndrome
3415	14278	Arthropathy Of The Hand
3416	1428	Endocrine Pancreas Disease
3417	14283	Primary Hypertrophic Osteoarthropathy
3418	14284	Patellofemoral Pain Syndrome
3419	14286	Neurogenic Arthropathy
3420	14287	Brawny Scleritis
3421	14289	Ebstein Anomaly
3422	14291	LEOPARD Syndrome
3423	14292	Vulvar Dystrophy
3424	14305	Tuberculous Empyema
3425	14308	Skin Epithelioid Hemangioma
3426	14311	Norovirus Gastroenteritis
3427	14312	Nontoxic Uninodular Goiter
3428	14313	Thyroid Nodule
3429	14319	Pleuropneumonia
3430	1432	Blindness
3431	14320	Generalized Anxiety Disorder
3432	14323	Marfan Syndrome
3433	14324	Plasmodium Malariae Malaria
3434	14325	Mixed Malaria
3435	14326	Avian Malaria
3436	14327	Gonococcal Pericarditis
3437	14330	Parkinson's Disease
3438	14332	Postencephalitic Parkinson Disease
3439	14336	Estrogen Excess
3440	14338	Pseudomonal Pneumonia
3441	14339	Paraphrenia
3442	14350	Suppurative Thyroiditis
3443	14351	Riedel's Fibrosing Thyroiditis
3444	14353	Acute Thyroiditis
3445	1436	Corneal Ectasia
3446	14360	Opisthorchis Viverrini Infectious Disease
3447	14363	Congenital Syphilitic Meningitis
3448	14365	Systemic Primary Carnitine Deficiency Disease
3449	14374	Norwegian Scabies
3450	14384	Parietal Lobe Neoplasm
3451	1439	Pyuria
3452	14392	Thrombophlebitis Migrans
3453	14397	Protozoal Dysentery
3454	1440	Machado-Joseph Disease
3455	14400	Capillary Leak Syndrome
3456	14401	Cutis Marmorata
3457	14402	Critical Illness Polyneuropathy
3458	1441	Spinocerebellar Ataxia
3459	14413	Labyrinthine Bilateral Reactive Loss
3460	14415	Legg-Calve-Perthes Disease
3461	14418	Dracunculiasis
3462	14419	Mansonella Ozzardi Infectious Disease
3463	1442	Alpers Syndrome
3464	14421	Brugia Malayi Filariasis
3465	14422	Dipetalonemiasis
3466	14423	Glossopharyngeal Neuralgia
3467	14425	Secondary Malignant Neoplasm Of Intra-abdominal Lymph Node
3468	14426	Secondary Malignant Neoplasm Of Intrathoracic Lymph Node
3469	14427	Abnormality Of Glucagon Secretion
3470	1443	Cerebral Degeneration
3471	14433	Enterohemorrhagic Escherichia Coli Infectious Disease
3472	14434	Enterotoxigenic Escherichia Coli Infectious Disease
3473	14435	Chronic Tubotympanic Suppurative Otitis Media
3474	14443	Cholinergic Urticaria
3475	14444	Sclerosing Keratitis
3476	14445	Chronic Closed-angle Glaucoma
3477	14447	Gonadal Dysgenesis
3478	14448	46 XY Gonadal Dysgenesis
3479	14449	Mixed Gonadal Dysgenesis
3480	14450	46 XX Gonadal Dysgenesis
3481	14451	Hyperkalemic Periodic Paralysis
3482	14452	Hypokalemic Periodic Paralysis
3483	14453	Farmer's Lung
3484	14456	Brucella Melitensis Brucellosis
3485	14457	Brucella Abortus Brucellosis
3486	14459	Hemangioma Of Orbit
3487	14463	Cavernous Hemangioma Of Orbit
3488	14464	Neuroleptic Malignant Syndrome
3489	14467	Drug-induced Persisting Amnestic Disease
3490	14472	Hantavirus Pulmonary Syndrome
3491	14473	Adenovirus Pneumonia
3492	14474	Respiratory Syncytial Virus Pneumonia
3493	14475	Parainfluenzal Pneumonia
3494	14476	SARS Coronavirus Pneumonia
3495	14477	Cytomegalovirus Pneumonia
3496	14482	Herpes Gestationis
3497	14483	Chorea Gravidarum
3498	14484	Sporotrichosis
3499	14489	Ureteral Lymphoma
3500	14490	Metastasis To The Ureter
3501	14491	Regional Ureteric Cancer
3502	14492	Metastatic Neoplasm Of Ureter
3503	14495	Dumping Syndrome
3504	14497	Wolman Disease
3505	14498	Lipoid Proteinosis
3506	14499	Fabry Disease
3507	145	Papilledema Associated With Retinal Disorder
3508	14500	Fucosidosis
3509	14501	Sjogren-Larsson Syndrome
3510	14502	Cholesterol Ester Storage Disease
3511	14503	Neuronal Ceroid Lipofuscinosis
3512	14504	Niemann-Pick Disease
3513	14507	Peripheral Degeneration Of Cornea
3514	14512	Candidal Paronychia
3515	14515	WAGR Syndrome
3516	14518	Idiopathic Cysts Of Iris And Ciliary Body
3517	14520	Adenovirus Gastroenteritis
3518	14521	Cutaneous Breast Cancer
3519	14522	Partial Arterial Retinal Occlusion
3520	14523	Argyll Robertson Pupil
3521	14524	Senile Degeneration Of Brain
3522	14525	Reye Syndrome
3523	14529	External Pathological Resorption
3524	1453	Atrophic Glossitis
3525	14530	Syringomyelia And Syringobulbia
3526	14534	Malignant Cardiac Peripheral Nerve Sheath Neoplasm
3527	14535	Malignant Cardiac Germ Cell Tumor
3528	14539	Metastasis To Heart
3529	14542	Macular Or Paramacular Focal Retinitis And Retinochoroiditis
3530	14544	Rete Testis Adenocarcinoma
3531	14545	Seminal Vesicle Adenocarcinoma
3532	14546	Sphenoidal Sinus Cancer
3533	14547	Sphenoid Sinus Squamous Cell Carcinoma
3534	14548	Steroid-induced Glaucoma - Borderline
3535	14549	Tympanosclerosis Involving Tympanic Membrane, Ear Ossicles And Middle Ear
3536	1455	Geographic Tongue
3537	14550	Root Resorption
3538	14555	Foster-Kennedy Syndrome
3539	14557	Primary Pulmonary Hypertension
3540	14558	Nontoxic Multinodular Goiter
3541	14559	Anaerobic Meningitis
3542	1456	Glossitis
3543	14566	Disease Of Cellular Proliferation
3544	1458	Postsurgical Hypothyroidism
3545	1459	Hypothyroidism
3546	146	Papilledema
3547	1460	Atheroembolism Of Kidney
3548	1461	Cholesterol Embolism
3549	1465	Salmonella Septicemia
3550	14654	Prostatitis
3551	1466	Salmonella Infectious Disease
3552	14669	Acrodysostosis
3553	1467	Serous Labyrinthitis
3554	14670	Hypertelorism, Microtia, Facial Clefting Syndrome
3555	14671	Multiple Intestinal Atresia
3556	14676	Congenital Contricting Bands
3557	14679	VACTERL Association
3558	1468	Labyrinthitis
3559	14680	Hereditary Inflammatory Vasculitis
3560	14681	Silver-Russell Syndrome
3561	14683	Binder Syndrome
3562	14686	Axenfeld-Rieger Syndrome
3563	14687	Diastrophic Dysplasia
3564	1469	Single Major Depressive Episode In Full Remission
3565	14692	Smith-Lemli-Opitz Syndrome
3566	14693	Clouston Syndrome
3567	14694	Johanson-Blizzard Syndrome
3568	14695	Galactokinase Deficiency
3569	14699	Thrombocytopenia-absent Radius Syndrome
3570	1470	Major Depressive Disorder
3571	14701	Propionic Acidemia
3572	14702	Branchiootorenal Syndrome
3573	14705	Pfeiffer Syndrome
3574	14711	FG Syndrome
3575	14717	Centronuclear Myopathy
3576	14720	Type I Ehlers-Danlos Syndrome
3577	14723	Beta-ketothiolase Deficiency
3578	14725	Autosomal Dominant Microcephaly
3579	14727	Dominant Cogenital Severe Sensorineural Deafness
3580	14731	Weaver Syndrome
3581	14735	Hereditary Angioedema
3582	14737	Craniofrontonasal Syndrome
3583	14739	Progressive High-tone Neural Deafness
3584	1474	Aggressive Periodontitis
3585	14743	Trichorhinophalangeal Syndrome Type I
3586	14744	Partington Syndrome
3587	14748	Sotos Syndrome
3588	14749	Methylmalonic Acidemia
3589	1475	Lymphangioma
3590	14753	Isovaleric Acidemia
3591	14755	Argininosuccinic Aciduria
3592	14756	Autosomal Dominant Type IV Ehlers-Danlos Syndrome
3593	14757	Type III Ehlers-Danlos Syndrome
3594	14759	Autosomal Recessive Type IV Ehlers-Danlos Syndrome
3595	14761	Greig Cephalopolysyndactyly Syndrome
3596	14762	Calcaneonavicular Coalition
3597	14764	Larsen Syndrome
3598	14766	Renal Agenesis
3599	14768	Saethre-Chotzen Syndrome
3600	14773	Cartilage-hair Hypoplasia
3601	14775	Type VI Ehlers-Danlos Syndrome
3602	14777	Benign Familial Neonatal Epilepsy
3603	14778	Blepharophimosis, Ptosis, And Epicanthus Inversus Syndrome
3604	14780	KBG Syndrome
3605	14784	Olivopontocerebellar Atrophy
3606	14787	Fryns Syndrome
3607	14789	Spondyloepiphyseal Dysplasia Congenita
3608	14791	Leber Congenital Amaurosis
3609	14793	Hypohidrotic Ectodermal Dysplasia
3610	14796	Dubowitz Syndrome
3611	14798	Blount's Disease
3612	1483	Gingival Disease
3613	1485	Cystic Fibrosis
3614	1486	Secondary Syphilitic Chorioretinitis
3615	1487	Secondary Syphilitic Uveitis
3616	1491	Corneal Anesthesia And Hypoesthesia
3617	1492	Eye And Adnexa Disease
3618	1495	Cystic Echinococcosis
3619	1496	Echinococcosis
3620	1498	Cholera
3621	1499	Vibrio Infectious Disease
3622	15	Reproductive System Disease
3623	150	Disease Of Mental Health
3624	1508	Candidiasis
3625	1509	Avoidant Personality Disorder
3626	1510	Personality Disorder
3627	1511	Residual Schizophrenia Chronic State With Acute Exacerbation
3628	1512	Chronic Gonorrhea Of Cervix
3629	1513	Chronic Cervicitis
3630	1515	Mitral Valve Syphilitic Endocarditis
3631	1516	Syphilitic Endocarditis
3632	1517	Cecal Benign Neoplasm
3633	1518	Cecal Disease
3634	1519	Cecum Carcinoma
3635	1520	Colon Carcinoma
3636	1521	Cecum Cancer
3637	1522	Cecum Lymphoma
3638	1523	Colon Lymphoma
3639	1525	Nodular Nonsuppurative Panniculitis
3640	1526	Panniculitis
3641	1528	Penile Non-neoplastic Disease
3642	1529	Penile Disease
3643	153	Fibroepithelial Neoplasm
3644	1530	Male Non-neoplastic Reproductive System Disease
3645	1532	Pleural Disease
3646	154	Mixed Cell Type Cancer
3647	1540	Parathyroid Carcinoma
3648	1542	Head And Neck Carcinoma
3649	1543	Metastatic Neoplasm Of Parathyroid
3650	155	Glandular And Epithelial Neoplasm
3651	1550	Gestational Diabetes Complicating Pregnancy, Childbirth, Or The Puerperium
3652	1554	Vibratory Urticaria
3653	1555	Urticaria
3654	1556	Arthus Reaction
3655	1557	Hypersensitivity Reaction Type III Disease
3656	1558	Angioedema
3657	1561	Cognitive Disorder
3658	1562	Chromoblastomycosis
3659	1563	Dermatomycosis
3660	1564	Fungal Infectious Disease
3661	1568	Calculus Of Gallbladder And Bile Duct With Acute And Chronic Cholecystitis
3662	1569	Mechanical Ectropion
3663	157	Epithelial Carcinoma
3664	1570	Ectropion
3665	1571	Spastic Ectropion
3666	1572	Normal Pressure Hydrocephalus
3667	1573	Communicating Hydrocephalus
3668	1574	Alcohol Abuse
3669	1575	Rheumatic Disease
3670	1577	Limited Scleroderma
3671	1578	Pulmonary Systemic Sclerosis
3672	1579	Respiratory System Disease
3673	1580	Diffuse Scleroderma
3674	1583	Laryngeal Tuberculosis
3675	1584	Acute Chest Syndrome
3676	1585	Rheumatic Pneumonia
3677	1586	Rheumatic Fever
3678	1587	Thrombocytopenia Due To Platelet Alloimmunization
3679	1588	Thrombocytopenia
3680	159	Mesothelial Neoplasm
3681	1591	Renovascular Hypertension
3682	1592	Secondary Malignant Neoplasm Of Retroperitoneum And Peritoneum
3683	1593	Metastasis To The Peritoneum
3684	1595	Endogenous Depression
3685	1596	Mental Depression
3686	1597	Single Episode Mild Major Depression
3687	1599	Single Episode Moderate Major Depression
3688	16	Integumentary System Disease
3689	1602	Lymphadenitis
3690	1607	Hypoglycemic Coma
3691	161	Keratosis
3692	1612	Breast Cancer
3693	1614	Male Breast Cancer
3694	1616	Benign Eccrine Breast Spiradenoma
3695	1618	Breast Fibroadenoma
3696	162	Cancer
3697	1620	Breast Fibroepithelial Tumor
3698	1623	Breast Leiomyoma
3699	1624	Breast Soft Tissue Tumor
3700	1625	Breast Adenoma
3701	1626	Breast Duct Papilloma
3702	1627	Intraductal Papilloma
3703	1628	Intraductal Papillary Breast Neoplasm
3704	1629	Breast Myofibroblastoma
3705	163	Mucoepidermoid Tumor
3706	1631	Benign Breast Phyllodes Tumor
3707	1634	Breast Papillomatosis
3708	1637	Breast Angiomatosis
3709	1638	Central Nervous System Tuberculosis
3710	1639	Skeletal Tuberculosis
3711	164	Cystic, Mucinous, And Serous Neoplasm
3712	1641	Benign Breast Adenomyoepithelioma
3713	1642	Breast Adenomyoepithelioma
3714	1647	Female Breast Upper-inner Quadrant Cancer
3715	1649	Female Breast Lower-inner Quadrant Cancer
3716	1650	Female Breast Axillary Tail Cancer
3717	1657	Ventricular Septal Defect
3718	1659	Supratentorial Cancer
3719	166	Melanotic Neuroectodermal Tumor
3720	1660	Malignant Pineal Area Germ Cell Neoplasm
3721	1661	Malignant Intracranial Germ Cell Neoplasm
3722	1664	Pineoblastoma
3723	1665	Central Nervous System Embryonal Cancer
3724	1666	Hip Enthesopathy
3725	1667	Peripheral Enthesopathy
3726	1670	Behcet's Syndrome Arthropathy
3727	1672	Spontaneous Tension Pneumothorax
3728	1673	Pneumothorax
3729	1677	Low Implantation Of Placenta
3730	1678	Chronic Interstitial Cystitis
3731	1679	Cystitis
3732	1680	Chronic Cystitis
3733	1681	Heart Septal Defect
3734	1682	Congenital Heart Disease
3735	1685	Glaucoma Associated With Vascular Disorder
3736	1686	Glaucoma
3737	1687	Neovascular Glaucoma
3738	169	Neuroendocrine Tumor
3739	1695	Congenital Ichthyosis
3740	1697	Ichthyosis
3741	1699	Congenital Ichthyosiform Erythroderma
3742	17	Musculoskeletal System Disease
3743	170	Endocrine Gland Cancer
3744	1700	X-linked Ichthyosis
3745	1701	Steroid Inherited Metabolic Disorder
3746	1702	Ichthyosis Vulgaris
3747	1703	Richter's Syndrome
3748	1709	Rickettsiosis
3749	171	Neuroectodermal Tumor
3750	1712	Aortic Valve Stenosis
3751	1713	Benign Shuddering Attacks
3752	172	Clear Cell Acanthoma
3753	1724	Duodenal Ulcer
3754	1725	Peritoneum Cancer
3755	1726	Partial Of Retinal Vein Occlusion
3756	1727	Retinal Vein Occlusion
3757	1729	Retinal Vascular Occlusion
3758	173	Eccrine Sweat Gland Neoplasm
3759	1730	Histoplasmosis Pneumonia
3760	1731	Histoplasmosis
3761	1733	Cryptosporidiosis
3762	1734	Viral Gastroenteritis
3763	1737	Duodenal Benign Neoplasm
3764	1738	Small Intestine Leiomyoma
3765	174	Acanthoma
3766	1741	Drug-induced Psychotic Disease With Delusion
3767	1742	Drug Psychosis
3768	1744	Malignant Lymphatic Vessel Tumor
3769	1748	Conjunctiva Squamous Cell Carcinoma
3770	1749	Squamous Cell Carcinoma
3771	175	Vascular Cancer
3772	1751	Malignant Conjunctiva Melanoma
3773	1752	Ocular Melanoma
3774	1754	Mitral Valve Stenosis
3775	1756	Facial Nerve Disease
3776	1757	Facial Hemiatrophy
3777	1758	Histoplasma Capsulatum Pneumonia
3778	1759	American Histoplasmosis
3779	176	Cardiovascular Cancer
3780	1760	Facial Nerve Neoplasm
3781	1761	Melkersson-Rosenthal Syndrome
3782	1762	Cheilitis
3783	1766	Factitious Disorder
3784	1768	Conversion Disorder
3785	1770	Toxic Megacolon
3786	1776	Labyrinthine Unilateral Reactive Loss
3787	1777	Unilateral Hyperactive Labyrinth
3788	178	Vascular Disease
3789	1781	Thyroid Cancer
3790	1785	Pituitary Cancer
3791	1786	Adrenal Rest Tumor
3792	1787	Pericarditis
3793	1788	Peritoneal Mesothelioma
3794	1789	Benign Peritoneal Mesothelioma
3795	1790	Malignant Mesothelioma
3796	1791	Peritoneal Carcinoma
3797	1792	Pancreas Lymphoma
3798	1793	Pancreatic Cancer
3799	1795	Tumor Of Exocrine Pancreas
3800	1796	Pancreas Sarcoma
3801	1798	Pancreatic Endocrine Carcinoma
3802	1799	Islet Cell Tumor
3803	18	Urinary System Disease
3804	180	Ossifying Fibroma
3805	1800	Neuroendocrine Carcinoma
3806	1801	Secondary Malignant Neoplasm To The Pancreas
3807	1802	Mononeuritis
3808	1803	Neuritis
3809	1804	Coxsackie Pericarditis
3810	1805	Coxsackie Carditis
3811	1806	Coxsackie Endocarditis
3812	1811	Reflex Sympathetic Dystrophy
3813	182	Calcinosis
3814	1822	Secondary Lacrimal Atrophy
3815	1823	Petit Mal Status
3816	1824	Status Epilepticus
3817	1825	Childhood Absence Epilepsy
3818	1826	Epilepsy Syndrome
3819	1827	Idiopathic Generalized Epilepsy
3820	1829	Urethral Stricture
3821	1832	Mild Hyperemesis Gravidarum
3822	1835	Mononeuritis Multiplex
3823	1837	Diabetic Ketoacidosis
3824	1838	Menkes Disease
3825	184	Bone Cancer
3826	1844	Mononeuritis Of Upper Limb
3827	1845	Strongylida Infectious Disease
3828	1849	Cannabis Dependence
3829	1852	Intrahepatic Cholestasis
3830	1856	Cherubism
3831	1858	McCune Albright Syndrome
3832	1862	Jaw Cancer
3833	1863	Skull Cancer
3834	1866	Giant Cell Reparative Granuloma
3835	1869	Chronic Rheumatic Pericarditis
3836	1873	Abortion Complicated By Metabolic Disorder
3837	1875	Impotence
3838	1876	Sexual Dysfunction
3839	1882	Atrial Heart Septal Defect
3840	1883	Hepatitis C
3841	1884	Viral Hepatitis
3842	1886	Flaviviridae Infectious Disease
3843	1891	Optic Nerve Disease
3844	1893	Eczematous Dermatitis Of Eyelid
3845	1894	Noninfectious Dermatoses Of Eyelid
3846	1895	Allergic Contact Dermatitis Of Eyelid
3847	1896	Sigmoid Neoplasm
3848	1897	Sigmoid Disease
3849	1901	Vagina Sarcoma
3850	1906	Malignant Skin Fibrous Histiocytoma
3851	1907	Malignant Fibroxanthoma
3852	1908	Cutaneous Fibrohistiocytic Neoplasm
3853	1909	Melanoma
3854	1910	Vaginal Yolk Sac Tumor
3855	1911	Endodermal Sinus Tumor
3856	1912	Metastasis To Vagina
3857	1913	Alternating Exotropia With A Pattern
3858	1919	Lesch-Nyhan Syndrome
3859	192	Sex Cord-gonadal Stromal Tumor
3860	1920	Hyperuricemia
3861	1921	Klinefelter's Syndrome
3862	1922	Endocrine Syndrome
3863	1923	Sex Differentiation Disease
3864	1924	Hypogonadism
3865	1925	Coffin-Siris Syndrome
3866	1926	Gaucher's Disease
3867	1927	Sphingolipidosis
3868	1928	Williams-Beuren Syndrome
3869	1929	Supravalvular Aortic Stenosis
3870	193	Reproductive Organ Cancer
3871	1930	Laurence-Moon Syndrome
3872	1931	Hypothalamic Disease
3873	1932	Angelman Syndrome
3874	1933	Rubinstein-Taybi Syndrome
3875	1934	Dysostosis
3876	1935	Bardet-Biedl Syndrome
3877	1936	Atherosclerosis
3878	1938	Primary Bacillaceae Infectious Disease
3879	194	Gonadal Tissue Neoplasm
3880	1941	Intermittent Alternating Exotropia
3881	1942	Intermittent Squint
3882	1943	Telogen Effluvium
3883	1947	Trichomoniasis
3884	1949	Cholecystitis
3885	195	Reproductive Endocrine Cancer
3886	1954	Benign Hypertensive Heart Disease
3887	196	Acinar Cell Tumor
3888	1962	Fallopian Tube Disease
3889	1963	Fallopian Tube Carcinoma
3890	1964	Fallopian Tube Cancer
3891	1965	Fallopian Tube Leiomyosarcoma
3892	1966	Fallopian Tube Soft Tissue Neoplasm
3893	1967	Leiomyosarcoma
3894	1969	Cerebral Palsy
3895	197	Glandular Cell Epithelial Neoplasm
3896	1970	Fallopian Tube Carcinosarcoma
3897	1973	Fallopian Tube Adenosarcoma
3898	1974	Adenosarcoma
3899	1975	Thymus Lipoma
3900	1977	Lipoma Of The Mediastinum
3901	1978	Juxtapapillary Focal Choroiditis And Chorioretinitis
3902	1979	Focal Chorioretinitis
3903	198	Mesonephric Tumor
3904	1982	Rhabdoviridae Infectious Disease
3905	1983	Mononegavirales Infectious Disease
3906	1984	Rectal Neoplasm
3907	1986	Perinatal Disease
3908	1987	Fetal Disease
3909	1988	Rectum Lymphoma
3910	1990	Metastasis To The Rectum
3911	1991	Metastases To Large Intestine
3912	1992	Rectum Malignant Melanoma
3913	1993	Rectum Cancer
3914	1995	Rectum Sarcoma
3915	1996	Rectum Adenocarcinoma
3916	1998	Lutembacher's Syndrome
3917	1999	Chronic Eustachian Salpingitis
3918	200	Giant Cell Tumor
3919	2000	Otosalpingitis
3920	2001	Neuroma
3921	2005	Tracheal Tuberculosis
3922	2006	Preretinal Fibrosis
3923	2007	Degeneration Of Macula And Posterior Pole
3924	201	Connective Tissue Cancer
3925	2010	Impaired Mobility Of Ear Ossicles Except Malleus
3926	2012	Nezelof Syndrome
3927	2014	Perinatal Digestive System Disorder
3928	2018	Hyperinsulinism
3929	2021	Placenta Cancer
3930	2022	Metastatic Neoplasm To The Placenta
3931	2024	Placental Choriocarcinoma
3932	2025	Gestational Choriocarcinoma
3933	2027	Fetal Or Neonatal Hemorrhage
3934	203	Exostosis
3935	2030	Anxiety Disorder
3936	2033	Communication Disorder
3937	2034	Encephalomalacia
3938	2038	Urogenital Abnormality
3939	204	Enthesopathy
3940	2043	Hepatitis B
3941	2044	Drug-induced Hepatitis
3942	2047	Hepatitis D
3943	2048	Autoimmune Hepatitis
3944	205	Hyperostosis
3945	2050	Acute Maxillary Sinusitis
3946	2051	Maxillary Sinusitis
3947	2053	Reactive Cutaneous Fibrous Lesion
3948	2055	Post-traumatic Stress Disorder
3949	2058	Chronic Mucocutaneous Candidiasis
3950	2059	Vulvar Disease
3951	206	Hereditary Multiple Exostoses
3952	2060	Vulvar Nodular Hidradenoma
3953	2061	Nodular Hidradenoma
3954	2062	Vulvar Tumor Of Skin Appendage Origin
3955	2064	Vulvar Syringoma
3956	2065	Syringoma
3957	2066	Vulvar Angiokeratoma
3958	2068	Bartholin's Gland Neoplasm
3959	2069	Vulvar Acquired Melanocytic Nevus
3960	2070	Vulvar Melanocytic Neoplasm
3961	2071	Vulvar Squamous Papilloma
3962	2072	Vulvar Squamous Tumor
3963	2073	Perinatal Intestinal Perforation
3964	2074	Intestinal Perforation
3965	2075	Minor Vestibular Glands Adenoma
3966	2076	Vulvar Glandular Tumor
3967	2077	Vulvar Congenital Melanocytic Nevus
3968	2078	Chondroid Syringoma Of The Vulva
3969	2079	Eccrine Mixed Tumor Of Skin
3970	208	Hereditary Neoplastic Syndrome
3971	2080	Vulvar Trichoepithelioma
3972	2083	Vulvar Soft Tissue Tumor
3973	2085	Vulvar Blue Nevus
3974	2086	Blue Nevus
3975	2088	Outlet Dysfunction Constipation
3976	2089	Constipation
3977	2092	Transient Arthritis
3978	2093	Vulvar Melanoma
3979	2094	Vulvar Sweat Gland Cancer
3980	2095	Sweat Gland Cancer
3981	2096	Vulvar Sarcoma
3982	2097	Vulval Paget's Disease
3983	2098	Vulva Adenocarcinoma
3984	2099	Extramammary Paget's Disease
3985	210	Heel Spur
3986	2100	Vulvar Metastasis
3987	2101	Vulva Squamous Cell Carcinoma
3988	2106	Thomsen Disease
3989	2108	Transplant-related Disease
3990	211	Ankle Or Tarsus Enthesopathy
3991	2112	Cystoisosporiasis
3992	2113	Coccidiosis
3993	2115	B Cell Deficiency
3994	2120	Focal Dermal Hypoplasia
3995	2121	Ectodermal Dysplasia
3996	2122	Pneumonic Tularemia
3997	2123	Tularemia
3998	2124	Intracranial Neoplasm
3999	2127	Brain Germinoma
4000	2128	Intracranial Germinoma
4001	2129	Atypical Teratoid Rhabdoid Tumor
4002	2131	Childhood Malignant Central Nervous System Neoplasm
4003	2132	Brain Sarcoma
4004	2133	Central Nervous System Sarcoma
4005	2135	Temporal Lobe Neoplasm
4006	2139	Paraurethral Gland Neoplasm
4007	214	Teeth Hard Tissue Disease
4008	2140	Urethral Urothelial Papilloma
4009	2142	Urethra Leiomyoma
4010	2143	Ovarian Malignant Mesothelioma
4011	2145	Malignant Ovarian Cyst
4012	2146	Ovary Sarcoma
4013	2147	Ovary Soft Tissue Neoplasm
4014	2148	Tuberculous Oophoritis
4015	2149	Urogenital Tuberculosis
4016	2150	Ovarian Lymphoma
4017	2151	Malignant Ovarian Surface Epithelial-stromal Neoplasm
4018	2152	Ovary Epithelial Cancer
4019	2153	Ovarian Wilms' Cancer
4020	2154	Nephroblastoma
4021	2155	Malignant Ovarian Germ Cell Neoplasm
4022	2156	Ovarian Germ Cell Cancer
4023	2158	Lung Metastasis
4024	216	Dental Caries
4025	2163	Nasal Cavity Disease
4026	217	Enamel Caries
4027	2170	Vaginitis
4028	2172	Malignant Eyelid Tumor
4029	2173	Eyelid Neoplasm
4030	2174	Ocular Cancer
4031	2176	Carbuncle
4032	2177	Complications Mainly Related To Pregnancy
4033	2179	Diabetes Mellitus Insulin Dependent Type, Uncontrolled, With Ophthalmic Manifestations
4034	218	Ascending Colon Cancer
4035	2180	Diabetic Oculopathy
4036	2181	Post-surgical Hypoinsulinemia
4037	2186	Macrocephaly
4038	2187	Amelogenesis Imperfecta
4039	219	Colon Cancer
4040	221	Acute Perichondritis Of Pinna
4041	2211	Factor XIII Deficiency
4042	2212	Coagulation Protein Disease
4043	2213	Hemorrhagic Disease
4044	2214	Inherited Blood Coagulation Disease
4045	2215	Factor VII Deficiency
4046	2216	Factor V Deficiency
4047	2217	Bernard-Soulier Syndrome
4048	2218	Blood Platelet Disease
4049	2219	Glanzmann's Thrombasthenia
4050	222	Perichondritis Of Auricle
4051	2222	Factor X Deficiency
4052	2223	Platelet Storage Pool Deficiency
4053	2224	Hemorrhagic Thrombocythemia
4054	2225	Megakaryocytic Tumor
4055	2226	Chronic Myeloproliferative Disease
4056	2227	Malignant Neoplasm Of Lymphatic And Hemopoietic Tissue
4057	2228	Thrombocytosis
4058	2229	Factor XI Deficiency
4059	223	Basilar Artery Insufficiency
4060	2230	Hemophilia
4061	2231	Factor XII Deficiency
4062	2232	Coagulation Factor Deficiency
4063	2233	Partial Epilepsy With Impairment Of Consciousness
4064	2234	Focal Epilepsy
4065	2235	Prothrombin Deficiency
4066	2236	Congenital Afibrinogenemia
4067	2237	Hepatitis
4068	2239	Granulomatous Hepatitis
4069	224	Transient Cerebral Ischemia
4070	2242	Mild Recurrent Major Depression
4071	2247	Spondylosis
4072	225	Syndrome
4073	2251	Hypertrophic Elongation Of Cervix
4074	2253	Cervix Disease
4075	2255	Short Rib-polydactyly Syndrome
4076	2256	Osteochondrodysplasia
4077	2257	Primary Spirochaetales Infectious Disease
4078	2265	Treponema Infectious Disease
4079	227	Ankylosis
4080	2271	Oropharyngeal Candidiasis
4081	2272	Vulvovaginal Candidiasis
4082	2273	Vulvovaginitis
4083	2275	Pharyngitis
4084	2277	Gonadal Disease
4085	2279	Joint Derangement
4086	2280	Hidradenitis Suppurativa
4087	2282	Hidradenitis
4088	2283	Keratopathy
4089	2286	Capillary Lymphangioma
4090	229	Female Reproductive System Disease
4091	2297	Leptospirosis
4092	230	Lateral Sclerosis
4093	2300	Spondylolysis
4094	2301	Atrophy Of Prostate
4095	2303	Stereotypic Movement Disorder
4096	231	Motor Neuron Disease
4097	2312	Nocardiosis
4098	2313	Primary Actinomycetales Infectious Disease
4099	2314	Malt Worker's Lung
4100	2316	Brain Ischemia
4101	2320	Obstructive Lung Disease
4102	2321	Dyspepsia
4103	2323	Prostate Non-neoplastic Disease
4104	2324	Coxsackie Meningitis
4105	2325	Enterovirus Meningitis
4106	2326	Gastroenteritis
4107	2327	Viral Gastritis
4108	2328	Astrovirus Gastroenteritis
4109	2329	Rotavirus Gastroenteritis
4110	233	Ocular Tuberculosis
4111	2334	Metastatic Carcinoma
4112	2338	Mandibular Cancer
4113	2339	Crouzon Syndrome
4114	234	Colon Adenocarcinoma
4115	2340	Craniosynostosis
4116	2344	Polyclonal Hypergammaglobulinemia
4117	2345	Plasma Protein Metabolism Disease
4118	2346	Monoclonal Paraproteinemia
4119	2347	Generalized Atherosclerosis
4120	2348	Arteriosclerotic Cardiovascular Disease
4121	2349	Arteriosclerosis
4122	235	Colonic Benign Neoplasm
4123	2350	Iron Overload
4124	2351	Iron Metabolism Disease
4125	2352	Hemochromatosis
4126	2354	Myelophthisic Anemia
4127	2355	Anemia
4128	2361	Macrocytic Anemia
4129	2364	Post-thrombotic Syndrome
4130	2365	West Nile Encephalitis
4131	2366	West Nile Fever
4132	2367	Neuroaxonal Dystrophy
4133	2368	Gangliosidosis
4134	2369	Diabetes Mellitus Insulin Dependent Type Not Stated As Uncontrolled With Renal Manifestations
4135	237	Adhesions And Disruptions Of Iris And Ciliary Body
4136	2370	Diabetic Nephropathy
4137	2373	Hereditary Elliptocytosis
4138	2376	Chronic Progressive Multiple Sclerosis
4139	2377	Multiple Sclerosis
4140	2378	Relapsing-remitting Multiple Sclerosis
4141	238	Pupil Disease
4142	2381	Vibrio Cholerae O1 Biovar El Tor Cholera
4143	2382	Kernicterus
4144	2383	Neonatal Jaundice
4145	2384	Wernicke Encephalopathy
4146	2385	Thiamine Deficiency
4147	2388	Renal Artery Disease
4148	2389	Fibromuscular Dysplasia
4149	239	Iridodialysis
4150	2392	Glandular Cystitis
4151	2394	Ovarian Cancer
4152	2399	Ovarian Clear Cell Neoplasm
4153	240	Iris Disease
4154	2401	Clitoris Cancer
4155	2402	Lymphangiectasis
4156	2409	Rhinosporidiosis
4157	2410	Skin Granular Cell Tumor
4158	2411	Granular Cell Tumor
4159	2412	Skin Tumor Of Neural Origin
4160	2413	Epithelioid And Spindle Cell Nevus
4161	2415	Benign Skin Melanocytic Nevus
4162	2417	Melanocytic Nevus
4163	2421	Skin Fibrous Tissue Neoplasm
4164	2423	Halo Nevus
4165	2424	Intradermal Nevus
4166	2425	Cutaneous Ganglioneuroma
4167	2426	Gangliocytoma
4168	2430	Skin Glomus Tumor
4169	2431	Glomus Tumor
4170	2433	Epidermal Appendage Tumor
4171	2434	Intraepidermal Nevus
4172	2435	Skin Glomangioma
4173	2436	Glomangioma
4174	2437	Skin Compound Nevus
4175	2438	Dermis Tumor
4176	2441	Frontal Sinus Squamous Cell Carcinoma
4177	2444	Hyperpituitarism
4178	2446	Gigantism
4179	2449	Acromegaly
4180	2450	Central Retinal Vein Occlusion
4181	2451	Protein S Deficiency
4182	2452	Thrombophilia
4183	2455	Angular Blepharoconjunctivitis
4184	2456	Blepharoconjunctivitis
4185	2457	Giant Papillary Conjunctivitis
4186	2458	Papillary Conjunctivitis
4187	2460	Anterior Dislocation Of Lens
4188	2462	Retinal Vascular Disease
4189	2467	Reactive Confusion
4190	2468	Psychotic Disorder
4191	2469	Swine Erysipelas
4192	2470	Erysipelothrix Infectious Disease
4193	2471	Erysipelothrix Rhusiopathiae Infectious Disease
4194	2473	Opportunistic Mycosis
4195	2474	Vernal Conjunctivitis
4196	2475	Chronic Conjunctivitis
4197	2476	Hereditary Spastic Paraplegia
4198	2477	Motor Peripheral Neuropathy
4199	2478	Spinocerebellar Degeneration
4200	2479	Central Nervous System Origin Vertigo
4201	248	Trachea Leiomyoma
4202	2481	Infantile Epileptic Encephalopathy
4203	2485	Phosphorus Metabolism Disease
4204	2487	Hypercholesterolemia
4205	2490	Congenital Nervous System Abnormality
4206	2491	Sensory Peripheral Neuropathy
4207	2492	Hereditary Peripheral Neuropathy
4208	2493	Gastric Antral Vascular Ectasia
4209	2494	Angiodysplasia
4210	2495	Senile Angioma
4211	2497	Enamel Erosion
4212	2498	Tooth Erosion
4213	250	Chronic Brain Damage
4214	2503	AIDS-related Vulvovaginal Candidiasis
4215	2508	Takayasu's Arteritis
4216	251	Alcohol-induced Mental Disorder
4217	2510	Kluver-Bucy Syndrome
4218	2512	Nevoid Basal Cell Carcinoma Syndrome
4219	2513	Basal Cell Carcinoma
4220	2514	Meningococcal Optic Neuritis
4221	2515	Meningococcal Infectious Disease
4222	2516	Intracranial Cavernous Angioma
4223	2517	Intracranial Structure Hemangioma
4224	2518	Orchitis
4225	2519	Testicular Disease
4226	252	Alcoholic Psychosis
4227	2524	Abnormal Glucose Tolerance In Mother Complicating Pregnancy Childbirth And/or Puerperium
4228	2526	Prostate Adenocarcinoma
4229	2527	Nephrosis
4230	2528	Myeloid Metaplasia
4231	2529	Splenic Disease
4232	2530	Splenic Abscess
4233	2531	Hematologic Cancer
4234	2533	Splenic Infarction
4235	2536	Chronic Inflammatory Demyelinating Polyneuritis
4236	2537	Inflammatory And Toxic Neuropathy
4237	2538	Landau-Kleffner Syndrome
4238	254	Hemangioma Of Intra-abdominal Structure
4239	2544	Extratemporal Epilepsy
4240	2545	Congenital Epilepsy
4241	2546	Atonic Epilepsy
4242	2547	Intractable Epilepsy
4243	2548	Reflex Epilepsy
4244	2549	Aggravated Epilepsy
4245	255	Hemangioma
4246	2550	Tactile Epilepsy
4247	2551	Anosognostic Epilepsy
4248	2555	Granulomatous Angiitis
4249	2556	Relapsing Polychondritis
4250	2557	Chondromalacia
4251	2559	Opiate Dependence
4252	256	Hemangioma Of Spleen
4253	2560	Morphine Dependence
4254	2562	Suppurative Periapical Periodontitis
4255	2563	Serratia Septicemia
4256	2565	Macular Corneal Dystrophy
4257	2566	Corneal Dystrophy
4258	2567	Primary Enterobacteriaceae Infectious Disease
4259	2568	Cervicitis
4260	2569	Retinal Drusen
4261	2570	Malignant Histiocytic Disease
4262	2571	Langerhans-cell Histiocytosis
4263	2573	Drug-induced Delirium
4264	2574	Diabetes Mellitus Insulin Dependent Type Uncontrolled With Renal Manifestations
4265	2575	Barbiturate Dependence
4266	2580	Rhizomelic Chondrodysplasia Punctata
4267	2581	Chondrodysplasia Punctata
4268	2582	Acatalasia
4269	2583	Agammaglobulinemia
4270	2584	Nephrotic Syndrome With Lesion Of Endothelial Glomerulonephritis
4271	2585	Nephrotic Syndrome With Lesion Of Segmental Hyalinosis
4272	2586	Nephrotic Syndrome With Lesion Of Hypocomplementemic Glomerulonephritis
4273	2587	Nephrotic Syndrome With Lesion Of Mesangiocapillary Glomerulonephritis
4274	2588	Nephrotic Syndrome With Lesion Of Persistent Glomerulonephritis
4275	2589	Nephrotic Syndrome With Lesion Of Membranous Glomerulonephritis
4276	259	Abortion Complicated By Embolism
4277	2590	Familial Nephrotic Syndrome
4278	2591	Nephrotic Syndrome With Lesion Of Lobular Glomerulonephritis
4279	2592	Nephrotic Syndrome With Lesion Of Focal Glomerulosclerosis
4280	2595	Glottis Cancer
4281	2596	Larynx Cancer
4282	2597	Glottis Neoplasm
4283	2598	Laryngeal Benign Neoplasm
4284	2599	Glottis Carcinoma
4285	26	Pancreas Disease
4286	260	Hepatic Flexure Cancer
4287	2600	Laryngeal Carcinoma
4288	2601	Juxtacortical Chondroma
4289	2602	Chondroma
4290	2609	Adenomyoma
4291	261	Transverse Colon Cancer
4292	2614	Serous Surface Papilloma
4293	2615	Papilloma
4294	2616	Wolffian Duct Adenoma
4295	262	Kidney Hemangiopericytoma
4296	2620	Ductal, Lobular, And Medullary Neoplasm
4671	3151	Skin Squamous Cell Carcinoma
4297	2621	Autonomic Nervous System Neoplasm
4298	2622	Neuroblastic Tumor
4299	2623	Neuronal And Glio-neuronal Neoplasm
4300	2626	Choroid Plexus Papilloma
4301	2629	Papillary Serous Cystadenoma
4302	263	Kidney Cancer
4303	2630	Papillary Cystadenoma
4304	2631	Serous Cystadenoma
4305	2632	Papillary Serous Adenocarcinoma
4306	2633	Mucinous Cystadenoma
4307	2634	Cystadenoma
4308	2635	Mucinous Neoplasm
4309	2636	Ovarian Brenner Tumor
4310	2639	Breast Pericanalicular Fibroadenoma
4311	264	Hemangiopericytoma
4312	2640	Struma Ovarii
4313	2641	Ovarian Germ Cell Monodermal And Highly Specialized Teratoma
4314	2642	Lymphangiomyoma
4315	2643	Perivascular Epithelioid Cell Tumor
4316	2645	Benign Mesothelioma
4317	2647	Parachordoma
4318	2648	Sebaceous Adenoma
4319	2649	Chondroblastoma
4320	265	Spleen Angiosarcoma
4321	2651	Intraductal Papillomatosis
4322	2653	Benign Fibrous Mesothelioma
4323	2654	Serous Neoplasm
4324	2656	Breast Intracanalicular Fibroadenoma
4325	2658	Dermoid Cyst
4326	266	Malignant Soft Tissue Neoplasm Of The Spleen
4327	2660	Cystic Teratoma
4328	2661	Myoepithelioma
4329	2664	Sweat Gland Neoplasm
4330	2667	Benign Mesenchymoma
4331	2668	Mesenchymoma
4332	2669	Pacinian Tumor
4333	2670	Transitional Papilloma
4334	2671	Transitional Cell Carcinoma
4335	2673	Cystic Nephroma
4336	2676	Papillary Pseudomucinous Cystadenoma
4337	2678	Adult Mesoblastic Nephroma
4338	2679	Dysembryoplastic Neuroepithelial Tumor
4339	268	Liver Angiosarcoma
4340	2680	Pediatric Central Nervous System Tumor
4341	2681	Nevus
4342	2682	Intracystic Papillary Adenoma
4343	2683	Adenofibroma
4344	2685	Ossifying Fibromyxoid Tumor
4345	2687	Skin Sarcoma
4346	2689	Lymphangiosarcoma
4347	2691	Myoma
4348	2696	Leydig Cell Tumor
4349	2697	Renal Adenoma
4350	2698	Nephrogenic Adenofibroma
4351	2699	Sinonasal Papilloma
4352	270	Liver Sarcoma
4353	2700	Mucinous Adenofibroma
4354	2701	Nodular Tenosynovitis
4355	2702	Pigmented Villonodular Synovitis
4356	2703	Synovitis
4357	2704	Malignant Giant Cell Tumor Of The Tendon Sheath
4358	2705	Malignant Giant Cell Tumor
4359	2706	Synovium Cancer
4360	2708	Mushroom Workers' Lung
4361	271	Hemangioma Of Liver
4362	2710	Sick Building Syndrome
4363	2712	Phimosis
4364	2717	Bloom Syndrome
4365	2718	Hemopneumothorax
4366	272	Hepatic Vascular Disease
4367	2722	Acrodermatitis
4368	2723	Dermatitis
4369	2724	Port-wine Stain
4370	2725	Capillary Hemangioma
4371	2726	Acne Nevus
4372	2728	Pilosebaceous Hamartoma
4373	2729	Dyskeratosis Congenita
4374	2730	Epidermolysis Bullosa
4375	2731	Vesiculobullous Skin Disease
4376	2732	Rothmund-Thomson Syndrome
4377	2733	Skin Atrophy
4378	2734	Keratosis Follicularis
4379	2736	Hajdu-Cheney Syndrome
4380	2737	Witkop-Von Sallmann Disease
4381	2738	Pseudoxanthoma Elasticum
4382	2739	Gilbert Syndrome
4383	2741	Bilirubin Metabolic Disorder
4384	2742	Auditory System Disease
4385	2743	Pyeloureteritis Cystica
4386	2744	Pyelitis
4387	2745	Narcissistic Personality Disorder
4388	2746	Glycogen Storage Disease V
4389	2747	Glycogen Storage Disease
4390	2748	Glycogen Storage Disease III
4391	2749	Glycogen Storage Disease I
4392	275	Gastric Hemangioma
4393	2750	Glycogen Storage Disease IV
4394	2751	Glycogen Storage Disease VIII
4395	2752	Glycogen Storage Disease II
4396	2753	Nervous System Lysosomal Storage Disease
4397	2754	Glycogen Storage Disease VI
4398	2755	Mycobacterium Avium Complex Disease
4399	2756	Paratuberculosis
4400	2757	Mycobacterium Infectious Disease
4401	2762	Bone Carcinoma
4402	2763	Ethmoid Sinus Squamous Cell Carcinoma
4403	2764	Ethmoid Sinus Adenoid Cystic Carcinoma
4404	2766	Ethmoid Sinus Adenocarcinoma
4405	2768	Transient Tic Disorder
4406	2769	Tic Disorder
4407	277	Chorioangioma
4408	2770	Diaper Rash
4409	2771	Atopic Dermatitis And Related Conditions
4410	2772	Irritant Dermatitis
4411	2773	Contact Dermatitis
4412	2775	Long Bone Adamantinoma
4413	2776	Adamantinoma
4414	2777	Malignant Neoplasm Of Short Bones Of Upper Limb
4415	2778	Tumors Of Body Of Uterus, With Delivery
4416	2779	Tumors Of Body Of Uterus Complicating Pregnancy, Childbirth, Or The Puerperium
4417	2780	Rectosigmoid Junction Neoplasm
4418	2781	Rectosigmoid Cancer
4419	2782	Rectosigmoid Junction Cancer
4420	2784	Lung Sarcoma
4421	2785	Dandy-Walker Syndrome
4422	2786	Cerebellar Disease
4423	2788	Ciliophora Infectious Disease
4424	2789	Parasitic Protozoa Infectious Disease
4425	2790	Necatoriasis
4426	2791	Hookworm Infectious Disease
4427	2797	Idiopathic Interstitial Pneumonia
4428	2798	Bronchiolitis Obliterans Organizing Pneumonia
4429	2799	Bronchiolitis Obliterans
4430	28	Endocrine System Disease
4431	280	Ear Tuberculosis
4432	2800	Acute Interstitial Pneumonia
4433	2801	Nonspecific Interstitial Pneumonia
4434	2809	Primary Bartonellaceae Infectious Disease
4435	2810	Middle Lobe Syndrome
4436	2814	Malignant Neoplasm Of Acoustic Nerve
4437	2815	Cranial Nerve Malignant Neoplasm
4438	2816	Malignant Oculomotor Nerve Tumor
4439	2817	Cranial Nerve III Tumor
4440	2825	Nose Disease
4441	2828	Acalculous Cholecystitis
4442	283	Leukemic Reticuloendotheliosis Of Intra-abdominal Lymph Nodes
4443	2832	Geotrichosis
4444	2833	Dehydration Polycythemia
4445	2834	Acquired Polycythemia
4446	2835	Polycythemia Due To Hypoxia
4447	2838	Stress Polycythemia
4448	2839	Erythropoietin Polycythemia
4449	284	Malignant Neoplasm Of Abdomen
4450	2841	Asthma
4451	2842	Jervell-Lange Nielsen Syndrome
4452	2843	Long QT Syndrome
4453	2846	Bruxism
4454	2848	Melancholia
4455	285	Hairy Cell Leukemia
4456	2853	Atrophy Of Thyroid
4457	2855	Hyperthyroxinemia
4458	2856	Euthyroid Sick Syndrome
4459	2857	Abscess Of Thyroid
4460	2859	Hemoglobin C Disease
4461	2860	Hemoglobinopathy
4462	2861	Congenital Nonspherocytic Hemolytic Anemia
4463	2862	Glucosephosphate Dehydrogenase Deficiency
4464	287	Vision Disorder
4465	2870	Endometrial Adenocarcinoma
4466	2871	Endometrial Carcinoma
4467	2873	Metastatic Tumor To The Larynx
4468	2874	Metastasis To The Neck
4469	2876	Laryngeal Squamous Cell Carcinoma
4470	2877	Larynx Sarcoma
4471	2878	Throat Carcinoma
4472	2879	Nodular Degeneration Of Cornea
4473	288	Endometriosis Of Uterus
4474	2880	Hantavirus Infectious Disease
4475	2882	Cysts Of Iris, Ciliary Body And Anterior Chamber
4476	2883	Prostatic Adenoma
4477	2885	Benign Prostate Phyllodes Tumor
4478	2887	Prostate Leiomyoma
4479	2889	Retrocochlear Disease
4480	289	Endometriosis
4481	2890	Primary Klebsiella Infectious Disease
4482	2891	Thyroid Adenoma
4483	2892	Exocervical Carcinoma
4484	2893	Cervix Carcinoma
4485	2898	Commensal Streptococcal Infectious Disease
4486	2905	Commensal Escherichia Coli Infectious Disease
4487	2906	Rhabditida Infectious Disease
4488	2907	Goldenhar Syndrome
4489	2908	Treacher Collins Syndrome
4490	2910	Septic Abortion
4491	2913	Acute Pancreatitis
4492	2914	Immune System Disease
4493	2916	Hypersensitivity Reaction Type IV Disease
4494	2917	Cryoglobulinemia
4495	2918	Paraproteinemia
4496	292	Lacrimal System Cancer
4497	2920	Membranoproliferative Glomerulonephritis
4498	2921	Glomerulonephritis
4499	2926	Klippel-Trenaunay Syndrome
4500	2929	Newcastle Disease
4501	293	Lacrimal Gland Carcinoma
4502	2930	Avulavirus Infectious Disease
4503	2934	Aleutian Mink Disease
4504	2935	Chediak-Higashi Syndrome
4505	2936	Parvoviridae Infectious Disease
4506	2937	Human Herpesvirus 8 Infectious Disease
4507	2938	Epstein-Barr Virus Infectious Disease
4508	2939	Herpesviridae Infectious Disease
4509	294	Lacrimal Gland Cancer
4510	2942	Bronchiolitis
4511	2943	Poxviridae Infectious Disease
4512	2945	Severe Acute Respiratory Syndrome
4513	2946	Coronavirus Infectious Disease
4514	2947	Yellow Fever Virus Infectious Disease
4515	2948	Coronaviridae Infectious Disease
4516	2949	Nidovirales Infectious Disease
4517	295	Eye Carcinoma
4518	2950	Orbivirus Infectious Disease
4519	2951	Motion Sickness
4520	2952	Inner Ear Disease
4521	2956	Intra-abdominal Lymphangioma
4522	2957	Pulmonary Tuberculosis
4523	2958	Environmental Illness
4524	2959	Hyperimmunoglobulin Syndrome
4525	296	Mixed Lacrimal Gland Cancer
4526	2960	Photosensitive Trichothiodystrophy
4527	2961	DNA Repair Deficiency
4528	2962	Cockayne Syndrome
4529	2964	Periarthritis
4530	2965	Bursitis
4531	297	Pleomorphic Adenoma Carcinoma
4532	2972	Renal Artery Obstruction
4533	2973	Kidney Cortex Necrosis
4534	2974	Multicystic Dysplastic Kidney
4535	2975	Cystic Kidney
4536	2976	Glomerular Vascular Disorder
4537	2977	Primary Hyperoxaluria
4538	2978	Carbohydrate Metabolic Disorder
4539	298	Lacrimal Gland Adenocarcinoma
4540	2980	Bone Marrow Tansplantation Nephropathy
4541	2981	Kidney Papillary Necrosis
4542	2982	Perinephritis
4543	2983	Anuria
4544	2985	Chronic Rejection Of Renal Transplant
4545	2986	IgA Glomerulonephritis
4546	2987	Familial Mediterranean Fever
4547	2988	Antiphospholipid Syndrome
4548	2989	Atypical Small Acinar Proliferation Of The Prostate Gland
4549	299	Adenocarcinoma
4550	2990	Tumor Of Specialized Prostatic Stroma
4551	2991	Stromal Neoplasm
4552	2992	Prostate Neuroendocrine Neoplasm
4553	2994	Germ Cell Cancer
4554	2995	Ovarian Mixed Germ Cell-sex Cord Neoplasm
4555	2996	Mixed Germ Cell-sex Cord Neoplasm
4556	2997	Sertoli-Leydig Cell Tumor
4557	2998	Testicular Cancer
4558	2999	Granulosa Cell Tumor
4559	3	Disease By Environmental Exposure
4560	3001	Female Reproductive Endometrioid Cancer
4561	3002	Ovary Neuroendocrine Neoplasm
4562	3003	Nipple Neoplasm
4563	3004	Breast Myoepithelial Neoplasm
4564	3007	Breast Ductal Carcinoma
4565	3008	Invasive Ductal Carcinoma
4566	3009	Breast Neuroendocrine Neoplasm
4567	3010	Lobular Neoplasia
4568	3011	Breast Granular Cell Tumor
4569	3012	Li-Fraumeni Syndrome
4570	3013	Intraductal Breast Neoplasm
4571	3015	Breast Papillary Neoplasm
4572	3016	Breast Malignant Phyllodes Tumor
4573	3017	Breast Sarcoma
4574	3019	Postpartum Acute Renal Failure
4575	302	Substance Abuse
4576	3020	Complication Of Labor And/or Delivery
4577	3021	Acute Kidney Failure
4578	3022	Complication Of The Puerperium
4579	3024	Prostatic Acinar Adenocarcinoma
4580	3025	Acinar Cell Carcinoma
4581	3026	Metastatic Prostatic Adenocarcinoma
4582	3027	Metastatic Adenocarcinoma
4583	3028	Intramucosal Adenocarcinoma Colon Adenoma
4584	3029	Colon Mucinous Adenocarcinoma
4585	303	Substance-related Disorder
4586	3030	Mucinous Adenocarcinoma
4587	3033	Colon Signet Ring Adenocarcinoma
4588	3038	Submucosal Invasive Colon Adenocarcinoma
4589	3039	Cecum Adenocarcinoma
4590	3042	Allergic Contact Dermatitis
4591	3044	Food Allergy
4592	3047	Wissler's Syndrome
4593	3049	Churg-Strauss Syndrome
4594	305	Carcinoma
4595	3052	Balkan Nephropathy
4596	3055	Paratyphoid Fever
4597	3056	Paramyxoviridae Infectious Disease
4598	306	Dyskinetic Syndrome
4599	3067	Taste Disorder
4600	3068	Glioblastoma Multiforme
4601	3069	Astrocytoma
4602	3070	Malignant Glioma
4603	3071	Gliosarcoma
4604	3072	Secondary Glioblastoma Multiforme
4605	3073	Brain Glioblastoma Multiforme
4606	3074	Giant Cell Glioblastoma
4607	3076	Adult Astrocytic Tumour
4608	3077	Anaplastic Childhood Astrocytoma
4609	3078	Grade III Astrocytoma
4610	3079	Juvenile Astrocytoma
4611	308	Early Myoclonic Encephalopathy
4612	3081	Cystic Lymphangioma
4613	3082	Interstitial Lung Disease
4614	3083	Chronic Obstructive Pulmonary Disease
4615	3086	Gingival Overgrowth
4616	3087	Gingivitis
4617	3089	Granulomatous Orchitis
4618	3090	Testicular Non-neoplastic Disease
4619	3091	Acinetobacter Infectious Disease
4620	3092	Opportunistic Moraxellaceae Infectious Disease
4621	3093	Nervous System Cancer
4622	3094	Neuroepithelial Neoplasm
4623	3095	Germ Cell And Embryonal Cancer
4624	3096	Stenosis Of Lacrimal Sac
4625	3097	Stenosis And Insufficiency Of Lacrimal Passage
4626	3098	Small Cell Sarcoma
4627	310	MERRF Syndrome
4628	3100	Ureaplasma Urealyticum Urethritis
4629	3101	Primary Mycoplasmatales Infectious Disease
4630	3102	Cervical Rib Syndrome
4631	3103	Thoracic Outlet Syndrome
4632	3106	Nematoda Infectious Disease
4633	3107	Toxascariasis
4634	3108	Ascaridiasis
4635	3109	Idiopathic CD4-positive T-lymphocytopenia
4636	3110	Papillary Cystadenocarcinoma
4637	3111	Cystadenocarcinoma
4638	3112	Papillary Adenocarcinoma
4639	3113	Papillary Carcinoma
4640	3114	Serous Cystadenocarcinoma
4641	3115	Urinary Tract Transitional Cell Cancer
4642	3116	Kidney Benign Neoplasm
4643	3117	Hepatobiliary Benign Neoplasm
4644	3118	Hepatobiliary Disease
4645	3119	Gastrointestinal System Cancer
4646	312	Tenosynovitis Of Foot And Ankle
4647	3120	Gallbladder Papillomatosis
4648	3121	Gallbladder Cancer
4649	3122	Gastric Outlet Obstruction
4650	3125	Multiple Endocrine Neoplasia
4651	3127	Proctitis
4652	3128	Anus Disease
4653	313	Synovitis And Tenosynovitis
4654	3132	Porphyria Cutanea Tarda
4655	3133	Acute Porphyria
4656	3134	Facial Dermatosis
4657	3136	Scalp Dermatosis
4658	3137	Multiple Symmetrical Lipomatosis
4659	3138	Acanthosis Nigricans
4660	314	Tenosynovial Giant Cell Tumor
4661	3140	Scleredema Adultorum
4662	3141	Mucinoses
4663	3142	Leg Dermatosis
4664	3143	Eczematous Skin Disease
4665	3144	Cutis Laxa
4666	3145	Hyperlipoproteinemia Type III
4667	3146	Lipid Metabolism Disorder
4668	3148	Dermal Unilateral Segmental Cavernous Angioma
4669	3149	Keratoacanthoma
4670	315	Synovium Neoplasm
4672	3153	Lipomatosis
4673	3156	Incontinentia Pigmenti Achromians
4674	3157	Congenital Melanocytic Nevus
4675	3158	Hand Dermatosis
4676	3159	Photosensitivity Disease
4677	3162	Malignant Spindle Cell Melanoma
4678	3163	Spindle Cell Cancer
4679	3164	Hair Nevus
4680	3165	Skin Benign Neoplasm
4681	3166	Leukemoid Reaction
4682	3168	Squamous Cell Neoplasm
4683	3169	Papillary Epithelial Neoplasm
4684	3171	Respiratory Tract Papilloma
4685	3172	Papillary Adenoma
4686	3173	Fallopian Tube Serous Papilloma
4687	3177	Verrucous Papilloma
4688	3178	Skin Papilloma
4689	3179	Inverted Papilloma
4690	318	Progressive Muscular Atrophy
4691	3181	Oligodendroglioma
4692	3183	Childhood Oligodendroglioma
4693	3184	Spinal Cord Oligodendroglioma
4694	3185	Spinal Cord Glioma
4695	3186	Adult Oligodendroglioma
4696	3187	Brain Oligodendroglioma
4697	319	Spinal Cord Disease
4698	3191	Nemaline Myopathy
4699	3192	Neurilemmoma
4700	3193	Peripheral Nerve Sheath Neoplasm
4701	3196	Cellular Schwannoma
4702	3197	Schwannoma Of Twelfth Cranial Nerve
4703	3198	Hypoglossal Nerve Neoplasm
4704	3199	C-P Angle Neurinoma
4705	320	Vascular Myelopathy
4706	3200	Cerebellopontine Angle Tumor
4707	3201	Sympathetic Neurilemmoma
4708	3202	Neurilemmoma Of The Fifth Cranial Nerve
4709	3203	Macrocystic Neurilemmoma
4710	3204	Neurilemmomatosis
4711	3205	Melanotic Neurilemmoma
4712	3206	Plexiform Schwannoma
4713	3208	Sensation Disorder
4714	3209	Junctional Epidermolysis Bullosa
4715	321	Tropical Spastic Paraparesis
4716	3210	Pelizaeus-Merzbacher Disease
4717	3211	Lysosomal Storage Disease
4718	3212	Hereditary Central Nervous System Demyelinating Disease
4719	3213	Demyelinating Disease
4720	3215	Infectious Bovine Rhinotracheitis
4721	3216	Jejunal Somatostatinoma
4722	3217	Small Intestinal Delta Cell Somatostatin Producing Tumor
4723	3218	Jejunal Neoplasm
4724	322	Myelitis
4725	3222	Causalgia
4726	3223	Complex Regional Pain Syndrome
4727	3225	Tracheal Disease
4728	3227	Tracheal Stenosis
4729	3229	Gastric Dilatation
4730	323	Human T-lymphotropic Virus 1 Infectious Disease
4731	3230	High Pressure Neurological Syndrome
4732	3231	Occupational Disease
4733	3234	Central Nervous System Lymphoma
4734	3239	Pigmented Spindle Cell Nevus
4735	3240	Aspiration Pneumonitis
4736	3241	Lipid Pneumonia
4737	3246	Embryonal Rhabdomyosarcoma
4738	3247	Rhabdomyosarcoma
4739	3250	Pleomorphic Rhabdomyosarcoma
4740	3251	Prostate Embryonal Rhabdomyosarcoma
4741	3252	Prostate Rhabdomyosarcoma
4742	3253	Embryonal Extrahepatic Bile Duct Rhabdomyosarcoma
4743	3254	Bile Duct Rhabdomyosarcoma
4744	3255	Botryoid Rhabdomyosarcoma
4745	3256	Embryonal Childhood Rhabdomyosarcoma
4746	3257	Pediatric Rhabdomyosarcoma
4747	3258	Orbit Embryonal Rhabdomyosarcoma
4748	3259	Orbit Rhabdomyosarcoma
4749	326	Ischemia
4750	3260	Spindle Cell Rhabdomyosarcoma
4751	3261	Job's Syndrome
4752	3262	Phagocyte Bactericidal Dysfunction
4753	3263	Piebaldism
4754	3264	Subacute Leukemia
4755	3265	Chronic Granulomatous Disease
4756	3267	Mucinous Ovarian Cystadenoma
4757	3269	Ovarian Cystadenoma
4758	327	Syringomyelia
4759	3274	Proliferative Type Fibrocystic Change Of Breast
4760	3275	Thymoma
4761	3276	Thymus Epithelial Cancer
4762	3277	Thymus Cancer
4763	3278	Encapsulated Thymoma
4764	3279	Spindle Cell Thymoma
4765	3280	Mixed Type Thymoma
4766	3281	Combined Thymoma
4767	3282	Dendritic Cell Thymoma
4768	3283	Invasive Malignant Thymoma
4769	3284	Thymic Carcinoma
4770	3292	Monkeypox
4771	3293	Lumpy Skin Disease
4772	3295	Fowlpox
4773	3296	Infectious Ectromelia
4774	3297	Infectious Myxomatosis
4775	3298	Vaccinia
4776	3299	Yersinia Pseudotuberculosis Infectious Disease
4777	3300	Yersinia Infectious Disease
4778	3301	Gonadoblastoma
4779	3302	Chordoma
4780	3303	Notochordal Cancer
4781	3304	Germinoma
4782	3305	Teratocarcinoma
4783	3306	Mixed Germ Cell Cancer
4784	3307	Teratoma
4785	3308	Embryonal Carcinoma
4786	3309	Neurodermatitis
4787	331	Central Nervous System Disease
4788	3310	Atopic Dermatitis
4789	3312	Bipolar Disorder
4790	3314	Angiomyolipoma
4791	3315	Lipoma
4792	3316	Perivascular Tumor
4793	3317	Hepatic Angiomyolipoma
4794	3318	Epithelioid Type Angiomyolipoma
4795	3319	Lymphangioleiomyomatosis
4796	332	Amyotrophic Lateral Sclerosis
4797	3320	Tay-Sachs Disease
4798	3321	Gangliosidosis GM2
4799	3322	Gangliosidosis GM1
4800	3323	Sandhoff Disease
4801	3324	Mood Disorder
4802	3325	Hyperglobulinemic Purpura
4803	3326	Purpura
4804	3327	Partial Motor Epilepsy
4805	3328	Temporal Lobe Epilepsy
4806	3329	Benign Epilepsy With Centrotemporal Spikes
4807	333	Chronic Factitious Illness With Physical Symptoms
4808	3330	Partial Sensory Epilepsy
4809	3331	Frontal Lobe Epilepsy
4810	3332	Haemonchiasis
4811	334	Histrionic Personality Disorder
4812	3340	Lymphangioendothelioma
4813	3341	Osteitis Fibrosa
4814	3342	Bone Inflammation Disease
4815	3343	Mucolipidosis
4816	3345	Xanthomatosis
4817	3347	Osteosarcoma
4818	3349	Osteogenic Neoplasm
4819	3350	Mesenchymal Cell Neoplasm
4820	3351	Bone Angioendothelial Sarcoma
4821	3352	Malignant Fibrous Histiocytoma Of Bone
4822	3354	Fibrosarcoma Of Bone
4823	3355	Fibrosarcoma
4824	3356	Localized Osteosarcoma
4825	3357	Extraosseous Osteosarcoma
4826	3359	Malignant Extraskeletal Cartilaginous And Osseous Tumor
4827	336	Non-traumatic Tendon Rupture
4828	3360	Multifocal Osteogenic Sarcoma
4829	3361	Pediatric Osteosarcoma
4830	3362	Coronary Aneurysm
4831	3365	Recurrent Osteosarcoma
4832	3367	Bone Leiomyosarcoma
4833	3368	Bone Ewing's Sarcoma
4834	3369	Peripheral Primitive Neuroectodermal Tumor
4835	337	Spinal Accessory Nerve Neoplasm
4836	3371	Chondrosarcoma
4837	3372	Chondroblastic Osteosarcoma
4838	3373	Juxtacortical Osteosarcoma
4839	3374	Peripheral Osteosarcoma
4840	3376	Bone Osteosarcoma
4841	3377	Small Cell Osteogenic Sarcoma
4842	3378	Conventional Central Osteosarcoma
4843	3379	Metachronous Osteosarcoma Of The Bone
4844	338	Cranial Nerve Neoplasm
4845	3381	Liposarcoma Of Bone
4846	3382	Liposarcoma
4847	3384	Metastatic Osteosarcoma
4848	3385	Bacterial Vaginosis
4849	3388	Periodontal Disease
4850	3389	Papillon-Lefevre Disease
4851	339	Accessory Nerve Disease
4852	3390	Palmoplantar Keratosis
4853	3393	Coronary Artery Disease
4854	3401	Inappropriate ADH Syndrome
4855	3402	Ectopic Hormone Secretion Syndrome Associated With Neoplasia
4856	3403	Hypergammaglobulinemia
4857	3404	Benign Monoclonal Gammopathy
4858	3405	Histiocytosis
4859	3407	Carotid Artery Disease
4860	341	Peripheral Vascular Disease
4861	3410	Carotid Artery Thrombosis
4862	3412	Infectious Canine Hepatitis
4863	3413	Alpha-mannosidosis
4864	3414	Mannosidase Deficiency Disease
4865	3417	Glossopharyngeal Nerve Neoplasm
4866	3418	Glossopharyngeal Nerve Disease
4867	3419	Optic Nerve Neoplasm
4868	342	Subclavian Artery Aneurysm
4869	3420	Neoplasm Of Visual Pathway
4870	3421	Trochlear Nerve Neoplasm
4871	3426	Vestibular Disease
4872	3428	Granulomatous Myositis
4873	3429	Inclusion Body Myositis
4874	3431	Cerebritis
4875	3436	Viral Laryngitis
4876	3437	Laryngitis
4877	344	Disease Of Biological Process
4878	3443	Mammary Paget's Disease
4879	3444	Scrotum Paget's Disease
4880	3445	Scrotal Carcinoma
4881	3446	Anal Paget's Disease
4882	3447	Anus Adenocarcinoma
4883	3448	Penis Paget's Disease
4884	3449	Penis Carcinoma
4885	345	Uterine Disease
4886	3450	Cutaneous Paget's Disease
4887	3451	Skin Carcinoma
4888	3454	Brain Infarction
4889	3456	Cervix Erosion
4890	3457	Invasive Lobular Carcinoma
4891	3458	Breast Adenocarcinoma
4892	3459	Breast Carcinoma
4893	3461	Breast Hamartoma
4894	3462	Hamartoma
4895	3463	Breast Disease
4896	3464	Hamartoma Of Skin Appendage
4897	3465	Congenital Nevus Of Skin
4898	3466	Cartilaginous Hamartoma
4899	3467	Mesenchymal Hamartoma
4900	3470	Hamartoma Of Central Nervous System
4901	3472	Hamartoma Of Lung
4902	3473	Brain Hamartoma
4903	3476	Lipomatous Hamartoma
4904	3478	Iris Cancer
4905	3479	Uveal Cancer
4906	348	Blepharochalasis
4907	3480	Uveal Disease
4908	3481	Septicemic Plague
4909	3482	Plague
4910	3485	Oxyurida Infectious Disease
4911	3486	Necrobiosis Lipoidica
4912	3487	Metabolic Skin Disease
4913	3488	Cellulitis
4914	349	Systemic Mastocytosis
4915	3490	Noonan Syndrome
4916	3491	Turner Syndrome
4917	3492	Mixed Connective Tissue Disease
4918	3493	Signet Ring Cell Adenocarcinoma
4919	3494	Bile Duct Signet Ring Cell Carcinoma
4920	3495	Extrahepatic Bile Duct Adenocarcinoma
4921	3497	Pancreatic Signet Ring Cell Adenocarcinoma
4922	3498	Pancreatic Ductal Adenocarcinoma
4923	3499	Gallbladder Signet Ring Cell Adenocarcinoma
4924	350	Mastocytosis
4925	3500	Gallbladder Adenocarcinoma
5045	3687	MELAS Syndrome
4926	3501	Ampullary Signet Ring Cell Adenocarcinoma
4927	3502	Ampulla Of Vater Adenocarcinoma
4928	3503	Breast Signet Ring Cell Adenocarcinoma
4929	3504	Prostate Signet Ring Cell Adenocarcinoma
4930	3507	Dermatofibrosarcoma Protuberans
4931	3508	Stricture Or Kinking Of Ureter
4932	3512	Neurofibrosarcoma
4933	3516	Adult Fibrosarcoma
4934	3517	Conventional Fibrosarcoma
4935	3519	Non-metastatic Fibrosarcoma
4936	3520	Pediatric Fibrosarcoma
4937	3521	Childhood Soft Tissue Sarcoma
4938	3522	Lateral Medullary Syndrome
4939	3523	Brain Stem Infarction
4940	3525	Middle Cerebral Artery Infarction
4941	3526	Cerebral Infarction
4942	3527	Cerebral Arterial Disease
4943	3528	Anterior Cerebral Artery Infarction
4944	3529	Central Core Myopathy
4945	3530	Chronic Wasting Disease
4946	3532	Peste Des Petits Ruminants Infectious Disease
4947	3533	Morbillivirus Infectious Disease
4948	3534	Lafora Disease
4949	3535	Unverricht-Lundborg Syndrome
4950	3540	Choroid Plexus Cancer
4951	3541	Cerebral Ventricle Cancer
4952	3542	Adult Choroid Plexus Cancer
4953	3544	Atypical Choroid Plexus Papilloma
4954	3545	Childhood Choroid Plexus Cancer
4955	3546	Somatosensory Disorder
4956	355	Mast-cell Sarcoma
4957	3557	Superior Mesenteric Artery Syndrome
4958	3558	Duodenal Obstruction
4959	3559	Pseudomyxoma Peritonei
4960	356	Intrathoracic Lymph Node Mast Cell Malignancy
4961	3565	Meningioma
4962	3568	Viral Hemorrhagic Septicemia
4963	357	Upper Limb Lymph Node Mast Cell Malignancy
4964	3571	Liver Cancer
4965	3572	Intracranial Sinus Thrombosis
4966	3574	Lateral Sinus Thrombosis
4967	3575	Cavernous Sinus Thrombosis
4968	3576	Sagittal Sinus Thrombosis
4969	3577	Sertoli Cell Tumor
4970	3578	Ovarian Gonadoblastoma
4971	3579	Testicular Gonadoblastoma
4972	3580	Testicular Mixed Germ Cell-sex Cord-stromal Neoplasm
4973	3583	Enterotoxemia
4974	3584	Commensal Clostridium Infectious Disease
4975	3586	Puerperal Pyrexia Of Unknown Origin
4976	3587	Pancreatic Ductal Carcinoma
4977	3589	Poor Prognosis Metastatic Gestational Trophoblastic Tumor
4978	3590	Gestational Trophoblastic Neoplasm
4979	3591	Nonmetastatic Gestational Trophoblastic Tumor
4980	3593	Epithelioid Trophoblastic Tumor
4981	3594	Choriocarcinoma
4982	3596	Placental Site Trophoblastic Tumor
4983	3597	Good Prognosis Metastatic Gestational Trophoblastic Tumor
4984	3602	Toxic Encephalopathy
4985	3603	Mucinous Cystadenocarcinoma
4986	3604	Ovarian Mucinous Cystadenocarcinoma
4987	3605	Ovarian Cystadenocarcinoma
4988	3606	Ovarian Mucinous Adenocarcinoma
4989	3607	Appendix Mucinous Cystadenocarcinoma
4990	3608	Appendix Adenocarcinoma
4991	3609	Breast Mucinous Cystadenocarcinoma
4992	361	Cervix Endometriosis
4993	3610	Breast Mucinous Carcinoma
4994	3611	Acute Retinal Necrosis Syndrome
4995	3612	Retinitis
4996	3613	Canavan Disease
4997	3614	Kallmann Syndrome
4998	3615	Infiltrating Angiolipoma
4999	3616	Angiolipoma
5000	3617	Epidural Spinal Canal Angiolipoma
5001	3618	Epidural Neoplasm
5002	3620	Central Nervous System Cancer
5003	3621	Central Nervous System Neuroepithelial Neoplasm
5004	3627	Aortic Aneurysm
5005	363	Uterine Cancer
5006	3633	Beta-mannosidosis
5007	3635	Congenital Myasthenic Syndrome
5008	3636	Commensal Desulfovibrionaceae Infectious Disease
5009	3637	Childhood Spinal Cord Tumor
5010	3639	Spinal Cord Intramedullary Teratoma
5011	364	Spontaneous Rupture Of Bladder
5012	3640	Central Nervous System Teratoma
5013	3641	Conus Medullaris Neoplasm
5014	3642	Empty Sella Syndrome
5015	3643	Sella Turcica Neoplasm
5016	3644	Hypothalamic Neoplasm
5017	3646	Necrosis Of Pituitary
5018	3648	Inborn Errors Pyruvate Metabolism
5019	3649	Pyruvate Decarboxylase Deficiency
5020	365	Bladder Disease
5021	3650	Lactic Acidosis
5022	3651	Pyruvate Carboxylase Deficiency Disease
5023	3652	Leigh Disease
5024	3653	Laboratory Infectious Disease
5025	3659	Sialuria
5026	366	Olfactory Nerve Neoplasm
5027	3660	Wheat Allergic Reaction
5028	3663	Cutaneous Mastocytosis
5029	3664	Mast Cell Neoplasm
5030	3665	Diffuse Cutaneous Mastocytosis
5031	3666	Cutaneous Solitary Mastocytoma
5032	3667	Cardiovirus Infectious Disease
5033	3668	Picornaviridae Infectious Disease
5034	3669	Intermittent Claudication
5035	367	Olfactory Nerve Disease
5036	3671	Pericoronitis
5037	3672	Rhabdoid Cancer
5038	3674	Kidney Rhabdoid Cancer
5039	3675	Childhood Kidney Neoplasm
5040	3677	Pulmonary Plasma Cell Granuloma
5041	368	Cerebrum Cancer
5042	3680	Malignant Neoplasm Of Lip, Oral Cavity And Pharynx
5043	3683	Lung Benign Neoplasm
5044	3686	Helicobacter Pylori Infectious Disease
5046	3688	Plexopathy
5047	3689	Brachial Plexus Neuritis
5048	369	Olfactory Neuroblastoma
5049	3690	Brachial Plexus Neuropathy
5050	3691	Anal Colloid Adenocarcinoma
5051	3692	Anal Canal Adenocarcinoma
5052	3693	Ampulla Of Vater Mucinous Adenocarcinoma
5053	3694	Adnexal Mucinous Adenocarcinoma
5054	3695	Adnexa Adenocarcinoma
5055	3696	Acute Sanguinous Otitis Media
5056	3697	Acute Transudative Otitis Media
5057	3698	Bile Duct Mucinous Adenocarcinoma
5058	3699	Uterine Ligament Mucinous Adenocarcinoma
5059	37	Skin Disease
5060	370	Malignant Olfactory Nerve Tumor
5061	3700	Uterine Ligament Adenocarcinoma
5062	3701	Cervical Mucinous Adenocarcinoma
5063	3702	Cervical Adenocarcinoma
5064	3703	Prostate Colloid Adenocarcinoma
5065	3704	Fallopian Tube Mucinous Adenocarcinoma
5066	3705	Fallopian Tube Mucinous Tumor
5067	3706	Fallopian Tube Adenocarcinoma
5068	3707	Endometrial Mucinous Adenocarcinoma
5069	3709	Rectum Mucinous Adenocarcinoma
5070	371	Extracranial Neuroblastoma
5071	3710	Bladder Colloid Adenocarcinoma
5072	3711	Bladder Adenocarcinoma
5073	3713	Ovary Adenocarcinoma
5074	3715	Non-suppurative Otitis Media And Eustachian Tube Disorder
5075	3716	Mucinous Stomach Adenocarcinoma
5076	3717	Gastric Adenocarcinoma
5077	3718	Arterivirus Infectious Disease
5078	3720	Extramedullary Plasmacytoma
5079	3721	Plasmacytoma
5080	3722	Solitary Osseous Plasmacytoma
5081	3723	Solitary Plasmacytoma Of Chest Wall
5082	3726	Puerperal Disease
5083	3728	Acute Allergic Sanguinous Otitis Media
5084	3729	Respirovirus Infectious Disease
5085	373	Infant Nutrition Disorder
5086	3730	Pneumonic Pasteurellosis
5087	3731	Primary Pasteurellaceae Infectious Disease
5088	3732	Bovine Respiratory Disease Complex
5089	3733	Theileriasis
5090	3737	Verrucous Carcinoma
5091	3739	Human Papillomavirus Related Squamous Cell Carcinoma
5092	374	Nutrition Disease
5093	3740	Vulva Verrucous Carcinoma
5094	3741	Bladder Verrucous Squamous Cell Carcinoma
5095	3742	Bladder Squamous Cell Carcinoma
5096	3743	Cervical Verrucous Carcinoma
5097	3744	Cervical Squamous Cell Carcinoma
5098	3747	Esophagus Verrucous Carcinoma
5099	3748	Esophagus Squamous Cell Carcinoma
5100	3749	Urethral Verrucous Carcinoma
5101	3750	Urethra Squamous Cell Carcinoma
5102	3751	Plantar Verrucous Skin Carcinoma
5103	3752	Larynx Verrucous Carcinoma
5104	3753	Hermansky-Pudlak Syndrome
5105	3755	Antithrombin III Deficiency
5106	3756	Protein C Deficiency
5107	3758	Fusobacterium Infectious Disease
5108	3762	Cytochrome-c Oxidase Deficiency Disease
5109	3763	Hermaphroditism
5110	3764	Denys-Drash Syndrome
5111	3765	Pseudohermaphroditism
5112	3766	Leukorrhea
5113	3767	Vaginal Discharge
5114	3770	Pulmonary Fibrosis
5115	3772	Intraventricular Meningioma
5116	3773	Third Ventricle Chordoid Glioma
5117	3774	Chordoid Glioma
5118	3777	Granuloma Annulare
5119	3781	Anovulation
5120	3783	Coffin-Lowry Syndrome
5121	379	External Ear Disease
5122	3798	Pleural Empyema
5123	3799	Feline Panleukopenia
5124	3800	Avian Leukosis
5125	3803	Crigler-Najjar Syndrome
5126	3805	Porokeratosis
5127	3809	Epidural Spinal Canal Meningioma
5128	381	Arthropathy
5129	3810	Chondrogenic Neoplasm
5130	3812	Mediastinum Chondroma
5131	3813	Central Nervous System Chondroma
5132	3814	Extraskeletal Chondroma
5133	3816	Glossopharyngeal Nerve Paralysis
5134	3817	Cranial Nerve Palsy
5135	3818	Photoallergic Dermatitis
5136	3819	Toxicodendron Dermatitis
5137	3820	Primary Chlamydiaceae Infectious Disease
5138	3821	Posterior Cerebral Artery Infarction
5139	3825	Shwartzman Phenomenon
5140	3827	Congenital Diaphragmatic Hernia
5141	3828	Chromophobe Adenoma
5142	3829	Pituitary Adenoma
5143	3836	Posttransplantation Lymphoproliferative Disease
5144	3837	Benign Lymphoproliferative Disease
5145	3838	Skin Lymphoproliferative Disease
5146	384	Wolff-Parkinson-White Syndrome
5147	3840	Craniopharyngioma
5148	3842	Skull Base Neoplasm
5149	3843	Diencephalic Neoplasm
5150	3844	Pediatric Craniopharyngioma
5151	3845	Childhood Intracranial Neoplasm
5152	3846	Adamantinous Craniopharyngioma
5153	3847	Papillary Craniopharyngioma
5154	3848	Adult Craniopharyngioma
5155	3849	Adult Intracranial Neoplasm
5156	3850	Hemangiopericytic Tumor
5157	3852	Peutz-Jeghers Syndrome
5158	3855	Seminal Vesicle Tumor
5159	3856	Male Reproductive Organ Cancer
5160	3857	Large Cell Medulloblastoma
5161	3859	Relapsed Medulloblastoma
5162	386	Postpericardiotomy Syndrome
5163	3860	Cerebellar Vermis Medulloblastoma
5164	3861	Medullomyoblastoma
5165	3862	FAP Associated Medulloblastoma
5166	3863	Region 17p13 Allelic Loss Associated Medulloblastoma
5167	3864	Adult Medulloblastoma
5168	3865	Adult Central Nervous System Primitive Neuroectodermal Neoplasm
5169	3866	Desmoplastic Medulloblastoma
5170	3867	Nevoid Basal Cell Carcinoma Syndrome Associated Medulloblastoma
5171	3868	Melanotic Medulloblastoma
5172	3869	Childhood Medulloblastoma
5173	3870	Childhood Central Nervous System Primitive Neuroectodermal Neoplasm
5174	3871	Medulloblastoma With Leptomeningeal Spread
5175	3872	Leptomeningeal Metastases
5176	3873	Nodular Medulloblastoma
5177	3875	Thrombophlebitis
5178	3876	Colonic Pseudo-obstruction
5179	3877	Functional Colonic Disease
5180	3878	Intestinal Pseudo-obstruction
5181	3881	Proteus Infectious Disease
5182	3883	Lynch Syndrome
5183	3890	Acute Intermittent Porphyria
5184	3891	Placental Insufficiency
5185	3892	Insulinoma
5186	3893	Hidrocystoma
5187	3895	Apocrine Adenoma
5188	3896	Hidradenoma
5189	3898	Skin Appendage Adenoma
5190	3899	Skin Appendage Neoplasm
5191	390	Obstetric Venous Problem
5192	3901	Vulvitis
5193	3902	Pseudorabies
5194	3904	Bronchus Carcinoma
5195	3905	Lung Carcinoma
5196	3906	Bronchial Neoplasm
5197	3907	Lung Squamous Cell Carcinoma
5198	3908	Non-small Cell Lung Carcinoma
5199	3909	Bronchogenic Lung Adenocarcinoma
5200	3910	Lung Adenocarcinoma
5201	3911	Progeria
5202	3914	Serous Cystadenoma Of Ovary
5203	3916	Borderline Malignancy Serous Cystadenoma
5204	3917	Pancreatic Serous Cystadenoma
5205	3918	Pancreatic Cystadenoma
5206	3919	Pancreatic Serous Cystic Neoplasm
5207	3923	Diffuse Lipomatosis
5208	3924	Main Bronchus Cancer
5209	3925	Steroid Lipomatosis
5210	3926	Mediastinal Lipomatosis
5211	3927	Pelvic Lipomatosis
5212	3928	Adiposis Dolorosa
5213	3930	Otitis Interna
5214	3933	Anterior Compartment Syndrome
5215	3939	Lipomatous Cancer
5216	3944	Arenaviridae Infectious Disease
5217	3946	Pituitary-dependent Cushing's Disease
5218	3947	Adrenal Gland Hyperfunction
5219	3948	Adrenocortical Carcinoma
5220	3950	Adrenal Carcinoma
5221	3951	Acute Myocarditis
5222	3952	Adrenal Cortex Disease
5223	3953	Adrenal Gland Cancer
5224	3959	Adrenal Cortical Adenocarcinoma
5225	396	Loeffler Endocarditis
5226	3962	Follicular Thyroid Carcinoma
5227	3963	Thyroid Carcinoma
5228	3964	Trabecular Follicular Adenocarcinoma
5229	3965	Merkel Cell Carcinoma
5230	3968	Papillary Follicular Thyroid Adenocarcinoma
5231	3969	Papillary Thyroid Carcinoma
5232	397	Restrictive Cardiomyopathy
5233	3973	Thyroid Medullary Carcinoma
5234	3974	Medullary Carcinoma
5235	3978	Extrinsic Cardiomyopathy
5236	398	Cutaneous Tuberculosis
5237	3981	Pantothenate Kinase-associated Neurodegeneration
5238	3982	Meige Syndrome
5239	3983	Oesophagostomiasis
5240	3984	Strongylus Equinus Infectious Disease
5241	3985	Ostertagiasis
5242	399	Tuberculosis
5243	3996	Urinary System Cancer
5244	3997	Urinary Tract Infiltrating Transitional Cell Carcinoma
5245	3998	Bartholin's Gland Transitional Cell Carcinoma
5246	3999	Bartholin's Gland Carcinoma
5247	4	Disease
5248	4000	Ovary Transitional Cell Carcinoma
5249	4001	Ovarian Carcinoma
5250	4003	Schneiderian Carcinoma
5251	4005	Endometrial Transitional Cell Carcinoma
5252	4006	Bladder Transitional Cell Carcinoma
5253	4007	Bladder Carcinoma
5254	4008	Fallopian Tube Transitional Cell Carcinoma
5255	4009	Renal Pelvis And Ureter Transitional Cell Cancer
5256	401	Multidrug-resistant Tuberculosis
5257	4010	Renal Pelvis And Ureter Cancer
5258	4011	Prostate Transitional Cell Carcinoma
5259	4012	Papillary Transitional Carcinoma
5260	4013	Urethra Transitional Cell Carcinoma
5261	4014	Sarcomatoid Transitional Cell Carcinoma
5262	4015	Spindle Cell Carcinoma
5263	402	Oral Tuberculosis
5264	4020	Psychomotor Disease
5265	4022	Ureterocele
5266	4023	Linitis Plastica
5267	4024	Scirrhous Adenocarcinoma
5268	4025	Steatitis
5269	4026	Vitamin E Deficiency
5270	4027	Fetal Distress
5271	4028	Angioma Serpiginosum
5272	4029	Gastritis
5273	403	Mouth Disease
5274	4030	Eosinophilic Gastritis
5275	4031	Eosinophilic Gastroenteritis
5276	4033	Bacterial Gastritis
5277	4034	Fungal Gastritis
5278	4035	Lymphocytic Gastritis
5279	4036	Helicobacter Pylori Gastritis
5280	4037	Necrotizing Gastritis
5281	4038	Granulomatous Gastritis
5282	4039	Crohn's Associated Gastritis
5283	404	Gastrointestinal Tuberculosis
5284	4043	Skeletal Muscle Cancer
5285	4044	Skeletal Muscle Neoplasm
5286	4045	Muscle Cancer
5287	4047	Liver Rhabdomyosarcoma
5413	4232	Extraosseous Ewing's Sarcoma
5288	4048	Central Nervous System Rhabdomyosarcoma
5289	4049	Mediastinum Rhabdomyosarcoma
5290	4050	Mediastinum Sarcoma
5291	4051	Alveolar Rhabdomyosarcoma
5292	4052	Rhabdomyosarcoma Recurrent
5293	4053	Rectum Rhabdomyosarcoma
5294	4054	Prostate Sarcoma
5295	4055	Ectomesenchymoma
5296	4056	Adult Rhabdomyosarcoma
5297	4057	Gallbladder Rhabdomyosarcoma
5298	4058	Gallbladder Sarcoma
5299	4059	Ovary Rhabdomyosarcoma
5300	4060	Breast Rhabdomyosarcoma
5301	4061	Testis Rhabdomyosarcoma
5302	4062	Testis Sarcoma
5303	4064	Bile Duct Sarcoma
5304	4065	Mixed Type Rhabdomyosarcoma
5305	4066	Anus Rhabdomyosarcoma
5306	4067	Anus Sarcoma
5307	407	Hepatic Tuberculosis
5308	4071	Duodenogastric Reflux
5309	4072	Duodenal Disease
5310	4073	Pancreatic Cystadenocarcinoma
5311	4074	Pancreas Adenocarcinoma
5312	4075	Bile Duct Cystadenocarcinoma
5313	4076	Pleomorphic Adenoma Of The Breast
5314	4077	Metastasizing Mixed Tumor Of Salivary Gland
5315	4078	Tricuspid Valve Stenosis
5316	4079	Heart Valve Disease
5317	4080	Tricuspid Valve Insufficiency
5318	4084	Testicular Trophoblastic Tumor
5319	4085	Trophoblastic Neoplasm
5320	4086	Testicular Germ Cell Tumor Non-seminomatous
5321	4087	Testicular Pure Germ Cell Tumor
5322	4088	Torovirus Infectious Disease
5323	409	Liver Disease
5324	4090	Agnosia
5325	4091	Caliciviridae Infectious Disease
5326	4092	Vesicular Exanthema Of Swine
5327	4099	Metastatic Squamous Cell Carcinoma
5328	410	Tuberculous Ascites
5329	4102	Secondary Carcinoma
5330	4104	Rinderpest
5331	4105	Canine Distemper
5332	4106	Commensal Bacteroidaceae Infectious Disease
5333	4107	Primary Flavobacteriaceae Infectious Disease
5334	4109	Tick Infestation
5335	411	Bovine Tuberculosis
5336	4110	Parasitic Ectoparasitic Infectious Disease
5337	4111	Cervical Adenosarcoma
5338	4112	Cervical Carcinosarcoma
5339	4113	Uterine Corpus Adenosarcoma
5340	4114	Uterine Body Mixed Cancer
5341	4115	Ovarian Mesodermal Adenosarcoma
5342	4117	Vaginal Adenosarcoma
5343	4118	Colon Neuroendocrine Neoplasm
5344	4119	Intestinal Neuroendocrine Benign Tumor
5345	412	Atypical Mycobacterium Infectious Disease
5346	4121	West Nile Virus Infectious Disease
5347	4123	Nail Disease
5348	413	Avian Tuberculosis
5349	4131	Erythrasma
5350	4136	Myxosarcoma
5351	4137	Common Bile Duct Disease
5352	4138	Bile Duct Disease
5353	414	Cardiovascular Tuberculosis
5354	4140	Biliary Dyskinesia
5355	4141	Intraorbital Meningioma
5356	4142	Meningioma By Site
5357	4143	Orbital Cancer
5358	4144	Herpes Zoster Dermatitis
5359	4147	Gastrointestinal Adenoma
5360	4148	Gastrointestinal Neuroendocrine Benign Tumor
5361	4151	Skull Base Chordoma
5362	4152	Chondroid Chordoma
5363	4153	Spinal Chordoma
5364	4154	Dentinogenesis Imperfecta
5365	4156	Primary Syphilis
5366	4157	Secondary Syphilis
5367	4159	Skin Cancer
5368	4160	Differentiating Neuroblastoma
5369	4161	Relapsed Neuroblastoma
5370	4163	Ganglioneuroblastoma
5371	4164	Cerebral Neuroblastoma
5372	4165	Regional Neuroblastoma
5373	4166	Syphilis
5374	417	Hypersensitivity Reaction Type II Disease
5375	4170	Localized Resectable Neuroblastoma
5376	4172	Localized Unresectable Neuroblastoma
5377	4173	Disseminated Neuroblastoma
5378	4175	Rh Isoimmunization
5379	4176	Blood Group Incompatibility
5380	418	Systemic Scleroderma
5381	4183	Pseudopseudohypoparathyroidism
5382	4184	Pseudohypoparathyroidism
5383	4186	Articulation Disorder
5384	4188	Echolalia
5385	4189	Mutism
5386	419	Scleroderma
5387	4193	Intracranial Thrombosis
5388	4194	Glucose Metabolism Disease
5389	4195	Hyperglycemia
5390	4196	Femoral Neuropathy
5391	420	Hypertrichosis
5392	4200	Commensal Bifidobacteriales Infectious Disease
5393	4201	Peroneal Neuropathy
5394	4202	Brain Stem Glioma
5395	4203	Brain Stem Cancer
5396	4205	Cerebellum Cancer
5397	4206	Childhood Brain Stem Neoplasm
5398	4207	Childhood Infratentorial Neoplasm
5399	4209	Brainstem Intraparenchymal Clear Cell Meningioma
5400	421	Hair Disease
5401	4210	Clear Cell Meningioma
5402	4211	Posterior Cranial Fossa Meningioma
5403	4217	Malignant Ovarian Brenner Tumor
5404	422	Congenital Structural Myopathy
5405	4223	Pyoderma
5406	4224	Adult Soft Tissue Sarcoma
5407	4226	Endometrial Stromal Sarcoma
5408	4227	Uterine Corpus Endometrial Stromal Sarcoma
5409	4228	Stromal Sarcoma
5410	423	Myopathy
5411	4230	Smooth Muscle Cancer
5412	4231	Histiocytoma
5414	4233	Clear Cell Sarcoma
5415	4235	Spindle Cell Sarcoma
5416	4236	Carcinosarcoma
5417	4238	Malignant Soft Tissue Neoplasm Of Central Nervous System
5418	4239	Alveolar Soft Part Sarcoma
5419	424	Pulmonary Immaturity
5420	4240	Malignant Miscellaneous Mesenchymal Tumor
5421	4242	Kidney Sarcoma
5422	4245	Extraskeletal Cartilaginous And Osseous Tumor
5423	4246	Malignant Mediastinal Mesenchymal Tumor
5424	4247	Coronary Restenosis
5425	4248	Coronary Stenosis
5426	4249	Gerstmann-Straussler-Scheinker Syndrome
5427	425	Certain Conditions Originating In The Perinatal Period
5428	4250	Conjunctivochalasis
5429	4251	Conjunctival Disease
5430	4252	Alexander Disease
5431	4253	Melorheostosis
5432	4254	Osteosclerosis
5433	4256	Rheumatism
5434	4257	Caffey Disease
5435	4258	Weissenbacher-Zweymller Syndrome
5436	4260	Gait Apraxia
5437	4263	Drug-induced Akathisia
5438	4265	Angiomyoma
5439	4266	Intravascular Angioleiomyoma
5440	4267	Akinetic Mutism
5441	4270	Encephalitozoonosis
5442	4271	Microsporidiosis
5443	4273	Bovine Hemorrhagic Syndrome
5444	4274	Pestivirus Infectious Disease
5445	4277	Penis Basal Cell Carcinoma
5446	4278	Scrotum Basal Cell Carcinoma
5447	4279	Infundibulocystic Basal Cell Carcinoma
5448	4280	Nodular Basal Cell Carcinoma
5449	4281	Metatypical Basal Cell Carcinoma
5450	4282	Pigmented Basal Cell Carcinoma
5451	4283	Anal Margin Basal Cell Carcinoma
5452	4284	Anal Margin Carcinoma
5453	4285	Complications Of Pregnancy, Childbirth And The Puerperium
5454	4286	Sebaceous Basal Cell Carcinoma
5455	4287	External Ear Basal Cell Carcinoma
5456	4288	External Ear Carcinoma
5457	4289	Micronodular Basal Cell Carcinoma
5458	429	Gynatresia
5459	4290	Adamantinoid Basal Cell Epithelioma
5460	4291	Fibroepithelial Basal Cell Carcinoma
5461	4292	Morpheaform Basal Cell Carcinoma
5462	4293	Clear Cell Basal Cell Carcinoma
5463	4294	Adenoid Basal Cell Carcinoma
5464	4295	Follicular Basal Cell Carcinoma
5465	4297	Scimitar Syndrome
5466	4298	Respiratory System Abnormality
5467	4299	Infiltrative Basal Cell Carcinoma
5468	4300	Superficial Basal Cell Carcinoma
5469	4301	Vulva Basal Cell Carcinoma
5470	4302	Cystic Basal Cell Carcinoma
5471	4303	Sarcomatoid Basal Cell Carcinoma
5472	4304	Signet Ring Basal Cell Carcinoma
5473	4305	Bone Giant Cell Tumor
5474	4306	Radiculopathy
5475	4307	Polyradiculopathy
5476	4308	Polyradiculoneuropathy
5477	431	Myofascial Pain Syndrome
5478	4310	Smooth Muscle Tumor
5479	4313	Epidermolysis Bullosa Acquisita
5480	4318	Visna
5481	4320	Non-gestational Choriocarcinoma
5482	4321	Large Cell Acanthoma
5483	4322	Pilar Sheath Acanthoma
5484	4323	Epidermolytic Acanthoma
5485	4324	Acantholytic Acanthoma
5486	4325	Ebola Hemorrhagic Fever
5487	4326	Filoviridae Infectious Disease
5488	4327	Marburg Hemorrhagic Fever
5489	4329	Erdheim-Chester Disease
5490	433	Intraventricular Hemorrhage From Any Perinatal Cause
5491	4330	Non-langerhans-cell Histiocytosis
5492	4331	Burning Mouth Syndrome
5493	4332	Familial Hypophosphatemia
5494	4333	Parovarian Cyst
5495	4334	Splenic Manifestation Of Prolymphocytic Leukemia
5496	4336	Tinea Favosa
5497	4337	Tinea Capitis
5498	434	Anterior Mediastinum Cancer
5499	4346	Variegate Porphyria
5500	4347	Lymphocele
5501	4349	Complications Occurring Mainly In The Course Of Labor And Delivery
5502	435	Malignant Neoplasm Of Thymus, Heart And Mediastinum
5503	4350	Bovine Anaplasmosis
5504	4351	Primary Anaplasmataceae Infectious Disease
5505	4352	Ciliary Body Cancer
5506	4353	Ciliary Body Disease
5507	4356	Regressing Malignant Melanoma
5508	4357	Experimental Melanoma
5509	4358	Metastatic Melanoma
5510	4359	Amelanotic Melanoma
5511	436	Posterior Mediastinum Cancer
5512	4360	Epithelioid Cell Melanoma
5513	4362	Cervical Cancer
5514	4364	Malignant Breast Melanoma
5515	4367	Apparent Mineralocorticoid Excess Syndrome
5516	4369	Brain Hypoxia-Ischemia
5517	437	Myasthenia Gravis
5518	4370	Stomach Diverticulosis
5519	4371	Schnitzler Syndrome
5520	4372	Intracranial Embolism
5521	4374	Silo Filler's Disease
5522	4375	Agricultural Workers' Disease
5523	4376	Milk Allergic Reaction
5524	4377	Egg Allergy
5525	4378	Peanut Allergic Reaction
5526	4379	Nut Allergic Reaction
5527	438	Autoimmune Disease Of The Nervous System
5528	4381	Conventional Alveolar Rhabdomyosarcoma
5529	4383	Solid Alveolar Rhabdomyosarcoma
5530	4384	Orbit Alveolar Rhabdomyosarcoma
5531	4385	Papillary Squamous Carcinoma
5532	4386	Myofibroma
5533	4387	Recurrent Peripheral Primitive Neuroectodermal Tumor
5534	4388	Bone Peripheral Neuroepithelioma
5535	4389	Soft Tissue Peripheral Neuroepithelioma
5536	439	Neuromuscular Junction Disease
5537	4393	Henipavirus Infectious Disease
5538	4394	Reticulohistiocytic Granuloma
5539	4397	Granulomatous Dermatitis
5540	4398	Pustulosis Of Palm And Sole
5541	4399	Acneiform Dermatitis
5542	440	Neuromuscular Disease
5543	4400	Dermatosis Papulosa Nigra
5544	4403	Cervical Glandular Tumor
5545	4404	Occupational Dermatitis
5546	4406	Spongiotic Dermatitis
5547	4407	Phototoxic Dermatitis
5548	4409	Folliculitis
5549	4410	Contact Dermatitis Due To Arnica
5550	4411	Hepatitis E
5551	4412	Astroviridae Infectious Disease
5552	4413	Cervix Melanoma
5553	4415	Fibrous Histiocytoma
5554	4418	Cutaneous Fibrous Histiocytoma
5555	4419	Benign Deep Fibrous Histiocytoma
5556	4422	Malignant Adenofibroma
5557	4423	Sea-blue Histiocyte Syndrome
5558	4424	Juvenile Xanthogranuloma
5559	4425	Lipogranuloma
5560	4428	Dyslexia
5561	4430	Somatostatinoma
5562	4432	Pancreatic Somatostatinoma
5563	4433	Pancreatic Delta Cell Neoplasm
5564	4434	Small Intestine Neuroendocrine Neoplasm
5565	4435	Cavernous Sinus Meningioma
5566	4436	Anterior Cranial Fossa Meningioma
5567	4437	Skull Base Meningioma
5568	4438	Central Nervous System Germinoma
5569	4439	Central Nervous System Germ Cell Tumor
5570	4440	Seminoma
5571	4441	Dysgerminoma
5572	4442	Cervical Alveolar Soft Part Sarcoma
5573	4443	Cervical Soft Tissue Tumor
5574	4445	Arachnoid Cyst
5575	4446	Central Nervous System Cyst
5576	4447	Cystoid Macular Edema
5577	4448	Macular Degeneration
5578	4449	Macular Retinal Edema
5579	445	Bartter Disease
5580	4450	Renal Cell Carcinoma
5581	4451	Renal Carcinoma
5582	4452	Recurrent Renal Cell Carcinoma
5583	4454	Childhood Kidney Cell Carcinoma
5584	4455	Hereditary Renal Cell Carcinoma
5585	446	Hyperaldosteronism
5586	4463	Multilocular Clear Cell Renal Cell Carcinoma
5587	4464	Collecting Duct Carcinoma
5588	4465	Papillary Renal Cell Carcinoma
5589	4467	Renal Clear Cell Carcinoma
5590	4468	Clear Cell Adenocarcinoma
5591	447	Renal Tubular Transport Disease
5592	4471	Chromophobe Adenocarcinoma
5593	4472	Mucinous Tubular And Spindle Renal Cell Carcinoma
5594	4473	Sarcomatoid Renal Cell Carcinoma
5595	4478	Drug-Induced Dyskinesia
5596	4479	Pseudohypoaldosteronism
5597	448	Facial Neoplasm
5598	4480	Achondroplasia
5599	4481	Allergic Rhinitis
5600	4483	Rhinitis
5601	4486	Malignant Biphasic Mesothelioma
5602	4488	Sarcomatoid Mesothelioma
5603	4489	Malignant Epithelial Mesothelioma
5604	449	Head Neoplasm
5605	4490	Malignant Peritoneal Solitary Fibrous Tumor
5606	4491	Persian Gulf Syndrome
5607	4492	Avian Influenza
5608	4493	Orthomyxoviridae Infectious Disease
5609	4496	Metastatic Malignant Neoplasm To The Cervix
5610	4499	Child Nutrition Disorder
5611	450	Myotonic Disease
5612	4500	Hypokalemia
5613	4501	Orofaciodigital Syndrome
5614	4502	Relapsed Angiosarcoma
5615	4504	Central Nervous System Angiosarcoma
5616	4505	Pediatric Angiosarcoma
5617	4509	Angiosarcoma Associated With Lymphedema
5618	4510	Aorta Angiosarcoma
5619	4511	Breast Angiosarcoma
5620	4512	Conventional Angiosarcoma
5621	4513	Gallbladder Angiosarcoma
5622	4514	Thyroid Angiosarcoma
5623	4515	Thyroid Sarcoma
5624	4517	Skin Angiosarcoma
5625	452	Pleomorphic Adenoma
5626	4520	Cervical Endometrial Stromal Sarcoma
5627	4521	Cervix Endometrial Stromal Tumor
5628	4522	Superior Vena Cava Angiosarcoma
5629	4524	Prostate Angiosarcoma
5630	4525	Mediastinum Angiosarcoma
5631	4527	Ovarian Angiosarcoma
5632	4531	Mucoepidermoid Carcinoma
5633	4534	Hallermann-Streiff Syndrome
5634	4535	Hypotrichosis
5635	4539	Labyrinthine Disease
5636	4540	Dysgraphia
5637	4541	Nominal Aphasia
5638	4542	Basophil Adenoma
5639	4543	Retrograde Amnesia
5640	4545	Mesenchymal Chondrosarcoma
5641	4546	Pediatric Mesenchymal Chondrosarcoma
5642	4547	Adult Mesenchymal Chondrosarcoma
5643	4548	Extraskeletal Mesenchymal Chondrosarcoma
5644	4549	Extraosseous Chondrosarcoma
5645	4550	Anal Gland Neoplasm
5646	4551	Anus Neoplasm
5647	4552	Large Cell Carcinoma
5648	4553	Thymus Large Cell Carcinoma
5649	4554	Type C Thymoma
5650	4555	Ovarian Large-cell Neuroendocrine Carcinoma
5651	4556	Lung Large Cell Carcinoma
5652	4557	Oral Leukoedema
5653	4558	Ludwig's Angina
5654	456	Ascariasis
5655	4560	Non Specific Chronic Endometritis
5656	4561	Granulomatous Endometritis
5657	4562	Subacute Bacterial Endocarditis
5658	457	Ascaridida Infectious Disease
5659	4582	Metastatic Meningioma
5660	4583	Deletion Of Short Arm Of Chromosome 1 (1p) Associated Meningioma
5661	4584	Choroid Plexus Meningioma
5662	4585	Relapsed Meningioma
5663	4586	Familial Meningioma
5664	4587	Benign Meningioma
5665	4588	Secretory Meningioma
5666	4589	Deletion Of Chromosome 22 Associated Meningioma
5667	4590	Multiple Meningiomas
5668	4591	Lymphoplasmacyte-rich Meningioma
5669	4593	Pediatric Meningioma
5670	4594	Microcystic Meningioma
5671	4595	Adult Meningioma
5672	4596	Central Nervous System Adult Tumor
5673	4598	Deletion Of Chromosome 3p Associated Meningioma
5674	4603	Epidermolytic Hyperkeratosis
5675	4606	Bile Duct Cancer
5676	4607	Biliary Tract Cancer
5677	4608	Common Bile Duct Neoplasm
5678	461	Muscle Benign Neoplasm
5679	4610	Intestinal Benign Neoplasm
5680	4613	Ulnar Neuropathy
5681	4615	Carcinoma Of Unknown Primary
5682	4616	Bovine Atypical Interstitial Pneumonia
5683	4617	Periapical Granuloma
5684	4618	Maxillary Neoplasm
5685	462	Cancer By Anatomical Entity
5686	4621	Holoprosencephaly
5687	4624	Ollier Disease
5688	4625	Enchondromatosis
5689	4626	Hydranencephaly
5690	4627	Ideomotor Apraxia
5691	4629	Porcine Reproductive And Respiratory Syndrome
5692	4630	Inverted Transitional Papilloma
5693	4631	Inverted Papilloma Of Paranasal Sinus
5694	4633	Nasal Cavity Inverting Papilloma
5695	4636	Submandibular Adenitis
5696	4637	Cervical Adenitis
5697	4638	Postauricular Lymphadenitis
5698	4639	Suppurative Lymphadenitis
5699	4640	Axillary Adenitis
5700	4641	Bacteroides Infectious Disease
5701	4644	Epidermolysis Bullosa Simplex
5702	4645	Retinal Cancer
5703	4647	Trilateral Retinoblastoma
5704	4648	Familial Retinoblastoma
5705	4650	Bilateral Retinoblastoma
5706	4651	Unilateral Retinoblastoma
5707	4653	Intraocular Retinoblastoma
5708	4655	Relapsed Retinoblastoma
5709	4656	Extraocular Retinoblastoma
5710	4658	Benign Mastocytoma
5711	4659	Extracutaneous Mastocytoma
5712	4660	Indolent Systemic Mastocytosis
5713	4661	Multiple Chemical Sensitivity
5714	4662	Thalamic Disease
5715	4664	Filamentary Keratitis
5716	4665	Superficial Keratitis Without Conjunctivitis
5717	4667	Kyphosis
5718	4668	Congenital Kyphosis
5719	467	Venous Hemangioma
5720	4671	Freemartinism
5721	4674	Androgen Insensitivity Syndrome
5722	4675	Uremic Neuropathy
5723	4676	Uremia
5724	4677	Keratitis
5725	4678	Thymus Mucoepidermoid Carcinoma
5726	4679	Breast Mucoepidermoid Carcinoma
5727	468	Intramuscular Hemangioma
5728	4680	Breast Metaplastic Carcinoma
5729	4681	Bile Duct Mucoepidermoid Carcinoma
5730	4682	Extrahepatic Bile Duct Carcinoma
5731	4683	Cutaneous Mucoepidermoid Carcinoma
5732	4684	Skin Appendage Carcinoma
5733	4685	Lacrimal Gland Mucoepidermoid Carcinoma
5734	4686	Mucoepidermoid Esophageal Carcinoma
5735	4687	Mucoepidermoid Thyroid Carcinoma
5736	4688	Laryngeal Mucoepidermoid Carcinoma
5737	469	Deep Angioma
5738	4690	Childhood Mediastinal Neurogenic Tumor
5739	4691	Malignant Mediastinal Neurogenic Neoplasm
5740	4692	Endophthalmitis
5741	4693	Nerve Plexus Neoplasm
5742	4694	Malignant Peripheral Nerve Neoplasm
5743	4696	Intraneural Perineurioma
5744	4697	Perineurioma
5745	4698	Nerve Root Neoplasm
5746	4699	Epicardium Cancer
5747	47	Prostate Disease
5748	470	Verrucous Keratotic Hemangioma
5749	4700	Bathing Trunk Nevus
5750	4702	Mongolian Spot
5751	4705	Childhood Brain Tumor
5752	4706	Infratentorial Cancer
5753	4707	Cervicomedullary Junction Neoplasm
5754	4708	Foramen Magnum Meningioma
5755	471	Skin Hemangioma
5756	4711	Krebs 2 Carcinoma
5757	4712	Gastric Mesenchymal Neoplasm
5758	4714	Obstetrical Pelvic Hematoma
5759	4715	Gastric Neuroendocrine Neoplasm
5760	4716	Malignant Gastric Germ Cell Tumor
5761	4717	Extragonadal Germ Cell Cancer
5762	4719	Bone Giant Cell Sarcoma
5763	472	Subglottic Angioma
5764	4723	Intracranial Hypotension
5765	4724	Brain Edema
5766	4725	Neck Neoplasm
5767	4726	Anterior Synechiae
5768	4727	Adhesions Of Iris
5769	4730	Vasomotor Rhinitis
5770	4731	Atrophic Rhinitis
5771	4734	Calciphylaxis
5772	4737	Somatoform Disorder
5773	4738	Iris Or Ciliary Body Disorder
5774	4739	Testicular Brenner Tumor
5775	474	Histiocytoid Hemangioma
5776	4742	Mixed Embryonal Carcinoma And Teratoma Of The Testis
5777	4743	Mixed Testicular Germ Cell Tumor
5778	4744	Placenta Accreta
5779	4746	Olfaction Disorder
5780	4748	Childhood Supratentorial Neoplasm
5781	4749	Middle Cranial Fossa Meningioma
5782	4751	Striatonigral Degeneration
5783	4752	Multiple System Atrophy
5784	4754	Dictyocaulus Infectious Disease
5785	4756	Testicular Leydig Cell Tumor
5786	4757	Sex Cord-stromal Neoplasm
5787	4758	Peripheral Anterior Synechiae
5788	476	Breast Hemangioma
5789	4760	Malignant Catarrh
5790	4762	Vasculogenic Impotence
5791	4765	Pulmonary Blastoma
5792	4766	Embryoma
5793	4767	Classic Pulmonary Blastoma
5794	4768	Epithelial Predominant Pulmonary Blastoma
5795	4769	Pleuropulmonary Blastoma
5796	4772	Mesoblastic Nephroma
5797	4773	Congenital Mesoblastic Nephroma
5798	4775	Feline Acquired Immunodeficiency Syndrome
5799	4776	Rapidly Progressive Glomerulonephritis
5800	4777	Exudative Glomerulonephritis
5801	4778	Proliferative Glomerulonephritis
5802	4779	Focal Embolic Glomerulonephritis
5803	478	Breast Vascular Neoplasm
5804	4780	Anti-basement Membrane Glomerulonephritis
5805	4781	Diffuse Glomerulonephritis
5806	4782	Subacute Glomerulonephritis
5807	4783	Mesangial Proliferative Glomerulonephritis
5808	4784	Immune-complex Glomerulonephritis
5809	4786	Primitive Neuroectodermal Tumor With Leptomeningeal Spread
5810	4787	Cerebellopontine Angle Primitive Neuroectodermal
5811	4788	Intracranial Primitive Neuroectodermal Tumor
5812	479	Angiokeratoma
5813	4790	Medulloepithelioma
5814	4791	Supratentorial Primitive Neuroectodermal Tumor
5815	4794	Ependymoblastoma
5816	4795	Tay-Sachs Disease AB Variant
5817	4796	Space Motion Sickness
5818	4797	SM-AHNMD
5819	4798	Aggressive Systemic Mastocytosis
5820	4799	AIDS-related Idiopathic Thrombocytopenic Purpura
5821	48	Male Reproductive System Disease
5822	480	Movement Disease
5823	4800	Iris Vascular Disorder
5824	4804	Border Disease
5825	4807	Swine Vesicular Disease
5826	4808	Enterovirus Infectious Disease
5827	4809	Enzootic Porcine Encephalomyelitis
5828	481	Central Nervous System Hereditary Degenerative Disease
5829	4810	Cerebrotendinous Xanthomatosis
5830	4812	Adult Brainstem Gliosarcoma
5831	4813	Adult Brain Stem Glioma
5832	4814	Ganglioneuroma Of The Retroperitoneum
5833	4816	Maturing Ganglioneuroma
5834	4817	Ganglioneuroma
5835	4818	Lung Occult Non-small Cell Carcinoma
5836	4819	Lung Occult Carcinoma
5837	482	Hemangioma Of Peripheral Nerve
5838	4828	Metastatic Lung Carcinoma
5839	4829	Adenosquamous Cell Lung Carcinoma
5840	483	Cavernous Hemangioma
5841	4830	Adenosquamous Carcinoma
5842	4831	Spleen Mast Cell Malignancy
5843	4832	Non Small Cell Lung Cancer Recurrent
5844	4833	Recurrent Lung Carcinoma
5845	4837	Gorham's Disease
5846	4838	Myoepithelial Carcinoma
5847	4839	Sebaceous Adenocarcinoma
5848	484	Vascular Hemostatic Disease
5849	4840	Sebaceous Carcinoma
5850	4841	Malignant Tumor Of Epidermal Appendage
5851	4843	Subependymal Glioma
5852	4844	Benign Ependymoma
5853	4845	Pilomyxoid Astrocytoma
5854	4846	Cauda Equina Intradural Extramedullary Astrocytoma
5855	4847	Cauda Equina Neoplasm
5856	4848	Cerebellar Astrocytoma
5857	4850	Glioma Of Visual Pathway
5858	4851	Pilocytic Astrocytoma
5859	4852	Pleomorphic Xanthoastrocytoma
5860	4853	Pilocytic Astrocytoma Of Cerebellum
5861	4855	Diencephalic Astrocytomas
5862	4856	Gliofibroma
5863	4857	Diffuse Astrocytoma
5864	4858	Pineal Gland Astrocytoma
5865	486	Glomeruloid Hemangioma
5866	4860	Brain Stem Astrocytic Neoplasm
5867	4863	Spinal Cord Astrocytoma
5868	4864	Rubella Virus Infectious Disease
5869	4865	Togaviridae Infectious Disease
5870	4866	Salivary Gland Adenoid Cystic Carcinoma
5871	4867	Cervical Adenoid Cystic Carcinoma
5872	4868	Prostate Adenoid Cystic Carcinoma
5873	4869	Laryngeal Adenoid Cystic Carcinoma
5874	4870	Lacrimal Gland Adenoid Cystic Carcinoma
5875	4871	Cutaneous Adenocystic Carcinoma
5876	4872	Lung Adenoid Cystic Carcinoma
5877	4873	Anterior Horn Cell Disease
5878	4875	Trachea Adenoid Cystic Carcinoma
5879	4876	Trachea Carcinoma
5880	4877	Breast Adenoid Cystic Carcinoma
5881	4878	Esophageal Adenoid Cystic Carcinoma
5882	4879	Bartholin's Gland Adenoid Cystic Carcinoma
5883	488	Malignant Bone Vascular Tumor
5884	4880	Kidney Clear Cell Sarcoma
5885	4882	Pediatric Soft Part Clear Cell Sarcoma
5886	4884	Peritoneal Neoplasm
5887	4885	Colorado Tick Fever
5888	4887	Rotavirus Infectious Disease
5889	4889	Lymph Node Tuberculosis
5890	4890	Juvenile Myoclonic Epilepsy
5891	4892	Middle Ear Adenocarcinoma
5892	4893	Middle Ear Carcinoma
5893	4894	Rete Ovarii Adenocarcinoma
5894	4895	Rete Ovarii Neoplasm
5895	4896	Bile Duct Adenocarcinoma
5896	4897	Bile Duct Carcinoma
5897	4898	Adenocarcinoma In A Polyp
5898	490	Hemangioma Of Lung
5899	4900	Mixed Cell Adenocarcinoma
5900	4901	Peritoneal Serous Adenocarcinoma
5901	4902	Appendix Carcinoma
5902	4903	Granular Cell Carcinoma
5903	4904	Intestinal Type Carcinoma
5904	4905	Pancreatic Carcinoma
5905	4906	Small Intestine Adenocarcinoma
5906	4907	Small Intestine Carcinoma
5907	4908	Anal Carcinoma
5908	4910	Urethra Adenocarcinoma
5909	4911	Superficial Spreading Adenocarcinoma
5910	4912	Disseminated Adenocarcinoma
5911	4914	Esophagus Adenocarcinoma
5912	4915	Basophilic Carcinoma
5913	4916	Pituitary Carcinoma
5914	4917	Villous Adenocarcinoma
5915	4918	Renal Pelvis Adenocarcinoma
5916	4919	Renal Pelvis Carcinoma
5917	492	Acquired Hemangioma
5918	4920	Eccrine Adenocarcinoma
5919	4921	Eccrine Sweat Gland Cancer
5920	4922	Breast Secretory Carcinoma
5921	4923	Thymus Adenocarcinoma
5922	4924	Human Papillomavirus Related Adenocarcinoma
5923	4925	Human Papillomavirus Related Carcinoma
5924	4926	Bronchiolo-alveolar Adenocarcinoma
5925	4927	Klatskin's Tumor
5926	4928	Intrahepatic Cholangiocarcinoma
5927	4929	Tubular Adenocarcinoma
5928	4930	Nasal Cavity Adenocarcinoma
5929	4931	Nasal Cavity Carcinoma
5930	4932	Ampulla Of Vater Carcinoma
5931	4933	Apocrine Adenocarcinoma
5932	4934	Apocrine Sweat Gland Cancer
5933	4935	Acidophil Carcinoma
5934	4936	Mixed Eosinophil-basophil Carcinoma
5935	4937	Oxyphilic Adenocarcinoma
5936	4938	Ureter Adenocarcinoma
5937	4939	Ureter Carcinoma
5938	4942	Combined Hepatocellular Carcinoma And Cholangiocarcinoma
5939	4943	Adenocarcinoma In Situ
5940	4944	Gastroesophageal Junction Adenocarcinoma
5941	4947	Cholangiocarcinoma
5942	4948	Gallbladder Carcinoma
5943	495	Sclerosing Hemangioma
5944	4952	Postpoliomyelitis Syndrome
5945	4953	Poliomyelitis
5946	4955	Central Nervous System Melanocytic Neoplasm
5947	4956	Leptomeningeal Neoplasm
5948	4957	Meninges Hemangiopericytoma
5949	4958	Central Nervous System Hemangiopericytoma
5950	4959	Epidermolysis Bullosa Dystrophica
5951	496	Spindle Cell Hemangioma
5952	4960	Bone Marrow Cancer
5953	4961	Bone Marrow Disease
5954	4962	Pericardial Tuberculosis
5955	4964	Neurotic Disorder
5956	4966	Adrenocortical Hyperplasia
5957	4967	Adrenal Hyperplasia
5958	4968	Nelson Syndrome
5959	4969	Gerstmann Syndrome
5960	4970	Prosopagnosia
5961	4971	Myelofibrosis
5962	4972	Myelodysplastic Myeloproliferative Cancer
5963	4974	Actinobacillosis
5964	4975	Actinobacillus Infectious Disease
5965	4976	Elephantiasis
5966	4977	Lymphedema
5967	4978	Ewing's Family Recurrent Tumor
5968	4979	Recurrent Primitive Neuroectodermal Tumor
5969	4982	Metastatic Ewing's Sarcoma
5970	4983	Metastatic Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor
5971	4985	Extraosseous Ewings Sarcoma-primitive Neuroepithelial Tumor
5972	4986	Nonparalytic Poliomyelitis
5973	4987	Recurrent Ewing's Sarcoma
5974	4988	Alcoholic Pancreatitis
5975	4989	Pancreatitis
5976	4990	Essential Tremor
5977	4991	Optic Nerve Astrocytoma
5978	4992	Optic Nerve Glioma
5979	4993	Atypical Polypoid Adenomyoma
5980	4994	Adenomyoma Of Uterine Corpus
5981	4995	Cervical Adenomyoma
5982	4997	Camurati-Engelmann Disease
5983	4998	Trichorhinophalangeal Syndrome Type II
5984	4999	Syphilitic Alopecia
5985	50	Thyroid Gland Disease
5986	5000	Cutaneous Syphilis
5987	5002	Equine Infectious Anemia
5988	5003	Eunuchism
5989	5006	Adult Primary Liver Cancer
5990	5007	Resectable Hepatocellular Carcinoma
5991	501	Central Nervous System Hemangioma
5992	5015	Hepatocellular Fibrolamellar Carcinoma
5993	5016	Hepatocellular Clear Cell Carcinoma
5994	5017	Hepatitis Virus Related Hepatocellular Carcinoma
5995	5019	Non-resectable Hepatocellular Carcinoma
5996	502	Central Nervous System Mesenchymal Non-meningothelial Tumor
5997	5022	Aflatoxins-related Hepatocellular Carcinoma
5998	5026	Sclerosing Hepatic Carcinoma
5999	5027	Recurrent Hepatocellular Carcinoma
6000	5028	Recurrent Cancer Of Liver
6001	5029	Alphavirus Infectious Disease
6002	5030	Pineal Parenchymal Tumor Of Intermediate Differentiation
6003	5031	Adult Pineal Parenchymal Tumor
6004	5032	Pineal Gland Cancer
6005	5039	Myoblastoma
6006	5040	Malignant Granular Cell Esophageal Tumor
6007	5041	Esophageal Cancer
6008	5042	Malignant Granular Cell Myoblastoma
6009	5043	Vulvar Granular Cell Tumor
6010	5044	Cardiac Granular Cell Neoplasm
6011	5046	Mediastinal Granular Cell Myoblastoma
6012	5047	Neurohypophysis Granular Cell Tumor
6013	5048	Posterior Pituitary Gland Neoplasm
6014	505	Hobnail Hemangioma
6015	5050	Ehrlich Tumor Carcinoma
6016	5052	Melioidosis
6017	5053	Primary Burkholderia Infectious Disease
6018	5055	Neuronal And Mixed Neuronal-glial Tumor Of Cerebellum
6019	5056	Adult Cerebellar Neoplasm
6020	5057	Papillary Meningioma Of The Cerebellum
6021	5058	Rhabdoid Meningioma
6022	5059	Childhood Cerebellar Neoplasm
6023	5062	Phencyclidine Abuse
6024	5063	Basosquamous Carcinoma
6025	5069	Uterine Corpus Soft Tissue Neoplasm
6026	507	Adjustment Disorder
6027	5070	Neoplasm Of Body Of Uterus
6028	5071	Central Nervous System Soft Tissue Neoplasm
6029	5072	Meninges Gliomatosis
6030	5073	Malignant Neoplasm Of Meninges
6031	5074	Malignant Ependymoma
6032	5075	Myxopapillary Ependymoma
6033	5076	Mixed Glioma
6034	5077	Subependymal Giant Cell Astrocytoma
6035	5078	Ganglioglioma
6036	5082	Liver Cirrhosis
6037	5083	Iodine Hypothyroidism
6038	5085	Transmissible Gastroenteritis Of Swine
6039	5086	Transmissible Enteritis Of Turkeys
6040	5087	Feline Infectious Peritonitis
6041	5088	Mixed Epithelial Stromal Tumour
6042	5090	Sternum Cancer
6043	5093	Thoracic Cancer
6044	5097	Axillary Cancer
6045	5099	Middle Ear Cancer
6046	5100	Middle Ear Disease
6047	5101	Auricular Cancer
6048	5102	Inner Ear Cancer
6049	5104	Testicular Infarct
6050	5107	Achromic Nevus
6051	5112	Swayback
6052	5113	Nutritional Deficiency Disease
6053	5115	Bovine Virus Diarrhea-mucosal Disease
6054	5116	Central Nervous System Dermoid Cyst
6055	5117	Dermoid Cyst Of Ovary
6056	5118	Ovarian Cystic Teratoma
6057	5119	Ovarian Cyst
6058	512	Epididymal Neoplasm
6059	5120	Roseolovirus Infectious Disease
6060	5123	Mediastinum Leiomyoma
6061	5124	Fallopian Tube Leiomyoma
6062	5125	Extrahepatic Bile Duct Leiomyoma
6063	5126	Central Nervous System Leiomyoma
6064	5127	Bizarre Leiomyoma
6065	5128	Deep Leiomyoma
6066	5129	Simple Partial Epilepsy
6067	5132	Leiomyoma Cutis
6068	5133	Skin Tumor Of Smooth Muscle Origin
6069	5134	Anus Leiomyoma
6070	5136	Lung Leiomyoma
6071	5137	Pericardium Leiomyoma
6072	5138	Leiomyomatosis
6073	5139	Cellular Leiomyoma
6074	5140	Gallbladder Leiomyoma
6075	5142	Vulvar Leiomyoma
6076	5143	Large Bowel Leiomyoma
6077	5146	Appendix Leiomyoma
6078	5147	Dartoic Leiomyoma
6079	5149	Epithelioid Neurofibroma
6080	5150	Neurofibroma Of Gallbladder
6081	5151	Plexiform Neurofibroma
6082	5152	Cellular Neurofibroma
6083	5153	Atypical Neurofibroma
6084	5154	Borna Disease
6085	5155	Multiple Mucosal Neuroma
6086	5157	Benign Pleural Mesothelioma
6087	5158	Pleural Cancer
6088	5160	Arteriosclerosis Obliterans
6089	5161	Monckeberg Arteriosclerosis
6090	5162	Arteriolosclerosis
6091	5165	Uterine Corpus Sarcoma
6092	5166	Endometrial Stromal Tumor
6093	5169	Ovarian Endometrioid Stromal Sarcoma
6094	5170	Vaginal Endometrial Stromal Sarcoma
6095	5171	Vaginal Endometrial Stromal Tumor
6096	5172	Endometrium Carcinoma In Situ
6097	5176	Renal Wilms' Tumor
6098	5178	Metachronous Kidney Wilms' Tumor
6099	5179	Mixed Cell Type Kidney Wilms' Tumor
6100	518	Scrotum Neoplasm
6101	5182	Blastema Predominant Kidney Wilms' Tumor
6102	5183	Hereditary Wilms' Tumor
6103	5184	Recurrent Nephroblastoma
6104	5185	Anaplastic Renal Wilms' Tumor
6105	5189	Epithelial Predominant Wilms' Tumor
6106	519	Aortitis
6107	5190	Cervical Wilms' Tumor
6108	5191	Stromal Predominant Kidney Wilms' Tumor
6109	5193	Nodular Ganglioneuroblastoma
6110	5194	Intermixed Schwannian Stroma-rich Ganglioneuroblastoma
6111	5195	Peripheral Nervous System Ganglioneuroblastoma
6112	5196	Fallopian Tube Adenomatoid Tumor
6113	5199	Ureteral Obstruction
6114	520	Aortic Disease
6115	5200	Urinary Tract Obstruction
6116	5204	Fructose-1,6-bisphosphatase Deficiency
6117	5205	Inborn Errors Fructose Metabolism
6118	5207	Monodermal Teratoma
6119	5208	Malignant Struma Ovarii
6120	5209	Benign Struma Ovarii
6121	5212	Congenital Disorder Of Glycosylation
6122	5213	Chronic Inflammatory Demyelinating Polyradiculoneuropathy
6123	5214	Demyelinating Polyneuropathy
6124	5215	Ephemeral Fever
6125	5221	Chronic Polyneuropathy
6126	5222	Acute Necrotizing Encephalitis
6127	5223	Infertility
6128	5224	Acute Hemorrhagic Encephalitis
6129	5225	Von Economo's Disease
6130	5226	Vaginal Blue Nevus
6131	5227	Cellular Blue Nevus
6132	5228	Common Blue Nevus
6133	5230	Hepatoerythropoietic Porphyria
6134	5231	Peritoneal And Retroperitoneal Tumors
6135	5232	Aortic Valve Prolapse
6136	5233	Glomangiosarcoma
6137	5236	Subungual Glomus Tumor
6138	5238	Benign Perivascular Tumor
6139	5239	Glomus Tumor Of Uncertain Malignant Potential
6140	524	Central Nervous System AIDS Arteritis
6141	5240	Retinal Hemangioblastoma
6142	5241	Hemangioblastoma
6143	5242	Resectable Cholangiocellular Carcinoma
6144	5244	Visual Alteration
6145	5245	Recurrent Cholangiocellular Carcinoma
6146	5246	Hilar Cholangiocellular Carcinoma
6147	5247	Liver Fluke-related Cholangiocarcinoma
6148	5248	Parasite-related Carcinoma
6149	525	Central Nervous System Vasculitis
6150	5250	Non-resectable Cholangiocellular Carcinoma
6151	5251	Inflammatory Leiomyosarcoma
6152	5252	Leiomyosarcoma Recurrent
6153	5253	Conventional Leiomyosarcoma
6154	5254	Central Nervous System Leiomyosarcoma
6155	5255	Leiomyosarcoma Nonmetastatic
6156	5258	Granular Cell Leiomyosarcoma
6157	5259	Colon Leiomyosarcoma
6158	526	Human Immunodeficiency Virus Infectious Disease
6159	5260	Colon Sarcoma
6160	5261	Heart Leiomyosarcoma
6161	5262	Heart Sarcoma
6162	5263	Ovary Leiomyosarcoma
6163	5264	Epithelioid Leiomyosarcoma
6164	5265	Lung Leiomyosarcoma
6165	5266	Leiomyosarcoma Metastatic
6166	5267	Anus Leiomyosarcoma
6167	5268	Myxoid Leiomyosarcoma
6168	5271	Small Intestine Leiomyosarcoma
6169	5272	Small Intestinal Sarcoma
6170	5273	Cutaneous Leiomyosarcoma
6171	5274	Malignant Dermis Tumor
6172	5275	Gallbladder Leiomyosarcoma
6173	5276	Esophagus Leiomyosarcoma
6174	5278	Pediatric Leiomyosarcoma
6175	528	Hydrarthrosis
6176	5280	Gastric Leiomyosarcoma
6177	5281	Malignant Mesenchymal Neoplasm Of The Stomach
6178	5282	Prostate Leiomyosarcoma
6179	5283	Vagina Leiomyosarcoma
6180	5284	Retroperitoneal Leiomyosarcoma
6181	5285	Breast Leiomyosarcoma
6182	5286	Vulvar Leiomyosarcoma
6183	5287	Kidney Leiomyosarcoma
6184	5288	Larynx Leiomyosarcoma
6185	5289	Uterus Leiomyosarcoma
6186	529	Blepharospasm
6187	5290	Uterine Corpus Smooth Muscle Neoplasm
6188	5291	Adult Leiomyosarcoma
6189	5292	Mediastinum Leiomyosarcoma
6190	5293	Extrahepatic Bile Duct Leiomyosarcoma
6191	5294	Vessel Leiomyosarcoma
6192	5295	Intestinal Disease
6193	5296	Liver Leiomyosarcoma
6194	5297	Rectum Leiomyosarcoma
6195	5299	Endometrial Clear Cell Adenocarcinoma
6196	53	Pituitary Gland Disease
6197	530	Eyelid Disease
6198	5301	Fallopian Tube Clear Cell Adenocarcinoma
6199	5302	Uterine Ligament Clear Cell Adenocarcinoma
6200	5303	Cervical Clear Cell Adenocarcinoma
6201	5304	Ovarian Clear Cell Adenocarcinoma
6202	5305	Malignant Ovarian Clear Cell Neoplasm
6203	5306	Bladder Clear Cell Adenocarcinoma
6204	5307	Urethra Clear Cell Adenocarcinoma
6205	5308	Ampulla Of Vater Clear Cell Adenocarcinoma
6206	5309	Epithelial-myoepithelial Carcinoma
6207	5310	Glycogen-rich Clear Cell Breast Carcinoma
6208	5312	Miscellaneous Mesenchymal Neoplasm
6209	5313	Vulvar Alveolar Soft Part Sarcoma
6210	5314	Alveolar Soft Part Sarcoma Recurrent
6211	5316	Alveolar Soft Part Sarcoma Nonmetastatic
6212	5317	Alveolar Soft Part Sarcoma Metastatic
6213	5323	Fallopian Tube Serous Tumor
6214	5324	Fallopian Tube Germ Cell Cancer
6215	5325	Roberts Syndrome
6216	5326	Partial Recent Retinal Detachment With Single Defect
6217	5327	Retinal Detachment
6218	5328	Retinal Detachment And Defect
6219	533	Thymus Gland Disease
6220	5330	Dental Pulp Disease
6221	5331	Testicular Granulosa Cell Tumor
6222	5334	Paraphimosis
6223	5335	Renal Neoplasm With T(6;11)(p21;q12)
6224	5337	Epulis
6225	5338	Gingival Hypertrophy
6226	5339	Cyclic Hematopoiesis
6227	534	Persistent Disorder Of Initiating Or Maintaining Wakefulness
6228	5340	Anterograde Amnesia
6229	5341	Pineal Region Yolk Sac Tumor
6230	5342	Childhood Endodermal Sinus Tumor
6231	5343	Central Nervous System Endodermal Sinus Tumor
6232	5344	Testicular Yolk Sac Tumor
6233	5345	Testicular Non-seminomatous Germ Cell Cancer
6234	5346	Mediastinal Endodermal Sinus Tumor
6235	5347	Mediastinal Non-seminomatous Germ Cell Cancer
6236	5348	Adult Endodermal Sinus Tumor
6237	5349	Central Nervous System Adult Germ Cell Tumor
6238	535	Sleep Disorder
6239	5350	Ovarian Endodermal Sinus Tumor
6240	5351	Ovarian Primitive Germ Cell Tumor
6241	5353	Colonic Disease
6242	5354	Lung PAP-AD
6243	5355	Mucinous Bronchioloalveolar Lung Carcinoma
6244	5358	Non-mucinous Bronchioloalveolar Lung Carcinoma
6245	5359	Pure BAC
6246	536	Persistent Disorder Of Initiating Or Maintaining Sleep
6247	5360	AD-BAC
6248	5361	Mixed Mucinous And Non-mucinous Bronchioloalveolar Lung Carcinoma
6249	5362	Focal Epithelial Hyperplasia
6250	5363	Myxoid Liposarcoma
6251	5364	Pulmonary Coin Lesion
6252	5368	Wolffian Duct Adenocarcinoma
6253	5369	Ovine Progressive Interstitial Pneumonia
6254	5370	Breast Hemangiopericytoma
6255	5373	Retroperitoneal Hemangiopericytoma
6256	5374	Pilomatrixoma
6257	5375	Hair Follicle Neoplasm
6258	5376	Skin Pilomatrix Carcinoma
6259	5378	Hemoglobin D Disease
6260	5379	Hemoglobin E Disease
6261	538	Internuclear Ophthalmoplegia
6262	5380	Lupus Vulgaris
6263	5381	Bile Duct Adenoma
6264	5382	Bartholin's Gland Adenoma
6265	5384	Bile Duct Cystadenoma
6266	5385	Mixed Cell Adenoma
6267	5386	Lung Adenoma
6268	5387	Middle Ear Adenoma
6269	5389	Oxyphilic Adenoma
6270	539	Ophthalmoplegia
6271	5390	Clear Cell Adenoma
6272	5391	Bronchus Adenoma
6273	5392	Acidophil Adenoma
6274	5393	Brain Angioma
6275	5394	Prolactinoma
6276	5395	Functioning Pituitary Adenoma
6277	5396	Prolactin Producing Pituitary Tumor
6278	5397	Ductal Adenoma
6279	5398	Lipoadenoma
6280	5399	Ovine Pulmonary Adenomatosis
6281	540	Strabismus
6282	5400	Trabecular Adenoma
6283	5401	Water-clear Cell Adenoma
6284	5402	Vaginal Adenoma
6285	5403	Microcystic Adenoma
6286	5404	Atypical Adenoma
6287	5408	Paget's Disease Of Bone
6288	5409	Lung Small Cell Carcinoma
6289	541	Convergence Insufficiency Or Palsy
6290	5410	Pulmonary Neuroendocrine Tumor
6291	5411	Lung Oat Cell Carcinoma
6292	5414	Lung Occult Small Cell Carcinoma
6293	5416	Recurrent Small Cell Lung Cancer
6294	5418	Schizoaffective Disorder
6295	5419	Schizophrenia
6296	5421	Lung Combined Type Small Cell Carcinoma
6297	5422	Combined Carcinoma Of Lung
6298	5423	Central Nervous System Hemangioblastoma
6299	5425	Ovarian Hyperstimulation Syndrome
6300	5426	Premature Ovarian Failure
6301	5427	Urinary Bladder Villous Adenoma
6302	5429	Bladder Flat Intraepithelial Lesion
6303	543	Dystonia
6304	5430	Intraurothelial Neoplasia
6305	5432	Bladder Papillary Transitional Cell Neoplasm
6306	5433	Urinary Tract Papillary Transitional Cell Benign Neoplasm
6307	5434	Scrapie
6308	5435	Variant Creutzfeldt-Jakob Disease
6309	5437	Intrahepatic Bile Duct Adenoma
6310	5438	Extrahepatic Bile Duct Adenoma
6311	5439	Papillary Hidradenoma
6312	5442	Eccrine Acrospiroma
6313	5443	Clear Cell Hidradenoma
6314	5444	Spiradenoma
6315	5445	Syringocystadenoma Papilliferum
6316	5446	Eccrine Papillary Adenoma
6317	5453	Pulmonary Venoocclusive Disease
6318	5455	Pulmonary Vascular Disorder
6319	5456	Spinal Vascular Disorder
6320	5457	Laryngeal Neuroendocrine Tumor
6321	5460	Contagious Pleuropneumonia
6322	5461	Primary Mycoplasma Infectious Disease
6323	5462	African Swine Fever
6324	5463	Cochlear Disease
6325	5465	Conjunctival Intraepithelial Neoplasm
6326	5467	Conjunctival Cancer
6327	5468	Biliary Papillomatosis
6328	5469	Biliary Tract Intraductal Papillary Mucinous Neoplasm
6329	5472	Tumor Of The Thecoma Fibroma Group
6330	5474	Ovarian Serous Adenofibroma
6331	5475	Uterine Corpus Adenofibroma
6332	5476	Cervical Adenofibroma
6333	5477	Clear Cell Adenofibroma
6334	5478	Fallopian Tube Adenofibroma
6335	5479	Papillary Adenofibroma
6336	548	Malignant Hypertensive Heart Disease
6337	5480	Ovarian Endometrioid Adenofibroma
6338	5482	Cystadenofibroma
6339	5484	Fibrous Synovial Sarcoma
6340	5485	Synovial Sarcoma
6341	5486	Metastatic Synovial Sarcoma
6342	5487	Spindle Cell Synovial Sarcoma
6343	5488	Mediastinum Synovial Sarcoma
6344	5489	Adult Synovial Sarcoma
6345	5491	Pediatric Synovial Sarcoma
6346	5492	Biphasic Synovial Sarcoma
6347	5493	Recurrent Synovial Sarcoma
6348	5494	Epithelioid Cell Synovial Sarcoma
6349	5495	Monophasic Synovial Sarcoma
6350	5496	Nonmetastatic Synovial Sarcoma
6351	5497	Hepadnaviridae Infectious Disease
6352	5500	Cellular Ependymoma
6353	5501	Pediculus Humanus Capitis Infestation
6354	5502	Lice Infestation
6355	5503	Spinal Cord Ependymoma
6356	5504	Tanycytic Ependymoma
6357	5505	Papillary Ependymoma
6358	5507	Clear Cell Ependymoma
6359	5508	Brain Stem Ependymoma
6360	5509	Pediatric Ependymoma
6361	551	Toxic Pneumonitis
6362	5510	Pineal Dysgerminoma
6363	5511	Dysgerminoma Of Ovary
6364	5513	Pediculus Humanus Corporis Infestation
6365	5514	Breast Squamous Cell Carcinoma
6366	5515	Nasal Cavity Squamous Cell Carcinoma
6367	5516	Gastric Squamous Cell Carcinoma
6368	5517	Stomach Carcinoma
6369	5518	Penis Squamous Cell Carcinoma
6370	5519	Colon Squamous Cell Carcinoma
6371	552	Pneumonia
6372	5520	Head And Neck Squamous Cell Carcinoma
6373	5521	Keratinizing Squamous Cell Carcinoma
6374	5522	Basaloid Squamous Cell Carcinoma
6375	5524	Adenoid Squamous Cell Carcinoma
6376	5525	Anal Squamous Cell Carcinoma
6377	5526	Middle Ear Squamous Cell Carcinoma
6378	5527	Ampulla Of Vater Squamous Cell Carcinoma
6379	5528	Rectum Squamous Cell Carcinoma
6380	5529	Lacrimal Gland Squamous Cell Carcinoma
6381	5530	Thymus Squamous Cell Carcinoma
6382	5531	Ovarian Squamous Cell Carcinoma
6383	5532	Ovarian Squamous Cell Neoplasm
6384	5533	Endometrial Squamous Cell Carcinoma
6385	5534	Renal Pelvis Squamous Cell Carcinoma
6386	5535	Gallbladder Squamous Cell Carcinoma
6387	5536	Sarcomatoid Squamous Cell Skin Carcinoma
6388	5537	Squamous Cell Bile Duct Carcinoma
6389	5538	External Ear Squamous Cell Carcinoma
6390	5539	Ureter Squamous Cell Carcinoma
6391	5540	Fallopian Tube Squamous Cell Carcinoma
6392	5545	Anal Neuroendocrine Tumor
6393	5546	Femoral Cancer
6394	5547	Pulmonary Artery Choriocarcinoma
6395	5549	CNS Choriocarcinoma
6396	5550	Choriocarcinoma Of Ovary
6397	5551	Choriocarcinoma Of The Testis
6398	5552	Mediastinum Choriocarcinoma
6399	5553	Pineal Region Choriocarcinoma
6400	5554	Childhood Neoplasm Of The Testis
6401	5556	Testicular Malignant Germ Cell Cancer
6402	5557	Testicular Germ Cell Cancer
6403	5559	Mediastinal Cancer
6404	5560	Mediastinal Mesenchymal Tumor
6405	5561	Gastric Teratoma
6406	5562	Dermoid Cyst With Malignant Transformation
6407	5563	Malignant Teratoma
6408	5564	Fallopian Tube Teratoma
6409	5565	Adult Teratoma
6410	5566	Mature Teratoma
6411	5567	Ovarian Germ Cell Teratoma
6412	5568	Mediastinum Teratoma
6413	5569	Malignant Syringoma
6414	557	Kidney Disease
6415	5570	Malignant Acrospiroma
6416	5572	Beckwith-Wiedemann Syndrome
6417	5573	Classical Swine Fever
6418	5574	VIPoma
6419	5575	Delayed Puberty
6420	5576	Inhibited Male Orgasm
6421	5577	Gastrinoma
6422	5578	Small Intestinal Gastrinoma
6423	5579	Gastric Gastrinoma
6424	558	Acute Pyelonephritis Without Lesion Of Renal Medullary Necrosis
6425	5580	Pancreatic Gastrinoma
6426	5583	Lung Giant Cell Carcinoma
6427	5585	Ferguson-Smith Tumor
6428	5587	Volkmann Contracture
6429	5588	Lung Papillary Adenocarcinoma
6430	559	Acute Pyelonephritis
6431	5590	Aggressive Digital Papillary Adenocarcinoma
6432	5591	Eccrine Papillary Adenocarcinoma
6433	5592	Breast Papillary Carcinoma
6434	5593	Gastric Papillary Adenocarcinoma
6435	5594	Intraductal Papillary Adenocarcinoma With Invasion
6436	5595	Papillary Thymic Adenocarcinoma
6437	5597	Fallopian Tube Papillary Adenocarcinoma
6438	5598	Fallopian Tube Serous Adenocarcinoma
6439	5599	Precursor T-lymphoblastic Lymphoma/leukemia
6440	560	Jaw-winking Syndrome
6441	5600	Precursor Lymphoblastic Lymphoma/leukemia
6442	5601	T-cell Neoplasm
6443	5602	T-cell Adult Acute Lymphocytic Leukemia
6444	5603	Acute T Cell Leukemia
6445	5604	Adult Acute Lymphocytic Leukemia
6446	5605	Breast Medullary Carcinoma
6447	5608	Dental Pulp Calcification
6448	5609	Congenital Adrenal Gland Disorder
6449	561	Trigeminal Nerve Disease
6450	5611	Anaplastic Intraspinal Meningioma
6451	5612	Spinal Cancer
6452	5613	Anaplastic Meningioma
6453	5614	Eye Disease
6454	5615	Spinal Canal Intradural Extramedullary Neoplasm
6455	5616	Intraepithelial Neoplasm
6456	562	Third Cranial Nerve Disease
6457	5621	Histiocytic And Dendritic Cell Cancer
6458	5622	Major Puerperal Infectious Disease
6459	5623	Adenosquamous Breast Carcinoma
6460	5624	Adenosquamous Bile Duct Carcinoma
6461	5625	Esophageal Adenosquamous Carcinoma
6462	5626	Thymus Adenosquamous Carcinoma
6463	5627	Adenosquamous Gallbladder Carcinoma
6464	5628	Ampulla Of Vater Adenosquamous Carcinoma
6465	5629	Adenosquamous Colon Carcinoma
6466	563	Primary Fusobacteriaceae Infectious Disease
6467	5630	Bartholin's Gland Adenosquamous Carcinoma
6468	5631	Endometrial Adenosquamous Carcinoma
6469	5632	Optic Nerve Sheath Meningioma
6470	5633	Visual Pathway Meningioma
6471	5634	Adenosquamous Prostate Carcinoma
6472	5635	Gastric Adenosquamous Carcinoma
6473	5636	Cervical Adenosquamous Carcinoma
6474	5637	Adenosquamous Pancreas Carcinoma
6475	5638	Malignant Giant Cell Tumor Of Soft Parts
6476	5639	Rete Testis Neoplasm
6477	5641	Diffuse Pulmonary Fibrosis
6478	5642	Localized Pulmonary Fibrosis
6479	5643	Urethral Villous Adenoma
6480	5644	Tricuspid Valve Prolapse
6481	5648	Choroid Plexus Carcinoma
6482	5649	Solid Carcinoma
6483	565	Bilateral Hypoactive Labyrinth
6484	5651	Anaplastic Carcinoma
6485	5652	Metaplastic Carcinoma
6486	5655	Chiasmal Syndrome
6487	5656	Cranial Nerve Disease
6488	5658	Lipid-rich Carcinoma
6489	5659	Invasive Carcinoma
6490	566	Labyrinthine Dysfunction
6491	5660	Lymphoepithelioma-like Carcinoma
6492	5662	Pleomorphic Carcinoma
6493	5663	Helicobacter Pylori-related Carcinoma
6494	5665	External Ear Cancer
6495	5667	Sweat Gland Carcinoma
6496	5670	Comedo Carcinoma
6497	5672	Large Intestine Cancer
6498	5675	Cribriform Carcinoma
6499	5677	Extragonadal Nonseminomatous Germ Cell Tumor
6500	5678	Nerve Fibre Bundle Defect
6501	5679	Retinal Disease
6502	5680	Embryonal Testis Carcinoma
6503	5681	Ovarian Embryonal Carcinoma
6504	5683	Hereditary Breast Ovarian Cancer
6505	5684	Spondyloepimetaphyseal Dysplasia, Sponastrime Type
6506	5687	Flat Adenoma Syndrome
6507	5688	Werner Syndrome
6508	5690	Atypical Lipomatous Tumor
6509	5691	Visual Cortex Disease
6510	5692	Cellular Myxoid Liposarcoma
6511	5693	Adult Liposarcoma
6512	5694	Esophagus Liposarcoma
6513	5695	Pediatric Liposarcoma
6514	5696	Larynx Liposarcoma
6515	5697	Liposarcoma Of The Ovary
6516	5698	Fibroblastic Liposarcoma
6517	5699	Kidney Liposarcoma
6518	57	Aortic Valve Insufficiency
6519	5700	Gastric Liposarcoma
6520	5701	Breast Liposarcoma
6521	5702	Pleomorphic Liposarcoma
6522	5703	Mixed Liposarcoma
6523	5704	Sclerosing Liposarcoma
6524	5705	Spindle Cell Liposarcoma
6525	5707	Liposarcoma Nonmetastatic
6526	5708	Liposarcoma Metastatic
6527	5709	Mixed-type Liposarcoma
6528	571	Median Neuropathy
6529	5710	Liposarcoma Recurrent
6530	5711	Vulvar Liposarcoma
6531	5712	Cutaneous Liposarcoma
6532	5713	Mediastinum Liposarcoma
6533	5714	Intracranial Liposarcoma
6534	5715	Functionless Pituitary Adenoma
6535	5716	Hormone Producing Pituitary Cancer
6536	5717	Recurrent Pituitary Tumor
6537	5718	Adrenal Neuroblastoma
6538	5719	Adrenal Medulla Cancer
6539	572	Mononeuritis Of Upper Limb And Mononeuritis Multiplex
6540	5720	Neuroblastomas Of The Adrenal Gland And Sympathetic Nervous System
6541	5723	Optic Atrophy
6542	5724	Seminal Vesicle Cystadenoma
6543	5725	Rete Ovarii Cystadenoma
6544	5726	Uterine Ligament Papillary Cystadenoma
6545	5727	Uterine Ligament Cancer
6546	5728	Diffuse Peritoneal Leiomyomatosis
6547	5729	Intravenous Leiomyomatosis
6548	573	Nerve Compression Syndrome
6549	5730	Salpingitis Isthmica Nodosa
6550	5731	Chronic Salpingitis
6551	5732	Pyosalpinx
6552	5733	Salpingitis
6553	5738	Secondary Myelofibrosis
6554	574	Peripheral Nervous System Disease
6555	5740	Small Intestinal Vasoactive Intestinal Peptide Producing Tumor
6556	5741	Pancreatic Vasoactive Intestinal Peptide Producing Tumor
6557	5742	Pancreatic Acinar Cell Adenocarcinoma
6558	5743	Acinic Cell Breast Carcinoma
6559	5744	Ovary Serous Adenocarcinoma
6560	5746	Ovarian Serous Cystadenocarcinoma
6561	5747	Uterine Ligament Serous Adenocarcinoma
6562	5748	Rheumatic Pulmonary Valve Disease
6563	5749	Pulmonary Valve Disease
6564	5750	Uterine Corpus Serous Adenocarcinoma
6565	5751	Pancreatic Serous Cystadenocarcinoma
6566	5752	Cervical Serous Adenocarcinoma
6567	5757	Endocervicitis
6568	5758	Malignant Mesenchymoma
6569	5759	Sebaceous Gland Neoplasm
6570	576	Proteinuria
6571	5760	Sebaceous Breast Carcinoma
6572	5761	Vulvar Sebaceous Carcinoma
6573	5763	Lung Clear Cell-sugar-tumor
6574	5764	Lung Meningioma
6575	5765	Primary Ectopic Meningioma
6576	5766	Pulmonary Sclerosing Hemangioma
6577	5767	Hilar Lung Neoplasm
6578	5768	Nager Syndrome
6579	5769	Verruciform Xanthoma Of Skin
6580	5770	Mycobacterium Avium-intracellulare Lymphadenitis
6581	5771	Mycobacterium Avium Complex Lymphadenitis
6582	5772	Central Nervous System Hematologic Cancer
6583	5773	Oral Submucous Fibrosis
6584	5774	Giant Hemangioma
6585	5775	Cavernous Hemangioma Of Colon
6586	5776	Cavernous Hemangioma Of Face
6587	5777	Rectum Neuroendocrine Neoplasm
6588	578	Urination Disorder
6589	5781	Atrophic Flaccid Tympanic Membrane
6590	5782	Tympanic Membrane Disease
6591	5784	Esophageal Neuroendocrine Tumor
6592	5785	Recurrent Hepatoblastoma
6593	5786	Recurrent Childhood Cancer Of Liver
6594	5789	Mixed Hepatoblastoma
6595	5790	Resectable Hepatoblastoma
6596	5792	Hepatoblastoma With Pure Fetal Epithelial Differentiation
6597	5796	Nonresectable Hepatoblastoma
6598	5797	Mixed Hepatoblastoma With Teratoid Features
6599	5798	Macrotrabecular Hepatoblastoma
6600	580	Acute Urate Nephropathy
6601	5802	Hepatoblastoma With Combined Fetal Epithelial Differentiation
6602	5804	Discrete Subaortic Stenosis
6603	5805	Subvalvular Aortic Stenosis
6604	5806	Stork Bite
6605	5809	Childhood Parosteal Osteogenic Sarcoma
6606	581	Gouty Nephropathy
6607	5810	Adenosine Deaminase Deficiency
6608	5812	MHC Class II Deficiency
6609	5813	Purine Nucleoside Phosphorylase Deficiency
6610	5815	Cerebral Lymphoma
6611	5818	ALPS-associated Lymphoma
6612	5819	Localized Lymphoma
6613	582	Hemoglobinuria
6614	5820	Composite Lymphoma
6615	5821	Methotrexate-associated Lymphoproliferation
6616	5822	Gray Zone Lymphoma
6617	5823	Pediatric Lymphoma
6618	5825	Adult Lymphoma
6619	5826	Breast Lymphoma
6620	5828	Endometrioid Ovary Carcinoma
6621	5829	Uterine Ligament Endometrioid Adenocarcinoma
6622	583	Hemolytic Anemia
6623	5830	Cervical Endometrioid Adenocarcinoma
6624	5831	Fallopian Tube Endometrioid Adenocarcinoma
6625	5832	Metastatic Endometrioid Carcinoma
6626	5834	Spermatocytoma
6627	5838	Extragonadal Seminoma
6628	5842	Testis Seminoma
6629	5843	Posteroinferior Myocardial Infarction
6630	5844	Myocardial Infarction
6631	5845	Anterolateral Myocardial Infarction
6632	5846	Septal Myocardial Infarction
6633	5847	Posterior Myocardial Infarction
6634	5848	Apical Myocardial Infarction
6635	5849	Subendocardial Myocardial Infarction
6636	585	Nephrolithiasis
6637	5850	Inferior Myocardial Infarction
6638	5851	Posterolateral Myocardial Infarction
6639	5852	Inferolateral Myocardial Infarct
6640	5853	Lateral Myocardial Infarction
6641	5854	Silent Myocardial Infarction
6642	5855	Anteroseptal Myocardial Infarction
6643	5857	Secondary Chondrosarcoma
6644	5859	Periosteal Chondrosarcoma
6645	5861	Myxoid Chondrosarcoma
6646	5862	Localized Chondrosarcoma
6647	5863	Recurrent Chondrosarcoma
6648	5865	Metastatic Chondrosarcoma
6649	5866	Juxtacortical Chondrosarcoma
6650	5867	Clear Cell Chondrosarcoma
6651	587	Tuberculous Lung Cavity
6652	5870	Eosinophilic Pneumonia
6653	5872	Placental Necrosis
6654	5874	Retroperitoneal Germ Cell Neoplasm
6655	5875	Retroperitoneal Cancer
6656	5876	Apocrine Sweat Gland Neoplasm
6657	5877	Endocardium Cancer
6658	5884	Benign Intermediate Mesothelioma
6659	5886	Mixed Embryonal Carcinoma And Teratoma With Seminoma Of The Testis
6660	5888	Congenital Cystic Kidney Disease
6661	5889	Anaplastic Ependymoma
6662	589	Congenital Hemolytic Anemia
6663	5890	Malignant Adult Ependymoma
6664	5893	Childhood Malignant Mesenchymoma
6665	5894	Adult Malignant Mesenchymoma
6666	5895	Clear Cell Cystadenofibroma
6667	5896	Ovarian Clear Cell Cystadenofibroma
6668	5897	Ovarian Clear Cell Adenofibroma
6669	5898	Polycystic Kidney Disease
6670	5900	Meningeal Melanocytoma
6671	5907	Penis Non-invasive Verrucous Carcinoma
6672	5908	Penis Verrucous Carcinoma
6673	591	Phobic Disorder
6674	5913	Brachial Plexus Neoplasm
6675	5914	Nonencapsulated Sclerosing Carcinoma
6676	5915	Uterus Intravascular Leiomyomatosis
6677	5916	Uterine Corpus Leiomyomatosis
6678	5917	Uterine Corpus Diffuse Leiomyomatosis
6679	5918	Localized Unresectable Adult Primary Liver Cancer
6680	5919	Localized Unresectable Adult Primary Hepatoma
6681	5920	Malignant Fibrous Histiocytoma Metastatic
6682	5921	Adult Brainstem Mixed Glioma
6683	5922	Adult Brainstem Astrocytoma
6684	5923	Distal Biliary Tract Carcinoma
6685	5924	Recurrent Extrahepatic Bile Duct Cancer
6686	5926	Extrahepatic Bile Duct Small Cell Adenocarcinoma
6687	5928	Autosomal Recessive Polycystic Kidney
6688	593	Agoraphobia
6689	5931	Unresectable Extrahepatic Bile Duct Cancer
6690	5933	Resectable Bile Duct Cancer
6691	5934	Localized Extrahepatic Bile Duct Cancer
6692	5936	Ovarian Mixed Germ Cell Neoplasm
6693	5937	Autosomal Dominant Polycystic Kidney
6694	594	Panic Disorder
6695	5940	Malignant Peripheral Nerve Sheath Tumor
6696	5941	Lung Carcinoma Metastatic To The Brain
6697	5948	Angiokeratoma Of Mibelli
6698	5949	Angiokeratoma Circumscriptum
6699	5957	Bladder Urachal Squamous Cell Carcinoma
6700	5958	Bladder Urachal Carcinoma
6701	5963	Schistosoma Hematobium-related Bladder Squamous Cell Carcinoma
6702	5973	Kidney Pelvis Papillary Carcinoma
6703	5974	Renal Pelvis Transitional Cell Carcinoma
6704	5975	Renal Pelvis Papillary Tumor
6705	5976	Occlusion Precerebral Artery
6706	5977	Renal Pelvis Neoplasm
6707	5979	Human Papilloma Virus Related Vulvar Squamous Cell Carcinoma
6708	5980	Hemispheric Anaplastic Astrocytoma
6709	5981	Hamartoma Of Hypothalamus
6710	5982	Kidney Fibrosarcoma
6711	5983	Kidney Osteogenic Sarcoma
6712	5989	Clear Cell Myomelanocytic Tumor Of The Falciform Ligament/Ligamentum Teres
6713	599	Specific Phobia
6714	5990	Internal Auditory Canal Meningioma
6715	5991	Early Onset Breast Ovarian Cancer Syndrome
6716	5996	Blunt Duct Adenosis Of Breast
6717	5997	Non-proliferative Fibrocystic Change Of The Breast
6718	5998	Microglandular Adenosis
6719	5999	Apocrine Adenosis Of Breast
6720	600	Animal Phobia
6721	6000	Congestive Heart Failure
6722	6001	Breast Fibrosarcoma
6723	6003	Aleukemic Leukemia Cutis
6724	6004	Aleukemic Leukemia
6725	6013	Mediastinum Embryonal Carcinoma
6726	6014	Mediastinal Germ Cell Cancer
6727	6015	Adult Central Nervous System Teratoma
6728	6016	Adult Central Nervous System Mature Teratoma
6729	6017	Central Nervous System Mature Teratoma
6730	6018	Adult Central Nervous System Immature Teratoma
6731	6019	Central Nervous System Immature Teratoma
6732	602	Cancerophobia
6733	6020	Metastatic MPNST
6734	6021	Malignant Testicular Leydig Cell Tumor
6735	6022	Central Nervous System Melanoma
6736	6023	Metastasis To The Parathyroid Gland
6737	6024	Selective IgE Deficiency Disease
6738	6025	Selective Immunoglobulin Deficiency Disease
6739	603	AIDS Phobia
6740	6031	Disseminated Squamous Cell Carcinoma
6741	6032	Juvenile Type Testicular Granulosa Cell Tumor
6742	6033	Heart Fibrosarcoma
6743	6034	Heart Malignant Hemangiopericytoma
6744	6037	Spindle Cell Intraocular Melanoma
6745	6039	Uveal Melanoma
6746	6041	Choroid Spindle Cell Melanoma
6747	6043	Ciliary Body Spindle Cell Melanoma
6748	6045	AIDS Retinopathy
6749	6048	Telangiectatic Glomangioma
6750	605	Flying Phobia
6751	6050	Esophageal Disease
6752	6052	Central Nervous System Childhood Germ Cell Tumor
6753	6053	Pediatric Germ Cell Cancer
6754	6054	Frontal Sinus Schneiderian Papilloma
6755	6055	Paranasal Sinus Schneiderian Papilloma
6756	6059	Nasal Vestibule Papilloma
6757	606	Brown-Sequard Syndrome
6758	6065	Urinary Tract Non-invasive Transitional Cell Neoplasm
6759	6067	Ovarian Mucinous Neoplasm
6760	607	Paraplegia
6761	6071	Resectable Duodenal Carcinoma
6762	6077	Localized Malignant Mesothelioma
6763	6078	Secondary Malignant Neoplasm To The Nervous System
6764	6079	Drop Secondary Malignant Neoplasm To The Spinal Cord
6765	6080	Spinal Cord Secondary Cancer
6766	6081	Childhood Testicular Endodermal Sinus Neoplasm
6767	6082	Pediatric Testicular Germ Cell Tumor
6768	6083	Childhood Ovarian Endodermal Sinus Tumor
6769	6084	Pediatric Ovarian Germ Cell Tumor
6770	6085	Meningeal Melanoma
6771	6086	Malignant Leptomeningeal Tumor
6772	6087	Predominant Disturbance Of Emotions
6773	6088	Acute Stress Disorder
6774	6089	Pediatric Leptomeningeal Melanoma
6775	609	Skin Abnormality
6776	6090	Adult Leptomeningeal Melanoma
6777	6091	Ampulla Of Vater Intestinal Type Adenocarcinoma
6778	6098	Thalamic Neoplasm
6779	61	Mitral Valve Disease
6780	6101	Signet Ring Cell Variant Cervical Mucinous Adenocarcinoma
6781	6102	Herpetic Gastritis
6782	6103	Thoracic Spinal Canal And Spinal Cord Meningioma
6783	6104	Mixed Embryonal Carcinoma And Teratoma Of The Mediastinum
6784	6105	Mediastinum Malignant Teratoma
6785	6107	Mediastinal Mixed Non-seminomatous Germ Cell Tumor
6786	6108	Mesenchymal Hamartoma Of The Liver
6787	6109	Hepatic And Intrahepatic Bile Duct Non-epithelial Neoplasm
6788	611	Leukocyte-adhesion Deficiency Syndrome
6789	6110	Jugular Foramen Meningioma
6790	6111	Jugular Foramen Neoplasm
6791	6112	Cerebral Meningioma
6792	6113	Intracerebral Cystic Meningioma
6793	6114	Cerebral Convexity Meningioma
6794	6115	Lateral Ventricle Meningioma
6795	6118	Renal Pelvis Inverted Papilloma
6796	6119	Renal Pelvis Urothelial Papilloma
6797	612	Primary Immunodeficiency Disease
6798	6122	AIDS-related Anal Cancer
6799	6126	Anal Canal Carcinoma
6800	6128	Gliomatosis Cerebri
6801	613	T Lymphocyte Deficiency
6802	6132	Bronchitis
6803	6139	Uterine Corpus Epithelioid Leiomyosarcoma
6804	614	Lymphopenia
6805	6148	Nasal Cavity Carcinoma In Situ
6806	615	Leukopenia
6807	616	Deltaretrovirus Infectious Disease
6808	6160	Childhood Choriocarcinoma Of The Testis
6809	6161	Childhood Testicular Mixed Germ Cell Tumor
6810	6162	Childhood Embryonal Testis Carcinoma
6811	6163	Familial Renal Papillary Carcinoma
6812	6166	Prostatic Urethra Urothelial Carcinoma
6813	6167	Prostatic Urethral Cancer
6814	617	Retroviridae Infectious Disease
6815	6170	Ovarian Carcinosarcoma
6816	6171	Uterine Carcinosarcoma
6817	6174	Sporadic Conventional Renal Cell Carcinoma
6818	6175	Mediastinal Neurilemmoma
6819	6178	Metastatic Ovarian Small Cell Carcinoma With Hypercalcemia
6820	6179	Ovarian Small Cell Carcinoma
6821	6180	Cytomegalovirus Gastritis
6822	6184	Squamous Cell Carcinoma Of Unknown Primary
6823	619	Lymphoproliferative Disease
6824	6190	Rectum Kaposi's Sarcoma
6825	6192	Inflammatory MFH
6826	6193	Epithelioid Sarcoma
6827	6195	Conjunctivitis
6828	6196	Reactive Arthritis
6829	6197	Conventional Malignant Hemangiopericytoma
6830	6198	Corneal Intraepithelial Neoplasm
6831	6199	Cornea Cancer
6832	62	Aortic Valve Disease
6833	620	Blood Protein Disease
6834	6200	Recurrent Malignant Pericardial Mesothelioma
6835	6201	Pericardial Mesothelioma
6836	6202	Mesothelioma Malignant Recurrent
6837	6203	Thyroid Hyalinizing Trabecular Adenoma
6838	6204	Follicular Adenoma
6839	6208	Mediastinal Osteogenic Sarcoma
6840	6209	Malignant Mediastinum Hemangiopericytoma
6841	621	Simian Acquired Immunodeficiency Syndrome
6842	6210	Bladder Diffuse Clear Cell Adenocarcinoma
6843	6211	Mixed Epithelial Tumor Of Ovary
6844	6212	Ovarian Endometrial Cancer
6845	6213	Ovarian Serous Tumor
6846	6214	Ovarian Papillary Neoplasm
6847	6217	Gastric Diffuse Adenocarcinoma
6848	622	Lentivirus Infectious Disease
6849	6225	Cronkhite-Canada Syndrome
6850	6227	Articular Cartilage Disease
6851	6228	Peritoneal Serous Papillary Adenocarcinoma
6852	6229	Childhood Mature Teratoma Of The Ovary
6853	6230	Childhood Teratoma Of The Ovary
6854	6231	Mature Teratoma Of The Ovary
6855	6232	Ovarian Biphasic Or Triphasic Teratoma
6856	6239	Non-invasive Bladder Papillary Urothelial Neoplasm
6857	624	Transient Hypogammaglobulinemia Of Infancy
6858	6240	Transitional Cell Intraepithelial Neoplasm
6859	6244	Familial Renal Oncocytoma
6860	6245	Renal Oncocytoma
6861	6246	Oncocytic Neoplasm
6862	6249	Mediastinum Seminoma
6863	625	Transient Hypogammaglobulinemia
6864	6250	Epstein-Barr Virus Related Carcinoma
6865	6255	Growth Hormone Secreting Pituitary Adenoma
6866	6256	Malignant Growth Hormone Secreting Neoplasm Of Pituitary
6867	6257	Chromophil Adenoma Of The Kidney
6868	6258	Type 1 Papillary Adenoma Of The Kidney
6869	6259	Type 2 Papillary Adenoma Of The Kidney
6870	626	Complement Deficiency
6871	6262	Follicular Dendritic Cell Sarcoma
6872	6263	Inflammatory Breast Carcinoma
6873	6268	Recurrent Extraskeletal Chondrosarcoma
6874	627	Severe Combined Immunodeficiency
6875	6270	Gastric Cardia Carcinoma
6876	6271	Gastric Cardia Adenocarcinoma
6877	6273	Metastasis To Pituitary Gland
6878	6274	Malignant Thyroid Stimulating Hormone Producing Neoplasm Of Pituitary Gland
6879	6275	TSH Producing Pituitary Tumor
6880	6276	Malignant ACTH Producing Neoplasm Of Pituitary Gland
6881	6277	ACTH-producing Pituitary Tumor
6882	6278	Ovarian Mucinous Malignant Adenofibroma
6883	628	Combined T Cell And B Cell Immunodeficiency
6884	6284	Epicardium Lipoma
6885	6285	Heart Lipoma
6886	6286	Childhood Cerebellar Astrocytic Neoplasm
6887	6287	Recurrent Pediatric Cerebellar Astrocytoma
6888	6288	Recurrent Childhood Brain Tumor
6889	629	Congenital Disorder Of Natural Immunity
6890	6291	Cerebral Hemisphere Lipoma
6891	6292	Intracranial Lipoma
6892	6293	Central Nervous System Lipoma
6893	6294	Corpus Callosum Lipoma
6894	6296	Herpes Simplex Virus Esophagitis
6895	6297	Viral Esophagitis
6896	630	Genetic Disease
6897	6301	Prostate Basal Cell Carcinoma
6898	6307	Ectopic Thymus
6899	6308	Metastatic Transitional Cell Cancer Of The Renal Pelvis And Ureter
6900	631	Fibromyalgia
6901	6312	Clivus Chordoma
6902	6313	Clivus Chondroid Chordoma
6903	6314	Ovarian Fetiform Teratoma
6904	6315	Ovarian Solid Teratoma
6905	6316	Bartholin's Gland Adenocarcinoma
6906	6322	Tibial Adamantinoma
6907	6327	Ovarian Dermoid Cyst With Adenocarcinoma
6908	6328	Ovarian Dermoid Cyst With Secondary Carcinoma
6909	6329	Ovarian Dermoid Cyst With Secondary Tumor
6910	633	Myositis
6911	6331	Immature Teratoma Of Ovary
6912	6332	Adult Malignant Hemangiopericytoma
6913	6333	Adult Intracranial Malignant Hemangiopericytoma
6914	6334	Anterior Optic Tract Meningioma
6915	6335	Bilateral Meningioma Of Optic Nerve
6916	6337	Cerebellopontine Angle Meningioma
6917	6338	Testicular Tumor Of The Thecoma Fibroma Group
6918	6339	Vulvar Eccrine Adenocarcinoma
6919	6344	Melanocytic Psammomatous MPNST
6920	6345	Malignant Melanocytic Neoplasm Of The Peripheral Nerve Sheath
6921	635	Acquired Immunodeficiency Syndrome
6922	6354	CLL/SLL
6923	636	Central Pontine Myelinolysis
6924	6361	Renal Cell Carcinoma With Constitutional Chromosome 3 Translocations
6925	6364	Migraine
6926	6367	Acral Lentiginous Melanoma
6927	637	Metabolic Brain Disease
6928	6370	Hepatic Osteogenic Sarcoma
6929	6376	Hypersplenism
6930	6379	Diffuse Meningeal Melanocytosis
6931	638	Demyelinating Disease Of Central Nervous System
6932	6380	Adult Brain Medulloblastoma
6933	6381	Anterior Foramen Magnum Meningioma
6934	6382	Recurrent Childhood Glioma Of Brain Stem
6935	6383	Childhood Brain Stem Glioma
6936	6384	Recurrent Childhood Central Nervous System Tumor
6937	6385	Recurrent Childhood Brainstem Astrocytoma
6938	6386	Childhood Brainstem Astrocytoma
6939	639	Acute Disseminated Encephalomyelitis
6940	64	Epithelial Tissue Disease
6941	640	Encephalomyelitis
6942	6404	Metanephric Adenoma
6943	6405	Ovarian Papillary Cystadenoma
6944	6406	Double Outlet Right Ventricle
6945	6407	Ovarian Surface Papilloma
6946	6408	Ovary Papillary Carcinoma
6947	641	CNS Demyelinating Autoimmune Disease
6948	6419	Tetralogy Of Fallot
6949	642	Demyelinating Encephalopathy
6950	6420	Pulmonary Valve Stenosis
6951	6423	Childhood Central Nervous System Mature Teratoma
6952	6424	Pediatric CNS Teratoma
6953	6425	Eyelid Carcinoma
6954	6428	Cervical Adenoid Basal Carcinoma
6955	643	Progressive Multifocal Leukoencephalopathy
6956	6432	Pulmonary Hypertension
6957	6438	Malignant Choroid Melanoma
6958	644	Leukoencephalopathy
6959	6445	Ovarian Endometrioid Malignant Adenofibroma
6960	6446	Ceruminous Carcinoma
6961	6447	Ceruminous Tumor
6962	6448	Vulvar Apocrine Adenocarcinoma
6963	6451	Central Nervous System Fibrosarcoma
6964	6457	Cowden Disease
6965	6458	Cerebellar Liponeurocytoma
6966	6459	Lipoma Of The Rectum
6967	646	Viral Encephalitis
6968	6460	Large Intestine Lipoma
6969	6467	Bone Recurrent Ewing's Sarcoma
6970	6468	Mucinous Cystadenofibroma
6971	6469	Ovarian Mucinous Adenofibroma
6972	647	Polyomavirus Infectious Disease
6973	6474	Childhood Teratocarcinoma Of The Testis
6974	6476	Clear Cell Variant Infiltrating Bladder Urothelial Carcinoma
6975	6477	Invasive Bladder Transitional Cell Carcinoma
6976	648	Kuru
6977	6481	Bladder Signet Ring Cell Adenocarcinoma
6978	6482	Lung Acinar Adenocarcinoma
6979	6483	Rete Testis Adenoma
6980	6484	Mediastinal Melanocytic Neurilemmoma
6981	6488	Metastatic Tumor To The Iris
6982	6489	Periosteal Osteogenic Sarcoma
6983	649	Prion Disease
6984	6491	Breast Capillary Hemangioma
6985	6492	Breast Epithelioid Hemangioma
6986	6494	Pediatric Myxoid Chondrosarcoma
6987	6495	Adult Myxoid Chondrosarcoma
6988	6496	Extraskeletal Myxoid Chondrosarcoma
6989	6498	Seborrheic Keratosis
6990	65	Connective Tissue Disease
6991	6500	Cerebellar Angioblastoma
6992	6501	Brain Stem Angioblastoma
6993	6505	Vaginal Spindle Cell Epithelioma
6994	6506	Anaplastic Seminoma
6995	6510	Lung Occult Squamous Cell Carcinoma
6996	6511	Glandular Pattern Ovarian Yolk Sac Tumor
6997	6512	Hepatoid Pattern Ovarian Yolk Sac Tumor
6998	6514	Polyvesicular Vitelline Pattern Ovarian Yolk Sac Tumor
6999	6517	Clivus Meningioma
7000	6518	Bartholin's Gland Adenomyoma
7001	652	Congenital Musculoskeletal Abnormality
7002	6522	Mixed Cell Uveal Melanoma
7003	6523	Ciliary Body Mixed Cell Melanoma
7004	6524	Malignant Ciliary Body Melanoma
7005	6525	Choroid Mixed Cell Melanoma
7006	653	Purine-pyrimidine Metabolic Disorder
7007	6530	Cortical Thymoma
7008	6532	Monomorphic B-cell PTLD
7009	6533	Monomorphic PTLD
7010	6535	Plasma Cell PTLD
7011	6536	Plasma Cell Neoplasm
7012	654	Overnutrition
7013	6540	Transient Organic Mental Disorder
7014	6543	Acne
7015	6544	Atypical Meningioma
7016	6545	Adult Atypical Meningioma
7017	6546	Secondary Cardiac Lymphoma
7018	6547	Heart Lymphoma
7019	6548	Angiomatous Meningioma
7020	6549	Schistosoma Hematobium-related Bladder Verrucous Squamous Cell Carcinoma
7021	655	Inherited Metabolic Disorder
7022	6552	Gastric Small Cell Carcinoma
7023	6553	Posterior Foramen Magnum Meningioma
7024	6554	Ovarian Clear Cell Malignant Adenofibroma
7025	6556	Hamartoma Of Spinal Cord
7026	6559	Ethmoid Sinus Schneiderian Papilloma
7027	656	Adrenal Adenoma
7028	6562	Ethmoid Sinus Inverted Papilloma
7029	6563	Metastatic Testicular Cancer
7030	6564	Neurilemmoma Of The Pleura
7031	6566	Posterior Uveal Melanoma
7032	6567	Uterine Corpus Myxoid Leiomyosarcoma
7033	6569	Micropapillomatosis Labialis
7034	657	Adenoma
7035	6571	Non-invasive Bladder Urothelial Carcinoma
7036	6573	Recurrent Adult Brain Tumor
7037	6574	Borderline Malignancy Papillary Mucinous Cystadenoma
7038	6575	Childhood Optic Tract Astrocytoma
7039	6576	Childhood Optic Nerve Glioma
7040	6577	Ovarian Dermoid Cyst With Sebaceous Adenoma
7041	6578	Ovarian Dermoid Cyst With Secondary Sebaceous Tumor
7042	6579	Chest Wall Bone Cancer
7043	6581	Breast Apocrine Carcinoma
7044	6585	Oncocytic Breast Carcinoma
7045	6587	Invasive Tubular Breast Carcinoma
7046	6590	Spondylitis
7047	6594	Bladder Colonic Type Adenocarcinoma
7048	6595	Gastric Tubular Adenocarcinoma
7049	66	Muscle Tissue Disease
7050	660	Adrenal Cortex Cancer
7051	6602	Recurrent Malignant Peritoneal Mesothelioma
7052	6603	Kummell's Disease
7053	6604	Spondylosis And Allied Disorder
7054	6605	Classic Variant Of Chromophobe Renal Cell Carcinoma
7055	6606	Eosinophilic Variant Of Chromophobe Renal Cell Carcinoma
7056	6607	Nervous System Hibernoma
7057	6608	Endobronchial Leiomyoma
7058	6609	Basaloid Squamous Cell Carcinoma Of The Head And Neck
7059	6610	Bone Epithelioid Hemangioma
7060	6612	Leukocyte Adhesion Deficiency
7061	6613	Vaginal Villous Adenoma
7062	6618	Unknown Primary Adenocarcinoma
7063	6620	X-linked Hyper IgM Syndrome
7064	6621	Cerebral Angioma
7065	6627	Cervical Adenoma Malignum
7066	6628	Malignant Neoplasm Of Nipple
7067	6629	Nipple Carcinoma
7068	663	Scrotal Angioma
7069	6630	Ovarian Dermoid Cyst With Secondary Sarcoma
7070	6631	Ovarian Dermoid Cyst With Leiomyosarcoma
7071	6632	Ovarian Dermoid Cyst With Angiosarcoma
7072	6634	Adult Central Nervous System Choriocarcinoma
7073	6639	Pediatric CNS Choriocarcinoma
7074	664	Angiokeratoma Of Fordyce
7075	6641	Breast Juvenile Papillomatosis
7076	6643	Baastrup's Syndrome
7077	6648	Adult Pineoblastoma
7078	6652	Diffuse Idiopathic Skeletal Hyperostosis
7079	6654	Childhood Central Nervous System Immature Teratoma
7080	6657	Breast Large Cell Neuroendocrine Carcinoma
7081	6658	Pulmonary Large Cell Neuroendocrine Carcinoma
7082	6659	Cervical Large Cell Neuroendocrine Carcinoma
7083	6663	Papillotubular Adenocarcinoma
7084	6667	Regressing Nevus
7085	6675	Menopausal Syndrome
7086	6676	Froelich's Syndrome
7087	6677	Diffuse Infiltrative Lymphocytosis Syndrome
7088	6678	Tooth And Nail Syndrome
7089	668	Myositis Ossificans
7090	6680	Capgras Syndrome
7091	6681	Diffuse Leiomyomatosis Syndrome
7092	6682	Spondylolisthesis
7093	6683	Aarskog-Scott Syndrome
7094	6686	Achard Syndrome
7095	6687	Achenbach Syndrome
7096	6688	Autoimmune Lymphoproliferative Syndrome
7097	6689	Adherence Syndrome
7098	6690	Acroparesthesia Syndrome
7099	6691	Aagenaes Syndrome
7100	6692	Barre-Lieou Syndrome
7101	6693	Testicular Monophasic Choriocarcinoma
7102	6696	Synchronous Multifocal Osteogenic Sarcoma
7103	6697	Asynchronous Multifocal Osteogenic Sarcoma
7104	67	Neural Tissue Disease
7105	670	Amphetamine Abuse
7106	6700	Gastric Fundus Carcinoma
7107	6702	Recurrent Stomach Cancer
7108	6703	Gastric Pylorus Carcinoma
7109	6704	Anaplastic Gastric Carcinoma
7110	6705	Gastric Body Carcinoma
7111	6706	Tubular Variant Testicular Seminoma
7112	6707	Malignant Triton Tumor
7113	6708	Recurrent Ovarian Epithelial Cancer
7114	6710	Metastatic Anal Cancer
7115	6712	Anterior Spinal Artery Syndrome
7116	6713	Cerebrovascular Disease
7117	6714	Circumscribed Storiform Collagenoma
7118	6715	Collagen Nevus Of Skin
7119	6716	Eruptive Collagenoma
7120	672	Spleen Cancer
7121	6721	Littre Gland Carcinoma
7122	6723	Malignant Type AB Thymoma
7123	6725	Spinal Stenosis
7124	6726	Fibrillary Astrocytoma
7125	6727	Colon Small Cell Carcinoma
7126	6728	Recurrent Pediatric Optic Nerve Astrocytoma
7127	6729	Recurrent Pediatric Optic Nerve Glioma
7128	6730	Recurrent Childhood Optic Tract Astrocytoma
7129	6731	Recurrent Glioma Of Childhood Visual Pathway
7130	6733	Intrahepatic Bile Duct Cystadenoma
7131	6735	Schwannoma Of Jugular Foramen
7132	674	Cleft Palate
7133	6740	Cervix Small Cell Carcinoma
7134	6741	Bilateral Breast Cancer
7135	6742	Synchronous Bilateral Breast Carcinoma
7136	6750	Malignant Fibrous Histiocytoma Recurrent
7137	6752	Internal Auditory Canal Lipoma
7138	6755	Amyloid Tumor
7139	6758	Chest Wall Lymphoma
7140	6759	Bone Lymphoma
7141	676	Juvenile Rheumatoid Arthritis
7142	6760	Lung Lymphoma
7143	6761	Skin Lymphoma
7144	6762	Sternum Lymphoma
7145	6764	Peripheral Neuroblastoma
7146	6774	Polyembryoma Of The Ovary
7147	6776	Breast Myoepithelial Carcinoma
7148	6777	Villoglandular Endometrial Endometrioid Adenocarcinoma
7149	6778	Renal Pelvis And Ureter Localized Transitional Cell Cancer
7150	678	Progressive Supranuclear Palsy
7151	6784	Pediatric Desmoplastic Small Round Cell Tumor
7152	6785	Desmoplastic Small Round Cell Tumor
7153	6786	Childhood Botryoid Rhabdomyosarcoma
7154	6787	Childhood Vagina Botryoid Rhabdomyosarcoma
7155	6788	Vagina Botryoid Rhabdomyosarcoma
7156	6789	Vulvar Childhood Botryoid-type Embryonal Rhabdomyosarcoma
7157	679	Basal Ganglia Disease
7158	6792	Mixed Endodermal Sinus Neoplasm And Teratoma With Seminoma Of The Testis
7159	68	Lymphomyeloid Tissue Disease
7160	680	Tauopathy
7161	6801	Recurrent Hematologic Cancer
7162	6802	Relapsed Precursor T Lymphoblastic Lymphoma/leukemia
7163	6803	Recurrent Adult Acute Lymphocytic Leukemia
7164	6804	Colon Kaposi Sarcoma
7165	6807	Hamartoma Moniliformis
7166	6808	Basaloid Follicular Hamartoma
7167	6809	Vaginal Tubular Adenoma
7168	681	Progressive Bulbar Palsy
7169	6811	Juvenile Pilocytic Astrocytoma
7170	6812	Childhood Pilocytic Astrocytoma
7171	682	Compartment Syndrome
7172	6820	Anaplastic Childhood Astrocytoma Of Brain
7173	6823	Pancreatoblastoma
7174	6826	Recurrent Cancer Of Pancreas
7175	6827	Pancreatic Solid Pseudopapillary Carcinoma
7176	6828	Non-resectable Pancreatic Carcinoma
7177	683	Motor Neuritis
7178	6830	Resectable Pancreas Carcinoma
7179	6835	Recurrent Anal Cancer
7180	6837	Rete Ovarii Adenoma
7181	6838	Rete Ovarii Cystadenofibroma
7182	6839	Breast Intraductal Proliferative Lesion
7183	684	Hepatocellular Carcinoma
7184	6840	Glandular Cell Intraepithelial Neoplasm
7185	6841	Flat Ductal Epithelial Atypia
7186	6844	Kidney Pelvis Sarcomatoid Transitional Cell Carcinoma
7187	6845	Infiltrating Ureter Transitional Cell Carcinoma
7188	6846	Familial Melanoma
7189	6847	Adult Botryoid Rhabdomyosarcoma
7190	6848	Adult Vagina Botryoid Rhabdomyosarcoma
7191	6849	Testicular Intratubular Germ Cell Neoplasia Of The Unclassified Type
7192	6850	Hamartoma Of Eccrine Sweat Gland
7193	6851	Linear Eccrine Nevus With Comedones
7194	6852	Eccrine Angiomatous Hamartoma
7195	6854	Ethmoid Sinus Ectopic Meningioma
7196	6856	Pineal Region Teratoma
7197	6857	Pineal Region Mature Teratoma
7198	6858	Pineal Region Immature Teratoma
7199	686	Liver Carcinoma
7200	6860	Endobronchial Hamartoma
7201	6861	Recurrent Cancer Of Gallbladder
7202	6865	Oxyphilic Endometrial Endometrioid Adenocarcinoma
7203	6867	Mediastinal Gray Zone Lymphoma
7204	6868	Mediastinal Malignant Lymphoma
7205	6869	Parasagittal Meningioma
7206	687	Hepatoblastoma
7207	6870	Cockade Nevus
7208	6871	Spinal Cord Neuroblastoma
7209	6872	Spinal Cord Primitive Neuroectodermal Neoplasm
7210	6873	Skin Tag
7211	6874	Type 1a ALPS
7212	6876	Mixed Childhood Rhabdomyosarcoma
7213	6879	Hamartoma Of Apocrine Sweat Gland
7214	688	Embryonal Cancer
7215	6880	Small Bowel Fibrosarcoma
7216	6886	Ureter Small Cell Carcinoma
7217	6887	Recurrent Ureteric Cancer
7218	6888	Ureter Transitional Cell Carcinoma
7219	6893	AIDS-related Cervical Cancer
7220	6894	AIDS-related Cervical Kaposi's Sarcoma
7221	6895	AIDS-related Kaposi's Sarcoma
7222	6897	Malposition And Malpresentation Of Fetus
7223	6898	Ovary Mixed Epithelial Carcinoma
7224	6899	Malignant Ovarian Mixed Epithelial Neoplasm
7225	69	Hemopoetic Tissue Disease
7226	690	Childhood Cancer Of Liver
7227	6901	Familiar Ovarian Carcinoma
7228	6903	Eye Lymphoma
7229	6905	AIDS-related Herpes Zoster
7230	6906	Glomangiomatosis
7231	6917	Predominantly Cortical Thymoma
7232	6919	Extramucosal (perianal) Adenocarcinoma
7233	6923	Fibrolipomatous Hamartoma Of Peripheral Nerve
7234	6925	Peroneal Nerve Paralysis
7235	6929	Retinal Edema
7236	693	Dental Enamel Hypoplasia
7237	6931	Papillary Extrahepatic Bile Duct Adenocarcinoma
7238	6932	Urinary Bladder Inverted Papilloma
7239	6933	Bladder Transitional Cell Papilloma
7240	6934	Urethra Inverted Papilloma
7241	6935	Ureter Inverted Papilloma
7242	6936	Ureter Urothelial Papilloma
7243	6938	Pediatric Intraocular Retinoblastoma
7244	6939	Childhood Brain Meningioma
7245	6943	Vulvar Inverted Follicular Keratosis
7246	6944	Vulvar Seborrheic Keratosis
7247	6945	Inverted Follicular Keratosis
7248	6947	Sphenoidal Sinus Neoplasm
7249	6948	Malignant Gastric Teratoma
7250	6949	Malignant Gastric Germ Cell Tumor
7251	6950	Combat Disorder
7252	6951	Telangiectatic Osteogenic Sarcoma
7253	6954	Epstein-Barr Virus Related Lymphoma
7254	6955	Intracranial Melanoma
7255	6956	Malignant Intracranial Neoplasm By Morphology
7256	6958	Aleukemic Monocytic Leukemia Cutis
7257	6959	Rectal Cloacogenic Carcinoma
7258	6961	Bartholin's Gland Squamous Cell Carcinoma
7259	6962	Recurrent Cancer Of Skin
7260	6969	Acute Canaliculitis
7261	6970	Acute Inflammation Of Lacrimal Passage
7262	6975	Bladder Urothelial Papillary Carcinoma
7263	6976	Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma
7264	6977	Pancreatic Cholera
7265	698	Dentin Sensitivity
7266	6980	Recurrent Rectosigmoid Cancer
7267	6981	Recurrent Colorectal Cancer
7268	6988	Peripheral Epithelioid Sarcoma
7269	6989	Non-neoplastic Non-molar Trophoblastic Disorder
7270	699	Mitochondrial Myopathy
7271	6990	Placental Site Nodule Or Plaque
7272	6991	Exaggerated Placental Site
7273	6992	Intraocular Mixed Cell Type Melanoma
7274	6993	Iris Mixed Cell Melanoma
7275	6994	Malignant Iris Melanoma
7276	6995	Metastasis To The Kidney
7277	6996	Intermediate Cell Type Choroid Melanoma
7278	6997	Intermediate Cell Type Ciliary Body Melanoma
7279	6998	Gallbladder Mucinous Carcinoma
7280	6999	Lung Recurrent Squamous Cell Carcinoma
7281	7	Disease Of Anatomical Entity
7282	70	Lymphoid Tissue Disease
7283	700	Mitochondrial Metabolism Disease
7284	7001	Recurrent Large Cell Carcinoma Of Lung
7285	7002	Recurrent Adenocarcinoma Of Lung
7286	7003	Malignant Vaginal Mixed Tumor Resembling Synovial Sarcoma
7287	7004	ACTH-secreting Pituitary Adenoma
7288	7005	Gemistocytic Astrocytoma
7289	7006	Childhood Cerebral Diffuse Astrocytoma
7290	7007	Childhood Cerebral Astrocytoma
7291	7008	Protoplasmic Astrocytoma
7292	7009	Adult Diffuse Astrocytoma
7293	701	Dentin Dysplasia
7294	7011	Recurrent Thyroid Carcinoma
7295	7012	Anaplastic Thyroid Carcinoma
7296	7013	Ovarian Mucinous Cystadenofibroma
7297	7014	Infiltrating Lipoma
7298	7015	Deep Fatty Neoplasm
7299	7016	Tendon Sheath Lipoma
7300	7017	Lumbosacral Lipoma
7301	7018	Secondary Malignant Neoplasm To The Adult Brain
7302	702	Tooth Abnormality
7303	7023	Borderline Ovarian Serous Neoplasm With Microinvasion
7304	7024	Mucinous Intrahepatic Cholangiocarcinoma
7305	7025	Anaplastic Malignant Intracranial Meningioma
7306	7026	Adult Malignant Meningioma
7307	7029	Site Specific Early Onset Breast Cancer Syndrome
7308	7030	Bronchial Mucus Gland Adenoma
7309	7031	Glottis Squamous Cell Carcinoma
7310	7032	Bile Duct Clear Cell Adenocarcinoma
7311	7033	Anisakiasis
7312	7037	Childhood Immature Teratoma Of Ovary
7313	7039	Borst-Jadassohn Intraepidermal Carcinoma
7314	7040	Uveal Epithelioid Cell Melanoma
7315	7041	Choroid Epithelioid Cell Melanoma
7316	7042	Ciliary Body Epithelioid Cell Melanoma
7317	7043	Metastatic Vulvar Cancer
7318	7045	Basaloid Lung Carcinoma
7319	7046	Cervical Basaloid Squamous Cell Carcinoma
7320	7047	Penis Basaloid Carcinoma
7321	7048	Vulvar Basaloid Squamous Cell Carcinoma
7322	7049	Basaloid Squamous Cell Skin Carcinoma
7323	705	Leber Hereditary Optic Neuropathy
7324	7050	Thymus Basaloid Carcinoma
7325	7051	Esophageal Basaloid Squamous Cell Carcinoma
7326	7053	Anaplastic Small Cell Thyroid Carcinoma
7327	7054	Multiple Skull Base Meningioma
7328	706	Mature B-cell Neoplasm
7329	7061	Precursor B Lymphoblastic Lymphoma/leukemia
7330	707	B-cell Lymphoma
7331	7070	Recurrent Pediatric Rhabdomyosarcoma
7332	7071	Spinal Cord Dermoid Cyst
7333	7074	Choroidal Hemorrhage And Rupture
7334	7075	Atypical Vulvar Nevus
7335	7076	Lipid-rich Breast Carcinoma
7336	7077	Malignant Melanocytic Peripheral Nerve Sheath Tumor Of Mediastinum
7337	7078	Malignant Mediastinal Peripheral Nerve Sheath Tumor
7338	7079	Adult Cystic Teratoma
7339	7081	Lung Mixed Small Cell And Squamous Cell Carcinoma
7340	7083	Recurrent Adult Primary Hepatoma
7341	7084	Recurrent Adult Primary Liver Cancer
7342	7086	Multicentric Papillary Thyroid Carcinoma
7343	7088	Columnar Cell Variant Papillary Carcinoma
7344	7089	Tall Cell Variant Papillary Carcinoma
7345	709	Splenic Manifestation Of Hairy Cell Leukemia
7346	7095	Pediatric Epithelioid Sarcoma
7347	7097	Macrocystic Pattern Testicular Yolk Sac Tumor
7348	7099	Ovarian Dermoid Cyst With Squamous Cell Carcinoma
7349	710	Splenic Manifestation Of Leukemia
7350	7103	Diaphragma Sellae Meningioma
7351	7105	Epiglottis Neoplasm
7352	711	Refractory Hairy Cell Leukemia
7353	712	Refractory Hematologic Cancer
7354	7127	Radiation Cystitis
7355	713	HCL-V
7356	7132	Urinary Bladder Small Cell Neuroendocrine Carcinoma
7357	7133	Gallbladder Small Cell Carcinoma
7358	7134	Esophagus Small Cell Carcinoma
7359	7136	Ampulla Of Vater Small Cell Carcinoma
7360	7138	Cystitis Cystica
7361	7139	Endometrial Small Cell Carcinoma
7362	7140	Bartholin's Gland Small Cell Carcinoma
7363	7141	Prostate Small Cell Carcinoma
7364	7142	Thymus Small Cell Carcinoma
7365	7144	Laryngeal Small Cell Carcinoma
7366	7145	Papillary Cystic Tumor
7367	7146	Langerhans Cell Sarcoma
7368	7147	Ankylosing Spondylitis
7369	7148	Rheumatoid Arthritis
7370	7149	Metastatic Parathyroid Cancer
7371	715	T-cell Leukemia
7372	7150	Recurrent Parathyroid Cancer
7373	7152	Prostate Stromal Sarcoma
7374	7154	Anaplastic Oligodendroglioma
7375	7155	Adult Undifferentiated Oligodendroglioma
7376	7156	Anaplastic Childhood Oligodendroglioma
7377	7157	Metastatic Squamous Neck Cancer With Occult Primary
7378	7158	Recurrent Metastatic Squamous Cell Cancer To The Neck With Occult Primary
7379	716	Human T-lymphotropic Virus 2 Infectious Disease
7380	7160	Rectum Leiomyoma
7381	7162	Recurrent Larynx Cancer
7382	7164	Mediastinum Mature Teratoma
7383	7165	Subacute Thyroiditis
7384	7166	Thyroiditis
7385	7168	Lung Occult Adenocarcinoma
7386	7169	Lung Occult Large Cell Carcinoma
7387	7170	Recurrent Non-cutaneous Melanoma
7388	7171	Recurrent Cutaneous Melanoma
7389	7173	Cloacogenic Carcinoma
7390	7174	Anus Basaloid Carcinoma
7391	7175	Anal Buschke-Lowenstein Tumor
7392	7177	Anal Canal Squamous Cell Carcinoma
7393	7179	Mixed Eosinophil-basophil Adenoma
7394	718	Autoimmune Hemolytic Anemia
7395	7181	Benign Dermal Neurilemmoma
7396	7186	Metastatic Childhood Sarcoma Of Soft Tissue
7397	7187	Subacute Lymphocytic Thyroiditis
7398	7188	Autoimmune Thyroiditis
7399	7191	Ovarian Endometrioid Cystadenoma
7400	7192	Hereditary Conventional Renal Cell Carcinoma
7401	7198	Maxillary Sinus Adenoid Cystic Carcinoma
7402	720	Normocytic Anemia
7403	7202	Intermediate Malignant Teratoma
7404	7206	Melanomatosis
7405	7207	Lung Combined Large Cell Neuroendocrine Carcinoma
7406	7210	Psammomatous Meningioma
7407	7211	Fibrous Meningioma
7408	7212	Meningothelial Meningioma
7409	7213	Transitional Meningioma
7410	7214	Noninvasive Malignant Thymoma
7411	7215	Relapsed Childhood Ependymoma
7412	722	Spontaneous Abortion
7413	7221	Gallbladder Papillary Carcinoma
7414	7222	Gallbladder Pleomorphic Giant Cell Adenocarcinoma
7415	7223	Breast Giant Fibroadenoma
7416	7224	Spinal Meninges Cancer
7417	7230	Postgerminal Center Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
7418	7231	Pediatric CNS Embryonal Cell Carcinoma
7419	7232	Central Nervous System Embryonal Carcinoma
7420	7233	Adult Central Nervous System Embryonal Carcinoma
7421	7234	Pancreatic Colloid Cystadenocarcinoma
7422	7235	Pancreatic Mucinous Cystadenoma
7423	7236	Pancreatic Invasive Mucinous Cystadenocarcinoma
7424	7237	Pancreatic Non-invasive Mucinous Cystadenocarcinoma
7425	7238	AIDS-related Gastric Kaposi's Sarcoma
7426	724	Female Stress Incontinence
7427	7241	Uterine Corpus Apoplectic Leiomyoma
7428	7242	Uterine Corpus Cellular Leiomyoma
7429	7244	Bladder Urachal Urothelial Carcinoma
7430	7245	Metastatic Endometrial Adenocarcinoma
7431	7246	Lymphoepithelioma-like Acinar Prostate Adenocarcinoma
7432	7252	Cerebral Meninges Malignant Neoplasm
7433	7256	Anaplastic Urethra Carcinoma
7434	7262	Gallbladder Anaplastic Carcinoma
7435	7263	Selective IgD Deficiency Disease
7436	7266	Familiar Fallopian Tube Carcinoma
7437	7267	Lung Clear Cell Carcinoma
7438	7268	Solid Carcinoma Of Lung With Mucus Formation
7439	7269	Cribriform Variant Testicular Seminoma
7440	727	Premenstrual Tension
7441	7273	Adrenal Gland Tuberculosis
7442	728	Nodular Episcleritis
7443	7280	Congenital Epulis
7444	7281	Uterine Corpus Adenocarcinofibroma
7445	7284	Skene Gland Carcinoma
7446	7289	Secretory Uterine Corpus Endometrioid Adenocarcinoma
7447	7293	Mucin-rich Endometrial Endometrioid Adenocarcinoma
7448	7295	Recurrent Childhood Soft Tissue Sarcoma
7449	7296	Nonmetastatic Childhood Soft Tissue Sarcoma
7450	7297	Childhood Extraosseous Osteosarcoma
7451	730	Urethral Benign Neoplasm
7452	7301	Inferior Vena Cava Leiomyosarcoma
7453	7302	Endodermal Sinus Pattern Testicular Yolk Sac Tumor
7454	7304	Breast Carcinoma Metastatic To The Brain
7455	7305	Astroblastoma
7456	7306	Anaplastic Oligoastrocytoma
7457	731	Urinary System Benign Neoplasm
7458	7312	Breast Adenomyoepithelial Adenosis
7459	7315	Jewett-Marshall Bladder Cancer
7460	7316	Inherited Neuropathy
7461	7319	Axonal Neuropathy
7462	732	Urethral Disease
7463	7320	Ovarian Serous Cystadenofibroma
7464	7323	Primary Cerebral Lymphoma In Immunocompetent Host
7465	7324	Hepatitis C Virus Related Hepatocellular Carcinoma
7466	7325	Hepatitis B Virus Related Hepatocellular Carcinoma
7467	7326	Cranial Pseudosarcomatous Fasciitis
7468	7327	Pseudosarcomatous Fibromatosis
7469	7328	Iris Spindle Cell Melanoma
7470	7332	Esophageal Tuberculosis
7471	7333	Nephrogenic Adenoma Of Urinary Bladder
7472	7334	Nephrogenic Adenoma
7473	7335	Extraocular Extension Of Melanoma
7474	734	Urethra Cancer
7475	7340	Pediatric Ovarian Dysgerminoma
7476	7344	Anaplastic Brainstem Astrocytoma
7477	7345	Anaplastic Glioma Of Brain Stem
7478	7347	Ovarian Stromal Hyperthecosis
7479	735	Metastatic Neoplasm Of Urethra
7480	7350	Thymic Dysplasia
7481	7351	Localized Askin's Tumor
7482	7352	Diencephalic Anaplastic Astrocytoma
7483	7356	Rectum Sarcomatoid Carcinoma
7484	7357	Rectal Anaplastic Carcinoma
7485	7358	Recurrent Rectal Cancer
7486	736	Male Urethral Cancer
7487	7360	Solid Pattern Testicular Yolk Sac Tumor
7488	7362	Teratoma Of CNS With Malignant Transformation
7489	7363	Vulvar Keratinizing Squamous Cell Carcinoma
7490	7364	Organic Anxiety Disorder
7491	7365	Kimura Disease
7492	7371	Superficial Urinary Bladder Cancer
7493	7378	Pituitary Hypoplasia
7494	7379	Adrenal Medulla Carcinoma
7495	738	Female Urethral Cancer
7496	7380	Squamous Cell Papilloma Of Skin
7497	7381	Lymphohistiocytoid Mesothelioma
7498	7384	Localized Resectable Adult Primary Hepatoma
7499	7385	Localized Resectable Adult Primary Liver Cancer
7500	7388	Pulmonary Vein Leiomyosarcoma
7501	7389	Pulmonary Artery Leiomyosarcoma
7502	739	Metastasis To The Urethra
7503	7390	Superior Vena Cava Leiomyosarcoma
7504	7391	Superior Vena Cava Malignant Neoplasm
7505	7398	Cerebral Primitive Neuroectodermal Tumor
7506	74	Hematopoietic System Disease
7507	7400	Nijmegen Breakage Syndrome
7508	7401	Colonic L-cell Glucagon-like Peptide Producing Tumor
7509	7402	L-cell Glucagon-like Peptide Producing Tumor
7510	7407	Metastatic Carcinoma To The Uterine Cervix
7511	7408	Vulvar Keratoacanthoma-like Carcinoma
7512	7409	Vulvar Non-keratinizing Squamous Cell Carcinoma
7513	7410	Vulvar Squamous Cell Carcinoma With Tumor Giant Cells
7514	7411	Ovarian Endometrioid Cystadenofibroma
7515	7419	Metaplastic Meningioma
7516	7420	Placental Infarction
7517	7423	Ovarian Mucinous Cystic Tumor With Mural Nodules
7518	7426	Cutaneous Anthrax
7519	7427	Anthrax Disease
7520	7428	Pineal Region Germinoma
7521	7429	Childhood Brain Germinoma
7522	743	Dermatographia
7523	7430	Childhood Germ Cell Brain Tumor
7524	7435	Polyvesicular Vitelline Pattern Testicular Yolk Sac Tumor
7525	7436	Sarcomatoid Uterine Corpus Endometrioid Adenocarcinoma
7526	7437	Uterus Perivascular Epithelioid Cell Tumor
7527	7438	Ovarian Clear Cell Cystadenocarcinoma
7528	7439	Polyp Of Middle Ear
7529	744	Muscle Calcification And Ossification
7530	7441	Chronic Metabolic Polyneuropathy
7531	7442	Monoclonal Gammopathy Of Uncertain Significance
7532	7444	Diffuse Intraductal Papillomatosis
7533	745	Epididymis Adenomatoid Tumor
7534	7455	Hypogonadotropism
7535	7457	Enterobiasis
7536	7459	Acantholytic Variant Squamous Cell Breast Carcinoma
7537	746	Adenomatoid Tumor
7538	7460	Spindle Cell Variant Squamous Cell Breast Carcinoma
7539	7461	Large Cell Keratinizing Variant Squamous Cell Breast Carcinoma
7540	7463	Childhood Pleomorphic Rhabdomyosarcoma
7541	7465	Chronic NK-cell Lymphocytosis
7542	7468	Spitz Nevus
7543	7469	Balloon Cell Nevus
7544	7470	Neural Nevus
7545	7471	Deep Penetrating Nevus
7546	7472	Recurrent Nevus
7547	7473	Recurrent Malignant Pleural Mesothelioma
7548	7474	Malignant Pleural Mesothelioma
7549	7475	Diverticulitis
7550	7479	Duodenal Somatostatinoma
7551	7480	Large Cell Carcinoma With Rhabdoid Phenotype
7552	7482	Petrous Apex Meningioma
7553	7483	Cervical Keratinizing Squamous Cell Carcinoma
7554	7486	Metastatic Renal Cell Carcinoma
7555	7488	Posterior Urethra Cancer
7556	7489	Osgood-Schlatter's Disease
7557	749	Active Peptic Ulcer Disease
7558	7491	Vulvar Proximal-type Epithelioid Sarcoma
7559	7492	Central Epithelioid Sarcoma
7560	7497	Brain Ependymoma
7561	7498	AIDS-related Human Papillomavirus Infectious Disease
7562	75	Lymphatic System Disease
7563	750	Peptic Ulcer Disease
7564	7501	Pediatric Infratentorial Ependymoma
7565	7502	Pediatric Supratentorial Ependymoma
7566	7503	Extrahepatic Bile Duct Papillary Adenoma
7567	7504	Mixed Embryonal Carcinoma And Endodermal Sinus Neoplasm Of The Testis
7568	7505	Small Intestine Neoplasm
7569	7506	Small Intestinal L-cell Glucagon-like Peptide Producing Tumor
7570	7507	Malformation Of Placenta
7571	7511	Breast Intraductal Papillomatosis
7572	7512	Localized Intraductal Papillomatosis
7573	7514	Wolffian Adnexal Neoplasm
7574	7515	Lumbar Spinal Canal And Spinal Cord Meningioma
7575	7516	Childhood Central Nervous System Mixed Germ Cell Tumor
7576	7517	Central Nervous System Mixed Germ Cell Tumor
7577	7518	Inhibited Female Orgasm
7578	7519	Endocervical Carcinoma
7579	752	Peptic Ulcer Perforation
7580	7520	Periductal Breast Myoepitheliosis
7581	7521	Breast Myoepitheliosis
7582	7522	Pediatric Infratentorial Ependymoblastoma
7583	7526	Metastatic Neoplasm To The Ciliary Body
7584	7527	Acute Gonococcal Endometritis
7585	7528	Acute Endometritis
7586	7531	Anal Gland Adenocarcinoma
7587	7532	Squamous Papillomatosis
7588	7533	Subareolar Duct Papillomatosis
7589	7537	Breast Cystic Hypersecretory Carcinoma
7590	7538	Breast Ductal Adenoma
7591	7539	Pregnancy Adenoma
7592	754	Bladder Tuberculosis
7593	7540	Breast Apocrine Adenoma
7594	7541	Mixed Epithelial/mesenchymal Metaplastic Breast Carcinoma
7595	7542	Osteosarcoma Arising In Bone Paget's Disease
7596	7543	Recurrent Squamous Cell Carcinoma Of The Esophagus
7597	7544	Recurrent Esophagus Cancer
7598	7549	Ceruminoma
7599	7551	Gonorrhea
7600	7553	Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
7601	7554	Paget's Disease And Intraductal Carcinoma Of Breast
7602	7555	HIV Leukoencephalopathy
7603	7558	Glossopharyngeal Motor Neuropathy
7604	7559	Asymmetric Motor Neuropathy
7605	7565	Vulvar Eccrine Porocarcinoma
7606	7566	Eccrine Porocarcinoma
7607	7567	Vulvar Clear Cell Hidradenocarcinoma
7608	7568	Adult Brain Meningioma
7609	757	Thyrotoxicosis With Toxic Single Thyroid Nodule
7610	7571	Malignant Cystic Nephroma
7611	7574	Pancreatic Intraductal Papillary-colloid Carcinoma
7612	7575	Pancreatic Intraductal Papillary-mucinous Neoplasm
7613	7576	Metastatic Pancreatic Adenocarcinoma
7614	7577	Pancreatic Foamy Gland Adenocarcinoma
7615	7578	Breast Scirrhous Carcinoma
7616	758	Situs Inversus
7617	7581	Psychogenic Depressive Psychosis
7618	7583	Glottis Verrucous Carcinoma
7619	7584	Subglottis Verrucous Carcinoma
7620	7585	Subglottis Squamous Cell Carcinoma
7621	7586	Supraglottis Verrucous Carcinoma
7622	7587	Supraglottis Squamous Cell Carcinoma
7623	7588	Mixed Endodermal Sinus Neoplasm And Teratoma Of The Testis
7624	7589	Ovarian Dermoid Cyst With Melanocytic Nevus
7625	759	Congenital Disorder
7626	7590	Ovarian Dermoid Cyst With Secondary Melanocytic Lesion
7627	7591	Gestational Ovarian Choriocarcinoma
7628	7593	Recurrent Pediatric Medulloblastoma
7629	7596	Asbestos-related Lung Carcinoma
7630	7598	Cervical Lymphoepithelioma-like Carcinoma
7631	7599	Lymphoepithelioma-like Thymic Carcinoma
7632	76	Stomach Disease
7633	7600	Infiltrating Bladder Lymphoepithelioma-like Carcinoma
7634	7601	Advanced Malignant Pleural Mesothelioma
7635	7602	Intracortical Osteogenic Sarcoma
7636	7603	Fibrosarcomatous Osteosarcoma
7637	7607	Chief Cell Adenoma
7638	7608	Parathyroid Adenoma
7639	7609	Parathyroid Transitional Clear Cell Adenoma
7640	761	Meningococcal Endocarditis
7641	7610	Mixed Cell Type Adenoma Of Parathyroid
7642	7611	Parathyroid Oncocytic Adenoma
7643	7612	Childhood Intracortical Osteosarcoma
7644	7613	Sarcomatosis Of The Meninges
7645	7614	Meninges Sarcoma
7646	7615	Sarcomatosis
7647	762	Bacterial Endocarditis
7648	763	Meningococcal Carditis
7649	7631	Adult Ependymoblastoma
7650	7632	Cowper Gland Carcinoma
7651	7633	Macular Holes
7652	7634	Suprasellar Meningioma
7653	7635	Gasserian Ganglion Meningioma
7654	7636	Recurrent Cancer Of Small Intestine
7655	7638	Paget's Disease And Invasive Ductal Carcinoma Of Breast
7656	7639	Malignant Granular Cell Skin Tumor
7657	764	Meningococcal Pericarditis
7658	7641	Non-resectable Small Intestine Carcinoma
7659	7642	Cholangiolocellular Carcinoma
7660	7643	Acantholytic Squamous Cell Skin Carcinoma
7661	7646	Multiple Spinal Canal And Spinal Cord Meningioma
7662	7650	Pulmonary Type Ovarian Small Cell Carcinoma
7663	7651	Hypercalcemic Type Ovarian Small Cell Carcinoma
7664	7652	Rare Cancer-associated Syndrome
7665	7656	Adult Infiltrating Astrocytic Neoplasm
7666	7657	Anaplastic Astrocytoma Of Adult
7667	7664	Endometrial Mixed Adenocarcinoma
7668	7665	Non-gestational Ovarian Choriocarcinoma
7669	767	Muscular Atrophy
7670	7671	Recurrent Penis Cancer
7671	7672	Regressing Non-cutaneous Melanoma
7672	7675	Testicular Fibroma
7673	7676	Testicular Thecoma
7674	7677	Bone Metastatic Ewing's Sarcoma
7675	7678	Sphenoid Sinus Inverted Papilloma
7676	7679	Sphenoid Sinus Schneiderian Papilloma
7677	768	Retinoblastoma
7678	7681	Mixed Choriocarcinoma And Teratoma Of The Testis
7679	7683	Dissecting Aortic Aneurysm
7680	7684	Maxillary Sinus Adenocarcinoma
7681	7685	Pancreatic Non-invasive Intraductal Papillary-mucinous Carcinoma
7682	7689	Leptomeninges Sarcoma
7683	769	Neuroblastoma
7684	7693	Abdominal Aortic Aneurysm
7685	7694	Bladder Urachal Adenocarcinoma
7686	7696	Lung Hilum Cancer
7687	7697	Pancreatic ACTH Hormone Producing Tumor
7688	7698	Non-functioning Pancreatic Endocrine Tumor
7689	77	Gastrointestinal System Disease
7690	7702	AIDS-related Oropharyngeal Candidiasis
7691	7704	Human Papilloma Virus Related Endocervical Adenocarcinoma
7692	7706	Cytomegalovirus Esophagitis
7693	7707	Rectum Signet Ring Adenocarcinoma
7694	7708	Perianal Skin Paget's Disease
7695	771	Retinal Cell Cancer
7696	7710	Metastatic Extraskeletal Chondrosarcoma
7697	7712	Recurrent Adult Soft Tissue Sarcoma
7698	7713	Tuberculum Sellae Meningioma
7699	7714	Metastatic Malignant Hemangiopericytoma
7700	7716	Mixed Ductal-endocrine Carcinoma
7701	7717	Colloid Carcinoma Of The Pancreas
7702	7718	Osteoclast-like Giant Cell Neoplasm Of The Pancreas
7703	772	Metastasis To The Retina
7704	7724	Generalized Convulsive Epilepsy
7705	7725	Epilepsy With Generalized Tonic-clonic Seizures
7706	7728	Chronic Allograft Arteriopathy
7707	7729	Acinar Cell Cystadenocarcinoma
7708	773	Metastasis To Eye
7709	7731	Childhood Malignant Hemangiopericytoma
7710	7732	Childhood Malignant Schwannoma
7711	7733	Signet Ring Cell Intrahepatic Cholangiocarcinoma
7712	7735	Pancreatic Colloid Cystadenoma
7713	7736	Retinal Telangiectasia
7714	7739	Human Papilloma Virus Related Penile Squamous Cell Carcinoma
7715	774	Retina Lymphoma
7716	7747	Pediatric Extraocular Retinoblastoma
7717	775	Intraocular Lymphoma
7718	7750	Adult Brain Ependymoma
7719	7752	Extrahepatic Biliary Papillomatosis
7720	7753	Recurrent Cancer Of Testis
7721	7754	Chondroid Hamartoma Of Lung
7722	7756	Neonatal Leukemia
7723	7757	Childhood Leukemia
7724	7762	Childhood Multilocular Cystic Kidney Neoplasm
7725	7763	Carcinoma Of Supraglottis
7726	7764	Subglottis Carcinoma
7727	7765	Coats Disease
7728	778	Delusional Disorder
7729	7786	Mixed Choriocarcinoma And Embryonal Carcinoma Of The Testis
7730	7787	Breast Osteosarcoma
7731	7788	Adult Spinal Cord Ependymoma
7732	7793	Recurrent Uterine Sarcoma
7733	7799	Transitional Cell Carcinoma Of The Ureter With Glandular Differentiation
7734	780	Placenta Disease
7735	7801	Plasmacytoma-like PTLD
7736	7805	Nonmetastatic Extraskeletal Osteosarcoma
7737	7806	Adult Spinal Cord Glioblastoma Multiforme
7738	7807	Choroid Necrotic Melanoma
7739	7808	Necrotic Uveal Melanoma
7740	7809	Anaplastic Giant Cell Thyroid Carcinoma
7741	7810	AIDS-related Cytomegalovirus Enterocolitis
7742	7812	Enterovirus Gastroenteritis
7743	7814	Cytomegalovirus Colitis
7744	7815	Recurrent Malignant Thymoma
7745	7817	Mixed Astrocytoma-ependymoma-oligodendroglioma
7746	7818	Petroclival Meningioma
7747	7819	Sphenoorbital Meningioma
7748	782	Renal Infectious Disease
7749	7820	Sphenocavernous Meningioma
7750	7824	Spinal Multifocal Clear Cell Meningioma
7751	7825	Chronic Toxic Polyneuropathy
7752	7826	Adult Papillary Meningioma
7753	7827	Adult Extraosseous Osteosarcoma
7754	783	End Stage Renal Failure
7755	7833	Cervical Papillary Squamous Cell Carcinoma
7756	7834	Human Papilloma Virus Related Cervical Squamous Cell Carcinoma
7757	7836	Mixed Acinar-endocrine Carcinoma
7758	7839	Infiltrating Nipple Syringomatous Adenoma
7759	784	Chronic Kidney Failure
7760	7840	Pancreatic Non-functioning Delta Cell Tumor
7761	7841	Pediatric Cerebral Ependymoblastoma
7762	7843	Female Breast Carcinoma
7763	7847	Vascular Hemorrhagic Disorder
7764	7848	Interdigitating Dendritic Cell Sarcoma
7765	7849	Dendritic Cell Sarcoma
7766	7850	Recurrent Uvea Melanoma
7767	7851	Pancreatic Intraductal Papillary-mucinous Adenoma
7768	7855	Recurrent Ovarian Germ Cell Neoplasm
7769	786	Laryngeal Disease
7770	7867	Adult Central Nervous System Germinoma
7771	7868	Maxillary Sinus Inverted Papilloma
7772	7875	Adult Xanthogranuloma
7773	7878	Uterine Corpus Atypical Polypoid Adenomyoma
7774	7880	Luteoma
7775	789	Hypotony Of Eye Associated With Another Ocular Disorder
7776	7890	Testicular Spermatocytic Seminoma With Sarcoma
7777	7891	Testicular Spermatocytic Seminoma
7778	7892	Breast Adenohibernoma
7779	7894	Mite Infestation
7780	790	Ocular Hypotension
7781	7902	Adult Extraosseous Chondrosarcoma
7782	7903	Intracranial Chondrosarcoma
7783	7907	Mixed Astrocytoma-ependymoma
7784	791	Disorganized Schizophrenia In Remission
7785	7910	Maxillary Sinus Squamous Cell Carcinoma
7786	7912	Mixed Oligodendroglioma-astrocytoma
7787	7915	Cervical Spinal Canal And Spinal Cord Meningioma
7788	7919	Nonmetastatic Extra-osseous Ewing's Sarcoma
7789	792	Disorganized Schizophrenia
7790	7920	Central Nervous System Benign Soft Tissue Neoplasm
7791	7921	Benign Mediastinal Psammomatous Neurilemmoma
7792	7922	Benign Mediastinal Neurilemmoma
7793	7926	Epithelial Malignant Thymoma
7794	7927	Malignant Type A Thymoma
7795	7928	Testis Refractory Cancer
7796	793	Schizophrenia In Remission
7797	7930	Glandular-alveolar Pattern Testicular Yolk Sac Tumor
7798	7931	Old Burn Scar-related Squamous Cell Carcinoma Of Skin
7799	7933	Childhood Precursor T-lymphoblastic Lymphoma/leukemia
7800	7936	Precursor T-lymphoblastic Lymphoma/leukemia Refractory
7801	7938	Dyschondroplasia
7802	794	Residual Schizophrenia In Remission
7803	7941	Barrett's Adenocarcinoma
7804	7945	Adult Central Nervous System Mixed Germ Cell Tumor
7805	7946	Recurrent Cancer Of Colon
7806	7949	Stroma-dominant And Stroma-poor Composite Ganglioneuroblastoma
7807	795	Residual Type Schizophrenia
7808	7951	Schwannian Stroma-rich And Stroma-poor Composite Ganglioneuroblastoma
7809	7953	Nipple Duct Carcinoma
7810	7956	EBV-related Posttransplantation Lymphoproliferative Disease
7811	7958	Sarcomatoid Penile Squamous Cell Carcinoma
7812	7959	Duodenal Gastrinoma
7813	7960	Malignant Spiradenoma
7814	7961	Cervical Non-keratinizing Squamous Cell Carcinoma
7815	7962	Tamoxifen-Related Endometrial Lesion
7816	7966	Type 3 ALPS
7817	7967	Lipid-cell Variant Infiltrating Bladder Urothelial Carcinoma
7818	7968	Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma
7819	7969	Nested Variant Infiltrating Bladder Urothelial Carcinoma
7820	7971	Microcystic Variant Infiltrating Bladder Urothelial Carcinoma
7821	7972	Lymphoma-like Variant Infiltrating Bladder Urothelial Carcinoma
7822	7979	Helicobacter Pylori-related Gastric Adenocarcinoma
7823	7983	Breast Malignant Eccrine Spiradenoma
7824	7984	Sclerosing Breast Papilloma
7825	7986	Cerebral Falx Meningioma
7826	799	Varicose Veins
7827	7994	Central Nervous System Osteosarcoma
7828	7996	Familial Glomangioma
7829	7997	Thyrotoxicosis
7830	7998	Hyperthyroidism
7831	8000	Frontal Convexity Meningioma
7832	8002	Supraglottis Neoplasm
7833	8003	Alveoli Adenoma
7834	8004	Ovarian Dermoid Cyst With Prolactin Secreting Adenoma
7835	8005	Ovarian Dermoid Cyst With Secondary Pituitary-type Tumor
7836	8006	Skin Meningioma
7837	8007	Pancoast Tumor
7838	8009	Penis Mixed Squamous Cell Carcinoma
7839	801	Hemarthrosis
7840	8011	Metastatic Fibrosarcoma
7841	8012	Benign Pericardial Teratoma
7842	8013	Penis Papillary Carcinoma
7843	8014	Ovarian Dermoid Cyst With Corticotropin Secreting Adenoma
7844	8016	Anaplastic Ganglioglioma
7845	8018	Renal Pelvis And Ureter Regional Transitional Cell Cancer
7846	8019	Renal Pelvis And Ureter Recurrent Transitional Cell Cancer
7847	8020	Glomangiomyoma
7848	8021	Medullary Carcinoma With Amyloid Stroma
7849	8022	Liver Fibrosarcoma
7850	8023	Myxoid Liposarcoma Of The Ovary
7851	8024	Male Genital Tuberculosis
7852	8025	Gastric Signet Ring Cell Adenocarcinoma
7853	8026	Intestinal Adenocarcinoma Of The Stomach
7854	8029	Sporadic Breast Cancer
7855	8030	Periocular Meningioma
7856	8031	Pineal Region Meningioma
7857	8036	Childhood Ovarian Embryonal Carcinoma
7858	8042	Testis Polyembryoma
7859	8043	Chest Wall Parachordoma
7860	8045	Recurrent Cancer Of Prostate
7861	8050	Bladder Tubulo-cystic Clear Cell Adenocarcinoma
7862	8051	Bladder Papillary Clear Cell Adenocarcinoma
7863	8055	Recurrent Urethral Cancer
7864	8057	Olfactory Groove Meningioma
7865	8058	Pituitary Stalk Meningioma
7866	8060	Frontal Sinus Inverted Papilloma
7867	8068	Intraductal Breast Myoepitheliosis
7868	807	Carotid Artery Occlusion
7869	8072	Sarcomatous Intrahepatic Cholangiocarcinoma
7870	8078	Childhood Central Nervous System Germinoma
7871	8079	Monomorphic T-cell PTLD
7872	8080	Ovarian Mucinous Cystic Tumor Associated With Pseudomyxoma Peritonei
7873	8081	Myxomatous Pattern Testicular Yolk Sac Tumor
7874	8082	Cellular Congenital Mesoblastic Nephroma
7875	8083	Classic Congenital Mesoblastic Nephroma
7876	8084	Cervical Squamotransitional Carcinoma
7877	8087	Ovarian Dermoid Cyst With Sebaceous Carcinoma
7878	8089	Advanced Adult Primary Hepatoma
7879	809	Cocaine Abuse
7880	8093	Maxillary Sinus Schneiderian Papilloma
7881	8094	Cervical Condylomatous Squamous Cell Carcinoma
7882	8096	Bladder Mixed Adenocarcinoma
7883	8097	Bladder Hepatoid Adenocarcinoma
7884	810	HIV-associated Lipodystrophy Syndrome
7885	8102	Fetal Adenoma
7886	8104	Vaginal Tubulovillous Adenoma
7887	8105	Extrahepatic Bile Duct Cystadenoma
7888	8106	Cellular Phase Chronic Idiopathic Myelofibrosis
7889	8107	S-T Syndrome
7890	8108	Fibroepithelial Polyp Of Urethra
7891	8109	Nephrogenic Adenoma Of The Urethra
7892	811	Lipodystrophy
7893	8110	Periampullary Adenocarcinoma
7894	8115	Recurrent Childhood Cerebral Astrocytoma
7895	8117	Neuronitis
7896	8118	Mature Gastric Teratoma
7897	8119	Anal Canal Paget's Disease
7898	8120	Adenocarcinoma In Villous Adenoma
7899	8121	Metastatic Extra-osseous Ewing's Sarcoma
7900	8122	Pseudovascular Skin Squamous Cell Carcinoma
7901	8125	Osteochondrosis
7902	813	Septic Arthritis
7903	8130	Breast Columnar Cell Mucinous Carcinoma
7904	8131	Sclerosing Mucoepidermoid Thyroid Carcinoma With Eosinophilia
7905	8133	Epiglottis Cancer
7906	8135	Gallbladder Lymphoma
7907	8136	Transitional Cell Carcinoma Of The Ureter With Mixed Differentiation
7908	8137	Thymus Clear Cell Carcinoma
7909	8138	Thymus Sarcomatoid Carcinoma
7910	8140	Adrenal Gland Ganglioneuroblastoma
7911	8144	Pregerminal Center Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
7912	8145	Metastatic Neoplasm To The Gallbladder
7913	8146	Anaplastic Secondary Supratentorial Astrocytic Neoplasm
7914	8148	Recurrent Childhood Malignant Germ Cell Tumor
7915	8149	Malignant Childhood Germ Cell Neoplasm
7916	8150	Pancreatic Invasive Intraductal Papillary-mucinous Carcinoma
7917	8151	Appendiceal L-cell Glucagon-like Peptide Producing Tumor
7918	8152	Distal 1/3 Of Common Bile Duct Adenocarcinoma
7919	8153	Fibroosseous Pseudotumor Of Digits
7920	8158	Complement Component 5 Deficiency
7921	8160	Adult Desmoplastic Small Round Cell Tumor
7922	8161	Thyroid Hurthle Cell Carcinoma
7923	8162	Thyroid Hurthle Cell Adenoma
7924	8163	Gallbladder Cancer Unresectable
7925	8167	Gallbladder Melanoma
7926	817	Interstitial Myocarditis
7927	8170	Fibroepithelial Polyp Of The Anus
7928	8177	Endocervical Type Cervical Adenomyoma
7929	8178	Endometrial Type Cervical Adenomyoma
7930	8179	Cervical Atypical Polypoid Adenomyoma
7931	8186	Fallopian Tube Gestational Choriocarcinoma
7932	8187	Gestational Uterine Corpus Choriocarcinoma
7933	8188	Uterine Corpus Choriocarcinoma
7934	819	Mediastinitis
7935	8192	Recurrent Vulva Cancer
7936	8193	Papillary Pattern Testicular Yolk Sac Tumor
7937	8194	Recurrent Pediatric Hepatoma
7938	8195	Hepatoid Pattern Testicular Yolk Sac Tumor
7939	8197	Ovarian Dermoid Cyst With Melanoma
7940	8199	Bursa Syphilis
7941	82	Myotonic Cataract
7942	820	Myocarditis
7943	8200	Tertiary Syphilis
7944	8203	Sacral Spinal Canal And Spinal Cord Meningioma
7945	8205	Alloimmunization
7946	8207	Hilar Lung Carcinoma
7947	8208	Lung Superior Sulcus Carcinoma
7948	8211	Fallopian Tube Cystadenofibroma
7949	8216	Parapharyngeal Meningioma
7950	8219	Recurrent Epithelioid Sarcoma
7951	8220	Recurrent Extraosseous Ewing's Sarcoma
7952	8221	Upper Clivus Meningioma
7953	8222	Adenocarcinoma In Tubular Adenoma
7954	8223	Penile Urethral Cancer
7955	8224	Central Breast Papilloma
7956	8225	Microscopic Breast Papilloma
7957	8227	Atypical Breast Papilloma
7958	8228	Metastatic Extraskeletal Osteosarcoma
7959	8229	Metastatic Small Intestinal Adenocarcinoma
7960	823	Periapical Periodontitis
7961	8230	Intrahepatic Biliary Papillomatosis
7962	8233	Inflammatory Liposarcoma
7963	8234	Malignant Hemangiopericytoma Recurrent
7964	8238	Metastatic Endometrial Carcinoma
7965	8239	Lower Clivus Meningioma
7966	824	Periodontitis
7967	8243	Meningeal Melanomatosis
7968	8244	Bone Recurrent PNET
7969	8246	Breast Myoid Hamartoma
7970	8251	Adult Pleomorphic Rhabdomyosarcoma
7971	8252	Chronic Rhinitis
7972	8255	Vulva Fibroepithelial Polyp
7973	8256	Olfactory Neural Tumor
7974	8257	Transitional Cell Carcinoma Of The Ureter With Squamous Differentiation
7975	8259	Bulbomembranous Urethral Cancer
7976	8269	Adenocarcinoma In Adenomatous Polyposis Coli
7977	827	Ureter Tuberculosis
7978	8272	Anterior Urethra Cancer
7979	8274	Synovial Angioma
7980	8275	Intratubular Embryonal Carcinoma
7981	8276	Hodgkin-like Posttransplantation Lymphoproliferative Disease
7982	8281	Recurrent Malignant Peripheral Nerve Sheath Neoplasm
7983	8282	Adult Epithelioid Sarcoma
7984	8283	Peritonitis
7985	8285	Nonmetastatic Epithelioid Sarcoma
7986	8286	Metastatic Epithelioid Sarcoma
7987	8287	Multiple Chondromatous Hamartoma Of Lung
7988	8288	Clear Cell Squamous Cell Skin Carcinoma
7989	8289	Breast Adenolipoma
7990	829	Crystal Arthropathy
7991	8292	Atypical Follicular Adenoma
7992	8295	Scabies
7993	83	Cataract
7994	8302	Mixed Endometrial Stromal And Smooth Muscle Tumor
7995	8303	Congenital Granular Cell Tumor
7996	8304	Lymph Node Palisaded Myofibroblastoma
7997	8305	Nonossifying Fibromyxoid Tumor
7998	8307	Early Invasive Cervical Adenocarcinoma
7999	8309	Metastatic Carcinoma From The Small Bowel
8000	8310	Sclerosing Adenosis Of Breast
8001	8329	Resectable Small Intestine Carcinoma
8002	833	Auditory System Cancer
8003	8331	Perineural Angioma
8004	8334	Testicular Intratubular Germ Cell Neoplasia With Extratubular Extension
8005	8335	Microglandular Adenosis Of Breast
8006	8336	Childhood Choriocarcinoma Of The Ovary
8007	8337	Appendicitis
8008	8338	Villoglandular Variant Cervical Mucinous Adenocarcinoma
8009	8339	Intestinal Variant Cervical Mucinous Adenocarcinoma
8010	8340	Endocervical Type Cervical Mucinous Adenocarcinoma
8011	8344	Type 1b ALPS
8012	8345	Type 2 ALPS
8013	8348	Localized PNET Of Bone
8014	8349	Metastatic Peripheral Neuroepithelioma Of Bone
8015	8352	Aortic Malignant Tumor
8016	8353	Epithelioid Malignant Peripheral Nerve Sheath Tumor
8017	8354	Complement Component 3 Deficiency
8018	8358	Pseudoglandular Variant Testicular Seminoma
8019	8361	Glassy Cell Variant Cervical Adenosquamous Carcinoma
8020	8362	Enteric Pattern Testicular Yolk Sac Tumor
8021	8365	Inferior Vena Cava Malignant Neoplasm
8022	8366	Esophageal Adenocarcinoma Recurrent
8023	8368	Chordoid Meningioma
8024	8369	Adult Malignant Schwannoma
8025	8376	Mixed Embryonal Carcinoma And Endodermal Sinus Neoplasm With Seminoma Of The Testis
8026	8381	Ectopic Calcitonin Production
8027	8382	Recurrent Endometrial Cancer
8028	8386	Ectopic Chorionic Gonadotropin Secretion Disease
8029	8387	Metastatic Non-cutaneous Melanoma
8030	8388	Mixed Embryonal Carcinoma And Seminoma Of The Testis
8031	8389	Lumbar Plexus Neoplasm
8032	8390	Mixed Choriocarcinoma And Seminoma Of The Testis
8033	8392	Reticular Pattern Testicular Yolk Sac Tumor
8034	8394	Adult Type Testicular Granulosa Cell Tumor
8035	8398	Osteoarthritis
8036	8399	Trombiculiasis
8037	84	Osteochondritis Dissecans
8038	840	Cork-handlers' Disease
8039	8400	Malignant Cornea Melanoma
8040	8401	Malignant Hemangiopericytoma Nonmetastatic
8041	8408	Meckel's Diverticulitis
8042	8409	Microinvasive Cervical Squamous Cell Carcinoma
8043	841	Extrinsic Allergic Alveolitis
8044	8410	Childhood Kidney Angiomyolipoma
8045	8411	Kidney Angiomyolipoma
8046	8413	Recurrent Extraskeletal Osteosarcoma
8047	8415	Carcinoma Arising In Nasal Papillomatosis
8048	8418	Congenital Fibrosarcoma
8049	8419	Colloid Adenoma
8050	8420	Malignant Glandular Tumor Of Peripheral Nerve Sheath
8051	8426	Follicular Infundibulum Tumor
8052	8427	Retinal Melanoma
8053	8428	Breast Apocrine Carcinoma In Situ
8054	8429	Testicular Seminoma With Syncytiotrophoblastic Cells
8055	8431	Physiological Polycythemia
8056	8432	Polycythemia
8057	8433	Thyroid Malformation
8058	8435	Drug Dependence Complicating Pregnancy, Childbirth, Or The Puerperium
8059	8437	Intestinal Obstruction
8060	8438	Afferent Loop Syndrome
8061	8439	Postgastrectomy Syndrome
8062	844	Chronic Depressive Disorder
8063	8440	Ileus
8064	8442	Paralytic Ileus
8065	8443	Brachial Plexus Lesion
8066	8444	Nerve Root And Plexus Disorder
8067	8445	Intestinal Volvulus
8068	8446	Intussusception
8069	8448	Intestinal Impaction
8070	8449	Vitamin B Deficiency
8071	845	Cyclothymic Disorder
8072	8451	Vitamin Deficiency
8073	8452	Malnutrition
8074	8453	Folic Acid Deficiency
8075	8454	Ariboflavinosis
8076	8455	Pyridoxine Deficiency Anemia
8077	8456	Choline Deficiency Disease
8078	8457	Pellagra
8079	8458	Thiamine And Niacin Deficiency State
8080	8459	Vitamin B 12 Deficiency
8081	846	Arthropathy Associated With Hematological Disorder
8082	8461	Aicardi Syndrome
8083	8463	Corneal Ulcer
8084	8464	Flat Retinoschisis
8085	8465	Retinoschisis
8086	8466	Retinal Degeneration
8087	8467	Retinoschisis And Retinal Cysts
8088	8469	Influenza
8089	8472	Localized Scleroderma
8090	8476	Whipple Disease
8091	8477	Malabsorption Syndrome
8092	8478	Actinomycosis
8093	848	Arthritis
8094	8481	Rheumatic Myocarditis
8095	8482	Transient Retinal Arterial Occlusion
8096	8483	Retinal Artery Occlusion
8097	8484	Maple Bark Strippers' Lung
8098	8485	Mucormycosis
8099	8487	Secondary Retinal Cyst
8100	8488	Polyhydramnios
8101	8489	Disorder Of Amniotic Fluid And Membranes
8102	849	Rheumatoid Lung Disease
8103	8490	Primary Hypotonic Uterine Dysfunction
8104	8491	Prolonged First Stage Of Labor
8105	8493	Abnormality Of Forces Of Labor
8106	8494	Dystocia
8107	8495	Prolonged Labor
8108	8498	Hereditary Night Blindness
8109	8499	Night Blindness
8110	850	Lung Disease
8111	8500	Hereditary Retinal Dystrophy
8112	8501	Fundus Dystrophy
8113	8502	Bullous Skin Disease
8114	8503	Impetigo Herpetiformis
8115	8504	Impetigo
8116	8505	Dermatitis Herpetiformis
8117	8506	Bullous Pemphigoid
8118	8507	Juvenile Dermatitis Herpetiformis
8119	8508	Subcorneal Pustular Dermatosis
8120	851	Bartholin's Duct Cyst
8121	8512	Puerperal Pulmonary Embolism
8122	8514	Acute Pulmonary Heart Disease
8123	8515	Cor Pulmonale
8124	8516	Pulmonary Embolism And Infarction
8125	8517	Acute Cor Pulmonale
8126	8519	Barbiturate Abuse
8127	8521	Recurrent Manic Episodes
8128	8523	Nodular Lymphoma Involving Lymph Nodes Of Axilla And Upper Limb
8129	8524	Nodular Lymphoma
8130	8525	Nodular Lymphoma Involving Intra-abdominal Lymph Nodes
8131	8527	Monocytic Leukemia
8132	8529	Ulcer Of Lower Limbs
8133	853	Polymyalgia Rheumatica
8134	8530	Toxic Gastroenteritis And Colitis
8135	8533	Hypopharynx Cancer
8136	8534	Gastroesophageal Reflux Disease
8137	8535	Ophthalmic Herpes Zoster
8138	8536	Herpes Zoster
8139	8538	Reticulosarcoma
8140	8539	Recurrent Manic Episodes In Full Remission
8141	854	Collagen Disease
8142	8540	Sezary's Disease Involving Lymph Nodes Of Head, Face, And Neck
8143	8541	Sezary's Disease
8144	8542	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Lymph Nodes Of Axilla And Upper Limb
8145	8543	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance
8146	8544	Chronic Fatigue Syndrome
8147	8545	Malignant Hyperthermia
8148	8549	Chronic Ulcer Of Skin
8149	8552	Chronic Myeloid Leukemia
8150	8553	Pyoderma Gangrenosum
8151	8556	Vallecula Cancer
8152	8557	Oropharynx Cancer
8153	8559	Carcinoma In Situ Of Female Genital Organs
8154	856	Biotinidase Deficiency
8155	8560	Carcinoma In Situ Of Breast And Genitourinary System
8156	8564	Lip Cancer
8157	8566	Herpes Simplex
8158	8567	Hodgkin's Lymphoma
8159	8568	Infectious Mononucleosis
8160	857	Multiple Carboxylase Deficiency
8161	8573	Lichen Nitidus
8162	8574	Lichen Disease
8163	8577	Ulcerative Colitis
8164	8578	Soft Palate Cancer
8165	8580	Malignant Histiocytosis
8166	8583	Burkitt's Tumor Or Lymphoma Involving Intrathoracic Lymph Nodes
8167	8584	Burkitt Lymphoma
8168	8586	Dysplasia Of Cervix
8169	8587	Burkitt's Tumor Or Lymphoma Extranodal And Solid Organ Sites
8170	859	Holocarboxylase Synthetase Deficiency
8171	8590	Acute Vascular Insufficiency Of Intestine
8172	8592	Reticulosarcoma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8173	8593	Chronic Monocytic Leukemia
8174	8596	Scarlet Fever
8175	8598	Mild Degree Recurrent Episode Manic Disorder
8176	8599	Sezary's Disease Involving Lymph Nodes Of Inguinal Region And Lower Limb
8177	8600	Carcinoid Syndrome
8178	8601	Upper Gum Cancer
8179	8602	Gum Cancer
8180	8604	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Intrapelvic Lymph Nodes
8181	8607	Herpetic Whitlow
8182	8609	Moderate Degree Recurrent Episode Manic Disease
8183	8611	Drug Induced Sleep Disorder
8184	8615	Spontaneous Abortion Complicated By Shock
8185	8616	Peyronie's Disease
8186	8618	Oral Cavity Cancer
8187	8619	Recurrent Hypersomnia
8188	862	Diplegia Of Upper Limb
8189	8620	Reticulosarcoma Involving Intrapelvic Lymph Nodes
8190	8622	Measles
8191	8623	Adhesions And Disruptions Of Pupillary Membranes
8192	8625	Postherpetic Trigeminal Neuralgia
8193	8626	Sezary's Disease Involving Spleen
8194	8627	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Lymph Nodes Of Inguinal Region And Lower Limb
8195	8628	Hodgkin's Lymphoma, Lymphocytic Depletion
8196	863	Nervous System Disease
8197	8630	Upper Lip Cancer
8198	8632	Kaposi's Sarcoma
8199	8633	Chronic Intestinal Vascular Insufficiency
8200	8634	Prostate Carcinoma In Situ
8201	8635	Uvula Cancer
8202	8638	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Intra-abdominal Lymph Nodes
8203	8639	Alcohol Withdrawal Delirium
8204	864	Phlebitis
8205	8640	Reticulosarcoma Involving Lymph Nodes Of Multiple Sites
8206	8641	Hodgkin's Paragranuloma Involving Lymph Nodes Of Axilla And Upper Limb
8207	8642	Hodgkin's Paragranuloma
8208	8643	Duodenitis
8209	8644	Gastroduodenitis
8210	8645	Subacute Delirium
8211	8646	Substance-induced Psychosis
8212	8649	Tongue Cancer
8213	865	Vasculitis
8214	8650	Hodgkin's Granuloma Involving Intrapelvic Lymph Nodes
8215	8651	Hodgkin's Granuloma
8216	8653	Hodgkin's Lymphoma, Mixed Cellularity, Involving Intrathoracic Lymph Nodes
8217	8654	Hodgkin's Lymphoma, Mixed Cellularity
8218	8656	Sezary's Disease Involving Lymph Nodes Of Multiple Sites
8219	8659	Chickenpox
8220	866	Vein Disease
8221	8660	Postcricoid Region Cancer
8222	8661	Lip Carcinoma In Situ
8223	8662	Carcinoma In Situ Of Digestive Organ
8224	8663	Aryepiglottic Fold Cancer
8225	8664	Nodular Lymphoma Involving Intrapelvic Lymph Nodes
8226	8667	Hodgkin's Sarcoma Involving Intra-abdominal Lymph Nodes
8227	867	Maxillary Sinus Cholesteatoma
8228	8670	Eating Disorder
8229	8672	Viral Exanthem
8230	8674	Lymphosarcoma Involving Intrapelvic Lymph Nodes
8231	8675	Lymphosarcoma
8232	8676	Malignant Histiocytosis Involving Lymph Nodes Of Multiple Sites
8233	8677	Perinatal Necrotizing Enterocolitis
8234	8680	Alcoholic Gastritis
8235	8681	Paraneoplastic Polyneuropathy
8236	8683	Myeloid Sarcoma
8237	8687	Skin Carcinoma In Situ
8238	8688	Tonsillar Pillar Cancer
8239	8689	Anorexia Nervosa
8240	869	Cholesteatoma
8241	8690	Mycosis Fungoides Involving Lymph Nodes Of Head, Face, And Neck
8242	8691	Mycosis Fungoides
8243	8692	Myeloid Leukemia
8244	8696	Subacute Monocytic Leukemia
8245	870	Neuropathy
8246	8701	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Lymph Nodes Of Head, Face, And Neck
8247	8702	Cheek Mucosa Cancer
8248	8703	Penis Herpetic Infectious Disease
8249	8704	Genital Herpes
8250	8712	Neurofibromatosis
8251	8716	Lymphosarcoma And Reticulosarcoma
8252	8717	Decubitus Ulcer
8253	8718	Carcinoma In Situ Of Respiratory System
8254	8719	In Situ Carcinoma
8255	872	Soft Tissue Disease
8256	8725	Vascular Dementia
8257	8729	Milker's Nodule
8258	873	Anaerobic Pneumonia
8259	8731	Carotid Body Cancer
8260	8736	Smallpox
8261	8738	Leukoplakia Of Penis
8262	874	Bacterial Pneumonia
8263	8741	Seborrheic Dermatitis
8264	8742	Hodgkin's Granuloma Involving Lymph Nodes Of Head, Face, And Neck
8265	8743	Erythema Infectiosum
8266	8745	Universal Ulcerative Colitis
8267	8747	Subacute Myeloid Leukemia
8268	8748	Acute Dermatitis Due To Solar Radiation
8269	8749	Actinic Reticuloid And Actinic Granuloma
8270	8751	Hodgkin's Granuloma Involving Intrathoracic Lymph Nodes
8271	8752	Tuberculous Pneumonia
8272	8754	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Lymph Nodes Of Inguinal Region And Lower Limb
8273	8757	Gastric Mucosal Hypertrophy
8274	8758	Lymphosarcoma Involving Lymph Nodes Of Multiple Sites
8275	876	Pyomyositis
8276	8761	Megakaryocytic Leukemia
8277	8762	Herpes Simplex Virus Otitis Externa
8278	8765	Herpes Simplex Virus Septicemia
8279	8766	Lymphosarcoma Involving Intra-abdominal Lymph Nodes
8280	8767	Malignant Histiocytosis Involving Lymph Nodes Of Axilla And Upper Limb
8281	8768	Nodular Lymphoma Involving Spleen
8282	8769	Malignant Histiocytosis Involving Lymph Nodes Of Inguinal Region And Lower Limb
8283	8770	Reticulosarcoma Involving Intra-abdominal Lymph Nodes
8284	8771	Contagious Pustular Dermatitis
8285	8773	Nodular Lymphoma Involving Lymph Nodes Of Head, Face, And Neck
8286	8775	Ulcerative Proctosigmoiditis
8287	8778	Crohn's Disease
8288	8781	Rubella
8289	8785	Postherpetic Polyneuropathy
8290	8787	Disseminated Chorioretinitis
8291	8791	Breast Carcinoma In Situ
8292	8792	Eye Carcinoma In Situ
8293	8794	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Intrathoracic Lymph Nodes
8294	8795	Hodgkin's Granuloma Involving Spleen
8295	8798	Hodgkin's Lymphoma, Mixed Cellularity, Involving Spleen
8296	8800	Lung Carcinoma In Situ
8297	8802	Trachea Carcinoma In Situ
8298	8803	Repetitive Intrusions Of Sleep
8299	8805	Intermediate Coronary Syndrome
8300	8806	Malignant Histiocytosis Involving Intrapelvic Lymph Nodes
8301	8807	Allergic Gastroenteritis And Colitis
8302	8811	Malignant Histiocytosis Involving Intrathoracic Lymph Nodes
8303	8812	Measles Virus Otitis Media
8304	882	Heterophyiasis
8305	8820	Ulcerative Ileocolitis
8306	8825	Hodgkin's Paragranuloma Involving Spleen
8307	8826	Colon Carcinoma In Situ
8308	8828	Systemic Inflammatory Response Syndrome
8309	883	Parasitic Helminthiasis Infectious Disease
8310	8832	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Lymph Nodes Of Multiple Sites
8311	8836	Burkitt's Tumor Or Lymphoma Involving Lymph Nodes Of Head, Face, And Neck
8312	8837	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Lymph Nodes Of Head, Face, And Neck
8313	8838	Hodgkin's Lymphoma, Nodular Sclerosis
8314	8839	Herpes Zoster Keratoconjunctivitis
8315	884	Metagonimiasis
8316	8844	Tuberculous Erythema Nodosum
8317	8847	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Lymph Nodes Of Multiple Sites
8318	8849	Sublingual Gland Cancer
8319	885	Fascioliasis
8320	8850	Salivary Gland Cancer
8321	8852	Hodgkin's Granuloma Involving Intra-abdominal Lymph Nodes
8322	8854	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Intrathoracic Lymph Nodes
8323	8857	Lupus Erythematosus
8324	8858	Tonsil Cancer
8325	8860	Lymphosarcoma Involving Spleen
8326	8861	Pulmonary Subvalvular Stenosis
8327	8864	Acute Monocytic Leukemia
8328	8866	Actinic Keratosis
8329	8867	Molluscum Contagiosum
8330	8868	Mycosis Fungoides Involving Lymph Nodes Of Multiple Sites
8331	8869	Neuromyelitis Optica
8332	887	Trematoda Infectious Disease
8333	8870	Nodular Lymphoma Involving Intrathoracic Lymph Nodes
8334	8871	Hodgkin's Lymphoma, Nodular Sclerosis, Extranodal And Solid Organ Sites
8335	8872	Penis Carcinoma In Situ
8336	8875	Hodgkin's Sarcoma Involving Lymph Nodes Of Multiple Sites
8337	8876	Herpetic Vulvovaginitis
8338	888	Fasciolopsiasis
8339	8881	Rosacea
8340	8883	Lower Lip Cancer
8341	8886	Chorioretinitis
8342	889	Inborn Metabolic Brain Disease
8343	8892	Pityriasis Rosea
8344	8893	Psoriasis
8345	890	Mitochondrial Encephalomyopathy
8346	8903	Hodgkin's Granuloma Involving Lymph Nodes Of Axilla And Upper Limb
8347	8904	Nodular Lymphoma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8348	8906	Herpes Zoster Otitis Externa
8349	8907	Ulcerative Proctitis
8350	891	Progressive Myoclonus Epilepsy
8351	8912	Tinea Nigra
8352	8913	Dermatophytosis
8353	8914	Burkitt's Tumor Or Lymphoma Involving Intrapelvic Lymph Nodes
8354	8915	Herpes Zoster Meningitis
8355	8916	Mycosis Fungoides Involving Lymph Nodes Of Axilla And Upper Limb
8356	8918	Hodgkin's Sarcoma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8357	8919	Mycosis Fungoides Involving Lymph Nodes Of Inguinal Region And Lower Limb
8358	8920	Leukoplakia Of Vagina
8359	8921	Noninflammatory Vaginal Disorder
8360	8923	Skin Melanoma
8361	8924	Autoimmune Thrombocytopenic Purpura
8362	8925	Primary Thrombocytopenia
8363	8927	Learning Disability
8364	8928	Lymphosarcoma Involving Lymph Nodes Of Head, Face, And Neck
8365	8929	Atrophic Gastritis
8366	893	Wilson Disease
8367	8930	Retromolar Area Cancer
8368	8931	Evans' Syndrome
8369	8932	Herpes Zoster Iridocyclitis
8370	8936	Plantar Fascial Fibromatosis
8371	8937	Waldeyer's Ring Cancer
8372	8938	Reticulosarcoma Involving Intrathoracic Lymph Nodes
8373	8939	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Lymph Nodes Of Axilla And Upper Limb
8374	894	Nervous System Heredodegenerative Disease
8375	8941	Seborrheic Infantile Dermatitis
8376	8943	Lattice Corneal Dystrophy
8377	8946	Severe Nonproliferative Diabetic Retinopathy
8378	8947	Diabetic Retinopathy
8379	895	Copper Metabolism Disease
8380	8955	Sideroblastic Anemia
8381	8956	Cowpox
8382	8958	Lymphosarcoma Involving Lymph Nodes Of Axilla And Upper Limb
8383	8959	Hodgkin's Lymphoma, Mixed Cellularity, Involving Lymph Nodes Of Inguinal Region And Lower Limb
8384	896	Metal Metabolism Disorder
8385	8962	Measles Virus Keratoconjunctivitis
8386	8964	Hodgkin's Sarcoma Involving Spleen
8387	8969	Tonsillar Fossa Cancer
8388	8970	Subacute Sclerosing Panencephalitis
8389	8973	Hodgkin's Lymphoma, Mixed Cellularity, Involving Lymph Nodes Of Multiple Sites
8390	8974	Burkitt's Tumor Or Lymphoma Involving Lymph Nodes Of Axilla And Upper Limb
8391	8976	Peripheral Lymph Node Tuberculosis
8392	8977	Malignant Histiocytosis Involving Lymph Nodes Of Head, Face, And Neck
8393	8978	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Lymph Nodes Of Inguinal Region And Lower Limb
8394	8979	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Intrapelvic Lymph Nodes
8395	898	Polycystic Kidney Disease
8396	8980	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance Involving Spleen
8397	8986	Narcolepsy
8398	899	Choledochal Cyst
8399	8990	Hodgkin's Granuloma Involving Lymph Nodes Of Multiple Sites
8400	8991	Cervix Uteri Carcinoma In Situ
8401	8992	Hodgkin's Granuloma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8402	8994	Hodgkin's Sarcoma Involving Lymph Nodes Of Head, Face, And Neck
8403	8995	Malignant Histiocytosis Involving Intra-abdominal Lymph Nodes
8404	8997	Polycythemia Vera
8405	90	Degenerative Disc Disease
8406	900	Hepatopulmonary Syndrome
8407	9001	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Spleen
8408	9007	Sudden Infant Death Syndrome
8409	9008	Psoriatic Arthritis
8410	901	Liver Lymphoma
8515	9199	Cataplexy And Narcolepsy
8411	9010	Burkitt's Tumor Or Lymphoma Involving Lymph Nodes Of Multiple Sites
8412	9011	Larynx Carcinoma In Situ
8413	9017	Sezary's Disease Involving Lymph Nodes Of Axilla And Upper Limb
8414	9019	Mycosis Fungoides Involving Spleen
8415	902	Malignant Non-epithelial Hepatic And Intrahepatic Bile Duct Neoplasm
8416	9020	Reticulosarcoma Involving Spleen
8417	9021	Esophageal Leukoplakia
8418	9024	Intestine Carcinoma In Situ
8419	9025	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Intra-abdominal Lymph Nodes
8420	903	Gastrointestinal Lymphoma
8421	9033	Hodgkin's Sarcoma Involving Lymph Nodes Of Axilla And Upper Limb
8422	9036	Parotid Gland Cancer
8423	9037	Burkitt's Tumor Or Lymphoma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8424	9039	Hodgkin's Paragranuloma Involving Lymph Nodes Of Head, Face, And Neck
8425	9040	Reticulosarcoma Involving Lymph Nodes Of Head, Face, And Neck
8426	9041	Hodgkin's Lymphoma, Mixed Cellularity, Involving Lymph Nodes Of Axilla And Upper Limb
8427	9042	Polyp Of Corpus Uteri
8428	9043	Uterine Cervix Leukoplakia
8429	9046	Nodular Lymphoma Involving Lymph Nodes Of Multiple Sites
8430	905	Zellweger Syndrome
8431	9051	Herpes Simplex Virus Meningitis
8432	9052	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Lymph Nodes Of Axilla And Upper Limb
8433	9053	Bladder Carcinoma In Situ
8434	9054	Lymphosarcoma Involving Intrathoracic Lymph Nodes
8435	9059	Herpes Simplex Virus Gingivostomatitis
8436	906	Peroxisomal Disease
8437	9060	Pityriasis Versicolor
8438	9061	Alcohol Induced Sleep Disorder
8439	9063	Ritter's Disease
8440	9064	Hodgkin's Lymphoma, Lymphocytic-histiocytic Predominance, Extranodal And Solid Organ Sites
8441	9065	Leishmaniasis
8442	9067	Hodgkin's Paragranuloma Involving Intrathoracic Lymph Nodes
8443	907	Liver Fibroma
8444	9070	Pseudopolyposis Of Colon
8445	9071	Malignant Histiocytosis Involving Spleen
8446	9072	Lethal Midline Granuloma
8447	9074	Systemic Lupus Erythematosus
8448	9076	Discoid Lupus Erythematosus Of Eyelid
8449	9078	Hodgkin's Paragranuloma Involving Intrapelvic Lymph Nodes
8450	9079	Hodgkin's Paragranuloma Involving Lymph Nodes Of Multiple Sites
8451	9080	Macroglobulinemia
8452	9082	Mycosis Fungoides Involving Intrathoracic Lymph Nodes
8453	9084	Hodgkin's Lymphoma, Mixed Cellularity, Involving Intra-abdominal Lymph Nodes
8454	9087	Anal Carcinoma In Situ
8455	9088	Parapsoriasis
8456	9091	REM Sleep Behavior Disorder
8457	9092	Hodgkin's Sarcoma Involving Intrathoracic Lymph Nodes
8458	9093	Hodgkin's Paragranuloma Involving Intra-abdominal Lymph Nodes
8459	9095	Esophagus Carcinoma In Situ
8460	9097	Erythematosquamous Dermatosis
8461	9098	Sebaceous Gland Disease
8462	910	Occipital Lobe Neoplasm
8463	9103	Carcinoma In Situ Of Male Genital Organs
8464	9105	Mycosis Fungoides Involving Intrapelvic Lymph Nodes
8465	9108	Uterus Carcinoma In Situ
8466	9109	Mycosis Fungoides Involving Intra-abdominal Lymph Nodes
8467	9111	Cutaneous Leishmaniasis
8468	9113	Granuloma Inguinale
8469	9114	Varicella-zoster Virus Pneumonia
8470	9115	Rubella Virus Arthritis
8471	9117	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Spleen
8472	9119	Acute Myeloid Leukemia
8473	9120	Amyloidosis
8474	9121	Hodgkin's Lymphoma, Mixed Cellularity, Extranodal And Solid Organ Sites
8475	9123	Eczema Herpeticum
8476	9124	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Intra-abdominal Lymph Nodes
8477	9125	Lower Gum Cancer
8478	913	Atrophic Muscular Disease
8479	9130	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Intrapelvic Lymph Nodes
8480	9132	Liver Carcinoma In Situ
8481	9138	Stomach Carcinoma In Situ
8482	914	Peliosis Hepatis
8483	9140	Xeroderma Of Eyelid
8484	9141	Herpes Simplex Virus Meningoencephalitis
8485	9142	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Lymph Nodes Of Multiple Sites
8486	9143	Burkitt's Tumor Or Lymphoma Involving Spleen
8487	9146	Visceral Leishmaniasis
8488	9149	Hard Palate Cancer
8489	9150	Hodgkin's Lymphoma, Mixed Cellularity, Involving Intrapelvic Lymph Nodes
8490	9153	Variola Minor
8491	9155	Mucocutaneous Leishmaniasis
8492	9157	Hodgkin's Lymphoma, Nodular Sclerosis, Involving Intrathoracic Lymph Nodes
8493	9158	Sezary's Disease Involving Intra-abdominal Lymph Nodes
8494	9159	Gas Gangrene
8495	916	Liver Neoplasm
8496	9161	Sezary's Disease Involving Intrapelvic Lymph Nodes
8497	9164	Achalasia
8498	9165	Neurotic Excoriation
8499	9169	Wiskott-Aldrich Syndrome
8500	917	Liver Leiomyoma
8501	9173	Submandibular Gland Cancer
8502	9174	Rectum Carcinoma In Situ
8503	918	Liver Inflammatory Pseudotumor
8504	9180	Amebic Colitis
8505	9181	Amebiasis
8506	9182	Pemphigus
8507	9184	Sleep Arousal Disorder
8508	9186	Hodgkin's Paragranuloma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8509	9188	Vestibule Of Mouth Cancer
8510	9189	Generalized Hyperhidrosis
8511	9191	Diabetic Macular Edema
8512	9192	Dyskinesia Of Esophagus
8513	9195	Herpes Simplex Virus Keratitis
8514	9198	Sezary's Disease Involving Intrathoracic Lymph Nodes
8516	92	Speech Disorder
8517	920	Childhood Liver Neoplasm
8518	9201	Lichen Planus
8519	9202	Disorder Of Optic Chiasm Associated With Pituitary Neoplasm And Disorder
8520	9203	Burkitt's Tumor Or Lymphoma Involving Intra-abdominal Lymph Nodes
8521	9206	Barrett's Esophagus
8522	9207	Periodic Limb Movement Disorder
8523	9210	Geniculate Herpes Zoster
8524	9212	Pityriasis Rubra Pilaris
8525	9214	Herpes Simplex Virus Iridocyclitis
8526	9216	Hodgkin's Lymphoma, Lymphocytic Depletion, Involving Lymph Nodes Of Head, Face, And Neck
8527	9217	Herpes Zoster Eyelid Dermatitis
8528	9220	Central Sleep Apnea
8529	9222	Lymphosarcoma Involving Lymph Nodes Of Inguinal Region And Lower Limb
8530	9224	Vulva Herpetic Infectious Disease
8531	9225	Hodgkin's Sarcoma Involving Intrapelvic Lymph Nodes
8532	9227	Hodgkin's Lymphoma, Mixed Cellularity, Involving Lymph Nodes Of Head, Face, And Neck
8533	9228	Congenital Rubella
8534	9230	Dyshidrosis
8535	9234	Kidney Carcinoma In Situ
8536	9235	Pyriform Sinus Cancer
8537	9240	Erythromelalgia
8538	9241	Reticulosarcoma Involving Lymph Nodes Of Axilla And Upper Limb
8539	9245	Alagille Syndrome
8540	9246	Cerebral Amyloid Angiopathy
8541	9248	Pallister-Hall Syndrome
8542	9249	Beemer-Langer Syndrome
8543	9250	Acrocallosal Syndrome
8544	9252	Amino Acid Metabolic Disorder
8545	9253	Gastrointestinal Stromal Tumor
8546	9254	Mast-cell Leukemia
8547	9255	Frontotemporal Dementia
8548	9256	Colorectal Cancer
8549	9258	Waardenburg's Syndrome
8550	9261	Nasopharynx Carcinoma
8551	9263	Homocystinuria
8552	9264	Sulfuraminoacidemia
8553	9265	Histidine Metabolism Disease
8554	9266	Cystinuria
8555	9267	Urea Cycle Disorder
8556	9268	Glycine Encephalopathy
8557	9269	Maple Syrup Urine Disease
8558	927	Metastatic Malignant Neoplasm To Brain
8559	9270	Alkaptonuria
8560	9271	Ornithine Carbamoyltransferase Deficiency
8561	9273	Citrullinemia
8562	9274	Hyperlysinemia
8563	9275	Tyrosinemia
8564	9277	Primary Cerebellar Degeneration
8565	9278	Hyperargininemia
8566	9279	Hyperhomocysteinemia
8567	928	CNS Metastases
8568	9280	Carbamoyl Phosphate Synthetase I Deficiency Disease
8569	9281	Phenylketonuria
8570	9282	Ocular Hypertension
8571	9283	Borderline Glaucoma
8572	9286	Priapism
8573	9287	Penile Vascular Disorder
8574	929	Myopathy Of Extraocular Muscle
8575	9296	Cleft Lip
8576	9297	Lip Disease
8577	9299	Myocardium Cancer
8578	93	Language Disorder
8579	930	Orbital Disease
8580	9300	Neurofibroma Of The Heart
8581	9305	Splenic Tuberculosis
8582	9306	Mechanical Strabismus
8583	9307	Rectal Prolapse
8584	931	Monieziasis
8585	9310	Nasal Cavity Neoplasm
8586	9312	Chronic Ethmoiditis
8587	9314	Glaucoma Associated With Anomalies Of Iris
8588	9317	Lymphangitis
8589	9321	Intervertebral Disc Disorder
8590	933	Cestoda Infectious Disease
8591	9335	Scotoma
8592	9336	Bestiality
8593	9339	Urethral False Passage
8594	934	Viral Infectious Disease
8595	9340	Cheilopalatoschisis
8596	9341	Urethral Diverticulum
8597	9346	Taylor's Syndrome
8598	9348	Carotid Artery Dissection
8599	9351	Diabetes Mellitus
8600	9352	Type 2 Diabetes Mellitus
8601	9353	Congenital Hip Dislocation
8602	9357	Hyperemesis Gravidarum
8603	9358	Fibular Collateral Ligament Bursitis
8604	9359	Enthesopathy Of Knee
8605	936	Brain Disease
8606	9360	Intrinsic Asthma
8607	9362	Status Asthmaticus
8608	9365	Vesiculitis
8609	9368	Keratoconjunctivitis
8610	9369	Orbital Plasma Cell Granuloma
8611	937	DNA Virus Infectious Disease
8612	9370	Exophthalmos
8613	9373	Postural Kyphosis
8614	9375	Fuchs' Heterochromic Uveitis
8615	9377	Pigment Dispersion Syndrome Of Iris
8616	9378	Glaucomatocyclitic Crisis
8617	9379	Glaucoma With Ocular Inflammation
8618	9383	Iridocyclitis
8619	9384	Gonococcal Iridocyclitis
8620	9385	Gonococcal Eye Infectious Disease
8621	9388	Lens-induced Iridocyclitis
8622	9389	Infectious Anterior Uveitis
8623	9392	Tracheitis
8624	9395	Croup
8625	9396	Acute Laryngitis
8626	9398	Epiglottitis
8627	9401	Epididymo-orchitis
8628	9402	Epididymitis
8629	9403	Isolated Explosive Disorder
8630	9405	Pituitary Dwarfism
8631	9406	Hypopituitarism
8632	9407	Strictly Posterior Acute Myocardial Infarction
8633	9408	Acute Myocardial Infarction
8634	9409	Diabetes Insipidus
8635	9410	Panhypopituitarism
8636	9411	Gonococcal Endocarditis
8637	9413	Congenital Abnormalities Of Uterus Complicating Pregnancy, Childbirth, Or The Puerperium
8765	9700	Bacterial Conjunctivitis
8766	9709	Rosacea Conjunctivitis
8638	9414	Abnormality Of Organs And Soft Tissues Of Pelvis Complicating Pregnancy, Childbirth, Or The Puerperium
8639	9415	Allergic Asthma
8640	9422	Abscess Of Eyelid
8641	9423	Blepharitis
8642	9426	Tuberculous Bronchiectasis
8643	9427	Hypertensive Encephalopathy
8644	9428	Intracranial Hypertension
8645	9432	Renal Glycosuria
8646	9439	Chronic Cholangitis
8647	9442	Cervical Mullerian Papilloma
8648	9443	Cervix Blue Nevus
8649	9445	Cervix Squamous Papilloma
8650	9446	Cholangitis
8651	9450	Infectious Disease Of The Breast And Nipple Associated With Childbirth
8652	9452	Fatty Liver Disease
8653	9455	Lipid Storage Disease
8654	9459	Isthmus Cancer
8655	946	Dientamoebiasis
8656	9460	Uterine Corpus Cancer
8657	9461	Exposure Keratitis
8658	9462	Cholesteatoma Of External Ear
8659	9463	Otitis Externa
8660	9467	Nail-patella Syndrome
8661	9468	Salmonella Meningitis
8662	9470	Bacterial Meningitis
8663	9471	Meningitis
8664	9473	Mononeuritis Of Lower Limb
8665	9476	Sheehan Syndrome
8666	9477	Pulmonary Embolism
8667	9478	Postpartum Depression
8668	9483	Ulcerative Blepharitis
8669	9487	Meckel's Diverticulum
8670	949	Chronic Dacryoadenitis
8671	9496	Unilateral Hypoactive Labyrinth
8672	9498	Pulmonary Eosinophilia
8673	9499	Disseminated Eosinophilic Collagen Disease
8674	950	Dacryoadenitis
8675	9500	Leukocyte Disease
8676	9502	Chronic Eosinophilic Pneumonia
8677	9503	Loeffler Syndrome
8678	9504	Benign Mammary Dysplasia
8679	9505	Cannabis Abuse
8680	9506	Acute Ethmoiditis
8681	9507	Ethmoid Sinusitis
8682	951	Toxic Myopathy
8683	9512	Simple Chronic Conjunctivitis
8684	9513	Plasmacytic Leukemia
8685	9514	Multiple Myeloma And Immunoproliferative Neoplasm
8686	9518	Abortion Complicated By Renal Failure
8687	952	Acute Dacryoadenitis
8688	9521	Laron Syndrome
8689	9528	Acute Renal Failure With Lesion Of Renal Medullary Necrosis
8690	9530	Rhesus Isoimmunisation Affecting Management Of Mother
8691	9531	Latent Syphilis
8692	9534	Tuberculous Pneumothorax
8693	9535	Arenavirus Hemorrhagic Fever
8694	9537	Lassa Fever
8695	9538	Multiple Myeloma
8696	9540	Vascular Skin Disease
8697	9541	Osteosclerotic Myeloma
8698	9543	Plasma Cell Myeloma PTLD
8699	9544	Refractory Plasma Cell Neoplasm
8700	9545	Recurrent Plasma Cell Neoplasm
8701	9547	Non-secretory Myeloma
8702	955	Benign Neurilemmoma
8703	9550	Indolent Myeloma
8704	9551	Smoldering Myeloma
8705	9552	Adrenal Gland Hypofunction
8706	9553	Adrenal Gland Disease
8707	956	Peripheral Nerve Schwannoma
8708	9561	Nasopharyngeal Disease
8709	9562	Primary Ciliary Dyskinesia
8710	9563	Bronchiectasis
8711	9565	Dextrocardia
8712	9574	Choanal Atresia
8713	9577	Neonatal Candidiasis
8714	9579	Pseudomonas Septicemia
8715	9584	Venezuelan Equine Encephalitis
8716	9585	Equine Encephalitis
8717	9588	Encephalitis
8718	9589	Urethral Calculus
8719	959	Esophagus Squamous Cell Papilloma
8720	9590	Lower Urinary Tract Calculus
8721	9594	Ovarian Metastasis
8722	9597	Krukenberg Carcinoma
8723	9598	Fasciitis
8724	9599	Proliferative Fasciitis
8725	96	Staphyloenterotoxemia
8726	960	Esophagus Leiomyoma
8727	9600	Plantar Fasciitis
8728	9601	Ischemic Fasciitis
8729	9602	Necrotizing Fasciitis
8730	9603	Intravascular Fasciitis
8731	961	Neurofibroma Of The Esophagus
8732	9617	Orthostatic Proteinuria
8733	962	Neurofibroma
8734	9620	Vesicoureteral Reflux
8735	9621	Non-congenital Cyst Of Kidney
8736	9622	Kidney Hypertrophy
8737	963	Episodic Ataxia
8738	9630	Genetic Anomaly Of Leucocyte
8739	9631	Pelger-Huet Anomaly
8740	9637	Stomatitis
8741	9640	Sarcocystosis
8742	9642	Rheumatic Chorea
8743	9643	Babesiosis
8744	9647	Obstructed Labor
8745	9649	Congenital Nystagmus
8746	9650	Pathologic Nystagmus
8747	9651	Systolic Heart Failure
8748	9653	Pre-eclampsia Or Eclampsia Superimposed On Pre-existing Hypertension
8749	9654	Hypertension Complicating Pregnancy, Childbirth And The Puerperium
8750	9655	Oral Mucosa Leukoplakia
8751	9663	Aphthous Stomatitis
8752	9667	Placental Abruption
8753	9669	Senile Cataract
8754	9672	Noma
8755	9673	Ulcerative Stomatitis
8756	9675	Pulmonary Emphysema
8757	9678	Cervical Incompetence Complicating Pregnancy, Childbirth, Or The Puerperium
8758	9681	Cervical Incompetence
8759	9682	Yellow Fever
8760	9694	Toxic Myocarditis
8761	9697	Gonococcal Keratitis
8762	9698	Gonococcal Endophthalmia
8763	9699	Ophthalmia Neonatorum
8764	970	Tenosynovitis
8767	971	Tendinitis
8768	9714	Occlusion Of Gallbladder
8769	9717	Hydrops Of Gallbladder
8770	9718	Meningococcal Myocarditis
8771	9719	Proliferative Vitreoretinopathy
8772	972	Malignant Neoplasm Of Cerebrum Except Lobes And Ventricles
8773	9720	Vitreous Disease
8774	9722	Ophthalmia Nodosa
8775	9723	Vitreous Abscess
8776	9724	Purulent Endophthalmitis
8777	9726	Vitreous Detachment
8778	9728	Vitreous Membranes And Strands
8779	9729	Crystalline Deposits In Vitreous
8780	9733	Renal Tuberculosis
8781	9734	Urinary Tuberculosis
8782	9735	Acute Allergic Mucoid Otitis Media
8783	9736	Blue Drum Syndrome
8784	9739	Eustachian Tube Disease
8785	974	Upper Respiratory Tract Disease
8786	9740	Postcholecystectomy Syndrome
8787	9741	Biliary Tract Disease
8788	9742	Pelvic Varices
8789	9743	Diabetic Neuropathy
8790	9744	Type 1 Diabetes Mellitus
8791	9745	Perianal Hematoma
8792	9746	Hemorrhoid
8793	9749	Internal Hemorrhoid
8794	9751	Popliteal Cyst
8795	9753	Rupture Of Synovium
8796	9754	Ganglion Or Cyst Of Synovium/tendon/bursa
8797	9761	Arthropathy Associated With Dermatological Disorder
8798	9762	Perinatal Cyanotic Attack
8799	9764	Biliary Calculus With Cholecystitis
8800	9765	Emphysematous Cholecystitis
8801	9766	Xanthogranulomatous Cholecystitis
8802	9767	Myocardial Stunning
8803	9768	Heart Aneurysm
8804	9770	Retracted Nipple Associated With Childbirth
8805	9771	Transient Neonatal Thrombocytopenia
8806	9772	Hematological Disease Of Fetus And Newborn
8807	9773	Female Breast Upper-outer Quadrant Cancer
8808	9775	Diastolic Heart Failure
8809	9776	Senile Atrophy Of Choroid
8810	9778	Irritable Bowel Syndrome
8811	9779	Bowel Dysfunction
8812	9784	Trichinosis
8813	9786	Bulbar Polio
8814	9787	Foreign Body Granuloma Of Muscle
8815	9788	Myositis Fibrosa
8816	979	Angioid Streaks Of Choroid
8817	9790	Toxocariasis
8818	9794	Hereditary Choroidal Atrophy
8819	9795	Tuberculous Meningitis
8820	9799	Eye Degenerative Disease
8821	98	Staphylococcal Infectious Disease
8822	980	Choroidal Sclerosis
8823	9801	Tuberculous Peritonitis
8824	9804	Pneumococcal Peritonitis
8825	9805	Pneumococcal Infectious Disease
8826	9808	Goodpasture Syndrome
8827	9809	Hypersensitivity Vasculitis
8828	981	Diffuse Secondary Choroid Atrophy
8829	9810	Polyarteritis Nodosa
8830	9811	Partial Circumpapillary Choroid Dystrophy
8831	9814	Rheumatic Heart Disease
8832	9815	Recent Retinal Detachment, Total Or Subtotal
8833	9816	Partial Recent Retinal Detachment With Giant Tear
8834	9818	Retinal Defect
8835	9819	Delimited Old Retinal Detachment
8836	982	Disorganized Type Schizophrenia Subchronic State With Acute Exacerbation
8837	9820	Central Gyrate Choroidal Dystrophy
8838	9821	Choroideremia
8839	9822	Partial Central Choroid Dystrophy
8840	9823	Partial Recent Retinal Detachment With Retinal Dialysis
8841	9824	Total Or Subtotal Old Retinal Detachment
8842	9827	Radioulnar Synostosis
8843	9828	Neonatal Abstinence Syndrome
8844	9829	Drug Abstinence Syndrome Or Symptom
8845	9834	Hyperopia
8846	9835	Refractive Error
8847	9836	Refraction Or Accommodation Disorder
8848	9837	Hypertropia
8849	9838	Cyclotropia
8850	9839	Accommodative Esotropia
8851	984	Temporomandibular Joint Disorder
8852	9840	Esotropia
8853	9841	Hypotropia
8854	9842	Total Circumpapillary Dystrophy Of Choroid
8855	9843	Monofixation Syndrome
8856	9847	Peripheral Vertigo
8857	9848	Endolymphatic Hydrops
8858	9849	Meniere's Disease
8859	985	Disorganized Type Schizophrenia Subchronic State
8860	9854	Lingual-facial-buccal Dyskinesia
8861	9855	Syphilitic Interstitial Keratitis
8862	9856	Congenital Syphilis
8863	9857	Interstitial Keratitis
8864	9858	Deep Keratitis
8865	986	Alopecia Areata
8866	9861	Miliary Tuberculosis
8867	9866	Lactation Disorder
8868	9867	Toxic Maculopathy
8869	9868	Intestinal Disaccharidase Deficiency
8870	9869	Hereditary Fructose Intolerance Syndrome
8871	987	Alopecia
8872	9870	Galactosemia
8873	9877	Urethral Gland Abscess
8874	9878	Excessive Vomiting Starting After 22 Completed Weeks Of Gestation
8875	988	Mitral Valve Prolapse
8876	9880	Cardiovascular Syphilis
8877	9883	Becker Muscular Dystrophy
8878	9884	Muscular Dystrophy
8879	9888	Alternating Esotropia
8880	9889	Alternating Esotropia With A Pattern
8881	9890	Intermittent Alternating Esotropia
8882	9891	Alternating Esotropia With V Pattern
8883	9892	Median Arcuate Ligament Syndrome
8884	9893	Periodontosis
8885	9898	Villonodular Synovitis
8886	9899	Glaucoma Associated With Tumors Or Cysts
8887	990	Congenital Heart Block
8888	9900	Protracted Reactive Paranoid Psychosis
8889	9903	Meibomian Cyst
8890	9905	Follicular Mucinosis
8891	9908	Internal Hordeolum
8892	9909	Hordeolum
8893	9910	Central Corneal Ulcer
8894	9911	Infected Hydrocele
8895	9912	Hydrocele
8896	9913	Axillary Metastasis
8897	9915	Malignant Neoplasm Of Ribs, Sternum And Clavicle
8898	9916	Secondary Malignant Neoplasm To The Chest Wall
8899	9919	Malignant Neoplasm Of Thoracic Esophagus
8900	992	Omsk Hemorrhagic Fever
8901	9923	Developmental Coordination Disorder
8902	9925	Hyperostosis Frontalis Interna
8903	9929	Meningococcal Meningitis
8904	993	Flavivirus Infectious Disease
8905	9930	Primary Neisseriaceae Infectious Disease
8906	9931	Waterhouse-Friderichsen Syndrome
8907	9935	Chronic Inflammation Of Lacrimal Passage
8908	9936	Chronic Canaliculitis
8909	9937	Chronic Dacryocystitis
8910	9938	Dacryocystitis
8911	9939	Dacryocystocele
8912	9940	Congenital Or Acquired Abnormality Of Vulva Complicating Pregnancy, Childbirth, Or The Puerperium
8913	9942	Lymph Node Disease
8914	9943	Syphilitic Episcleritis
8915	9945	Constant Exophthalmos
8916	9946	Steroid-induced Glaucoma
8917	9948	Residual Stage Corticosteroid-induced Glaucoma
8918	9952	Acute Lymphocytic Leukemia
8919	9953	B- And T-cell Mixed Leukemia
8920	9954	Null-cell Leukemia
8921	9955	Hypoplastic Left Heart Syndrome
8922	9957	Periostitis
8923	9958	Hemometra
8924	9965	Toxoplasmosis
8925	9969	Carotenemia
8926	997	Uterine Inversion
8927	9970	Obesity
8928	9971	Hypervitaminosis D
8929	9972	Hypervitaminosis A
8930	9973	Substance Dependence
8931	9974	Drug Dependence
8932	9975	Cocaine Dependence
8933	9976	Heroin Dependence
8934	9977	Hallucinogen Dependence
8935	9978	Acute Female Pelvic Peritonitis
8936	998	Eosinophilia-myalgia Syndrome
8937	9986	Orbit Lymphoma
8938	9987	Orbit Sarcoma
8939	9988	Tertiary Neurosyphilis
8940	9989	Metastasis To The Orbit
8941	999	Eosinophilia
8942	9993	Hypoglycemia
8943	9995	Endocrine And Metabolic Disturbances Specific To The Fetus And Newborn
8944	9997	Peripartum Cardiomyopathy
8945	complicated_by	Complicated_by
8946	composed_of	Composed_of
8947	derives_from	Derives_from
8948	has_material_basis_in	Has_material_basis_in
8949	has_symptom	Has_symptom
8950	inheres_in	Inheres_in
8951	is_a	Is_a
8952	located_in	Located_in
8953	occurs_with	Occurs_with
8954	part_of	Part_of
8955	realized_by	Realized_by
8956	realized_by_supression_with	Realized_by_supression_with
8957	results_in	Results_in
8958	results_in_formation_of	Results_in_formation_of
8959	transmitted_by	Transmitted_by
\.


--
-- Name: disease_ontology_mirrors_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('disease_ontology_mirrors_id_seq', 8959, true);


--
-- Data for Name: diseases; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY diseases (id, doid, name, created_at, updated_at) FROM stdin;
2	1612	Breast Cancer	2015-05-20 18:10:07.563824	2015-05-20 18:10:07.563824
5	769	Neuroblastoma	2015-05-20 18:10:07.847521	2015-05-20 18:10:07.847521
7	1909	Melanoma	2015-05-20 18:10:08.317619	2015-05-20 18:10:08.317619
23	4947	Cholangiocarcinoma	2015-05-20 18:10:13.601054	2015-05-20 18:10:13.601054
26	3069	Astrocytoma	2015-05-20 18:10:14.869115	2015-05-20 18:10:14.869115
36	12603	Acute Leukemia	2015-05-20 18:10:16.658596	2015-05-20 18:10:16.658596
45	0050929	Mucosal Melanoma	2015-05-20 18:10:23.237437	2015-05-20 18:10:23.237437
46	1520	Colon Carcinoma	2015-05-20 18:10:23.28621	2015-05-20 18:10:23.28621
47	9256	Colorectal Cancer	2015-05-20 18:10:23.417529	2015-05-20 18:10:23.417529
48	6367	Acral Lentiginous Melanoma	2015-05-20 18:10:23.456518	2015-05-20 18:10:23.456518
49	3910	Lung Adenocarcinoma	2015-05-20 18:10:23.491026	2015-05-20 18:10:23.491026
50	4450	Renal Cell Carcinoma	2015-05-20 18:10:23.53195	2015-05-20 18:10:23.53195
51	0060075	Estrogen-receptor Positive Breast Cancer	2015-05-20 18:10:23.58233	2015-05-20 18:10:23.58233
53	4465	Papillary Renal Cell Carcinoma	2015-05-20 18:10:23.68657	2015-05-20 18:10:23.68657
1	8552	Chronic Myeloid Leukemia	2015-05-20 18:10:07.219653	2015-05-20 18:12:13.33222
3	3908	Non-small Cell Lung Carcinoma	2015-05-20 18:10:07.603696	2015-05-20 18:12:14.123255
4	0050905	Inflammatory Myofibroblastic Tumor	2015-05-20 18:10:07.80951	2015-05-20 18:12:14.498971
6	9256	Colorectal Cancer	2015-05-20 18:10:08.274873	2015-05-20 18:12:15.186512
8	9256	Colorectal Cancer	2015-05-20 18:10:08.447705	2015-05-20 18:12:15.907839
9	1781	Thyroid Cancer	2015-05-20 18:10:08.975237	2015-05-20 18:12:16.298932
10	2394	Ovarian Cancer	2015-05-20 18:10:09.395959	2015-05-20 18:12:16.747522
11	1612	Breast Cancer	2015-05-20 18:10:09.613639	2015-05-20 18:12:17.581862
12	5520	Head And Neck Squamous Cell Carcinoma	2015-05-20 18:10:09.691844	2015-05-20 18:12:17.99594
13	0050746	Mantle Cell Lymphoma	2015-05-20 18:10:09.730126	2015-05-20 18:12:18.575318
14	10534	Stomach Cancer	2015-05-20 18:10:09.769076	2015-05-20 18:12:19.174513
15	715	T-cell Leukemia	2015-05-20 18:10:09.963234	2015-05-20 18:12:19.532516
16	5635	Gastric Adenosquamous Carcinoma	2015-05-20 18:10:10.048709	2015-05-20 18:12:19.959142
17	1324	Lung Cancer	2015-05-20 18:10:10.131249	2015-05-20 18:12:20.592053
18	0060075	Estrogen-receptor Positive Breast Cancer	2015-05-20 18:10:10.176128	2015-05-20 18:12:21.066891
19	9119	Acute Myeloid Leukemia	2015-05-20 18:10:10.396402	2015-05-20 18:12:21.571254
20	9952	Acute Lymphocytic Leukemia	2015-05-20 18:10:10.633792	2015-05-20 18:12:22.119027
21	5015	Hepatocellular Fibrolamellar Carcinoma	2015-05-20 18:10:10.92512	2015-05-20 18:12:22.452081
22	3908	Non-small Cell Lung Carcinoma	2015-05-20 18:10:12.277873	2015-05-20 18:12:22.936573
24	4007	Bladder Carcinoma	2015-05-20 18:10:13.653875	2015-05-20 18:12:23.927984
25	3909	Bronchogenic Lung Adenocarcinoma	2015-05-20 18:10:14.717438	2015-05-20 18:12:24.486638
27	3068	Glioblastoma Multiforme	2015-05-20 18:10:14.911911	2015-05-20 18:12:25.807613
28	0050908	Myelodysplastic Syndrome	2015-05-20 18:10:14.952577	2015-05-20 18:12:26.33031
29	0050908	Myelodysplastic Syndrome	2015-05-20 18:10:15.241912	2015-05-20 18:12:26.799202
30	10747	Lymphoid Leukemia	2015-05-20 18:10:15.504887	2015-05-20 18:12:27.291453
31	4960	Bone Marrow Cancer	2015-05-20 18:10:15.568141	2015-05-20 18:12:27.78557
32	8997	Polycythemia Vera	2015-05-20 18:10:15.616063	2015-05-20 18:12:28.482085
33	9119	Acute Myeloid Leukemia	2015-05-20 18:10:15.698082	2015-05-20 18:12:29.108253
34	9253	Gastrointestinal Stromal Tumor	2015-05-20 18:10:15.746471	2015-05-20 18:12:29.560928
35	14145	Malignant Anus Melanoma	2015-05-20 18:10:16.254207	2015-05-20 18:12:29.733376
37	9538	Multiple Myeloma	2015-05-20 18:10:16.733863	2015-05-20 18:12:30.167654
38	3910	Lung Adenocarcinoma	2015-05-20 18:10:16.98565	2015-05-20 18:12:30.351068
39	9119	Acute Myeloid Leukemia	2015-05-20 18:10:17.396486	2015-05-20 18:12:30.502004
40	3068	Glioblastoma Multiforme	2015-05-20 18:10:17.766131	2015-05-20 18:12:30.703661
41	9253	Gastrointestinal Stromal Tumor	2015-05-20 18:10:20.031915	2015-05-20 18:12:30.837766
42	9119	Acute Myeloid Leukemia	2015-05-20 18:10:21.104057	2015-05-20 18:12:30.979844
43	3973	Thyroid Medullary Carcinoma	2015-05-20 18:10:21.327257	2015-05-20 18:12:31.161016
44	6477	Invasive Bladder Transitional Cell Carcinoma	2015-05-20 18:10:22.072543	2015-05-20 18:12:31.392326
52	643	Progressive Multifocal Leukoencephalopathy	2015-05-20 18:10:23.636987	2015-05-20 18:12:32.728665
\.


--
-- Name: diseases_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('diseases_id_seq', 53, true);


--
-- Data for Name: drugs; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY drugs (id, name, pubchem_id, created_at, updated_at) FROM stdin;
1	N/A	\N	2015-05-20 18:10:07.259854	2015-05-20 18:10:07.259854
2	Nilotinib	\N	2015-05-20 18:10:07.346668	2015-05-20 18:10:07.346668
3	Dasatinib	\N	2015-05-20 18:10:07.353733	2015-05-20 18:10:07.353733
4	Imatinib	\N	2015-05-20 18:10:07.397163	2015-05-20 18:10:07.397163
5	MK-2206	\N	2015-05-20 18:10:07.584167	2015-05-20 18:10:07.584167
6	Crizotinib	\N	2015-05-20 18:10:07.626101	2015-05-20 18:10:07.626101
7	CH5424802	\N	2015-05-20 18:10:07.747438	2015-05-20 18:10:07.747438
8	TAE684	\N	2015-05-20 18:10:07.986562	2015-05-20 18:10:07.986562
9	Sorafenib	\N	2015-05-20 18:10:08.171274	2015-05-20 18:10:08.171274
10	Trametinib	\N	2015-05-20 18:10:08.25097	2015-05-20 18:10:08.25097
11	Panitumumab	\N	2015-05-20 18:10:08.297555	2015-05-20 18:10:08.297555
12	Dabrafenib	\N	2015-05-20 18:10:08.337452	2015-05-20 18:10:08.337452
13	Cetuximab	\N	2015-05-20 18:10:08.470506	2015-05-20 18:10:08.470506
14	PD0325901	\N	2015-05-20 18:10:08.511344	2015-05-20 18:10:08.511344
15	PLX4720	\N	2015-05-20 18:10:08.516032	2015-05-20 18:10:08.516032
16	Nutlin-3	\N	2015-05-20 18:10:08.558582	2015-05-20 18:10:08.558582
17	Capecitabine	\N	2015-05-20 18:10:08.598021	2015-05-20 18:10:08.598021
18	Vemurafenib	\N	2015-05-20 18:10:08.602921	2015-05-20 18:10:08.602921
19	Bevacizumab	\N	2015-05-20 18:10:08.607216	2015-05-20 18:10:08.607216
20	Dacarbazine	\N	2015-05-20 18:10:08.767571	2015-05-20 18:10:08.767571
21	Temozolomide	\N	2015-05-20 18:10:08.772878	2015-05-20 18:10:08.772878
22	AZD6244	\N	2015-05-20 18:10:09.24578	2015-05-20 18:10:09.24578
23	Olaparib	\N	2015-05-20 18:10:09.420674	2015-05-20 18:10:09.420674
24	Palbociclib (PD-0332991)	\N	2015-05-20 18:10:09.988394	2015-05-20 18:10:09.988394
25	BYL719	\N	2015-05-20 18:10:10.194091	2015-05-20 18:10:10.194091
26	Palbociclib	\N	2015-05-20 18:10:10.230853	2015-05-20 18:10:10.230853
27	GW-2580	\N	2015-05-20 18:10:10.654369	2015-05-20 18:10:10.654369
28	Erlotinib	\N	2015-05-20 18:10:10.903963	2015-05-20 18:10:10.903963
29	Daunorubicin	\N	2015-05-20 18:10:10.986611	2015-05-20 18:10:10.986611
30	Idarubicin	\N	2015-05-20 18:10:11.022533	2015-05-20 18:10:11.022533
31	Gefitinib	\N	2015-05-20 18:10:12.014272	2015-05-20 18:10:12.014272
32	Premetrexed	\N	2015-05-20 18:10:12.358501	2015-05-20 18:10:12.358501
33	Stauroporine	\N	2015-05-20 18:10:12.518384	2015-05-20 18:10:12.518384
34	Dacomitinib	\N	2015-05-20 18:10:12.554162	2015-05-20 18:10:12.554162
35	Neratinib	\N	2015-05-20 18:10:12.596004	2015-05-20 18:10:12.596004
36	Lapatinib	\N	2015-05-20 18:10:12.764269	2015-05-20 18:10:12.764269
37	Hormone Therapy	\N	2015-05-20 18:10:13.059819	2015-05-20 18:10:13.059819
38	Tamoxifen	\N	2015-05-20 18:10:13.117107	2015-05-20 18:10:13.117107
39	Fulvestrant	\N	2015-05-20 18:10:13.122183	2015-05-20 18:10:13.122183
40	Ponatinib	\N	2015-05-20 18:10:13.618903	2015-05-20 18:10:13.618903
41	PD173074	\N	2015-05-20 18:10:13.672642	2015-05-20 18:10:13.672642
42	Pazopanib	\N	2015-05-20 18:10:13.719069	2015-05-20 18:10:13.719069
43	AG1296	\N	2015-05-20 18:10:13.763038	2015-05-20 18:10:13.763038
44	ATRA	\N	2015-05-20 18:10:13.803876	2015-05-20 18:10:13.803876
45	CEP701	\N	2015-05-20 18:10:13.84416	2015-05-20 18:10:13.84416
46	SU5614	\N	2015-05-20 18:10:14.391759	2015-05-20 18:10:14.391759
47	Bortezomib	\N	2015-05-20 18:10:14.734649	2015-05-20 18:10:14.734649
48	Fasudil	\N	2015-05-20 18:10:14.739783	2015-05-20 18:10:14.739783
49	Pegylated IFN-2a	\N	2015-05-20 18:10:15.635291	2015-05-20 18:10:15.635291
50	TG101348	\N	2015-05-20 18:10:15.672796	2015-05-20 18:10:15.672796
51	SU11248	\N	2015-05-20 18:10:16.512561	2015-05-20 18:10:16.512561
52	Regorafenib	\N	2015-05-20 18:10:16.594412	2015-05-20 18:10:16.594412
53	NVP-BEZ235	\N	2015-05-20 18:10:17.259063	2015-05-20 18:10:17.259063
54	ARRY-142886	\N	2015-05-20 18:10:17.265304	2015-05-20 18:10:17.265304
55	Carmustine	\N	2015-05-20 18:10:17.786443	2015-05-20 18:10:17.786443
56	O(6)-benzylguanine	\N	2015-05-20 18:10:17.860744	2015-05-20 18:10:17.860744
57	NSC348884	\N	2015-05-20 18:10:19.2626	2015-05-20 18:10:19.2626
58	Valproic Acid	\N	2015-05-20 18:10:19.302196	2015-05-20 18:10:19.302196
59	17-AAG	\N	2015-05-20 18:10:19.75889	2015-05-20 18:10:19.75889
60	Crenolanib	\N	2015-05-20 18:10:20.05601	2015-05-20 18:10:20.05601
61	CH5132799	\N	2015-05-20 18:10:20.396173	2015-05-20 18:10:20.396173
62	Rapamycin	\N	2015-05-20 18:10:20.431748	2015-05-20 18:10:20.431748
63	Motesanib	\N	2015-05-20 18:10:21.349624	2015-05-20 18:10:21.349624
64	AZD1480	\N	2015-05-20 18:10:21.409283	2015-05-20 18:10:21.409283
65	Doxorubicin	\N	2015-05-20 18:10:21.664846	2015-05-20 18:10:21.664846
66	Everolimus	\N	2015-05-20 18:10:22.093431	2015-05-20 18:10:22.093431
67	Carfilzomib	\N	2015-05-20 18:10:23.439357	2015-05-20 18:10:23.439357
68	Plx4032	\N	2015-05-20 18:10:23.508558	2015-05-20 18:10:23.508558
69	Letrozole	\N	2015-05-20 18:10:23.607593	2015-05-20 18:10:23.607593
70	5-hydroxytryptophan	\N	2015-05-20 18:10:23.661087	2015-05-20 18:10:23.661087
71	2-(4-(3-quinolin-6-ylmethyl-3h-(1	\N	2015-05-20 18:10:23.706889	2015-05-20 18:10:23.706889
72	2	\N	2015-05-20 18:10:23.711586	2015-05-20 18:10:23.711586
73	3)triazolo(4	\N	2015-05-20 18:10:23.715731	2015-05-20 18:10:23.715731
74	5-b)pyrazin-5-yl)pyrazol-1-yl)ethanol	\N	2015-05-20 18:10:23.720069	2015-05-20 18:10:23.720069
\.


--
-- Data for Name: evidence_levels; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY evidence_levels (id, level, description, created_at, updated_at) FROM stdin;
1	C	\N	2015-05-20 18:10:07.225639	2015-05-20 18:10:07.225639
2	A	\N	2015-05-20 18:10:07.288739	2015-05-20 18:10:07.288739
3	B	\N	2015-05-20 18:10:07.328225	2015-05-20 18:10:07.328225
4	D	\N	2015-05-20 18:10:09.22637	2015-05-20 18:10:09.22637
\.


--
-- Data for Name: evidence_types; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY evidence_types (id, evidence_type, created_at, updated_at) FROM stdin;
1	Diagnostic	2015-05-20 18:10:07.223141	2015-05-20 18:10:07.223141
2	Predictive	2015-05-20 18:10:07.326416	2015-05-20 18:10:07.326416
3	Prognostic	2015-05-20 18:10:08.663169	2015-05-20 18:10:08.663169
\.


--
-- Data for Name: genes; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY genes (id, entrez_id, name, description, official_name, created_at, updated_at, clinical_description) FROM stdin;
1	238	ALK	ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.	anaplastic lymphoma receptor tyrosine kinase	2015-05-20 18:09:52.308134	2015-05-20 18:09:52.308134	\N
2	207	AKT1	AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.	v-akt murine thymoma viral oncogene homolog 1	2015-05-20 18:09:52.577001	2015-05-20 18:09:52.577001	\N
3	369	ARAF	ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.	A-Raf proto-oncogene, serine/threonine kinase	2015-05-20 18:09:52.80755	2015-05-20 18:09:52.80755	\N
4	25	ABL1	ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.	ABL proto-oncogene 1, non-receptor tyrosine kinase	2015-05-20 18:09:53.048787	2015-05-20 18:09:53.048787	\N
5	673	BRAF	BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.	B-Raf proto-oncogene, serine/threonine kinase	2015-05-20 18:09:53.313006	2015-05-20 18:09:53.313006	\N
6	672	BRCA1	BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy indivudals to assess risk.	breast cancer 1, early onset	2015-05-20 18:09:53.570203	2015-05-20 18:09:53.570203	\N
7	675	BRCA2	BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy indivudals to assess risk.	breast cancer 2, early onset	2015-05-20 18:09:53.833828	2015-05-20 18:09:53.833828	\N
8	595	CCND1	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	cyclin D1	2015-05-20 18:09:54.061705	2015-05-20 18:09:54.061705	\N
9	894	CCND2	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	cyclin D2	2015-05-20 18:09:54.278584	2015-05-20 18:09:54.278584	\N
10	896	CCND3	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.	cyclin D3	2015-05-20 18:09:54.468106	2015-05-20 18:09:54.468106	\N
11	898	CCNE1	Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.	cyclin E1	2015-05-20 18:09:54.683256	2015-05-20 18:09:54.683256	\N
12	1021	CDK6	CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	cyclin-dependent kinase 6	2015-05-20 18:09:54.87979	2015-05-20 18:09:54.87979	\N
13	1019	CDK4	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	cyclin-dependent kinase 4	2015-05-20 18:09:55.086647	2015-05-20 18:09:55.086647	\N
14	1029	CDKN2A	CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. One mechanism by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.	cyclin-dependent kinase inhibitor 2A	2015-05-20 18:09:55.370556	2015-05-20 18:09:55.370556	\N
15	1050	CEBPA	AML with mutated CEBPA' is a provisional entity in the WHO classification of acute myeloid leukemia (AML) and is recommended to be tested for in patients with AML. CEBPA mutations are particularly associated with cytogenetically normal AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha protein while C-terminal mutations reduce the DNA-binding potential of this transcription factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	CCAAT/enhancer binding protein (C/EBP), alpha	2015-05-20 18:09:55.614418	2015-05-20 18:09:55.614418	\N
16	3337	DNAJB1	DNAJB1 works upstream of MDM2, stabilizing the complex and facilitating p53 turnover. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.	DnaJ (Hsp40) homolog, subfamily B, member 1	2015-05-20 18:09:55.846773	2015-05-20 18:09:55.846773	\N
17	5566	PRKACA	PRKACA has been studied in breast cancer and has been found to mediate resistance to HER2 targeted therapies. It has also been found to contain a mutation hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.	protein kinase, cAMP-dependent, catalytic, alpha	2015-05-20 18:09:56.048272	2015-05-20 18:09:56.048272	\N
18	1788	DNMT3A	DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.	DNA (cytosine-5-)-methyltransferase 3 alpha	2015-05-20 18:09:56.259227	2015-05-20 18:09:56.259227	\N
19	1956	EGFR	EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in non-small cell lung cancer.	epidermal growth factor receptor	2015-05-20 18:09:56.494493	2015-05-20 18:09:56.494493	\N
20	2064	ERBB2	ERBB2, commonly referred to as HER2, is amplified in HER2-positive breast cancer, and is treated in a separate manner than the other subtypes of breast cancer. Apart from being amplified, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.	erb-b2 receptor tyrosine kinase 2	2015-05-20 18:09:56.834772	2015-05-20 18:09:56.834772	\N
21	2099	ESR1	ESR1 has been a focus in breast cancer for quite some time, but has also shown significance in endometrial, ovarian and other cancer types. ER-positive breast cancer that is resistant to hormone therapy has instigated clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of the protein have been implicated in hormone resistance and anti-estrogen therapies. This has spurred efforts to develop therapeutics that act to degrade the protein, rather than act as an antagonist. These agents are currently in clinical trials and have seen some success, highlighting the importance of sequencing efforts in treating breast cancer.	estrogen receptor 1	2015-05-20 18:09:57.114261	2015-05-20 18:09:57.114261	\N
22	2263	FGFR2	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	fibroblast growth factor receptor 2	2015-05-20 18:09:57.396516	2015-05-20 18:09:57.396516	\N
23	2261	FGFR3	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	fibroblast growth factor receptor 3	2015-05-20 18:09:57.656784	2015-05-20 18:09:57.656784	\N
24	2322	FLT3	FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.	fms-related tyrosine kinase 3	2015-05-20 18:09:57.878975	2015-05-20 18:09:57.878975	\N
25	2624	GATA2	GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.	GATA binding protein 2	2015-05-20 18:09:58.103188	2015-05-20 18:09:58.103188	\N
26	3417	IDH1	IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.	isocitrate dehydrogenase 1 (NADP+), soluble	2015-05-20 18:09:58.346654	2015-05-20 18:09:58.346654	\N
27	3418	IDH2	IDH2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall prognosis in AML patients, its utility as a prognostic marker in MDS is still under debate. Additionally, IDH2 (R140) has been associated with improved overall survival in AML. IDH2 mutations have been associated with improved prognosis in gliomas.	isocitrate dehydrogenase 2 (NADP+), mitochondrial	2015-05-20 18:09:58.590429	2015-05-20 18:09:58.590429	\N
28	3717	JAK2	JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.	Janus kinase 2	2015-05-20 18:09:58.811626	2015-05-20 18:09:58.811626	\N
29	3815	KIT	c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	2015-05-20 18:09:59.026006	2015-05-20 18:09:59.026006	\N
30	3845	KRAS	Mutations in the RAS family of proteins have frequently observed across cancer types. The amino acid positions account for the overwhelming majority of these mutations, G12, G13 and Q61. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeted these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	Kirsten rat sarcoma viral oncogene homolog	2015-05-20 18:09:59.294394	2015-05-20 18:09:59.294394	\N
31	5604	MAP2K1	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	mitogen-activated protein kinase kinase 1	2015-05-20 18:09:59.532991	2015-05-20 18:09:59.532991	\N
32	4209	MEF2D	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	myocyte enhancer factor 2D	2015-05-20 18:09:59.718477	2015-05-20 18:09:59.718477	\N
33	1436	CSF1R	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	colony stimulating factor 1 receptor	2015-05-20 18:09:59.937344	2015-05-20 18:09:59.937344	\N
34	4255	MGMT	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	O-6-methylguanine-DNA methyltransferase	2015-05-20 18:10:00.123636	2015-05-20 18:10:00.123636	\N
35	4869	NPM1	AML with mutated NPM1 is provisional entity in the WHO classification of AML and is recommended to be tested for in patients with cytogenetically normal AML (CN-AML). Evaluation of FLT3 mutations should be evaluated concurrently as they have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia, indicating it may require additional mutations to promote leukemic development.	nucleophosmin (nucleolar phosphoprotein B23, numatrin)	2015-05-20 18:10:00.315556	2015-05-20 18:10:00.315556	\N
36	4893	NRAS	Mutations in the RAS family of proteins have frequently observed across cancer types. The amino acid positions account for the overwhelming majority of these mutations, G12, G13 and Q61. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeted these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	neuroblastoma RAS viral (v-ras) oncogene homolog	2015-05-20 18:10:00.531126	2015-05-20 18:10:00.531126	\N
37	5290	PIK3CA	PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha	2015-05-20 18:10:00.755891	2015-05-20 18:10:00.755891	\N
38	5156	PDGFRA	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	platelet-derived growth factor receptor, alpha polypeptide	2015-05-20 18:10:00.98554	2015-05-20 18:10:00.98554	\N
39	5371	PML	The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	promyelocytic leukemia	2015-05-20 18:10:01.192685	2015-05-20 18:10:01.192685	\N
40	5914	RARA	The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	retinoic acid receptor, alpha	2015-05-20 18:10:01.387329	2015-05-20 18:10:01.387329	\N
41	5728	PTEN	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	phosphatase and tensin homolog	2015-05-20 18:10:01.623288	2015-05-20 18:10:01.623288	\N
42	5979	RET	RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.	ret proto-oncogene	2015-05-20 18:10:01.866873	2015-05-20 18:10:01.866873	\N
43	861	RUNX1	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	runt-related transcription factor 1	2015-05-20 18:10:02.108304	2015-05-20 18:10:02.108304	\N
44	23451	SF3B1	SF3B1 mutations have been described in several myeloid malignancies, predominantly myelodysplastic syndromes (MDS), as well as other hematologic malignancies and breast cancer. SF3B1 is one of several genes involved in RNA splicing that has been identified as recurrently mutated in MDS and other malignanices. The mutations affecting SF3B1 are typically heterozygous, point mutations suspected to be functionally deleterious with K700E described as a major hotspot mutation. MDS patients with SF3B1 mutations have been reported to have better overall and event-free survival than their wildtype counterparts. Additionally, these mutations are highly associated with subtypes of MDS characterized by ringed sideroblasts (refractory anemia with ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ring sideroblasts).	splicing factor 3b, subunit 1, 155kDa	2015-05-20 18:10:02.337005	2015-05-20 18:10:02.337005	\N
45	7157	TP53	TP53 mutations are universal across cancer types. Loss of tumor suppressors is most recognized by large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide variants, or missense mutations. These variants are also very broadly distributed throughout the gene, not localizing in any particular hotspot. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) have been found to have prognostic impact on patient outcomes.	tumor protein p53	2015-05-20 18:10:02.597278	2015-05-20 18:10:02.597278	\N
46	7248	TSC1	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	tuberous sclerosis 1	2015-05-20 18:10:02.806315	2015-05-20 18:10:02.806315	\N
47	7249	TSC2	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	tuberous sclerosis 2	2015-05-20 18:10:03.001473	2015-05-20 18:10:03.001473	\N
48	7307	U2AF1	U2AF1 is one of several spliceosome complex genes frequently mutated in a variety of hematologic malignancies, particularly de novo myelodysplastic syndromes (MDS), as well as solid tumors such as lung and pancreatic cancers. Two hotspot mutations (S34 and Q157) occur within the two zinc-finger domains of the U2AF1 protein. These mutations have been associated with altered splicing patterns in vitro and in vivo. U2AF1 mutations in MDS have been associated with an increased risk of transformation to secondary acute myeloid leukemia, however, the impact of these mutations on overall survival has been an area of debate.	U2 small nuclear RNA auxiliary factor 1	2015-05-20 18:10:03.214531	2015-05-20 18:10:03.214531	\N
49	7490	WT1	WT1 is a tumor suppressor gene associated with the development of Wilms' Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.	Wilms tumor 1	2015-05-20 18:10:03.448935	2015-05-20 18:10:03.448935	\N
50	2475	MTOR	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	mechanistic target of rapamycin (serine/threonine kinase)	2015-05-20 18:10:03.660994	2015-05-20 18:10:03.660994	\N
51	4851	NOTCH1	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	notch 1	2015-05-20 18:10:03.861503	2015-05-20 18:10:03.861503	\N
52	4921	DDR2	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	discoidin domain receptor tyrosine kinase 2	2015-05-20 18:10:04.063218	2015-05-20 18:10:04.063218	\N
53	4233	MET	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	MET proto-oncogene, receptor tyrosine kinase	2015-05-20 18:10:04.270994	2015-05-20 18:10:04.270994	\N
54	4067	LYN	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	LYN proto-oncogene, Src family tyrosine kinase	2015-05-20 18:10:04.470928	2015-05-20 18:10:04.470928	\N
55	6697	SPR	A summary for this gene has yet to be developed! Add one now by clicking the "Edit Gene" button.	sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)	2015-05-20 18:10:04.654809	2015-05-20 18:10:04.654809	\N
\.


--
-- Data for Name: sources; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY sources (id, pubmed_id, study_type, description, created_at, updated_at) FROM stdin;
1	24889366	\N	Rossi et al., 2014, Int. J. Oncol.	2015-05-20 18:09:52.345387	2015-05-20 18:10:24.370266
2	23401436	\N	Shaw et al., 2013, J. Clin. Oncol.	2015-05-20 18:09:52.35135	2015-05-20 18:10:24.771367
3	16095999	\N	Bellacosa et al., 2005, Adv. Cancer Res.	2015-05-20 18:09:52.588994	2015-05-20 18:10:25.084655
4	15023437	\N	Fresno Vara et al., 2004, Cancer Treat. Rev.	2015-05-20 18:09:52.593265	2015-05-20 18:10:25.407603
5	15676015	\N	Lee et al., 2005, APMIS	2015-05-20 18:09:52.8203	2015-05-20 18:10:25.816378
6	24569458	\N	Imielinski et al., 2014, J. Clin. Invest.	2015-05-20 18:09:52.825812	2015-05-20 18:10:26.209261
7	15719031	\N	Ren, 2005, Nat. Rev. Cancer	2015-05-20 18:09:53.06528	2015-05-20 18:10:26.651865
8	17457302	\N	Weisberg et al., 2007, Nat. Rev. Cancer	2015-05-20 18:09:53.069699	2015-05-20 18:10:26.975928
9	19724843	\N	Li et al., 2009, Oncol. Rep.	2015-05-20 18:09:53.325994	2015-05-20 18:10:27.690843
10	23594689	\N	Pakneshan et al., 2013, Pathology	2015-05-20 18:09:53.329995	2015-05-20 18:10:28.082789
11	24366442	\N	Nelson et al., 2014, Ann. Intern. Med.	2015-05-20 18:09:53.582682	2015-05-20 18:10:28.740017
12	12432268	\N	Diehl, Cancer Biol. Ther.	2015-05-20 18:09:54.07603	2015-05-20 18:10:29.150005
13	24387133	\N	Casimiro et al., 2014, Expert Opin Investig Drugs	2015-05-20 18:09:54.080364	2015-05-20 18:10:29.512949
14	14965268	\N	Mazumder et al., 2004, Curr Cancer Drug Targets	2015-05-20 18:09:54.697855	2015-05-20 18:10:29.987309
15	20370706	\N	Graf et al., 2010, Mini Rev Med Chem	2015-05-20 18:09:54.89227	2015-05-20 18:10:30.343219
16	24089445	\N	Sheppard et al., 2013, Clin. Cancer Res.	2015-05-20 18:09:54.897187	2015-05-20 18:10:32.226883
17	20473920	\N	Shima et al., 2011, Int. J. Cancer	2015-05-20 18:09:55.385693	2015-05-20 18:10:32.553893
18	23111194	\N	Bradly et al., 2012, Diagn. Mol. Pathol.	2015-05-20 18:09:55.389937	2015-05-20 18:10:32.916465
19	19357394	\N	Vardiman et al., 2009, Blood	2015-05-20 18:09:55.64015	2015-05-20 18:10:33.284893
20	11242107	\N	Pabst et al., 2001, Nat. Genet.	2015-05-20 18:09:55.645497	2015-05-20 18:10:33.605878
21	9012825	\N	Zhang et al., 1997, Proc. Natl. Acad. Sci. U.S.A.	2015-05-20 18:09:55.649535	2015-05-20 18:10:33.945043
22	24578576	\N	Honeyman et al., 2014, Science	2015-05-20 18:09:55.857689	2015-05-20 18:10:34.319224
23	24909179	\N	Moody et al., 2015, Oncogene	2015-05-20 18:09:56.064848	2015-05-20 18:10:34.68991
24	24167195	\N	Kim et al., 2013, Blood	2015-05-20 18:09:56.270845	2015-05-20 18:10:35.111693
25	24656771	\N	Russler-Germain et al., 2014, Cancer Cell	2015-05-20 18:09:56.275098	2015-05-20 18:10:35.51213
26	23953842	\N	Yewale et al., 2013, Biomaterials	2015-05-20 18:09:56.506145	2015-05-20 18:10:35.878051
27	18712184	\N	Charpidou et al., In Vivo	2015-05-20 18:09:56.509951	2015-05-20 18:10:36.244897
28	16947083	\N	Badache et al., 2006, J Mammary Gland Biol Neoplasia	2015-05-20 18:09:56.850571	2015-05-20 18:10:36.605224
29	10878580	\N	Yu et al., 2000, Bioessays	2015-05-20 18:09:56.857258	2015-05-20 18:10:36.951421
30	24185510	\N	Robinson et al., 2013, Nat. Genet.	2015-05-20 18:09:57.125034	2015-05-20 18:10:37.424321
31	22279420	\N	Mohibi et al., 2011, J Carcinog	2015-05-20 18:09:57.128711	2015-05-20 18:10:37.784782
32	18636142	\N	Katoh, 2008, Int. J. Oncol.	2015-05-20 18:09:57.41365	2015-05-20 18:10:38.130832
33	23558953	\N	Wu et al., 2013, Cancer Discov	2015-05-20 18:09:57.419114	2015-05-20 18:10:38.664633
34	12951584	\N	Stirewalt et al., 2003, Nat. Rev. Cancer	2015-05-20 18:09:57.904355	2015-05-20 18:10:39.079105
35	22541434	\N	Kumar et al., 2012, Cell	2015-05-20 18:09:58.115651	2015-05-20 18:10:39.509969
36	25619630	\N	Mir et al., 2015, Cancer Med	2015-05-20 18:09:58.122376	2015-05-20 18:10:39.94703
37	24065766	\N	Lu et al., 2013, Genes Dev.	2015-05-20 18:09:58.35793	2015-05-20 18:10:40.321814
38	19228619	\N	Yan et al., 2009, N. Engl. J. Med.	2015-05-20 18:09:58.361526	2015-05-20 18:10:40.792294
39	22417203	\N	Patel et al., 2012, N. Engl. J. Med.	2015-05-20 18:09:58.608768	2015-05-20 18:10:41.178253
40	17133099	\N	Levine et al., 2007, Curr. Opin. Hematol.	2015-05-20 18:09:58.82463	2015-05-20 18:10:41.96907
41	23944364	\N	Stankov et al., 2014, Curr. Pharm. Des.	2015-05-20 18:09:59.037184	2015-05-20 18:10:42.316673
42	22589270	\N	Prior et al., 2012, Cancer Res.	2015-05-20 18:09:59.311394	2015-05-20 18:10:42.715786
43	23226219	\N	Chou et al., 2012, PLoS ONE	2015-05-20 18:10:00.328101	2015-05-20 18:10:43.047203
44	18073307	\N	Elisei et al., 2008, J. Clin. Endocrinol. Metab.	2015-05-20 18:10:01.88082	2015-05-20 18:10:43.423314
45	25465739	\N	Perri et al., 2015, Crit. Rev. Oncol. Hematol.	2015-05-20 18:10:01.885163	2015-05-20 18:10:43.801124
46	21995386	\N	Papaemmanuil et al., 2011, N. Engl. J. Med.	2015-05-20 18:10:02.34852	2015-05-20 18:10:44.165504
47	24136165	\N	Cazzola et al., 2013, Blood	2015-05-20 18:10:02.354091	2015-05-20 18:10:44.973409
48	20182602	\N	Olivier et al., 2010, Cold Spring Harb Perspect Biol	2015-05-20 18:10:02.613721	2015-05-20 18:10:45.365123
49	25311244	\N	Okeyo-Owuor et al., 2015, Leukemia	2015-05-20 18:10:03.229048	2015-05-20 18:10:45.866519
50	22158538	\N	Graubert et al., 2012, Nat. Genet.	2015-05-20 18:10:03.232884	2015-05-20 18:10:46.243925
51	25212276		Schmidt et al., 2014, Leukemia	2015-05-20 18:10:07.215546	2015-05-20 18:10:46.625399
52	20537386		An et al., 2010, Leuk. Res.	2015-05-20 18:10:07.286382	2015-05-20 18:10:46.979819
53	15194504	Cell Line	Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.	2015-05-20 18:10:07.374074	2015-05-20 18:10:47.366451
54	23888070		Beaver et al., 2013, Clin. Cancer Res.	2015-05-20 18:10:07.561957	2015-05-20 18:10:47.698444
55	20979473	Clinical Trial	Choi et al., 2010, N. Engl. J. Med.	2015-05-20 18:10:07.601834	2015-05-20 18:10:48.044802
56	21575866		Sakamoto et al., 2011, Cancer Cell	2015-05-20 18:10:07.728924	2015-05-20 18:10:48.482527
57	21030459		Sasaki et al., 2010, Cancer Res.	2015-05-20 18:10:07.807814	2015-05-20 18:10:49.317377
58	22072639		Bresler et al., 2011, Sci Transl Med	2015-05-20 18:10:07.886082	2015-05-20 18:10:49.738451
59	21948233		Heuckmann et al., 2011, Clin. Cancer Res.	2015-05-20 18:10:07.923798	2015-05-20 18:10:50.139184
60	18923525		George et al., 2008, Nature	2015-05-20 18:10:07.964861	2015-05-20 18:10:50.572219
61	24569458		Imielinski et al., 2014, J. Clin. Invest.	2015-05-20 18:10:08.149972	2015-05-20 18:10:50.976523
62	23325582	Clinical trial	Peeters et al., 2013, Clin. Cancer Res.	2015-05-20 18:10:08.273045	2015-05-20 18:10:51.376519
63	23020132	Clinical trial	Flaherty et al., 2012, N. Engl. J. Med.	2015-05-20 18:10:08.314958	2015-05-20 18:10:51.748768
64	21166657	Meta analysis	Lee et al., 2011, Br. J. Dermatol.	2015-05-20 18:10:08.362523	2015-05-20 18:10:52.15041
65	23463675	Clinical trial	Ponti et al., 2013, J. Clin. Pathol.	2015-05-20 18:10:08.396581	2015-05-20 18:10:52.553729
66	19001320	In vitro study	Di Nicolantonio et al., 2008, J. Clin. Oncol.	2015-05-20 18:10:08.445951	2015-05-20 18:10:52.920225
67	23845441	In vitro study	Rad et al., 2013, Cancer Cell	2015-05-20 18:10:08.493621	2015-05-20 18:10:53.300436
68	23812671	In vitro study	Ji et al., 2013, Clin. Cancer Res.	2015-05-20 18:10:08.534376	2015-05-20 18:10:53.891949
69	22180495	In vivo study	Yang et al., 2012, Cancer Res.	2015-05-20 18:10:08.579809	2015-05-20 18:10:54.244625
70	20619739	Retrospective study	De Roock et al., 2010, Lancet Oncol.	2015-05-20 18:10:08.624626	2015-05-20 18:10:54.643151
71	24594804	Metaanalysis	Chen et al., 2014, PLoS ONE	2015-05-20 18:10:08.661144	2015-05-20 18:10:55.012684
72	24586605	Retrospective study	Meckbach et al., 2014, PLoS ONE	2015-05-20 18:10:08.745548	2015-05-20 18:10:55.42775
73	24583796	Clinical trial	Menzies et al., 2014, Clin. Cancer Res.	2015-05-20 18:10:08.789941	2015-05-20 18:10:55.897173
74	24576830	In vitro study	Nissan et al., 2014, Cancer Res.	2015-05-20 18:10:08.827073	2015-05-20 18:10:56.295485
75	24388723	Retrospective study	Nagore et al., 2014, J. Am. Acad. Dermatol.	2015-05-20 18:10:08.898593	2015-05-20 18:10:57.670252
76	23524406	Case report	Rudin et al., 2013, J Thorac Oncol	2015-05-20 18:10:08.93748	2015-05-20 18:10:58.089822
77	21594703	Retrospective study	Howell et al., 2011, Ann. Surg. Oncol.	2015-05-20 18:10:08.973441	2015-05-20 18:10:58.423598
78	24570209	Retrospective study	Crescenzi et al., 2014, Horm. Metab. Res.	2015-05-20 18:10:09.007763	2015-05-20 18:10:58.820502
79	24588959	Perspective study	Zhang et al., 2014, Diagn Pathol	2015-05-20 18:10:09.044661	2015-05-20 18:10:59.238588
80	24354346	Retrospective study	Walczyk et al., 2014, Clin. Endocrinol. (Oxf)	2015-05-20 18:10:09.080206	2015-05-20 18:10:59.623125
81	24396464	Retrospective study	He et al., 2014, Oncol Lett	2015-05-20 18:10:09.153662	2015-05-20 18:10:59.97064
82	21098728	In vitro study	Corcoran et al., 2010, Sci Signal	2015-05-20 18:10:09.223799	2015-05-20 18:11:00.346012
83	23031422	Case report	Ponti et al., 2012, J Hematol Oncol	2015-05-20 18:10:09.266474	2015-05-20 18:11:00.713258
84	23346317	Review	Goff, 2013, J Gynecol Oncol	2015-05-20 18:10:09.393596	2015-05-20 18:11:01.087363
85	17070615		Gautschi et al., 2007, Lung Cancer	2015-05-20 18:10:09.498326	2015-05-20 18:11:01.446938
86	15961768		Arnold et al., 2005, J. Clin. Oncol.	2015-05-20 18:10:09.611088	2015-05-20 18:11:01.94417
87	16309541		Thomas et al., 2005, Int J Exp Pathol	2015-05-20 18:10:09.690081	2015-05-20 18:11:02.36725
88	17891190		Jares et al., 2007, Nat. Rev. Cancer	2015-05-20 18:10:09.728361	2015-05-20 18:11:02.790549
89	10547574		Takano et al., 1999, J. Pathol.	2015-05-20 18:10:09.766624	2015-05-20 18:11:03.198148
90	14612939		Oshimo et al., 2003, Int. J. Oncol.	2015-05-20 18:10:09.917043	2015-05-20 18:11:03.581868
91	23079656		Sawai et al., 2012, Cancer Cell	2015-05-20 18:10:09.959468	2015-05-20 18:11:03.945027
92	12432043		Keyomarsi et al., 2002, N. Engl. J. Med.	2015-05-20 18:10:10.010192	2015-05-20 18:11:04.314105
93	10224221		Donnellan et al., 1999, FASEB J.	2015-05-20 18:10:10.046729	2015-05-20 18:11:04.670197
94	25002028		Vora et al., 2014, Cancer Cell	2015-05-20 18:10:10.173885	2015-05-20 18:11:05.123193
95	23898052		Logan et al., 2013, Anticancer Res.	2015-05-20 18:10:10.21106	2015-05-20 18:11:05.506709
96	23111194		Bradly et al., 2012, Diagn. Mol. Pathol.	2015-05-20 18:10:10.318327	2015-05-20 18:11:05.980329
97	19965647	Retrospective study	Burnett et al., 2010, Blood	2015-05-20 18:10:10.393986	2015-05-20 18:11:06.437679
98	18450602	Retrospective study	Schlenk et al., 2008, N. Engl. J. Med.	2015-05-20 18:10:10.472638	2015-05-20 18:11:06.869853
99	14726504	Retrospective study	Frhling et al., 2004, J. Clin. Oncol.	2015-05-20 18:10:10.507483	2015-05-20 18:11:07.278839
100	24186003		Lilljebjrn et al., 2014, Leukemia	2015-05-20 18:10:10.631918	2015-05-20 18:11:07.677009
101	22328973		Hammerman et al., 2011, Cancer Discov	2015-05-20 18:10:10.674947	2015-05-20 18:11:08.120458
102	24578576	Retrospective study	Honeyman et al., 2014, Science	2015-05-20 18:10:10.923381	2015-05-20 18:11:08.639609
103	22081665	Retrospective study	LaRochelle et al., 2011, Oncotarget	2015-05-20 18:10:10.965027	2015-05-20 18:11:09.058868
104	23632886	Retrospective study	Gaidzik et al., 2013, Blood	2015-05-20 18:10:11.039893	2015-05-20 18:11:10.398725
105	21067377	Retrospective study	Ley et al., 2010, N. Engl. J. Med.	2015-05-20 18:10:11.077076	2015-05-20 18:11:10.834604
106	24512939	Retrospective study	El Ghannam et al., Blood Cells Mol. Dis.	2015-05-20 18:10:11.248816	2015-05-20 18:11:11.241059
107	22490330	Retrospective study	Ribeiro et al., 2012, Blood	2015-05-20 18:10:11.285571	2015-05-20 18:11:11.878977
108	22291079	Retrospective study	Marcucci et al., 2012, J. Clin. Oncol.	2015-05-20 18:10:11.318809	2015-05-20 18:11:12.279542
109	16730237		Ji et al., 2006, Cancer Cell	2015-05-20 18:10:11.990538	2015-05-20 18:11:12.715788
110	15118125		Paez et al., 2004, Science	2015-05-20 18:10:12.03212	2015-05-20 18:11:13.130188
111	24736073		Lim et al., 2014, J Thorac Oncol	2015-05-20 18:10:12.076143	2015-05-20 18:11:13.489972
112	24457318		Fukihara et al., 2014, Oncology	2015-05-20 18:10:12.132334	2015-05-20 18:11:14.620623
113	24662454		Douillard et al., 2014, J Thorac Oncol	2015-05-20 18:10:12.165903	2015-05-20 18:11:15.010415
114	25668228	Review	Denis et al., 2015, Clin. Chim. Acta	2015-05-20 18:10:12.274664	2015-05-20 18:11:15.412892
115	24636847		Li et al., 2014, Lung Cancer	2015-05-20 18:10:12.334307	2015-05-20 18:11:15.826821
116	15728811		Kobayashi et al., 2005, N. Engl. J. Med.	2015-05-20 18:10:12.381188	2015-05-20 18:11:16.162766
117	24623981		Ding et al., 2014, Onco Targets Ther	2015-05-20 18:10:12.416296	2015-05-20 18:11:16.58398
118	24729716		Li et al., 2014, Onco Targets Ther	2015-05-20 18:10:12.456011	2015-05-20 18:11:16.995208
119	24658966		Ai et al., 2014, Amino Acids	2015-05-20 18:10:12.497116	2015-05-20 18:11:17.310109
120	21430269		Sequist et al., 2011, Sci Transl Med	2015-05-20 18:10:12.534883	2015-05-20 18:11:17.735807
121	23220880		Bose et al., 2013, Cancer Discov	2015-05-20 18:10:12.578278	2015-05-20 18:11:18.146789
122	24185512		Toy et al., 2013, Nat. Genet.	2015-05-20 18:10:13.041757	2015-05-20 18:11:18.66896
123	24185510		Robinson et al., 2013, Nat. Genet.	2015-05-20 18:10:13.096997	2015-05-20 18:11:19.014389
124	24550739	Case study	Borad et al., 2014, PLoS Genet.	2015-05-20 18:10:13.599148	2015-05-20 18:11:19.509669
125	23558953		Wu et al., 2013, Cancer Discov	2015-05-20 18:10:13.651534	2015-05-20 18:11:19.92188
126	12357354	In vitro study	Tse et al., 2002, Leukemia	2015-05-20 18:10:13.744127	2015-05-20 18:11:20.337367
127	19965647		Burnett et al., 2010, Blood	2015-05-20 18:10:13.786031	2015-05-20 18:11:20.755365
128	14726387	Clinical trial	Smith et al., 2004, Blood	2015-05-20 18:10:13.819994	2015-05-20 18:11:21.125151
129	15626738	In vitro study	Bagrintseva et al., 2005, Blood	2015-05-20 18:10:13.860692	2015-05-20 18:11:21.620096
130	11290608	Retrospective study	Yamamoto et al., 2001, Blood	2015-05-20 18:10:13.896035	2015-05-20 18:11:22.007109
131	17957027	Retrospective study	Gale et al., 2008, Blood	2015-05-20 18:10:13.927732	2015-05-20 18:11:22.369393
132	21537333		Schnittger et al., 2011, Leukemia	2015-05-20 18:10:14.021006	2015-05-20 18:11:22.728409
133	24801015		Port et al., 2014, Ann. Hematol.	2015-05-20 18:10:14.212129	2015-05-20 18:11:23.15879
134	11585760	Retrospective study	Whitman et al., 2001, Cancer Res.	2015-05-20 18:10:14.276525	2015-05-20 18:11:23.541765
135	18230792	In vitro study	Zhang et al., 2008, J. Natl. Cancer Inst.	2015-05-20 18:10:14.341644	2015-05-20 18:11:23.967689
136	17965322	Retrospective study	Bacher et al., 2008, Blood	2015-05-20 18:10:14.532835	2015-05-20 18:11:24.356019
137	17940205	Retrospective study	Whitman et al., 2008, Blood	2015-05-20 18:10:14.568669	2015-05-20 18:11:24.71678
138	22368270	Clinical trial	Man et al., 2012, Blood	2015-05-20 18:10:14.608425	2015-05-20 18:11:25.128735
139	22624710		Barbacid, 2012, Cancer Cell	2015-05-20 18:10:14.715404	2015-05-20 18:11:25.481468
140	20376086	Retrospective study	Ho et al., 2010, Leukemia	2015-05-20 18:10:14.757744	2015-05-20 18:11:25.877708
141	20805365	Retrospective study	Schnittger et al., 2010, Blood	2015-05-20 18:10:14.794242	2015-05-20 18:11:26.395796
142	20368538	Retrospective study	Wagner et al., 2010, J. Clin. Oncol.	2015-05-20 18:10:14.828476	2015-05-20 18:11:26.791551
143	19933982	Retrospective study	Dubbink et al., 2009, Neurology	2015-05-20 18:10:14.867233	2015-05-20 18:11:27.163009
144	20127344	Retrospective study	Bleeker et al., 2010, Acta Neuropathol.	2015-05-20 18:10:14.90879	2015-05-20 18:11:27.546941
145	20494930	Retrospective study	Thol et al., 2010, Haematologica	2015-05-20 18:10:14.950656	2015-05-20 18:11:27.926452
146	20538800	Retrospective study	Abbas et al., 2010, Blood	2015-05-20 18:10:14.99706	2015-05-20 18:11:28.484942
147	22616558		Zhou et al., 2012, Leuk. Lymphoma	2015-05-20 18:10:15.134358	2015-05-20 18:11:28.910029
148	20421455	Retrospective study	Thol et al., 2010, Blood	2015-05-20 18:10:15.167432	2015-05-20 18:11:29.320656
149	21596855		Green et al., 2011, Blood	2015-05-20 18:10:15.202072	2015-05-20 18:11:29.738833
150	21997850		Lin et al., 2012, Ann. Hematol.	2015-05-20 18:10:15.240053	2015-05-20 18:11:30.15695
151	22033490		Patnaik et al., 2012, Leukemia	2015-05-20 18:10:15.278644	2015-05-20 18:11:31.09337
152	16081687	Retrospective study	Levine et al., 2005, Blood	2015-05-20 18:10:15.424463	2015-05-20 18:11:31.568942
153	19287384	Retrospective study	Kilpivaara et al., 2009, Nat. Genet.	2015-05-20 18:10:15.566037	2015-05-20 18:11:32.023627
154	16709929	Clinical trial	Kiladjian et al., 2006, Blood	2015-05-20 18:10:15.614126	2015-05-20 18:11:32.454412
155	18394554	In vitro study	Wernig et al., 2008, Cancer Cell	2015-05-20 18:10:15.654406	2015-05-20 18:11:32.800555
156	16384925	Retrospective study	Cairoli et al., 2006, Blood	2015-05-20 18:10:15.696268	2015-05-20 18:11:33.183784
157	10485475	Retrospective study	Taniguchi et al., 1999, Cancer Res.	2015-05-20 18:10:15.74473	2015-05-20 18:11:33.548611
158	12000708	Retrospective study	Corless et al., 2002, Am. J. Pathol.	2015-05-20 18:10:15.804592	2015-05-20 18:11:34.123694
159	16551858	Retrospective study	Wardelmann et al., 2006, Clin. Cancer Res.	2015-05-20 18:10:15.843944	2015-05-20 18:11:34.450998
160	15217946	Retrospective study	Boldrini et al., 2004, Clin. Cancer Res.	2015-05-20 18:10:15.925547	2015-05-20 18:11:34.778113
161	23775962	Clinical trial	Hodi et al., 2013, J. Clin. Oncol.	2015-05-20 18:10:15.962254	2015-05-20 18:11:35.149674
162	18421059	Observational study	Hodi et al., 2008, J. Clin. Oncol.	2015-05-20 18:10:16.251405	2015-05-20 18:11:35.588761
163	19671763	In vitro study	Woodman et al., 2009, Mol. Cancer Ther.	2015-05-20 18:10:16.304537	2015-05-20 18:11:35.994249
164	17372901	In vitro study	Antonescu et al., 2007, Int. J. Cancer	2015-05-20 18:10:16.395155	2015-05-20 18:11:36.36518
165	16954519		Heinrich et al., 2006, J. Clin. Oncol.	2015-05-20 18:10:16.447443	2015-05-20 18:11:36.739603
166	16638875		Prenen et al., 2006, Clin. Cancer Res.	2015-05-20 18:10:16.489657	2015-05-20 18:11:37.15256
167	16618717	Retrospective study	Livre et al., 2006, Cancer Res.	2015-05-20 18:10:16.534881	2015-05-20 18:11:37.57197
168	24559322	Clinical trial	Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther	2015-05-20 18:10:16.573423	2015-05-20 18:11:38.081142
169	15696205	Retrospective study	Pao et al., 2005, PLoS Med.	2015-05-20 18:10:16.613869	2015-05-20 18:11:38.616245
170	24571676	Retrospective study	Andrade et al., 2014, BMC Cancer	2015-05-20 18:10:16.656745	2015-05-20 18:11:39.000249
171	19934290	Retrospective study	Ogino et al., 2009, Clin. Cancer Res.	2015-05-20 18:10:16.698955	2015-05-20 18:11:39.366743
172	18528420	Retrospective study	Chng et al., 2008, Leukemia	2015-05-20 18:10:16.731995	2015-05-20 18:11:39.869255
173	18794081	Retrospective study	Riely et al., 2008, Clin. Cancer Res.	2015-05-20 18:10:16.774385	2015-05-20 18:11:40.391256
174	11208838	Retrospective study	Schiller et al., 2001, J. Clin. Oncol.	2015-05-20 18:10:16.808569	2015-05-20 18:11:40.819424
175	15597105	Metaanalysis	Mascaux et al., 2005, Br. J. Cancer	2015-05-20 18:10:16.845668	2015-05-20 18:11:41.221875
176	18202412	In vitro study	Livre et al., 2008, J. Clin. Oncol.	2015-05-20 18:10:16.919041	2015-05-20 18:11:41.570924
177	19794967		Marchetti et al., 2009, Neoplasia	2015-05-20 18:10:16.983865	2015-05-20 18:11:41.906006
178	23014527	Retrospective study	Dogan et al., 2012, Clin. Cancer Res.	2015-05-20 18:10:17.029839	2015-05-20 18:11:42.693189
179	23524406	case report	Rudin et al., 2013, J Thorac Oncol	2015-05-20 18:10:17.194136	2015-05-20 18:11:43.079182
180	19029981	In vivo study	Engelman et al., 2008, Nat. Med.	2015-05-20 18:10:17.239002	2015-05-20 18:11:43.422296
181	20978259	Clinical trial	De Roock et al., 2010, JAMA	2015-05-20 18:10:17.46167	2015-05-20 18:11:43.837592
182	19915144		Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.	2015-05-20 18:10:17.595365	2015-05-20 18:11:44.258496
183	19915144	In vitro study	Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.	2015-05-20 18:10:17.634366	2015-05-20 18:11:44.860823
184	11070098		Esteller et al., 2000, N. Engl. J. Med.	2015-05-20 18:10:17.763625	2015-05-20 18:11:45.403778
185	15758010	Clinical Trial	Hegi et al., 2005, N. Engl. J. Med.	2015-05-20 18:10:17.878266	2015-05-20 18:11:45.821269
186	20007775		Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.	2015-05-20 18:10:17.915926	2015-05-20 18:11:46.185695
187	19059939	Retrospective study	Schlenk et al., 2009, Haematologica	2015-05-20 18:10:18.08818	2015-05-20 18:11:46.553992
188	22417203	Retrospective study	Patel et al., 2012, N. Engl. J. Med.	2015-05-20 18:10:18.13357	2015-05-20 18:11:46.972906
189	16455956	Retrospective study	Thiede et al., 2006, Blood	2015-05-20 18:10:18.16659	2015-05-20 18:11:47.448971
190	16076867	Retrospective study	Schnittger et al., 2005, Blood	2015-05-20 18:10:18.20026	2015-05-20 18:11:47.913744
191	19357394		Vardiman et al., 2009, Blood	2015-05-20 18:10:18.240514	2015-05-20 18:11:48.292381
192	24927407		Ehninger et al., 2014, Blood Cancer J	2015-05-20 18:10:18.414197	2015-05-20 18:11:48.650596
193	15659725		Falini et al., 2005, N. Engl. J. Med.	2015-05-20 18:10:18.717821	2015-05-20 18:11:49.061518
194	19047294	Retrospective study	Bchner et al., 2009, J. Clin. Oncol.	2015-05-20 18:10:18.817146	2015-05-20 18:11:49.478684
195	24855211		Linch et al., 2014, Blood	2015-05-20 18:10:18.850538	2015-05-20 18:11:49.894349
196	22430270	Retrospective study	Gaidzik et al., 2012, J. Clin. Oncol.	2015-05-20 18:10:18.88498	2015-05-20 18:11:50.31483
197	20026798	Retrospective study	Becker et al., 2010, J. Clin. Oncol.	2015-05-20 18:10:18.954937	2015-05-20 18:11:50.758935
198	16051734	Retrospective study	Dhner et al., 2005, Blood	2015-05-20 18:10:18.988608	2015-05-20 18:11:51.149085
199	19587375	Retrospective study	Schnittger et al., 2009, Blood	2015-05-20 18:10:19.059701	2015-05-20 18:11:51.567002
200	24859829		Tian et al., 2014, Int. J. Hematol.	2015-05-20 18:10:19.171468	2015-05-20 18:11:51.966883
201	21719597	In vitro study	Balusu et al., 2011, Blood	2015-05-20 18:10:19.240669	2015-05-20 18:11:52.523719
202	24797300		Tassara et al., 2014, Blood	2015-05-20 18:10:19.282149	2015-05-20 18:11:52.978526
203	22180178	Clinical trial	Jakob et al., 2012, Cancer	2015-05-20 18:10:19.490033	2015-05-20 18:11:53.361379
204	15951308	Retrospective study	Bowen et al., 2005, Blood	2015-05-20 18:10:19.530587	2015-05-20 18:11:53.761009
205	24666267	Meta analysis	Therkildsen et al., 2014, Acta Oncol	2015-05-20 18:10:19.565275	2015-05-20 18:11:54.075663
206	16434492	Clinical trial	Bacher et al., 2006, Blood	2015-05-20 18:10:19.700338	2015-05-20 18:11:54.440607
207	18375819	Case report	Banerji et al., 2008, Mol. Cancer Ther.	2015-05-20 18:10:19.738741	2015-05-20 18:11:54.780244
208	23861977	Retrospective study	Tschandl et al., 2013, PLoS ONE	2015-05-20 18:10:19.85916	2015-05-20 18:11:55.166821
209	23569304	Clinical trial	Trunzer et al., 2013, J. Clin. Oncol.	2015-05-20 18:10:19.89642	2015-05-20 18:11:55.51945
210	21576590	Case report	Soon et al., 2011, Arch Dermatol	2015-05-20 18:10:19.935438	2015-05-20 18:11:55.955669
211	22745105		Heinrich et al., 2012, Clin. Cancer Res.	2015-05-20 18:10:20.030243	2015-05-20 18:11:56.380899
212	15928335		Corless et al., 2005, J. Clin. Oncol.	2015-05-20 18:10:20.127357	2015-05-20 18:11:56.788347
213	15146165		Lasota et al., 2004, Lab. Invest.	2015-05-20 18:10:20.206076	2015-05-20 18:11:57.103793
214	21558396		Tanaka et al., 2011, Clin. Cancer Res.	2015-05-20 18:10:20.375885	2015-05-20 18:11:57.519774
215	15647370		Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.	2015-05-20 18:10:20.411409	2015-05-20 18:11:57.939678
216	19223544		Sartore-Bianchi et al., 2009, Cancer Res.	2015-05-20 18:10:20.448126	2015-05-20 18:11:58.445985
217	22357840		Liao et al., 2012, Clin. Cancer Res.	2015-05-20 18:10:20.482623	2015-05-20 18:11:59.253161
218	8674046		Yoshida et al., 1996, Cancer Res.	2015-05-20 18:10:21.102195	2015-05-20 18:11:59.593821
219	20085938		Courtney et al., 2010, J. Clin. Oncol.	2015-05-20 18:10:21.183351	2015-05-20 18:11:59.97369
220	22479427		Carico et al., 2012, PLoS ONE	2015-05-20 18:10:21.240671	2015-05-20 18:12:00.445929
221	21422803		Coxon et al., 2012, J. Endocrinol. Invest.	2015-05-20 18:10:21.325104	2015-05-20 18:12:00.862103
222	23056499		Couto et al., 2012, PLoS ONE	2015-05-20 18:10:21.386558	2015-05-20 18:12:01.288416
223	18073307		Elisei et al., 2008, J. Clin. Endocrinol. Metab.	2015-05-20 18:10:21.500603	2015-05-20 18:12:01.655839
224	9839497		Egawa et al., 1998, Jpn. J. Clin. Oncol.	2015-05-20 18:10:21.535607	2015-05-20 18:12:02.212049
225	21995386		Papaemmanuil et al., 2011, N. Engl. J. Med.	2015-05-20 18:10:21.572323	2015-05-20 18:12:02.579649
226	22698404		Jackson et al., 2012, Cancer Cell	2015-05-20 18:10:21.645498	2015-05-20 18:12:02.956497
227	16489069		Olivier et al., 2006, Clin. Cancer Res.	2015-05-20 18:10:21.682172	2015-05-20 18:12:03.348139
228	9569050		Berns et al., 1998, Br. J. Cancer	2015-05-20 18:10:21.752007	2015-05-20 18:12:03.699914
229	22923433		Iyer et al., 2012, Science	2015-05-20 18:10:22.070508	2015-05-20 18:12:04.433364
230	19966866	Mouse model	Liang et al., 2010, Oncogene	2015-05-20 18:10:22.131441	2015-05-20 18:12:04.960514
231	22923433	Retrospective study	Iyer et al., 2012, Science	2015-05-20 18:10:22.174178	2015-05-20 18:12:05.34229
232	23029227		Qian et al., 2012, PLoS ONE	2015-05-20 18:10:22.260083	2015-05-20 18:12:05.775341
233	23861105		Wu et al., 2013, Am. J. Hematol.	2015-05-20 18:10:22.36606	2015-05-20 18:12:06.225396
234	18591546	Retrospective study	Virappane et al., 2008, J. Clin. Oncol.	2015-05-20 18:10:22.542866	2015-05-20 18:12:06.732683
235	19221039	Retrospective study	Gaidzik et al., 2009, Blood	2015-05-20 18:10:22.575955	2015-05-20 18:12:07.12766
236	19536888	Retrospective study	Renneville et al., 2009, Cancer	2015-05-20 18:10:22.657724	2015-05-20 18:12:07.756393
237	18559874	Retrospective study	Paschka et al., 2008, J. Clin. Oncol.	2015-05-20 18:10:22.788157	2015-05-20 18:12:08.819249
238	20664172		Di Nicolantonio et al., 2010, J. Clin. Invest.	2015-05-20 18:10:23.283382	2015-05-20 18:12:09.329896
239	21642685		Carvajal et al., 2011, JAMA	2015-05-20 18:10:23.333926	2015-05-20 18:12:09.76093
240	18510589		Lutzky et al., 2008, Pigment Cell Melanoma Res	2015-05-20 18:10:23.3748	2015-05-20 18:12:10.156312
241	24107445		Zecchin et al., 2013, Mol. Cancer Ther.	2015-05-20 18:10:23.414978	2015-05-20 18:12:10.475996
242	24132921		Dai et al., 2013, Clin. Cancer Res.	2015-05-20 18:10:23.454361	2015-05-20 18:12:10.909803
243	24035431		Gautschi et al., 2013, Lung Cancer	2015-05-20 18:10:23.489336	2015-05-20 18:12:11.306488
244	24622468		Voss et al., 2014, Clin. Cancer Res.	2015-05-20 18:10:23.529642	2015-05-20 18:12:11.732893
245	25401474		Schwarz et al., 2014, J. Clin. Invest.	2015-05-20 18:10:23.579537	2015-05-20 18:12:12.142808
246	21677200		Bainbridge et al., 2011, Sci Transl Med	2015-05-20 18:10:23.634733	2015-05-20 18:12:12.528208
247	23610116		Diamond et al., 2013, J. Clin. Oncol.	2015-05-20 18:10:23.684615	2015-05-20 18:12:12.907838
\.


--
-- Data for Name: variant_origins; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY variant_origins (id, origin) FROM stdin;
1	Somatic
2	Germline
\.


--
-- Data for Name: variants; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY variants (id, gene_id, name, description, created_at, updated_at) FROM stdin;
1	4	BCR-ABL	The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response.	2015-05-20 18:10:04.698841	2015-05-20 18:10:04.698841
2	4	BCR-ABL T315I	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	2015-05-20 18:10:04.717841	2015-05-20 18:10:04.717841
3	4	BCR-ABL E255K	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	2015-05-20 18:10:04.73219	2015-05-20 18:10:04.73219
4	2	E17K	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase ihibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.	2015-05-20 18:10:04.757281	2015-05-20 18:10:04.757281
5	1	EML4-ALK	The EML4-ALK fusion has been seen in non-small cell lung cancer, and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib.	2015-05-20 18:10:04.770255	2015-05-20 18:10:04.770255
6	1	EML4-ALK C1156Y	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.	2015-05-20 18:10:04.782277	2015-05-20 18:10:04.782277
7	1	EML4-ALK L1196M	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.	2015-05-20 18:10:04.794377	2015-05-20 18:10:04.794377
8	1	F1174L	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	2015-05-20 18:10:04.806901	2015-05-20 18:10:04.806901
9	1	R1275Q	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This, and the geldanamycin deriviative 17-DMAG, has been shown to be effective in NSCLC cell lines.	2015-05-20 18:10:04.819329	2015-05-20 18:10:04.819329
10	3	S214C	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	2015-05-20 18:10:04.834509	2015-05-20 18:10:04.834509
11	5	V600D	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	2015-05-20 18:10:04.850372	2015-05-20 18:10:04.850372
12	5	V600E	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, KRAS, and CDK2NA mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. While the drugs cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	2015-05-20 18:10:04.862321	2015-05-20 18:10:04.862321
13	5	V600E/V600M	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	2015-05-20 18:10:04.874654	2015-05-20 18:10:04.874654
14	5	V600E AMPLIFICATION	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.	2015-05-20 18:10:04.886076	2015-05-20 18:10:04.886076
15	5	V600M	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	2015-05-20 18:10:04.897707	2015-05-20 18:10:04.897707
16	5	V600R	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	2015-05-20 18:10:04.911621	2015-05-20 18:10:04.911621
17	5	V600	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutation pages on the left sidebar.	2015-05-20 18:10:04.926439	2015-05-20 18:10:04.926439
18	8	AMPLIFICATION	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.	2015-05-20 18:10:04.945639	2015-05-20 18:10:04.945639
19	8	EXPRESSION	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.	2015-05-20 18:10:04.959233	2015-05-20 18:10:04.959233
96	38	D842I	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	2015-05-20 18:10:06.100568	2015-05-20 18:10:06.100568
20	8	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	2015-05-20 18:10:04.973956	2015-05-20 18:10:04.973956
21	9	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	2015-05-20 18:10:04.989563	2015-05-20 18:10:04.989563
22	9	PROMOTER DEMETHYLATION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	2015-05-20 18:10:05.004448	2015-05-20 18:10:05.004448
23	10	LOSS	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.	2015-05-20 18:10:05.01847	2015-05-20 18:10:05.01847
24	11	OVEREXPRESSION	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.	2015-05-20 18:10:05.031745	2015-05-20 18:10:05.031745
25	13	EXPRESSION	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	2015-05-20 18:10:05.047749	2015-05-20 18:10:05.047749
26	12	EXPRESSION	CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	2015-05-20 18:10:05.064336	2015-05-20 18:10:05.064336
27	14	PROMOTER HYPERMETHYLATION	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.	2015-05-20 18:10:05.079428	2015-05-20 18:10:05.079428
28	15	N-TERMINAL FRAME SHIFT	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	2015-05-20 18:10:05.09363	2015-05-20 18:10:05.09363
29	15	MUTATION	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	2015-05-20 18:10:05.110116	2015-05-20 18:10:05.110116
30	33	MEF2D-CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.	2015-05-20 18:10:05.125152	2015-05-20 18:10:05.125152
31	16	DNAJB1-PRKACA	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	2015-05-20 18:10:05.140991	2015-05-20 18:10:05.140991
32	18	R882	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	2015-05-20 18:10:05.156283	2015-05-20 18:10:05.156283
97	38	D842V	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	2015-05-20 18:10:06.112728	2015-05-20 18:10:06.112728
33	19	L858R	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.	2015-05-20 18:10:05.171757	2015-05-20 18:10:05.171757
34	19	T790M	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. The third generation TKI's are being developed with this resistance problem in mind, and early stage experiments have shown some efficacy of these drugs in previously resistant tumors with mutant EGFR.	2015-05-20 18:10:05.185983	2015-05-20 18:10:05.185983
35	20	D769H	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.200091	2015-05-20 18:10:05.200091
36	20	D769Y	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.213485	2015-05-20 18:10:05.213485
37	20	DEL 755-759	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.227816	2015-05-20 18:10:05.227816
38	20	G309A	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.243393	2015-05-20 18:10:05.243393
39	20	L755S	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.	2015-05-20 18:10:05.256786	2015-05-20 18:10:05.256786
40	20	L755W	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.269637	2015-05-20 18:10:05.269637
41	20	P780INS	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.282994	2015-05-20 18:10:05.282994
42	20	R678Q	ERBB2 R678Q was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.295235	2015-05-20 18:10:05.295235
43	20	R896C	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.307744	2015-05-20 18:10:05.307744
44	20	V777L	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.333504	2015-05-20 18:10:05.333504
45	20	V842I	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	2015-05-20 18:10:05.347742	2015-05-20 18:10:05.347742
46	21	L536Q	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	2015-05-20 18:10:05.3607	2015-05-20 18:10:05.3607
47	21	N538G	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. N538G is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	2015-05-20 18:10:05.373656	2015-05-20 18:10:05.373656
48	21	Y537C	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	2015-05-20 18:10:05.386922	2015-05-20 18:10:05.386922
49	21	Y537N	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	2015-05-20 18:10:05.399201	2015-05-20 18:10:05.399201
50	21	Y537S	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	2015-05-20 18:10:05.414957	2015-05-20 18:10:05.414957
51	22	FGFR2-MGEA5	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	2015-05-20 18:10:05.42806	2015-05-20 18:10:05.42806
52	23	FGFR3-BAIAP2L1	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	2015-05-20 18:10:05.442843	2015-05-20 18:10:05.442843
53	23	FGFR3-TACC3	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	2015-05-20 18:10:05.456589	2015-05-20 18:10:05.456589
54	24	ITD MUTATIONS	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	2015-05-20 18:10:05.471224	2015-05-20 18:10:05.471224
55	24	TKD MUTATIONS	FLT3 tyrosine kinase domain mutations (aka FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.	2015-05-20 18:10:05.488277	2015-05-20 18:10:05.488277
56	25	EXPRESSION	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.	2015-05-20 18:10:05.502645	2015-05-20 18:10:05.502645
57	26	R132	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	2015-05-20 18:10:05.517208	2015-05-20 18:10:05.517208
58	26	R132C	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	2015-05-20 18:10:05.530608	2015-05-20 18:10:05.530608
59	26	R132H	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	2015-05-20 18:10:05.546761	2015-05-20 18:10:05.546761
60	26	R132L	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.	2015-05-20 18:10:05.559362	2015-05-20 18:10:05.559362
61	27	R140Q/L	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140Q/L mutants have shown improved overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.	2015-05-20 18:10:05.571561	2015-05-20 18:10:05.571561
62	27	R172K	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.	2015-05-20 18:10:05.585808	2015-05-20 18:10:05.585808
63	28	V617F	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases, occuring in around half of all MPD's. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	2015-05-20 18:10:05.599398	2015-05-20 18:10:05.599398
64	29	D816V	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	2015-05-20 18:10:05.613333	2015-05-20 18:10:05.613333
65	29	EXON 11 MUTATIONS	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	2015-05-20 18:10:05.625806	2015-05-20 18:10:05.625806
66	29	INTERNAL DUPLICATION	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	2015-05-20 18:10:05.645938	2015-05-20 18:10:05.645938
67	29	EXON 13 MUTATIONS	c-KIT exon 13 mutations are relatively rare compared to other c-KIT mutations. These mutations lie within the tyrosine kinase 1 domain, and are found primarily in melanoma and gastrointestinal stromal tumors. Cell lines harboring these mutations show sensitivity to imatinib and sunitinib treatment. However, only imatinib has seen use in clinical settings to date, with sunitinib entering trials in imatinib-resistant cases.	2015-05-20 18:10:05.658857	2015-05-20 18:10:05.658857
68	29	EXON 14 MUTATIONS	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.	2015-05-20 18:10:05.671106	2015-05-20 18:10:05.671106
69	29	EXON 17 MUTATIONS	c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.	2015-05-20 18:10:05.685225	2015-05-20 18:10:05.685225
70	29	EXON 9 MUTATIONS	c-KIT exon 9 mutations lie within the dimerization motif of the protein. Relative to other KIT mutations, exon 9 mutations have been associated with better overall survival. In exon 9 mutants, imatinib has shown efficacy both in vitro and in vivo.	2015-05-20 18:10:05.699774	2015-05-20 18:10:05.699774
71	29	L576P	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	2015-05-20 18:10:05.714721	2015-05-20 18:10:05.714721
72	29	V654A	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	2015-05-20 18:10:05.729547	2015-05-20 18:10:05.729547
73	30	EXON 1 MUTATIONS	A study by Livre et al in 2006 showed that colorectal cancer patients with KRAS exon 1 mutations had low cetuximab response rates.	2015-05-20 18:10:05.745409	2015-05-20 18:10:05.745409
74	30	EXON 2 MUTATIONS	In a study by Pao et al in 2005, non-small cell lung cancer patients harboring KRAS exon 2 mutations were associated with resistance to the EGFR inhibitors gefinitib and erlotinib.	2015-05-20 18:10:05.766704	2015-05-20 18:10:05.766704
75	30	G12	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.781168	2015-05-20 18:10:05.781168
76	30	G12/G13	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.79582	2015-05-20 18:10:05.79582
77	30	G12C	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.81235	2015-05-20 18:10:05.81235
78	30	G12D	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.829502	2015-05-20 18:10:05.829502
79	30	G13	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.846682	2015-05-20 18:10:05.846682
80	30	G13D	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	2015-05-20 18:10:05.859487	2015-05-20 18:10:05.859487
81	31	P124S	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.	2015-05-20 18:10:05.873425	2015-05-20 18:10:05.873425
82	31	Q56P	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.	2015-05-20 18:10:05.899089	2015-05-20 18:10:05.899089
83	32	MEF2D-CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.	2015-05-20 18:10:05.913613	2015-05-20 18:10:05.913613
84	34	PROMOTER METHYLATION	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.	2015-05-20 18:10:05.926546	2015-05-20 18:10:05.926546
85	35	EXON 12 MUTATIONS	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	2015-05-20 18:10:05.941873	2015-05-20 18:10:05.941873
86	35	W288FS	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	2015-05-20 18:10:05.957616	2015-05-20 18:10:05.957616
87	36	EXON 1 MUTATIONS	NRAS exon 1 mutations were studied by Jakob et al in 2012 and were shown to be correlated with poorer overall survival relative to wild-type NRAS in melanoma patients.	2015-05-20 18:10:05.972926	2015-05-20 18:10:05.972926
88	36	EXON 2 MUTATIONS	NRAS exon 2 mutations have been shown to be correlated with poorer overall survival in melanoma patients and colorectal cancer patients, however no prognostic impact was seen in acute myeloid leukemia patients.	2015-05-20 18:10:05.987168	2015-05-20 18:10:05.987168
89	36	EXON 3 MUTATIONS	In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.	2015-05-20 18:10:05.999849	2015-05-20 18:10:05.999849
90	36	EXON 4 MUTATIONS	In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.	2015-05-20 18:10:06.013462	2015-05-20 18:10:06.013462
91	36	G12	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	2015-05-20 18:10:06.027086	2015-05-20 18:10:06.027086
92	36	G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	2015-05-20 18:10:06.044858	2015-05-20 18:10:06.044858
93	36	Q61	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	2015-05-20 18:10:06.059954	2015-05-20 18:10:06.059954
94	36	Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	2015-05-20 18:10:06.073757	2015-05-20 18:10:06.073757
95	36	Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	2015-05-20 18:10:06.087204	2015-05-20 18:10:06.087204
98	38	D842Y	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	2015-05-20 18:10:06.126798	2015-05-20 18:10:06.126798
99	38	DEL I843	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	2015-05-20 18:10:06.141126	2015-05-20 18:10:06.141126
100	38	DI842-843IM	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	2015-05-20 18:10:06.155016	2015-05-20 18:10:06.155016
101	37	E542K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	2015-05-20 18:10:06.16794	2015-05-20 18:10:06.16794
102	37	E545K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	2015-05-20 18:10:06.183173	2015-05-20 18:10:06.183173
103	37	EXON 20 MUTATIONS	PIK3CA H1047R is one of the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	2015-05-20 18:10:06.196755	2015-05-20 18:10:06.196755
104	37	EXON 9 MUTATIONS	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	2015-05-20 18:10:06.209054	2015-05-20 18:10:06.209054
105	37	H1047R	PIK3CA H1047R is one of the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	2015-05-20 18:10:06.222174	2015-05-20 18:10:06.222174
106	39	PML-RARA	The PML-RARa fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.	2015-05-20 18:10:06.2363	2015-05-20 18:10:06.2363
107	17	DNAJB1-PRKACA	This fusion has been found to be very recurrent in a rare form of adolescent liver cancer, hepatocellular fibrolamellar carcinoma. In a 2014 study, authors found Honeyman et al observed this fusion in all 15 of the FL-HCC cases they examined, and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.	2015-05-20 18:10:06.252156	2015-05-20 18:10:06.252156
108	41	R233*	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	2015-05-20 18:10:06.266033	2015-05-20 18:10:06.266033
109	40	PML-RARA	The PML-RARa fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and Arsenic Trioxide for treating these patients, and early results seem promising.	2015-05-20 18:10:06.280783	2015-05-20 18:10:06.280783
110	42	C634W	RET C639W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C639W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	2015-05-20 18:10:06.29525	2015-05-20 18:10:06.29525
111	42	M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	2015-05-20 18:10:06.313016	2015-05-20 18:10:06.313016
112	44	K666N	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.	2015-05-20 18:10:06.327722	2015-05-20 18:10:06.327722
113	44	K700E	SF3B1 K700E is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients. Additionally, these mutations are the most common SF3B1 mutation observed in MDS and highly associated with subtypes of MDS that are defined by ringed sideroblasts.	2015-05-20 18:10:06.340915	2015-05-20 18:10:06.340915
129	6	LOSS-OF-FUNCTION	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	2015-05-20 18:10:06.631498	2015-05-20 18:10:06.631498
114	45	R175H	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant.	2015-05-20 18:10:06.355588	2015-05-20 18:10:06.355588
115	45	R248Q	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.	2015-05-20 18:10:06.368628	2015-05-20 18:10:06.368628
116	45	R248W	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.	2015-05-20 18:10:06.383386	2015-05-20 18:10:06.383386
117	45	R249T	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	2015-05-20 18:10:06.397415	2015-05-20 18:10:06.397415
118	45	R249W	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	2015-05-20 18:10:06.411027	2015-05-20 18:10:06.411027
119	45	R273C	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	2015-05-20 18:10:06.460402	2015-05-20 18:10:06.460402
120	45	R273H	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	2015-05-20 18:10:06.47648	2015-05-20 18:10:06.47648
121	45	V173G/A	While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.	2015-05-20 18:10:06.492909	2015-05-20 18:10:06.492909
122	46	FRAMESHIFT TRUNCATION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	2015-05-20 18:10:06.509231	2015-05-20 18:10:06.509231
123	46	LOSS-OF-FUNCTION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	2015-05-20 18:10:06.529482	2015-05-20 18:10:06.529482
124	47	LOSS-OF-FUNCTION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	2015-05-20 18:10:06.548631	2015-05-20 18:10:06.548631
125	48	Q157P/R	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	2015-05-20 18:10:06.568491	2015-05-20 18:10:06.568491
126	48	S34Y/F	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.	2015-05-20 18:10:06.584365	2015-05-20 18:10:06.584365
127	49	EXON 7 MUTATIONS	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	2015-05-20 18:10:06.600539	2015-05-20 18:10:06.600539
128	49	EXON 9 MUTATIONS	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	2015-05-20 18:10:06.61595	2015-05-20 18:10:06.61595
130	7	LOSS-OF-FUNCTION	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	2015-05-20 18:10:06.648032	2015-05-20 18:10:06.648032
131	19	EXON 19 DELETION	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.	2015-05-20 18:10:06.666345	2015-05-20 18:10:06.666345
132	19	G719S	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.	2015-05-20 18:10:06.683247	2015-05-20 18:10:06.683247
133	51	D1643H	Activating mutations in NOTCH1, including D1643H, have been shown to be poor prognostic markers in lung cancer.	2015-05-20 18:10:06.69978	2015-05-20 18:10:06.69978
134	51	R2328W	Activating mutations in NOTCH1, including R2328W, have been shown to be poor prognostic markers in lung cancer.	2015-05-20 18:10:06.715941	2015-05-20 18:10:06.715941
135	51	V2444FS	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.	2015-05-20 18:10:06.732154	2015-05-20 18:10:06.732154
136	51	S2275FS	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.	2015-05-20 18:10:06.75254	2015-05-20 18:10:06.75254
137	52	L63V	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.769962	2015-05-20 18:10:06.769962
138	52	L239R	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.787483	2015-05-20 18:10:06.787483
139	52	G253C	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.807495	2015-05-20 18:10:06.807495
140	52	G505S	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.824163	2015-05-20 18:10:06.824163
141	52	I638F	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.	2015-05-20 18:10:06.842712	2015-05-20 18:10:06.842712
142	52	G774V	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.861277	2015-05-20 18:10:06.861277
143	52	S768R	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.	2015-05-20 18:10:06.879561	2015-05-20 18:10:06.879561
144	53	AMPLIFICATION	MET amplification, like EGFR T790M, has been shown to be capable of driving acquired resistance to dacomitinib in patients with lung adenocarcinoma.	2015-05-20 18:10:06.897619	2015-05-20 18:10:06.897619
145	30	G12V	KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	2015-05-20 18:10:06.914457	2015-05-20 18:10:06.914457
146	30	G12A	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	2015-05-20 18:10:06.931955	2015-05-20 18:10:06.931955
147	50	Q2223K	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:06.951237	2015-05-20 18:10:06.951237
148	38	G853D	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:06.968619	2015-05-20 18:10:06.968619
149	5	G469L	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:06.985397	2015-05-20 18:10:06.985397
150	29	K642E	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.002211	2015-05-20 18:10:07.002211
151	54	D189Y	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.019653	2015-05-20 18:10:07.019653
152	38	V536E	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.03347	2015-05-20 18:10:07.03347
153	55	NM_003124:C.448A>G	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.051506	2015-05-20 18:10:07.051506
154	22	P235R	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.083525	2015-05-20 18:10:07.083525
155	53	M1268T	A summary for this variant has yet to be developed! Add one now by clicking the "Edit Variant" button.	2015-05-20 18:10:07.09727	2015-05-20 18:10:07.09727
\.


--
-- Data for Name: evidence_items; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY evidence_items (id, description, clinical_significance, evidence_direction, evidence_type_id, evidence_level_id, disease_id, source_id, variant_id, created_at, updated_at, rating, status, remote_errors, remote_ids, variant_origin_id, variant_hgvs, drug_interaction_description) FROM stdin;
1	Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.	Positive	Does Not Support	1	1	1	51	1	2015-05-20 18:10:07.229474	2015-05-20 18:10:07.229474	2	accepted	\N	\N	1	N/A	\N
2	The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.	Positive	Supports	1	2	1	52	1	2015-05-20 18:10:07.290258	2015-05-20 18:10:07.290258	4	accepted	\N	\N	1	N/A	\N
3	The use of second-generation BCR-ABL targeted therapies has been effective in patients resistant to imatinib.	Sensitivity	Supports	2	3	1	52	1	2015-05-20 18:10:07.32975	2015-05-20 18:10:07.32975	4	accepted	\N	\N	1	N/A	\N
4	COS7 cell lines transfected with BCR/ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	Resistance or Non-Response	Supports	2	1	1	53	3	2015-05-20 18:10:07.376559	2015-05-20 18:10:07.376559	4	accepted	\N	\N	1	N/A	\N
5	COS7 cell lines transfected with BCR/ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	Resistance or Non-Response	Supports	2	1	1	53	2	2015-05-20 18:10:07.476738	2015-05-20 18:10:07.476738	4	accepted	\N	\N	1	N/A	\N
6	In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.	Resistance or Non-Response	Supports	2	3	1	52	2	2015-05-20 18:10:07.513861	2015-05-20 18:10:07.513861	4	accepted	\N	\N	1	N/A	\N
7	PIK3CA mutation, but not AKT1 E17K, has been shown to confer sensitiity to the AKT inhibitor MK-2206 in breast cancer cell lines.	Sensitivity	Does Not Support	2	3	2	54	4	2015-05-20 18:10:07.566033	2015-05-20 18:10:07.566033	3	accepted	\N	\N	1	14:105246551-105246551 (C->T)	\N
8	In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.	Sensitivity	Supports	2	3	3	55	5	2015-05-20 18:10:07.606658	2015-05-20 18:10:07.606658	4	accepted	\N	\N	1	N/A	\N
9	In patients with non-small cell lung cancer harboring EML4-ALK fusion, the C1156Y variant has been shown to confer resistance to crizotinib.	Resistance or Non-Response	Supports	2	3	3	55	6	2015-05-20 18:10:07.676458	2015-05-20 18:10:07.676458	4	accepted	\N	\N	1	N/A	\N
10	CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation	Sensitivity	Supports	2	1	3	56	7	2015-05-20 18:10:07.731114	2015-05-20 18:10:07.731114	3	accepted	\N	\N	1	N/A	\N
11	In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.	Resistance or Non-Response	Supports	2	3	3	55	7	2015-05-20 18:10:07.768018	2015-05-20 18:10:07.768018	4	accepted	\N	\N	1	N/A	\N
12	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	Resistance or Non-Response	Supports	2	1	4	57	8	2015-05-20 18:10:07.811292	2015-05-20 18:10:07.811292	3	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
13	CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	Sensitivity	Supports	2	1	5	56	8	2015-05-20 18:10:07.849917	2015-05-20 18:10:07.849917	3	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
14	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	Resistance or Non-Response	Supports	2	1	5	58	8	2015-05-20 18:10:07.888541	2015-05-20 18:10:07.888541	3	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
15	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	Sensitivity	Supports	2	1	5	59	8	2015-05-20 18:10:07.926112	2015-05-20 18:10:07.926112	3	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
16	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition	Sensitivity	Supports	2	1	5	60	8	2015-05-20 18:10:07.96743	2015-05-20 18:10:07.96743	4	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
17	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	Resistance or Non-Response	Supports	2	1	3	57	8	2015-05-20 18:10:08.004405	2015-05-20 18:10:08.004405	3	accepted	\N	\N	1	2:29443695-29443695 (G->T)	\N
18	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation	Sensitivity	Supports	2	1	5	58	9	2015-05-20 18:10:08.044402	2015-05-20 18:10:08.044402	3	accepted	\N	\N	1	2:29432664-29432664 (C->T)	\N
19	TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.	Sensitivity	Supports	2	1	5	60	9	2015-05-20 18:10:08.079613	2015-05-20 18:10:08.079613	3	accepted	\N	\N	1	2:29432664-29432664 (C->T)	\N
20	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	Resistance or Non-Response	Supports	2	1	5	60	9	2015-05-20 18:10:08.116265	2015-05-20 18:10:08.116265	3	accepted	\N	\N	1	2:29432664-29432664 (C->T)	\N
21	In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.	Sensitivity	Supports	2	3	3	61	10	2015-05-20 18:10:08.152286	2015-05-20 18:10:08.152286	2	accepted	\N	\N	1	X:47426121-47426121 (C->G)	\N
22	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro	Sensitivity	Supports	2	1	3	61	10	2015-05-20 18:10:08.190771	2015-05-20 18:10:08.190771	3	accepted	\N	\N	1	X:47426121-47426121 (C->G)	\N
23	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro	Sensitivity	Supports	2	1	3	61	10	2015-05-20 18:10:08.235234	2015-05-20 18:10:08.235234	3	accepted	\N	\N	1	X:47426121-47426121 (C->G)	\N
24	In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)	Resistance or Non-Response	Supports	2	3	6	62	17	2015-05-20 18:10:08.276646	2015-05-20 18:10:08.276646	3	accepted	\N	\N	1	N/A	\N
25	Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone	Sensitivity	Supports	2	3	7	63	17	2015-05-20 18:10:08.320109	2015-05-20 18:10:08.320109	3	accepted	\N	\N	1	N/A	\N
26	BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma	Positive	Supports	1	3	7	64	17	2015-05-20 18:10:08.364888	2015-05-20 18:10:08.364888	4	accepted	\N	\N	1	N/A	\N
27	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	Sensitivity	Supports	2	3	7	65	11	2015-05-20 18:10:08.398778	2015-05-20 18:10:08.398778	5	accepted	\N	\N	1	7:140453135-140453136 (CA->AT)	\N
28	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	Resistance or Non-Response	Supports	2	1	8	66	12	2015-05-20 18:10:08.44992	2015-05-20 18:10:08.44992	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
29	Combined PD0325901 and PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation	Sensitivity	Supports	2	1	8	67	12	2015-05-20 18:10:08.4958	2015-05-20 18:10:08.4958	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
30	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy	Sensitivity	Supports	2	1	8	68	12	2015-05-20 18:10:08.536545	2015-05-20 18:10:08.536545	2	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
31	Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.	Sensitivity	Supports	2	1	6	69	12	2015-05-20 18:10:08.58212	2015-05-20 18:10:08.58212	2	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
32	Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF	Resistance or Non-Response	Supports	2	3	6	70	12	2015-05-20 18:10:08.627279	2015-05-20 18:10:08.627279	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
33	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	Poor Outcome	Supports	3	2	6	71	12	2015-05-20 18:10:08.66496	2015-05-20 18:10:08.66496	5	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
34	Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation	Sensitivity	Supports	2	1	6	69	12	2015-05-20 18:10:08.713546	2015-05-20 18:10:08.713546	2	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
35	BRAF status does not predict prognosis in patients treated with dacarbazine or temozolomide.	N / A	Does Not Support	2	3	7	72	12	2015-05-20 18:10:08.74763	2015-05-20 18:10:08.74763	2	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
36	Dabrafenib with trametinib provides higher response rate and lower toxicity-as compared to chemotherapy-in patients with melanoma.	Sensitivity	Supports	2	3	7	73	12	2015-05-20 18:10:08.792168	2015-05-20 18:10:08.792168	5	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
37	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.	Resistance or Non-Response	Does Not Support	2	1	7	74	12	2015-05-20 18:10:08.829804	2015-05-20 18:10:08.829804	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
38	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.	Resistance or Non-Response	Supports	2	1	7	74	12	2015-05-20 18:10:08.866606	2015-05-20 18:10:08.866606	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
39	BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	Poor Outcome	Supports	3	3	7	75	12	2015-05-20 18:10:08.900835	2015-05-20 18:10:08.900835	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
40	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.	Resistance or Non-Response	Supports	2	3	3	76	12	2015-05-20 18:10:08.940005	2015-05-20 18:10:08.940005	2	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
41	BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer	Positive	Supports	1	3	9	77	12	2015-05-20 18:10:08.976976	2015-05-20 18:10:08.976976	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
42	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	Positive	Supports	1	3	9	78	12	2015-05-20 18:10:09.009973	2015-05-20 18:10:09.009973	5	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
43	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	Positive	Supports	1	3	9	79	12	2015-05-20 18:10:09.046687	2015-05-20 18:10:09.046687	5	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
44	Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.	Poor Outcome	Does Not Support	3	3	9	80	12	2015-05-20 18:10:09.082792	2015-05-20 18:10:09.082792	5	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
45	BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	Poor Outcome	Supports	3	3	9	77	12	2015-05-20 18:10:09.123867	2015-05-20 18:10:09.123867	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
46	BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	Poor Outcome	Supports	3	3	9	81	12	2015-05-20 18:10:09.155685	2015-05-20 18:10:09.155685	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
47	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	Poor Outcome	Supports	3	3	9	77	12	2015-05-20 18:10:09.191386	2015-05-20 18:10:09.191386	3	accepted	\N	\N	1	7:140453136-140453136 (A->T)	\N
48	COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244) resistant. The mechanim of this resistence was shown to be amplification of the BRAF V600E gene.	Resistance or Non-Response	Supports	2	4	6	82	14	2015-05-20 18:10:09.228067	2015-05-20 18:10:09.228067	4	accepted	\N	\N	1	N/A	\N
49	A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.	Sensitivity	Supports	2	3	7	83	13	2015-05-20 18:10:09.269386	2015-05-20 18:10:09.269386	3	accepted	\N	\N	1	N/A	\N
50	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	Sensitivity	Supports	2	3	7	65	15	2015-05-20 18:10:09.305224	2015-05-20 18:10:09.305224	5	accepted	\N	\N	1	7:140453137-140453137 (C->T)	\N
51	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	Sensitivity	Supports	2	3	7	65	16	2015-05-20 18:10:09.350546	2015-05-20 18:10:09.350546	5	accepted	\N	\N	1	7:140453136-140453137 (AC->CT)	\N
52	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.	Sensitivity	Supports	2	3	10	84	129	2015-05-20 18:10:09.399922	2015-05-20 18:10:09.399922	4	accepted	\N	\N	2	N/A	\N
53	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.	Sensitivity	Supports	2	3	10	84	130	2015-05-20 18:10:09.458756	2015-05-20 18:10:09.458756	4	accepted	\N	\N	2	N/A	\N
54	Inceased copy number of CCND1 is associated with poorer overall survival.	Poor Outcome	Supports	3	3	3	85	18	2015-05-20 18:10:09.500691	2015-05-20 18:10:09.500691	3	accepted	\N	\N	1	N/A	\N
55	Three studies have found no significant survival impact for CCND1 in lung cancer.	Poor Outcome	Does Not Support	3	3	3	85	19	2015-05-20 18:10:09.533804	2015-05-20 18:10:09.533804	3	accepted	\N	\N	1	N/A	\N
56	Three studies have associated CCND1 expression with poorer survival.	Poor Outcome	Supports	3	3	3	85	19	2015-05-20 18:10:09.568736	2015-05-20 18:10:09.568736	3	accepted	\N	\N	1	N/A	\N
57	Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.	Positive	Supports	1	3	11	86	20	2015-05-20 18:10:09.616398	2015-05-20 18:10:09.616398	4	accepted	\N	\N	1	N/A	\N
58	In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.	Poor Outcome	Supports	3	3	11	86	20	2015-05-20 18:10:09.65319	2015-05-20 18:10:09.65319	4	accepted	\N	\N	1	N/A	\N
59	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.	Poor Outcome	Supports	3	3	12	87	20	2015-05-20 18:10:09.693695	2015-05-20 18:10:09.693695	4	accepted	\N	\N	1	N/A	\N
60	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.	Poor Outcome	Supports	3	3	13	88	20	2015-05-20 18:10:09.732058	2015-05-20 18:10:09.732058	4	accepted	\N	\N	1	N/A	\N
61	Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.	Poor Outcome	Supports	3	1	14	89	21	2015-05-20 18:10:09.770982	2015-05-20 18:10:09.770982	4	accepted	\N	\N	1	N/A	\N
62	Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	Poor Outcome	Supports	3	1	14	89	21	2015-05-20 18:10:09.804886	2015-05-20 18:10:09.804886	4	accepted	\N	\N	1	N/A	\N
63	Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.	Poor Outcome	Supports	3	1	14	89	21	2015-05-20 18:10:09.842519	2015-05-20 18:10:09.842519	4	accepted	\N	\N	1	N/A	\N
64	Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.	Poor Outcome	Supports	3	1	14	89	21	2015-05-20 18:10:09.880145	2015-05-20 18:10:09.880145	4	accepted	\N	\N	1	N/A	\N
65	CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.	Negative	Supports	1	1	14	90	22	2015-05-20 18:10:09.919383	2015-05-20 18:10:09.919383	3	accepted	\N	\N	1	N/A	\N
66	Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.	Sensitivity	Supports	2	1	15	91	23	2015-05-20 18:10:09.96644	2015-05-20 18:10:09.96644	3	accepted	\N	\N	1	N/A	\N
67	Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels.	Poor Outcome	Supports	3	3	11	92	24	2015-05-20 18:10:10.013386	2015-05-20 18:10:10.013386	4	accepted	\N	\N	1	N/A	\N
68	Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.	Poor Outcome	Supports	3	3	16	93	24	2015-05-20 18:10:10.051199	2015-05-20 18:10:10.051199	4	accepted	\N	\N	1	N/A	\N
69	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	Poor Outcome	Supports	3	3	16	93	24	2015-05-20 18:10:10.086898	2015-05-20 18:10:10.086898	4	accepted	\N	\N	1	N/A	\N
70	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	Poor Outcome	Supports	3	3	17	93	24	2015-05-20 18:10:10.133855	2015-05-20 18:10:10.133855	4	accepted	\N	\N	1	N/A	\N
71	In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.	Sensitivity	Supports	2	1	18	94	25	2015-05-20 18:10:10.17832	2015-05-20 18:10:10.17832	4	accepted	\N	\N	1	N/A	\N
72	Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer.	Better Outcome	Supports	3	3	18	95	25	2015-05-20 18:10:10.213441	2015-05-20 18:10:10.213441	3	accepted	\N	\N	1	N/A	\N
73	In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.	Sensitivity	Supports	2	1	18	94	26	2015-05-20 18:10:10.248203	2015-05-20 18:10:10.248203	4	accepted	\N	\N	1	N/A	\N
74	Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer.	Better Outcome	Supports	3	3	18	95	26	2015-05-20 18:10:10.283576	2015-05-20 18:10:10.283576	3	accepted	\N	\N	1	N/A	\N
75	In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter overall survival.	Poor Outcome	Supports	3	3	3	96	27	2015-05-20 18:10:10.320563	2015-05-20 18:10:10.320563	3	accepted	\N	\N	1	N/A	\N
76	In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence.	Poor Outcome	Supports	3	3	3	96	27	2015-05-20 18:10:10.353544	2015-05-20 18:10:10.353544	3	accepted	\N	\N	1	N/A	\N
77	CEBPA mutation status had no impact on ATRA treatment response in older (>60) patients with AML	N / A	Does Not Support	2	3	19	97	29	2015-05-20 18:10:10.398853	2015-05-20 18:10:10.398853	4	accepted	\N	\N	1	N/A	\N
78	CEBPA mutation was associated with improved overall survival in older (>60) patients with AML	Better Outcome	Supports	3	3	19	97	29	2015-05-20 18:10:10.437751	2015-05-20 18:10:10.437751	4	accepted	\N	\N	1	N/A	\N
79	CEBPA mutation was significantly associated with complete remission	Better Outcome	Supports	3	3	19	98	29	2015-05-20 18:10:10.474723	2015-05-20 18:10:10.474723	4	accepted	\N	\N	1	N/A	\N
80	FLT3 mutations did not alter overall survival in younger (16-60), cytogenetically normal AML patients with CEBPA	N / A	Does Not Support	3	3	19	99	28	2015-05-20 18:10:10.509779	2015-05-20 18:10:10.509779	2	accepted	\N	\N	1	N/A	\N
81	Overall survival was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA mutations	Better Outcome	Supports	3	3	19	99	28	2015-05-20 18:10:10.563001	2015-05-20 18:10:10.563001	3	accepted	\N	\N	1	N/A	\N
82	Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA	Better Outcome	Supports	3	3	19	99	28	2015-05-20 18:10:10.595787	2015-05-20 18:10:10.595787	3	accepted	\N	\N	1	N/A	\N
83	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580	Sensitivity	Supports	2	1	20	100	30	2015-05-20 18:10:10.635521	2015-05-20 18:10:10.635521	3	accepted	\N	\N	1	N/A	\N
84	In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	139	2015-05-20 18:10:10.677191	2015-05-20 18:10:10.677191	4	accepted	\N	\N	1	N/A	\N
85	In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	140	2015-05-20 18:10:10.71018	2015-05-20 18:10:10.71018	4	accepted	\N	\N	1	N/A	\N
86	In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	142	2015-05-20 18:10:10.745005	2015-05-20 18:10:10.745005	4	accepted	\N	\N	1	N/A	\N
87	In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	141	2015-05-20 18:10:10.779803	2015-05-20 18:10:10.779803	4	accepted	\N	\N	1	N/A	\N
88	In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	138	2015-05-20 18:10:10.810525	2015-05-20 18:10:10.810525	4	accepted	\N	\N	1	N/A	\N
89	In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	Supports	2	1	3	101	137	2015-05-20 18:10:10.841598	2015-05-20 18:10:10.841598	4	accepted	\N	\N	1	N/A	\N
90	In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.	Sensitivity	Supports	2	3	3	101	143	2015-05-20 18:10:10.87761	2015-05-20 18:10:10.87761	3	accepted	\N	\N	1	N/A	\N
91	A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.	Positive	Supports	1	3	21	102	31	2015-05-20 18:10:10.927367	2015-05-20 18:10:10.927367	4	accepted	\N	\N	1	N/A	\N
92	Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	Resistance or Non-Response	Does Not Support	2	3	19	103	32	2015-05-20 18:10:10.968944	2015-05-20 18:10:10.968944	4	accepted	\N	\N	1	N/A	\N
93	Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	Sensitivity	Supports	2	3	19	103	32	2015-05-20 18:10:11.004293	2015-05-20 18:10:11.004293	4	accepted	\N	\N	1	N/A	\N
94	Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients	Negative	Supports	1	3	19	104	32	2015-05-20 18:10:11.041918	2015-05-20 18:10:11.041918	3	accepted	\N	\N	1	N/A	\N
95	DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes	Positive	Supports	1	3	19	105	32	2015-05-20 18:10:11.079291	2015-05-20 18:10:11.079291	5	accepted	\N	\N	1	N/A	\N
96	DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype)	Positive	Supports	1	3	19	105	32	2015-05-20 18:10:11.120991	2015-05-20 18:10:11.120991	4	accepted	\N	\N	1	N/A	\N
97	DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients	Positive	Supports	1	3	19	104	32	2015-05-20 18:10:11.152106	2015-05-20 18:10:11.152106	3	accepted	\N	\N	1	N/A	\N
98	DNMT3A R882 mutations occur most often in de novo AML patients with intermediate cytogenic risk.	Positive	Supports	1	3	19	103	32	2015-05-20 18:10:11.187081	2015-05-20 18:10:11.187081	3	accepted	\N	\N	1	N/A	\N
99	DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients	Positive	Supports	1	3	19	104	32	2015-05-20 18:10:11.218041	2015-05-20 18:10:11.218041	3	accepted	\N	\N	1	N/A	\N
100	DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients	Positive	Supports	1	3	19	106	32	2015-05-20 18:10:11.251353	2015-05-20 18:10:11.251353	3	accepted	\N	\N	1	N/A	\N
101	Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A	Positive	Supports	1	3	19	107	32	2015-05-20 18:10:11.287674	2015-05-20 18:10:11.287674	3	accepted	\N	\N	1	N/A	\N
102	Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML	N / A	Does Not Support	3	3	19	108	32	2015-05-20 18:10:11.321043	2015-05-20 18:10:11.321043	4	accepted	\N	\N	1	N/A	\N
103	In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.	N / A	Does Not Support	3	3	19	104	32	2015-05-20 18:10:11.353779	2015-05-20 18:10:11.353779	3	accepted	\N	\N	1	N/A	\N
104	In a large cohort of cytogenetically normal AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival	N / A	Does Not Support	3	3	19	104	32	2015-05-20 18:10:11.388567	2015-05-20 18:10:11.388567	3	accepted	\N	\N	1	N/A	\N
105	In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD	N / A	Does Not Support	3	3	19	107	32	2015-05-20 18:10:11.424949	2015-05-20 18:10:11.424949	4	accepted	\N	\N	1	N/A	\N
106	There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	N / A	Does Not Support	3	3	19	103	32	2015-05-20 18:10:11.457588	2015-05-20 18:10:11.457588	4	accepted	\N	\N	1	N/A	\N
107	DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients	Better Outcome	Supports	3	3	19	104	32	2015-05-20 18:10:11.491901	2015-05-20 18:10:11.491901	3	accepted	\N	\N	1	N/A	\N
108	AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	Poor Outcome	Supports	3	3	19	105	32	2015-05-20 18:10:11.528952	2015-05-20 18:10:11.528952	5	accepted	\N	\N	1	N/A	\N
109	Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882)	Poor Outcome	Supports	3	3	19	107	32	2015-05-20 18:10:11.560406	2015-05-20 18:10:11.560406	3	accepted	\N	\N	1	N/A	\N
110	De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	Poor Outcome	Supports	3	3	19	105	32	2015-05-20 18:10:11.59529	2015-05-20 18:10:11.59529	4	accepted	\N	\N	1	N/A	\N
111	DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	Poor Outcome	Supports	3	3	19	108	32	2015-05-20 18:10:11.628652	2015-05-20 18:10:11.628652	4	accepted	\N	\N	1	N/A	\N
112	DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs	Poor Outcome	Supports	3	3	19	104	32	2015-05-20 18:10:11.661224	2015-05-20 18:10:11.661224	3	accepted	\N	\N	1	N/A	\N
113	In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML	Poor Outcome	Supports	3	2	19	104	32	2015-05-20 18:10:11.694009	2015-05-20 18:10:11.694009	3	accepted	\N	\N	1	N/A	\N
114	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.	Poor Outcome	Supports	3	3	19	105	32	2015-05-20 18:10:11.728742	2015-05-20 18:10:11.728742	5	accepted	\N	\N	1	N/A	\N
115	In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.	Poor Outcome	Supports	3	3	19	106	32	2015-05-20 18:10:11.763651	2015-05-20 18:10:11.763651	5	accepted	\N	\N	1	N/A	\N
116	In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	Poor Outcome	Supports	3	3	19	108	32	2015-05-20 18:10:11.799913	2015-05-20 18:10:11.799913	4	accepted	\N	\N	1	N/A	\N
117	In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3	Poor Outcome	Supports	3	3	19	107	32	2015-05-20 18:10:11.841794	2015-05-20 18:10:11.841794	4	accepted	\N	\N	1	N/A	\N
118	In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	Poor Outcome	Supports	3	3	19	108	32	2015-05-20 18:10:11.881946	2015-05-20 18:10:11.881946	4	accepted	\N	\N	1	N/A	\N
119	Young AML patients (<60 years old) with DNMT3A mutation have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A	Poor Outcome	Supports	3	3	19	107	32	2015-05-20 18:10:11.923843	2015-05-20 18:10:11.923843	3	accepted	\N	\N	1	N/A	\N
120	Young AML patients (<60 years old) with DNMT3A R882 mutations have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A	Poor Outcome	Supports	3	3	19	107	32	2015-05-20 18:10:11.954535	2015-05-20 18:10:11.954535	3	accepted	\N	\N	1	N/A	\N
121	Exon 19 deletion has been shown to be correlated with gefitinib response.	Sensitivity	Supports	2	1	3	109	131	2015-05-20 18:10:11.992836	2015-05-20 18:10:11.992836	4	accepted	\N	\N	1	N/A	\N
122	Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.	Sensitivity	Supports	2	1	3	110	132	2015-05-20 18:10:12.03439	2015-05-20 18:10:12.03439	4	accepted	\N	\N	1	N/A	\N
123	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib in the EGFR L858R setting.	N / A	Does Not Support	2	3	3	111	33	2015-05-20 18:10:12.079107	2015-05-20 18:10:12.079107	3	accepted	\N	\N	1	7:55259514-55259515 (CT->AG)	\N
124	In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.	Sensitivity	Supports	2	3	3	112	33	2015-05-20 18:10:12.134413	2015-05-20 18:10:12.134413	4	accepted	\N	\N	1	7:55259514-55259515 (CT->AG)	\N
125	Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.	Better Outcome	Supports	3	3	3	113	33	2015-05-20 18:10:12.16878	2015-05-20 18:10:12.16878	3	accepted	\N	\N	1	7:55259514-55259515 (CT->AG)	\N
126	Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.	Sensitivity	Supports	2	1	3	110	33	2015-05-20 18:10:12.205474	2015-05-20 18:10:12.205474	4	accepted	\N	\N	1	N/A	\N
127	The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.	Resistance or Non-Response	Supports	2	2	22	114	34	2015-05-20 18:10:12.280262	2015-05-20 18:10:12.280262	5	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
128	In a NSCLC patient with T790M and L858R mutation, combination treatment with erlotinib and premetrexed has shown to be effective, reducing tumor size and resulting in stable disease.	Sensitivity	Supports	2	3	3	115	34	2015-05-20 18:10:12.336695	2015-05-20 18:10:12.336695	3	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
129	In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.	Resistance or Non-Response	Supports	2	3	3	116	34	2015-05-20 18:10:12.383675	2015-05-20 18:10:12.383675	3	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
130	In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.	Poor Outcome	Supports	3	3	3	117	34	2015-05-20 18:10:12.419262	2015-05-20 18:10:12.419262	4	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
131	Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.	Poor Outcome	Supports	3	3	3	118	34	2015-05-20 18:10:12.458656	2015-05-20 18:10:12.458656	4	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
132	In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.	Sensitivity	Supports	2	4	3	119	34	2015-05-20 18:10:12.499281	2015-05-20 18:10:12.499281	1	accepted	\N	\N	1	7:55249071-55249071 (C->T)	\N
133	In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.	Resistance or Non-Response	Supports	2	3	3	120	34	2015-05-20 18:10:12.536954	2015-05-20 18:10:12.536954	4	accepted	\N	\N	1	N/A	\N
134	In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	35	2015-05-20 18:10:12.580597	2015-05-20 18:10:12.580597	4	accepted	\N	\N	1	17:37880261-37880261 (G->C)	\N
135	In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	36	2015-05-20 18:10:12.633043	2015-05-20 18:10:12.633043	4	accepted	\N	\N	1	17:37880261-37880261 (G->T)	\N
136	In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	37	2015-05-20 18:10:12.670447	2015-05-20 18:10:12.670447	5	accepted	\N	\N	1	N/A	\N
137	In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	38	2015-05-20 18:10:12.706075	2015-05-20 18:10:12.706075	5	accepted	\N	\N	1	17:37868205-37868205 (G->C)	\N
138	The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	Resistance or Non-Response	Supports	2	1	11	121	39	2015-05-20 18:10:12.747773	2015-05-20 18:10:12.747773	5	accepted	\N	\N	1	17:37880220-37880220 (T->C)	\N
139	The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	Sensitivity	Supports	2	1	11	121	39	2015-05-20 18:10:12.78279	2015-05-20 18:10:12.78279	5	accepted	\N	\N	1	17:37880220-37880220 (T->C)	\N
140	MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	Sensitivity	Supports	2	1	11	121	40	2015-05-20 18:10:12.813516	2015-05-20 18:10:12.813516	5	accepted	\N	\N	1	N/A	\N
141	In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	41	2015-05-20 18:10:12.842992	2015-05-20 18:10:12.842992	5	accepted	\N	\N	1	N/A	\N
142	MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	Sensitivity	Supports	2	1	11	121	42	2015-05-20 18:10:12.885195	2015-05-20 18:10:12.885195	5	accepted	\N	\N	1	N/A	\N
143	In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	43	2015-05-20 18:10:12.918595	2015-05-20 18:10:12.918595	5	accepted	\N	\N	1	17:37881616-37881616 (C->T)	\N
144	In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	44	2015-05-20 18:10:12.955872	2015-05-20 18:10:12.955872	5	accepted	\N	\N	1	17:37881000-37881000 (G->T)	\N
145	In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.	Sensitivity	Supports	2	1	11	121	45	2015-05-20 18:10:13.000209	2015-05-20 18:10:13.000209	5	accepted	\N	\N	1	17:37881332-37881332 (G->A)	\N
146	MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	Supports	2	1	11	122	46	2015-05-20 18:10:13.043828	2015-05-20 18:10:13.043828	3	accepted	\N	\N	1	N/A	\N
147	The L536Q ligand binding domain mutation have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in MCF7 cell lines.	Sensitivity	Supports	2	1	11	123	46	2015-05-20 18:10:13.099377	2015-05-20 18:10:13.099377	5	accepted	\N	\N	1	N/A	\N
148	MCF7 cell lines harboring the N538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	Supports	2	1	11	122	47	2015-05-20 18:10:13.148889	2015-05-20 18:10:13.148889	3	accepted	\N	\N	1	N/A	\N
149	The N538G ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	Supports	2	1	11	123	47	2015-05-20 18:10:13.194257	2015-05-20 18:10:13.194257	5	accepted	\N	\N	1	N/A	\N
150	MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	Supports	2	1	11	122	48	2015-05-20 18:10:13.242039	2015-05-20 18:10:13.242039	3	accepted	\N	\N	1	6:152419923-152419923 (A->G)	\N
151	The Y537C ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	Supports	2	1	11	123	48	2015-05-20 18:10:13.295624	2015-05-20 18:10:13.295624	5	accepted	\N	\N	1	6:152419923-152419923 (A->G)	\N
152	MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	Supports	2	1	11	122	49	2015-05-20 18:10:13.352153	2015-05-20 18:10:13.352153	3	accepted	\N	\N	1	6:152419922-152419922 (T->A)	\N
153	The Y537N ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	Supports	2	1	11	123	49	2015-05-20 18:10:13.410661	2015-05-20 18:10:13.410661	5	accepted	\N	\N	1	6:152419922-152419922 (T->A)	\N
154	MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	Supports	2	1	11	122	50	2015-05-20 18:10:13.502799	2015-05-20 18:10:13.502799	3	accepted	\N	\N	1	6:152419923-152419923 (A->C)	\N
155	The Y537S ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	Supports	2	1	11	123	50	2015-05-20 18:10:13.550554	2015-05-20 18:10:13.550554	5	accepted	\N	\N	1	6:152419923-152419923 (A->C)	\N
156	In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response.	Sensitivity	Supports	2	3	23	124	51	2015-05-20 18:10:13.603088	2015-05-20 18:10:13.603088	2	accepted	\N	\N	1	N/A	\N
157	Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074.	Sensitivity	Supports	2	1	24	125	52	2015-05-20 18:10:13.655885	2015-05-20 18:10:13.655885	3	accepted	\N	\N	1	N/A	\N
158	In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	Sensitivity	Supports	2	3	23	124	53	2015-05-20 18:10:13.702209	2015-05-20 18:10:13.702209	3	accepted	\N	\N	1	N/A	\N
159	AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat	Sensitivity	Supports	2	1	19	126	54	2015-05-20 18:10:13.746235	2015-05-20 18:10:13.746235	4	accepted	\N	\N	1	N/A	\N
160	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation	Resistance or Non-Response	Supports	2	3	19	127	54	2015-05-20 18:10:13.788117	2015-05-20 18:10:13.788117	3	accepted	\N	\N	1	N/A	\N
161	CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations	Sensitivity	Supports	2	3	19	128	54	2015-05-20 18:10:13.822016	2015-05-20 18:10:13.822016	4	accepted	\N	\N	1	N/A	\N
162	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	Resistance or Non-Response	Supports	2	1	19	129	54	2015-05-20 18:10:13.862756	2015-05-20 18:10:13.862756	3	accepted	\N	\N	1	N/A	\N
163	WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type	Positive	Supports	1	3	19	130	54	2015-05-20 18:10:13.898144	2015-05-20 18:10:13.898144	3	accepted	\N	\N	1	N/A	\N
164	FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43)	Resistance or Non-Response	Supports	2	3	19	131	54	2015-05-20 18:10:13.930514	2015-05-20 18:10:13.930514	4	accepted	\N	\N	1	N/A	\N
165	Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate	Resistance or Non-Response	Supports	2	3	19	131	54	2015-05-20 18:10:13.963012	2015-05-20 18:10:13.963012	3	accepted	\N	\N	1	N/A	\N
166	FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation	N / A	Does Not Support	3	3	19	132	54	2015-05-20 18:10:14.023189	2015-05-20 18:10:14.023189	4	accepted	\N	\N	1	N/A	\N
167	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD	N / A	Does Not Support	3	3	19	107	54	2015-05-20 18:10:14.052049	2015-05-20 18:10:14.052049	4	accepted	\N	\N	1	N/A	\N
168	Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate	N / A	Does Not Support	3	3	19	131	54	2015-05-20 18:10:14.085389	2015-05-20 18:10:14.085389	2	accepted	\N	\N	1	N/A	\N
169	A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation	Poor Outcome	Supports	3	3	19	132	54	2015-05-20 18:10:14.120728	2015-05-20 18:10:14.120728	4	accepted	\N	\N	1	N/A	\N
170	AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3	Poor Outcome	Supports	3	3	19	130	54	2015-05-20 18:10:14.149976	2015-05-20 18:10:14.149976	3	accepted	\N	\N	1	N/A	\N
171	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.	Poor Outcome	Supports	3	3	19	105	54	2015-05-20 18:10:14.183486	2015-05-20 18:10:14.183486	5	accepted	\N	\N	1	N/A	\N
172	Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD	Poor Outcome	Supports	3	2	19	133	54	2015-05-20 18:10:14.21517	2015-05-20 18:10:14.21517	2	accepted	\N	\N	1	N/A	\N
173	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3	Poor Outcome	Supports	3	3	19	132	54	2015-05-20 18:10:14.249288	2015-05-20 18:10:14.249288	4	accepted	\N	\N	1	N/A	\N
174	Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	Poor Outcome	Supports	3	3	19	134	54	2015-05-20 18:10:14.278577	2015-05-20 18:10:14.278577	4	accepted	\N	\N	1	N/A	\N
175	Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation	Poor Outcome	Supports	3	3	19	132	54	2015-05-20 18:10:14.311394	2015-05-20 18:10:14.311394	4	accepted	\N	\N	1	N/A	\N
176	Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation.	Sensitivity	Supports	2	1	19	135	54	2015-05-20 18:10:14.343659	2015-05-20 18:10:14.343659	4	accepted	\N	\N	1	N/A	\N
177	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	Resistance or Non-Response	Supports	2	1	19	129	54	2015-05-20 18:10:14.373678	2015-05-20 18:10:14.373678	3	accepted	\N	\N	1	N/A	\N
178	CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations	Sensitivity	Supports	2	3	19	128	55	2015-05-20 18:10:14.406908	2015-05-20 18:10:14.406908	4	accepted	\N	\N	1	N/A	\N
179	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	Resistance or Non-Response	Supports	2	1	19	129	55	2015-05-20 18:10:14.436097	2015-05-20 18:10:14.436097	3	accepted	\N	\N	1	N/A	\N
180	WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type	Positive	Does Not Support	1	3	19	130	55	2015-05-20 18:10:14.464635	2015-05-20 18:10:14.464635	3	accepted	\N	\N	1	N/A	\N
181	AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3	N / A	Does Not Support	3	3	19	130	55	2015-05-20 18:10:14.502482	2015-05-20 18:10:14.502482	3	accepted	\N	\N	1	N/A	\N
182	Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed	Better Outcome	Supports	3	3	19	136	55	2015-05-20 18:10:14.534904	2015-05-20 18:10:14.534904	3	accepted	\N	\N	1	N/A	\N
183	In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3	Poor Outcome	Supports	3	3	19	137	55	2015-05-20 18:10:14.570976	2015-05-20 18:10:14.570976	4	accepted	\N	\N	1	N/A	\N
184	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance	Resistance or Non-Response	Supports	2	3	19	138	55	2015-05-20 18:10:14.610502	2015-05-20 18:10:14.610502	4	accepted	\N	\N	1	N/A	\N
185	Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation.	Resistance or Non-Response	Supports	2	1	19	135	55	2015-05-20 18:10:14.644296	2015-05-20 18:10:14.644296	4	accepted	\N	\N	1	N/A	\N
186	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	Resistance or Non-Response	Supports	2	1	19	129	55	2015-05-20 18:10:14.681607	2015-05-20 18:10:14.681607	3	accepted	\N	\N	1	N/A	\N
187	Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.	Sensitivity	Supports	2	3	25	139	56	2015-05-20 18:10:14.719495	2015-05-20 18:10:14.719495	4	accepted	\N	\N	1	N/A	\N
188	In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype.	Positive	Supports	1	3	19	140	57	2015-05-20 18:10:14.759802	2015-05-20 18:10:14.759802	2	accepted	\N	\N	1	N/A	\N
189	Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation	N / A	Does Not Support	3	3	19	141	57	2015-05-20 18:10:14.796724	2015-05-20 18:10:14.796724	3	accepted	\N	\N	1	N/A	\N
190	The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation	N / A	Does Not Support	3	3	19	142	57	2015-05-20 18:10:14.830722	2015-05-20 18:10:14.830722	2	accepted	\N	\N	1	N/A	\N
191	In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation.	Better Outcome	Supports	3	3	26	143	57	2015-05-20 18:10:14.871026	2015-05-20 18:10:14.871026	3	accepted	\N	\N	1	N/A	\N
192	In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation	Better Outcome	Supports	3	3	27	144	57	2015-05-20 18:10:14.914024	2015-05-20 18:10:14.914024	3	accepted	\N	\N	1	N/A	\N
193	IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival	Poor Outcome	Supports	3	3	28	145	57	2015-05-20 18:10:14.954723	2015-05-20 18:10:14.954723	4	accepted	\N	\N	1	N/A	\N
194	IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation	Positive	Supports	1	3	19	146	58	2015-05-20 18:10:14.99986	2015-05-20 18:10:14.99986	3	accepted	\N	\N	1	2:209113113-209113113 (G->A)	\N
195	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	N / A	Does Not Support	3	3	19	146	58	2015-05-20 18:10:15.034796	2015-05-20 18:10:15.034796	2	accepted	\N	\N	1	2:209113113-209113113 (G->A)	\N
196	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	N / A	Does Not Support	3	3	19	146	59	2015-05-20 18:10:15.066334	2015-05-20 18:10:15.066334	3	accepted	\N	\N	1	2:209113112-209113112 (C->T)	\N
197	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	N / A	Does Not Support	3	3	19	146	60	2015-05-20 18:10:15.102244	2015-05-20 18:10:15.102244	3	accepted	\N	\N	1	2:209113112-209113112 (C->A)	\N
198	AML patients with IDH2 mutations such as R140Q/L have event free survival and overall survival similar to those with wild-type IDH2	N / A	Does Not Support	3	3	19	147	61	2015-05-20 18:10:15.136751	2015-05-20 18:10:15.136751	2	accepted	\N	\N	1	N/A	\N
199	In patients with IDH2 R140Q/L mutation, the presence of mutation does not impact overall survival or disease free survival.	N / A	Does Not Support	3	3	19	148	61	2015-05-20 18:10:15.169657	2015-05-20 18:10:15.169657	3	accepted	\N	\N	1	N/A	\N
200	In AML, patients with IDH2 R140K mutation have improved overall survival compared to those with wild-type IDH2	Better Outcome	Supports	3	3	19	149	61	2015-05-20 18:10:15.204223	2015-05-20 18:10:15.204223	3	accepted	\N	\N	1	N/A	\N
346	Rapamycin inhibits transformation induced by mutation in PIK3CA	Sensitivity	Supports	2	1	11	215	105	2015-05-20 18:10:20.962751	2015-05-20 18:10:20.962751	3	accepted	\N	\N	1	3:178952085-178952085 (A->G)	\N
201	In patients suffering from MDS, the presence of IDH2 mutation such as R140Q/L do not confer prognostic value (overall survival)	N / A	Does Not Support	3	3	29	150	61	2015-05-20 18:10:15.243805	2015-05-20 18:10:15.243805	2	accepted	\N	\N	1	N/A	\N
202	R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	N / A	Does Not Support	3	3	29	151	61	2015-05-20 18:10:15.280775	2015-05-20 18:10:15.280775	3	accepted	\N	\N	1	N/A	\N
203	AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	N / A	Does Not Support	3	3	19	147	62	2015-05-20 18:10:15.321081	2015-05-20 18:10:15.321081	2	accepted	\N	\N	1	15:90631838-90631838 (C->T)	\N
204	In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2	Poor Outcome	Supports	3	3	19	149	62	2015-05-20 18:10:15.35441	2015-05-20 18:10:15.35441	3	accepted	\N	\N	1	15:90631838-90631838 (C->T)	\N
205	In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival)	N / A	Does Not Support	3	3	29	150	62	2015-05-20 18:10:15.393863	2015-05-20 18:10:15.393863	2	accepted	\N	\N	1	15:90631838-90631838 (C->T)	\N
206	JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).	Positive	Supports	1	3	1	152	63	2015-05-20 18:10:15.426533	2015-05-20 18:10:15.426533	4	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
207	JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML)	Positive	Supports	1	3	1	152	63	2015-05-20 18:10:15.461875	2015-05-20 18:10:15.461875	4	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
208	JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL).	Negative	Supports	1	3	30	152	63	2015-05-20 18:10:15.506748	2015-05-20 18:10:15.506748	4	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
209	The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer	Positive	Supports	1	3	31	153	63	2015-05-20 18:10:15.570151	2015-05-20 18:10:15.570151	4	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
210	In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.	Sensitivity	Supports	2	3	32	154	63	2015-05-20 18:10:15.617855	2015-05-20 18:10:15.617855	4	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
211	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells	Sensitivity	Supports	2	1	32	155	63	2015-05-20 18:10:15.656497	2015-05-20 18:10:15.656497	3	accepted	\N	\N	1	9:5073770-5073770 (G->T)	\N
212	In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT	Poor Outcome	Supports	3	3	33	156	64	2015-05-20 18:10:15.700071	2015-05-20 18:10:15.700071	4	accepted	\N	\N	1	4:55599321-55599321 (A->T)	\N
213	KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT	Positive	Supports	1	3	34	157	65	2015-05-20 18:10:15.748195	2015-05-20 18:10:15.748195	2	accepted	\N	\N	1	N/A	\N
214	KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST	N / A	Does Not Support	3	3	34	158	65	2015-05-20 18:10:15.807829	2015-05-20 18:10:15.807829	3	accepted	\N	\N	1	N/A	\N
215	There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	N / A	Does Not Support	3	3	34	159	65	2015-05-20 18:10:15.845991	2015-05-20 18:10:15.845991	3	accepted	\N	\N	1	N/A	\N
216	KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT	Poor Outcome	Supports	3	3	34	157	65	2015-05-20 18:10:15.884776	2015-05-20 18:10:15.884776	3	accepted	\N	\N	1	N/A	\N
217	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer	N / A	Does Not Support	3	3	17	160	65	2015-05-20 18:10:15.927926	2015-05-20 18:10:15.927926	2	accepted	\N	\N	1	N/A	\N
218	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	Better Outcome	Supports	3	3	7	161	65	2015-05-20 18:10:15.96446	2015-05-20 18:10:15.96446	3	accepted	\N	\N	1	N/A	\N
219	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	Better Outcome	Supports	3	3	7	161	67	2015-05-20 18:10:16.008199	2015-05-20 18:10:16.008199	3	accepted	\N	\N	1	N/A	\N
220	GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT	Poor Outcome	Supports	3	3	34	159	68	2015-05-20 18:10:16.048897	2015-05-20 18:10:16.048897	3	accepted	\N	\N	1	N/A	\N
221	KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT	Positive	Supports	1	3	34	157	69	2015-05-20 18:10:16.080795	2015-05-20 18:10:16.080795	3	accepted	\N	\N	1	N/A	\N
222	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	Better Outcome	Supports	3	3	7	161	69	2015-05-20 18:10:16.128063	2015-05-20 18:10:16.128063	3	accepted	\N	\N	1	N/A	\N
223	There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	N / A	Does Not Support	3	3	34	159	70	2015-05-20 18:10:16.177804	2015-05-20 18:10:16.177804	3	accepted	\N	\N	1	N/A	\N
224	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer	N / A	Does Not Support	3	3	17	160	70	2015-05-20 18:10:16.216041	2015-05-20 18:10:16.216041	2	accepted	\N	\N	1	N/A	\N
225	In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment.	Sensitivity	Supports	2	3	35	162	66	2015-05-20 18:10:16.256918	2015-05-20 18:10:16.256918	3	accepted	\N	\N	1	N/A	\N
226	The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.	Sensitivity	Supports	2	1	7	163	71	2015-05-20 18:10:16.307588	2015-05-20 18:10:16.307588	3	accepted	\N	\N	1	N/A	\N
227	The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.	Resistance or Non-Response	Supports	2	1	7	163	71	2015-05-20 18:10:16.349848	2015-05-20 18:10:16.349848	3	accepted	\N	\N	1	N/A	\N
228	Ba/F3 cells harboring the KIT L576P mutation are sensitive to dasantinib, nilotinib and imatinib.	Sensitivity	Supports	2	1	3	164	71	2015-05-20 18:10:16.398841	2015-05-20 18:10:16.398841	3	accepted	\N	\N	1	N/A	\N
229	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	Resistance or Non-Response	Supports	2	1	34	165	72	2015-05-20 18:10:16.449717	2015-05-20 18:10:16.449717	3	accepted	\N	\N	1	4:55594258-55594258 (T->C)	\N
230	In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.	Sensitivity	Supports	2	3	34	166	72	2015-05-20 18:10:16.491698	2015-05-20 18:10:16.491698	3	accepted	\N	\N	1	4:55594258-55594258 (T->C)	\N
231	Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab	Resistance or Non-Response	Supports	2	3	6	167	73	2015-05-20 18:10:16.537026	2015-05-20 18:10:16.537026	4	accepted	\N	\N	1	N/A	\N
232	KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	Sensitivity	Does Not Support	2	3	6	168	74	2015-05-20 18:10:16.575749	2015-05-20 18:10:16.575749	4	accepted	\N	\N	1	N/A	\N
233	In NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib and erlotinib	Resistance or Non-Response	Supports	2	3	3	169	74	2015-05-20 18:10:16.617884	2015-05-20 18:10:16.617884	3	accepted	\N	\N	1	N/A	\N
234	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	Positive	Supports	1	3	36	170	75	2015-05-20 18:10:16.660329	2015-05-20 18:10:16.660329	3	accepted	\N	\N	1	N/A	\N
235	In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival.	N / A	Does Not Support	3	3	8	171	75	2015-05-20 18:10:16.701193	2015-05-20 18:10:16.701193	4	accepted	\N	\N	1	N/A	\N
236	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival	Poor Outcome	Supports	3	3	37	172	75	2015-05-20 18:10:16.736783	2015-05-20 18:10:16.736783	3	accepted	\N	\N	1	N/A	\N
237	KRAS mutations in lung cancer patients are not associated with smoking history, age or gender	Positive	Does Not Support	1	3	3	173	75	2015-05-20 18:10:16.776586	2015-05-20 18:10:16.776586	3	accepted	\N	\N	1	N/A	\N
238	There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC	N / A	Does Not Support	3	3	3	174	75	2015-05-20 18:10:16.811411	2015-05-20 18:10:16.811411	3	accepted	\N	\N	1	N/A	\N
239	A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC	Poor Outcome	Supports	3	3	3	175	75	2015-05-20 18:10:16.847728	2015-05-20 18:10:16.847728	3	accepted	\N	\N	1	N/A	\N
240	Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS	Resistance or Non-Response	Supports	2	3	6	70	76	2015-05-20 18:10:16.878579	2015-05-20 18:10:16.878579	3	accepted	\N	\N	1	N/A	\N
241	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer	Resistance or Non-Response	Supports	2	1	6	176	76	2015-05-20 18:10:16.921189	2015-05-20 18:10:16.921189	3	accepted	\N	\N	1	N/A	\N
242	KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer	Poor Outcome	Supports	3	1	6	176	76	2015-05-20 18:10:16.950949	2015-05-20 18:10:16.950949	3	accepted	\N	\N	1	N/A	\N
243	KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.	Resistance or Non-Response	Supports	2	3	38	177	146	2015-05-20 18:10:16.987491	2015-05-20 18:10:16.987491	3	accepted	\N	\N	1	N/A	\N
244	KRAS G12C occur more frequently in women than men	Positive	Supports	1	3	17	178	77	2015-05-20 18:10:17.032242	2015-05-20 18:10:17.032242	2	accepted	\N	\N	1	12:25398285-25398285 (C->A)	\N
245	KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.	Resistance or Non-Response	Supports	2	3	38	177	77	2015-05-20 18:10:17.073438	2015-05-20 18:10:17.073438	3	accepted	\N	\N	1	N/A	\N
246	KRAS G12D mutation occurs in never smokers significantly more often than in smokers	Positive	Supports	1	3	17	178	78	2015-05-20 18:10:17.126122	2015-05-20 18:10:17.126122	3	accepted	\N	\N	1	12:25398284-25398284 (C->T)	\N
247	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.	Resistance or Non-Response	Supports	2	3	3	179	78	2015-05-20 18:10:17.199888	2015-05-20 18:10:17.199888	2	accepted	\N	\N	1	12:25398284-25398284 (C->T)	\N
248	The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression.	Sensitivity	Supports	2	1	3	180	78	2015-05-20 18:10:17.241211	2015-05-20 18:10:17.241211	4	accepted	\N	\N	1	12:25398284-25398284 (C->T)	\N
249	KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.	Resistance or Non-Response	Supports	2	3	38	177	78	2015-05-20 18:10:17.281432	2015-05-20 18:10:17.281432	3	accepted	\N	\N	1	N/A	\N
250	KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.	Resistance or Non-Response	Supports	2	3	38	177	145	2015-05-20 18:10:17.323931	2015-05-20 18:10:17.323931	3	accepted	\N	\N	1	N/A	\N
251	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	Positive	Supports	1	3	36	170	79	2015-05-20 18:10:17.361269	2015-05-20 18:10:17.361269	3	accepted	\N	\N	1	N/A	\N
252	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival	Poor Outcome	Supports	3	3	39	172	79	2015-05-20 18:10:17.402042	2015-05-20 18:10:17.402042	3	accepted	\N	\N	1	N/A	\N
253	KRAS mutations in lung cancer patients are not associated with smoking history, age or gender	Positive	Does Not Support	1	3	3	173	79	2015-05-20 18:10:17.43264	2015-05-20 18:10:17.43264	3	accepted	\N	\N	1	N/A	\N
254	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model	Resistance or Non-Response	Supports	2	1	8	181	80	2015-05-20 18:10:17.46389	2015-05-20 18:10:17.46389	4	accepted	\N	\N	1	12:25398281-25398281 (C->T)	\N
255	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model	Sensitivity	Supports	2	1	8	181	80	2015-05-20 18:10:17.494819	2015-05-20 18:10:17.494819	4	accepted	\N	\N	1	12:25398281-25398281 (C->T)	\N
256	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS	Sensitivity	Supports	2	3	8	181	80	2015-05-20 18:10:17.529802	2015-05-20 18:10:17.529802	4	accepted	\N	\N	1	12:25398281-25398281 (C->T)	\N
257	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS	Better Outcome	Supports	3	3	8	181	80	2015-05-20 18:10:17.564377	2015-05-20 18:10:17.564377	4	accepted	\N	\N	1	12:25398281-25398281 (C->T)	\N
258	The MAP2K1 P124S mutation confers increased resistance to AZD6244 inhibition by about 5 fold.	Resistance or Non-Response	Supports	2	1	7	182	81	2015-05-20 18:10:17.597503	2015-05-20 18:10:17.597503	3	accepted	\N	\N	1	15:66729162-66729162 (C->T)	\N
259	MAP2K1 Q56P confers increased resistance to inhibition by AZD6244 by 100 fold.	Resistance or Non-Response	Supports	2	1	7	183	82	2015-05-20 18:10:17.638536	2015-05-20 18:10:17.638536	3	accepted	\N	\N	1	15:66727451-66727451 (A->C)	\N
260	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580	Sensitivity	Supports	2	1	20	100	83	2015-05-20 18:10:17.676936	2015-05-20 18:10:17.676936	3	accepted	\N	\N	1	N/A	\N
261	In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.	Resistance or Non-Response	Supports	2	3	3	120	144	2015-05-20 18:10:17.720825	2015-05-20 18:10:17.720825	4	accepted	\N	\N	1	N/A	\N
262	MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.	Sensitivity	Supports	2	3	40	184	84	2015-05-20 18:10:17.769008	2015-05-20 18:10:17.769008	4	accepted	\N	\N	1	N/A	\N
263	MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.	Better Outcome	Supports	3	3	40	184	84	2015-05-20 18:10:17.808591	2015-05-20 18:10:17.808591	4	accepted	\N	\N	1	N/A	\N
264	In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.	Sensitivity	Supports	2	4	40	184	84	2015-05-20 18:10:17.843481	2015-05-20 18:10:17.843481	4	accepted	\N	\N	1	N/A	\N
265	In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.	Sensitivity	Supports	2	2	40	185	84	2015-05-20 18:10:17.880293	2015-05-20 18:10:17.880293	5	accepted	\N	\N	1	N/A	\N
266	NOTCH1 gain-of-function mutations, including D1643H, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	Poor Outcome	Supports	3	3	3	186	133	2015-05-20 18:10:17.918207	2015-05-20 18:10:17.918207	4	accepted	\N	\N	1	N/A	\N
267	NOTCH1 gain-of-function mutations, including R2328W, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	Poor Outcome	Supports	3	3	3	186	134	2015-05-20 18:10:17.95705	2015-05-20 18:10:17.95705	4	accepted	\N	\N	1	N/A	\N
268	NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	Poor Outcome	Supports	3	3	3	186	136	2015-05-20 18:10:17.990278	2015-05-20 18:10:17.990278	4	accepted	\N	\N	1	N/A	\N
269	NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.	Poor Outcome	Supports	3	3	3	186	135	2015-05-20 18:10:18.024054	2015-05-20 18:10:18.024054	4	accepted	\N	\N	1	N/A	\N
270	ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status	Resistance or Non-Response	Supports	2	3	19	127	85	2015-05-20 18:10:18.057016	2015-05-20 18:10:18.057016	3	accepted	\N	\N	1	N/A	\N
271	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD	Sensitivity	Supports	2	3	19	187	85	2015-05-20 18:10:18.090272	2015-05-20 18:10:18.090272	2	accepted	\N	\N	1	N/A	\N
272	Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.	Sensitivity	Supports	2	3	19	188	85	2015-05-20 18:10:18.136117	2015-05-20 18:10:18.136117	2	accepted	\N	\N	1	N/A	\N
273	NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	Positive	Does Not Support	1	3	19	189	85	2015-05-20 18:10:18.168725	2015-05-20 18:10:18.168725	3	accepted	\N	\N	1	N/A	\N
274	NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	Negative	Supports	1	3	19	190	85	2015-05-20 18:10:18.206652	2015-05-20 18:10:18.206652	4	accepted	\N	\N	1	N/A	\N
275	AML with mutated NPM1 is a provisional entity in WHO classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	Positive	Supports	1	2	19	191	85	2015-05-20 18:10:18.242691	2015-05-20 18:10:18.242691	5	accepted	\N	\N	1	N/A	\N
276	NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes	Positive	Supports	1	3	19	131	85	2015-05-20 18:10:18.273372	2015-05-20 18:10:18.273372	2	accepted	\N	\N	1	N/A	\N
277	NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.	Positive	Supports	1	3	19	190	85	2015-05-20 18:10:18.307582	2015-05-20 18:10:18.307582	4	accepted	\N	\N	1	N/A	\N
278	NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia	Positive	Supports	1	3	19	189	85	2015-05-20 18:10:18.341991	2015-05-20 18:10:18.341991	3	accepted	\N	\N	1	N/A	\N
279	NPM1 mutations were associated with normal karyotype in older (>60) patients	Positive	Supports	1	3	19	187	85	2015-05-20 18:10:18.377318	2015-05-20 18:10:18.377318	3	accepted	\N	\N	1	N/A	\N
280	CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy	Sensitivity	Supports	2	4	19	192	85	2015-05-20 18:10:18.416465	2015-05-20 18:10:18.416465	2	accepted	\N	\N	1	N/A	\N
281	CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy	Sensitivity	Supports	2	4	19	192	85	2015-05-20 18:10:18.447139	2015-05-20 18:10:18.447139	2	accepted	\N	\N	1	N/A	\N
282	NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43)	Sensitivity	Supports	2	3	19	131	85	2015-05-20 18:10:18.479932	2015-05-20 18:10:18.479932	4	accepted	\N	\N	1	N/A	\N
283	Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved	Sensitivity	Supports	2	3	19	187	85	2015-05-20 18:10:18.517224	2015-05-20 18:10:18.517224	3	accepted	\N	\N	1	N/A	\N
284	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD	N / A	Does Not Support	3	3	19	107	85	2015-05-20 18:10:18.553137	2015-05-20 18:10:18.553137	4	accepted	\N	\N	1	N/A	\N
285	Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation	N / A	Does Not Support	3	3	19	141	85	2015-05-20 18:10:18.589445	2015-05-20 18:10:18.589445	3	accepted	\N	\N	1	N/A	\N
286	Complete remission rates were higher and both disease-free and overall survival were longer for patients with Exon 12 NPM1 mutations.	Better Outcome	Supports	3	3	19	189	85	2015-05-20 18:10:18.649742	2015-05-20 18:10:18.649742	3	accepted	\N	\N	1	N/A	\N
287	Complete remission rates were higher and event-free survival was longer for normal karyotype AML patients with Exon 12 NPM1 mutations.	Better Outcome	Supports	3	3	19	190	85	2015-05-20 18:10:18.685958	2015-05-20 18:10:18.685958	5	accepted	\N	\N	1	N/A	\N
288	Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	Better Outcome	Supports	3	3	19	193	85	2015-05-20 18:10:18.719923	2015-05-20 18:10:18.719923	3	accepted	\N	\N	1	N/A	\N
289	Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed	Better Outcome	Supports	3	3	19	136	85	2015-05-20 18:10:18.754985	2015-05-20 18:10:18.754985	3	accepted	\N	\N	1	N/A	\N
290	Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2	Better Outcome	Supports	3	3	19	188	85	2015-05-20 18:10:18.785219	2015-05-20 18:10:18.785219	2	accepted	\N	\N	1	N/A	\N
291	Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants	Better Outcome	Supports	3	3	19	194	85	2015-05-20 18:10:18.819262	2015-05-20 18:10:18.819262	3	accepted	\N	\N	1	N/A	\N
292	NPM1 mutation was associated with higher complete remission rates, lower cumulative incidence of relapse and higher overall survival in intermediate risk AML patients	Better Outcome	Supports	3	3	19	195	85	2015-05-20 18:10:18.852798	2015-05-20 18:10:18.852798	4	accepted	\N	\N	1	N/A	\N
293	NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients	Better Outcome	Supports	3	3	19	196	85	2015-05-20 18:10:18.887511	2015-05-20 18:10:18.887511	3	accepted	\N	\N	1	N/A	\N
294	NPM1 mutation without FLT3-ITD was significantly associated with complete remission	Better Outcome	Supports	3	3	19	98	85	2015-05-20 18:10:18.924605	2015-05-20 18:10:18.924605	3	accepted	\N	\N	1	N/A	\N
295	NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old	Better Outcome	Supports	3	3	19	197	85	2015-05-20 18:10:18.957729	2015-05-20 18:10:18.957729	4	accepted	\N	\N	1	N/A	\N
296	Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival, relapse-free survival and response to induction chemotherapy	Better Outcome	Supports	3	3	19	198	85	2015-05-20 18:10:18.990604	2015-05-20 18:10:18.990604	4	accepted	\N	\N	1	N/A	\N
297	Coocurrence of FLT3-ITD mutations significantly reduced overall survival of normal karyotype AML patients	Poor Outcome	Supports	3	3	19	189	85	2015-05-20 18:10:19.024874	2015-05-20 18:10:19.024874	4	accepted	\N	\N	1	N/A	\N
298	Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15)	Poor Outcome	Supports	3	3	19	199	85	2015-05-20 18:10:19.062175	2015-05-20 18:10:19.062175	2	accepted	\N	\N	1	N/A	\N
299	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3	Poor Outcome	Supports	3	3	19	132	85	2015-05-20 18:10:19.096748	2015-05-20 18:10:19.096748	4	accepted	\N	\N	1	N/A	\N
300	Patients with NPM1 mutations and low levels of FLT3-ITD have worse overall survival and cumulative incidence of relapse than those with NPM1 mutations alone in intermediate risk AML patients	Poor Outcome	Supports	3	3	19	195	85	2015-05-20 18:10:19.140075	2015-05-20 18:10:19.140075	3	accepted	\N	\N	1	N/A	\N
301	TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD	Poor Outcome	Supports	3	3	19	200	85	2015-05-20 18:10:19.173469	2015-05-20 18:10:19.173469	3	accepted	\N	\N	1	N/A	\N
302	Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation	Poor Outcome	Supports	3	3	19	132	85	2015-05-20 18:10:19.209211	2015-05-20 18:10:19.209211	4	accepted	\N	\N	1	N/A	\N
303	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD	Sensitivity	Supports	2	1	19	201	85	2015-05-20 18:10:19.242807	2015-05-20 18:10:19.242807	3	accepted	\N	\N	1	N/A	\N
304	For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid	Sensitivity	Supports	2	3	19	202	85	2015-05-20 18:10:19.284214	2015-05-20 18:10:19.284214	2	accepted	\N	\N	1	N/A	\N
305	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients)	Positive	Does Not Support	1	3	19	105	86	2015-05-20 18:10:19.321562	2015-05-20 18:10:19.321562	4	accepted	\N	\N	1	5:170837546-170837547 (0->TCAG)	\N
306	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype)	Positive	Supports	1	3	19	105	86	2015-05-20 18:10:19.368177	2015-05-20 18:10:19.368177	4	accepted	\N	\N	1	5:170837546-170837547 (0->TCAG)	\N
307	NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.	Sensitivity	Supports	2	4	19	193	86	2015-05-20 18:10:19.40342	2015-05-20 18:10:19.40342	3	accepted	\N	\N	1	5:170837546-170837547 (0->TCAG)	\N
308	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	Sensitivity	Supports	2	1	19	201	86	2015-05-20 18:10:19.446567	2015-05-20 18:10:19.446567	3	accepted	\N	\N	1	5:170837546-170837547 (0->TCAG)	\N
309	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS	Poor Outcome	Supports	3	3	7	203	87	2015-05-20 18:10:19.492287	2015-05-20 18:10:19.492287	3	accepted	\N	\N	1	N/A	\N
310	The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)	N / A	Does Not Support	3	3	19	204	88	2015-05-20 18:10:19.533301	2015-05-20 18:10:19.533301	3	accepted	\N	\N	1	N/A	\N
311	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	Poor Outcome	Supports	3	3	6	205	88	2015-05-20 18:10:19.567329	2015-05-20 18:10:19.567329	3	accepted	\N	\N	1	N/A	\N
312	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS	Poor Outcome	Supports	3	3	7	203	88	2015-05-20 18:10:19.599882	2015-05-20 18:10:19.599882	3	accepted	\N	\N	1	N/A	\N
313	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	Poor Outcome	Supports	3	2	6	205	89	2015-05-20 18:10:19.636296	2015-05-20 18:10:19.636296	3	accepted	\N	\N	1	N/A	\N
314	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	Poor Outcome	Supports	3	2	6	205	90	2015-05-20 18:10:19.669851	2015-05-20 18:10:19.669851	3	accepted	\N	\N	1	N/A	\N
315	NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML	N / A	Does Not Support	3	3	19	206	91	2015-05-20 18:10:19.702518	2015-05-20 18:10:19.702518	3	accepted	\N	\N	1	N/A	\N
316	Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation	Sensitivity	Supports	2	3	7	207	92	2015-05-20 18:10:19.741367	2015-05-20 18:10:19.741367	2	accepted	\N	\N	1	1:115258744-115258744 (C->T)	\N
317	In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy.	Resistance or Non-Response	Does Not Support	2	3	6	70	93	2015-05-20 18:10:19.775937	2015-05-20 18:10:19.775937	3	accepted	\N	\N	1	N/A	\N
318	Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.	Resistance or Non-Response	Supports	2	3	6	70	93	2015-05-20 18:10:19.818729	2015-05-20 18:10:19.818729	3	accepted	\N	\N	1	N/A	\N
319	Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk	Positive	Supports	1	3	7	208	93	2015-05-20 18:10:19.861361	2015-05-20 18:10:19.861361	3	accepted	\N	\N	1	N/A	\N
320	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	Resistance or Non-Response	Supports	2	3	7	209	93	2015-05-20 18:10:19.898796	2015-05-20 18:10:19.898796	4	accepted	\N	\N	1	N/A	\N
321	In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months	Sensitivity	Supports	2	3	7	210	94	2015-05-20 18:10:19.937659	2015-05-20 18:10:19.937659	2	accepted	\N	\N	1	1:115256528-115256529 (TT->CA)	\N
322	In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months	Sensitivity	Supports	2	3	7	210	95	2015-05-20 18:10:19.967902	2015-05-20 18:10:19.967902	2	accepted	\N	\N	1	1:115256528-115256529 (TT->CC)	\N
323	In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	Sensitivity	Supports	2	1	41	211	96	2015-05-20 18:10:20.034616	2015-05-20 18:10:20.034616	4	accepted	\N	\N	1	4:55152092-55152093 (GA->AT)	\N
324	In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	Sensitivity	Supports	2	1	41	211	97	2015-05-20 18:10:20.081353	2015-05-20 18:10:20.081353	4	accepted	\N	\N	1	4:55152093-55152093 (A->T)	\N
325	GIST cancer with D842V mutation is resistant to imatinib.	Resistance or Non-Response	Supports	2	3	41	212	97	2015-05-20 18:10:20.129393	2015-05-20 18:10:20.129393	4	accepted	\N	\N	1	4:55152093-55152093 (A->T)	\N
326	While cancer with PVGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.	Resistance or Non-Response	Supports	2	3	41	165	97	2015-05-20 18:10:20.169397	2015-05-20 18:10:20.169397	4	accepted	\N	\N	1	4:55152093-55152093 (A->T)	\N
327	GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	Negative	Supports	1	3	41	213	97	2015-05-20 18:10:20.208148	2015-05-20 18:10:20.208148	3	accepted	\N	\N	1	4:55152093-55152093 (A->T)	\N
328	In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	Sensitivity	Supports	2	1	41	211	98	2015-05-20 18:10:20.253856	2015-05-20 18:10:20.253856	4	accepted	\N	\N	1	4:55152092-55152092 (G->T)	\N
329	In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	Sensitivity	Supports	2	1	41	211	99	2015-05-20 18:10:20.293973	2015-05-20 18:10:20.293973	4	accepted	\N	\N	1	N/A	\N
330	In CHO cells with PDGFRA D842-843IM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	Sensitivity	Supports	2	1	41	211	100	2015-05-20 18:10:20.333335	2015-05-20 18:10:20.333335	4	accepted	\N	\N	1	N/A	\N
331	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	Sensitivity	Supports	2	1	11	214	101	2015-05-20 18:10:20.378002	2015-05-20 18:10:20.378002	4	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
332	Rapamycin inhibits transformation induced by mutation in PIK3CA	Sensitivity	Supports	2	1	11	215	101	2015-05-20 18:10:20.415769	2015-05-20 18:10:20.415769	3	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
333	The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.	Resistance or Non-Response	Supports	2	4	6	216	101	2015-05-20 18:10:20.450249	2015-05-20 18:10:20.450249	3	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
334	Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.	Poor Outcome	Supports	3	4	6	217	101	2015-05-20 18:10:20.485071	2015-05-20 18:10:20.485071	2	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
335	The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation.	Poor Outcome	Supports	3	4	6	216	101	2015-05-20 18:10:20.526084	2015-05-20 18:10:20.526084	3	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
336	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	N / A	Does Not Support	2	3	6	168	101	2015-05-20 18:10:20.566295	2015-05-20 18:10:20.566295	4	accepted	\N	\N	1	3:178936082-178936082 (G->A)	\N
337	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	Sensitivity	Supports	2	1	11	214	102	2015-05-20 18:10:20.595777	2015-05-20 18:10:20.595777	4	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
338	Rapamycin inhibits transformation induced by mutation in PIK3CA	Sensitivity	Supports	2	1	11	215	102	2015-05-20 18:10:20.62751	2015-05-20 18:10:20.62751	3	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
339	The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.	Resistance or Non-Response	Supports	2	4	6	216	102	2015-05-20 18:10:20.658131	2015-05-20 18:10:20.658131	3	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
340	Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.	Poor Outcome	Supports	3	4	6	217	102	2015-05-20 18:10:20.703469	2015-05-20 18:10:20.703469	2	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
341	The presence of exon 9 (such as E545K) or exon 20 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	Poor Outcome	Supports	3	4	6	216	102	2015-05-20 18:10:20.748571	2015-05-20 18:10:20.748571	3	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
342	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	N / A	Does Not Support	2	3	6	168	102	2015-05-20 18:10:20.7978	2015-05-20 18:10:20.7978	4	accepted	\N	\N	1	3:178936091-178936091 (G->A)	\N
343	Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA	Resistance or Non-Response	Supports	2	3	6	70	103	2015-05-20 18:10:20.856229	2015-05-20 18:10:20.856229	3	accepted	\N	\N	1	N/A	\N
344	In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA	N / A	Does Not Support	2	3	6	70	104	2015-05-20 18:10:20.894925	2015-05-20 18:10:20.894925	3	accepted	\N	\N	1	N/A	\N
345	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	Sensitivity	Supports	2	1	11	214	105	2015-05-20 18:10:20.930597	2015-05-20 18:10:20.930597	4	accepted	\N	\N	1	3:178952085-178952085 (A->G)	\N
347	The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R) were associated with lack of panitumumab or cetuximab response.	Resistance or Non-Response	Supports	2	4	6	216	105	2015-05-20 18:10:20.996526	2015-05-20 18:10:20.996526	3	accepted	\N	\N	1	3:178952085-178952085 (A->G)	\N
348	The presence of exon 20 (such as H1047R) or exon 9 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	Poor Outcome	Supports	3	4	6	216	105	2015-05-20 18:10:21.037467	2015-05-20 18:10:21.037467	3	accepted	\N	\N	1	3:178952085-178952085 (A->G)	\N
349	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	N / A	Does Not Support	2	3	6	168	105	2015-05-20 18:10:21.069015	2015-05-20 18:10:21.069015	4	accepted	\N	\N	1	3:178952085-178952085 (A->G)	\N
350	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	Sensitivity	Supports	2	3	42	218	106	2015-05-20 18:10:21.106027	2015-05-20 18:10:21.106027	5	accepted	\N	\N	1	N/A	\N
351	A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.	Positive	Supports	1	3	21	102	107	2015-05-20 18:10:21.145671	2015-05-20 18:10:21.145671	4	accepted	\N	\N	1	N/A	\N
352	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.	Sensitivity	Supports	2	1	2	219	108	2015-05-20 18:10:21.185553	2015-05-20 18:10:21.185553	4	accepted	\N	\N	1	10:89717672-89717672 (C->T)	\N
353	PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients.	Poor Outcome	Does Not Support	3	3	40	220	108	2015-05-20 18:10:21.243108	2015-05-20 18:10:21.243108	3	accepted	\N	\N	1	10:89717672-89717672 (C->T)	\N
354	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	Sensitivity	Supports	2	3	42	218	109	2015-05-20 18:10:21.284618	2015-05-20 18:10:21.284618	5	accepted	\N	\N	1	N/A	\N
355	Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.	Resistance or Non-Response	Supports	2	1	43	221	110	2015-05-20 18:10:21.329631	2015-05-20 18:10:21.329631	3	accepted	\N	\N	1	10:43609950-43609950 (C->G)	\N
356	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	Sensitivity	Supports	2	1	43	222	111	2015-05-20 18:10:21.388904	2015-05-20 18:10:21.388904	3	accepted	\N	\N	1	10:43617416-43617416 (T->C)	\N
357	Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.	Resistance or Non-Response	Supports	2	1	43	221	111	2015-05-20 18:10:21.430748	2015-05-20 18:10:21.430748	3	accepted	\N	\N	1	10:43617416-43617416 (T->C)	\N
358	In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.	Positive	Supports	1	3	43	223	111	2015-05-20 18:10:21.502819	2015-05-20 18:10:21.502819	5	accepted	\N	\N	1	10:43617416-43617416 (T->C)	\N
359	Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.	Poor Outcome	Supports	3	3	43	224	111	2015-05-20 18:10:21.537943	2015-05-20 18:10:21.537943	4	accepted	\N	\N	1	10:43617416-43617416 (T->C)	\N
360	Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex.	Better Outcome	Supports	3	4	29	225	112	2015-05-20 18:10:21.574438	2015-05-20 18:10:21.574438	3	accepted	\N	\N	1	2:198267359-198267359 (C->A)	\N
361	Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex.	Better Outcome	Supports	3	4	29	225	113	2015-05-20 18:10:21.605766	2015-05-20 18:10:21.605766	3	accepted	\N	\N	1	2:198266834-198266834 (T->C)	\N
362	Breast tumors in a mouse model with R175H mutation are more responsive to doxorubicin than breast tumors with wild type TP53.	Sensitivity	Supports	2	1	11	226	114	2015-05-20 18:10:21.647848	2015-05-20 18:10:21.647848	3	accepted	\N	\N	1	17:7578406-7578406 (C->T)	\N
363	Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	Poor Outcome	Supports	3	3	11	227	114	2015-05-20 18:10:21.684332	2015-05-20 18:10:21.684332	3	accepted	\N	\N	1	17:7578406-7578406 (C->T)	\N
364	Breast cancer patients who harbor R248Q mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	Poor Outcome	Supports	3	3	11	227	115	2015-05-20 18:10:21.715966	2015-05-20 18:10:21.715966	3	accepted	\N	\N	1	17:7577538-7577538 (C->T)	\N
365	In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	Poor Outcome	Supports	3	3	11	228	115	2015-05-20 18:10:21.754575	2015-05-20 18:10:21.754575	3	accepted	\N	\N	1	17:7577538-7577538 (C->T)	\N
366	In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.	Poor Outcome	Supports	3	3	11	227	116	2015-05-20 18:10:21.790208	2015-05-20 18:10:21.790208	3	accepted	\N	\N	1	17:7577539-7577539 (G->A)	\N
367	In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53.	Poor Outcome	Supports	3	3	11	228	117	2015-05-20 18:10:21.831329	2015-05-20 18:10:21.831329	3	accepted	\N	\N	1	17:7577535-7577535 (C->G)	\N
368	In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53.	Poor Outcome	Supports	3	3	11	228	118	2015-05-20 18:10:21.863902	2015-05-20 18:10:21.863902	3	accepted	\N	\N	1	17:7577536-7577536 (T->A)	\N
369	Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	Poor Outcome	Supports	3	3	11	227	119	2015-05-20 18:10:21.895183	2015-05-20 18:10:21.895183	3	accepted	\N	\N	1	17:7577121-7577121 (G->A)	\N
370	In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	Poor Outcome	Supports	3	3	11	228	119	2015-05-20 18:10:21.928067	2015-05-20 18:10:21.928067	3	accepted	\N	\N	1	17:7577121-7577121 (G->A)	\N
371	Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	Poor Outcome	Supports	3	3	11	227	120	2015-05-20 18:10:21.960547	2015-05-20 18:10:21.960547	3	accepted	\N	\N	1	17:7577120-7577120 (C->T)	\N
372	In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	Poor Outcome	Supports	3	3	11	228	120	2015-05-20 18:10:21.99911	2015-05-20 18:10:21.99911	3	accepted	\N	\N	1	17:7577120-7577120 (C->T)	\N
373	Breast tumor with R175H mutation are more responsive to doxorubicin than breast tumors with wild type TP53.	Poor Outcome	Supports	3	3	11	228	121	2015-05-20 18:10:22.038259	2015-05-20 18:10:22.038259	3	accepted	\N	\N	1	N/A	\N
374	A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus.	Sensitivity	Supports	2	3	44	229	122	2015-05-20 18:10:22.075292	2015-05-20 18:10:22.075292	3	accepted	\N	\N	1	N/A	\N
375	Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.	Sensitivity	Supports	2	1	3	230	122	2015-05-20 18:10:22.133881	2015-05-20 18:10:22.133881	3	accepted	\N	\N	1	N/A	\N
376	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	Sensitivity	Supports	2	3	24	231	123	2015-05-20 18:10:22.176271	2015-05-20 18:10:22.176271	3	accepted	\N	\N	1	N/A	\N
377	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	Sensitivity	Supports	2	3	24	229	124	2015-05-20 18:10:22.218868	2015-05-20 18:10:22.218868	3	accepted	\N	\N	1	N/A	\N
378	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.	Positive	Does Not Support	1	4	19	232	125	2015-05-20 18:10:22.262173	2015-05-20 18:10:22.262173	3	accepted	\N	\N	1	N/A	\N
379	In patients with AML, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.	N / A	Does Not Support	3	4	19	232	125	2015-05-20 18:10:22.29316	2015-05-20 18:10:22.29316	2	accepted	\N	\N	1	N/A	\N
380	In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.	N / A	Does Not Support	3	4	29	232	125	2015-05-20 18:10:22.329236	2015-05-20 18:10:22.329236	2	accepted	\N	\N	1	N/A	\N
381	After adjust for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.	Poor Outcome	Supports	3	4	29	233	125	2015-05-20 18:10:22.368733	2015-05-20 18:10:22.368733	3	accepted	\N	\N	1	N/A	\N
382	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.	Positive	Does Not Support	1	4	19	232	126	2015-05-20 18:10:22.399857	2015-05-20 18:10:22.399857	3	accepted	\N	\N	1	N/A	\N
383	In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.	N / A	Does Not Support	3	4	19	232	126	2015-05-20 18:10:22.436048	2015-05-20 18:10:22.436048	2	accepted	\N	\N	1	N/A	\N
384	In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.	N / A	Does Not Support	3	4	29	232	126	2015-05-20 18:10:22.471851	2015-05-20 18:10:22.471851	2	accepted	\N	\N	1	N/A	\N
385	After adjust for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.	Poor Outcome	Supports	3	4	29	233	126	2015-05-20 18:10:22.502321	2015-05-20 18:10:22.502321	3	accepted	\N	\N	1	N/A	\N
386	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML	Resistance or Non-Response	Supports	2	3	19	234	127	2015-05-20 18:10:22.545043	2015-05-20 18:10:22.545043	3	accepted	\N	\N	1	N/A	\N
387	No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML	N / A	Does Not Support	3	3	19	235	127	2015-05-20 18:10:22.578155	2015-05-20 18:10:22.578155	3	accepted	\N	\N	1	N/A	\N
388	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML	N / A	Does Not Support	3	3	19	235	127	2015-05-20 18:10:22.614828	2015-05-20 18:10:22.614828	4	accepted	\N	\N	1	N/A	\N
389	Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	236	127	2015-05-20 18:10:22.660388	2015-05-20 18:10:22.660388	2	accepted	\N	\N	1	N/A	\N
390	Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence	Poor Outcome	Supports	3	3	19	236	127	2015-05-20 18:10:22.693368	2015-05-20 18:10:22.693368	2	accepted	\N	\N	1	N/A	\N
391	Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	235	127	2015-05-20 18:10:22.724662	2015-05-20 18:10:22.724662	3	accepted	\N	\N	1	N/A	\N
392	WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients	Poor Outcome	Supports	3	3	19	237	127	2015-05-20 18:10:22.790739	2015-05-20 18:10:22.790739	3	accepted	\N	\N	1	N/A	\N
393	WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	234	127	2015-05-20 18:10:22.833864	2015-05-20 18:10:22.833864	3	accepted	\N	\N	1	N/A	\N
394	WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	234	127	2015-05-20 18:10:22.880055	2015-05-20 18:10:22.880055	3	accepted	\N	\N	1	N/A	\N
395	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML	Resistance or Non-Response	Supports	2	3	19	234	128	2015-05-20 18:10:22.924617	2015-05-20 18:10:22.924617	3	accepted	\N	\N	1	N/A	\N
396	No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML	N / A	Does Not Support	3	3	19	235	128	2015-05-20 18:10:22.968109	2015-05-20 18:10:22.968109	3	accepted	\N	\N	1	N/A	\N
397	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.	N / A	Does Not Support	3	3	19	235	128	2015-05-20 18:10:23.012156	2015-05-20 18:10:23.012156	4	accepted	\N	\N	1	N/A	\N
398	Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	235	128	2015-05-20 18:10:23.059827	2015-05-20 18:10:23.059827	3	accepted	\N	\N	1	N/A	\N
399	WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	234	128	2015-05-20 18:10:23.101349	2015-05-20 18:10:23.101349	3	accepted	\N	\N	1	N/A	\N
400	WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML	Poor Outcome	Supports	3	3	19	234	128	2015-05-20 18:10:23.146666	2015-05-20 18:10:23.146666	3	accepted	\N	\N	1	N/A	\N
401	WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients	Poor Outcome	Supports	3	3	19	237	128	2015-05-20 18:10:23.187385	2015-05-20 18:10:23.187385	3	accepted	\N	\N	1	N/A	\N
402	Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction (>50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity by positron emission tomography (PET) imaging after dasatinib treatment. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas.	Sensitivity	Supports	2	3	45	163	71	2015-05-20 18:10:23.24002	2015-05-20 18:10:23.24002	5	accepted	\N	\N	1	N/A	\N
403	To formally test this hypothesis, we took advantage of HCT116 cells in which the KRAS D13 mutant allele had been genetically deleted by homologous recombination (15). Strikingly, we found that HCT116-derivative cells retaining only the KRAS WT allele (named HKh-2 and HKe-3; Supplemental Table 3) were sensitive to everolimus, while the parental and the isogenic cells carrying mutated KRAS were equally resistant to this compound (Figure 2A).	Resistance or Non-Response	Supports	2	1	46	238	80	2015-05-20 18:10:23.289266	2015-05-20 18:10:23.289266	4	accepted	\N	\N	1	N/A	\N
404	Figure 1 of paper shows that V654A was associated with progression of disease in one case of a mucosal melanoma. Results were from a Phase II clinical trial.	Resistance or Non-Response	Supports	2	3	45	239	72	2015-05-20 18:10:23.336503	2015-05-20 18:10:23.336503	5	accepted	\N	\N	1	N/A	\N
405	Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.	Sensitivity	Supports	2	3	45	240	150	2015-05-20 18:10:23.378252	2015-05-20 18:10:23.378252	5	accepted	\N	\N	1	N/A	\N
406	From the screen, we discovered that proteasome inhibitors show selectivity toward BRAF V600Emutant cells, irrespective of PTEN or RB1 expression. Preferential targeting of BRAF-mutant cells by proteasome inhibitors was corroborated in a second BRAF V600E isogenic model, as well as in a panel of colorectal cancer cell lines by the use of the proteasome inhibitor carfilzomib. Notably, carfilzomib also showed striking in vivo activity in a BRAF-mutant human colorectal cancer xenograft model. Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF V600E blockade by PLX4720 reversed sensitivity to carfilzomib in BRAF-mutant colorectal cancer cells. Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600Emutant colorectal tumors.	Sensitivity	Supports	2	1	47	241	12	2015-05-20 18:10:23.419753	2015-05-20 18:10:23.419753	3	accepted	\N	\N	1	N/A	\N
407	PDGFRA G853D mutation found in an acral melanoma sample. In vitro testing showed that G853D induced IL-3independent growth could be inhibited by either imatinib or crenolanib to different extent.	Sensitivity	Supports	2	1	48	242	148	2015-05-20 18:10:23.458699	2015-05-20 18:10:23.458699	4	accepted	\N	\N	1	N/A	\N
408	Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance.	Resistance or Non-Response	Supports	2	3	49	243	149	2015-05-20 18:10:23.49272	2015-05-20 18:10:23.49272	3	accepted	\N	\N	1	N/A	\N
409	Authors of study investigated genomic changes in metastatic renal cancer patients with long term benefit from rapalog treatment. Patient 3 (treated with everolimus), in study, was found to have a novel MTOR mutation, Q2223K. This residue was in the PI3K kinase domain structure. In vitro, functional validation confirmed that this variant was activating and was sensitive to rapamycin and rapalogs, everolimus and temsirolimus.	Sensitivity	Supports	2	3	50	244	147	2015-05-20 18:10:23.534686	2015-05-20 18:10:23.534686	5	accepted	\N	\N	1	N/A	\N
410	Deep kinome sequencing in ER+ breast cancer clinical samples that progressed on letrozole and discovered LYN D189Y mutation associated with lack of response. Biochemical follow up studies show that this mutation is associated with lack of response to letrozole. Experimental evidence: http://bit.ly/1KyZ8vU	Resistance or Non-Response	Supports	2	1	51	245	151	2015-05-20 18:10:23.585451	2015-05-20 18:10:23.585451	3	accepted	\N	\N	1	N/A	\N
411	Identified through whole genome analysis of two patients with Dopa (3,4-dihydroxyphenylalanine) responsive dystonia (DRD) [Mendelian Inheritance in Man (MIM) #128230]	Better Outcome	Supports	2	3	52	246	153	2015-05-20 18:10:23.639248	2015-05-20 18:10:23.639248	4	accepted	\N	\N	2	N/A	\N
412	The patient was confirmed as having a heterozygous MET mutation at M1268T. The patient had a reduction of 35% in the sum of one-dimensional measurements of target lesions after receiving treatment for 53 weeks, achieving a confirmed partial response by RECIST version 1.04.	Sensitivity	Supports	2	3	53	247	155	2015-05-20 18:10:23.688999	2015-05-20 18:10:23.688999	3	accepted	\N	\N	1	N/A	\N
\.


--
-- Data for Name: drugs_evidence_items; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY drugs_evidence_items (drug_id, evidence_item_id) FROM stdin;
1	1
1	2
2	3
3	3
4	4
4	5
4	6
5	7
6	8
6	9
7	10
6	11
6	12
7	13
6	14
6	15
8	16
6	17
6	18
8	19
8	20
9	21
9	22
10	23
11	24
12	25
10	25
1	26
12	27
13	28
11	28
9	28
14	29
15	29
15	30
16	30
17	31
18	31
19	31
13	32
1	33
18	34
20	35
21	35
12	36
10	36
1	37
1	38
1	39
12	40
1	41
1	42
1	43
1	44
1	45
1	46
1	47
22	48
12	49
12	50
12	51
23	52
23	53
1	54
1	55
1	56
1	57
1	58
1	59
1	60
1	61
1	62
1	63
1	64
1	65
24	66
1	67
1	68
1	69
1	70
25	71
26	72
25	73
26	74
1	75
1	76
1	77
1	78
1	79
1	80
1	81
1	82
4	83
27	83
3	84
3	85
3	86
3	87
3	88
3	89
3	90
28	90
1	91
29	92
30	93
1	94
1	95
1	96
1	97
1	98
1	99
1	100
1	101
1	102
1	103
1	104
1	105
1	106
1	107
1	108
1	109
1	110
1	111
1	112
1	113
1	114
1	115
1	116
1	117
1	118
1	119
1	120
31	121
31	122
31	123
28	123
31	123
28	123
1	124
1	125
31	126
28	127
28	128
32	128
31	129
1	130
1	131
33	132
34	133
35	134
35	135
35	136
35	137
36	138
35	139
35	140
35	141
35	142
36	142
35	143
35	144
35	145
37	146
38	147
39	147
37	148
38	149
39	149
37	150
38	151
39	151
37	152
38	153
39	153
37	154
38	155
39	155
40	156
41	157
42	158
40	158
43	159
44	160
45	161
29	162
1	163
1	164
1	165
1	166
1	167
1	168
1	169
1	170
1	171
1	172
1	173
1	174
1	175
9	176
46	177
45	178
29	179
1	180
1	181
1	182
1	183
9	184
9	185
46	186
47	187
48	187
1	188
1	189
1	190
1	191
1	192
1	193
1	194
1	195
1	196
1	197
1	198
1	199
1	200
1	201
1	202
1	203
1	204
1	205
1	206
1	207
1	208
1	209
49	210
50	211
1	212
1	213
1	214
1	215
1	216
1	217
4	218
4	219
1	220
1	221
4	222
1	223
1	224
4	225
3	226
4	227
2	227
9	227
3	228
4	228
2	228
4	229
51	230
13	231
52	232
31	233
28	233
1	234
1	235
1	236
1	237
1	238
1	239
13	240
13	241
1	242
31	243
28	243
1	244
31	245
28	245
1	246
12	247
53	248
54	248
31	249
28	249
31	250
28	250
1	251
1	252
1	253
13	254
13	255
13	256
13	257
22	258
22	259
4	260
27	260
34	261
55	262
1	263
56	264
21	265
1	266
1	267
1	268
1	269
44	270
44	271
29	272
1	273
1	274
1	275
1	276
1	277
1	278
1	279
1	280
1	281
1	282
1	283
1	284
1	285
1	286
1	287
1	288
1	289
1	290
1	291
1	292
1	293
1	294
1	295
1	296
1	297
1	298
1	299
1	300
1	301
1	302
57	303
44	303
58	304
1	305
1	306
1	307
57	308
1	309
1	310
1	311
1	312
1	313
1	314
1	315
59	316
13	317
13	318
1	319
18	320
21	321
21	322
60	323
60	324
4	325
4	326
1	327
60	328
60	329
60	330
61	331
62	332
13	333
11	333
1	334
1	335
52	336
61	337
62	338
13	339
11	339
1	340
1	341
52	342
13	343
13	344
61	345
62	346
13	347
11	347
1	348
52	349
44	350
1	351
1	352
1	353
44	354
63	355
64	356
63	357
1	358
1	359
1	360
1	361
65	362
1	363
1	364
1	365
1	366
1	367
1	368
1	369
1	370
1	371
1	372
1	373
66	374
62	375
66	376
66	377
1	378
1	379
1	380
1	381
1	382
1	383
1	384
1	385
1	386
1	387
1	388
1	389
1	390
1	391
1	392
1	393
1	394
1	395
1	396
1	397
1	398
1	399
1	400
1	401
3	402
66	403
4	404
4	405
67	406
4	407
68	408
66	409
69	410
70	411
71	412
72	412
73	412
74	412
\.


--
-- Name: drugs_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('drugs_id_seq', 74, true);


--
-- Data for Name: events; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY events (id, created_at, updated_at, action, description, originating_user_id, subject_id, subject_type) FROM stdin;
\.


--
-- Name: events_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('events_id_seq', 1, false);


--
-- Name: evidence_items_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('evidence_items_id_seq', 412, true);


--
-- Name: evidence_levels_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('evidence_levels_id_seq', 4, true);


--
-- Name: evidence_types_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('evidence_types_id_seq', 3, true);


--
-- Data for Name: feeds; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY feeds (id, created_at, updated_at, owner_id, event_id, acknowledged) FROM stdin;
\.


--
-- Name: feeds_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('feeds_id_seq', 1, false);


--
-- Data for Name: gene_aliases; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY gene_aliases (id, name) FROM stdin;
1	CD246
2	NBLST3
3	AKT
4	CWS6
5	PKB
6	PKB-ALPHA
7	PRKBA
8	RAC
9	RAC-ALPHA
10	A-RAF
11	ARAF1
12	PKS2
13	RAFA1
14	ABL
15	JTK7
16	bcr/abl
17	c-ABL
18	c-ABL1
19	p150
20	v-abl
21	B-RAF1
22	BRAF1
23	NS7
24	RAFB1
25	BRCAI
26	BRCC1
27	BROVCA1
28	FANCS
29	IRIS
30	PNCA4
31	PPP1R53
32	PSCP
33	RNF53
34	BRCC2
35	BROVCA2
36	FACD
37	FAD
38	FAD1
39	FANCD
40	FANCD1
41	GLM3
42	PNCA2
43	XRCC11
44	BCL1
45	D11S287E
46	PRAD1
47	U21B31
48	KIAK0002
49	MPPH3
50	CCNE
51	MCPH12
52	PLSTIRE
53	CMM3
54	PSK-J3
55	ARF
56	CDK4I
57	CDKN2
58	CMM2
59	INK4
60	INK4A
61	MLM
62	MTS-1
63	MTS1
64	P14
65	P14ARF
66	P16
67	P16-INK4A
68	P16INK4
69	P16INK4A
70	P19
71	P19ARF
72	TP16
73	C/EBP-alpha
74	CEBP
75	HSPF1
76	Hdj1
77	Hsp40
78	RSPH16B
79	Sis1
80	PKACA
81	PPNAD4
82	DNMT3A2
83	M.HsaIIIA
84	TBRS
85	ERBB
86	ERBB1
87	HER1
88	NISBD2
89	PIG61
90	mENA
91	CD340
92	HER-2
93	HER-2/neu
94	HER2
95	MLN 19
96	NEU
97	NGL
98	TKR1
99	ER
100	ESR
101	ESRA
102	ESTRR
103	Era
104	NR3A1
105	BBDS
106	BEK
107	BFR-1
108	CD332
109	CEK3
110	CFD1
111	ECT1
112	JWS
113	K-SAM
114	KGFR
115	TK14
116	TK25
117	ACH
118	CD333
119	CEK2
120	HSFGFR3EX
121	JTK4
122	CD135
123	FLK-2
124	FLK2
125	STK1
126	DCML
127	IMD21
128	MONOMAC
129	NFE1B
130	HEL-216
131	HEL-S-26
132	IDCD
133	IDH
134	IDP
135	IDPC
136	PICD
137	D2HGA2
138	ICD-M
139	IDHM
140	IDPM
141	mNADP-IDH
142	JTK10
143	THCYT3
144	C-Kit
145	CD117
146	PBT
147	SCFR
148	C-K-RAS
149	CFC2
150	K-RAS2A
151	K-RAS2B
152	K-RAS4A
153	K-RAS4B
154	KI-RAS
155	KRAS1
156	KRAS2
157	NS
158	NS3
159	RASK2
160	CFC3
161	MAPKK1
162	MEK1
163	MKK1
164	PRKMK1
165	C-FMS
166	CD115
167	CSF-1R
168	CSFR
169	FIM2
170	FMS
171	HDLS
172	M-CSF-R
173	B23
174	NPM
175	ALPS4
176	CMNS
177	N-ras
178	NCMS
179	NRAS1
180	NS6
181	CLOVE
182	CWS5
183	MCAP
184	MCM
185	MCMTC
186	PI3K
187	p110-alpha
188	CD140A
189	PDGFR-2
190	PDGFR2
191	RHEPDGFRA
192	MYL
193	PP8675
194	RNF71
195	TRIM19
196	NR1B1
197	RAR
198	10q23del
199	BZS
200	CWS1
201	DEC
202	GLM2
203	MHAM
204	MMAC1
205	PTEN1
206	TEP1
207	CDHF12
208	CDHR16
209	HSCR1
210	MEN2A
211	MEN2B
212	MTC1
213	PTC
214	RET-ELE1
215	RET51
216	AML1
217	AML1-EVI-1
218	AMLCR1
219	CBFA2
220	EVI-1
221	PEBP2aB
222	Hsh155
223	MDS
224	PRP10
225	PRPF10
226	SAP155
227	SF3b155
228	BCC7
229	LFS1
230	P53
231	TRP53
232	LAM
233	TSC
234	PPP1R160
235	TSC4
236	FP793
237	RN
238	RNU2AF1
239	U2AF35
240	U2AFBP
241	AWT1
242	EWS-WT1
243	GUD
244	NPHS4
245	WAGR
246	WIT-2
247	WT33
248	FRAP
249	FRAP1
250	FRAP2
251	RAFT1
252	RAPT1
253	AOS5
254	AOVD1
255	TAN1
256	hN1
257	MIG20a
258	NTRKR3
259	TKT
260	TYRO10
261	AUTS9
262	DFNB97
263	HGFR
264	RCCP2
265	c-Met
266	JTK8
267	p53Lyn
268	p56Lyn
269	SDR38C1
\.


--
-- Data for Name: gene_aliases_genes; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY gene_aliases_genes (gene_alias_id, gene_id) FROM stdin;
1	1
2	1
3	2
4	2
5	2
6	2
7	2
8	2
9	2
10	3
11	3
12	3
13	3
14	4
15	4
16	4
17	4
18	4
19	4
20	4
21	5
22	5
23	5
24	5
25	6
26	6
27	6
28	6
29	6
30	6
31	6
32	6
33	6
34	7
35	7
36	7
37	7
38	7
39	7
40	7
41	7
42	7
43	7
44	8
45	8
46	8
47	8
48	9
49	9
50	11
51	12
52	12
53	13
54	13
55	14
56	14
57	14
58	14
59	14
60	14
61	14
62	14
63	14
64	14
65	14
66	14
67	14
68	14
69	14
70	14
71	14
72	14
73	15
74	15
75	16
76	16
77	16
78	16
79	16
80	17
81	17
82	18
83	18
84	18
85	19
86	19
87	19
88	19
89	19
90	19
91	20
92	20
93	20
94	20
95	20
96	20
97	20
98	20
99	21
100	21
101	21
102	21
103	21
104	21
105	22
106	22
107	22
108	22
109	22
110	22
111	22
112	22
113	22
114	22
115	22
116	22
117	23
118	23
119	23
120	23
121	23
122	24
123	24
124	24
125	24
126	25
127	25
128	25
129	25
130	26
131	26
132	26
133	26
134	26
135	26
136	26
137	27
138	27
133	27
139	27
134	27
140	27
141	27
142	28
143	28
144	29
145	29
146	29
147	29
148	30
149	30
150	30
151	30
152	30
153	30
154	30
155	30
156	30
157	30
158	30
159	30
160	31
161	31
162	31
163	31
164	31
165	33
166	33
167	33
168	33
169	33
170	33
171	33
172	33
173	35
174	35
175	36
176	36
177	36
178	36
179	36
180	36
181	37
182	37
183	37
184	37
185	37
186	37
187	37
188	38
189	38
190	38
191	38
192	39
193	39
194	39
195	39
196	40
197	40
198	41
199	41
200	41
201	41
202	41
203	41
204	41
205	41
206	41
207	42
208	42
209	42
210	42
211	42
212	42
213	42
214	42
215	42
216	43
217	43
218	43
219	43
220	43
221	43
222	44
223	44
224	44
225	44
226	44
227	44
228	45
229	45
230	45
231	45
232	46
233	46
232	47
234	47
235	47
236	48
237	48
238	48
239	48
240	48
241	49
242	49
243	49
244	49
245	49
246	49
247	49
248	50
249	50
250	50
251	50
252	50
253	51
254	51
255	51
256	51
257	52
258	52
259	52
260	52
261	53
262	53
263	53
264	53
265	53
266	54
267	54
268	54
269	55
\.


--
-- Name: gene_aliases_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('gene_aliases_id_seq', 269, true);


--
-- Name: genes_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('genes_id_seq', 55, true);


--
-- Data for Name: genes_sources; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY genes_sources (gene_id, source_id, created_at, updated_at) FROM stdin;
1	1	2015-05-20 18:09:52.347843	2015-05-20 18:09:52.347843
1	2	2015-05-20 18:09:52.354336	2015-05-20 18:09:52.354336
2	3	2015-05-20 18:09:52.590722	2015-05-20 18:09:52.590722
2	4	2015-05-20 18:09:52.594633	2015-05-20 18:09:52.594633
3	5	2015-05-20 18:09:52.822515	2015-05-20 18:09:52.822515
3	6	2015-05-20 18:09:52.827369	2015-05-20 18:09:52.827369
4	7	2015-05-20 18:09:53.066855	2015-05-20 18:09:53.066855
4	8	2015-05-20 18:09:53.071079	2015-05-20 18:09:53.071079
5	9	2015-05-20 18:09:53.327712	2015-05-20 18:09:53.327712
5	10	2015-05-20 18:09:53.331348	2015-05-20 18:09:53.331348
6	11	2015-05-20 18:09:53.58545	2015-05-20 18:09:53.58545
7	11	2015-05-20 18:09:53.844511	2015-05-20 18:09:53.844511
8	12	2015-05-20 18:09:54.077502	2015-05-20 18:09:54.077502
8	13	2015-05-20 18:09:54.081822	2015-05-20 18:09:54.081822
9	12	2015-05-20 18:09:54.289891	2015-05-20 18:09:54.289891
9	13	2015-05-20 18:09:54.292113	2015-05-20 18:09:54.292113
10	12	2015-05-20 18:09:54.488609	2015-05-20 18:09:54.488609
10	13	2015-05-20 18:09:54.490972	2015-05-20 18:09:54.490972
11	14	2015-05-20 18:09:54.700097	2015-05-20 18:09:54.700097
12	15	2015-05-20 18:09:54.894448	2015-05-20 18:09:54.894448
12	16	2015-05-20 18:09:54.89888	2015-05-20 18:09:54.89888
13	15	2015-05-20 18:09:55.098855	2015-05-20 18:09:55.098855
13	16	2015-05-20 18:09:55.101441	2015-05-20 18:09:55.101441
14	17	2015-05-20 18:09:55.38716	2015-05-20 18:09:55.38716
14	18	2015-05-20 18:09:55.391306	2015-05-20 18:09:55.391306
15	19	2015-05-20 18:09:55.642441	2015-05-20 18:09:55.642441
15	20	2015-05-20 18:09:55.647078	2015-05-20 18:09:55.647078
15	21	2015-05-20 18:09:55.651012	2015-05-20 18:09:55.651012
16	22	2015-05-20 18:09:55.859271	2015-05-20 18:09:55.859271
17	22	2015-05-20 18:09:56.062192	2015-05-20 18:09:56.062192
17	23	2015-05-20 18:09:56.066276	2015-05-20 18:09:56.066276
18	24	2015-05-20 18:09:56.272804	2015-05-20 18:09:56.272804
18	25	2015-05-20 18:09:56.276446	2015-05-20 18:09:56.276446
19	26	2015-05-20 18:09:56.507569	2015-05-20 18:09:56.507569
19	27	2015-05-20 18:09:56.511288	2015-05-20 18:09:56.511288
20	28	2015-05-20 18:09:56.853295	2015-05-20 18:09:56.853295
20	29	2015-05-20 18:09:56.859589	2015-05-20 18:09:56.859589
21	30	2015-05-20 18:09:57.126517	2015-05-20 18:09:57.126517
21	31	2015-05-20 18:09:57.130783	2015-05-20 18:09:57.130783
22	32	2015-05-20 18:09:57.415869	2015-05-20 18:09:57.415869
22	33	2015-05-20 18:09:57.420692	2015-05-20 18:09:57.420692
23	32	2015-05-20 18:09:57.668327	2015-05-20 18:09:57.668327
23	33	2015-05-20 18:09:57.670816	2015-05-20 18:09:57.670816
24	34	2015-05-20 18:09:57.905901	2015-05-20 18:09:57.905901
24	19	2015-05-20 18:09:57.908063	2015-05-20 18:09:57.908063
25	35	2015-05-20 18:09:58.118662	2015-05-20 18:09:58.118662
25	36	2015-05-20 18:09:58.124709	2015-05-20 18:09:58.124709
26	37	2015-05-20 18:09:58.359337	2015-05-20 18:09:58.359337
26	38	2015-05-20 18:09:58.362813	2015-05-20 18:09:58.362813
27	37	2015-05-20 18:09:58.60417	2015-05-20 18:09:58.60417
27	38	2015-05-20 18:09:58.606434	2015-05-20 18:09:58.606434
27	39	2015-05-20 18:09:58.610207	2015-05-20 18:09:58.610207
28	40	2015-05-20 18:09:58.82624	2015-05-20 18:09:58.82624
29	41	2015-05-20 18:09:59.038756	2015-05-20 18:09:59.038756
30	42	2015-05-20 18:09:59.312972	2015-05-20 18:09:59.312972
35	43	2015-05-20 18:10:00.329787	2015-05-20 18:10:00.329787
35	19	2015-05-20 18:10:00.332046	2015-05-20 18:10:00.332046
42	44	2015-05-20 18:10:01.882519	2015-05-20 18:10:01.882519
42	45	2015-05-20 18:10:01.886945	2015-05-20 18:10:01.886945
44	46	2015-05-20 18:10:02.350802	2015-05-20 18:10:02.350802
44	47	2015-05-20 18:10:02.355661	2015-05-20 18:10:02.355661
45	48	2015-05-20 18:10:02.615587	2015-05-20 18:10:02.615587
48	49	2015-05-20 18:10:03.230644	2015-05-20 18:10:03.230644
48	50	2015-05-20 18:10:03.234258	2015-05-20 18:10:03.234258
\.


--
-- Data for Name: ratings; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY ratings (id, value, evidence_item_id, user_id, created_at, updated_at) FROM stdin;
\.


--
-- Name: ratings_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('ratings_id_seq', 1, false);


--
-- Data for Name: roles; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY roles (id, name, description, created_at, updated_at) FROM stdin;
\.


--
-- Name: roles_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('roles_id_seq', 1, false);


--
-- Data for Name: roles_users; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY roles_users (role_id, user_id, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: schema_migrations; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY schema_migrations (version) FROM stdin;
20140805184308
20141021192035
20141022180523
20141022195329
20141108234203
20141108234935
20141109000136
20141114222425
20150107205621
20150115231117
20150116220720
20150116230539
20150116230632
20150204192653
20150205000010
20150205205734
20150205210725
20150210191015
20150210204445
20150219202227
20150220160805
20150220182109
20150223170106
20150227204142
20150227212146
20150303202505
20150305200429
20150319181853
20150416182633
20150501151624
20150511191452
20150512184905
\.


--
-- Name: sources_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('sources_id_seq', 247, true);


--
-- Data for Name: subscriptions; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY subscriptions (id, user_id, subscribable_id, subscribable_type, type, created_at, updated_at, action_type, action_class) FROM stdin;
\.


--
-- Name: subscriptions_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('subscriptions_id_seq', 1, false);


--
-- Data for Name: suggested_changes; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY suggested_changes (id, suggested_changes, moderated_id, moderated_type, user_id, status, created_at, updated_at) FROM stdin;
\.


--
-- Name: suggested_changes_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('suggested_changes_id_seq', 1, false);


--
-- Data for Name: tsv_releases; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY tsv_releases (id, path, created_at, updated_at) FROM stdin;
\.


--
-- Name: tsv_releases_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('tsv_releases_id_seq', 1, false);


--
-- Name: users_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('users_id_seq', 1, false);


--
-- Data for Name: variant_groups; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY variant_groups (id, name, description, created_at, updated_at) FROM stdin;
10	KIT Exon 17	\N	2015-05-20 18:10:15.720591	2015-05-20 18:10:15.720591
11	KIT Exon 11	\N	2015-05-20 18:10:15.773246	2015-05-20 18:10:15.773246
1	Imatinib Resistance	While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. 	2015-05-20 18:10:07.437103	2015-05-20 18:10:23.772017
2	ALK Fusions	ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. 	2015-05-20 18:10:07.633703	2015-05-20 18:10:23.786116
6	TKI Resistance	EGFR pathway activation is a nearly ubiquitous hallmark of cancer. Many tyrosine kinase inhibitors have been developed to target EGFR pathway activity. One such inhibitor, erlotinib, has demonstrated efficacy in an EGFR over-active setting. However, the T790M missense mutation has shown to confer resistance to this inhibitor in cell lines and case studies.  	2015-05-20 18:10:12.301777	2015-05-20 18:10:23.799138
3	Crizotinib Resistance	The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. 	2015-05-20 18:10:07.701562	2015-05-20 18:10:23.813213
4	Other V600's	While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. 	2015-05-20 18:10:08.419696	2015-05-20 18:10:23.824345
7	HER2 Activating	HER2-positive breast cancer is widely recognized as a molecular subtype of breast cancer. While amplification of ERBB2 is a common mechanism for activation of the pathway, missense mutations have also demonstrated activation potential. These activating missense mutations also confer senstivity to the targeted therapeutic neratinib. 	2015-05-20 18:10:12.602492	2015-05-20 18:10:23.839498
8	ESR1 Ligand-Binding Domain	ER-positive breast cancer is the most common of the breast cancer subtypes. Hormone therapy has been widely effective in treating the disease, however sequencing of resistant patients has uncovered a number of missense mutations in mediating this resistance. Many of these mutations lie within the ligand-binding domain, and contribute to constitutive activity of the receptor. This has lead to the development of estrogen receptor degrading agents such as fulvestrant, which have shown early efficacy in clinical trials.  	2015-05-20 18:10:13.066077	2015-05-20 18:10:23.850857
9	FGFR fusions	FGFR fusions have been demonstrated across many cancer types to have oncogenic potential. FGFR2 and FGFR3 have been shown to be fused to many 3' partners, which may act as a vehicle for pathway activation. Treatment of cell lines harboring FGFR2 fusions with pazopanib has shown mild "anti-tumor" activities, and both ponatinib and pazopanib have shown efficacy in case studies.  	2015-05-20 18:10:13.62488	2015-05-20 18:10:23.860734
12	NPM1 Exon 12	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	2015-05-20 18:10:19.343943	2015-05-20 18:10:23.872343
13	PTEN Loss-of-Function	PTEN loss is a common event in breast cancer, as well as others. The most common single nucleotide variant resulting in PTEN loss is a R233 nonsense mutation. Cell lines harboring this mutation behave similarly to cell lines harboring larger insertion or deletion events, in that they both respond to PI3K-mTOR inhibitors with impeded growth. 	2015-05-20 18:10:21.209893	2015-05-20 18:10:23.884193
14	Motesanib Resistance	RET activation is a common oncogenic marker of medullary thyroid carcinoma. Treatment of these patients with the targeted therapeutic motesanib has shown to be effective. However, the missense mutations C634W and M918T have shown to confer motesanib resistance in cell lines. 	2015-05-20 18:10:21.358772	2015-05-20 18:10:23.896766
15	TSC Loss	Inactivating events in TSC1 and TSC2 have been observed in a number of cancer types. Cell lines and case studies have shown that in the loss of TSC, the mTOR inhibitor everolimus has seen significant anti-tumorigenic activity. 	2015-05-20 18:10:22.101868	2015-05-20 18:10:23.906893
5	BRCA Germline Variants	BRCA germline variants have long been recognized as important potential predictors of breast and ovarian cancer risk. 	2015-05-20 18:10:09.428355	2015-05-20 18:10:23.917588
\.


--
-- Data for Name: variant_group_variants; Type: TABLE DATA; Schema: public; Owner: acoffman
--

COPY variant_group_variants (variant_id, variant_group_id, created_at, updated_at) FROM stdin;
3	1	2015-05-20 18:10:07.458877	2015-05-20 18:10:07.458877
2	1	2015-05-20 18:10:07.499087	2015-05-20 18:10:07.499087
2	1	2015-05-20 18:10:07.543233	2015-05-20 18:10:07.543233
5	2	2015-05-20 18:10:07.644229	2015-05-20 18:10:07.644229
6	2	2015-05-20 18:10:07.698762	2015-05-20 18:10:07.698762
6	3	2015-05-20 18:10:07.713085	2015-05-20 18:10:07.713085
7	2	2015-05-20 18:10:07.791218	2015-05-20 18:10:07.791218
7	3	2015-05-20 18:10:07.794203	2015-05-20 18:10:07.794203
8	3	2015-05-20 18:10:08.029039	2015-05-20 18:10:08.029039
11	4	2015-05-20 18:10:08.43006	2015-05-20 18:10:08.43006
13	4	2015-05-20 18:10:09.291878	2015-05-20 18:10:09.291878
15	4	2015-05-20 18:10:09.335025	2015-05-20 18:10:09.335025
16	4	2015-05-20 18:10:09.375969	2015-05-20 18:10:09.375969
129	5	2015-05-20 18:10:09.442203	2015-05-20 18:10:09.442203
130	5	2015-05-20 18:10:09.484192	2015-05-20 18:10:09.484192
34	6	2015-05-20 18:10:12.317022	2015-05-20 18:10:12.317022
34	6	2015-05-20 18:10:12.562197	2015-05-20 18:10:12.562197
35	7	2015-05-20 18:10:12.617223	2015-05-20 18:10:12.617223
36	7	2015-05-20 18:10:12.655147	2015-05-20 18:10:12.655147
38	7	2015-05-20 18:10:12.732078	2015-05-20 18:10:12.732078
41	7	2015-05-20 18:10:12.865693	2015-05-20 18:10:12.865693
43	7	2015-05-20 18:10:12.941203	2015-05-20 18:10:12.941203
44	7	2015-05-20 18:10:12.985034	2015-05-20 18:10:12.985034
45	7	2015-05-20 18:10:13.027435	2015-05-20 18:10:13.027435
46	8	2015-05-20 18:10:13.080221	2015-05-20 18:10:13.080221
46	8	2015-05-20 18:10:13.131159	2015-05-20 18:10:13.131159
47	8	2015-05-20 18:10:13.172464	2015-05-20 18:10:13.172464
47	8	2015-05-20 18:10:13.224075	2015-05-20 18:10:13.224075
48	8	2015-05-20 18:10:13.269786	2015-05-20 18:10:13.269786
48	8	2015-05-20 18:10:13.326613	2015-05-20 18:10:13.326613
49	8	2015-05-20 18:10:13.391989	2015-05-20 18:10:13.391989
49	8	2015-05-20 18:10:13.468123	2015-05-20 18:10:13.468123
50	8	2015-05-20 18:10:13.530577	2015-05-20 18:10:13.530577
50	8	2015-05-20 18:10:13.583658	2015-05-20 18:10:13.583658
51	9	2015-05-20 18:10:13.634768	2015-05-20 18:10:13.634768
52	9	2015-05-20 18:10:13.682366	2015-05-20 18:10:13.682366
53	9	2015-05-20 18:10:13.72961	2015-05-20 18:10:13.72961
64	10	2015-05-20 18:10:15.730115	2015-05-20 18:10:15.730115
65	11	2015-05-20 18:10:15.78413	2015-05-20 18:10:15.78413
65	11	2015-05-20 18:10:15.831424	2015-05-20 18:10:15.831424
65	11	2015-05-20 18:10:15.870453	2015-05-20 18:10:15.870453
65	11	2015-05-20 18:10:15.911137	2015-05-20 18:10:15.911137
65	11	2015-05-20 18:10:15.949356	2015-05-20 18:10:15.949356
65	11	2015-05-20 18:10:15.986853	2015-05-20 18:10:15.986853
69	10	2015-05-20 18:10:16.107366	2015-05-20 18:10:16.107366
69	10	2015-05-20 18:10:16.157212	2015-05-20 18:10:16.157212
66	11	2015-05-20 18:10:16.28367	2015-05-20 18:10:16.28367
71	11	2015-05-20 18:10:16.333127	2015-05-20 18:10:16.333127
71	11	2015-05-20 18:10:16.376361	2015-05-20 18:10:16.376361
71	11	2015-05-20 18:10:16.431703	2015-05-20 18:10:16.431703
72	11	2015-05-20 18:10:16.476878	2015-05-20 18:10:16.476878
72	11	2015-05-20 18:10:16.51965	2015-05-20 18:10:16.51965
146	6	2015-05-20 18:10:17.015901	2015-05-20 18:10:17.015901
77	6	2015-05-20 18:10:17.108191	2015-05-20 18:10:17.108191
78	6	2015-05-20 18:10:17.309659	2015-05-20 18:10:17.309659
145	6	2015-05-20 18:10:17.347411	2015-05-20 18:10:17.347411
144	6	2015-05-20 18:10:17.746914	2015-05-20 18:10:17.746914
86	12	2015-05-20 18:10:19.354634	2015-05-20 18:10:19.354634
86	12	2015-05-20 18:10:19.389256	2015-05-20 18:10:19.389256
86	12	2015-05-20 18:10:19.431625	2015-05-20 18:10:19.431625
86	12	2015-05-20 18:10:19.473216	2015-05-20 18:10:19.473216
96	1	2015-05-20 18:10:20.065517	2015-05-20 18:10:20.065517
97	1	2015-05-20 18:10:20.109777	2015-05-20 18:10:20.109777
97	1	2015-05-20 18:10:20.152906	2015-05-20 18:10:20.152906
97	1	2015-05-20 18:10:20.191497	2015-05-20 18:10:20.191497
97	1	2015-05-20 18:10:20.235949	2015-05-20 18:10:20.235949
98	1	2015-05-20 18:10:20.278484	2015-05-20 18:10:20.278484
99	1	2015-05-20 18:10:20.319187	2015-05-20 18:10:20.319187
100	1	2015-05-20 18:10:20.360806	2015-05-20 18:10:20.360806
108	13	2015-05-20 18:10:21.224556	2015-05-20 18:10:21.224556
108	13	2015-05-20 18:10:21.267741	2015-05-20 18:10:21.267741
110	14	2015-05-20 18:10:21.36928	2015-05-20 18:10:21.36928
111	14	2015-05-20 18:10:21.487286	2015-05-20 18:10:21.487286
122	15	2015-05-20 18:10:22.113921	2015-05-20 18:10:22.113921
122	15	2015-05-20 18:10:22.159664	2015-05-20 18:10:22.159664
123	15	2015-05-20 18:10:22.201245	2015-05-20 18:10:22.201245
124	15	2015-05-20 18:10:22.244669	2015-05-20 18:10:22.244669
\.


--
-- Name: variant_groups_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('variant_groups_id_seq', 15, true);


--
-- Name: variant_origins_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('variant_origins_id_seq', 2, true);


--
-- Name: variants_id_seq; Type: SEQUENCE SET; Schema: public; Owner: acoffman
--

SELECT pg_catalog.setval('variants_id_seq', 155, true);


--
-- PostgreSQL database dump complete
--

